<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40825726</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0253-3758</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Zhonghua xin xue guan bing za zhi</Title><ISOAbbreviation>Zhonghua Xin Xue Guan Bing Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Noodles, journals, and hypertrophic cardiomyopathy].</ArticleTitle><Pagination><StartPage>853</StartPage><EndPage>854</EndPage><MedlinePgn>853-854</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112148-20250521-00384</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Z Y</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Dazhu County People's Hospital, Dazhou 635100, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Xin Xue Guan Bing Za Zhi</MedlineTA><NlmUniqueID>7910682</NlmUniqueID><ISSNLinking>0253-3758</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>22</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40825726</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112148-20250521-00384</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40839925</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>165</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>Takotsubo cardiomyopathy induced by diabetic ketoacidosis.</ArticleTitle><Pagination><StartPage>107156</StartPage><MedlinePgn>107156</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2025.107156</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0025-7753(25)00384-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yifei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Tsinghua Changgung Hospital, Tsinghua Medicine, Tsinghua University, Changping District, Beijing 102218, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Tsinghua Changgung Hospital, Tsinghua Medicine, Tsinghua University, Changping District, Beijing 102218, China. Electronic address: hra01560@btch.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Tsinghua Changgung Hospital, Tsinghua Medicine, Tsinghua University, Changping District, Beijing 102218, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839925</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2025.107156</ArticleId><ArticleId IdType="pii">S0025-7753(25)00384-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40838922</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2405-5018</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>JACC. Clinical electrophysiology</Title><ISOAbbreviation>JACC Clin Electrophysiol</ISOAbbreviation></Journal><ArticleTitle>Electrical Storm in Patients With Hypertrophic Cardiomyopathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S2405-500X(25)00555-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacep.2025.06.035</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Therapeutic strategies for electrical storm (ES) in patients with hypertrophic cardiomyopathy (HCM) are not well defined, yet this population is at risk for ventricular arrhythmias (VAs).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to analyze acute management, in-hospital mortality, and long-term outcomes of patients with HCM experiencing ES.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This multicenter study retrospectively enrolled patients with ES complicating HCM between 2017 and 2023 in 6 tertiary centers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-three patients were included (mean age 61.5 &#xb1; 15.2 years, 73.9% male, left ventricular ejection fraction 50% &#xb1; 14%). Five patients (22%) had an apical aneurysm. Ten (43.4%) patients had a history of VA, including 3 with previous ES. The majority of VAs were monomorphic ventricular tachycardias (18 patients [78%]). Most patients received amiodarone (n = 20 [87%]) and beta-blockers (n = 16 [70%]). For 10 patients (44%), a radiofrequency catheter ablation was performed (including 2 endo-epicardial ablations), resulting in negative programmed ventricular stimulation in 4 patients. During their hospital management, 8 patients experienced recurrences of VA (2 [25%] previously ablated and 6 [75%] nonablated). Two (9%) patients died during the index hospitalization and 4 other patients died following discharge (median follow-up 18 months). Seven patients (30%) experienced recurrences of arrhythmias, including 4 who had undergone ablation. Radiofrequency ablation was not associated with better outcomes (recurrence rate or overall survival) in this study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ES in HCM frequently resolves using antiarrhythmic drugs. Many patients will present with VA recurrences. Long-term outcomes were poor, and one-fourth of the patients ended up dying at 18 months. Further studies are warranted to better analyze radiofrequency outcomes in this specific population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Groussin</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Rennes, Centre Hospitalier Universitaire (CHU) Rennes, INSERM, LTSI-UMR 1099, Rennes, France. Electronic address: pierre.groussin@chu-rennes.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dezecot</LastName><ForeName>Melvyn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Rennes, Centre Hospitalier Universitaire (CHU) Rennes, INSERM, LTSI-UMR 1099, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Decaudin</LastName><ForeName>Donovan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Rennes, Centre Hospitalier Universitaire (CHU) Rennes, INSERM, LTSI-UMR 1099, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavin</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Rennes, Centre Hospitalier Universitaire (CHU) Rennes, INSERM, LTSI-UMR 1099, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ninni</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ollitrault</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Caen University Hospital, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Champ Rigot</LastName><ForeName>Laure</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Caen University Hospital, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Font</LastName><ForeName>Jonaz</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Caen University Hospital, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Da Costa</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital of Saint Etienne, Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sellal</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Nancy University Hospital, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammache</LastName><ForeName>N&#xe9;fissa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Nancy University Hospital, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salaun</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Dijon University Hospital, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guenancia</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Dijon University Hospital, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mabo</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Rennes, Centre Hospitalier Universitaire (CHU) Rennes, INSERM, LTSI-UMR 1099, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benali</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital of Saint Etienne, Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Rapha&#xeb;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Rennes, Centre Hospitalier Universitaire (CHU) Rennes, INSERM, LTSI-UMR 1099, Rennes, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Clin Electrophysiol</MedlineTA><NlmUniqueID>101656995</NlmUniqueID><ISSNLinking>2405-500X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">catheter ablation</Keyword><Keyword MajorTopicYN="N">electrical storm</Keyword><Keyword MajorTopicYN="N">hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">ventricular arrhythmia</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>10</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40838922</ArticleId><ArticleId IdType="doi">10.1016/j.jacep.2025.06.035</ArticleId><ArticleId IdType="pii">S2405-500X(25)00555-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40843315</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2950-1334</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2025</Year><Month>Nov</Month></PubDate></JournalIssue><Title>JHLT open</Title><ISOAbbreviation>JHLT Open</ISOAbbreviation></Journal><ArticleTitle>Cardiomyopathy as indication for pediatric heart transplantation.</ArticleTitle><Pagination><StartPage>100360</StartPage><MedlinePgn>100360</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100360</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhlto.2025.100360</ELocationID><Abstract><AbstractText>Pediatric cardiomyopathy (CMP), with an incidence of approximately 1 in 100,000 children, remains a critical clinical challenge. Often progressive, these myocardial disorders frequently culminate in end-stage heart failure, establishing CMP as the primary indication for pediatric heart transplantation. Key considerations for transplantation include specific CMP etiologies and subtypes alongside established listing criteria and strategies to navigate waitlist complexities. The evolving role of mechanical circulatory support, especially ventricular assist devices (VADs), has transformed bridging strategies and significantly improved survival to transplant. Contemporary post-transplant outcomes demonstrate continued improvement, with advancements in survival rates and ongoing refinement of essential long-term management strategies. This review provides a comprehensive analysis of pediatric CMP as it progresses to end-stage heart failure requiring transplantation. It synthesizes current knowledge on etiologies, clinical presentations, transplant evaluation, the transformative impact of VADs, and contemporary post-transplant management, aiming to equip clinicians with an updated framework for complex decision-making and optimizing outcomes in this high-risk population.</AbstractText><CopyrightInformation>&#xa9; 2025 International Society for Heart and Lung Transplantation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raissadati</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics (Cardiology), Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tolani</LastName><ForeName>Drishti</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pediatrics (Cardiology), Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Profita</LastName><ForeName>Elizabeth L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Pediatrics (Cardiology), Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JHLT Open</MedlineTA><NlmUniqueID>9918716187806676</NlmUniqueID><ISSNLinking>2950-1334</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dilated cardiomyopathy</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">heart transplant</Keyword><Keyword MajorTopicYN="N">hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">pediatric</Keyword><Keyword MajorTopicYN="N">restrictive cardiomyopathy</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>4</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843315</ArticleId><ArticleId IdType="pmc">PMC12365339</ArticleId><ArticleId IdType="doi">10.1016/j.jhlto.2025.100360</ArticleId><ArticleId IdType="pii">S2950-1334(25)00155-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lipshultz S.E., Sleeper L.A., Towbin J.A., et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348:1647&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">12711739</ArticleId></ArticleIdList></Reference><Reference><Citation>Towbin J.A., Lowe A.M., Colan S.D., et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867&#x2013;1876.</Citation><ArticleIdList><ArticleId IdType="pubmed">17047217</ArticleId></ArticleIdList></Reference><Reference><Citation>Kindel S.J., Miller E.M., Gupta R., et al. Pediatric cardiomyopathy: importance of genetic and metabolic evaluation. J Card Fail. 2012;18:396&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345128</ArticleId><ArticleId IdType="pubmed">22555271</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk R., Naftel D., Hoffman T.M., et al. Outcome of pediatric patients with dilated cardiomyopathy listed for transplant: a multi-institutional study. J Heart Lung Transplant. 2009;28:1322&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4296522</ArticleId><ArticleId IdType="pubmed">19782601</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossano J.W., Singh T.P., Cherikh W.S., et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty-second Pediatric Heart Transplantation Report&#x2014;2019; focus theme: donor and recipient size match. J Heart Lung Transplant. 2019;38:1028&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6819143</ArticleId><ArticleId IdType="pubmed">31548029</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan M.F., Tajik A.J. Modern imaging techniques in cardiomyopathies. Circ Res. 2017;121:874&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">28912188</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox G.F., Sleeper L.A., Lowe A.M., et al. Factors associated with establishing a causal diagnosis for children with cardiomyopathy. Pediatrics. 2006;118:1519&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015543</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipshultz S.E., Law Y.M., Asante-Korang A., et al. Cardiomyopathy in children: classification and diagnosis: a scientific statement from the American Heart Association. Circulation. 2019;140:e9&#x2013;e68.</Citation><ArticleIdList><ArticleId IdType="pubmed">31132865</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashley E.A., Hershberger R.E., Caleshu C., et al. Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2012;126:142&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3721666</ArticleId><ArticleId IdType="pubmed">22645291</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B., Colvin M., Cook J., et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134:e579&#x2013;e646.</Citation><ArticleIdList><ArticleId IdType="pubmed">27832612</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T.M., Hsu D.T., Kantor P., et al. Pediatric cardiomyopathies. Circ Res. 2017;121:855&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657298</ArticleId><ArticleId IdType="pubmed">28912187</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware S.M. Genetics of paediatric cardiomyopathies. Curr Opin Pediatr. 2017;29:534&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777578</ArticleId><ArticleId IdType="pubmed">28700417</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakdawala N.K., Thune J.J., Colan S.D., et al. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet. 2012;5:503&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3646896</ArticleId><ArticleId IdType="pubmed">22949430</ArticleId></ArticleIdList></Reference><Reference><Citation>Feingold B., Mahle W.T., Auerbach S., et al. Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the American Heart Association. Circulation. 2017;136:e200&#x2013;e231.</Citation><ArticleIdList><ArticleId IdType="pubmed">28838934</ArticleId></ArticleIdList></Reference><Reference><Citation>van Berlo J.H., de Voogt W.G., van der Kooi A.J., et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) 2005;83:79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">15551023</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaglia F., Towbin J.A., Craigen W.J., et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics. 2004;114:925&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">15466086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ommen S.R., Ho C.Y., Asif I.M., et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1239&#x2013;e1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">38718139</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott P., Andersson B., Arbustini E., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">17916581</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishnani P.S., Steiner R.D., Bali D., et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8:267&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110959</ArticleId><ArticleId IdType="pubmed">16702877</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z., McMahon C.J., Smith L.R., et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation. 2005;112:1612&#x2013;1617.</Citation><ArticleIdList><ArticleId IdType="pubmed">16144992</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal G.N., de Paula A.C., Leone C., Kim C.A. Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young. 2010;20:254&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">20416133</ArticleId></ArticleIdList></Reference><Reference><Citation>Takenaka T., Teraguchi H., Yoshida A., et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008;51:50&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">18522775</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts A.E., Allanson J.E., Tartaglia M., Gelb B.D. Noonan syndrome. Lancet. 2013;381:333&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267483</ArticleId><ArticleId IdType="pubmed">23312968</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson J.D., Lowe A.M., Salbert B.A., et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2012;164:442&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">22980313</ArticleId></ArticleIdList></Reference><Reference><Citation>Colan S.D., Lipshultz S.E., Lowe A.M., et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007;115:773&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">17261650</ArticleId></ArticleIdList></Reference><Reference><Citation>Webber S.A., Lipshultz S.E., Sleeper L.A., et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. Circulation. 2012;126:1237&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">22843787</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh M.A., Grenier M.A., Jefferies J.L., et al. Conduction abnormalities in pediatric patients with restrictive cardiomyopathy. Circ Heart Fail. 2012;5:267&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">22260945</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Hata Y., Hirono K., et al. A wide and specific spectrum of genetic variants and genotype-phenotype correlations revealed by next-generation sequencing in patients with left ventricular noncompaction. J Am Heart Assoc. 2017;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5634278</ArticleId><ArticleId IdType="pubmed">28855170</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen S.E., Jensen B., Aung N., et al. Excessive trabeculation of the left ventricle: JACC: cardiovascular imaging expert panel paper. JACC Cardiovasc Imaging. 2023;16:408&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9988693</ArticleId><ArticleId IdType="pubmed">36764891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen-Chowdhry S., Syrris P., Prasad S.K., et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52:2175&#x2013;2187.</Citation><ArticleIdList><ArticleId IdType="pubmed">19095136</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorzi A., Perazzolo Marra M., Rigato I., et al. Nonischemic left ventricular scar as a substrate of life-threatening ventricular arrhythmias and sudden cardiac death in competitive athletes. Circ Arrhythm Electrophysiol. 2016;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4956679</ArticleId><ArticleId IdType="pubmed">27390211</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauce B., Nava A., Beffagna G., et al. Multiple mutations in desmosomal proteins encoding genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm. 2010;7:22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">20129281</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley C.A. Carnitine deficiency disorders in children. Ann N Y Acad Sci. 2004;1033:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15591002</ArticleId></ArticleIdList></Reference><Reference><Citation>Canter C.E., Shaddy R.E., Bernstein D., et al. Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;115:658&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">17261651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopper R.K., Hansmann G., Hollander S.A., et al. Clinical management and transplant considerations in pediatric pulmonary hypertension due to left heart disease: a scientific statement from the American Heart Association. Circ Heart Fail. 2025;18</Citation><ArticleIdList><ArticleId IdType="pubmed">39648916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ditaranto R., Caponetti A.G., Ferrara V., et al. Pediatric restrictive cardiomyopathies. Front Pediatr. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8822222</ArticleId><ArticleId IdType="pubmed">35145940</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller R.J., Weintraub R., Addonizio L.J., et al. Outcome of idiopathic restrictive cardiomyopathy in children. Am J Cardiol. 2002;90:501&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">12208410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu R.S., Gupta S., Brown R.N., et al. Clinical outcomes after cardiac transplantation in muscular dystrophy patients. J Heart Lung Transplant. 2010;29:432&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">19864165</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser C.D., Jr, Jaquiss R.D., Rosenthal D.N., et al. Prospective trial of a pediatric ventricular assist device. N Engl J Med. 2012;367:532&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">22873533</ArticleId></ArticleIdList></Reference><Reference><Citation>Amdani S., Boyle G., Saarel E.V., et al. Waitlist and post-heart transplant outcomes for children with nondilated cardiomyopathy. Ann Thorac Surg. 2021;112:188&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">32768427</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafar F., Castleberry C., Khan M.S., et al. Pediatric heart transplant waiting list mortality in the era of ventricular assist devices. J Heart Lung Transplant. 2015;34:82&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">25447574</ArticleId></ArticleIdList></Reference><Reference><Citation>Organ Procurement and Transplantation Network. Guidance Addressing the Use of Pediatric Heart Exceptions. Available at: &#x2329;https://optn.transplant.hrsa.gov/media/4406/guidance-addressing-the-use-of-pediatric-heart-exceptions.pdf&#x232a;,&#xa0;accessed, e.g., December 15, 2024.</Citation></Reference><Reference><Citation>Magnetta D.A., Godown J., West S., et al. Impact of the 2016 revision of US Pediatric Heart Allocation Policy on waitlist characteristics and outcomes. Am J Transplant. 2019;19:3276&#x2013;3283.</Citation><ArticleIdList><ArticleId IdType="pubmed">31544351</ArticleId></ArticleIdList></Reference><Reference><Citation>Power A., Sweat K.R., Roth A., et al. Contemporary Pediatric Heart Transplant Waitlist Mortality. J Am Coll Cardiol. 2024;84:620&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">39111968</ArticleId></ArticleIdList></Reference><Reference><Citation>Blume E.D., Naftel D.C., Bastardi H.J., et al. Outcomes of children bridged to heart transplantation with ventricular assist devices: a multi-institutional study. Circulation. 2006;113:2313&#x2013;2319.</Citation><ArticleIdList><ArticleId IdType="pubmed">16702487</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorts A., Conway J., Schweiger M., et al. ISHLT consensus statement for the selection and management of pediatric and congenital heart disease patients on ventricular assist devices endorsed by the American Heart Association. J Heart Lung Transplant. 2021;40:709&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">34193359</ArticleId></ArticleIdList></Reference><Reference><Citation>May L.J., Montez-Rath M.E., Yeh J., et al. Impact of ventricular assist device placement on longitudinal renal function in children with end-stage heart failure. J Heart Lung Transplant. 2016;35:449&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">26653933</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedland-Little J.M., Hong B.J., Gossett J.G., et al. Changes in renal function after left ventricular assist device placement in pediatric patients: a pedimacs analysis. J Heart Lung Transplant. 2018;37:1218&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pubmed">30293616</ArticleId></ArticleIdList></Reference><Reference><Citation>Raissadati A., Pihkala J., Jahnukainen T., et al. Late outcome after paediatric heart transplantation in Finland. Interact Cardiovasc Thorac Surg. 2016;23:18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986750</ArticleId><ArticleId IdType="pubmed">27034098</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong D., Eisenberg R., Lamour J.M., et al. Waitlist and posttransplant outcomes of children and young adults with hypertrophic cardiomyopathy. Ann Thorac Surg. 2023;116:588&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">35690136</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40828044</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-1315</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Radiology</Title><ISOAbbreviation>Radiology</ISOAbbreviation></Journal><ArticleTitle>A Contemporary Review of Imaging in Arrhythmogenic Cardiomyopathy.</ArticleTitle><Pagination><StartPage>e242190</StartPage><MedlinePgn>e242190</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1148/radiol.242190</ELocationID><Abstract><AbstractText>Arrhythmogenic cardiomyopathy (ACM) is a rare inherited disease characterized by fibrofatty replacement of the myocardium, associated with lethal arrhythmias and heart failure. ACM diagnosis is challenging, as it involves clinical, genetic, and multiparametric imaging assessments. Imaging plays a central role in evaluating ACM by targeting the intertwined morphofunctional and tissue abnormalities. Cardiac MRI is the reference technique due to its ability to depict both types of abnormalities comprehensively and without radiation. Over the past decade, advances in regional deformation analysis and tissue characterization have improved detection of early-stage disease and recognition of left ventricular (LV) involvement, expanding beyond the classic right ventricle phenotype and leading to updated diagnostic criteria. CT, with its superior and isotropic spatial resolution, strong native contrast for adipose tissue, and potential dynamic four-dimensional acquisition, could play a key role in ACM diagnosis and characterization, particularly in patients with implanted devices. This review explores the strengths and limitations of cardiac MRI and CT in ACM evaluation, emphasizing LV involvement and new diagnostic criteria. It also addresses key challenges, such as the prognostic value of cardiac MRI and structural disease progression, while discussing the latest advancements and future directions for both modalities.</AbstractText><CopyrightInformation>&#xa9; RSNA, 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laredo</LastName><ForeName>Mikael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7326-2656</Identifier><AffiliationInfo><Affiliation>Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;, CNRS, INSERM, 15 rue de l'&#xc9;cole de M&#xe9;decine, 75006 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe9; de Rythmologie, Institut de Cardiologie, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Universitaire Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiometabolism and Nutrition (IHU ICAN), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charpentier</LastName><ForeName>Etienne</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3265-5912</Identifier><AffiliationInfo><Affiliation>Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;, CNRS, INSERM, 15 rue de l'&#xc9;cole de M&#xe9;decine, 75006 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiometabolism and Nutrition (IHU ICAN), Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imagerie Cardiovasculaire et Thoracique, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Universitaire Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandjbakhch</LastName><ForeName>Estelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unit&#xe9; de Rythmologie, Institut de Cardiologie, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Universitaire Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiometabolism and Nutrition (IHU ICAN), Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe9; de Cardiog&#xe9;n&#xe9;tique et Myog&#xe9;n&#xe9;tique, Service de Biochimie M&#xe9;tabolique, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Universitaire Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence des Maladies Cardiaques H&#xe9;r&#xe9;ditaires ou Rares, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Universitaire Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redheuil</LastName><ForeName>Alban</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1002-9902</Identifier><AffiliationInfo><Affiliation>Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;, CNRS, INSERM, 15 rue de l'&#xc9;cole de M&#xe9;decine, 75006 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiometabolism and Nutrition (IHU ICAN), Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imagerie Cardiovasculaire et Thoracique, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Universitaire Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kachenoura</LastName><ForeName>Nadjia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5269-3246</Identifier><AffiliationInfo><Affiliation>Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;, CNRS, INSERM, 15 rue de l'&#xc9;cole de M&#xe9;decine, 75006 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiometabolism and Nutrition (IHU ICAN), Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Radiology</MedlineTA><NlmUniqueID>0401260</NlmUniqueID><ISSNLinking>0033-8419</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>10</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40828044</ArticleId><ArticleId IdType="doi">10.1148/radiol.242190</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40825737</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0253-3758</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Zhonghua xin xue guan bing za zhi</Title><ISOAbbreviation>Zhonghua Xin Xue Guan Bing Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Genetic factors for risk stratification in dilated cardiomyopathy].</ArticleTitle><Pagination><StartPage>946</StartPage><EndPage>951</EndPage><MedlinePgn>946-951</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112148-20250528-00402</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Hospital, National Center of Gerontology, Chinese Academy of Medical Sciences, Institute of Geriatric Medicine, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Hospital, National Center of Gerontology, Chinese Academy of Medical Sciences, Institute of Geriatric Medicine, Beijing 100730, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Xin Xue Guan Bing Za Zhi</MedlineTA><NlmUniqueID>7910682</NlmUniqueID><ISSNLinking>0253-3758</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="chi"><AbstractText>&#x6269;&#x5f20;&#x578b;&#x5fc3;&#x808c;&#x75c5;&#xff08;DCM&#xff09;&#x662f;&#x4e00;&#x79cd;&#x4e34;&#x5e8a;&#x8868;&#x73b0;&#x591a;&#x6837;&#x3001;&#x9884;&#x540e;&#x5dee;&#x5f02;&#x5927;&#x7684;&#x5fc3;&#x808c;&#x75be;&#x75c5;&#xff0c;&#x7cbe;&#x51c6;&#x7684;&#x5371;&#x9669;&#x5206;&#x5c42;&#x548c;&#x9884;&#x540e;&#x8bc4;&#x4f30;&#x5bf9;&#x4e8e;&#x4e34;&#x5e8a;&#x6cbb;&#x7597;&#x548c;&#x7ba1;&#x7406;&#x8be5;&#x75c5;&#x81f3;&#x5173;&#x91cd;&#x8981;&#x3002;&#x8fd1;&#x5e74;&#x6765;&#xff0c;&#x968f;&#x7740;&#x9057;&#x4f20;&#x5b66;&#x548c;&#x8868;&#x89c2;&#x9057;&#x4f20;&#x5b66;&#x7814;&#x7a76;&#x7684;&#x6df1;&#x5165;&#xff0c;&#x7279;&#x5b9a;&#x57fa;&#x56e0;&#x4e0e;DCM&#x9884;&#x540e;&#x7684;&#x5173;&#x7cfb;&#x9010;&#x6e10;&#x88ab;&#x63ed;&#x793a;&#x3002;&#x8fd9;&#x4e9b;&#x53d1;&#x73b0;&#x4e3a;&#x4e34;&#x5e8a;&#x51b3;&#x7b56;&#x63d0;&#x4f9b;&#x4e86;&#x66f4;&#x4e3a;&#x79d1;&#x5b66;&#x7684;&#x4f9d;&#x636e;&#xff0c;&#x4e5f;&#x4fc3;&#x8fdb;&#x4e86;&#x65b0;&#x578b;&#x5371;&#x9669;&#x5206;&#x5c42;&#x6a21;&#x578b;&#x7684;&#x6784;&#x5efa;&#xff0c;&#x63a8;&#x52a8;DCM&#x6cbb;&#x7597;&#x5411;&#x4e2a;&#x6027;&#x5316;&#x3001;&#x7cbe;&#x51c6;&#x5316;&#x65b9;&#x5411;&#x53d1;&#x5c55;&#x3002;&#x8be5;&#x6587;&#x7efc;&#x8ff0;DCM&#x5371;&#x9669;&#x5206;&#x5c42;&#x4e2d;&#x9057;&#x4f20;&#x56e0;&#x7d20;&#x76f8;&#x5173;&#x7684;&#x6700;&#x65b0;&#x7814;&#x7a76;&#x8fdb;&#x5c55;&#xff0c;&#x65e8;&#x5728;&#x4e3a;&#x9884;&#x540e;&#x8bc4;&#x4f30;&#x548c;&#x4e34;&#x5e8a;&#x7ba1;&#x7406;&#x63d0;&#x4f9b;&#x53c2;&#x8003;&#x3002;.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>22</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40825737</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112148-20250528-00402</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40832599</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Nobiletin protected against hypertrophic cardiomyopathy via targeting PPAR&#x3b1;.</ArticleTitle><Pagination><StartPage>1628625</StartPage><MedlinePgn>1628625</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1628625</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2025.1628625</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Hypertrophic cardiomyopathy is an independent risk factor for heart failure. <i>Citrus reticulata</i> (<i>C. reticulata</i>) is a traditional Chinese medicine with a variety of chemical components and pharmacological effects. The mechanisms of <i>C. reticulata</i> for treating hypertrophic cardiomyopathy are still unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this study, we used network pharmacology techniques combined with bioinformatics analysis and identified the active ingredient in <i>C. reticulata</i> to protect against hypertrophic cardiomyopathy. We analyzed the Gene Expression Omnibus (GEO) database from human heart tissue with hypertrophic cardiomyopathy to reveal the potential targets. Finally, molecular docking and <i>in vitro</i> validation were used to reveal the binding of the potential targets and the main active component of <i>C. reticulata</i>.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Our results revealed that there are five main active ingredients of <i>C. reticulata</i> (nobiletin, naringenin, sitosterol, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl) chroman-4-one, and citromitin). By analyzing the intersecting genes between <i>C. reticulata</i> and hypertrophic cardiomyopathy, 40 hub genes were obtained. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis indicated that the responses to oxidative stress and fatty acids were the main pathways for <i>C. reticulata</i> to act against hypertrophic cardiomyopathy. The protein-protein interaction analysis results showed that the main active ingredients of <i>C. reticulata</i> were nobiletin and naringenin, while peroxisome proliferator-activated receptors (PPAR)&#x3b1; might be the potential targets of <i>C. reticulata</i> in treating hypertrophic cardiomyopathy. The molecular docking results showed that the main active ingredient, nobiletin, could bind to PPAR&#x3b1; with a strong hydrogen-bonding interaction force. <i>In vitro</i> results validated that nobiletin might directly bind to PPAR&#x3b1;, thereby increasing the expression of lipid metabolism-related genes and relieving hypertrophic responses of cardiomyocytes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The nuclear receptor PPAR&#x3b1; might be the potential endogenous receptor of the active ingredients of <i>C. reticulata</i>.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Zhou, Chen, Cai, Lian, Wang, Li, Wang, Wu and Wang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Chang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Hexin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lian</LastName><ForeName>Zuqian</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Luping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target &amp; Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qinghuo</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Cancan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Foreign Languages, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiaoqian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target &amp; Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Panxia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target &amp; Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Citrus reticulata</Keyword><Keyword MajorTopicYN="N">PPAR&#x3b1;</Keyword><Keyword MajorTopicYN="N">hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">naringenin</Keyword><Keyword MajorTopicYN="N">nobiletin</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>5</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40832599</ArticleId><ArticleId IdType="pmc">PMC12358417</ArticleId><ArticleId IdType="doi">10.3389/fphar.2025.1628625</ArticleId><ArticleId IdType="pii">1628625</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angola B., Botswana B. F., Burundi C. V. Cameroon (2023). World health statistics 2023: monitoring health for the SDGs. Sustain. Dev. Goals.</Citation></Reference><Reference><Citation>Bai Y., Zheng J.-P., Lu F., Zhang X.-L., Sun C.-P., Guo W.-H., et al. (2022). Prevalence, incidence and mortality of hypertrophic cardiomyopathy based on a population cohort of 21.9 million in China. Sci. Rep. 12 (1), 18799. 10.1038/s41598-022-20042-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-20042-9</ArticleId><ArticleId IdType="pmc">PMC9637201</ArticleId><ArticleId IdType="pubmed">36335106</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Zhong J., Wang L.-l., Chen Y.-y. (2021). Mitochondrial transfer in cardiovascular disease: from mechanisms to therapeutic implications. Front. Cardiovasc. Med. 8, 771298. 10.3389/fcvm.2021.771298</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.771298</ArticleId><ArticleId IdType="pmc">PMC8661009</ArticleId><ArticleId IdType="pubmed">34901230</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornell W. D., Cieplak P., Bayly C. I., Gould I. R., Merz K. M., Ferguson D. M., et al. (1996). A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117 (19), 5179&#x2013;5197. 10.1021/ja955032e</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja955032e</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Dalt L., Cabodevilla A. G., Goldberg I. J., Norata G. D. (2023). Cardiac lipid metabolism, mitochondrial function, and heart failure. Cardiovasc Res. 119 (10), 1905&#x2013;1914. 10.1093/cvr/cvad100</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvad100</ArticleId><ArticleId IdType="pmc">PMC10681665</ArticleId><ArticleId IdType="pubmed">37392421</ArticleId></ArticleIdList></Reference><Reference><Citation>Dungu J. N., Hardy-Wallace A., Dimarco A. D., Savage H. O. (2024). Hypertrophic cardiomyopathy. Curr. Heart Fail Rep. 21 (4), 428&#x2013;438. 10.1007/s11897-024-00654-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11897-024-00654-0</ArticleId><ArticleId IdType="pubmed">38488965</ArticleId></ArticleIdList></Reference><Reference><Citation>Fougerat A., Bruse J., Polizzi A., Montagner A., Guillou H., Wahli W. (2024). Lipid sensing by PPAR&#x3b1;: role in controlling hepatocyte gene regulatory networks and the metabolic response to fasting. Prog. Lipid Res. 96, 101303. 10.1016/j.plipres.2024.101303</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2024.101303</ArticleId><ArticleId IdType="pubmed">39521352</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan X., Shu Z., Yan D., Li J., Ofaim S., Albert R., et al. (2023). Network medicine framework reveals generic herbsymptom effectiveness of traditional Chinese medicine. Sci. Adv. 9, eadh0215. 10.1126/sciadv.adh0215</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.adh0215</ArticleId><ArticleId IdType="pmc">PMC10610911</ArticleId><ArticleId IdType="pubmed">37889962</ArticleId></ArticleIdList></Reference><Reference><Citation>Grevengoed T. J., Klett E. L., Coleman R. A. (2014). Acyl-CoA metabolism and partitioning. Annu. Rev. Nutr. 34 (1), 1&#x2013;30. 10.1146/annurev-nutr-071813-105541</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-nutr-071813-105541</ArticleId><ArticleId IdType="pmc">PMC5881898</ArticleId><ArticleId IdType="pubmed">24819326</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y. H., Moon H. J., You B. R., Park W. H. (2009). The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol. Rep. 22 (1), 215&#x2013;221. 10.3892/or_00000427</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or_00000427</ArticleId><ArticleId IdType="pubmed">19513526</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Li W., Sun H., Guo X., Zhou Y., Liu J., et al. (2024). Mitochondrial transfer in the progression and treatment of cardiac disease. Life Sci. 358, 123119. 10.1016/j.lfs.2024.123119</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2024.123119</ArticleId><ArticleId IdType="pubmed">39395616</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S., Pulikuri S., Zhu Y., Qi C., Kanwar Y. S., Yeldandi A. V., et al. (1998). Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am. J. Pathol. 153 (2), 349&#x2013;354. 10.1016/s0002-9440(10)65577-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9440(10)65577-0</ArticleId><ArticleId IdType="pmc">PMC1852994</ArticleId><ArticleId IdType="pubmed">9708794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke Z., Fan C., Li J., Wang L., Li H., Tian W., et al. (2023). Nobiletin Intake attenuates hepatic lipid profiling and oxidative stress in HFD-Induced nonalcoholic-fatty-liver-disease mice. Molecules 28 (6), 2570. 10.3390/molecules28062570</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28062570</ArticleId><ArticleId IdType="pmc">PMC10054910</ArticleId><ArticleId IdType="pubmed">36985541</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo Y. E., Song J., Bae S. (2018). Use of plant and herb derived medicine for therapeutic usage in cardiology. Medicines 5 (2), 38. 10.3390/medicines5020038</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines5020038</ArticleId><ArticleId IdType="pmc">PMC6023439</ArticleId><ArticleId IdType="pubmed">29690545</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieger E., Koraimann G., Vriend G. (2002). Increasing the precision of comparative models with YASARA NOVA--a self-parameterizing force field. Proteins 47 (3), 393&#x2013;402. 10.1002/prot.10104</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.10104</ArticleId><ArticleId IdType="pubmed">11948792</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieger E., Vriend G. (2015). New ways to boost molecular dynamics simulations. J. Comput. Chem. 36 (13), 996&#x2013;1007. 10.1002/jcc.23899</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.23899</ArticleId><ArticleId IdType="pmc">PMC6680170</ArticleId><ArticleId IdType="pubmed">25824339</ArticleId></ArticleIdList></Reference><Reference><Citation>Legchenko E., Chouvarine P., Borchert P., Fernandez-Gonzalez A., Snay E., Meier M., et al. (2018). PPAR&#x3b3; agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci. Transl. Med. 10, eaao0303. 10.1126/scitranslmed.aao0303</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aao0303</ArticleId><ArticleId IdType="pubmed">29695452</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu E. H., Zhao P., Duan L., Zheng G.-D., Guo L., Yang H., et al. (2013). Simultaneous determination of six bioactive flavonoids in Citri Reticulatae Pericarpium by rapid resolution liquid chromatography coupled with triple quadrupole electrospray tandem mass spectrometry. Food Chem. 141 (4), 3977&#x2013;3983. 10.1016/j.foodchem.2013.06.077</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2013.06.077</ArticleId><ArticleId IdType="pubmed">23993574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirza A. Z., Althagafi I. I., Shamshad H. (2019). Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications. Eur. J. Med. Chem. 166, 502&#x2013;513. 10.1016/j.ejmech.2019.01.067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.01.067</ArticleId><ArticleId IdType="pubmed">30739829</ArticleId></ArticleIdList></Reference><Reference><Citation>Montminy M. R., Gonzalez G. A., Yamamoto K. K. (1990). Regulation of cAMP-inducible genes by CREB. Trends Neurosci. 13 (5), 184&#x2013;188. 10.1016/0166-2236(90)90045-c</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-2236(90)90045-c</ArticleId><ArticleId IdType="pubmed">1693237</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray C. J. L. (2022). The Global Burden of Disease Study at 30 years. Nat. Med. 28 (10), 2019&#x2013;2026. 10.1038/s41591-022-01990-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01990-1</ArticleId><ArticleId IdType="pubmed">36216939</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa Y., Nishikimi T., Kuwahara K. (2019). Atrial and brain natriuretic peptides: hormones secreted from the heart. Peptides 111, 18&#x2013;25. 10.1016/j.peptides.2018.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2018.05.012</ArticleId><ArticleId IdType="pubmed">29859763</ArticleId></ArticleIdList></Reference><Reference><Citation>Noordali H., Loudon B. L., Frenneaux M. P., Madhani M. (2018). Cardiac metabolism &#x2014; a promising therapeutic target for heart failure. Pharmacol. Ther. 182, 95&#x2013;114. 10.1016/j.pharmthera.2017.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2017.08.001</ArticleId><ArticleId IdType="pubmed">28821397</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J., Meng L., Li R., Wang Z., Yuan W., Li Y., et al. (2024). Naringenin protects against septic cardiomyopathy in mice by targeting HIF-1&#x3b1;. Biochem. Biophys. Res. Commun. 704, 149613. 10.1016/j.bbrc.2024.149613</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2024.149613</ArticleId><ArticleId IdType="pubmed">38387325</ArticleId></ArticleIdList></Reference><Reference><Citation>Previs M. J., O&#x2019;Leary T. S., Morley M. P., Palmer B. M., LeWinter M., Yob J. M., et al. (2022). Defects in the proteome and metabolome in human hypertrophic cardiomyopathy. Circ.:Heart Fail. 15 (6), e009521. 10.1161/circheartfailure.121.009521</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circheartfailure.121.009521</ArticleId><ArticleId IdType="pmc">PMC9708114</ArticleId><ArticleId IdType="pubmed">35543134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan V., Pace B. S. (2011). Regulation of &#x3b3;-globin gene expression involves signaling through the p38 MAPK/CREB1 pathway. Blood Cells Mol. Dis. 47 (1), 12&#x2013;22. 10.1016/j.bcmd.2011.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcmd.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3695476</ArticleId><ArticleId IdType="pubmed">21497119</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbarvaziri S., Kooiker K. B., Ellenberger M., Fajardo G., Zhao M., Roest A. S. V., et al. (2021). Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy. Circulation 144 (21), 1714&#x2013;1731. 10.1161/circulationaha.121.053575</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.121.053575</ArticleId><ArticleId IdType="pmc">PMC8608736</ArticleId><ArticleId IdType="pubmed">34672721</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio-Ru&#xed;z M. E., Plata-Corona J. C., Soria-Castro E., D&#xed;az-Ju&#xe1;rez J. A., S&#xe1;nchez-Aguilar M. (2024). Pleiotropic effects of peroxisome proliferator-activated receptor alpha and gamma agonists on myocardial damage: molecular mechanisms and clinical evidence&#x2014;A narrative review. Cells 13 (17), 1488. 10.3390/cells13171488</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells13171488</ArticleId><ArticleId IdType="pmc">PMC11394383</ArticleId><ArticleId IdType="pubmed">39273057</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlittler M., Pramstaller P. P., Rossini A., De Bortoli M. (2023). Myocardial fibrosis in hypertrophic cardiomyopathy: a perspective from fibroblasts. Int. J. Mol. Sci. 24 (19), 14845. 10.3390/ijms241914845</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241914845</ArticleId><ArticleId IdType="pmc">PMC10573356</ArticleId><ArticleId IdType="pubmed">37834293</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastian S. A., Panthangi V., Singh K., Rayaroth S., Gupta A., Shantharam D., et al. (2023). Hypertrophic cardiomyopathy: current treatment and future options. Curr. Probl. Cardiol. 48 (4), 101552. 10.1016/j.cpcardiol.2022.101552</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2022.101552</ArticleId><ArticleId IdType="pubmed">36529236</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorbagi M., Fayek N. M., Shao P., Farag M. A. (2022). Citrus reticulata blanco (the common mandarin) fruit: an updated review of its bioactive, extraction types, food quality, therapeutic merits, and bio-waste valorization practices to maximize its economic value. Food Biosci. 47, 101699. 10.1016/j.fbio.2022.101699</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fbio.2022.101699</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan J., Zhang Z., Wu C., Tian S., Zang Y., Jin G., et al. (2023). Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456. Signal Transduct. Target. Ther. 8 (1), 414. 10.1038/s41392-023-01660-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01660-9</ArticleId><ArticleId IdType="pmc">PMC10587311</ArticleId><ArticleId IdType="pubmed">37857609</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Gao F., Hu F., Wu J. (2022a). Nobiletin alleviates astrocyte activation and oxidative stress induced by hypoxia In Vitro. Molecules 27 (6), 1962. 10.3390/molecules27061962</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27061962</ArticleId><ArticleId IdType="pmc">PMC8953234</ArticleId><ArticleId IdType="pubmed">35335325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Cai Y., Jian L., Cheung C. W., Zhang L., Xia Z. (2021). Impact of peroxisome proliferator-activated receptor-&#x3b1; on diabetic cardiomyopathy. Cardiovasc. Diabetol. 20 (1), 2. 10.1186/s12933-020-01188-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-01188-0</ArticleId><ArticleId IdType="pmc">PMC7783984</ArticleId><ArticleId IdType="pubmed">33397369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Wang J., Yao K., Wang S., Nie M., Zhao Y., et al. (2022b). Metabolic characterization of hypertrophic cardiomyopathy in human heart. Nat. Cardiovasc. Res. 1 (5), 445&#x2013;461. 10.1038/s44161-022-00057-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44161-022-00057-1</ArticleId><ArticleId IdType="pubmed">39195941</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Ma Y., Xu Q., Shikov A. N., Pozharitskaya O. N., Flisyuk E. V., et al. (2023). Flavonoids and saponins: what have we got or missed? Phytomedicine 109, 154580. 10.1016/j.phymed.2022.154580</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2022.154580</ArticleId><ArticleId IdType="pubmed">36610132</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijnker P. J. M., Dinani R., van der Laan N. C., Alg&#xfc;l S., Knollmann B. C., Verkerk A. O., et al. (2024). Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium&#x2013;glucose cotransporter 2 inhibitors. Cardiovasc. Res. 120 (3), 301&#x2013;317. 10.1093/cvr/cvae004</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvae004</ArticleId><ArticleId IdType="pmc">PMC10939456</ArticleId><ArticleId IdType="pubmed">38240646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Zheng D., Qin Y., Liu Z., Zhang G., Zhu X., et al. (2017). Nobiletin attenuates adverse cardiac remodeling after acute myocardial infarction in rats via restoring autophagy flux. Biochem. Biophys. Res. Commun. 492 (2), 262&#x2013;268. 10.1016/j.bbrc.2017.08.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.08.064</ArticleId><ArticleId IdType="pubmed">28830813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahya S. A., Al-Shawi N. N. (2024). Hepatoprotective effect of nobiletin against 5-fluorouracil induce hepatotoxicity. Curr. Res. Pharmacol. Drug Discov. 7, 100199. 10.1016/j.crphar.2024.100199</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crphar.2024.100199</ArticleId><ArticleId IdType="pmc">PMC11474214</ArticleId><ArticleId IdType="pubmed">39411523</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y., Tang D., Chen M., Huang X., Zhang G., Zeng L., et al. (2023). SRplot: a free online platform for data visualization and graphing. PLoS One 18 (11), e0294236. 10.1371/journal.pone.0294236</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0294236</ArticleId><ArticleId IdType="pmc">PMC10635526</ArticleId><ArticleId IdType="pubmed">37943830</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y., Yuan H., Wang C., Pattabiraman N., Rao M., Pestell R. G., et al. (2006). 3-Phosphoinositide-Dependent protein Kinase-1 activates the peroxisome proliferator-activated Receptor-&#x3b3; and promotes adipocyte differentiation. Mol. Endocrinol. 20 (2), 268&#x2013;278. 10.1210/me.2005-0197</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2005-0197</ArticleId><ArticleId IdType="pubmed">16150867</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X., Sun S., Guo Y., Liu Y., Yang D., Li G., et al. (2018). Citri reticulatae pericarpium (Chenpi): Botany, ethnopharmacology, phytochemistry, and pharmacology of a frequently used traditional Chinese medicine. J. Ethnopharmacol. 220, 265&#x2013;282. 10.1016/j.jep.2018.03.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2018.03.031</ArticleId><ArticleId IdType="pubmed">29628291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Qiu H., Huang J., Ding S., Huang B., Zhou P., et al. (2019). EETs/PPARs activation together mediates the preventive effect of naringenin in high glucose-induced cardiomyocyte hypertrophy. Biomed. Pharmacother. 109, 1498&#x2013;1505. 10.1016/j.biopha.2018.10.176</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.10.176</ArticleId><ArticleId IdType="pubmed">30551401</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N., Wen-Ying W., Yang Z., Che Y., Jin Y.-G., Liao H.-H., et al. (2017). Nobiletin, a polymethoxy flavonoid, protects against cardiac hypertrophy induced by pressure-overload via inhibition of NAPDH oxidases and endoplasmic reticulum stress. Cell. Physiol. Biochem. 42 (4), 1313&#x2013;1325. 10.1159/000478960</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000478960</ArticleId><ArticleId IdType="pubmed">28700997</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Luo P., Chen J., Yang C., Xia F., Zhang J., et al. (2022). Dissection of targeting molecular mechanisms of aristolochic acid-induced nephrotoxicity via a combined deconvolution strategy of chemoproteomics and metabolomics. Int. J. Biol. Sci. 18 (5), 2003&#x2013;2017. 10.7150/ijbs.69618</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.69618</ArticleId><ArticleId IdType="pmc">PMC8935225</ArticleId><ArticleId IdType="pubmed">35342337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L., Gu W., Kui F., Gao F., Niu Y., Li W., et al. (2021). The mechanism and candidate compounds of aged citrus peel (chenpi) preventing chronic obstructive pulmonary disease and its progression to lung cancer. Food Nutr. Res. 65. 10.29219/fnr.v65.7526</Citation><ArticleIdList><ArticleId IdType="doi">10.29219/fnr.v65.7526</ArticleId><ArticleId IdType="pmc">PMC8254466</ArticleId><ArticleId IdType="pubmed">34262419</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J., Wang J., Ye W., Lu J., Li C., Zhang D., et al. (2022). Citri reticulatae pericarpium (Chenpi): a multi-efficacy pericarp in treating cardiovascular diseases. Biomed. Pharmacother. 154, 113626. 10.1016/j.biopha.2022.113626</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113626</ArticleId><ArticleId IdType="pubmed">36058153</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Y., Song L., Wang Z., Ma A., Liu T., Gu H., et al. (2004). Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am. J. Med. 116(1):14&#x2013;18. 10.1016/j.amjmed.2003.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2003.05.009</ArticleId><ArticleId IdType="pubmed">14706660</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840763</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2615</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Trends in cardiovascular medicine</Title><ISOAbbreviation>Trends Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Inflammatory Cardiomyopathy Framing the Invisible in Precision Medicine.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1050-1738(25)00110-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tcm.2025.08.006</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsch&#xf6;pe</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Deutsches Herzzentrum der Charit&#xe9;, Klinik f&#xfc;r Kardiologie, Angiologie und Intensivmedizin, Augustenburger Platz 1, 13353, Berlin, Germany; Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Charit&#xe9;platz 1, 10117, Berlin, Germany; DZHK (German Centre for Cardiovascular Research) partner site Berlin, Berlin, Germany; Berlin Institute of Health at Charit&#xe9; / BCRT - Universit&#xe4;tsmedizin Berlin, Charit&#xe9;platz 1, 10117, Berlin, Germany. Electronic address: Carsten.tschoepe@dhzc-charite.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Trends Cardiovasc Med</MedlineTA><NlmUniqueID>9108337</NlmUniqueID><ISSNLinking>1050-1738</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Genetic</Keyword><Keyword MajorTopicYN="N">Inflammatory Cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Myocarditis</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>19</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840763</ArticleId><ArticleId IdType="doi">10.1016/j.tcm.2025.08.006</ArticleId><ArticleId IdType="pii">S1050-1738(25)00110-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840785</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-1740</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Progress in cardiovascular diseases</Title><ISOAbbreviation>Prog Cardiovasc Dis</ISOAbbreviation></Journal><ArticleTitle>Fabry disease cardiomyopathy: A state-of-the-art review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0033-0620(25)00114-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pcad.2025.08.003</ELocationID><Abstract><AbstractText>Fabry disease or Anderson-Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of &#x3b1;-galactosidase A (GLA), leading to systemic accumulation of globotriaosyl-ceramide (Gb3). Initially described in 1898 as a dermatological condition, Fabry disease is now recognized as a progressive multisystem disorder with significant cardiac involvement. Cardiomyopathy in Fabry disease arises from Gb3 accumulation in cardiac tissue, resulting in structural changes such as fibrosis and left ventricular hypertrophy (LVH), and functional impairments including diastolic dysfunction and heart failure. The deacylated derivative, lysoGb3, serves as a biomarker of cardiac involvement. Diagnosis relies on enzyme assays, genetic testing, and advanced cardiac imaging modalities like echocardiography and cardiac MRI. Management strategies are centered around enzyme replacement therapy, and prognosis varies due to phenotypic heterogeneity and severity of disease progression. Psychological and social burdens further complicate patient care. However, underdiagnosis remains a concerning issue, particularly in individuals with unexplained cardiomyopathies. Early recognition through increased clinical awareness and genetic screening is crucial for timely intervention. Ongoing research is essential to develop new therapies targeting the genetic and metabolic roots of the disease. This systematic review comprehensively examines current evidence regarding the mechanisms, diagnosis, treatment, and prognosis of cardiomyopathy associated with Fabry disease, providing insight that may enhance clinical practice and guide future research initiatives.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pande</LastName><ForeName>Shivangi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Albert Einstein College of Medicine, New York City, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varzideh</LastName><ForeName>Fahimeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine, Albert Einstein College of Medicine, New York City, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gambardella</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Albert Einstein College of Medicine, New York City, NY 10461, USA; International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit, Department of Advanced Biomedical Sciences, "Federico II" University, Naples 80131, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankauskas</LastName><ForeName>Stanislovas S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Albert Einstein College of Medicine, New York City, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerasuolo</LastName><ForeName>Federica Andrea</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Albert Einstein College of Medicine, New York City, NY 10461, USA; International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit, Department of Advanced Biomedical Sciences, "Federico II" University, Naples 80131, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit, Department of Advanced Biomedical Sciences, "Federico II" University, Naples 80131, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kansakar</LastName><ForeName>Urna</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Medicine, Albert Einstein College of Medicine, New York City, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Luca</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Albert Einstein College of Medicine, New York City, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurland</LastName><ForeName>Irwin J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Albert Einstein College of Medicine, New York City, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidoli</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Department of Genetics, Albert Einstein College of Medicine, New York City, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iaccarino</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine and Surgery, "Federico II" University, Naples 80131, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadoshima</LastName><ForeName>Junichi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, Rutgers-New Jersey Medical School, 185 South Orange Ave, Newark, NJ 07103, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santulli</LastName><ForeName>Gaetano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, Albert Einstein College of Medicine, New York City, NY 10461, USA; International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit, Department of Advanced Biomedical Sciences, "Federico II" University, Naples 80131, Italy; Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Neuroimmunology and Inflammation (INI), Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York City, NY 10461, USA. Electronic address: gaetano.santulli@einsteinmed.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prog Cardiovasc Dis</MedlineTA><NlmUniqueID>0376442</NlmUniqueID><ISSNLinking>0033-0620</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anderson-Fabry disease</Keyword><Keyword MajorTopicYN="N">Diastolic Dysfunction</Keyword><Keyword MajorTopicYN="N">Lysosomes</Keyword><Keyword MajorTopicYN="N">Mitochondria</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>19</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840785</ArticleId><ArticleId IdType="doi">10.1016/j.pcad.2025.08.003</ArticleId><ArticleId IdType="pii">S0033-0620(25)00114-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40846385</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>24</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Nonischemic Cardiomyopathy in Adult-Onset PPA2-Deficient Mitochondrial Disease.</ArticleTitle><Pagination><StartPage>104676</StartPage><MedlinePgn>104676</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.104676</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)01456-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nonischemic cardiomyopathy (NICM) can be caused by single-gene mutations, including genes such as inorganic pyrophosphatase 2 (PPA2) with multisystem effects.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 28-year-old woman presenting with respiratory symptoms was discharged with a diagnosis of decompensated idiopathic NICM. Her NICM progressively worsened, and the patient underwent a heart transplant at the age of 38 and again at the age of 42. At age 47, genetic testing confirmed 2 mutations in the PPA2 gene that had caused her NICM.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This patient is to our knowledge the oldest published to date (48 years) presenting with cardiac symptoms who has PPA2 deficiency, a mitochondrial disease characterized by sudden cardiac death in infancy.</AbstractText><AbstractText Label="TAKE-HOME MESSAGE" NlmCategory="CONCLUSIONS">This case exemplifies the utility of employing genetic testing early in the diagnostic workup of NICM before applying the designation "idiopathic."</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Th&#xe9;berge</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Medical Genetics, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Code</LastName><ForeName>Jillianne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Education, Department of Curriculum and Pedagogy, University of British Columbia, Vancouver, Canada; HeartLife Foundation of Canada, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoo</LastName><ForeName>John K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Chi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ignaszewski</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Virani</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toma</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roston</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlak</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehman</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Medical Genetics, University of British Columbia, Vancouver, Canada. Electronic address: anna.lehman@vch.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PPA2</Keyword><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">mitochondrial disease</Keyword><Keyword MajorTopicYN="N">monogenic</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures Dr Roston has received honoraria from Cardurion Pharma and Solid Biosciences (advisory board). Dr Sedlak has received honoraria for speaking engagements and advisory boards from Eli-Lilly, Novo Nordisk, Novartis, KYE Pharmaceuticals, Amgen, Sanofi, Pfizer, Bayer, Pendopharm, CCRN, and CPD Network. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846385</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.104676</ArticleId><ArticleId IdType="pii">S2666-0849(25)01456-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40825735</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0253-3758</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Zhonghua xin xue guan bing za zhi</Title><ISOAbbreviation>Zhonghua Xin Xue Guan Bing Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[A case of acromegalic cardiomyopathy with progressive cardiac enlargement].</ArticleTitle><Pagination><StartPage>934</StartPage><EndPage>938</EndPage><MedlinePgn>934-938</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112148-20250624-00468</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Q Y</ForeName><Initials>QY</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Hospital of Lanzhou University, Gansu Provincial Clinical Medical Research Center for Cardiovascular Diseases, Lanzhou 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Hospital of Lanzhou University, Gansu Provincial Clinical Medical Research Center for Cardiovascular Diseases, Lanzhou 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Z X</ForeName><Initials>ZX</Initials><AffiliationInfo><Affiliation>Department of Radiology, First Hospital of Lanzhou University, Lanzhou 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Y H</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Echocardiography Room of Department of Cardiology, First Hospital of Lanzhou University, Lanzhou 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Radiology, First Hospital of Lanzhou University, Lanzhou 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Hospital of Lanzhou University, Gansu Provincial Clinical Medical Research Center for Cardiovascular Diseases, Lanzhou 730000, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Xin Xue Guan Bing Za Zhi</MedlineTA><NlmUniqueID>7910682</NlmUniqueID><ISSNLinking>0253-3758</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="chi"><AbstractText>&#x8be5;&#x6587;&#x62a5;&#x9053;1&#x4f8b;&#x80a2;&#x7aef;&#x80a5;&#x5927;&#x75c7;&#xff08;&#x5782;&#x4f53;&#x817a;&#x7624;&#x578b;&#xff09;&#x6027;&#x5fc3;&#x808c;&#x75c5;&#x60a3;&#x8005;&#xff0c;&#x56e0;&#x53cd;&#x590d;&#x5fc3;&#x529b;&#x8870;&#x7aed;&#x52a0;&#x91cd;&#x591a;&#x6b21;&#x5c31;&#x8bca;&#xff0c;&#x7ecf;&#x89c4;&#x8303;&#x7684;&#x836f;&#x7269;&#x548c;&#x5668;&#x68b0;&#x6cbb;&#x7597;&#x540e;&#x4ecd;&#x8868;&#x73b0;&#x4e3a;&#x5fc3;&#x810f;&#x8fdb;&#x884c;&#x6027;&#x589e;&#x5927;&#xff0c;&#x4ee5;&#x671f;&#x4e3a;&#x4e34;&#x5e8a;&#x80a2;&#x7aef;&#x80a5;&#x5927;&#x75c7;&#x6027;&#x5fc3;&#x808c;&#x75c5;&#x6240;&#x81f4;&#x5fc3;&#x529b;&#x8870;&#x7aed;&#x60a3;&#x8005;&#x7684;&#x8bca;&#x6cbb;&#x63d0;&#x4f9b;&#x7ecf;&#x9a8c;&#x3002;.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>22</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40825735</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112148-20250624-00468</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40831768</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-4497</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Federal practitioner : for the health care professionals of the VA, DoD, and PHS</Title><ISOAbbreviation>Fed Pract</ISOAbbreviation></Journal><ArticleTitle>Importance of Recognizing Hypertrophic Cardiomyopathy in the Preoperative Clinic.</ArticleTitle><Pagination><StartPage>166</StartPage><EndPage>170</EndPage><MedlinePgn>166-170</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12788/fp.0567</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Hypertrophic cardiomyopathy is a relatively common inherited disorder that may be asymptomatic. It is a common cause of sudden cardiac death and can lead to catastrophic cardiovascular collapse in the operating room if previously undiagnosed. This case report discusses the implications of unsuspected hypertrophic cardiomyopathy for anesthesia management.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="UNASSIGNED">A veteran aged 55 years presented to the preadmission testing clinic prior to undergoing outpatient surveillance colonoscopy under anesthesia. His initial medical history was unremarkable. On physical examination, a murmur with benign characteristics was detected. However, further evaluation with echocardiography, revealed severe hypertrophic obstructive cardiomyopathy. The patient was ultimately referred for septal myectomy consideration.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Hypertrophic cardiomyopathy is a relatively common disorder that often remains undiagnosed. This condition has critical implications for preoperative evaluation, as patients with this disorder may develop sudden, unexpected, and refractory hypotension upon induction of anesthesia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Frontline Medical Communications Inc., Parsippany, NJ, USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Botti</LastName><ForeName>Anne McRae</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Chalmers P. Wylie VA Ambulatory Care Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bope</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Chalmers P. Wylie VA Ambulatory Care Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botti</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Chalmers P. Wylie VA Ambulatory Care Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brower</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chalmers P. Wylie VA Ambulatory Care Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wada</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>OhioHealth, Columbus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arensman</LastName><ForeName>Meredith</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chalmers P. Wylie VA Ambulatory Care Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Fed Pract</MedlineTA><NlmUniqueID>9500574</NlmUniqueID><ISSNLinking>1078-4497</ISSNLinking></MedlineJournalInfo><CoiStatement>Author disclosures: The authors report no actual or potential conflicts of interest with regard to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40831768</ArticleId><ArticleId IdType="pmc">PMC12360806</ArticleId><ArticleId IdType="doi">10.12788/fp.0567</ArticleId><ArticleId IdType="pii">fp-42-04-166</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cheng Z, Fang T, Huang J, Guo Y, Alam M, Qian H. Hypertrophic cardiomyopathy: from phenotype and pathogenesis to treatment. Front Cardiovasc Med. 2021;8:722340. doi: 10.3389/fcvm.2021.722340.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.722340</ArticleId><ArticleId IdType="pmc">PMC8572854</ArticleId><ArticleId IdType="pubmed">34760939</ArticleId></ArticleIdList></Reference><Reference><Citation>Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249&#x2013;1254. doi: 10.1016/j.jacc.2015.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.01.019</ArticleId><ArticleId IdType="pubmed">25814232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley N, Dietrich J, Nyhan D, Mitter N, Yee MS, Brady M. Hypertrophic cardiomyopathy: a review. Anesth Analg. 2015;120(3):554&#x2013;569. doi: 10.1213/ANE.0000000000000538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000000538</ArticleId><ArticleId IdType="pubmed">25695573</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(4):372&#x2013;389. doi: 10.1016/j.jacc.2021.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.12.002</ArticleId><ArticleId IdType="pubmed">35086660</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorda P, Garcia-Alvarez A. Hypertrophic cardiomyopathy: sudden cardiac death risk stratification in adults. Glob Cardiol Sci Pract. 2018;3(25) doi: 10.21542/gcsp.2018.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.21542/gcsp.2018.25</ArticleId><ArticleId IdType="pmc">PMC6209451</ArticleId><ArticleId IdType="pubmed">30393637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis. 1985;28(1)(85):1&#x2013;83. 90024&#x2013;6. doi: 10.1016/0033-0620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0033-0620</ArticleId><ArticleId IdType="pubmed">3160067</ArticleId></ArticleIdList></Reference><Reference><Citation>Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778&#x2013;1785. doi: 10.1056/NEJM200006153422403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200006153422403</ArticleId><ArticleId IdType="pubmed">10853000</ArticleId></ArticleIdList></Reference><Reference><Citation>Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet. 2017;389(10075)(16):1253&#x2013;1267. 31321&#x2013;6. doi: 10.1016/S0140-6736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736</ArticleId><ArticleId IdType="pubmed">27912983</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowin EJ, Maron BJ, Appelbaum E, et al. Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. Am J Cardiol. 2012;110(7):1027&#x2013;1032. doi: 10.1016/j.amjcard.2012.05.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2012.05.035</ArticleId><ArticleId IdType="pubmed">22809754</ArticleId></ArticleIdList></Reference><Reference><Citation>Losi MA, Nistri S, Galderisi M, et al. Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound. 2010;8(7) doi: 10.1186/1476-7120-8-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-7120-8-7</ArticleId><ArticleId IdType="pmc">PMC2848131</ArticleId><ArticleId IdType="pubmed">20236538</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Z, Li L, Li X, et al. Effect of mavacamten on chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial. JAMA Cardiol. 2023;8(10):957&#x2013;965. doi: 10.1001/jamacardio.2023.3030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2023.3030</ArticleId><ArticleId IdType="pmc">PMC10463173</ArticleId><ArticleId IdType="pubmed">37639259</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang J, Liu Y, Zhu Y, et al. First-in-human transapical beating-heart septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2023;82(7):575&#x2013;586. doi: 10.1016/j.jacc.2023.05.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.05.052</ArticleId><ArticleId IdType="pubmed">37558369</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain P, Patel PA, Fabbro M., 2nd Hypertrophic cardiomyopathy and left ventricular outflow tract obstruction: expecting the unexpected. J Cardiothorac Vasc Anesth. 2018;32(1):467&#x2013;477. doi: 10.1053/j.jvca.2017.04.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2017.04.054</ArticleId><ArticleId IdType="pubmed">28967624</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliac LC, Barron ME, Maron BJ. Hypertrophic cardiomyopathy. Anesthesiology. 2006;104(1):183&#x2013;192. doi: 10.1097/00000542-200601000-00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200601000-00025</ArticleId><ArticleId IdType="pubmed">16394705</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40831067</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1520-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Diabetes/metabolism research and reviews</Title><ISOAbbreviation>Diabetes Metab Res Rev</ISOAbbreviation></Journal><ArticleTitle>Established and Emerging Roles of Epigenetic Regulation in Diabetic Cardiomyopathy.</ArticleTitle><Pagination><StartPage>e70081</StartPage><MedlinePgn>e70081</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70081</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/dmrr.70081</ELocationID><Abstract><AbstractText>An increasing number of individuals are at high risk of type 2 diabetes (T2DM) and its cardiovascular (CV) complications, which challenges healthcare systems with an increased risk of developing CV diseases. Patients with T2DM exhibit a unique cardiac phenotype termed diabetic cardiomyopathy (DCM). DCM usually involves complex and multifactorial pathogenic drivers, including myocardial inflammation, fibrosis, hypertrophy, and early diastolic dysfunction, which potentially evolve into systolic dysfunction and heart failure. There is a lack of effective treatments for DCM on the basis of the complexity of the disease per se and poor understanding of the mechanisms behind disease development and progression. Despite the considerable research attention on the onset of DCM development and progression, understanding of the full spectrum of pathogenic mechanisms has not yet been fully deciphered. Epigenetic alterations, including DNA methylation, histone modifications, bromodomain extra-terminal (BET)-containing reader proteins, and RNA-based mechanisms (e.g., miRs, lncRNAs, circRNA), are significantly associated with the initiation and evolution of DCM, particularly in the early stage. In this review, we provide insights into the evidence of epigenetic alterations related to DCM development and progression characteristics. Furthermore, the uniqueness of epigenetic changes in DCM in specific cell types within diabetic hearts is discussed. We also review epigenetic cooperation in the context of DCM development and epigenetic biomarkers related to DCM progression. With recent advancements in technology, epitranscriptomics-related to DCM has been uniquely discussed. Finally, this review may provide new avenues for potential implications for future research and the discovery of novel treatment targets for preventing the onset and progression of DCM.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Diabetes/Metabolism Research and Reviews published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Russell-Hallinan</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karuna</LastName><ForeName>Narainrit</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4050-7469</Identifier><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lezoualc'h</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Metabolic and Cardiovascular Disease, INSERM, University Toulouse III-Paul Sabatier, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matullo</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Hana</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Diabetes and Complications Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernard</LastName><ForeName>Monique</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Aix-Marseille University, CNRS, CRMBM, Facult&#xe9; de M&#xe9;decine, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devaux</LastName><ForeName>Yvan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badimon</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilahur</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rieusset</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratoire CarMeN, UMR INSERM U1060/INRA U1397, Universit&#xe9; Claude Bernard Lyon1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derumeaux</LastName><ForeName>Genevi&#xe8;ve A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Physiology, INSERM U955, Universit&#xe9; Paris Est Cr&#xe9;teil (UPEC), AP-HP, Henri Mondor Hospital, FHU SENEC, Facult&#xe9; de Sant&#xe9; de Cr&#xe9;teil, Cr&#xe9;teil cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Chris J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-8749-0732</Identifier><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Innovative Medicines Initiative</Agency><Country/></Grant><Grant><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>European Union's Horizon 2020 research and innovation programme and EFPIA</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diabetes Metab Res Rev</MedlineTA><NlmUniqueID>100883450</NlmUniqueID><ISSNLinking>1520-7552</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058065" MajorTopicYN="Y">Diabetic Cardiomyopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="Y">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BET proteins</Keyword><Keyword MajorTopicYN="N">DNA methylation</Keyword><Keyword MajorTopicYN="N">circRNAs</Keyword><Keyword MajorTopicYN="N">diabetic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">epigenetics</Keyword><Keyword MajorTopicYN="N">epitranscriptomics</Keyword><Keyword MajorTopicYN="N">histone modifications</Keyword><Keyword MajorTopicYN="N">lncRNA</Keyword><Keyword MajorTopicYN="N">miRNA</Keyword></KeywordList><CoiStatement>Y.D. holds patents on RNA biomarkers of cardiovascular disease and is a member of the molecular diagnostics company, Firalis SA. C.J.W. holds patents on epigenetic therapy for cardiomyopathy. Other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>1</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40831067</ArticleId><ArticleId IdType="pmc">PMC12365466</ArticleId><ArticleId IdType="doi">10.1002/dmrr.70081</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD 2021 Diabetes Collaborators , &#x201c;Global, Regional, and National Burden of Diabetes From 1990 to 2021, With Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021,&#x201d; Lancet 402, no. 10397 (2023): 203&#x2013;234, 10.1016/s0140-6736(23)01301-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(23)01301-6</ArticleId><ArticleId IdType="pmc">PMC10364581</ArticleId><ArticleId IdType="pubmed">37356446</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2019 Risk Factors Collaborators , &#x201c;Global Burden of 87 Risk Factors in 204 Countries and Territories, 1990&#x2013;2019: A Systematic Analysis for the Global Burden of Disease Study 2019,&#x201d; Lancet 396, no. 10258 (2020): 1223&#x2013;1249, 10.1016/s0140-6736(20)30752-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30752-2</ArticleId><ArticleId IdType="pmc">PMC7566194</ArticleId><ArticleId IdType="pubmed">33069327</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedisheim M., Carcarino E., Vandiedonck C., Roussel R., Gautier J. F., and Venteclef N., &#x201c;Regulation of Inflammation in Diabetes: From Genetics to Epigenomics Evidence,&#x201d; Molecular Metabolism 41 (2020): 101041, 10.1016/j.molmet.2020.101041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2020.101041</ArticleId><ArticleId IdType="pmc">PMC7394913</ArticleId><ArticleId IdType="pubmed">32603690</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertero E., Dudek J., Cochain C., et&#xa0;al., &#x201c;Immuno&#x2010;Metabolic Interfaces in Cardiac Disease and Failure,&#x201d; Cardiovascular Research 118, no. 1 (2022): 37&#x2013;52, 10.1093/cvr/cvab036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvab036</ArticleId><ArticleId IdType="pubmed">33537710</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishi S., Gidding S. S., Reis J. P., et&#xa0;al., &#x201c;Association of Insulin Resistance and Glycemic Metabolic Abnormalities With LV Structure and Function in Middle Age: The CARDIA Study,&#x201d; JACC: Cardiovascular Imaging 10, no. 2 (2017): 105&#x2013;114, 10.1016/j.jcmg.2016.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2016.02.033</ArticleId><ArticleId IdType="pmc">PMC11961232</ArticleId><ArticleId IdType="pubmed">27544896</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannel W. B., Hjortland M., and Castelli W. P., &#x201c;Role of Diabetes in Congestive Heart Failure: The Framingham Study,&#x201d; American Journal of Cardiology 34, no. 1 (1974): 29&#x2013;34, 10.1016/0002-9149(74)90089-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(74)90089-7</ArticleId><ArticleId IdType="pubmed">4835750</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcao&#x2010;Pires I. and Leite&#x2010;Moreira A. F., &#x201c;Diabetic Cardiomyopathy: Understanding the Molecular and Cellular Basis to Progress in Diagnosis and Treatment,&#x201d; Heart Failure Reviews 17, no. 3 (2012): 325&#x2013;344, 10.1007/s10741-011-9257-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-011-9257-z</ArticleId><ArticleId IdType="pubmed">21626163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernande L., Thibault H., Bergerot C., et&#xa0;al., &#x201c;Systolic Myocardial Dysfunction in Patients With Type 2 Diabetes Mellitus: Identification at MR Imaging With Cine Displacement Encoding With Stimulated Echoes,&#x201d; Radiology 265, no. 2 (2012): 402&#x2013;409, 10.1148/radiol.12112571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.12112571</ArticleId><ArticleId IdType="pmc">PMC3480812</ArticleId><ArticleId IdType="pubmed">22929334</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernande L., Bergerot C., Girerd N., et&#xa0;al., &#x201c;Longitudinal Myocardial Strain Alteration Is Associated With Left Ventricular Remodeling in Asymptomatic Patients With Type 2 Diabetes Mellitus,&#x201d; Journal of the American Society of Echocardiography 27, no. 5 (2014): 479&#x2013;488, 10.1016/j.echo.2014.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2014.01.001</ArticleId><ArticleId IdType="pubmed">24508363</ArticleId></ArticleIdList></Reference><Reference><Citation>Poornima I. G., Parikh P., and Shannon R. P., &#x201c;Diabetic Cardiomyopathy: The Search for a Unifying Hypothesis,&#x201d; Circulation Research 98, no. 5 (2006): 596&#x2013;605, 10.1161/01.res.0000207406.94146.c2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.res.0000207406.94146.c2</ArticleId><ArticleId IdType="pubmed">16543510</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper M. E. and El&#x2010;Osta A., &#x201c;Epigenetics: Mechanisms and Implications for Diabetic Complications,&#x201d; Circulation Research 107, no. 12 (2010): 1403&#x2013;1413, 10.1161/circresaha.110.223552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.110.223552</ArticleId><ArticleId IdType="pubmed">21148447</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling C. and Ronn T., &#x201c;Epigenetics in Human Obesity and Type 2 Diabetes,&#x201d; Cell Metabolism 29, no. 5 (2019): 1028&#x2013;1044, 10.1016/j.cmet.2019.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.03.009</ArticleId><ArticleId IdType="pmc">PMC6509280</ArticleId><ArticleId IdType="pubmed">30982733</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte C., Terruzzi I., and Ambrosio G., &#x201c;Metabolic Memory in Diabetes: Permanent Scar, Legacy, or Ongoing Domino Effect?,&#x201d; Cardiovascular Research 118, no. 1 (2022): 4&#x2013;6, 10.1093/cvr/cvab104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvab104</ArticleId><ArticleId IdType="pubmed">33744936</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinsey T. A., Foo R., Anene&#x2010;Nzelu C. G., et&#xa0;al., &#x201c;Emerging Epigenetic Therapies of Cardiac Fibrosis and Remodelling in Heart Failure: From Basic Mechanisms to Early Clinical Development,&#x201d; Cardiovascular Research 118, no. 18 (2023): 3482&#x2013;3498, 10.1093/cvr/cvac142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvac142</ArticleId><ArticleId IdType="pmc">PMC10202443</ArticleId><ArticleId IdType="pubmed">36004821</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Zhao D., Beeraka N. M., et&#xa0;al., &#x201c;A Recent Update on the Epigenetic Repertoire and Chromatin Modifying Therapy in Diabetes Mellitus: A Comprehensive Review,&#x201d; Current Medicinal Chemistry 30, no. 18 (2023): 2020&#x2013;2038, 10.2174/0929867329666220802090446.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867329666220802090446</ArticleId><ArticleId IdType="pubmed">35927905</ArticleId></ArticleIdList></Reference><Reference><Citation>Multhaup M. L., Seldin M. M., Jaffe A. E., et&#xa0;al., &#x201c;Mouse&#x2010;Human Experimental Epigenetic Analysis Unmasks Dietary Targets and Genetic Liability for Diabetic Phenotypes,&#x201d; Cell Metabolism 21, no. 1 (2015): 138&#x2013;149, 10.1016/j.cmet.2014.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2014.12.014</ArticleId><ArticleId IdType="pmc">PMC4340475</ArticleId><ArticleId IdType="pubmed">25565211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie R. H. and Abel E. D., &#x201c;Basic Mechanisms of Diabetic Heart Disease,&#x201d; Circulation Research 126, no. 11 (2020): 1501&#x2013;1525, 10.1161/circresaha.120.315913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.120.315913</ArticleId><ArticleId IdType="pmc">PMC7251974</ArticleId><ArticleId IdType="pubmed">32437308</ArticleId></ArticleIdList></Reference><Reference><Citation>Maack C., Lehrke M., Backs J., et&#xa0;al., &#x201c;Heart Failure and Diabetes: Metabolic Alterations and Therapeutic Interventions: A State&#x2010;of&#x2010;the&#x2010;Art Review From the Translational Research Committee of the Heart Failure Association&#x2010;European Society of Cardiology,&#x201d; European Heart Journal 39, no. 48 (2018): 4243&#x2013;4254, 10.1093/eurheartj/ehy596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy596</ArticleId><ArticleId IdType="pmc">PMC6302261</ArticleId><ArticleId IdType="pubmed">30295797</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinh W., Futh R., Nickl W., et&#xa0;al., &#x201c;Elevated Plasma Levels of TNF&#x2010;Alpha and Interleukin&#x2010;6 in Patients With Diastolic Dysfunction and Glucose Metabolism Disorders,&#x201d; Cardiovascular Diabetology 8, no. 1 (2009): 58, 10.1186/1475-2840-8-58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2840-8-58</ArticleId><ArticleId IdType="pmc">PMC2778641</ArticleId><ArticleId IdType="pubmed">19909503</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z. G., Jin Q., Fan M., et&#xa0;al., &#x201c;Myocardial Remodeling in Diabetic Cardiomyopathy Associated With Cardiac Mast Cell Activation,&#x201d; PLoS One 8, no. 3 (2013): e60827, 10.1371/journal.pone.0060827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0060827</ArticleId><ArticleId IdType="pmc">PMC3612033</ArticleId><ArticleId IdType="pubmed">23556005</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadhav A., Tiwari S., Lee P., and Ndisang J. F., &#x201c;The Heme Oxygenase System Selectively Enhances the Anti&#x2010;Inflammatory Macrophage&#x2010;M2 Phenotype, Reduces Pericardial Adiposity, and Ameliorated Cardiac Injury in Diabetic Cardiomyopathy in Zucker Diabetic Fatty Rats,&#x201d; Journal of Pharmacology and Experimental Therapeutics 345, no. 2 (2013): 239&#x2013;249, 10.1124/jpet.112.200808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.112.200808</ArticleId><ArticleId IdType="pubmed">23442249</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermann D., Rutschow S., Van Linthout S., et&#xa0;al., &#x201c;Inhibition of p38 Mitogen&#x2010;Activated Protein Kinase Attenuates Left Ventricular Dysfunction by Mediating Pro&#x2010;Inflammatory Cardiac Cytokine Levels in a Mouse Model of Diabetes Mellitus,&#x201d; Diabetologia 49, no. 10 (2006): 2507&#x2013;2513, 10.1007/s00125-006-0385-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-006-0385-2</ArticleId><ArticleId IdType="pubmed">16937126</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell&#x2010;Hallinan A., Watson C. J., O'Dwyer D., Grieve D. J., and O'Neill K. M., &#x201c;Epigenetic Regulation of Endothelial Cell Function by Nucleic Acid Methylation in Cardiac Homeostasis and Disease,&#x201d; Cardiovascular Drugs and Therapy 35, no. 5 (2021): 1025&#x2013;1044, 10.1007/s10557-020-07019-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-020-07019-4</ArticleId><ArticleId IdType="pmc">PMC8452583</ArticleId><ArticleId IdType="pubmed">32748033</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman R. R., Paul S. K., Bethel M. A., Matthews D. R., and Neil H. A., &#x201c;10&#x2010;Year Follow&#x2010;Up of Intensive Glucose Control in Type 2 Diabetes,&#x201d; New England Journal of Medicine 359, no. 15 (2008): 1577&#x2013;1589, 10.1056/nejmoa0806470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa0806470</ArticleId><ArticleId IdType="pubmed">18784090</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal L., Azad N., Bahn G. D., et&#xa0;al., &#x201c;Long&#x2010;Term Follow&#x2010;Up of Intensive Glycaemic Control on Renal Outcomes in the Veterans Affairs Diabetes Trial (VADT),&#x201d; Diabetologia 61, no. 2 (2018): 295&#x2013;299, 10.1007/s00125-017-4473-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4473-2</ArticleId><ArticleId IdType="pmc">PMC5747983</ArticleId><ArticleId IdType="pubmed">29101421</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group , &#x201c;Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study,&#x201d; JAMA 290, no. 16 (2003): 2159&#x2013;2167, 10.1001/jama.290.16.2159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.290.16.2159</ArticleId><ArticleId IdType="pmc">PMC2622725</ArticleId><ArticleId IdType="pubmed">14570951</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkozy M., Szucs G., Fekete V., et&#xa0;al., &#x201c;Transcriptomic Alterations in the Heart of Non&#x2010;Obese Type 2 Diabetic Goto&#x2010;Kakizaki Rats,&#x201d; Cardiovascular Diabetology 15, no. 1 (2016): 110, 10.1186/s12933-016-0424-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-016-0424-3</ArticleId><ArticleId IdType="pmc">PMC4975916</ArticleId><ArticleId IdType="pubmed">27496100</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesherwani V., Shahshahan H. R., and Mishra P. K., &#x201c;Cardiac Transcriptome Profiling of Diabetic Akita Mice Using Microarray and Next Generation Sequencing,&#x201d; PLoS One 12, no. 8 (2017): e0182828, 10.1371/journal.pone.0182828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182828</ArticleId><ArticleId IdType="pmc">PMC5570368</ArticleId><ArticleId IdType="pubmed">28837672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao J. and Liu Y., &#x201c;Epigenetics of Methylation Modifications in Diabetic Cardiomyopathy,&#x201d; Frontiers in Endocrinology 14 (2023): 1119765, 10.3389/fendo.2023.1119765.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1119765</ArticleId><ArticleId IdType="pmc">PMC10050754</ArticleId><ArticleId IdType="pubmed">37008904</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaenisch R. and Bird A., &#x201c;Epigenetic Regulation of Gene Expression: How the Genome Integrates Intrinsic and Environmental Signals,&#x201d; supplement, Nature Genetics 33, no. Sl (2003): 245&#x2013;254, 10.1038/ng1089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1089</ArticleId><ArticleId IdType="pubmed">12610534</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating S. T., Plutzky J., and El&#x2010;Osta A., &#x201c;Epigenetic Changes in Diabetes and Cardiovascular Risk,&#x201d; Circulation Research 118, no. 11 (2016): 1706&#x2013;1722, 10.1161/circresaha.116.306819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.116.306819</ArticleId><ArticleId IdType="pmc">PMC5593074</ArticleId><ArticleId IdType="pubmed">27230637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A. J., Wang S., Wang B. J., et&#xa0;al., &#x201c;Epigenetic Regulation Associated With Sirtuin 1 in Complications of Diabetes Mellitus,&#x201d; Frontiers in Endocrinology 11 (2020): 598012, 10.3389/fendo.2020.598012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.598012</ArticleId><ArticleId IdType="pmc">PMC7848207</ArticleId><ArticleId IdType="pubmed">33537003</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia L. and Song M., &#x201c;Role of Non&#x2010;Coding RNA in Diabetic Cardiomyopathy,&#x201d; Advances in Experimental Medicine and Biology 1229 (2020): 181&#x2013;195, 10.1007/978-981-15-1671-9_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-15-1671-9_10</ArticleId><ArticleId IdType="pubmed">32285412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain S., Khan A. W., Akhmedov A., et&#xa0;al., &#x201c;Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD,&#x201d; Circulation Research 127, no. 10 (2020): 1261&#x2013;1273, 10.1161/circresaha.120.317132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.120.317132</ArticleId><ArticleId IdType="pubmed">32815777</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P. M. and Singal R., &#x201c;DNA Methylation and Cancer,&#x201d; Journal of Clinical Oncology 22, no. 22 (2004): 4632&#x2013;4642, 10.1200/jco.2004.07.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2004.07.151</ArticleId><ArticleId IdType="pubmed">15542813</ArticleId></ArticleIdList></Reference><Reference><Citation>Arechederra M., Daian F., Yim A., et&#xa0;al., &#x201c;Hypermethylation of Gene Body CpG Islands Predicts High Dosage of Functional Oncogenes in Liver Cancer,&#x201d; Nature Communications 9, no. 1 (2018): 3164, 10.1038/s41467-018-05550-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05550-5</ArticleId><ArticleId IdType="pmc">PMC6082886</ArticleId><ArticleId IdType="pubmed">30089774</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Han H., De Carvalho D. D., Lay F. D., Jones P. A., and Liang G., &#x201c;Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer,&#x201d; Cancer Cell 26, no. 4 (2014): 577&#x2013;590, 10.1016/j.ccr.2014.07.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2014.07.028</ArticleId><ArticleId IdType="pmc">PMC4224113</ArticleId><ArticleId IdType="pubmed">25263941</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Xiong F., Wu G., et&#xa0;al., &#x201c;Gene Body Methylation in Cancer: Molecular Mechanisms and Clinical Applications,&#x201d; Clinical Epigenetics 14, no. 1 (2022): 154, 10.1186/s13148-022-01382-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13148-022-01382-9</ArticleId><ArticleId IdType="pmc">PMC9706891</ArticleId><ArticleId IdType="pubmed">36443876</ArticleId></ArticleIdList></Reference><Reference><Citation>Neri F., Rapelli S., Krepelova A., et&#xa0;al., &#x201c;Intragenic DNA Methylation Prevents Spurious Transcription Initiation,&#x201d; Nature 543, no. 7643 (2017): 72&#x2013;77, 10.1038/nature21373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21373</ArticleId><ArticleId IdType="pubmed">28225755</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhat R., Mongad D., Raji S., et&#xa0;al., &#x201c;Epigenetic Modifier Alpha&#x2010;Ketoglutarate Modulates Aberrant Gene Body Methylation and Hydroxymethylation Marks in Diabetic Heart,&#x201d; Epigenetics &amp; Chromatin 16, no. 1 (2023): 12, 10.1186/s13072-023-00489-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13072-023-00489-4</ArticleId><ArticleId IdType="pmc">PMC10134649</ArticleId><ArticleId IdType="pubmed">37101286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli R. M. and Zhang Y., &#x201c;TET Enzymes, TDG and the Dynamics of DNA Demethylation,&#x201d; Nature 502, no. 7472 (2013): 472&#x2013;479, 10.1038/nature12750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12750</ArticleId><ArticleId IdType="pmc">PMC4046508</ArticleId><ArticleId IdType="pubmed">24153300</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Control and Complications Trial (DCCT): Results of Feasibility Study. The DCCT Research Group,&#x201d; Diabetes Care 10, no. 1 (1987): 1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">2882967</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group , &#x201c;Epidemiology of Diabetes Interventions and Complications (EDIC). Design, Implementation, and Preliminary Results of a Long&#x2010;Term Follow&#x2010;Up of the Diabetes Control and Complications Trial Cohort,&#x201d; Diabetes Care 22, no. 1 (1999): 99&#x2013;111, 10.2337/diacare.22.1.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.22.1.99</ArticleId><ArticleId IdType="pmc">PMC2745938</ArticleId><ArticleId IdType="pubmed">10333910</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Miao F., Braffett B. H., et&#xa0;al., &#x201c;DNA Methylation Mediates Development of HbA1c&#x2010;Associated Complications in Type 1 Diabetes,&#x201d; Nature Metabolism 2, no. 8 (2020): 744&#x2013;762, 10.1038/s42255-020-0231-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-020-0231-8</ArticleId><ArticleId IdType="pmc">PMC7590966</ArticleId><ArticleId IdType="pubmed">32694834</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong C. R., Clarke K., and Levelt E., &#x201c;Metabolic Remodeling in Diabetic Cardiomyopathy,&#x201d; Cardiovascular Research 113, no. 4 (2017): 422&#x2013;430, 10.1093/cvr/cvx018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvx018</ArticleId><ArticleId IdType="pmc">PMC5412022</ArticleId><ArticleId IdType="pubmed">28177068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Miao F., Paterson A. D., et&#xa0;al., &#x201c;Epigenomic Profiling Reveals an Association Between Persistence of DNA Methylation and Metabolic Memory in the DCCT/EDIC Type 1 Diabetes Cohort,&#x201d; Proceedings of the National Academy of Sciences of the USA 113, no. 21 (2016): E3002&#x2013;E3011, 10.1073/pnas.1603712113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1603712113</ArticleId><ArticleId IdType="pmc">PMC4890596</ArticleId><ArticleId IdType="pubmed">27162351</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers R. B., Fomovsky G. M., Lee S., et&#xa0;al., &#x201c;Deletion of Thioredoxin&#x2010;Interacting Protein Improves Cardiac Inotropic Reserve in the Streptozotocin&#x2010;Induced Diabetic Heart,&#x201d; American Journal of Physiology&#x2014;Heart and Circulatory Physiology 310, no. 11 (2016): H1748&#x2013;H1759, 10.1152/ajpheart.00051.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00051.2016</ArticleId><ArticleId IdType="pmc">PMC4935523</ArticleId><ArticleId IdType="pubmed">27037370</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q., Pu J., Yuan A., et&#xa0;al., &#x201c;Liver X Receptor Agonist Treatment Attenuates Cardiac Dysfunction in Type 2 Diabetic db/db Mice,&#x201d; Cardiovascular Diabetology 13, no. 1 (2014): 149, 10.1186/s12933-014-0149-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-014-0149-0</ArticleId><ArticleId IdType="pmc">PMC4245833</ArticleId><ArticleId IdType="pubmed">25416469</ArticleId></ArticleIdList></Reference><Reference><Citation>Toperoff G., Aran D., Kark J. D., et&#xa0;al., &#x201c;Genome&#x2010;Wide Survey Reveals Predisposing Diabetes Type 2&#x2010;Related DNA Methylation Variations in Human Peripheral Blood,&#x201d; Human Molecular Genetics 21, no. 2 (2012): 371&#x2013;383, 10.1093/hmg/ddr472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr472</ArticleId><ArticleId IdType="pmc">PMC3276288</ArticleId><ArticleId IdType="pubmed">21994764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju W., Liu K., Ouyang S., Liu Z., He F., and Wu J., &#x201c;Changes in N6&#x2010;Methyladenosine Modification Modulate Diabetic Cardiomyopathy by Reducing Myocardial Fibrosis and Myocyte Hypertrophy,&#x201d; Frontiers in Cell and Developmental Biology 9 (2021): 702579, 10.3389/fcell.2021.702579.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.702579</ArticleId><ArticleId IdType="pmc">PMC8334868</ArticleId><ArticleId IdType="pubmed">34368154</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson E., Vavakova M., Perfilyev A., et&#xa0;al., &#x201c;Differential DNA Methylation and Expression of miRNAs in Adipose Tissue From Twin Pairs Discordant for Type 2 Diabetes,&#x201d; Diabetes 70, no. 10 (2021): 2402&#x2013;2418, 10.2337/db20-0324.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db20-0324</ArticleId><ArticleId IdType="pubmed">34315727</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T. I., Kao Y. H., Chen Y. C., Pan N. H., Lin Y. K., and Chen Y. J., &#x201c;Cardiac Peroxisome&#x2010;Proliferator&#x2010;Activated Receptor Expression in Hypertension Co&#x2010;Existing With Diabetes,&#x201d; Clinical Science 121, no. 7 (2011): 305&#x2013;312, 10.1042/cs20100529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/cs20100529</ArticleId><ArticleId IdType="pubmed">21501116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T. I., Kao Y. H., Chen Y. C., Pan N. H., and Chen Y. J., &#x201c;Oxidative Stress and Inflammation Modulate Peroxisome Proliferator&#x2010;Activated Receptors With Regional Discrepancy in Diabetic Heart,&#x201d; European Journal of Clinical Investigation 40, no. 8 (2010): 692&#x2013;699, 10.1111/j.1365-2362.2010.02318.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.2010.02318.x</ArticleId><ArticleId IdType="pubmed">20561028</ArticleId></ArticleIdList></Reference><Reference><Citation>Boovarahan S. R., Chellappan D. R., Ali N., et&#xa0;al., &#x201c;Diabetic Hearts Exhibit Global DNA Hypermethylation That Alter the Mitochondrial Functional Genes to Enhance the Sensitivity of the Heart to Ischemia Reperfusion Injury,&#x201d; Biomedicines 10, no. 12 (2022): 3065, 10.3390/biomedicines10123065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10123065</ArticleId><ArticleId IdType="pmc">PMC9776053</ArticleId><ArticleId IdType="pubmed">36551820</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao H., Tao J. Y., Song Z. Y., et&#xa0;al., &#x201c;MeCP2 Triggers Diabetic Cardiomyopathy and Cardiac Fibroblast Proliferation by Inhibiting RASSF1A,&#x201d; Cellular Signalling 63 (2019): 109387, 10.1016/j.cellsig.2019.109387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2019.109387</ArticleId><ArticleId IdType="pubmed">31398393</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoccoro A. and Coppede F., &#x201c;Mitochondrial DNA Methylation and Human Diseases,&#x201d; International Journal of Molecular Sciences 22, no. 9 (2021): 4594, 10.3390/ijms22094594.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094594</ArticleId><ArticleId IdType="pmc">PMC8123858</ArticleId><ArticleId IdType="pubmed">33925624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechta M., Ingerslev L. R., Fabre O., Picard M., and Barres R., &#x201c;Evidence Suggesting Absence of Mitochondrial DNA Methylation,&#x201d; Frontiers in Genetics 8 (2017): 166, 10.3389/fgene.2017.00166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2017.00166</ArticleId><ArticleId IdType="pmc">PMC5671948</ArticleId><ArticleId IdType="pubmed">29163634</ArticleId></ArticleIdList></Reference><Reference><Citation>Mposhi A., Van der Wijst M. G., Faber K. N., and Rots M. G., &#x201c;Regulation of Mitochondrial Gene Expression, the Epigenetic Enigma,&#x201d; Frontiers in Bioscience 22, no. 7 (2017): 1099&#x2013;1113, 10.2741/4535.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/4535</ArticleId><ArticleId IdType="pubmed">28199194</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehman A., Kumari R., Kamthan A., et&#xa0;al., &#x201c;Cell&#x2010;Free Circulating Mitochondrial DNA: An Emerging Biomarker for Airborne Particulate Matter Associated With Cardiovascular Diseases,&#x201d; Free Radical Biology and Medicine 195 (2023): 103&#x2013;120, 10.1016/j.freeradbiomed.2022.12.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2022.12.083</ArticleId><ArticleId IdType="pubmed">36584454</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L. D., Linarelli L. E., Liu L., et&#xa0;al., &#x201c;Insulin Resistance Is Associated With Epigenetic and Genetic Regulation of Mitochondrial DNA in Obese Humans,&#x201d; Clinical Epigenetics 7, no. 1 (2015): 60, 10.1186/s13148-015-0093-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13148-015-0093-1</ArticleId><ArticleId IdType="pmc">PMC4479353</ArticleId><ArticleId IdType="pubmed">26110043</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao K., Lv W., Wang X., et&#xa0;al., &#x201c;Hypermethylation of Hepatic Mitochondrial ND6 Provokes Systemic Insulin Resistance,&#x201d; Advanced Science 8, no. 11 (2021): 2004507, 10.1002/advs.202004507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202004507</ArticleId><ArticleId IdType="pmc">PMC8188198</ArticleId><ArticleId IdType="pubmed">34141522</ArticleId></ArticleIdList></Reference><Reference><Citation>Mposhi A., Liang L., Mennega K. P., et&#xa0;al., &#x201c;The Mitochondrial Epigenome: An Unexplored Avenue to Explain Unexplained Myopathies?,&#x201d; International Journal of Molecular Sciences 23, no. 4 (2022): 2197, 10.3390/ijms23042197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23042197</ArticleId><ArticleId IdType="pmc">PMC8879787</ArticleId><ArticleId IdType="pubmed">35216315</ArticleId></ArticleIdList></Reference><Reference><Citation>Rautenberg E. K., Hamzaoui Y., and Coletta D. K., &#x201c;Mini&#x2010;Review: Mitochondrial DNA Methylation in Type 2 Diabetes and Obesity,&#x201d; Frontiers in Endocrinology 13 (2022): 968268, 10.3389/fendo.2022.968268.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.968268</ArticleId><ArticleId IdType="pmc">PMC9453027</ArticleId><ArticleId IdType="pubmed">36093112</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y. F., Zhu J. J., Yu T. X., et&#xa0;al., &#x201c;Hypermethylation of Mitochondrial DNA in Vascular Smooth Muscle Cells Impairs Cell Contractility,&#x201d; Cell Death &amp; Disease 11, no. 1 (2020): 35, 10.1038/s41419-020-2240-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-2240-7</ArticleId><ArticleId IdType="pmc">PMC6971246</ArticleId><ArticleId IdType="pubmed">31959742</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpulla R. C., &#x201c;Nucleus&#x2010;Encoded Regulators of Mitochondrial Function: Integration of Respiratory Chain Expression, Nutrient Sensing and Metabolic Stress,&#x201d; Biochimica et Biophysica Acta 1819, no. 9&#x2013;10 (2012): 1088&#x2013;1097, 10.1016/j.bbagrm.2011.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagrm.2011.10.011</ArticleId><ArticleId IdType="pmc">PMC3306451</ArticleId><ArticleId IdType="pubmed">22080153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammad G., Radhakrishnan R., and Kowluru R. A., &#x201c;Epigenetic Modifications Compromise Mitochondrial DNA Quality Control in the Development of Diabetic Retinopathy,&#x201d; Investigative Ophthalmology &amp; Visual Science 60, no. 12 (2019): 3943&#x2013;3951, 10.1167/iovs.19-27602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.19-27602</ArticleId><ArticleId IdType="pmc">PMC6759036</ArticleId><ArticleId IdType="pubmed">31546260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannister A. J. and Kouzarides T., &#x201c;Regulation of Chromatin by Histone Modifications,&#x201d; Cell Research 21, no. 3 (2011): 381&#x2013;395, 10.1038/cr.2011.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2011.22</ArticleId><ArticleId IdType="pmc">PMC3193420</ArticleId><ArticleId IdType="pubmed">21321607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein B. E., Meissner A., and Lander E. S., &#x201c;The Mammalian Epigenome,&#x201d; Cell 128, no. 4 (2007): 669&#x2013;681, 10.1016/j.cell.2007.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.01.033</ArticleId><ArticleId IdType="pubmed">17320505</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun M., Wu J., Workman J. L., and Li B., &#x201c;Readers of Histone Modifications,&#x201d; Cell Research 21, no. 4 (2011): 564&#x2013;578, 10.1038/cr.2011.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2011.42</ArticleId><ArticleId IdType="pmc">PMC3131977</ArticleId><ArticleId IdType="pubmed">21423274</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerra V. G. and Advani A., &#x201c;Histones and Heart Failure in Diabetes,&#x201d; Cellular and Molecular Life Sciences 75, no. 17 (2018): 3193&#x2013;3213, 10.1007/s00018-018-2857-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-018-2857-1</ArticleId><ArticleId IdType="pmc">PMC6063320</ArticleId><ArticleId IdType="pubmed">29934664</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmorstein R., &#x201c;Structure and Function of Histone Acetyltransferases,&#x201d; Cellular and Molecular Life Sciences 58, no. 5&#x2013;6 (2001): 693&#x2013;703, 10.1007/pl00000893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/pl00000893</ArticleId><ArticleId IdType="pmc">PMC11337361</ArticleId><ArticleId IdType="pubmed">11437231</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdone L., Caserta M., and Di Mauro E., &#x201c;Role of Histone Acetylation in the Control of Gene Expression,&#x201d; Biochemistry and Cell Biology 83, no. 3 (2005): 344&#x2013;353, 10.1139/o05-041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/o05-041</ArticleId><ArticleId IdType="pubmed">15959560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooistra S. M. and Helin K., &#x201c;Molecular Mechanisms and Potential Functions of Histone Demethylases,&#x201d; Nature Reviews Molecular Cell Biology 13, no. 5 (2012): 297&#x2013;311, 10.1038/nrm3327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3327</ArticleId><ArticleId IdType="pubmed">22473470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q. T., &#x201c;Epigenetic Regulation of Cardiac Development and Function by Polycomb Group and Trithorax Group Proteins,&#x201d; Developmental Dynamics 241, no. 6 (2012): 1021&#x2013;1033, 10.1002/dvdy.23796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.23796</ArticleId><ArticleId IdType="pmc">PMC3426356</ArticleId><ArticleId IdType="pubmed">22514007</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell&#x2010;Hallinan A., Watson C. J., and Baugh J. A., &#x201c;Epigenetics of Aberrant Cardiac Wound Healing,&#x201d; Comprehensive Physiology 8, no. 2 (2018): 451&#x2013;491, 10.1002/j.2040-4603.2018.tb00023.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.2040-4603.2018.tb00023.x</ArticleId><ArticleId IdType="pubmed">29687888</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagchi R. A. and Weeks K. L., &#x201c;Histone Deacetylases in Cardiovascular and Metabolic Diseases,&#x201d; Journal of Molecular and Cellular Cardiology 130 (2019): 151&#x2013;159, 10.1016/j.yjmcc.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2019.04.003</ArticleId><ArticleId IdType="pubmed">30978343</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X. Y., Geng Y. J., Liang J. L., et&#xa0;al., &#x201c;High Levels of Glucose Induce Apoptosis in Cardiomyocyte via Epigenetic Regulation of the Insulin&#x2010;Like Growth Factor Receptor,&#x201d; Experimental Cell Research 316, no. 17 (2010): 2903&#x2013;2909, 10.1016/j.yexcr.2010.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2010.07.004</ArticleId><ArticleId IdType="pubmed">20633551</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X. Y., Geng Y. J., Liang J. L., et&#xa0;al., &#x201c;High Levels of Glucose Induce &#x2018;Metabolic Memory&#x2019; in Cardiomyocyte via Epigenetic Histone H3 Lysine 9 Methylation,&#x201d; Molecular Biology Reports 39, no. 9 (2012): 8891&#x2013;8898, 10.1007/s11033-012-1756-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-012-1756-z</ArticleId><ArticleId IdType="pubmed">22707199</ArticleId></ArticleIdList></Reference><Reference><Citation>El&#x2010;Osta A., Brasacchio D., Yao D., et&#xa0;al., &#x201c;Transient High Glucose Causes Persistent Epigenetic Changes and Altered Gene Expression During Subsequent Normoglycemia,&#x201d; Journal of Experimental Medicine 205, no. 10 (2008): 2409&#x2013;2417, 10.1084/jem.20081188092608c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20081188092608c</ArticleId><ArticleId IdType="pmc">PMC2556800</ArticleId><ArticleId IdType="pubmed">18809715</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasacchio D., Okabe J., Tikellis C., et&#xa0;al., &#x201c;Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene&#x2010;Activating Epigenetic Marks That Coexist on the Lysine Tail,&#x201d; Diabetes 58, no. 5 (2009): 1229&#x2013;1236, 10.2337/db08-1666.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db08-1666</ArticleId><ArticleId IdType="pmc">PMC2671038</ArticleId><ArticleId IdType="pubmed">19208907</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson J. T., &#x201c;Set7 Methyltransferase Roles in Myocardial Protection From Chronic Stressors,&#x201d; Clinical Science 137, no. 1 (2023): 105&#x2013;108, 10.1042/cs20220773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/cs20220773</ArticleId><ArticleId IdType="pubmed">36601782</ArticleId></ArticleIdList></Reference><Reference><Citation>Siebel A. L., Fernandez A. Z., and El&#x2010;Osta A., &#x201c;Glycemic Memory Associated Epigenetic Changes,&#x201d; Biochemical Pharmacology 80, no. 12 (2010): 1853&#x2013;1859, 10.1016/j.bcp.2010.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2010.06.005</ArticleId><ArticleId IdType="pubmed">20599797</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda J. B., Lunardon G., Lima V. M., et&#xa0;al., &#x201c;Set7 Deletion Prevents Glucose Intolerance and Improves the Recovery of Cardiac Function After Ischemia and Reperfusion in Obese Female Mice,&#x201d; Cellular Physiology and Biochemistry 56, no. 3 (2022): 293&#x2013;309, 10.33594/000000535.</Citation><ArticleIdList><ArticleId IdType="doi">10.33594/000000535</ArticleId><ArticleId IdType="pubmed">35781359</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaikwad A. B., Sayyed S. G., Lichtnekert J., Tikoo K., and Anders H. J., &#x201c;Renal Failure Increases Cardiac Histone h3 Acetylation, Dimethylation, and Phosphorylation and the Induction of Cardiomyopathy&#x2010;Related Genes in Type 2 Diabetes,&#x201d; American Journal Of Pathology 176, no. 3 (2010): 1079&#x2013;1083, 10.2353/ajpath.2010.090528.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2010.090528</ArticleId><ArticleId IdType="pmc">PMC2832129</ArticleId><ArticleId IdType="pubmed">20075197</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbati S. A., Colussi C., Bacci L., et&#xa0;al., &#x201c;Transcription Factor CREM Mediates High Glucose Response in Cardiomyocytes and in a Male Mouse Model of Prolonged Hyperglycemia,&#x201d; Endocrinology 158, no. 7 (2017): 2391&#x2013;2405, 10.1210/en.2016-1960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2016-1960</ArticleId><ArticleId IdType="pubmed">28368536</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahtola E., Louhelainen M., Forsten H., et&#xa0;al., &#x201c;Sirtuin1&#x2010;p53, Forkhead Box O3a, p38 and Post&#x2010;Infarct Cardiac Remodeling in the Spontaneously Diabetic Goto&#x2010;Kakizaki Rat,&#x201d; Cardiovascular Diabetology 9, no. 1 (2010): 5, 10.1186/1475-2840-9-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2840-9-5</ArticleId><ArticleId IdType="pmc">PMC2835668</ArticleId><ArticleId IdType="pubmed">20105289</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagul P. K., Deepthi N., Sultana R., and Banerjee S. K., &#x201c;Resveratrol Ameliorates Cardiac Oxidative Stress in Diabetes Through Deacetylation of NFkB&#x2010;p65 and Histone 3,&#x201d; Journal of Nutritional Biochemistry 26, no. 11 (2015): 1298&#x2013;1307, 10.1016/j.jnutbio.2015.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnutbio.2015.06.006</ArticleId><ArticleId IdType="pubmed">26298192</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Tong Q., Zhang Z., et&#xa0;al., &#x201c;Inhibition of HDAC3 Prevents Diabetic Cardiomyopathy in OVE26 Mice via Epigenetic Regulation of DUSP5&#x2010;ERK1/2 Pathway,&#x201d; Clinical Science 131, no. 15 (2017): 1841&#x2013;1857, 10.1042/cs20170064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/cs20170064</ArticleId><ArticleId IdType="pmc">PMC5737625</ArticleId><ArticleId IdType="pubmed">28533215</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu T., Wu Q., Yao Q., et&#xa0;al., &#x201c;PRDM16 Exerts Critical Role in Myocardial Metabolism and Energetics in Type 2 Diabetes Induced Cardiomyopathy,&#x201d; Metabolism 146 (2023): 155658, 10.1016/j.metabol.2023.155658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2023.155658</ArticleId><ArticleId IdType="pubmed">37433344</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J. and Vakoc C. R., &#x201c;The Mechanisms Behind the Therapeutic Activity of BET Bromodomain Inhibition,&#x201d; Molecular Cell 54, no. 5 (2014): 728&#x2013;736, 10.1016/j.molcel.2014.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2014.05.016</ArticleId><ArticleId IdType="pmc">PMC4236231</ArticleId><ArticleId IdType="pubmed">24905006</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Q., McMahon S., Anand P., et&#xa0;al., &#x201c;BET Bromodomain Inhibition Suppresses Innate Inflammatory and Profibrotic Transcriptional Networks in Heart Failure,&#x201d; Science Translational Medicine 9, no. 390 (2017): eaah5084, 10.1126/scitranslmed.aah5084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aah5084</ArticleId><ArticleId IdType="pmc">PMC5544253</ArticleId><ArticleId IdType="pubmed">28515341</ArticleId></ArticleIdList></Reference><Reference><Citation>Borck P. C., Guo L. W., and Plutzky J., &#x201c;BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs,&#x201d; Circulation Research 126, no. 9 (2020): 1190&#x2013;1208, 10.1161/circresaha.120.315929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.120.315929</ArticleId><ArticleId IdType="pmc">PMC8111334</ArticleId><ArticleId IdType="pubmed">32324495</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N., Wu R., Tang D., and Kang R., &#x201c;The BET Family in Immunity and Disease,&#x201d; Signal Transduction and Targeted Therapy 6, no. 1 (2021): 23, 10.1038/s41392-020-00384-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00384-4</ArticleId><ArticleId IdType="pmc">PMC7813845</ArticleId><ArticleId IdType="pubmed">33462181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu J., Zhang D., Tian Y., Xie Z., and Zou M. H., &#x201c;BRD4 Inhibition by JQ1 Prevents High&#x2010;Fat Diet&#x2010;Induced Diabetic Cardiomyopathy by Activating PINK1/Parkin&#x2010;Mediated Mitophagy in Vivo,&#x201d; Journal of Molecular and Cellular Cardiology 149 (2020): 1&#x2013;14, 10.1016/j.yjmcc.2020.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2020.09.003</ArticleId><ArticleId IdType="pmc">PMC7736123</ArticleId><ArticleId IdType="pubmed">32941882</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M., Wang H. X., and Chen W. J., &#x201c;BET&#x2010;Inhibition by JQ1 Alleviates Streptozotocin&#x2010;Induced Diabetic Cardiomyopathy,&#x201d; Toxicology and Applied Pharmacology 352 (2018): 9&#x2013;18, 10.1016/j.taap.2018.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2018.05.018</ArticleId><ArticleId IdType="pubmed">29782963</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Sun Y., Li T., et&#xa0;al., &#x201c;Function of BRD4 in the Pathogenesis of High Glucose&#x2010;Induced Cardiac Hypertrophy,&#x201d; Molecular Medicine Reports 19, no. 1 (2019): 499&#x2013;507, 10.3892/mmr.2018.9681.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2018.9681</ArticleId><ArticleId IdType="pmc">PMC6297744</ArticleId><ArticleId IdType="pubmed">30483785</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray K. K., Nicholls S. J., Buhr K. A., et&#xa0;al., &#x201c;Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial,&#x201d; JAMA 323, no. 16 (2020): 1565&#x2013;1573, 10.1001/jama.2020.3308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.3308</ArticleId><ArticleId IdType="pmc">PMC7101505</ArticleId><ArticleId IdType="pubmed">32219359</ArticleId></ArticleIdList></Reference><Reference><Citation>Toth P. P., Schwartz G. G., Nicholls S. J., et&#xa0;al., &#x201c;Reduction in the Risk of Major Adverse Cardiovascular Events With the BET Protein Inhibitor Apabetalone in Patients With Recent Acute Coronary Syndrome, Type 2 Diabetes, and Moderate to High Likelihood of Non&#x2010;Alcoholic Fatty Liver Disease,&#x201d; American Journal of Preventive Cardiology 11 (2022): 100372, 10.1016/j.ajpc.2022.100372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpc.2022.100372</ArticleId><ArticleId IdType="pmc">PMC9419281</ArticleId><ArticleId IdType="pubmed">36039183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalantar&#x2010;Zadeh K., Schwartz G. G., Nicholls S. J., et&#xa0;al., &#x201c;Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results From the BETonMACE Randomized Controlled Trial,&#x201d; Clinical Journal of the American Society of Nephrology 16, no. 5 (2021): 705&#x2013;716, 10.2215/cjn.16751020.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/cjn.16751020</ArticleId><ArticleId IdType="pmc">PMC8259488</ArticleId><ArticleId IdType="pubmed">33906908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang R., Lee S., Senavirathne G., and Lai E. C., &#x201c;microRNAs in Action: Biogenesis, Function and Regulation,&#x201d; Nature Reviews Genetics 24, no. 12 (2023): 816&#x2013;833, 10.1038/s41576-023-00611-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-023-00611-y</ArticleId><ArticleId IdType="pmc">PMC11087887</ArticleId><ArticleId IdType="pubmed">37380761</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M., Liu Y., Zhang B., Shi Y., Cui L., and Zhao X., &#x201c;Inhibiting microRNA&#x2010;144 Abates Oxidative Stress and Reduces Apoptosis in Hearts of Streptozotocin&#x2010;Induced Diabetic Mice,&#x201d; Cardiovascular Pathology 24, no. 6 (2015): 375&#x2013;381, 10.1016/j.carpath.2015.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carpath.2015.06.003</ArticleId><ArticleId IdType="pubmed">26164195</ArticleId></ArticleIdList></Reference><Reference><Citation>Baseler W. A., Thapa D., Jagannathan R., Dabkowski E. R., Croston T. L., and Hollander J. M., &#x201c;miR&#x2010;141 as a Regulator of the Mitochondrial Phosphate Carrier (Slc25a3) in the Type 1 Diabetic Heart,&#x201d; American Journal of Physiology&#x2014;Cell Physiology 303, no. 12 (2012): C1244&#x2013;C1251, 10.1152/ajpcell.00137.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00137.2012</ArticleId><ArticleId IdType="pmc">PMC3532490</ArticleId><ArticleId IdType="pubmed">23034391</ArticleId></ArticleIdList></Reference><Reference><Citation>La Sala L., Cattaneo M., De Nigris V., et&#xa0;al., &#x201c;Oscillating Glucose Induces microRNA&#x2010;185 and Impairs an Efficient Antioxidant Response in Human Endothelial Cells,&#x201d; Cardiovascular Diabetology 15, no. 1 (2016): 71, 10.1186/s12933-016-0390-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-016-0390-9</ArticleId><ArticleId IdType="pmc">PMC4852407</ArticleId><ArticleId IdType="pubmed">27137793</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Fan J., Zhao Y., et&#xa0;al., &#x201c;Nuclear miR&#x2010;320 Mediates Diabetes&#x2010;Induced Cardiac Dysfunction by Activating Transcription of Fatty Acid Metabolic Genes to Cause Lipotoxicity in the Heart,&#x201d; Circulation Research 125, no. 12 (2019): 1106&#x2013;1120, 10.1161/circresaha.119.314898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.119.314898</ArticleId><ArticleId IdType="pmc">PMC6903355</ArticleId><ArticleId IdType="pubmed">31638474</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rooij E., Sutherland L. B., Thatcher J. E., et&#xa0;al., &#x201c;Dysregulation of microRNAs After Myocardial Infarction Reveals a Role of miR&#x2010;29 in Cardiac Fibrosis,&#x201d; Proceedings of the National Academy of Sciences of the USA 105, no. 35 (2008): 13027&#x2013;13032, 10.1073/pnas.0805038105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0805038105</ArticleId><ArticleId IdType="pmc">PMC2529064</ArticleId><ArticleId IdType="pubmed">18723672</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawal S., Munasinghe P. E., Nagesh P. T., et&#xa0;al., &#x201c;Down&#x2010;Regulation of miR&#x2010;15a/b Accelerates Fibrotic Remodelling in the Type 2 Diabetic Human and Mouse Heart,&#x201d; Clinical Science 131, no. 9 (2017): 847&#x2013;863, 10.1042/cs20160916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/cs20160916</ArticleId><ArticleId IdType="pubmed">28289072</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng B., Cao Y., Chen S., Chu X., Chu Y., and Chakrabarti S., &#x201c;miR&#x2010;200b Mediates Endothelial&#x2010;to&#x2010;Mesenchymal Transition in Diabetic Cardiomyopathy,&#x201d; Diabetes 65, no. 3 (2016): 768&#x2013;779, 10.2337/db15-1033.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db15-1033</ArticleId><ArticleId IdType="pubmed">26718496</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Du N., Zhang Q., et&#xa0;al., &#x201c;MicroRNA&#x2010;30d Regulates Cardiomyocyte Pyroptosis by Directly Targeting foxo3a in Diabetic Cardiomyopathy,&#x201d; Cell Death &amp; Disease 5, no. 10 (2014): e1479, 10.1038/cddis.2014.430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.430</ArticleId><ArticleId IdType="pmc">PMC4237254</ArticleId><ArticleId IdType="pubmed">25341033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H., Yang Y., Wang Y., Li J., Schiller P. W., and Peng T., &#x201c;MicroRNA&#x2010;195 Promotes Palmitate&#x2010;Induced Apoptosis in Cardiomyocytes by Down&#x2010;Regulating Sirt1,&#x201d; Cardiovascular Research 92, no. 1 (2011): 75&#x2013;84, 10.1093/cvr/cvr145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvr145</ArticleId><ArticleId IdType="pubmed">21622680</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao Y., Zhao Y., Liu Y., et&#xa0;al., &#x201c;miR&#x2010;483&#x2010;3p Regulates Hyperglycaemia&#x2010;Induced Cardiomyocyte Apoptosis in Transgenic Mice,&#x201d; Biochemical and Biophysical Research Communications 477, no. 4 (2016): 541&#x2013;547, 10.1016/j.bbrc.2016.06.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.06.051</ArticleId><ArticleId IdType="pubmed">27346130</ArticleId></ArticleIdList></Reference><Reference><Citation>Callis T. E., Pandya K., Seok H. Y., et&#xa0;al., &#x201c;MicroRNA&#x2010;208a Is a Regulator of Cardiac Hypertrophy and Conduction in Mice,&#x201d; Journal of Clinical Investigation 119, no. 9 (2009): 2772&#x2013;2786, 10.1172/jci36154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci36154</ArticleId><ArticleId IdType="pmc">PMC2735902</ArticleId><ArticleId IdType="pubmed">19726871</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng B., Chen S., George B., Feng Q., and Chakrabarti S., &#x201c;miR133a Regulates Cardiomyocyte Hypertrophy in Diabetes,&#x201d; Diabetes/Metabolism Research and Reviews 26, no. 1 (2010): 40&#x2013;49, 10.1002/dmrr.1054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.1054</ArticleId><ArticleId IdType="pubmed">20013939</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwabara Y., Horie T., Baba O., et&#xa0;al., &#x201c;MicroRNA&#x2010;451 Exacerbates Lipotoxicity in Cardiac Myocytes and High&#x2010;Fat Diet&#x2010;Induced Cardiac Hypertrophy in Mice Through Suppression of the LKB1/AMPK Pathway,&#x201d; Circulation Research 116, no. 2 (2015): 279&#x2013;288, 10.1161/circresaha.116.304707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.116.304707</ArticleId><ArticleId IdType="pubmed">25362209</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng B., Chen S., Gordon A. D., and Chakrabarti S., &#x201c;miR&#x2010;146a Mediates Inflammatory Changes and Fibrosis in the Heart in Diabetes,&#x201d; Journal of Molecular and Cellular Cardiology 105 (2017): 70&#x2013;76, 10.1016/j.yjmcc.2017.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2017.03.002</ArticleId><ArticleId IdType="pubmed">28279663</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng B., Liu J., Wang E., Su Z., and Chakrabarti S., &#x201c;Endothelial Derived miRNA&#x2010;9 Mediated Cardiac Fibrosis in Diabetes and Its Regulation by ZFAS1,&#x201d; PLoS One 17, no. 10 (2022): e0276076, 10.1371/journal.pone.0276076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0276076</ArticleId><ArticleId IdType="pmc">PMC9565427</ArticleId><ArticleId IdType="pubmed">36240130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Sit A., and Feinberg M. W., &#x201c;Role of miR&#x2010;181 Family in Regulating Vascular Inflammation and Immunity,&#x201d; Trends in Cardiovascular Medicine 24, no. 3 (2014): 105&#x2013;112, 10.1016/j.tcm.2013.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2013.09.002</ArticleId><ArticleId IdType="pmc">PMC3943593</ArticleId><ArticleId IdType="pubmed">24183793</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore A., Shindikar A., Fomison&#x2010;Nurse I., et&#xa0;al., &#x201c;Rapid Onset of Cardiomyopathy in STZ&#x2010;Induced Female Diabetic Mice Involves the Downregulation of Pro&#x2010;Survival Pim&#x2010;1,&#x201d; Cardiovascular Diabetology 13, no. 1 (2014): 68, 10.1186/1475-2840-13-68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2840-13-68</ArticleId><ArticleId IdType="pmc">PMC4073808</ArticleId><ArticleId IdType="pubmed">24685144</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildirim S. S., Akman D., Catalucci D., and Turan B., &#x201c;Relationship Between Downregulation of miRNAs and Increase of Oxidative Stress in the Development of Diabetic Cardiac Dysfunction: Junctin as a Target Protein of miR&#x2010;1,&#x201d; Cell Biochemistry and Biophysics 67, no. 3 (2013): 1397&#x2013;1408, 10.1007/s12013-013-9672-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12013-013-9672-y</ArticleId><ArticleId IdType="pubmed">23723006</ArticleId></ArticleIdList></Reference><Reference><Citation>You P., Chen H., Han W., and Deng J., &#x201c;miR&#x2010;200a&#x2010;3p Overexpression Alleviates Diabetic Cardiomyopathy Injury in Mice by Regulating Autophagy Through the FOXO3/Mst1/Sirt3/AMPK Axis,&#x201d; PeerJ 11 (2023): e15840, 10.7717/peerj.15840.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.15840</ArticleId><ArticleId IdType="pmc">PMC10506579</ArticleId><ArticleId IdType="pubmed">37727684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning S., Zhang S., and Guo Z., &#x201c;MicroRNA&#x2010;494 Regulates High Glucose&#x2010;Induced Cardiomyocyte Apoptosis and Autophagy by PI3K/AKT/mTOR Signalling Pathway,&#x201d; ESC Heart Fail 10, no. 2 (2023): 1401&#x2013;1411, 10.1002/ehf2.14311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.14311</ArticleId><ArticleId IdType="pmc">PMC10053280</ArticleId><ArticleId IdType="pubmed">36772911</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantino S., Paneni F., Luscher T. F., and Cosentino F., &#x201c;MicroRNA Profiling Unveils Hyperglycaemic Memory in the Diabetic Heart,&#x201d; European Heart Journal 37, no. 6 (2016): 572&#x2013;576, 10.1093/eurheartj/ehv599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv599</ArticleId><ArticleId IdType="pubmed">26553540</ArticleId></ArticleIdList></Reference><Reference><Citation>Delfan M., Delphan M., Kordi M. R., et&#xa0;al., &#x201c;High Intensity Interval Training Improves Diabetic Cardiomyopathy via miR&#x2010;1 Dependent Suppression of Cardiomyocyte Apoptosis in Diabetic Rats,&#x201d; Journal of Diabetes and Metabolic Disorders 19, no. 1 (2020): 145&#x2013;152, 10.1007/s40200-019-00485-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40200-019-00485-0</ArticleId><ArticleId IdType="pmc">PMC7270284</ArticleId><ArticleId IdType="pubmed">32550164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou J., Liang W. Y., Xiong S., et&#xa0;al., &#x201c;Identification of Hub Genes and Potential ceRNA Networks of Diabetic Cardiomyopathy,&#x201d; Scientific Reports 13, no. 1 (2023): 10258, 10.1038/s41598-023-37378-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-37378-5</ArticleId><ArticleId IdType="pmc">PMC10290640</ArticleId><ArticleId IdType="pubmed">37355664</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo R. and Nair S., &#x201c;Role of microRNA in Diabetic Cardiomyopathy: From Mechanism to Intervention,&#x201d; Biochimica et Biophysica Acta (BBA)&#x2014;Molecular Basis of Disease 1863, no. 8 (2017): 2070&#x2013;2077, 10.1016/j.bbadis.2017.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2017.03.013</ArticleId><ArticleId IdType="pmc">PMC5475364</ArticleId><ArticleId IdType="pubmed">28344129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh N. and Katare R., &#x201c;Molecular Mechanism of Diabetic Cardiomyopathy and Modulation of microRNA Function by Synthetic Oligonucleotides,&#x201d; Cardiovascular Diabetology 17, no. 1 (2018): 43, 10.1186/s12933-018-0684-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-018-0684-1</ArticleId><ArticleId IdType="pmc">PMC5863891</ArticleId><ArticleId IdType="pubmed">29566757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hathaway Q. A., Pinti M. V., Durr A. J., Waris S., Shepherd D. L., and Hollander J. M., &#x201c;Regulating microRNA Expression: At the Heart of Diabetes Mellitus and the Mitochondrion,&#x201d; American Journal of Physiology&#x2014;Heart and Circulatory Physiology 314, no. 2 (2018): H293&#x2013;H310, 10.1152/ajpheart.00520.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00520.2017</ArticleId><ArticleId IdType="pmc">PMC5867655</ArticleId><ArticleId IdType="pubmed">28986361</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z. and Chen C., &#x201c;Biological Functions and Clinical Prospects of Extracellular Non&#x2010;Coding RNAs in Diabetic Cardiomyopathy: An Updated Review,&#x201d; Journal of Cardiovascular Translational Research 15, no. 3 (2022): 469&#x2013;476, 10.1007/s12265-022-10217-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12265-022-10217-0</ArticleId><ArticleId IdType="pubmed">35175553</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakubik D., Fitas A., Eyileten C., et&#xa0;al., &#x201c;MicroRNAs and Long Non&#x2010;Coding RNAs in the Pathophysiological Processes of Diabetic Cardiomyopathy: Emerging Biomarkers and Potential Therapeutics,&#x201d; Cardiovascular Diabetology 20, no. 1 (2021): 55, 10.1186/s12933-021-01245-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01245-2</ArticleId><ArticleId IdType="pmc">PMC7916283</ArticleId><ArticleId IdType="pubmed">33639953</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariuki D., Aouizerat B. E., Asam K., et&#xa0;al., &#x201c;MicroRNA Biomarkers Target Genes and Pathways Associated With Type 2 Diabetes,&#x201d; Diabetes Research and Clinical Practice 203 (2023): 110868, 10.1016/j.diabres.2023.110868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2023.110868</ArticleId><ArticleId IdType="pubmed">37543292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X., Mei S., Wuyun Q., Zhou L., Sun D., and Yan J., &#x201c;Epigenetics in Diabetic Cardiomyopathy,&#x201d; Clinical Epigenetics 16, no. 1 (2024): 52, 10.1186/s13148-024-01667-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13148-024-01667-1</ArticleId><ArticleId IdType="pmc">PMC10996175</ArticleId><ArticleId IdType="pubmed">38581056</ArticleId></ArticleIdList></Reference><Reference><Citation>Macvanin M. T., Gluvic Z., Radovanovic J., Essack M., Gao X., and Isenovic E. R., &#x201c;Diabetic Cardiomyopathy: The Role of microRNAs and Long Non&#x2010;Coding RNAs,&#x201d; Frontiers in Endocrinology 14 (2023): 1124613, 10.3389/fendo.2023.1124613.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1124613</ArticleId><ArticleId IdType="pmc">PMC10025540</ArticleId><ArticleId IdType="pubmed">36950696</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopp F. and Mendell J. T., &#x201c;Functional Classification and Experimental Dissection of Long Noncoding RNAs,&#x201d; Cell 172, no. 3 (2018): 393&#x2013;407, 10.1016/j.cell.2018.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.01.011</ArticleId><ArticleId IdType="pmc">PMC5978744</ArticleId><ArticleId IdType="pubmed">29373828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C., Luo H., Liu B., Li F., Tschope C., and Fa X., &#x201c;Long Noncoding RNAs: A New Player in the Prevention and Treatment of Diabetic Cardiomyopathy?,&#x201d; Diabetes/Metabolism Research and Reviews 34, no. 8 (2018): e3056, 10.1002/dmrr.3056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3056</ArticleId><ArticleId IdType="pubmed">30160026</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant T., Dhanasekaran A., Bai X., et&#xa0;al., &#x201c;Genome&#x2010;Wide Differential Expression Profiling of lncRNAs and mRNAs Associated With Early Diabetic Cardiomyopathy,&#x201d; Scientific Reports 9, no. 1 (2019): 15345, 10.1038/s41598-019-51872-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-51872-9</ArticleId><ArticleId IdType="pmc">PMC6814824</ArticleId><ArticleId IdType="pubmed">31653946</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L., Lin H., Huang X., Weng J., Peng F., and Wu S., &#x201c;METTL14 Suppresses Pyroptosis and Diabetic Cardiomyopathy by Downregulating TINCR lncRNA,&#x201d; Cell Death &amp; Disease 13, no. 1 (2022): 38, 10.1038/s41419-021-04484-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-04484-z</ArticleId><ArticleId IdType="pmc">PMC8748685</ArticleId><ArticleId IdType="pubmed">35013106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Lin Y., Shen H., Yu S., and Xu J., &#x201c;LncRNA TUG1 Exacerbates Myocardial Fibrosis in Diabetic Cardiomyopathy by Modulating the microRNA&#x2010;145a&#x2010;5p/Cfl2 Axis,&#x201d; Journal of Cardiovascular Pharmacology 81, no. 3 (2023): 192&#x2013;202, 10.1097/fjc.0000000000001391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/fjc.0000000000001391</ArticleId><ArticleId IdType="pubmed">36450139</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L., Wang X., Guo S., et&#xa0;al., &#x201c;LncRNA HOTAIR Functions as a Competing Endogenous RNA to Upregulate SIRT1 by Sponging miR&#x2010;34a in Diabetic Cardiomyopathy,&#x201d; Journal of Cellular Physiology 234, no. 4 (2019): 4944&#x2013;4958, 10.1002/jcp.27296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27296</ArticleId><ArticleId IdType="pubmed">30216438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuo C., Jiang R., Lin X., and Shao M., &#x201c;LncRNA H19 Inhibits Autophagy by Epigenetically Silencing of DIRAS3 in Diabetic Cardiomyopathy,&#x201d; Oncotarget 8, no. 1 (2017): 1429&#x2013;1437, 10.18632/oncotarget.13637.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.13637</ArticleId><ArticleId IdType="pmc">PMC5352066</ArticleId><ArticleId IdType="pubmed">27903964</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Wang H., Yao B., Xu W., Chen J., and Zhou X., &#x201c;lncRNA H19/miR&#x2010;675 Axis Regulates Cardiomyocyte Apoptosis by Targeting VDAC1 in Diabetic Cardiomyopathy,&#x201d; Scientific Reports 6, no. 1 (2016): 36340, 10.1038/srep36340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36340</ArticleId><ArticleId IdType="pmc">PMC5087087</ArticleId><ArticleId IdType="pubmed">27796346</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Gu H., Chen J., and Zhou X., &#x201c;Involvement of Long Noncoding RNA MALAT1 in the Pathogenesis of Diabetic Cardiomyopathy,&#x201d; International Journal of Cardiology 202 (2016): 753&#x2013;755, 10.1016/j.ijcard.2015.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.10.019</ArticleId><ArticleId IdType="pubmed">26476026</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gonzalo&#x2010;Calvo D., Kenneweg F., Bang C., et&#xa0;al., &#x201c;Circulating long&#x2010;non Coding RNAs as Biomarkers of Left Ventricular Diastolic Function and Remodelling in Patients With Well&#x2010;Controlled Type 2 Diabetes,&#x201d; Scientific Reports 6, no. 1 (2016): 37354, 10.1038/srep37354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep37354</ArticleId><ArticleId IdType="pmc">PMC5118808</ArticleId><ArticleId IdType="pubmed">27874027</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Zhang W., Jin M., Chen J., Xu W., and Kong X., &#x201c;lncRNA MIAT Functions as a Competing Endogenous RNA to Upregulate DAPK2 by Sponging miR&#x2010;22&#x2010;3p in Diabetic Cardiomyopathy,&#x201d; Cell Death &amp; Disease 8, no. 7 (2017): e2929, 10.1038/cddis.2017.321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.321</ArticleId><ArticleId IdType="pmc">PMC5550866</ArticleId><ArticleId IdType="pubmed">28703801</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y., Wu H., Mai C., et&#xa0;al., &#x201c;LncRNA&#x2010;MIAT&#x2010;Mediated miR&#x2010;214&#x2010;3p Silencing is Responsible for IL&#x2010;17 Production and Cardiac Fibrosis in Diabetic Cardiomyopathy,&#x201d; Frontiers in Cell and Developmental Biology 8 (2020): 243, 10.3389/fcell.2020.00243.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00243</ArticleId><ArticleId IdType="pmc">PMC7174588</ArticleId><ArticleId IdType="pubmed">32351959</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas A. A., Feng B., and Chakrabarti S., &#x201c;ANRIL Regulates Production of Extracellular Matrix Proteins and Vasoactive Factors in Diabetic Complications,&#x201d; American Journal of Physiology. Endocrinology and Metabolism 314, no. 3 (2018): E191&#x2013;E200, 10.1152/ajpendo.00268.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00268.2017</ArticleId><ArticleId IdType="pubmed">29118015</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaux Y., Creemers E. E., Boon R. A., et&#xa0;al., &#x201c;Circular RNAs in Heart Failure,&#x201d; European Journal of Heart Failure 19, no. 6 (2017): 701&#x2013;709, 10.1002/ejhf.801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.801</ArticleId><ArticleId IdType="pubmed">28345158</ArticleId></ArticleIdList></Reference><Reference><Citation>Werfel S., Nothjunge S., Schwarzmayr T., Strom T. M., Meitinger T., and Engelhardt S., &#x201c;Characterization of Circular RNAs in Human, Mouse and Rat Hearts,&#x201d; Journal of Molecular and Cellular Cardiology 98 (2016): 103&#x2013;107, 10.1016/j.yjmcc.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2016.07.007</ArticleId><ArticleId IdType="pubmed">27476877</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan W. L., Lim B. T., Anene&#x2010;Nzelu C. G., et&#xa0;al., &#x201c;A Landscape of Circular RNA Expression in the Human Heart,&#x201d; Cardiovascular Research 113, no. 3 (2017): 298&#x2013;309, 10.1093/cvr/cvw250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvw250</ArticleId><ArticleId IdType="pubmed">28082450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Long B., Liu F., et&#xa0;al., &#x201c;A Circular RNA Protects the Heart From Pathological Hypertrophy and Heart Failure by Targeting miR&#x2010;223,&#x201d; European Heart Journal 37, no. 33 (2016): 2602&#x2013;2611, 10.1093/eurheartj/ehv713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv713</ArticleId><ArticleId IdType="pubmed">26802132</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong S., Tu C., Ye X., et&#xa0;al., &#x201c;Expression Profiling of Circular RNAs and Their Potential Role in Early&#x2010;Stage Diabetic Cardiomyopathy,&#x201d; Molecular Medicine Reports 22, no. 3 (2020): 1958&#x2013;1968, 10.3892/mmr.2020.11248.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2020.11248</ArticleId><ArticleId IdType="pmc">PMC7411360</ArticleId><ArticleId IdType="pubmed">32705182</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang C. M., Zhang M., Huang L., et&#xa0;al., &#x201c;CircRNA_000203 Enhances the Expression of Fibrosis&#x2010;Associated Genes by Derepressing Targets of miR&#x2010;26b&#x2010;5p, Col1a2 and CTGF, in Cardiac Fibroblasts,&#x201d; Scientific Reports 7, no. 1 (2017): 40342, 10.1038/srep40342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep40342</ArticleId><ArticleId IdType="pmc">PMC5228128</ArticleId><ArticleId IdType="pubmed">28079129</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B. and Yu J. W., &#x201c;A Novel Identified Circular RNA, circRNA_010567, Promotes Myocardial Fibrosis via Suppressing miR&#x2010;141 by Targeting TGF&#x2010;beta1,&#x201d; Biochemical and Biophysical Research Communications 487, no. 4 (2017): 769&#x2013;775, 10.1016/j.bbrc.2017.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.04.044</ArticleId><ArticleId IdType="pubmed">28412345</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Q., Sun Y., Yang F., et&#xa0;al., &#x201c;CircRNA DICAR as a Novel Endogenous Regulator for Diabetic Cardiomyopathy and Diabetic Pyroptosis of Cardiomyocytes,&#x201d; Signal Transduction and Targeted Therapy 8, no. 1 (2023): 99, 10.1038/s41392-022-01306-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01306-2</ArticleId><ArticleId IdType="pmc">PMC9992392</ArticleId><ArticleId IdType="pubmed">36882410</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan L., Wang T., Duan J., et&#xa0;al., &#x201c;Expression Profiles and Bioinformatic Analysis of Circular RNAs in Db/Db Mice With Cardiac Fibrosis,&#x201d; Diabetes, Metabolic Syndrome and Obesity 17 (2024): 2107&#x2013;2120, 10.2147/dmso.s465588.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/dmso.s465588</ArticleId><ArticleId IdType="pmc">PMC11128257</ArticleId><ArticleId IdType="pubmed">38799279</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Yang H., and Yang C., &#x201c;Circ&#x2010;AMOTL1 Enhances Cardiac Fibrosis Through Binding With EIF4A3 and Stabilizing MARCKS Expression in Diabetic Cardiomyopathy,&#x201d; Cellular Signalling 111 (2023): 110853, 10.1016/j.cellsig.2023.110853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2023.110853</ArticleId><ArticleId IdType="pubmed">37586467</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Zhang S., Xu L., et&#xa0;al., &#x201c;Involvement of circHIPK3 in the Pathogenesis of Diabetic Cardiomyopathy in Mice,&#x201d; Diabetologia 64, no. 3 (2021): 681&#x2013;692, 10.1007/s00125-020-05353-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-020-05353-8</ArticleId><ArticleId IdType="pubmed">33398455</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Y., Li M., Yu Q., et&#xa0;al., &#x201c;CircRNA CDR1as Promotes Cardiomyocyte Apoptosis Through Activating Hippo Signaling Pathway in Diabetic Cardiomyopathy,&#x201d; European Journal of Pharmacology 922 (2022): 174915, 10.1016/j.ejphar.2022.174915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2022.174915</ArticleId><ArticleId IdType="pubmed">35339477</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F., Li A., Qin Y., et&#xa0;al., &#x201c;A Novel Circular RNA Mediates Pyroptosis of Diabetic Cardiomyopathy by Functioning as a Competing Endogenous RNA,&#x201d; Molecular Therapy Nucleic Acids 17 (2019): 636&#x2013;643, 10.1016/j.omtn.2019.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.06.026</ArticleId><ArticleId IdType="pmc">PMC6700436</ArticleId><ArticleId IdType="pubmed">31400606</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen M., Wu Y., Li L., Zhang L., Liu G., and Wang R., &#x201c;CircMAP3K5 Promotes Cardiomyocyte Apoptosis in Diabetic Cardiomyopathy by Regulating miR&#x2010;22&#x2010;3p/DAPK2 Axis,&#x201d; Journal of Diabetes 16, no. 1 (2024): e13471, 10.1111/1753-0407.13471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1753-0407.13471</ArticleId><ArticleId IdType="pmc">PMC10809294</ArticleId><ArticleId IdType="pubmed">37735821</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin G., Wang Q., Hu X., et&#xa0;al., &#x201c;Profiling and Functional Analysis of Differentially Expressed Circular RNAs in High Glucose&#x2010;Induced Human Umbilical Vein Endothelial Cells,&#x201d; FEBS Open Bio 9, no. 9 (2019): 1640&#x2013;1651, 10.1002/2211-5463.12709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.12709</ArticleId><ArticleId IdType="pmc">PMC6722901</ArticleId><ArticleId IdType="pubmed">31369204</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W. and Sui Y., &#x201c;CircBPTF Knockdown Ameliorates High Glucose&#x2010;Induced Inflammatory Injuries and Oxidative Stress by Targeting the miR&#x2010;384/LIN28B Axis in Human Umbilical Vein Endothelial Cells,&#x201d; Molecular and Cellular Biochemistry 471, no. 1&#x2013;2 (2020): 101&#x2013;111, 10.1007/s11010-020-03770-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-020-03770-2</ArticleId><ArticleId IdType="pubmed">32524321</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Du G., Xie L., Xu Y., and Chen W., &#x201c;Circular RNA HMGCS1 Sponges MIR4521 to Aggravate Type 2 Diabetes&#x2010;Induced Vascular Endothelial Dysfunction,&#x201d; Elife 13 (2024): RP97267, 10.7554/elife.97267.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/elife.97267</ArticleId><ArticleId IdType="pmc">PMC11377038</ArticleId><ArticleId IdType="pubmed">39235443</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A. W., Paneni F., and Jandeleit&#x2010;Dahm K. A. M., &#x201c;Cell&#x2010;Specific Epigenetic Changes in Atherosclerosis,&#x201d; Clinical Science 135, no. 9 (2021): 1165&#x2013;1187, 10.1042/cs20201066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/cs20201066</ArticleId><ArticleId IdType="pmc">PMC8314213</ArticleId><ArticleId IdType="pubmed">33988232</ArticleId></ArticleIdList></Reference><Reference><Citation>Laakso M., &#x201c;Heart in Diabetes: A Microvascular Disease,&#x201d; supplement, Diabetes Care 34, no. S2 (2011): S145&#x2013;S149, 10.2337/dc11-s209.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc11-s209</ArticleId><ArticleId IdType="pmc">PMC3632152</ArticleId><ArticleId IdType="pubmed">21525446</ArticleId></ArticleIdList></Reference><Reference><Citation>Coco C., Sgarra L., Potenza M. A., et&#xa0;al., &#x201c;Can Epigenetics of Endothelial Dysfunction Represent the Key to Precision Medicine in Type 2 Diabetes Mellitus?,&#x201d; International Journal of Molecular Sciences 20, no. 12 (2019): 2949, 10.3390/ijms20122949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20122949</ArticleId><ArticleId IdType="pmc">PMC6628049</ArticleId><ArticleId IdType="pubmed">31212911</ArticleId></ArticleIdList></Reference><Reference><Citation>Paneni F., Costantino S., Battista R., et&#xa0;al., &#x201c;Adverse Epigenetic Signatures by Histone Methyltransferase Set7 Contribute to Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus,&#x201d; Circulation: Cardiovascular Genetics 8, no. 1 (2015): 150&#x2013;158, 10.1161/circgenetics.114.000671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circgenetics.114.000671</ArticleId><ArticleId IdType="pubmed">25472959</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepin M. E., Schiano C., Miceli M., et&#xa0;al., &#x201c;The Human Aortic Endothelium Undergoes Dose&#x2010;Dependent DNA Methylation in Response to Transient Hyperglycemia,&#x201d; Experimental Cell Research 400, no. 2 (2021): 112485, 10.1016/j.yexcr.2021.112485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2021.112485</ArticleId><ArticleId IdType="pmc">PMC8038422</ArticleId><ArticleId IdType="pubmed">33515594</ArticleId></ArticleIdList></Reference><Reference><Citation>Green H. L. H. and Brewer A. C., &#x201c;Dysregulation of 2&#x2010;Oxoglutarate&#x2010;Dependent Dioxygenases by Hyperglycaemia: Does This Link Diabetes and Vascular Disease?,&#x201d; Clinical Epigenetics 12, no. 1 (2020): 59, 10.1186/s13148-020-00848-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13148-020-00848-y</ArticleId><ArticleId IdType="pmc">PMC7189706</ArticleId><ArticleId IdType="pubmed">32345373</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabs M., Rose A. J., Lehmann L. H., et&#xa0;al., &#x201c;Inhibition of Endothelial Notch Signaling Impairs Fatty Acid Transport and Leads to Metabolic and Vascular Remodeling of the Adult Heart,&#x201d; Circulation 137, no. 24 (2018): 2592&#x2013;2608, 10.1161/circulationaha.117.029733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.117.029733</ArticleId><ArticleId IdType="pubmed">29353241</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E., Chen S., Wang H., Chen T., and Chakrabarti S., &#x201c;Non&#x2010;Coding RNA&#x2010;Mediated Endothelial&#x2010;to&#x2010;Mesenchymal Transition in Human Diabetic Cardiomyopathy, Potential Regulation by DNA Methylation,&#x201d; Cardiovascular Diabetology 22, no. 1 (2023): 303, 10.1186/s12933-023-02039-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-02039-4</ArticleId><ArticleId IdType="pmc">PMC10625293</ArticleId><ArticleId IdType="pubmed">37924123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E., Wang H., and Chakrabarti S., &#x201c;Endothelial&#x2010;to&#x2010;Mesenchymal Transition: An Underappreciated Mediator of Diabetic Complications,&#x201d; Frontiers in Endocrinology 14 (2023): 1050540, 10.3389/fendo.2023.1050540.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1050540</ArticleId><ArticleId IdType="pmc">PMC9911675</ArticleId><ArticleId IdType="pubmed">36777351</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathishkumar C., Prabu P., Balakumar M., et&#xa0;al., &#x201c;Augmentation of Histone Deacetylase 3 (HDAC3) Epigenetic Signature at the Interface of Proinflammation and Insulin Resistance in Patients With Type 2 Diabetes,&#x201d; Clinical Epigenetics 8, no. 1 (2016): 125, 10.1186/s13148-016-0293-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13148-016-0293-3</ArticleId><ArticleId IdType="pmc">PMC5122206</ArticleId><ArticleId IdType="pubmed">27904654</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Friehs I., Zhong Hu T., et&#xa0;al., &#x201c;Endocardial Fibroelastosis Is Caused by Aberrant Endothelial to Mesenchymal Transition,&#x201d; Circulation Research 116, no. 5 (2015): 857&#x2013;866, 10.1161/circresaha.116.305629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.116.305629</ArticleId><ArticleId IdType="pmc">PMC4344885</ArticleId><ArticleId IdType="pubmed">25587097</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Tan X., Tampe B., et&#xa0;al., &#x201c;Epigenetic Balance of Aberrant Rasal1 Promoter Methylation and Hydroxymethylation Regulates Cardiac Fibrosis,&#x201d; Cardiovascular Research 105, no. 3 (2015): 279&#x2013;291, 10.1093/cvr/cvv015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvv015</ArticleId><ArticleId IdType="pubmed">25616414</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan N. P., Tingle S. J., Shuttleworth V. G., et&#xa0;al., &#x201c;MiR&#x2010;126&#x2010;3p is Dynamically Regulated in Endothelial&#x2010;to&#x2010;Mesenchymal Transition During Fibrosis,&#x201d; International Journal of Molecular Sciences 22, no. 16 (2021): 8629, 10.3390/ijms22168629.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168629</ArticleId><ArticleId IdType="pmc">PMC8395326</ArticleId><ArticleId IdType="pubmed">34445337</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil N. S., Feng B., Su Z., Castellani C. A., and Chakrabarti S., &#x201c;Circular RNA Mediated Gene Regulation in Chronic Diabetic Complications,&#x201d; Scientific Reports 11, no. 1 (2021): 23766, 10.1038/s41598-021-02980-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02980-y</ArticleId><ArticleId IdType="pmc">PMC8660871</ArticleId><ArticleId IdType="pubmed">34887449</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuleta I. and Frangogiannis N. G., &#x201c;Fibrosis of the Diabetic Heart: Clinical Significance, Molecular Mechanisms, and Therapeutic Opportunities,&#x201d; Advanced Drug Delivery Reviews 176 (2021): 113904, 10.1016/j.addr.2021.113904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2021.113904</ArticleId><ArticleId IdType="pmc">PMC8444077</ArticleId><ArticleId IdType="pubmed">34331987</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao H., Shi P., Zhao X. D., Xuan H. Y., Gong W. H., and Ding X. S., &#x201c;DNMT1 Deregulation of SOCS3 Axis Drives Cardiac Fibroblast Activation in Diabetic Cardiac Fibrosis,&#x201d; Journal of Cellular Physiology 236, no. 5 (2021): 3481&#x2013;3494, 10.1002/jcp.30078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.30078</ArticleId><ArticleId IdType="pubmed">32989761</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao H., Shi P., Xuan H. Y., and Ding X. S., &#x201c;DNA Methyltransferase&#x2010;1 Inactivation of Androgen Receptor Axis Triggers Homocysteine Induced Cardiac Fibroblast Autophagy in Diabetic Cardiac Fibrosis,&#x201d; Archives of Biochemistry and Biophysics 692 (2020): 108521, 10.1016/j.abb.2020.108521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2020.108521</ArticleId><ArticleId IdType="pubmed">32800775</ArticleId></ArticleIdList></Reference><Reference><Citation>Che H., Wang Y., Li Y., et&#xa0;al., &#x201c;Inhibition of microRNA&#x2010;150&#x2010;5p Alleviates Cardiac Inflammation and Fibrosis via Targeting Smad7 in High Glucose&#x2010;Treated Cardiac Fibroblasts,&#x201d; Journal of Cellular Physiology 235, no. 11 (2020): 7769&#x2013;7779, 10.1002/jcp.29386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.29386</ArticleId><ArticleId IdType="pubmed">31710102</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Li W., Xu M., Huang H., Wang J., and Chen X., &#x201c;Micro&#x2010;RNA 21Targets Dual Specific Phosphatase 8 to Promote Collagen Synthesis in High Glucose&#x2010;Treated Primary Cardiac Fibroblasts,&#x201d; Canadian Journal of Cardiology 30, no. 12 (2014): 1689&#x2013;1699, 10.1016/j.cjca.2014.07.747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2014.07.747</ArticleId><ArticleId IdType="pubmed">25418215</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J., Xing W., Liu R., Zhang Y., Xie C., and Gong F., &#x201c;MiR&#x2010;32&#x2010;5p Influences High Glucose&#x2010;Induced Cardiac Fibroblast Proliferation and Phenotypic Alteration by Inhibiting DUSP1,&#x201d; BMC Molecular Biology 20, no. 1 (2019): 21, 10.1186/s12867-019-0135-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12867-019-0135-x</ArticleId><ArticleId IdType="pmc">PMC6704591</ArticleId><ArticleId IdType="pubmed">31438862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Jin H., Jiang S., and Xu Y., &#x201c;MicroRNA&#x2010;495 Inhibits the High Glucose&#x2010;Induced Inflammation, Differentiation and Extracellular Matrix Accumulation of Cardiac Fibroblasts Through Downregulation of NOD1,&#x201d; Cellular and Molecular Biology Letters 23, no. 1 (2018): 23, 10.1186/s11658-018-0089-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11658-018-0089-x</ArticleId><ArticleId IdType="pmc">PMC5941488</ArticleId><ArticleId IdType="pubmed">29760746</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F., Qin Y., Lv J., et&#xa0;al., &#x201c;Silencing Long Non&#x2010;Coding RNA Kcnq1ot1 Alleviates Pyroptosis and Fibrosis in Diabetic Cardiomyopathy,&#x201d; Cell Death &amp; Disease 9, no. 10 (2018): 1000, 10.1038/s41419-018-1029-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-1029-4</ArticleId><ArticleId IdType="pmc">PMC6155223</ArticleId><ArticleId IdType="pubmed">30250027</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhang Y. Y., Li T. T., et&#xa0;al., &#x201c;Ablation of Interleukin&#x2010;17 Alleviated Cardiac Interstitial Fibrosis and Improved Cardiac Function via Inhibiting Long Non&#x2010;Coding RNA&#x2010;AK081284 in Diabetic Mice,&#x201d; Journal of Molecular and Cellular Cardiology 115 (2018): 64&#x2013;72, 10.1016/j.yjmcc.2018.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2018.01.001</ArticleId><ArticleId IdType="pubmed">29305939</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng T., Liu M., Hu L., et&#xa0;al., &#x201c;LncRNA Airn Alleviates Diabetic Cardiac Fibrosis by Inhibiting Activation of Cardiac Fibroblasts via a m6A&#x2010;IMP2&#x2010;p53 Axis,&#x201d; Biology Direct 17, no. 1 (2022): 32, 10.1186/s13062-022-00346-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13062-022-00346-6</ArticleId><ArticleId IdType="pmc">PMC9670606</ArticleId><ArticleId IdType="pubmed">36384975</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia G., Hill M. A., and Sowers J. R., &#x201c;Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity,&#x201d; Circulation Research 122, no. 4 (2018): 624&#x2013;638, 10.1161/circresaha.117.311586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.117.311586</ArticleId><ArticleId IdType="pmc">PMC5819359</ArticleId><ArticleId IdType="pubmed">29449364</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Y., Zhou B., Su H., Liu Y., and Du C., &#x201c;miR&#x2010;150 Regulates High Glucose&#x2010;Induced Cardiomyocyte Hypertrophy by Targeting the Transcriptional Co&#x2010;Activator p300,&#x201d; Experimental Cell Research 319, no. 3 (2013): 173&#x2013;184, 10.1016/j.yexcr.2012.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2012.11.015</ArticleId><ArticleId IdType="pubmed">23211718</ArticleId></ArticleIdList></Reference><Reference><Citation>Raut S. K., Kumar A., Singh G. B., et&#xa0;al., &#x201c;miR&#x2010;30c Mediates Upregulation of Cdc42 and Pak1 in Diabetic Cardiomyopathy,&#x201d; Cardiovascular Therapeutics 33, no. 3 (2015): 89&#x2013;97, 10.1111/1755-5922.12113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1755-5922.12113</ArticleId><ArticleId IdType="pubmed">25781190</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen E., Diao X., Wang X., Chen R., and Hu B., &#x201c;MicroRNAs Involved in the Mitogen&#x2010;Activated Protein Kinase Cascades Pathway During Glucose&#x2010;Induced Cardiomyocyte Hypertrophy,&#x201d; American Journal Of Pathology 179, no. 2 (2011): 639&#x2013;650, 10.1016/j.ajpath.2011.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.04.034</ArticleId><ArticleId IdType="pmc">PMC3157194</ArticleId><ArticleId IdType="pubmed">21704010</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Li X., Lin Q., and Xu Q., &#x201c;Up&#x2010;Regulation of microRNA&#x2010;203 Inhibits Myocardial Fibrosis and Oxidative Stress in Mice With Diabetic Cardiomyopathy Through the Inhibition of PI3K/Akt Signaling Pathway via PIK3CA,&#x201d; Gene 715 (2019): 143995, 10.1016/j.gene.2019.143995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2019.143995</ArticleId><ArticleId IdType="pubmed">31336140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F., Li B., Wei Y. Z., et&#xa0;al., &#x201c;MicroRNA&#x2010;34a Regulates High Glucose&#x2010;Induced Apoptosis in H9c2 Cardiomyocytes,&#x201d; Journal of Huazhong University of Science and Technology 33, no. 6 (2013): 834&#x2013;839, 10.1007/s11596-013-1207-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11596-013-1207-7</ArticleId><ArticleId IdType="pubmed">24337844</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan Z. X., Lin Q. X., Deng C. Y., et&#xa0;al., &#x201c;miR&#x2010;1/miR&#x2010;206 Regulate Hsp60 Expression Contributing to Glucose&#x2010;Mediated Apoptosis in Cardiomyocytes,&#x201d; FEBS Letters 584, no. 16 (2010): 3592&#x2013;3600, 10.1016/j.febslet.2010.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2010.07.027</ArticleId><ArticleId IdType="pubmed">20655308</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X. Y., Song Y. H., Geng Y. J., et&#xa0;al., &#x201c;Glucose Induces Apoptosis of Cardiomyocytes via microRNA&#x2010;1 and IGF&#x2010;1,&#x201d; Biochemical and Biophysical Research Communications 376, no. 3 (2008): 548&#x2013;552, 10.1016/j.bbrc.2008.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2008.09.025</ArticleId><ArticleId IdType="pubmed">18801338</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng D., Ma J., Yu Y., et&#xa0;al., &#x201c;Silencing of miR&#x2010;195 Reduces Diabetic Cardiomyopathy in C57BL/6 Mice,&#x201d; Diabetologia 58, no. 8 (2015): 1949&#x2013;1958, 10.1007/s00125-015-3622-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-015-3622-8</ArticleId><ArticleId IdType="pmc">PMC4499474</ArticleId><ArticleId IdType="pubmed">25994075</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuo X., Bai K., Wang Y., et&#xa0;al., &#x201c;Long&#x2010;Chain Noncoding RNA&#x2010;GAS5/hsa&#x2010;miR&#x2010;138&#x2010;5p Attenuates High Glucose&#x2010;Induced Cardiomyocyte Damage by Targeting CYP11B2,&#x201d; Bioscience Reports 41, no. 9 (2021), 10.1042/bsr20202232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bsr20202232</ArticleId><ArticleId IdType="pmc">PMC8485392</ArticleId><ArticleId IdType="pubmed">33682891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu C., Zhang H., Wei D., and Sun Z., &#x201c;Silencing lncRNA GAS5 Alleviates Apoptosis and Fibrosis in Diabetic Cardiomyopathy by Targeting miR&#x2010;26a/b&#x2010;5p,&#x201d; Acta Diabetologica 58, no. 11 (2021): 1491&#x2013;1501, 10.1007/s00592-021-01745-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-021-01745-3</ArticleId><ArticleId IdType="pubmed">34091757</ArticleId></ArticleIdList></Reference><Reference><Citation>Simar D., Versteyhe S., Donkin I., et&#xa0;al., &#x201c;DNA Methylation Is Altered in B and NK Lymphocytes in Obese and Type 2 Diabetic Human,&#x201d; Metabolism 63, no. 9 (2014): 1188&#x2013;1197, 10.1016/j.metabol.2014.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2014.05.014</ArticleId><ArticleId IdType="pubmed">24996265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Goldberg J., Bremner J. D., and Vaccarino V., &#x201c;Global DNA Methylation Is Associated With Insulin Resistance: A Monozygotic Twin Study,&#x201d; Diabetes 61, no. 2 (2012): 542&#x2013;546, 10.2337/db11-1048.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db11-1048</ArticleId><ArticleId IdType="pmc">PMC3266395</ArticleId><ArticleId IdType="pubmed">22210312</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Wang X., Liu D., Yu L., Xue B., and Shi H., &#x201c;Epigenetic Regulation of Macrophage Polarization by DNA Methyltransferase 3b,&#x201d; Molecular Endocrinology 28, no. 4 (2014): 565&#x2013;574, 10.1210/me.2013-1293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2013-1293</ArticleId><ArticleId IdType="pmc">PMC3968399</ArticleId><ArticleId IdType="pubmed">24597547</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghuraman S., Donkin I., Versteyhe S., Barres R., and Simar D., &#x201c;The Emerging Role of Epigenetics in Inflammation and Immunometabolism,&#x201d; Trends in Endocrinology &amp; Metabolism 27, no. 11 (2016): 782&#x2013;795, 10.1016/j.tem.2016.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2016.06.008</ArticleId><ArticleId IdType="pubmed">27444065</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzik T. J. and Cosentino F., &#x201c;Epigenetics and Immunometabolism in Diabetes and Aging,&#x201d; Antioxid Redox Signal 29, no. 3 (2018): 257&#x2013;274, 10.1089/ars.2017.7299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7299</ArticleId><ArticleId IdType="pmc">PMC6012980</ArticleId><ArticleId IdType="pubmed">28891325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Suo W., Zhang X., et&#xa0;al., &#x201c;Targeting Epigenetics in Diabetic Cardiomyopathy: Therapeutic Potential of Flavonoids,&#x201d; Biomedicine &amp; Pharmacotherapy 157 (2023): 114025, 10.1016/j.biopha.2022.114025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.114025</ArticleId><ArticleId IdType="pubmed">36399824</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartosova L., Horvath C., Galis P., et&#xa0;al., &#x201c;Quercetin Alleviates Diastolic Dysfunction and Suppresses Adverse Pro&#x2010;Hypertrophic Signaling in Diabetic Rats,&#x201d; Frontiers in Endocrinology 13 (2022): 1029750, 10.3389/fendo.2022.1029750.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.1029750</ArticleId><ArticleId IdType="pmc">PMC9772025</ArticleId><ArticleId IdType="pubmed">36568083</ArticleId></ArticleIdList></Reference><Reference><Citation>Devarshi P. P., Jones A. D., Taylor E. M., Stefanska B., and Henagan T. M., &#x201c;Quercetin and Quercetin&#x2010;Rich Red Onion Extract Alter Pgc&#x2010;1alpha Promoter Methylation and Splice Variant Expression,&#x201d; PPAR Research 2017 (2017): 3235693, 10.1155/2017/3235693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/3235693</ArticleId><ArticleId IdType="pmc">PMC5278221</ArticleId><ArticleId IdType="pubmed">28191013</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawal S., Manning P., and Katare R., &#x201c;Cardiovascular microRNAs: As Modulators and Diagnostic Biomarkers of Diabetic Heart Disease,&#x201d; Cardiovascular Diabetology 13, no. 1 (2014): 44, 10.1186/1475-2840-13-44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2840-13-44</ArticleId><ArticleId IdType="pmc">PMC3976030</ArticleId><ArticleId IdType="pubmed">24528626</ArticleId></ArticleIdList></Reference><Reference><Citation>Makeyev E. V., Kolb V. A., and Spirin A. S., &#x201c;Cell&#x2010;Free Immunology: Construction and in Vitro Expression of a PCR&#x2010;based Library Encoding a Single&#x2010;Chain Antibody Repertoire,&#x201d; FEBS Letters 444, no. 2&#x2013;3 (1999): 177&#x2013;180, 10.1016/s0014-5793(99)00055-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0014-5793(99)00055-1</ArticleId><ArticleId IdType="pubmed">10050754</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J., Liao Y., Liu J., Liu W., and Yan D., &#x201c;Research Progress on Epigenetics of Diabetic Cardiomyopathy in Type 2 Diabetes,&#x201d; Frontiers in Cell and Developmental Biology 9 (2021): 777258, 10.3389/fcell.2021.777258.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.777258</ArticleId><ArticleId IdType="pmc">PMC8740193</ArticleId><ArticleId IdType="pubmed">35004678</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q. and Cao X., &#x201c;Epigenetic Regulation of the Innate Immune Response to Infection,&#x201d; Nature Reviews Immunology 19, no. 7 (2019): 417&#x2013;432, 10.1038/s41577-019-0151-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0151-6</ArticleId><ArticleId IdType="pubmed">30918351</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lu Q., and Chang C., &#x201c;Epigenetics in Health and Disease,&#x201d; Advances in Experimental Medicine and Biology 1253 (2020): 3&#x2013;55, 10.1007/978-981-15-3449-2_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-15-3449-2_1</ArticleId><ArticleId IdType="pubmed">32445090</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y., Zou J., Xu X., et&#xa0;al., &#x201c;Short&#x2010;Chain Fatty Acids Combined With Intronic DNA Methylation of HIF3A: Potential Predictors for Diabetic Cardiomyopathy,&#x201d; Clinical Nutrition 40, no. 6 (2021): 3708&#x2013;3717, 10.1016/j.clnu.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2021.04.007</ArticleId><ArticleId IdType="pubmed">34130016</ArticleId></ArticleIdList></Reference><Reference><Citation>Copier C. U., Leon L., Fernandez M., Contador D., and Calligaris S. D., &#x201c;Circulating miR&#x2010;19b and miR&#x2010;181b Are Potential Biomarkers for Diabetic Cardiomyopathy,&#x201d; Scientific Reports 7, no. 1 (2017): 13514, 10.1038/s41598-017-13875-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-13875-2</ArticleId><ArticleId IdType="pmc">PMC5647433</ArticleId><ArticleId IdType="pubmed">29044172</ArticleId></ArticleIdList></Reference><Reference><Citation>Leopold J. A. and Loscalzo J., &#x201c;Emerging Role of Precision Medicine in Cardiovascular Disease,&#x201d; Circulation Research 122, no. 9 (2018): 1302&#x2013;1315, 10.1161/circresaha.117.310782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.117.310782</ArticleId><ArticleId IdType="pmc">PMC6021027</ArticleId><ArticleId IdType="pubmed">29700074</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadd D. A., Hillary R. F., McCartney D. L., et&#xa0;al., &#x201c;Epigenetic Scores for the Circulating Proteome as Tools for Disease Prediction,&#x201d; eLife 11 (2022): e71802, 10.7554/elife.71802.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/elife.71802</ArticleId><ArticleId IdType="pmc">PMC8880990</ArticleId><ArticleId IdType="pubmed">35023833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hathaway Q. A., Roth S. M., Pinti M. V., et&#xa0;al., &#x201c;Machine&#x2010;Learning to Stratify Diabetic Patients Using Novel Cardiac Biomarkers and Integrative Genomics,&#x201d; Cardiovascular Diabetology 18, no. 1 (2019): 78, 10.1186/s12933-019-0879-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-019-0879-0</ArticleId><ArticleId IdType="pmc">PMC6560734</ArticleId><ArticleId IdType="pubmed">31185988</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweaad W. K., Stefanizzi F. M., Chamorro&#x2010;Jorganes A., Devaux Y., Emanueli C., and Eu&#x2010;Cca C. A., &#x201c;Relevance of N6&#x2010;Methyladenosine Regulators for Transcriptome: Implications for Development and the Cardiovascular System,&#x201d; Journal of Molecular and Cellular Cardiology 160 (2021): 56&#x2013;70, 10.1016/j.yjmcc.2021.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2021.05.006</ArticleId><ArticleId IdType="pubmed">33991529</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L. C., Liu Z. Y., Yang J. J., Zhao J. Y., and Tao H., &#x201c;m6A Epitranscriptomic Modification in Diabetic Microvascular Complications,&#x201d; Trends in Pharmacological Sciences 44, no. 12 (2023): 991&#x2013;1008, 10.1016/j.tips.2023.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2023.09.013</ArticleId><ArticleId IdType="pubmed">39492320</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagianni K., Bibi A., Made A., et&#xa0;al., &#x201c;Recommendations for Detection, Validation, and Evaluation of RNA Editing Events in Cardiovascular and Neurological/Neurodegenerative Diseases,&#x201d; Molecular Therapy Nucleic Acids 35, no. 1 (2024): 102085, 10.1016/j.omtn.2023.102085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2023.102085</ArticleId><ArticleId IdType="pmc">PMC10772297</ArticleId><ArticleId IdType="pubmed">38192612</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Qin D., Chen T., et&#xa0;al., &#x201c;Dysregulated Rbfox2 Produces Aberrant Splicing of Ca(V)1.2 Calcium Channel in Diabetes&#x2010;Induced Cardiac Hypertrophy,&#x201d; Cardiovascular Diabetology 22, no. 1 (2023): 168, 10.1186/s12933-023-01894-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-01894-5</ArticleId><ArticleId IdType="pmc">PMC10324275</ArticleId><ArticleId IdType="pubmed">37415128</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutter C. A., Jaworski E. A., Verma S. K., et&#xa0;al., &#x201c;Dysregulation of RBFOX2 Is an Early Event in Cardiac Pathogenesis of Diabetes,&#x201d; Cell Reports 15, no. 10 (2016): 2200&#x2013;2213, 10.1016/j.celrep.2016.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.05.002</ArticleId><ArticleId IdType="pmc">PMC4899142</ArticleId><ArticleId IdType="pubmed">27239029</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls S. J., Schwartz G. G., Buhr K. A., et&#xa0;al., &#x201c;Apabetalone and Hospitalization for Heart Failure in Patients Following an Acute Coronary Syndrome: A Prespecified Analysis of the BETonMACE Study,&#x201d; Cardiovascular Diabetology 20, no. 1 (2021): 13, 10.1186/s12933-020-01199-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-01199-x</ArticleId><ArticleId IdType="pmc">PMC7791841</ArticleId><ArticleId IdType="pubmed">33413345</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattick J. S., Amaral P. P., Carninci P., et&#xa0;al., &#x201c;Long Non&#x2010;coding RNAs: Definitions, Functions, Challenges and Recommendations,&#x201d; Nature Reviews Molecular Cell Biology 24, no. 6 (2023): 430&#x2013;447, 10.1038/s41580-022-00566-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-022-00566-8</ArticleId><ArticleId IdType="pmc">PMC10213152</ArticleId><ArticleId IdType="pubmed">36596869</ArticleId></ArticleIdList></Reference><Reference><Citation>Schorderet P. and Duboule D., &#x201c;Structural and Functional Differences in the Long Non&#x2010;Coding RNA Hotair in Mouse and Human,&#x201d; PLoS Genetics 7, no. 5 (2011): e1002071, 10.1371/journal.pgen.1002071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002071</ArticleId><ArticleId IdType="pmc">PMC3102750</ArticleId><ArticleId IdType="pubmed">21637793</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao L., Huang X., Xu M., et&#xa0;al., &#x201c;Value of Circulating miRNA&#x2010;21 in the Diagnosis of Subclinical Diabetic Cardiomyopathy,&#x201d; Molecular and Cellular Endocrinology 518 (2020): 110944, 10.1016/j.mce.2020.110944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2020.110944</ArticleId><ArticleId IdType="pubmed">32717421</ArticleId></ArticleIdList></Reference><Reference><Citation>Sopic M., Stopa V., and Devaux Y., &#x201c;Leveraging Epitranscriptomics for Cardiovascular Disease Theranostics,&#x201d; European Heart Journal 45, no. 13 (2024): 1098&#x2013;1100, 10.1093/eurheartj/ehad852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad852</ArticleId><ArticleId IdType="pubmed">38190430</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40830232</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2731-0590</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature cardiovascular research</Title><ISOAbbreviation>Nat Cardiovasc Res</ISOAbbreviation></Journal><ArticleTitle>Linking phospholipid metabolism to septic cardiomyopathy via HIF-1&#x3b1; overactivation.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s44161-025-00680-8</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kayki Mutlu</LastName><ForeName>Gizem</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3177-9438</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Walter J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0002-8522-530X</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Division of Cardiovascular and Thoracic Surgery, Duke Cardiovascular Research Center, Duke University School of Medicine, Durham, NC, USA. Walter.Koch@Duke.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cardiovasc Res</MedlineTA><NlmUniqueID>9918284280206676</NlmUniqueID><ISSNLinking>2731-0590</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40830232</ArticleId><ArticleId IdType="doi">10.1038/s44161-025-00680-8</ArticleId><ArticleId IdType="pii">10.1038/s44161-025-00680-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feng, Z. et al. MedComm. 6, e70109 (2025).</Citation><ArticleIdList><ArticleId IdType="pubmed">39991626</ArticleId><ArticleId IdType="pmc">11847631</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink, M. Acta Anaesthesiol. Scand. Suppl. 110, 87&#x2013;95 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9248546</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe, M. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-025-00687-1 (2025).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44161-025-00687-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Papandreou, I. et al. Cell. Metab. 3, 187&#x2013;197 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16517406</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;lscher, M. et al. Cardiovasc. Res. 94, 77&#x2013;86 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22258630</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano, M. et al. Nature 446, 444&#x2013;448 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17334357</ArticleId></ArticleIdList></Reference><Reference><Citation>Rius, J. et al. Nature 453, 807&#x2013;811 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18432192</ArticleId><ArticleId IdType="pmc">2669289</ArticleId></ArticleIdList></Reference><Reference><Citation>Amunugama, K., Pike, D. P. &amp; Ford, D. A. J. Lipid Res. 62, 100090 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34087197</ArticleId><ArticleId IdType="pmc">8243525</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullen, J. W. et al. Sci. Signal. 9, ra56 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27245613</ArticleId><ArticleId IdType="pmc">5541497</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice, T. W. et al. Crit. Care Med. 38, 1685&#x2013;1694 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20562702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40825741</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0253-3758</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Zhonghua xin xue guan bing za zhi</Title><ISOAbbreviation>Zhonghua Xin Xue Guan Bing Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Diagnosis and treatment progress of hemochromatosis related iron overload cardiomyopathy].</ArticleTitle><Pagination><StartPage>966</StartPage><EndPage>970</EndPage><MedlinePgn>966-970</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112148-20250606-00419</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>G N</ForeName><Initials>GN</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Xin Xue Guan Bing Za Zhi</MedlineTA><NlmUniqueID>7910682</NlmUniqueID><ISSNLinking>0253-3758</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="chi"><AbstractText>&#x8840;&#x8272;&#x75c5;&#x662f;&#x7531;&#x94c1;&#x8c03;&#x7d20;/&#x94c1;&#x8f6c;&#x8fd0;&#x86cb;&#x767d;&#x8f74;&#x76f8;&#x5173;&#x57fa;&#x56e0;&#x7a81;&#x53d8;&#x5bfc;&#x81f4;&#x7684;&#x5168;&#x8eab;&#x94c1;&#x8fc7;&#x8f7d;&#x9057;&#x4f20;&#x6027;&#x75be;&#x75c5;&#xff0c;&#x53ef;&#x5f15;&#x53d1;&#x591a;&#x5668;&#x5b98;&#x635f;&#x5bb3;&#xff0c;&#x5176;&#x4e2d;&#x94c1;&#x8fc7;&#x8f7d;&#x5fc3;&#x808c;&#x75c5;&#x662f;&#x5176;&#x4e3b;&#x8981;&#x6b7b;&#x4ea1;&#x539f;&#x56e0;&#x3002;&#x8840;&#x8272;&#x75c5;&#x662f;&#x5317;&#x6b27;&#x767d;&#x79cd;&#x4eba;&#x7fa4;&#x4e2d;&#x6700;&#x5e38;&#x89c1;&#x7684;&#x9057;&#x4f20;&#x6027;&#x75be;&#x75c5;&#x4e4b;&#x4e00;&#xff0c;&#x5728;&#x6211;&#x56fd;&#x7f55;&#x89c1;&#x4e14;&#x6613;&#x88ab;&#x6f0f;&#x8bca;&#x3001;&#x8bef;&#x8bca;&#x3002;&#x76ee;&#x524d;&#x901a;&#x8fc7;&#x8840;&#x6e05;&#x94c1;&#x4ee3;&#x8c22;&#x6307;&#x6807;&#x68c0;&#x6d4b;&#x3001;&#x5fc3;&#x810f;&#x78c1;&#x5171;&#x632f;T2&#x5f1b;&#x8c6b;&#x65f6;&#x95f4;&#x6d4b;&#x5b9a;&#x53ca;&#x57fa;&#x56e0;&#x6d4b;&#x5e8f;&#x7b49;&#x65b9;&#x6cd5;&#x53ef;&#x65e9;&#x671f;&#x8bca;&#x65ad;&#x8840;&#x8272;&#x75c5;&#xff0c;&#x800c;&#x9759;&#x8109;&#x653e;&#x8840;&#x548c;&#x94c1;&#x87af;&#x5408;&#x5242;&#x7b49;&#x6cbb;&#x7597;&#x53ef;&#x6709;&#x6548;&#x964d;&#x4f4e;&#x673a;&#x4f53;&#x94c1;&#x8d1f;&#x8377;&#xff0c;&#x5728;&#x75be;&#x75c5;&#x65e9;&#x671f;&#x9006;&#x8f6c;&#x6216;&#x5ef6;&#x7f13;&#x5668;&#x5b98;&#x635f;&#x5bb3;&#xff0c;&#x6539;&#x5584;&#x60a3;&#x8005;&#x9884;&#x540e;&#x3002;&#x8be5;&#x6587;&#x4ecb;&#x7ecd;&#x4e86;&#x8840;&#x8272;&#x75c5;&#x6027;&#x5fc3;&#x810f;&#x75c5;&#x5728;&#x57fa;&#x56e0;&#x5206;&#x578b;&#x3001;&#x53d1;&#x75c5;&#x673a;&#x5236;&#x3001;&#x4e34;&#x5e8a;&#x8868;&#x73b0;&#x3001;&#x8bca;&#x65ad;&#x65b9;&#x6cd5;&#x548c;&#x6cbb;&#x7597;&#x624b;&#x6bb5;&#x7b49;&#x65b9;&#x9762;&#x7684;&#x7814;&#x7a76;&#x8fdb;&#x5c55;&#x3002;.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>22</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40825741</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112148-20250606-00419</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40846367</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>24</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Secondary Cardiomyopathy Due to Selenium Deficiency: Multidimensional Cardiac Evaluation and Treatment.</ArticleTitle><Pagination><StartPage>104665</StartPage><MedlinePgn>104665</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.104665</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)01445-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Selenium deficiency can cause cardiomyopathy; however, the underlying mechanisms remain unclear. We report a case of cardiomyopathy associated with selenium deficiency in a patient with long-term enteral nutrition.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 2-year-old boy with gastrointestinal allergy developed secondary cardiomyopathy due to selenium deficiency resulting from an elemental diet. He presented with reduced left ventricular function and dilated ventricles. Serum selenium levels were undetectable. Myocardial scintigraphy showed perfusion-metabolism mismatches and fibrosis. Selenium supplementation and medications for heart failure led to significant cardiac recovery over a period of 1 year.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The patient's congenital heart disease allowed for evaluation before the onset of selenium deficiency cardiomyopathy. Myocardial scintigraphy revealed a characteristic perfusion-metabolism imbalance. Both selenium supplementation and treatment for ischemic heart disease were effective in improving cardiac function.</AbstractText><AbstractText Label="TAKE-HOME MESSAGES" NlmCategory="CONCLUSIONS">Myocardial scintigraphy is useful in diagnosing selenium deficiency cardiomyopathy. Selenium supplementation and management of ischemic heart disease are essential for treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hokkaido University, Sapporo, Hokkaido, Japan; Department of Pediatrics, Self Defense Forces Sapporo Hospital, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chida-Nagai</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hokkaido University, Sapporo, Hokkaido, Japan. Electronic address: ayakonagai@med.hokudai.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibukawa</LastName><ForeName>Naoyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hokkaido University, Sapporo, Hokkaido, Japan; Department of Pediatrics, Self Defense Forces Sapporo Hospital, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatsunori</LastName><ForeName>Itabashi</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hokkaido University, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Yuto</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hokkaido University, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hokkaido University, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamazawa</LastName><ForeName>Hirokuni</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hokkaido University, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Atsuhito</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hokkaido University, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">myocardial scintigraphy</Keyword><Keyword MajorTopicYN="N">selenium deficiency</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846367</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.104665</ArticleId><ArticleId IdType="pii">S2666-0849(25)01445-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40823717</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2058-1742</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>European heart journal. Quality of care &amp; clinical outcomes</Title><ISOAbbreviation>Eur Heart J Qual Care Clin Outcomes</ISOAbbreviation></Journal><ArticleTitle>Decline in alcoholic cardiomyopathy mortality in Europe: no time for complacency.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">qcaf073</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjqcco/qcaf073</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flather</LastName><ForeName>Marcus D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0001-5644-3116</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Norwich Medical School University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefil</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7137-2459</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Norwich Medical School University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adelaide Medical School, University of Adelaide, Adelaide, South Australia 5000, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Qual Care Clin Outcomes</MedlineTA><NlmUniqueID>101677796</NlmUniqueID><ISSNLinking>2058-1742</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Eur Heart J Qual Care Clin Outcomes. 2025 Jun 10:qcaf036. doi: 10.1093/ehjqcco/qcaf036.</RefSource><PMID Version="1">40493699</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>Conflict of interest: Authors confirm have that they have no financial or other conflicts of interest and this article is original and has not been submitted elsewhere.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40823717</ArticleId><ArticleId IdType="doi">10.1093/ehjqcco/qcaf073</ArticleId><ArticleId IdType="pii">8237260</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40821257</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Cardiomyopathy in the Shadow of Fibrillary Glomerulonephritis: An Unusual Indirect Association.</ArticleTitle><Pagination><StartPage>e87879</StartPage><MedlinePgn>e87879</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e87879</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.87879</ELocationID><Abstract><AbstractText>Fibrillary glomerulonephritis (FGN) is a rare and complex renal disease where the accumulation of non-amyloid microfibrils composed of polyclonal immunoglobulin G within the mesangium and glomerular capillaries results in structural and functional abnormalities in the kidney's filtering units.&#xa0;The direct link between FGN and cardiomyopathy is not well established. However, it may be caused secondarily by systemic inflammation, uremia, or other overlapping factors and comorbidities. In our case, it was believed to be significantly influenced and worsened by various comorbid conditions, with hypertension being the most common cardiovascular risk factor in FGN itself, contributing to structural and functional cardiac impairment, including left ventricular hypertrophy and systolic dysfunction, rather than direct myocardial infiltration or damage by fibrillary deposit. We have a case of a 60-year-old female who presented with a severe manifestation of FGN, associated with secondary cardiomyopathy and renal failure complications, including hypertension-related issues, nephrotic syndrome with significant proteinuria, peripheral edema, anasarca, and shortness of breath, initially leading to hospitalization. Her renal insufficiency subsequently progressed to end-stage renal disease, and the discovery of a nephrotic range of proteinuria led to a kidney biopsy, confirming the diagnosis of FGN. Her renal recovery remained poor due to persistent volume overload, which impeded renal recovery and which required the initiation of dialysis.&#xa0;The patient experienced a rare cardiac involvement related to underlying FGN, which could not be confirmed through a cardiac biopsy because she chose to refuse&#xa0;this invasive test.&#xa0; The treatment with prednisone and rituximab targeted FGN, reducing proteinuria and improving renal function, which allowed for a decrease in hemodialysis and normalization of the erythrocyte sedimentation rate and C-reactive protein at 12 months. Cardiac function also improved after six months, with lower brain natriuretic peptide levels, increased left ventricular ejection fraction (LVEF), and reversal of ventricular remodeling on echocardiogram, suggesting that early immunologic intervention can reverse cardiomyopathy and prevent progression. Longer follow-up is recommended, as improved LVEF is associated with a better prognosis in heart failure.&#xa0;FGN typically affects the kidneys, making cardiac issues uncommon. Therefore, further research is needed to understand the prevalence and mechanisms of cardiac involvement in FGN for developing targeted therapies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, Rijal et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rijal</LastName><ForeName>Satya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine, University of Michigan Health-Sparrow Hospital, East Lansing, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine, Michigan State University College of Human Medicine, East Lansing, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Maitri P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Internal Medicine, University of Michigan Health-Sparrow Hospital, East Lansing, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine, Michigan State University College of Human Medicine, East Lansing, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mudupula Vemula</LastName><ForeName>Sai Sushrutha</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Internal Medicine, University of Michigan Health-Sparrow Hospital, East Lansing, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine, Michigan State University College of Human Medicine, East Lansing, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanal</LastName><ForeName>Prakash</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Internal Medicine, Michigan State University College of Human Medicine, East Lansing, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine, University of Michigan Health-Sparrow Hospital, East Lansing, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duwadi</LastName><ForeName>Ayushma</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine, Michigan State University College of Human Medicine, East Lansing, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine, University of Michigan Health-Sparrow Hospital, East Lansing, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">endothelial injury</Keyword><Keyword MajorTopicYN="N">heavy proteinuria</Keyword><Keyword MajorTopicYN="N">interstitial fibrosis caused by the deposition of fibronectin and microfibrils in the vasculature</Keyword><Keyword MajorTopicYN="N">kidney disease and cardiac involvement and the success of chemotherapy</Keyword><Keyword MajorTopicYN="N">renin-angiotensin-aldosterone system</Keyword></KeywordList><CoiStatement>Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40821257</ArticleId><ArticleId IdType="pmc">PMC12351503</ArticleId><ArticleId IdType="doi">10.7759/cureus.87879</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clinical and pathologic features of fibrillary glomerulonephritis. Iskandar SS, Falk RJ, Jennette JC. Kidney Int. 1992;42:1401&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pubmed">1474772</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, Leung N, Fervenza FC. Clin J Am Soc Nephrol. 2011;6:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069369</ArticleId><ArticleId IdType="pubmed">21441134</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibrillary glomerulonephritis: clinicopathologic features and atypical cases from a multi-institutional cohort. Andeen NK, Troxell ML, Riazy M, et al. Clin J Am Soc Nephrol. 2019;14:1741&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6895488</ArticleId><ArticleId IdType="pubmed">31685544</ArticleId></ArticleIdList></Reference><Reference><Citation>New insights into immune mechanisms underlying response to rituximab in patients with membranous nephropathy: a prospective study and a review of the literature. Roccatello D, Sciascia S, Di Simone D, et al. Autoimmun Rev. 2016;15:529&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">26876383</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunotactoid glomerulopathy masquerading as heart failure. Ali K, Agrawal A, Karan A, Marsalisi C, O'Brien MC, Liu S, Jaikaransingh V. Cureus. 2024;16:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11293071</ArticleId><ArticleId IdType="pubmed">39092324</ArticleId></ArticleIdList></Reference><Reference><Citation>New developments in the diagnosis of fibrillary glomerulonephritis. Nasr SH, Fogo AB. Kidney Int. 2019;96:581&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">31227146</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibrillary glomerulonephritis and monoclonal gammopathy: potential diagnostic challenges. Da Y, Goh GH, Lau T, Chng WJ, Soekojo CY. Front Oncol. 2022;12:880923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9174543</ArticleId><ArticleId IdType="pubmed">35692803</ArticleId></ArticleIdList></Reference><Reference><Citation>Global, regional, and national burden of CKD due to glomerulonephritis from 1990 to 2019: a systematic analysis from the Global Burden of Disease Study 2019. Hu J, Ke R, Teixeira W, et al. Clin J Am Soc Nephrol. 2023;18:60&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101559</ArticleId><ArticleId IdType="pubmed">36719159</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibrillary glomerulonephritis: an update. Rosenstock JL, Markowitz GS. Kidney Int Rep. 2019;4:917&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6611949</ArticleId><ArticleId IdType="pubmed">31317113</ArticleId></ArticleIdList></Reference><Reference><Citation>Updates on the diagnosis and management of fibrillary glomerulonephritis. Attieh RM, Yang Y, Rosenstock JL. https://www.sciencedirect.com/science/article/pii/S2949813924000569. Adv Kidney Dis Health. 2024;31:374&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">39084762</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40827722</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-9645</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>European heart journal</Title><ISOAbbreviation>Eur Heart J</ISOAbbreviation></Journal><ArticleTitle>Cardiac myosin inhibitors in hypertrophic cardiomyopathy: the need for precision medicine.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ehaf507</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/eurheartj/ehaf507</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yilmaz</LastName><ForeName>Ali</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4526-8679</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Imaging, Department of Cardiology I, University Hospital M&#xfc;nster, Von-Esmarch-Strasse 48, D-48149 M&#xfc;nster, Germany &#xa0;Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J</MedlineTA><NlmUniqueID>8006263</NlmUniqueID><ISSNLinking>0195-668X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>7</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40827722</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehaf507</ArticleId><ArticleId IdType="pii">8237944</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846661</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2542-5641</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Chinese medical journal</Title><ISOAbbreviation>Chin Med J (Engl)</ISOAbbreviation></Journal><ArticleTitle>Oral microbiome between patients with non-obstructive and obstructive hypertrophic cardiomyopathy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/CM9.0000000000003777</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The profile and clinical significance of the oral microbiome in patients with non-obstructive hypertrophic cardiomyopathy (noHCM) and obstructive hypertrophic cardiomyopathy (oHCM) remain unexplored. The objective of this study was to evaluate the difference of oral microbiome between noHCM and oHCM patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This cross-sectional study enrolled 18 noHCM patients and 26 oHCM patients from Fuwai Hospital, Chinese Academy of Medical Sciences between 2020 and 2021. Clinical and periodontal evaluations were conducted, and subgingival plaque samples were collected. Metagenomic sequencing and subsequent microbial composition and functional analyses were performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to oHCM patients, those with noHCM had higher systolic blood pressure (138.1 &#xb1; 18.8 mmHg vs. 124.2 &#xb1; 13.8 mmHg, P = 0.007), a larger body circumference (neck circumference: 39.2 &#xb1; 4.0 cm vs. 35.1 &#xb1; 3.7 cm, P = 0.001; waist circumference: 99.7 &#xb1; 10.5 cm vs. 92.2 &#xb1; 10.8 cm, P = 0.027; hip circumference: 102.5 &#xb1; 5.6 cm vs. 97.5 &#xb1; 9.1 cm, P = 0.030), a greater left ventricular end-diastolic diameter (46.6 &#xb1; 4.9 mm vs. 43.1 &#xb1; 4.9 mm, P = 0.026), and a lower left ventricular ejection fraction (64.1 &#xb1; 5.7 % vs. 68.5 &#xb1; 7.8%, P = 0.048). While overall biodiversity and general microbial composition were similar between the noHCM and oHCM groups, ten taxa displayed significant differences at the genus and species levels, with Porphyromonas gingivalis showing the highest abundance and greater enrichment in noHCM (relative abundance: 7.79535 vs. 4.87697, P = 0.043). Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis identified ten distinct pathways, with pathways related to energy and amino acid metabolism being enriched in oHCM patients, and those associated with genetic information processing less abundant in the oHCM group. Metabolic potential analysis revealed ten significantly altered metabolites primarily associated with amino sugar and nucleotide sugar metabolism, porphyrin metabolism, pentose and glucuronate interconversion, and lysine degradation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The higher abundance of Porphyromonas gingivalis, which is known to impact cardiovascular health, in noHCM patients may partially account for clinical differences between the groups. Pathway enrichment and metabolic potential analyses suggest microbial functional shifts between noHCM and oHCM patients, potentially reflecting inherent metabolic changes in HCM.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Qianyi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing 100081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cardiomyopathy Ward, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Liu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Stomatology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Runzhi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing 100081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiomyopathy Ward, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiomyopathy Ward, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weiran</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing 100081, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin Med J (Engl)</MedlineTA><NlmUniqueID>7513795</NlmUniqueID><ISSNLinking>0366-6999</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enrichment analysis</Keyword><Keyword MajorTopicYN="N">Hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">KEGG pathway</Keyword><Keyword MajorTopicYN="N">Metabolic potential analysis</Keyword><Keyword MajorTopicYN="N">Metagenomic sequencing</Keyword><Keyword MajorTopicYN="N">Oral microbiota</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>22</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846661</ArticleId><ArticleId IdType="doi">10.1097/CM9.0000000000003777</ArticleId><ArticleId IdType="pii">00029330-990000000-01706</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>O&#x2019;Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014;35:2010&#x2013;2020. doi: 10.1093/eurheartj/eht439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/eht439</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006;114:2232&#x2013;2239. doi: 10.1161/circulationaha.106.644682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.106.644682</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther 2022;7:135. doi: 10.1038/s41392-022-00974-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00974-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Ying J, Ma H, Cui H. Microbiota-related metabolites fueling the understanding of ischemic heart disease. Imeta 2023;2:e94. doi: 10.1002/imt2.94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/imt2.94</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonelli A, Lumngwena EN, Ntusi NAB. The oral microbiome in the pathophysiology of cardiovascular disease. Nat Rev Cardiol 2023;20:386&#x2013;403. doi: 10.1038/s41569-022-00825-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-022-00825-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun 2017;8:845. doi: 10.1038/s41467-017-00900-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00900-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummen M, Mayerhofer CCK, Vestad B, Broch K, Awoyemi A, Storm-Larsen C, et al. Gut microbiota signature in heart failure defined from profiling of 2 independent cohorts. J Am Coll Cardiol 2018;71:1184&#x2013;1186. doi: 10.1016/j.jacc.2017.12.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2017.12.057</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell JA, Zheng T, Meric G, Marques FZ. The gut microbiome and hypertension. Nat Rev Nephrol 2023;19:153&#x2013;167. doi: 10.1038/s41581-022-00654-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00654-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian P, Xuedong Z, Xin X, Yuqing L, Yan L, Jiyao L, et al. The oral microbiome bank of China. Int J Oral Sci 2018;10:16. doi: 10.1038/s41368-018-0018-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41368-018-0018-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Integrative HMP (iHMP) Research Network Consortium. The integrative human microbiome project. Nature 2019;569:641&#x2013;648. doi: 10.1038/s41586-019-1238-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1238-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzosa EA, McIver LJ, Rahnavard G, Thompson LR, Schirmer M, Weingart G, et al. Species-level functional profiling of metagenomes and metatranscriptomes. Nat Methods 2018;15:962&#x2013;968. doi: 10.1038/s41592-018-0176-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-018-0176-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Bui FQ, Almeida-da-Silva CLC, Huynh B, Trinh A, Liu J, Woodward J, et al. Association between periodontal pathogens and systemic disease. Biomed J 2019;42:27&#x2013;35. doi: 10.1016/j.bj.2018.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2018.12.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Yang F, Bao Z. Gut microbiota and myocardial fibrosis. Eur J Pharmacol 2023;940:175355. doi: 10.1016/j.ejphar.2022.175355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2022.175355</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Li L, Wang C, Wang Q, Wang F, Xu X, et al. Dysbiosis of oral and gut microbiota and its association with metabolites in patients with different degrees of coronary artery stenosis. Chin Med J 2024;137:1121&#x2013;1123. doi: 10.1097/CM9.0000000000002943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000002943</ArticleId></ArticleIdList></Reference><Reference><Citation>Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012;486:207&#x2013;214. doi: 10.1038/nature11234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11234</ArticleId></ArticleIdList></Reference><Reference><Citation>Peron D, Prates RA, Antonio EL, Teixeira ILA, de Oliveira HA, Mansano BSDM, et al. A common oral pathogen Porphyromonas gingivalis induces myocarditis in rats. J Clin Periodontol 2022;49:506&#x2013;517. doi: 10.1111/jcpe.13595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpe.13595</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiheido-Watanabe Y, Maejima Y, Nakagama S, Fan Q, Tamura N, Sasano T. Porphyromonas gingivalis, a periodontal pathogen, impairs post-infarcted myocardium by inhibiting autophagosome-lysosome fusion. Int J Oral Sci 2023;15:42. doi: 10.1038/s41368-023-00251-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41368-023-00251-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryan NS, Burleigh MC, Easton C. The oral microbiome, nitric oxide and exercise performance. Nitric Oxide 2022;125-126:23&#x2013;30. doi: 10.1016/j.niox.2022.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.niox.2022.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangula P, Ravella K, Chukkapalli S, Rivera M, Srinivasan S, Hale A, et al. Polybacterial periodontal pathogens alter vascular and gut BH4/nNOS/NRF2-phase II enzyme expression. PLoS One 2015;10:e0129885. doi: 10.1371/journal.pone.0129885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0129885</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes L. Porphyromonas gingivalis. Trends Microbiol 2021;29:376&#x2013;377. doi: 10.1016/j.tim.2021.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2021.01.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang J, Yao K, Wang S, Nie M, Zhao Y, et al. Metabolic characterization of hypertrophic cardiomyopathy in human heart. Nat Cardiovasc Res 2022;1:445&#x2013;461. doi: 10.1038/s44161-022-00057-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44161-022-00057-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray LR, Tompkins SC, Taylor EB. Regulation of pyruvate metabolism and human disease. Cell Mol Life Sci 2014;71:2577&#x2013;2604. doi: 10.1007/s00018-013-1539-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1539-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakrou S, Liu Y, Zhu L, Greenland GV, Simsek B, Hebl VB, et al. Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy. Sci Rep 2021;11:13163. doi: 10.1038/s41598-021-89451-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-89451-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: Dynamic communities and host interactions. Nat Rev Microbiol 2018;16:745&#x2013;759. doi: 10.1038/s41579-018-0089-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0089-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbarvaziri S, Kooiker KB, Ellenberger M, Fajardo G, Zhao M, Vander Roest AS, et al. Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy. Circulation 2021;144:1714&#x2013;1731. doi: 10.1161/circulationaha.121.053575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.121.053575</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuldt M, van Driel B, Alg&#xfc;l S, Parbhudayal RY, Barge-Schaapveld DQCM, G&#xfc;&#xe7;l&#xfc; A, et al. Distinct metabolomic signatures in preclinical and obstructive hypertrophic cardiomyopathy. Cells 2021;10:2950. doi: 10.3390/cells10112950.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10112950</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye H, Borusak S, Eberl C, Krasenbrink J, Weiss AS, Chen SC, et al. Ecophysiology and interactions of a taurine-respiring bacterium in the mouse gut. Nat Commun 2023;14:5533. doi: 10.1038/s41467-023-41008-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41008-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Heggermont WA, Papageorgiou AP, Quaegebeur A, Deckx S, Carai P, Verhesen W, et al. Inhibition of microrna-146a and overexpression of its target dihydrolipoyl succinyltransferase protect against pressure overload-induced cardiac hypertrophy and dysfunction. Circulation 2017;136:747&#x2013;761. doi: 10.1161/circulationaha.116.024171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.116.024171</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli E, Fabbri C, D&#x2019;Accolti M, Soffritti I, Bassi C, Mazzacane S, et al. Defining the oral microbiome by whole-genome sequencing and resistome analysis: The complexity of the healthy picture. BMC Microbiol 2020;20:120. doi: 10.1186/s12866-020-01801-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-020-01801-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker JL, Mark Welch JL, Kauffman KM, McLean JS, He X. The oral microbiome: Diversity, biogeography and human health. Nat Rev Microbiol 2024;22:89&#x2013;104. doi: 10.1038/s41579-023-00963-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00963-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Bataineh MT, Dash NR, Elkhazendar M, Alnusairat DMH, Darwish IMI, Al-Hajjaj MS, et al. Revealing oral microbiota composition and functionality associated with heavy cigarette smoking. J Transl Med 2020;18:421. doi: 10.1186/s12967-020-02579-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02579-3</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40838531</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-8159</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Pacing and clinical electrophysiology : PACE</Title><ISOAbbreviation>Pacing Clin Electrophysiol</ISOAbbreviation></Journal><ArticleTitle>High-Precision Hemodynamic and Echocardiographic Assessment of Pacing in Obstructive Hypertrophic Cardiomyopathy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/pace.70024</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Left ventricular outflow obstruction drives symptoms and outcomes in obstructive hypertrophic cardiomyopathy (oHCM). Right ventricular pacing (RVP) can desynchronize the left ventricle to relieve this and allows control of atrioventricular delay (AVD) but may impair ventricular function. We used high-precision assessment to quantify the hemodynamic and echocardiographic effects of RVP in oHCM.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with oHCM and implanted dual-chamber pacing devices underwent continuous recording of ECG, beat-by-beat outflow tract continuous wave Doppler, and beat-by-beat, noninvasive finger-cuff blood pressure while pacing was alternated between atrium-only pacing and AV-sequential RVP at a range of AVDs at 5&#xa0;bpm above resting heart rate and 100&#xa0;bpm. Changes in systolic blood pressure (&#x2206;SBP) and left ventricular outflow tract gradient (&#x2206;LVOTg) were fitted to parabolas to produce reproducible, narrow confidence interval estimates of effects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty two patients were recruited (60% male, mean resting LVOTg 53&#xa0;mmHg). At just above resting heart rate (mean 75&#xa0;bpm), RVP produced mean peak &#x2206;SBP from AAI to DDD of 2.47&#xa0;mmHg (95% confidence interval: 0.19-4.76, p = 0.04). The mean AVD for peak &#x2206;SBP was 173.2&#xa0;ms. Mean LVOTg reduction at this AVD was 8.31&#xa0;mmHg (2.43-14.18, p &lt; 0.001). Apart from the hemodynamically optimum AVD, no other AVDs produced statistically significant increases in SBP. At 100&#xa0;bpm, greater increases in SBP and reductions in LVOTg were seen at hemodynamically optimal AVD.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Multiple alternation assessment allows precise, reproducible, narrow confidence interval quantification of hemodynamic and echocardiographic pacing effects. RVP can reduce LVOTg while preserving or improving cardiac output, but AVD is a key modifier of this relationship.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Pacing and Clinical Electrophysiology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohal</LastName><ForeName>Jagdeep S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-0442-4033</Identifier><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shun-Shin</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiew</LastName><ForeName>Kayla</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazawa</LastName><ForeName>Alejandra A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simader</LastName><ForeName>Florentina</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tangkongpanich</LastName><ForeName>Pannathorn</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahl</LastName><ForeName>Rahul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Ji-Jian</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>James P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naraen</LastName><ForeName>Akriti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saleh</LastName><ForeName>Keenan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samways</LastName><ForeName>Jack W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohaib</LastName><ForeName>S M Afzal</ForeName><Initials>SMA</Initials><AffiliationInfo><Affiliation>Barts Heart Centre, St Bartholomew's Hospital, West Smithfield, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanner</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leong</LastName><ForeName>Kevin M W</ForeName><Initials>KMW</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National University Heart Centre, National University Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Norman A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefroy</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanagaratnam</LastName><ForeName>Prapa</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>Darrel P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varnava</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whinnett</LastName><ForeName>Zachary I</ForeName><Initials>ZI</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Ahran D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0002-7597-0170</Identifier><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Coronary Flow Trust</Agency><Country/></Grant><Grant><GrantID>MR/X502959/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>IAA 2023/1</GrantID><Agency>Rosetrees Trust</Agency><Country/></Grant><Grant><Agency>NIHR Imperial Biomedical Research Centre</Agency><Country/></Grant><Grant><GrantID>FS/CRTF/21/24171</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pacing Clin Electrophysiol</MedlineTA><NlmUniqueID>7803944</NlmUniqueID><ISSNLinking>0147-8389</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">hemodynamics</Keyword><Keyword MajorTopicYN="N">hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">obstructive hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">right ventricular pacing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>7</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40838531</ArticleId><ArticleId IdType="doi">10.1111/pace.70024</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>M. S. Maron, I. Olivotto, S. Betocchi, et&#xa0;al., &#x201c;Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy,&#x201d; New England Journal of Medicine 348 (2003): 295&#x2013;303, https://doi.org/10.1056/NEJMoa021332.</Citation></Reference><Reference><Citation>L. Kappenberger, C. Linde, C. Daubert, et&#xa0;al., &#x201c;Pacing in Hypertrophic Obstructive Cardiomyopathy. A Randomized Crossover Study. PIC Study Group,&#x201d; European Heart Journal 18 (1997): 1249&#x2013;1256, https://doi.org/10.1093/oxfordjournals.eurheartj.a015435.</Citation></Reference><Reference><Citation>B. J. Maron, W. J. McKenna, G. K. Danielson, et&#xa0;al., &#x201c;American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines,&#x201d; Journal of American College of Cardiology 42 (2003): 1687&#x2013;1713, https://doi.org/10.1016/s0735&#x2010;1097(03)00941&#x2010;0.</Citation></Reference><Reference><Citation>Z. I. Whinnett, M. J. Shun&#x2010;Shin, M. Tanner, et&#xa0;al., &#x201c;Effects of Haemodynamically Atrio&#x2010;Ventricular Optimized His Bundle Pacing on Heart Failure Symptoms and Exercise Capacity: The His Optimized Pacing Evaluated for Heart Failure (HOPE&#x2010;HF) Randomized, Double&#x2010;blind, Cross&#x2010;Over Trial,&#x201d; European Journal of Heart Failure 25 (2023): 274&#x2013;283, https://doi.org/10.1002/ejhf.2736.</Citation></Reference><Reference><Citation>D. R. Ludwig, H. Tanaka, M. Friehling, J. Gorcsan 3rd, and D. Schwartzman, &#x201c;Further Deterioration of LV Ejection Fraction and Mechanical Synchrony During RV Apical Pacing in Patients With Heart Failure and LBBB,&#x201d; Journal of Cardiovascular Translational Research 6 (2013): 425&#x2013;429, https://doi.org/10.1007/s12265&#x2010;013&#x2010;9457&#x2010;0.</Citation></Reference><Reference><Citation>A. A. Miyazawa, D. P. Francis, and Z. I. Whinnett, &#x201c;Basic Principles of Hemodynamics in Pacing,&#x201d; Cardiac Electrophysiology Clinics 14 (2022): 133&#x2013;140, https://doi.org/10.1016/j.ccep.2021.12.001.</Citation></Reference><Reference><Citation>P. A. Pabari, K. Willson, B. Stegemann, et&#xa0;al., &#x201c;When Is an Optimization Not an Optimization? Evaluation of Clinical Implications of Information Content (Signal&#x2010;to&#x2010;Noise Ratio) in Optimization of Cardiac Resynchronization Therapy, and How to Measure and Maximize It,&#x201d; Heart Failure Reviews 16 (2011): 277&#x2013;290, https://doi.org/10.1007/s10741&#x2010;010&#x2010;9203&#x2010;5.</Citation></Reference><Reference><Citation>B. J. Maron, R. A. Nishimura, W. J. McKenna, H. Rakowski, M. E. Josephson, and R. S. Kieval, &#x201c;Assessment of Permanent Dual&#x2010;Chamber Pacing as a Treatment for Drug&#x2010;Refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. A Randomized, Double&#x2010;Blind, Crossover Study (M&#x2010;PATHY),&#x201d; Circulation 99 (1999): 2927&#x2013;2933, https://doi.org/10.1161/01.cir.99.22.2927.</Citation></Reference><Reference><Citation>A. J. Sharp, S. M. A. Sohaib, M. J. Shun&#x2010;Shin, et&#xa0;al., &#x201c;Improving Haemodynamic Optimization of Cardiac Resynchronization Therapy for Heart Failure,&#x201d; Physiological Measurement 40 (2019): 04NT01, https://doi.org/10.1088/1361&#x2010;6579/ab152c.</Citation></Reference><Reference><Citation>Z. I. Whinnett, S. M. A. Sohaib, M. Mason, et&#xa0;al., &#x201c;Multicenter Randomized Controlled Crossover Trial Comparing Hemodynamic Optimization Against Echocardiographic Optimization of AV and VV Delay of Cardiac Resynchronization Therapy: The BRAVO Trial,&#x201d; JACC: Cardiovascular Imaging 12 (2019): 1407&#x2013;1416, https://doi.org/10.1016/j.jcmg.2018.02.014.</Citation></Reference><Reference><Citation>C. H. Manisty, A. Al&#x2010;Hussaini, B. Unsworth, et&#xa0;al., &#x201c;The Acute Effects of Changes to AV Delay on BP and Stroke Volume: Potential Implications for Design of Pacemaker Optimization Protocols,&#x201d; Circulation: Arrhythmia and Electrophysiology 5 (2012): 122&#x2013;130, https://doi.org/10.1161/circep.111.964205.</Citation></Reference><Reference><Citation>Z. I. Whinnett, J. E. Davies, K. Willson, et&#xa0;al., &#x201c;Determination of Optimal Atrioventricular Delay for Cardiac Resynchronization Therapy Using Acute Non&#x2010;Invasive Blood Pressure,&#x201d; Europace 8 (2006): 358&#x2013;366, https://doi.org/10.1093/europace/eul017.</Citation></Reference><Reference><Citation>M. J. Shun&#x2010;Shin, A. A. Miyazawa, D. Keene, et&#xa0;al., &#x201c;How to Deliver Personalized Cardiac Resynchronization Therapy Through the Precise Measurement of the Acute Hemodynamic Response: Insights From the iSpot Trial,&#x201d; Journal of Cardiovascular Electrophysiology 30 (2019): 1610&#x2013;1619, https://doi.org/10.1111/jce.14001.</Citation></Reference><Reference><Citation>P. P. Dimitrow, J. Grodecki, B. Bacior, et&#xa0;al., &#x201c;The Importance of Ventricular Septal Morphology in the Effectiveness of Dual Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy,&#x201d; Pacing and Clinical Electrophysiology 23 (2000): 1324&#x2013;1329, https://doi.org/10.1111/j.1540&#x2010;8159.2000.tb00958.x.</Citation></Reference><Reference><Citation>I. Topilski, J. Sherez, G. Keren, and I. Copperman, &#x201c;Long&#x2010;Term Effects of Dual&#x2010;Chamber Pacing With Periodic Echocardiographic Evaluation of Optimal Atrioventricular Delay in Patients With Hypertrophic Cardiomyopathy &gt;50 Years of Age,&#x201d; American Journal of Cardiology 97 (2006): 1769&#x2013;1775, https://doi.org/10.1016/j.amjcard.2006.01.040.</Citation></Reference><Reference><Citation>D. Javidgonbadi, N. J. Abdon, B. Andersson, M. Schaufelberger, and I. &#xd6;stman&#x2010;Smith, &#x201c;Short Atrioventricular Delay Pacing Therapy in Young and Old Patients With Hypertrophic Obstructive Cardiomyopathy: Good Long&#x2010;Term Results and a Low Need for Reinterventions,&#x201d; Europace 20 (2018): 1683&#x2013;1691, https://doi.org/10.1093/europace/eux331.</Citation></Reference><Reference><Citation>D. Gras, C. Daubert, and P. Mabo, &#x201c;Value of Cardiac Pacing in Hypertrophic Obstructive Cardiomyopathy Refractory to Medical Treatment [in French],&#x201d; Archives Des Maladies Du Coeur Et Des Vaisseaux 88 (1995): 577&#x2013;583.</Citation></Reference><Reference><Citation>N. Inoue, T. Ishikawa, S. Sumita, et&#xa0;al., &#x201c;Long&#x2010;Term Follow&#x2010;Up of Atrioventricular Delay Optimization in Patients With Biventricular Pacing,&#x201d; Circulation Journal 69 (2005): 201&#x2013;204, https://doi.org/10.1253/circj.69.201.</Citation></Reference><Reference><Citation>Team RC, &#x201c;R: A Language and Environment for Statistical Computing,&#x201d; MSOR Connections 1 (2014).</Citation></Reference><Reference><Citation>K. McDonald, E. McWilliams, B. O'Keeffe, and B. Maurer, &#x201c;Functional Assessment of Patients Treated With Permanent Dual Chamber Pacing as a Primary Treatment for Hypertrophic Cardiomyopathy,&#x201d; European Heart Journal 9 (1988): 893&#x2013;898, https://doi.org/10.1093/oxfordjournals.eurheartj.a062584.</Citation></Reference><Reference><Citation>S. Seitler, S. De Zoysa Anthony, C. C. C. Obianyo, et&#xa0;al., &#x201c;Systolic Anterior Motion of the Anterior Mitral Valve Leaflet Begins in Subclinical Hypertrophic Cardiomyopathy,&#x201d; European Heart Journal &#x2010; Cardiovascular Imaging 25 (2023): 86&#x2013;94, https://doi.org/10.1093/ehjci/jead186.</Citation></Reference><Reference><Citation>A. J. Bank, R. M. Gage, and K. V. Burns, &#x201c;Right Ventricular Pacing, Mechanical Dyssynchrony, and Heart Failure,&#x201d; Journal of Cardiovascular Translational Research 5 (2012): 219&#x2013;231, https://doi.org/10.1007/s12265&#x2010;011&#x2010;9341&#x2010;8.</Citation></Reference><Reference><Citation>X. Jeanrenaud, J. J. Goy, and L. Kappenberger, &#x201c;Effects of Dual&#x2010;Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy,&#x201d; Lancet 339 (1992): 1318&#x2013;1323, https://doi.org/10.1016/0140&#x2010;6736(92)91961&#x2010;7.</Citation></Reference><Reference><Citation>J. M. Tolosana and E. Trucco, &#x201c;Cardiac Pacing in Patients With Hypertrophic Obstructive Cardiomyopathy,&#x201d; Global Cardiology Science and Practice 2018 (2018): 29, https://doi.org/10.21542/gcsp.2018.29.</Citation></Reference><Reference><Citation>R. A. Nishimura, J. M. Trusty, D. L. Hayes, et&#xa0;al., &#x201c;Dual&#x2010;Chamber Pacing for Hypertrophic Cardiomyopathy: A Randomized, Double&#x2010;Blind, Crossover Trial,&#x201d; Journal of American College of Cardiology 29 (1997): 435&#x2013;441, https://doi.org/10.1016/s0735&#x2010;1097(96)00473&#x2010;1.</Citation></Reference><Reference><Citation>A. D. Arnold, J. P. Howard, K. Chiew, et&#xa0;al., &#x201c;Right Ventricular Pacing for Hypertrophic Obstructive Cardiomyopathy: Meta&#x2010;Analysis and Meta&#x2010;Regression of Clinical Trials,&#x201d; European Heart Journal &#x2010; Quality of Care and Clinical Outcomes 5 (2019): 321&#x2013;333, https://doi.org/10.1093/ehjqcco/qcz006.</Citation></Reference><Reference><Citation>P. M. Elliott, A. Anastasakis, M. A. Borger, et&#xa0;al., &#x201c;2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC),&#x201d; European Heart Journal 35 (2014): 2733&#x2013;2779, https://doi.org/10.1093/eurheartj/ehu284.</Citation></Reference><Reference><Citation>S. R. Ommen, S. Mital, M. A. Burke, et&#xa0;al., &#x201c;2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,&#x201d; Journal of American College of Cardiology 76 (2020): e159&#x2013;e240, https://doi.org/10.1016/j.jacc.2020.08.045.</Citation></Reference><Reference><Citation>S. Riaz, S. R. McMahon, K. Stockey, M. Meyer, and A. Weissler&#x2010;Snir, &#x201c;Effect of Personalized Accelerated Pacing in Patients With Nonobstructive Hypertrophic Cardiomyopathy,&#x201d; Journal of American College of Cardiology 83 (2024): 1492&#x2013;1493, https://doi.org/10.1016/j.jacc.2024.01.036.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40831353</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-9645</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>European heart journal</Title><ISOAbbreviation>Eur Heart J</ISOAbbreviation></Journal><ArticleTitle>Reframing cirrhotic cardiomyopathy: a cardiologist's perspective on an overlooked HFpEF phenotype.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ehaf545</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/eurheartj/ehaf545</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2430-8953</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Geneva University Hospitals, University of Geneva, Rue Gabrielle Perret-Gentil 4, Geneva 1205, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Henri</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9074-6505</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0003-3698-9597</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J</MedlineTA><NlmUniqueID>8006263</NlmUniqueID><ISSNLinking>0195-668X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40831353</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehaf545</ArticleId><ArticleId IdType="pii">8238358</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40826335</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Predictive value of combined inflammatory markers for septic cardiomyopathy: a retrospective study.</ArticleTitle><Pagination><StartPage>1033</StartPage><MedlinePgn>1033</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1033</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-025-11447-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Septic cardiomyopathy (SCM) is a common but underdiagnosed complication of sepsis characterized by acute myocardial dysfunction driven by inflammatory and immune dysregulation. This study aimed to investigate the clinical characteristics, inflammatory profiles, and predictive markers associated with SCM, highlighting its diagnostic and prognostic importance.</AbstractText><AbstractText Label="METHODS">Clinical data from 89 controls and 71 SCM patients were retrospectively analyzed from January 2022 to July 2024. The differences in demographics, clinical characteristics, hematological parameters, inflammatory markers, and cardiac injury markers were compared between the two groups. Additionally, the risk factors for SCM were evaluated via univariate and multivariate logistic regression analyses. After that, the predictive capacity of each marker for SCM was assessed through the receiver operating characteristics curve analysis.</AbstractText><AbstractText Label="RESULTS">The SCM group had significantly higher levels of SOFA score, platelet-to-lymphocyte ratio (PLR), cardiac troponin I (cTnI), neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index, NT-proBNP, and inflammatory markers such as CRP, TNF-&#x3b1;, PCT, and IL-6 (<i>P</i>&#x2009;&lt;&#x2009;0.05). Multivariate analysis revealed that cTnI (OR&#x2009;=&#x2009;4.548, 95% CI: 1.164&#x2013;19.452, <i>P</i>&#x2009;=&#x2009;0.041), NLR (OR&#x2009;=&#x2009;4.231, 95% CI: 2.443&#x2013;7.328, <i>P</i>&#x2009;&lt;&#x2009;0.001), and CRP (OR&#x2009;=&#x2009;1.138, 95% CI: 1.061&#x2013;1.221, <i>P</i>&#x2009;&lt;&#x2009;0.001) were independent risk factors for SCM. The combined use of NLR, PLR, and CRP yielded an AUC of 0.962, with a sensitivity of 91.5% and specificity of 93.3%.</AbstractText><AbstractText Label="CONCLUSIONS">SCM is associated with pronounced inflammatory activation and myocardial injury. This study identifies cTnI, NLR, and CRP as independent risk factors. Notably, the combined use of NLR, CRP, and PLR significantly enhances diagnostic accuracy, providing a reliable basis for early identification and targeted intervention in SCM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Xianqi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Emergency Department, Zhongshan City People's Hospital, Zhongshan, Guangdong, 528400, China. sanmao291@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai</LastName><ForeName>Huiqiang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Emergency Department, Zhongshan City People's Hospital, Zhongshan, Guangdong, 528400, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inflammatory factor</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Septic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Systemic immune-inflammation index</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This research was provided by the Medical Ethics Committee of Zhongshan City People's Hospital (Approval No.2024-127) and conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived by the ethics committee because the study was retrospective and involved only anonymized data. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40826335</ArticleId><ArticleId IdType="pmc">PMC12363019</ArticleId><ArticleId IdType="doi">10.1186/s12879-025-11447-8</ArticleId><ArticleId IdType="pii">10.1186/s12879-025-11447-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Borges A, Bento L. Organ crosstalk and dysfunction in sepsis. Ann Intensive Care. 2024;14(1):147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11413314</ArticleId><ArticleId IdType="pubmed">39298039</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M, Perna B, Cesaro AE, Maritati M, Spampinato MD, Contini C, De Giorgio R. 2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department. J Clin Med. 2023;12(9):3188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10179263</ArticleId><ArticleId IdType="pubmed">37176628</ArticleId></ArticleIdList></Reference><Reference><Citation>Bode C, Weis S, Sauer A, Wendel-Garcia P, David S. Targeting the host response in sepsis: current approaches and future evidence. Crit Care. 2023;27(1):478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10698949</ArticleId><ArticleId IdType="pubmed">38057824</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady J, Horie S, Laffey JG. Role of the adaptive immune response in sepsis. Intensive Care Med Exp. 2020;8(Suppl 1):20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746432</ArticleId><ArticleId IdType="pubmed">33336293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Wang W, Lee M, Meng Q, Ren H. Current status of septic cardiomyopathy: basic science and clinical progress. Front Pharmacol. 2020;11:210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7062914</ArticleId><ArticleId IdType="pubmed">32194424</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Zhang Z. Sepsis-induced myocardial dysfunction: the role of mitochondrial dysfunction. Inflamm Res. 2021;70(4):379&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">33683374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimolai MC, Alvarez S, Bode C, Bugger H. Mitochondrial mechanisms in septic cardiomyopathy. Int J Mol Sci. 2015;16(8):17763&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4581220</ArticleId><ArticleId IdType="pubmed">26247933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakihana Y, Ito T, Nakahara M, Yamaguchi K, Yasuda T. Sepsis-induced myocardial dysfunction: pathophysiology and management. J Intensive Care. 2016;4: 22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4804632</ArticleId><ArticleId IdType="pubmed">27011791</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Zeng J, Yu X, Wang Z, Wang D, Zhou Q, Bai T, Xu Y. PCT, IL-6, and IL-10 facilitate early diagnosis and pathogen classifications in bloodstream infection. Ann Clin Microbiol Antimicrob. 2023;22(1):103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10662675</ArticleId><ArticleId IdType="pubmed">37986183</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhi F, Ma JW, Ji DD, Bao J, Li QQ. Causal associations between circulating cytokines and risk of sepsis and related outcomes: a two-sample Mendelian randomization study. Front Immunol. 2024;15:1336586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10948396</ArticleId><ArticleId IdType="pubmed">38504987</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Qin X, Zhang X, Zhang Y, Yuan F, Shi W, Liu B, Wei Y. Prognostic implications of systemic immune-inflammation index in myocardial infarction patients with and without diabetes: insights from the NOAFCAMI-SH registry. Cardiovasc Diabetol. 2024;23(1):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10804591</ArticleId><ArticleId IdType="pubmed">38254086</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone F, Liberale L, Preda A, Schindler TH, Montecucco F. Septic cardiomyopathy: from pathophysiology to the clinical setting. Cells. 2022;11(18):2833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9496713</ArticleId><ArticleId IdType="pubmed">36139408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Wang W, Lee M, Meng Q, Ren H. Current Status of Septic Cardiomyopathy: Basic Science and Clinical Progress. Front Pharmacol. 2020;11:210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7062914</ArticleId><ArticleId IdType="pubmed">32194424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakihana Y, Ito T, Nakahara M, Yamaguchi K, Yasuda T. Sepsis-induced myocardial dysfunction: pathophysiology and management. J Intensive Care. 2016;4(1): 22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4804632</ArticleId><ArticleId IdType="pubmed">27011791</ArticleId></ArticleIdList></Reference><Reference><Citation>Roldgaard M, Benfield T, Tingsg&#xe5;rd S. Blood neutrophil to lymphocyte ratio is associated with 90-day mortality and 60-day readmission in gram negative bacteremia: a multi-center cohort study. BMC Infect Dis. 2024;24(1):255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10893647</ArticleId><ArticleId IdType="pubmed">38395788</ArticleId></ArticleIdList></Reference><Reference><Citation>Reindl M, Tiller C, Holzknecht M, Lechner I, Henninger B, Mayr A, Brenner C, Klug G, Bauer A, Metzler B, et al. Association of myocardial injury with serum procalcitonin levels in patients with ST-elevation myocardial infarction. JAMA Netw Open. 2020;3(6):e207030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296390</ArticleId><ArticleId IdType="pubmed">32539151</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesur O, Delile E, Asfar P, Radermacher P. Hemodynamic support in the early phase of septic shock: a review of challenges and unanswered questions. Ann Intensive Care. 2018;8(1):102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206320</ArticleId><ArticleId IdType="pubmed">30374729</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroshima T, Kawaguchi S, Okada M. Current perspectives of mitochondria in Sepsis-Induced cardiomyopathy. Int J Mol Sci. 2024;25(9):4710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11083471</ArticleId><ArticleId IdType="pubmed">38731929</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Li M, Liu L, Deng L, Yulei X, Zhong Y, Liao B, Yu L, Feng J. Systemic immune-inflammation index as a novel predictor of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention: a meta-analysis of cohort studies. BMC Cardiovasc Disord. 2024;24(1):189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10985984</ArticleId><ArticleId IdType="pubmed">38561664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansar W, Ghosh S. C-Reactive Protein: A Clinical Marker in Cardiovascular Disease. Springer India. 2016;2(Chapter 7):143&#x2013;65. 10.1007/978-81-322-2680-.</Citation></Reference><Reference><Citation>Amezcua-Castillo E, Gonzalez-Pacheco H, Saenz-San Martin A, Mendez-Ocampo P, Gutierrez-Moctezuma I, Masso F, Sierra-Lara D, Springall R, Rodriguez E, Arias-Mendoza A et al. C-Reactive protein: the quintessential marker of systemic inflammation in coronary artery Disease-Advancing toward precision medicine. Biomedicines. 2023;11(9):2444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10525787</ArticleId><ArticleId IdType="pubmed">37760885</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Yu J, Li R, Zhou H, Chang X. New insights into the role of mitochondrial metabolic dysregulation and immune infiltration in septic cardiomyopathy by integrated bioinformatics analysis and experimental validation. Cell Mol Biol Lett. 2024;29(1):21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10826082</ArticleId><ArticleId IdType="pubmed">38291374</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yang W, Sun X, Xie L, Yang Y, Sang M, Jiao R. SS31 ameliorates sepsis-induced heart injury by inhibiting oxidative stress and inflammation. Inflammation. 2019;42(6):2170&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">31494795</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Zhang J, Jin W, Tian R, Wang R. [Corrigendum] role of Thrombospondin&#x2013;1 in sepsis&#x2013;induced myocardial injury. Mol Med Rep. 2023;27(6):113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10170490</ArticleId><ArticleId IdType="pubmed">37083065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Choi EJ, Choi EJ. Evolving paradigms in sepsis management: A narrative review. Cells 2024;13(14):1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11274781</ArticleId><ArticleId IdType="pubmed">39056754</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#x2019;Heureux M, Sternberg M, Brath L, Turlington J, Kashiouris MG. Sepsis-induced cardiomyopathy: a comprehensive review. Curr Cardiol Rep. 2020;22(5):35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222131</ArticleId><ArticleId IdType="pubmed">32377972</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrysohoou C, Konstantinou K, Tsioufis K. The Role of NT-proBNP Levels in the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction-It Is Not Always a Hide-and-Seek Game. J Cardiovasc Dev Dis. 2024;11(7):225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11277408</ArticleId><ArticleId IdType="pubmed">39057645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu JL, Yuan SQ, Huang T, Zhang LM, Xu XM, Yin HY, Wei JR, Lyu J. Influence of systolic blood pressure trajectory on in-hospital mortality in patients with sepsis. BMC Infect Dis. 2023;23(1):90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9926677</ArticleId><ArticleId IdType="pubmed">36782139</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna AK, Kinoshita T, Natarajan A, Schwager E, Linn DD, Dong J, Ghosh E, Vicario F, Maheshwari K. Association of systolic, diastolic, mean, and pulse pressure with morbidity and mortality in septic ICU patients: a nationwide observational study. Ann Intensive Care. 2023;13(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9941378</ArticleId><ArticleId IdType="pubmed">36807233</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai XT, Kong TZ, Zhang XJ, Luan B, Wang Y, Hou AJ. Relationship between increased systemic immune-inflammation index and coronary slow flow phenomenon. BMC Cardiovasc Disord. 2022;22(1): 362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9358856</ArticleId><ArticleId IdType="pubmed">35941535</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Qin X, Zhang X, Zhang Y, Yuan F, Shi W, Liu B, Wei Y, Investigators N-SR. Prognostic implications of systemic immune-inflammation index in myocardial infarction patients with and without diabetes: insights from the NOAFCAMI-SH registry. Cardiovasc Diabetol. 2024;23(1):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10804591</ArticleId><ArticleId IdType="pubmed">38254086</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40831362</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-9645</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>European heart journal</Title><ISOAbbreviation>Eur Heart J</ISOAbbreviation></Journal><ArticleTitle>Potential perspectives on high intensity exercise programmes in patients with hypertrophic cardiomyopathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ehaf547</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/eurheartj/ehaf547</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, No. 99 Longcheng Street, Taiyuan, Shanxi 030032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanxi Province Clinical Theranostics Technology Innovation Center for Immunologic and Rheumatic Diseases, Shanxi Province Clinical Research Center for Dermatologic and Immunologic Diseases (Rheumatic Diseases), Research and Innovation Team Project for Scientific Breakthroughs, Shanxi Bethune Hospital, No. 99 Longcheng Street, Taiyuan, Shanxi 030032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Junyan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Evidence-Based Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li-Yun</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, No. 99 Longcheng Street, Taiyuan, Shanxi 030032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanxi Province Clinical Theranostics Technology Innovation Center for Immunologic and Rheumatic Diseases, Shanxi Province Clinical Research Center for Dermatologic and Immunologic Diseases (Rheumatic Diseases), Research and Innovation Team Project for Scientific Breakthroughs, Shanxi Bethune Hospital, No. 99 Longcheng Street, Taiyuan, Shanxi 030032, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No.202303021222314</GrantID><Agency>Science and Technology Department of Shanxi Province Free Exploration Youth Project</Agency><Country/></Grant><Grant><GrantID>No. CXZX-202305</GrantID><Agency>Shanxi Province Clinical Theranostics Technology Innovation Center for Immunologic and Rheumatic Diseases</Agency><Country/></Grant><Grant><GrantID>No. LYZX-202501</GrantID><Agency>Shanxi Province Clinical Research Center for Dermatologic and Immunologic Diseases</Agency><Country/></Grant><Grant><GrantID>2024AOXIANG02</GrantID><Agency>Research and Innovation Team Project for Scientific Breakthroughs at Shanxi Bethune Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J</MedlineTA><NlmUniqueID>8006263</NlmUniqueID><ISSNLinking>0195-668X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>3</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40831362</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehaf547</ArticleId><ArticleId IdType="pii">8238361</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40830233</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2731-0590</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature cardiovascular research</Title><ISOAbbreviation>Nat Cardiovasc Res</ISOAbbreviation></Journal><ArticleTitle>Excessive HIF-1&#x3b1; driven by phospholipid metabolism causes septic cardiomyopathy through cytopathic hypoxia.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s44161-025-00687-1</ELocationID><Abstract><AbstractText>Septic cardiomyopathy, one manifestation of multiple organ dysfunction syndrome, is a challenging complication in sepsis, and cytopathic hypoxia has been proposed to have a key role in the pathophysiology of multiple organ dysfunction syndrome. However, the underlying mechanisms remain unknown. Here, we show that upregulation of hypoxia-inducible factor-1&#x3b1; (HIF-1&#x3b1;) in cardiomyocytes following lipopolysaccharide (LPS) treatment suppresses mitochondrial respiration via inducible nitric oxide synthase-dependent nitric oxide, leading to cytopathic hypoxia. Cardiac-specific heterozygous deletion of HIF-1&#x3b1; ameliorates mitochondrial and contractile dysfunction in a mouse model of septic cardiomyopathy. Mechanistically, nuclear factor-&#x3ba;B (NF-&#x3ba;B)-mediated upregulation of cyclooxygenase 2 (COX2) and secretory phospholipases A2 (sPLA2) enhances HIF-1&#x3b1; expression following LPS exposure, whereas their inhibition prevents LPS-induced HIF-1&#x3b1; upregulation, cytopathic hypoxia and contractile dysfunction. In addition, phospholipid metabolites (prostaglandins and lysophospholipids/free fatty acids, respectively) stabilize HIF-1&#x3b1; via protein kinase A activation. These findings highlight a crucial role of excessive HIF-1&#x3b1;, driven by LPS-enhanced phospholipid metabolism, in septic cardiomyopathy through induction of cytopathic hypoxia.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Masatsugu</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0394-8959</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Masataka</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1893-8171</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan. ikeda-m@cardiol.med.kyushu-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan. ikeda-m@cardiol.med.kyushu-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Kyushu University Beppu Hospital, Oita, Japan. ikeda-m@cardiol.med.kyushu-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Ko</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2107-3052</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furusawa</LastName><ForeName>Shun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishimaru</LastName><ForeName>Kosei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanamura</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Hiroko Deguchi</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozakura</LastName><ForeName>Eisho</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Pathobiology, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isayama</LastName><ForeName>Yoko Shojima</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kai</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Toru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsushima</LastName><ForeName>Shouji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ide</LastName><ForeName>Tomomi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3387-1550</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Ken-Ichi</ForeName><Initials>KI</Initials><Identifier Source="ORCID">0000-0003-2100-8477</Identifier><AffiliationInfo><Affiliation>Department of Molecular Pathobiology, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsutsui</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine and Graduate School, International University of Health and Welfare, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamaura</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Kohtaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP24K22274</GrantID><Agency>MEXT | Japan Society for the Promotion of Science (JSPS)</Agency><Country/></Grant><Grant><GrantID>JP24K02449</GrantID><Agency>MEXT | Japan Society for the Promotion of Science (JSPS)</Agency><Country/></Grant><Grant><GrantID>JP23H05481</GrantID><Agency>MEXT | Japan Society for the Promotion of Science (JSPS)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cardiovasc Res</MedlineTA><NlmUniqueID>9918284280206676</NlmUniqueID><ISSNLinking>2731-0590</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40830233</ArticleId><ArticleId IdType="doi">10.1038/s44161-025-00687-1</ArticleId><ArticleId IdType="pii">10.1038/s44161-025-00687-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Evans, L. et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit. Care Med. 49, e1063&#x2013;e1143 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34605781</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315, 801&#x2013;810 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26903338</ArticleId><ArticleId IdType="pmc">4968574</ArticleId></ArticleIdList></Reference><Reference><Citation>Beesley, S. J. et al. Septic cardiomyopathy. Crit Care Med 46, 625&#x2013;634 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29227368</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco, J. et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit. Care 12, R158 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19091069</ArticleId><ArticleId IdType="pmc">2646323</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink, M. Cytopathic hypoxia in sepsis. Acta Anaesthesiol. Scand. 110, 87&#x2013;95 (1997).</Citation></Reference><Reference><Citation>Fink, M. P. Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit. Care Clin. 17, 219&#x2013;237 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11219231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss, R. S. et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 27, 1230&#x2013;1251 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10446814</ArticleId></ArticleIdList></Reference><Reference><Citation>van Boxel, G. I., Doherty, W. L. &amp; Parmar, M. Cellular oxygen utilization in health and sepsis. Contin. Ed. Anaesth. Crit. Care Pain 12, 6 (2012).</Citation></Reference><Reference><Citation>Majmundar, A. J., Wong, W. J. &amp; Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294&#x2013;309 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20965423</ArticleId><ArticleId IdType="pmc">3143508</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. Cell 148, 399&#x2013;408 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22304911</ArticleId><ArticleId IdType="pmc">3437543</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon, M. C. Coming up for air: HIF-1 and mitochondrial oxygen consumption. Cell Metab. 3, 150&#x2013;151 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16517402</ArticleId></ArticleIdList></Reference><Reference><Citation>Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L. &amp; Denko, N. C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3, 187&#x2013;197 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16517406</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, J. W., Tchernyshyov, I., Semenza, G. L. &amp; Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177&#x2013;185 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16517405</ArticleId></ArticleIdList></Reference><Reference><Citation>Deguchi, H. et al. Roxadustat markedly reduces myocardial ischemia reperfusion injury in mice. Circ. J. 84, 1028&#x2013;1033 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32213720</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop, T. &amp; Ratcliffe, P. J. HIF hydroxylase pathways in cardiovascular physiology and medicine. Circ. Res. 117, 65&#x2013;79 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26089364</ArticleId><ArticleId IdType="pmc">4501273</ArticleId></ArticleIdList></Reference><Reference><Citation>Kido, M. et al. Hypoxia-inducible factor 1-&#x3b1; reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J. Am. Coll. Cardiol. 46, 2116&#x2013;2124 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16325051</ArticleId></ArticleIdList></Reference><Reference><Citation>Holscher, M. et al. Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J. Biol. Chem. 286, 11185&#x2013;11194 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21270129</ArticleId><ArticleId IdType="pmc">3064173</ArticleId></ArticleIdList></Reference><Reference><Citation>Moslehi, J. et al. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation 122, 1004&#x2013;1016 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20733101</ArticleId></ArticleIdList></Reference><Reference><Citation>Holscher, M. et al. Unfavourable consequences of chronic cardiac HIF-1&#x3b1; stabilization. Cardiovasc Res. 94, 77&#x2013;86 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22258630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekeredjian, R. et al. Conditional HIF-1&#x3b1; expression produces a reversible cardiomyopathy. PLoS ONE 5, e11693 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20657781</ArticleId><ArticleId IdType="pmc">2908132</ArticleId></ArticleIdList></Reference><Reference><Citation>McGettrick, A. F. &amp; O&#x2019;Neill, L. A. J. The role of HIF in immunity and inflammation. Cell Metab. 32, 524&#x2013;536 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32853548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan, H., Zhang, Q., Zhang, Y. P., Li, S. S. &amp; Ran, X. Unraveling the role of HIF-1&#x3b1; in sepsis: from pathophysiology to potential therapeutics-a narrative review. Crit. Care 28, 100 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38539163</ArticleId><ArticleId IdType="pmc">10976824</ArticleId></ArticleIdList></Reference><Reference><Citation>Rius, J. et al. NF-&#x3ba;B links innate immunity to the hypoxic response through transcriptional regulation of HIF-1&#x3b1;. Nature 453, 807&#x2013;811 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18432192</ArticleId><ArticleId IdType="pmc">2669289</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung, Y. J., Isaacs, J. S., Lee, S., Trepel, J. &amp; Neckers, L. IL-1&#x3b2;-mediated up-regulation of HIF-1&#x3b1; via an NF&#x3ba;B/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17, 2115&#x2013;2117 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12958148</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, S. et al. IL-6 promotes nuclear translocation of HIF-1&#x3b1; to aggravate chemoresistance of ovarian cancer cells. Eur. J. Pharmacol. 894, 173817 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33345849</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, J., Schmid, T. &amp; Brune, B. Tumor necrosis factor-&#x3b1; causes accumulation of a ubiquitinated form of hypoxia inducible factor-1&#x3b1; through a nuclear factor-&#x3ba;B-dependent pathway. Mol. Biol. Cell 14, 2216&#x2013;2225 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12808024</ArticleId><ArticleId IdType="pmc">194872</ArticleId></ArticleIdList></Reference><Reference><Citation>Salabei, J. K., Gibb, A. A. &amp; Hill, B. G. Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis. Nat. Protoc. 9, 421&#x2013;438 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24457333</ArticleId><ArticleId IdType="pmc">4063296</ArticleId></ArticleIdList></Reference><Reference><Citation>Poderoso, J. J., Helfenberger, K. &amp; Poderoso, C. The effect of nitric oxide on mitochondrial respiration. Nitric Oxide 88, 61&#x2013;72 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30999001</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, X. H. et al. Prostaglandin E2 induces hypoxia-inducible factor-1&#x3b1; stabilization and nuclear localization in a human prostate cancer cell line. J. Biol. Chem. 277, 50081&#x2013;50086 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12401798</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, T. C. et al. Stabilization of hypoxia-inducible factor-1&#x3b1; by prostacyclin under prolonged hypoxia via reducing reactive oxygen species level in endothelial cells. J. Biol. Chem. 280, 36567&#x2013;36574 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16115891</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, L. &amp; Clipstone, N. A. Prostaglandin F2&#x3b1; induces the normoxic activation of the hypoxia-inducible factor-1 transcription factor in differentiating 3T3-L1 preadipocytes: potential role in the regulation of adipogenesis. J. Cell. Biochem. 105, 89&#x2013;98 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18461556</ArticleId><ArticleId IdType="pmc">2634301</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasinopoulos, I., O&#x2019;Brien, D. R. &amp; Bhujwalla, Z. M. Inflammation, but not hypoxia, mediated HIF-1&#x3b1; activation depends on COX-2. Cancer Biol. Ther. 8, 31&#x2013;35 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19390242</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. J. et al. Regulation of hypoxia-inducible factor 1&#x3b1; (HIF-1&#x3b1;) by lysophosphatidic acid is dependent on interplay between p53 and Kruppel-like factor 5. J. Biol. Chem. 288, 25244&#x2013;25253 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23880760</ArticleId><ArticleId IdType="pmc">3757187</ArticleId></ArticleIdList></Reference><Reference><Citation>No, Y. R., Lee, S. J., Kumar, A. &amp; Yun, C. C. HIF1&#x3b1;-Induced by lysophosphatidic acid is stabilized via interaction with MIF and CSN5. PLoS ONE 10, e0137513 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26352431</ArticleId><ArticleId IdType="pmc">4564097</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo, J. et al. Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells. Commun Biol. 3, 638 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33128030</ArticleId><ArticleId IdType="pmc">7599230</ArticleId></ArticleIdList></Reference><Reference><Citation>Otake-Kasamoto, Y. et al. Lysophosphatidylserines derived from microbiota in Crohn&#x2019;s disease elicit pathological Th1 response. J. Exp. Med. 219, e20211291 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35608941</ArticleId><ArticleId IdType="pmc">9134096</ArticleId></ArticleIdList></Reference><Reference><Citation>MacPhee, M. et al. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 81, 957&#x2013;966 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7781071</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahama, M. et al. Organism-wide analysis of sepsis reveals mechanisms of systemic inflammation. Preprint at bioRxiv https://doi.org/10.1101/2023.01.30.526342 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37873155</ArticleId><ArticleId IdType="pmc">10592888</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullen, J. W. et al. Protein kinase A-dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1. Sci. Signal 9, ra56 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27245613</ArticleId><ArticleId IdType="pmc">5541497</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, L. F. et al. Reduction in ventilation-induced diaphragmatic mitochondrial injury through hypoxia-inducible factor 1&#x3b1; in a murine endotoxemia model. Int. J. Mol. Sci. 23, 1083 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35163007</ArticleId><ArticleId IdType="pmc">8835058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano, M. et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446, 444&#x2013;448 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17334357</ArticleId></ArticleIdList></Reference><Reference><Citation>van Hensbergen, V. P., Wu, Y., van Sorge, N. M. &amp; Touqui, L. Type IIA secreted phospholipase A2 in host defense against bacterial infections. Trends Immunol. 41, 313&#x2013;326 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32151494</ArticleId></ArticleIdList></Reference><Reference><Citation>Dore, E. &amp; Boilard, E. Roles of secreted phospholipase A(2) group IIA in inflammation and host defense. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 1864, 789&#x2013;802 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30905346</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider, J. M. et al. Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality. J. Clin. Invest. 131, e149236 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34428181</ArticleId><ArticleId IdType="pmc">8483752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kano, K., Aoki, J. &amp; Hla, T. Lysophospholipid mediators in health and disease. Annu. Rev. Pathol. 17, 459&#x2013;483 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34813354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura, I., Ichimura, A., Ohue-Kitano, R. &amp; Igarashi, M. Free fatty acid receptors in health and disease. Physiol. Rev. 100, 171&#x2013;210 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31487233</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, E. H. et al. Diagnosis and mortality prediction of sepsis via lysophosphatidylcholine 16:0 measured by MALDI-TOF MS. Sci. Rep. 10, 13833 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32796893</ArticleId><ArticleId IdType="pmc">7427783</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho, W. H. et al. Clinical significance of enzymatic lysophosphatidylcholine (LPC) assay data in patients with sepsis. Eur. J. Clin. Microbiol. Infect. Dis. 31, 1805&#x2013;1810 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22167258</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice, T. W. et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit. Care Med. 38, 1685&#x2013;1694 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20562702</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard, G. R. et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis study group. N. Engl. J. Med. 336, 912&#x2013;918 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9070471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurumbail, R. G., Kiefer, J. R. &amp; Marnett, L. J. Cyclooxygenase enzymes: catalysis and inhibition. Curr. Opin. Struct. Biol. 11, 752&#x2013;760 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11751058</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeiher, B. G. et al. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit. Care Med. 33, 1741&#x2013;1748 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16096451</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, R. J. et al. Evidence of myocardial hibernation in the septic heart. Crit. Care Med. 33, 2752&#x2013;2756 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16352955</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, R. J. Mitochondrial dysfunction, bioenergetic impairment, and metabolic down-regulation in sepsis. Shock 28, 24&#x2013;28 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17483747</ArticleId></ArticleIdList></Reference><Reference><Citation>Dengler, V. L., Galbraith, M. &amp; Espinosa, J. M. Transcriptional regulation by hypoxia inducible factors. Crit. Rev. Biochem. Mol. Biol. 49, 1&#x2013;15 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24099156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan, H. E. et al. Hypoxia-inducible factor-1&#x3b1; is a positive factor in solid tumor growth. Cancer Res. 60, 4010&#x2013;4015 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10945599</ArticleId></ArticleIdList></Reference><Reference><Citation>Agah, R. et al. Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. J. Clin. Invest. 100, 169&#x2013;179 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9202069</ArticleId><ArticleId IdType="pmc">508177</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda, S. et al. Marginal zone B cells exacerbate endotoxic shock via interleukin-6 secretion induced by Fc&#x3b1;/muR-coupled TLR4 signalling. Nat. Commun. 7, 11498 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27146354</ArticleId><ArticleId IdType="pmc">4858745</ArticleId></ArticleIdList></Reference><Reference><Citation>Furusawa, S. et al. Cardiac autoantibodies against cardiac troponin I in post-myocardial infarction heart failure: evaluation in a novel murine model and applications in therapeutics. Circ. Heart. Fail. 16, e010347 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37522180</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadokoro, T. et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight 5, e132747 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32376803</ArticleId><ArticleId IdType="pmc">7253028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda, M. et al. Excessive hypoxia-inducible factor-1&#x3b1; expression induces cardiac rupture via p53-dependent apoptosis after myocardial infarction. J. Am. Heart Assoc. 10, e020895 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34472375</ArticleId><ArticleId IdType="pmc">8649270</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto, H. D. et al. Iron overload via heme degradation in the endoplasmic reticulum triggers ferroptosis in myocardial ischemia-reperfusion injury. JACC Basic Transl. Sci. 7, 800&#x2013;819 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36061338</ArticleId><ArticleId IdType="pmc">9436815</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe, K. et al. Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis. Sci. Signal 15, eabn8017 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36318618</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda, M. et al. The Akt&#x2013;mTOR axis is a pivotal regulator of eccentric hypertrophy during volume overload. Sci. Rep. 5, 15881 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26515499</ArticleId><ArticleId IdType="pmc">4626834</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue, T. et al. Twinkle overexpression prevents cardiac rupture after myocardial infarction by alleviating impaired mitochondrial biogenesis. Am. J. Physiol. Heart. Circ. Physiol. 311, ajpheart 00044 02016 (2016).</Citation></Reference><Reference><Citation>Ikeda, M. et al. Heart rate reduction with ivabradine prevents cardiac rupture after myocardial infarction in mice. Cardiovasc. Drugs Ther. 36, 257&#x2013;262 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33411111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimaru, K. et al. Deferasirox targeting ferroptosis synergistically ameliorates myocardial ischemia reperfusion injury in conjunction with cyclosporine A. J. Am. Heart Assoc. 13, e031219 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38158218</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai, S. et al. Functional loss of DHRS7C induces intracellular Ca2<sup>+</sup> overload and myotube enlargement in C2C12 cells via calpain activation. Am. J. Physiol. Cell Physiol. 312, C29&#x2013;C39 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27806939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda, M. et al. Overexpression of TFAM or twinkle increases mtDNA copy number and facilitates cardioprotection associated with limited mitochondrial oxidative stress. PLoS ONE 10, e0119687 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25822152</ArticleId><ArticleId IdType="pmc">4379048</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda, M. et al. Immunomodulatory cell therapy using &#x3b1;GalCer-pulsed dendritic cells ameliorates heart failure in a murine dilated cardiomyopathy model. Circ. Heart. Fail. 15, e009366 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36268712</ArticleId><ArticleId IdType="pmc">9760469</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackers-Johnson, M. et al. A simplified, langendorff-free method for concomitant isolation of viable cardiac myocytes and nonmyocytes from the adult mouse heart. Circ. Res. 119, 909&#x2013;920 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27502479</ArticleId><ArticleId IdType="pmc">5965670</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40843168</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-634X</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in cell and developmental biology</Title><ISOAbbreviation>Front Cell Dev Biol</ISOAbbreviation></Journal><ArticleTitle>Matrisome remodeling in the myocardium of hypertrophic cardiomyopathy; novel targets for molecular diagnostics.</ArticleTitle><Pagination><StartPage>1641584</StartPage><MedlinePgn>1641584</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1641584</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcell.2025.1641584</ELocationID><Abstract><AbstractText>Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disorder characterized by left ventricular thickening and extracellular matrix (ECM) remodeling, often manifested as increased interstitial fibrosis that impair muscle function. The clinical and pathological presentations, as well as the genetic background, vary among patients, making HCM a heterogeneous disease with diverse clinical phenotyping and responses to treatment. In HCM, the myocardium exhibits an increased secretion of inflammatory mediators and ECM proteins, indicating a stress response to myocardial pathogenesis. The production of these ECM proteins is regulated by the interaction between cardiomyocytes and the surrounding stroma, including cardiac fibroblasts, immune cells, and microvasculature. This crosstalk defines the responsiveness to injury and the progression of the disease. In this review, we aim to dissect the composition of myocardial ECM in relation to HCM development, highlighting the key cellular contributions to ECM remodeling and identifying potential molecular targets for personalized diagnostics and therapeutics.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Ibrahim, Elfawy, Terracciano and Yacoub.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Ayman M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Zoology, Faculty of Science, Cairo University, Giza, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular Physiology, University Medical Center G&#xf6;ttingen, Georg-August, University G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elfawy</LastName><ForeName>Hasnaa A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Aswan Heart Center, Magdi Yacoub Heart Foundation, Aswan, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terracciano</LastName><ForeName>Cesare M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yacoub</LastName><ForeName>Magdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Aswan Heart Center, Magdi Yacoub Heart Foundation, Aswan, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Dev Biol</MedlineTA><NlmUniqueID>101630250</NlmUniqueID><ISSNLinking>2296-634X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECM</Keyword><Keyword MajorTopicYN="N">HCM</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">matrisome</Keyword><Keyword MajorTopicYN="N">secretome</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843168</ArticleId><ArticleId IdType="pmc">PMC12366102</ArticleId><ArticleId IdType="doi">10.3389/fcell.2025.1641584</ArticleId><ArticleId IdType="pii">1641584</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allouba M., Walsh R., Afify A., Hosny M., Halawa S., Galal A., et al. (2023). Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy. Eur. Heart J. 00, 5146&#x2013;5158. 10.1093/eurheartj/ehad372</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad372</ArticleId><ArticleId IdType="pmc">PMC10733735</ArticleId><ArticleId IdType="pubmed">37431535</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter C., Henseler A. S., Owenier C., Hesse J., Ding Z., Lautwein T., et al. (2023). IL-6 in the infarcted heart is preferentially formed by fibroblasts and modulated by purinergic signaling. J. Clin. Invest 133, e163799. 10.1172/JCI163799</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163799</ArticleId><ArticleId IdType="pmc">PMC10232006</ArticleId><ArticleId IdType="pubmed">36943408</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniak S., Pawlinski R., Mackman N. (2011). Protease-activated receptors and myocardial infarction. IUBMB Life 63, 383&#x2013;389. 10.1002/iub.441</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.441</ArticleId><ArticleId IdType="pmc">PMC3121912</ArticleId><ArticleId IdType="pubmed">21438116</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi T., Matsui T. (2011). The cardiomyocyte as a source of cytokines in cardiac injury. J. Cell Sci. Ther. 2012, 003. 10.4172/2157-7013.s5-003</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2157-7013.s5-003</ArticleId><ArticleId IdType="pmc">PMC3594870</ArticleId><ArticleId IdType="pubmed">23493668</ArticleId></ArticleIdList></Reference><Reference><Citation>Argraves W. S., Greene L. M., Cooley M. A., Gallagher W. M. (2003). Fibulins: physiological and disease perspectives. EMBO Rep. 4, 1127&#x2013;1131. 10.1038/sj.embor.7400033</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400033</ArticleId><ArticleId IdType="pmc">PMC1326425</ArticleId><ArticleId IdType="pubmed">14647206</ArticleId></ArticleIdList></Reference><Reference><Citation>Barallobre-Barreiro J., Loeys B., Mayr M., Rienks M., Verstraeten A., Kovacic J. C. (2020). Extracellular matrix in vascular disease, part 2/4: JACC focus seminar. J. Am. Coll. Cardiol. 75, 2189&#x2013;2203. 10.1016/j.jacc.2020.03.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.03.018</ArticleId><ArticleId IdType="pubmed">32354385</ArticleId></ArticleIdList></Reference><Reference><Citation>Barallobre-Barreiro J., Radovits T., Fava M., Mayr U., Lin W. Y., Ermolaeva E., et al. (2021). Extracellular matrix in heart failure: role of ADAMTS5 in proteoglycan remodeling. Circulation 144, 2021&#x2013;2034. 10.1161/CIRCULATIONAHA.121.055732</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.055732</ArticleId><ArticleId IdType="pmc">PMC8687617</ArticleId><ArticleId IdType="pubmed">34806902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi X., Yang C., Song Y., Yuan J., Cui J., Hu F., et al. (2021). Matrix metalloproteinases increase because of hypoperfusion in obstructive hypertrophic cardiomyopathy. Ann. Thorac. Surg. 111, 915&#x2013;922. 10.1016/j.athoracsur.2020.05.156</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2020.05.156</ArticleId><ArticleId IdType="pubmed">32738221</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischoff J., Editor G., Davis G. E., Senger D. R. (2005). Endothelial extracellular matrix. Circ. Res. 97, 1093&#x2013;1107. 10.1161/01.res.0000191547.64391.e3</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.res.0000191547.64391.e3</ArticleId><ArticleId IdType="pubmed">16306453</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancaccio M., Hirsch E., Notte A., Selvetella G., Lembo G., Tarone G. (2006). Integrin signalling: the tug-of-war in heart hypertrophy. Cardiovasc Res. 70, 422&#x2013;433. 10.1016/j.cardiores.2005.12.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2005.12.015</ArticleId><ArticleId IdType="pubmed">16466704</ArticleId></ArticleIdList></Reference><Reference><Citation>Brew K., Dinakarpandian D., Nagase H. (2000). Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477, 267&#x2013;283. 10.1016/s0167-4838(99)00279-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0167-4838(99)00279-4</ArticleId><ArticleId IdType="pubmed">10708863</ArticleId></ArticleIdList></Reference><Reference><Citation>Brew K., Nagase H. (2010). The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim. Biophys. Acta 1803, 55&#x2013;71. 10.1016/j.bbamcr.2010.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2010.01.003</ArticleId><ArticleId IdType="pmc">PMC2853873</ArticleId><ArticleId IdType="pubmed">20080133</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruggink A. H., van Oosterhout M. F. M., de Jonge N., Cleutjens J. P. M., van Wichen D. F., van Kuik J., et al. (2007). Type IV collagen degradation in the myocardial basement membrane after unloading of the failing heart by a left ventricular assist device. Lab. Investig. 87, 1125&#x2013;1137. 10.1038/labinvest.3700670</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.3700670</ArticleId><ArticleId IdType="pubmed">17876299</ArticleId></ArticleIdList></Reference><Reference><Citation>Bursac N. (2014). Cardiac fibroblasts in pressure overload hypertrophy: the enemy within? J. Clin. Investigation 124, 2850&#x2013;2853. 10.1172/JCI76628</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI76628</ArticleId><ArticleId IdType="pmc">PMC4071394</ArticleId><ArticleId IdType="pubmed">24937423</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Pacheco G. A., Garza-Veloz I., Castruita-De la Rosa C., Ramirez-Acu&#xf1;a J. M., Perez-Romero B. A., Guerrero-Rodriguez J. F., et al. (2020). The roles of matrix metalloproteinases and their inhibitors in human diseases. Int. J. Mol. Sci. 21, 9739&#x2013;9753. 10.3390/ijms21249739</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21249739</ArticleId><ArticleId IdType="pmc">PMC7767220</ArticleId><ArticleId IdType="pubmed">33419373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambronero F., Mar&#xed;n F., Rold&#xe1;n V., Hern&#xe1;ndez-Romero D., Vald&#xe9;s M., Lip G. Y. H. (2009). Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur. Heart J. 30, 139&#x2013;151. 10.1093/eurheartj/ehn538</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehn538</ArticleId><ArticleId IdType="pubmed">19136482</ArticleId></ArticleIdList></Reference><Reference><Citation>Camelliti P., Borg T. K., Kohl P. (2005). Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res. 65, 40&#x2013;51. 10.1016/j.cardiores.2004.08.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2004.08.020</ArticleId><ArticleId IdType="pubmed">15621032</ArticleId></ArticleIdList></Reference><Reference><Citation>Captur G., Heywood W. E., Coats C., Rosmini S., Patel V., Lopes L. R., et al. (2020). Identification of a multiplex biomarker panel for hypertrophic cardiomyopathy using quantitative proteomics and machine learning. Mol. Cell Proteomics 19, 114&#x2013;127. 10.1074/mcp.RA119.001586</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.RA119.001586</ArticleId><ArticleId IdType="pmc">PMC6944230</ArticleId><ArticleId IdType="pubmed">31243064</ArticleId></ArticleIdList></Reference><Reference><Citation>Chait A., den Hartigh L. J. (2020). Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front. Cardiovasc Med. 7, 22. 10.3389/fcvm.2020.00022</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2020.00022</ArticleId><ArticleId IdType="pmc">PMC7052117</ArticleId><ArticleId IdType="pubmed">32158768</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman S. L., Sicot F. X., Davis E. C., Huang J., Sasaki T., Chu M. L., et al. (2010). Fibulin-2 and fibulin-5 cooperatively function to form the internal elastic lamina and protect from vascular injury. Arterioscler. Thromb. Vasc. Biol. 30, 68&#x2013;74. 10.1161/ATVBAHA.109.196725</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.109.196725</ArticleId><ArticleId IdType="pmc">PMC2800831</ArticleId><ArticleId IdType="pubmed">19893004</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Smith L. R., Khandekar G., Patel P., Yu C. K., Zhang K., et al. (2020). Distinct effects of different matrix proteoglycans on collagen fibrillogenesis and cell-mediated collagen reorganization. Sci. Rep. 10, 19065&#x2013;13. 10.1038/s41598-020-76107-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-76107-0</ArticleId><ArticleId IdType="pmc">PMC7642422</ArticleId><ArticleId IdType="pubmed">33149218</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Huang X. N., Yan W., Chen K., Guo L., Tummalapali L., et al. (2005). Role of the integrin-linked kinase/PINCH1/alpha-parvin complex in cardiac myocyte hypertrophy. Lab. Investig. 85, 1342&#x2013;1356. 10.1038/labinvest.3700345</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.3700345</ArticleId><ArticleId IdType="pubmed">16170337</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R., Zhang H., Tang B., Luo Y., Yang Y., Zhong X., et al. (2024). Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets. Signal Transduct. Target. Ther. 9 (1), 130&#x2013;144. 10.1038/s41392-024-01840-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-024-01840-1</ArticleId><ArticleId IdType="pmc">PMC11139930</ArticleId><ArticleId IdType="pubmed">38816371</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X. Q., Li X., Wu X., Ding Y., Li Y., Zhou G., et al. (2023). Integrin beta-like 1 mediates fibroblast&#x2013;cardiomyocyte crosstalk to promote cardiac fibrosis and hypertrophy. Cardiovasc Res. 119, 1928&#x2013;1941. 10.1093/cvr/cvad104</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvad104</ArticleId><ArticleId IdType="pubmed">37395147</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wang L., Huang S., Ke J., Wang Q., Zhou Z., et al. (2021). Lutein attenuates angiotensin II- induced cardiac remodeling by inhibiting AP-1/IL-11 signaling. Redox Biol. 44, 102020. 10.1016/j.redox.2021.102020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2021.102020</ArticleId><ArticleId IdType="pmc">PMC8181194</ArticleId><ArticleId IdType="pubmed">34077894</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C., Chin M. T. (2021). Pathogenic mechanisms of hypertrophic cardiomyopathy beyond sarcomere dysfunction. Int. J. Mol. Sci. 22, 8933. 10.3390/ijms22168933</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168933</ArticleId><ArticleId IdType="pmc">PMC8396307</ArticleId><ArticleId IdType="pubmed">34445638</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen G., Herum K. M., Lunde I. G. S. (2019). Sweet, yet underappreciated: proteoglycans and extracellular matrix remodeling in heart disease. Matrix Biol. 75&#x2013;76, 286&#x2013;299. 10.1016/j.matbio.2018.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2018.01.001</ArticleId><ArticleId IdType="pubmed">29337052</ArticleId></ArticleIdList></Reference><Reference><Citation>Chute M., Aujla P., Jana S., Kassiri Z. (2019). The non-fibrillar side of fibrosis: contribution of the basement membrane, Proteoglycans, and glycoproteins to myocardial fibrosis. J. Cardiovasc Dev. Dis. 6, 35. 10.3390/jcdd6040035</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd6040035</ArticleId><ArticleId IdType="pmc">PMC6956278</ArticleId><ArticleId IdType="pubmed">31547598</ArticleId></ArticleIdList></Reference><Reference><Citation>Coats C. J., Heywood W. E., Virasami A., Ashrafi N., Syrris P., Dos Remedios C., et al. (2018). Proteomic analysis of the myocardium in hypertrophic obstructive cardiomyopathy. Circ. Genom Precis. Med. 11, e001974. 10.1161/CIRCGEN.117.001974</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCGEN.117.001974</ArticleId><ArticleId IdType="pubmed">30562113</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte M., Petraglia L., Cabaro S., Valerio V., Poggio P., Pilato E., et al. (2022). Epicardial adipose tissue and cardiac arrhythmias: focus on atrial fibrillation. Front. Cardiovasc Med. 9, 932262. 10.3389/fcvm.2022.932262</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.932262</ArticleId><ArticleId IdType="pmc">PMC9280076</ArticleId><ArticleId IdType="pubmed">35845044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook S. A. (2023). Understanding interleukin 11 as a disease gene and therapeutic target. Biochem. J. 480, 1987&#x2013;2008. 10.1042/BCJ20220160</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20220160</ArticleId><ArticleId IdType="pmc">PMC10754292</ArticleId><ArticleId IdType="pubmed">38054591</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooley M. A., Kern C. B., Fresco V. M., Wessels A., Thompson R. P., McQuinn T. C., et al. (2008). Fibulin-1 is required for morphogenesis of neural crest-derived structures. Dev. Biol. 319, 336&#x2013;345. 10.1016/j.ydbio.2008.04.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2008.04.029</ArticleId><ArticleId IdType="pmc">PMC2965525</ArticleId><ArticleId IdType="pubmed">18538758</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabiri B. E., Lee H., Parker K. K. (2012). A potential role for integrin signaling in mechanoelectrical feedback. Prog. Biophys. Mol. Biol. 110, 196&#x2013;203. 10.1016/j.pbiomolbio.2012.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbiomolbio.2012.07.002</ArticleId><ArticleId IdType="pmc">PMC4807692</ArticleId><ArticleId IdType="pubmed">22819851</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies L. C., Jenkins S. J., Allen J. E., Taylor P. R. (2013). Tissue-resident macrophages. Nat. Immunol. 14, 986&#x2013;995. 10.1038/ni.2705</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2705</ArticleId><ArticleId IdType="pmc">PMC4045180</ArticleId><ArticleId IdType="pubmed">24048120</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis G. E., Senger D. R. (2005). Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 97, 1093&#x2013;1107. 10.1161/01.RES.0000191547.64391.e3</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000191547.64391.e3</ArticleId><ArticleId IdType="pubmed">16306453</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao K. yue, Yang Z. G., Xu H. Y., Liu X., Zhang Q., Shi K., et al. (2016). Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis. J. Cardiovasc. Magnetic Reson. 18, 92&#x2013;11. 10.1186/s12968-016-0313-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-016-0313-7</ArticleId><ArticleId IdType="pmc">PMC5154013</ArticleId><ArticleId IdType="pubmed">27955698</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;ez J., Gonz&#xe1;lez A., Kovacic J. C. (2020). Myocardial interstitial fibrosis in nonischemic heart disease, part 3/4: JACC focus seminar. J. Am. Coll. Cardiol. 75, 2204&#x2013;2218. 10.1016/j.jacc.2020.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.03.019</ArticleId><ArticleId IdType="pmc">PMC7213023</ArticleId><ArticleId IdType="pubmed">32354386</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobaczewski M., Chen W., Frangogiannis N. G. (2011). Transforming growth factor (TGF)-&#x3b2; signaling in cardiac remodeling. J. Mol. Cell Cardiol. 51, 600&#x2013;606. 10.1016/j.yjmcc.2010.10.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2010.10.033</ArticleId><ArticleId IdType="pmc">PMC3072437</ArticleId><ArticleId IdType="pubmed">21059352</ArticleId></ArticleIdList></Reference><Reference><Citation>Dour C.Le, Wu W., B&#xe9;r&#xe9;ziat V., Capeau J., Vigouroux C., Worman H. J. (2017). Extracellular matrix remodeling and transforming growth factor-&#x3b2;signaling abnormalities induced by lamin a/c variants that cause lipodystrophy. J. Lipid Res. 58, 151&#x2013;163. 10.1194/jlr.M071381</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M071381</ArticleId><ArticleId IdType="pmc">PMC5234718</ArticleId><ArticleId IdType="pubmed">27845687</ArticleId></ArticleIdList></Reference><Reference><Citation>Eghbali M., Weber K. T. (1990). Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol. Cell Biochem. 96, 1&#x2013;14. 10.1007/BF00228448</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00228448</ArticleId><ArticleId IdType="pubmed">2146489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellims A. H., Taylor A. J., Mariani J. A., Ling L. H., Iles L. M., Maeder M. T., et al. (2014). Evaluating the utility of circulating biomarkers of collagen synthesis in hypertrophic cardiomyopathy. Circ. Heart Fail 7, 271&#x2013;278. 10.1161/CIRCHEARTFAILURE.113.000665</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.113.000665</ArticleId><ArticleId IdType="pubmed">24481111</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland T., Lunde I. G., Amundsen B. H., Gullestad L., Aakhus S. (2018). Espeland and co-workers respond. Tidsskrift Den norske legeforening 138. 10.4045/tidsskr.18.0865</Citation><ArticleIdList><ArticleId IdType="doi">10.4045/tidsskr.18.0865</ArticleId><ArticleId IdType="pubmed">30497251</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan D., Takawale A., Lee J., Kassiri Z. (2012). Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis and Tissue Repair 2012 5 (1), 15&#x2013;13. 10.1186/1755-1536-5-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1755-1536-5-15</ArticleId><ArticleId IdType="pmc">PMC3464725</ArticleId><ArticleId IdType="pubmed">22943504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L., Ellims A. H., Beale A. L., Taylor A. J., Murphy A., Dart A. M. (2017). Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Am. J. Transl. Res. 9, 5063&#x2013;5073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5714791</ArticleId><ArticleId IdType="pubmed">29218105</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhadian F., Contard F., Sabri A., Samuel J. L., Rappaport L. (1996). Fibronectin and basement membrane in cardiovascular organogenesis and disease pathogenesis. Cardiovasc Res. 32, 433&#x2013;442. 10.1016/s0008-6363(96)00119-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0008-6363(96)00119-8</ArticleId><ArticleId IdType="pubmed">8881506</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman A. M., Combes A., Wagner D., Kadakomi T., Kubota T., Li Y. Y., et al. (2000). The role of tumor necrosis factor in the pathophysiology of heart failure. J. Am. Coll. Cardiol. 35, 537&#x2013;544. 10.1016/s0735-1097(99)00600-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0735-1097(99)00600-2</ArticleId><ArticleId IdType="pubmed">10716453</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernlund E., Gyllenhammar T., Jablonowski R., Carlsson M., Larsson A., &#xc4;rnl&#xf6;v J., et al. (2017). Serum biomarkers of myocardial remodeling and coronary dysfunction in early stages of hypertrophic cardiomyopathy in the young. Pediatr. Cardiol. 38, 853&#x2013;863. 10.1007/s00246-017-1593-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-017-1593-x</ArticleId><ArticleId IdType="pmc">PMC5388706</ArticleId><ArticleId IdType="pubmed">28361263</ArticleId></ArticleIdList></Reference><Reference><Citation>
Finsen A. V., Lunde I. G., Sjaastad I., &#xd8;stli E. K., Lyngra M., Jarstadmarken H. O., et al.  (2011). Syndecan-4 is essential for development of concentric myocardial hypertrophy <i>via</i> stretch-induced activation of the Calcineurin-NFAT pathway. PLoS One
6, e28302. 10.1371/journal.pone.0028302

</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0028302</ArticleId><ArticleId IdType="pmc">PMC3229559</ArticleId><ArticleId IdType="pubmed">22164265</ArticleId></ArticleIdList></Reference><Reference><Citation>Foronjy R. F., Sun J., Lemaitre V., d&#x2019;Armiento J. M. (2008). Transgenic expression of matrix Metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model. Hypertens. Res. 31 (4), 725&#x2013;735. 10.1291/hypres.31.725</Citation><ArticleIdList><ArticleId IdType="doi">10.1291/hypres.31.725</ArticleId><ArticleId IdType="pubmed">18633185</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangogiannis N. G. (2020). Transforming growth Factor&#x2013;&#xdf; in tissue fibrosis. J. Exp. Med. 217, e20190103. 10.1084/jem.20190103</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190103</ArticleId><ArticleId IdType="pmc">PMC7062524</ArticleId><ArticleId IdType="pubmed">32997468</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieler R. A., Mortensen R. M. (2015). Immune cell and other non-cardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 131, 1019&#x2013;1030. 10.1161/CIRCULATIONAHA.114.008788</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.114.008788</ArticleId><ArticleId IdType="pmc">PMC4367123</ArticleId><ArticleId IdType="pubmed">25779542</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xfc;h S. M., Schoen I., Ries J., Vogel V. (2015). Molecular architecture of native fibronectin fibrils. Nat. Commun. 6, 7275&#x2013;10. 10.1038/ncomms8275</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8275</ArticleId><ArticleId IdType="pmc">PMC4468872</ArticleId><ArticleId IdType="pubmed">26041410</ArticleId></ArticleIdList></Reference><Reference><Citation>Fucikova A., Lenco J., Tambor V., Rehulkova H., Pudil R., Stulik J. (2016). Plasma concentration of fibronectin is decreased in patients with hypertrophic cardiomyopathy. Clin. Chim. Acta 463, 62&#x2013;66. 10.1016/j.cca.2016.09.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2016.09.024</ArticleId><ArticleId IdType="pubmed">27693530</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiu K., Nagai R. (2014). Fibroblast-mediated pathways in cardiac hypertrophy. J. Mol. Cell Cardiol. 70, 64&#x2013;73. 10.1016/j.yjmcc.2014.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2014.01.013</ArticleId><ArticleId IdType="pubmed">24492068</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogiraju R., Bochenek M. L., Sch&#xe4;fer K. (2019). Angiogenic endothelial cell signaling in cardiac hypertrophy and heart failure. Front. Cardiovasc Med. 6, 20. 10.3389/fcvm.2019.00020</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2019.00020</ArticleId><ArticleId IdType="pmc">PMC6415587</ArticleId><ArticleId IdType="pubmed">30895179</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot H. E., Al Ali L., van der Horst I. C. C., Schurer R. A. J., van der Werf H. W., Lipsic E., et al. (2019). Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. Clin. Res. Cardiol. 108, 612&#x2013;621. 10.1007/s00392-018-1387-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-018-1387-z</ArticleId><ArticleId IdType="pmc">PMC6529378</ArticleId><ArticleId IdType="pubmed">30367209</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J., Wang Y., Liang H., Yang B. (2023). Small leucine rich proteoglycan in fibrotic diseases: new frenemies? Int. J. Drug Discov. Pharmacol. 61&#x2013;78, 61&#x2013;78. 10.53941/IJDDP.2023.100005</Citation><ArticleIdList><ArticleId IdType="doi">10.53941/IJDDP.2023.100005</ArticleId></ArticleIdList></Reference><Reference><Citation>Haaf P., Garg P., Messroghli D. R., Broadbent D. A., Greenwood J. P., Plein S. (2016). Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J. Cardiovasc. Magnetic Reson. 18, 89&#x2013;12. 10.1186/s12968-016-0308-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-016-0308-4</ArticleId><ArticleId IdType="pmc">PMC5129251</ArticleId><ArticleId IdType="pubmed">27899132</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajsadeghi F., Nabavi V., Bhandari A., Choi A., Vincent H., Flores F., et al. (2014). Increased epicardial adipose tissue is associated with coronary artery disease and major adverse cardiovascular events. Atherosclerosis 237, 486&#x2013;489. 10.1016/j.atherosclerosis.2014.09.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2014.09.037</ArticleId><ArticleId IdType="pubmed">25463078</ArticleId></ArticleIdList></Reference><Reference><Citation>Halabi C. M., Broekelmann T. J., Lin M., Lee V. S., Chu M. L., Mecham R. P. (2017). Fibulin-4 is essential for maintaining arterial wall integrity in conduit but not muscular arteries. Sci. Adv. 3, e1602532. 10.1126/sciadv.1602532</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.1602532</ArticleId><ArticleId IdType="pmc">PMC5415335</ArticleId><ArticleId IdType="pubmed">28508064</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall C., Gehmlich K., Denning C., Pavlovic D. (2021). Complex relationship between cardiac fibroblasts and cardiomyocytes in health and disease. J. Am. Heart Assoc. 10, e019338&#x2013;15. 10.1161/JAHA.120.019338</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.019338</ArticleId><ArticleId IdType="pmc">PMC8174279</ArticleId><ArticleId IdType="pubmed">33586463</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna A., Frangogiannis N. G. (2019). The role of the TGF-&#x3b2; superfamily in myocardial infarction. Front. Cardiovasc Med. 6, 140. 10.3389/fcvm.2019.00140</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2019.00140</ArticleId><ArticleId IdType="pmc">PMC6760019</ArticleId><ArticleId IdType="pubmed">31620450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna A., Frangogiannis N. G. (2020). Inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther. 34, 849&#x2013;863. 10.1007/s10557-020-07071-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-020-07071-0</ArticleId><ArticleId IdType="pmc">PMC7479403</ArticleId><ArticleId IdType="pubmed">32902739</ArticleId></ArticleIdList></Reference><Reference><Citation>Harston R. K., Kuppuswamy D. (2011). Integrins are the necessary links to hypertrophic growth in cardiomyocytes. J. Signal Transduct. 2011, 521742&#x2013;521748. 10.1155/2011/521742</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/521742</ArticleId><ArticleId IdType="pmc">PMC3101892</ArticleId><ArticleId IdType="pubmed">21637377</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa K., Fujiwara H., Doyama K., Miyamae M., Fujiwara T., Suga S., et al. (1993). Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 88, 372&#x2013;380. 10.1161/01.cir.88.2.372</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.88.2.372</ArticleId><ArticleId IdType="pubmed">8339400</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiss C., Rodriguez-Mateos A., Kelm M. (2015). Central role of eNOS in the maintenance of endothelial homeostasis. Antioxid. Redox Signal 22, 1230&#x2013;1242. 10.1089/ars.2014.6158</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2014.6158</ArticleId><ArticleId IdType="pmc">PMC4410282</ArticleId><ArticleId IdType="pubmed">25330054</ArticleId></ArticleIdList></Reference><Reference><Citation>Herum K. M., Lunde I. G., Skrbic B., Louch W. E., Hasic A., Boye S., et al. (2015). Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart. Cardiovasc Res. 106, 217&#x2013;226. 10.1093/cvr/cvv002</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvv002</ArticleId><ArticleId IdType="pubmed">25587045</ArticleId></ArticleIdList></Reference><Reference><Citation>Herum K. M., Romaine A., Wang A., Melleby A. O., Strand M. E., Pacheco J., et al. (2020). Syndecan-4 protects the heart from the profibrotic effects of thrombin-cleaved osteopontin. J. Am. Heart Assoc. 9, e013518. 10.1161/JAHA.119.013518</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.013518</ArticleId><ArticleId IdType="pmc">PMC7033859</ArticleId><ArticleId IdType="pubmed">32000579</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hitscherich P., Lee E. J. (2021). Crosstalk between cardiac cells and macrophages postmyocardial infarction: insights from <i>in vitro</i> studies. Tissue Eng. Part B Rev.
27, 475&#x2013;485. 10.1089/ten.TEB.2020.0198

</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ten.TEB.2020.0198</ArticleId><ArticleId IdType="pmc">PMC8851218</ArticleId><ArticleId IdType="pubmed">33096955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho C. Y., L&#xf3;pez B., Coelho-Filho O. R., Lakdawala N. K., Cirino A. L., Jarolim P., et al. (2010). Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N. Engl. J. Med. 363, 552&#x2013;563. 10.1056/NEJMoa1002659</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1002659</ArticleId><ArticleId IdType="pmc">PMC3049917</ArticleId><ArticleId IdType="pubmed">20818890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho J. E., Shi L., Day S. M., Colan S. D., Russell M. W., Towbin J. A., et al. (2017). Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. Open Heart 4 (2), e000615. 10.1136/openhrt-2017-000615</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2017-000615</ArticleId><ArticleId IdType="pmc">PMC5687543</ArticleId><ArticleId IdType="pubmed">29177058</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;gye M., M&#xe1;ndi Y., Csan&#xe1;dy M., Sepp R., Buz&#xe1;s K. (2004). Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am. J. Cardiol. 94, 249&#x2013;251. 10.1016/j.amjcard.2004.03.078</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2004.03.078</ArticleId><ArticleId IdType="pubmed">15246916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotta Y., Sasaki S., Konishi M., Kinoshita H., Kuwahara K., Nakao K., et al. (2008). Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. Dev. Dyn. 237, 2947&#x2013;2954. 10.1002/dvdy.21726</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.21726</ArticleId><ArticleId IdType="pubmed">18816849</ArticleId></ArticleIdList></Reference><Reference><Citation>Hultg&#xe5;rdh-Nilsson A., Bor&#xe9;n J., Chakravarti S. (2015). The small leucine-rich repeat Proteoglycans in tissue repair and atherosclerosis. J. Intern Med. 278, 447&#x2013;461. 10.1111/joim.12400</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12400</ArticleId><ArticleId IdType="pmc">PMC4616156</ArticleId><ArticleId IdType="pubmed">26477596</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynes R. O., Naba A. (2012). Overview of the matrisome&#x2014;an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 4, a004903. 10.1101/cshperspect.a004903</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a004903</ArticleId><ArticleId IdType="pmc">PMC3249625</ArticleId><ArticleId IdType="pubmed">21937732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim A. M., Galal A., Halawa S., Elfawy H., Elshorbagy S., Roshdy M., et al. (2022a). Abstract 14969: transcriptome signature of cardiac fibroblasts in HCM patients identifies novel drivers of ECM remodeling and pro-inflammatory signaling. Circulation 146. 10.1161/circ.146.suppl_1.14969</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circ.146.suppl_1.14969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim A. M., Moss M. A., Gray Z., Rojo M. D., Burke C. M., Schwertfeger K. L., et al. (2020b). Diverse macrophage populations contribute to the inflammatory microenvironment in premalignant lesions during localized invasion. Front. Oncol. 10, 569985. 10.3389/fonc.2020.569985</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.569985</ArticleId><ArticleId IdType="pmc">PMC7541939</ArticleId><ArticleId IdType="pubmed">33072601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim A. M., Roshdy M., Elshorbagy S., Hosny M., Halawa S., Yehia D., et al. (2020a). An investigation of Fibulin-2 in hypertrophic cardiomyopathy. Int. J. Mol. Sci. 21, 1&#x2013;14. 10.3390/ijms21197176</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21197176</ArticleId><ArticleId IdType="pmc">PMC7583916</ArticleId><ArticleId IdType="pubmed">33003281</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim A. M., Roshdy M., Latif N., Sarathchandra P., Hosny M., Haikal S., et al. (2022b). Structural, molecular and functional characterization of the aorta in HCM. Eur. Heart J. 43. 10.1093/eurheartj/ehac544.1935</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac544.1935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim A. M., Sabet S., El-Ghor A. A., Kamel N., Anis S. E., Morris J. S., et al. (2018). Fibulin-2 is required for basement membrane integrity of mammary epithelium. Sci. Rep. 8, 14139. 10.1038/s41598-018-32507-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-32507-x</ArticleId><ArticleId IdType="pmc">PMC6148073</ArticleId><ArticleId IdType="pubmed">30237579</ArticleId></ArticleIdList></Reference><Reference><Citation>Imanaka-Yoshida K., Hiroe M., Nishikawa T., Ishiyama S., Shimojo T., Ohta Y., et al. (2001). Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab. Investig. 81, 1015&#x2013;1024. 10.1038/labinvest.3780313</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.3780313</ArticleId><ArticleId IdType="pubmed">11454990</ArticleId></ArticleIdList></Reference><Reference><Citation>Imanaka-Yoshida K., Tawara I., Yoshida T. (2020). Tenascin-C in cardiac disease: a sophisticated controller of inflammation, repair, and fibrosis. Am. J. Physiol. Cell Physiol. 319, C781-C796&#x2013;C796. 10.1152/ajpcell.00353.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00353.2020</ArticleId><ArticleId IdType="pubmed">32845719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioakeimidis N. S., Pitsis A., Zegkos T., Ntelios D., Kelpis T., Papamitsou T., et al. (2023). Periostin is overexpressed, correlated with fibrosis and differs among grades of cardiomyocyte hypertrophy in myectomy tissue of patients with hypertrophic cardiomyopathy. PLoS One 18, e0293427. 10.1371/journal.pone.0293427</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0293427</ArticleId><ArticleId IdType="pmc">PMC10631645</ArticleId><ArticleId IdType="pubmed">37939043</ArticleId></ArticleIdList></Reference><Reference><Citation>Israeli-Rosenberg S., Manso A. M., Okada H., Ross R. S. (2014). Integrins and integrin-associated proteins in the cardiac myocyte. Circ. Res. 114, 572&#x2013;586. 10.1161/CIRCRESAHA.114.301275</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.114.301275</ArticleId><ArticleId IdType="pmc">PMC3975046</ArticleId><ArticleId IdType="pubmed">24481847</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh N., Ohta H. (2013). Pathophysiological roles of FGF signaling in the heart. Front. Physiol. 4 (SEP), 247. 10.3389/fphys.2013.00247</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2013.00247</ArticleId><ArticleId IdType="pmc">PMC3764331</ArticleId><ArticleId IdType="pubmed">24046748</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh N., Ornitz D. M. (2008). Functional evolutionary history of the mouse fgf gene family. Dev. Dyn. 237, 18&#x2013;27. 10.1002/dvdy.21388</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.21388</ArticleId><ArticleId IdType="pubmed">18058912</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki J., Nakamura K., Matsubara H., Nakamura Y., Nishii N., Banba K., et al. (2009). Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy. Cardiovasc. Pathol. 18, 317&#x2013;322. 10.1016/j.carpath.2008.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carpath.2008.12.004</ArticleId><ArticleId IdType="pubmed">19211266</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahanyar J., Joyce D. L., Southard R. E., Loebe M., Noon G. P., Koerner M. M., et al. (2007). Decorin-mediated transforming growth Factor-&#x3b2; inhibition ameliorates adverse cardiac remodeling. J. Heart Lung Transplant. 26, 34&#x2013;40. 10.1016/j.healun.2006.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2006.10.005</ArticleId><ArticleId IdType="pubmed">17234515</ArticleId></ArticleIdList></Reference><Reference><Citation>Jallerat Q., Feinberg A. W. (2020). Extracellular matrix structure and composition in the early four-chambered embryonic heart. Cells 9, 285. 10.3390/cells9020285</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9020285</ArticleId><ArticleId IdType="pmc">PMC7072588</ArticleId><ArticleId IdType="pubmed">31991580</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang D. I., Lee A. H., Shin H. Y., Song H. R., Park J. H., Kang T. B., et al. (2021). The role of tumor necrosis factor alpha (TNF-&#x3b1;) in autoimmune disease and current TNF-&#x3b1; inhibitors in therapeutics. Int. J. Mol. Sci. 22, 2719. 10.3390/ijms22052719</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052719</ArticleId><ArticleId IdType="pmc">PMC7962638</ArticleId><ArticleId IdType="pubmed">33800290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jebran A.-F., Seidler T., Tiburcy M., Daskalaki M., Kutschka I., Fujita B., et al. (2025). Engineered heart muscle allografts for heart repair in Primates and humans. Nature 639 (8054), 503&#x2013;511. 10.1038/s41586-024-08463-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-08463-0</ArticleId><ArticleId IdType="pmc">PMC11903342</ArticleId><ArticleId IdType="pubmed">39880949</ArticleId></ArticleIdList></Reference><Reference><Citation>Jobe L. J., Mel&#xe9;ndez G. C., Levick S. P., Du Y., Brower G. L., Janicki J. S. (2009). TNF-&#x3b1; inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. Am. J. Physiol. Heart Circ. Physiol. 297, 1462&#x2013;1468. 10.1152/ajpheart.00442.2009</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00442.2009</ArticleId><ArticleId IdType="pmc">PMC2770768</ArticleId><ArticleId IdType="pubmed">19666842</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B. B., Cosson M. V., Tsansizi L. I., Holmes T. L., Gilmore T., Hampton K., et al. (2024). Perlecan (HSPG2) promotes structural, contractile, and metabolic development of human cardiomyocytes. Cell Rep. 43, 113668. 10.1016/j.celrep.2023.113668</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.113668</ArticleId><ArticleId IdType="pubmed">38198277</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanisicak O., Khalil H., Ivey M. J., Karch J., Maliken B. D., Correll R. N., et al. (2016). Genetic lineage tracing defines myofibroblast origin and function in the injured heart. Nat. Commun. 7, 12260. 10.1038/ncomms12260</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12260</ArticleId><ArticleId IdType="pmc">PMC5512625</ArticleId><ArticleId IdType="pubmed">27447449</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S. A., Dong H., Joyce J., Sasaki T., Chu M. L., Tsuda T. (2016). Fibulin-2 is essential for angiotensin II-induced myocardial fibrosis mediated by transforming growth factor (TGF)-&#x3b2;. Lab. Invest 96, 773&#x2013;783. 10.1038/labinvest.2016.52</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.2016.52</ArticleId><ArticleId IdType="pmc">PMC4920723</ArticleId><ArticleId IdType="pubmed">27111286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitaoka H., Kubo T., Baba Y., Yamasaki N., Matsumura Y., Furuno T., et al. (2012). Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy. J. Cardiol. 59, 209&#x2013;214. 10.1016/j.jjcc.2011.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2011.11.008</ArticleId><ArticleId IdType="pubmed">22218323</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitaoka H., Kubo T., Okawa M., Hayato K., Yamasaki N., Matsumura Y., et al. (2010). Impact of metalloproteinases on left ventricular remodeling and heart failure events in patients with hypertrophic cardiomyopathy. Circulation J. 74, 1191&#x2013;1196. 10.1253/circj.cj-09-1013</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.cj-09-1013</ArticleId><ArticleId IdType="pubmed">20453389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitaoka H., Kubo T., Okawa M., Takenaka N., Baba Y., Yamasaki N., et al. (2011). Plasma metalloproteinase levels and left ventricular remodeling in hypertrophic cardiomyopathy in patients with an identical mutation. J. Cardiol. 58, 261&#x2013;265. 10.1016/j.jjcc.2011.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2011.07.011</ArticleId><ArticleId IdType="pubmed">21890325</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch C. D., Lee C. M., Apte S. S. (2020). Aggrecan in cardiovascular development and disease. J. Histochem Cytochem 68, 777&#x2013;795. 10.1369/0022155420952902</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/0022155420952902</ArticleId><ArticleId IdType="pmc">PMC7649964</ArticleId><ArticleId IdType="pubmed">32870742</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstandin M. H., V&#xf6;lkers M., Collins B., Quijada P., Quintana M., De La Torre A., et al. (2013). Fibronectin contributes to pathological cardiac hypertrophy but not physiological growth. Basic Res. Cardiol. 108, 375. 10.1007/s00395-013-0375-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00395-013-0375-8</ArticleId><ArticleId IdType="pmc">PMC3813434</ArticleId><ArticleId IdType="pubmed">23912225</ArticleId></ArticleIdList></Reference><Reference><Citation>Krawetz R. J., Wu Y. E., Bertram K. L., Shonak A., Masson A. O., Ren G., et al. (2022). Synovial mesenchymal progenitor derived aggrecan regulates cartilage homeostasis and endogenous repair capacity. Cell Death and Dis. 13 (5), 470&#x2013;16. 10.1038/s41419-022-04919-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-04919-1</ArticleId><ArticleId IdType="pmc">PMC9117284</ArticleId><ArticleId IdType="pubmed">35585042</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan A., Chilton E., Raman J., Saxena P., McFarlane C., Trollope A. F., et al. (2021). Are interactions between epicardial adipose tissue, cardiac fibroblasts and cardiac myocytes instrumental in atrial fibrosis and atrial fibrillation? Cells 10, 2501. 10.3390/cells10092501</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10092501</ArticleId><ArticleId IdType="pmc">PMC8467050</ArticleId><ArticleId IdType="pubmed">34572150</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hn B., del Monte F., Hajjar R. J., Chang Y. S., Lebeche D., Arab S., et al. (2007). Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat. Med. 13 (8), 962&#x2013;969. 10.1038/nm1619</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1619</ArticleId><ArticleId IdType="pubmed">17632525</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasala G. P., Silva J. A., Allers C., Minguell J. J. (2012). Combination cell therapy for the treatment of acute myocardial infarction. Int. J. Cardiol. 157, 293&#x2013;294. 10.1016/j.ijcard.2012.03.125</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2012.03.125</ArticleId><ArticleId IdType="pubmed">22483420</ArticleId></ArticleIdList></Reference><Reference><Citation>Laser M., Willey C. D., Jiang W., Cooper G., 4th, Menick D. R., Zile M. R., et al. (2000). Integrin activation and focal complex formation in cardiac hypertrophy. J. Biol. Chem. 275, 35624&#x2013;35630. 10.1074/jbc.M006124200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M006124200</ArticleId><ArticleId IdType="pubmed">10958798</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavine K. J., Pinto A. R., Epelman S., Kopecky B. J., Clemente-Casares X., Godwin J., et al. (2018). The macrophage in cardiac homeostasis and disease: JACC macrophage in CVD series (part 4). J. Am. Coll. Cardiol. 72, 2213&#x2013;2230. 10.1016/j.jacc.2018.08.2149</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.08.2149</ArticleId><ArticleId IdType="pmc">PMC6209119</ArticleId><ArticleId IdType="pubmed">30360829</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Xie J., Chen J., Li R., Wu H., Zhang X., et al. (2017). Syndecan-4 deficiency accelerates the transition from compensated hypertrophy to heart failure following pressure overload. Cardiovasc. Pathol. 28, 74&#x2013;79. 10.1016/j.carpath.2017.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carpath.2017.03.008</ArticleId><ArticleId IdType="pubmed">28395201</ArticleId></ArticleIdList></Reference><Reference><Citation>
Li L., Fan D., Wang C., Wang J. Y., Cui X. B., Wu D., et al.  (2011). Angiotensin II increases periostin expression <i>via</i> Ras/p38 MAPK/CREB and ERK1/2/TGF-&#x3b2;1 pathways in cardiac fibroblasts. Cardiovasc Res.
91, 80&#x2013;89. 10.1093/cvr/cvr067

</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvr067</ArticleId><ArticleId IdType="pubmed">21367774</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillo R., Graziani F., Franceschi F., Iannaccone G., Massetti M., Olivotto I., et al. (2023). Inflammation across the spectrum of hypertrophic cardiac phenotypes. Heart Fail Rev. 28, 1065&#x2013;1075. 10.1007/s10741-023-10307-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-023-10307-4</ArticleId><ArticleId IdType="pmc">PMC10403403</ArticleId><ArticleId IdType="pubmed">37115472</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim D. S., Lutucuta S., Bachireddy P., Youker K., Evans A., Entman M., et al. (2001). Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103, 789&#x2013;791. 10.1161/01.cir.103.6.789</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.103.6.789</ArticleId><ArticleId IdType="pmc">PMC2779524</ArticleId><ArticleId IdType="pubmed">11171784</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeys B. L., Chen J., Neptune E. R., Judge D. P., Podowski M., Holm T., et al. (2005). A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet. 37 (3), 275&#x2013;281. 10.1038/ng1511</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1511</ArticleId><ArticleId IdType="pubmed">15731757</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi R., Betocchi S., Losi M. A., Tocchetti C. G., Aversa M., Miranda M., et al. (2003). Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 108, 1455&#x2013;1460. 10.1161/01.CIR.0000090687.97972.10</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000090687.97972.10</ArticleId><ArticleId IdType="pubmed">12952838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunde I. G., Aronsen J. M., Melleby A. O., Strand M. E., Skogestad J., Bendiksen B. A., et al. (2022). Cardiomyocyte-specific overexpression of syndecan-4 in mice results in activation of calcineurin-NFAT signalling and exacerbated cardiac hypertrophy. Mol. Biol. Rep. 49, 11795&#x2013;11809. 10.1007/s11033-022-07985-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-022-07985-y</ArticleId><ArticleId IdType="pmc">PMC9712407</ArticleId><ArticleId IdType="pubmed">36205855</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunde I. G., Herum K. M., Carlson C. C., Christensen G. (2016). Syndecans in heart fibrosis. Cell Tissue Res. 365, 539&#x2013;552. 10.1007/s00441-016-2454-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-016-2454-2</ArticleId><ArticleId IdType="pubmed">27411689</ArticleId></ArticleIdList></Reference><Reference><Citation>Macintyre C., Lakdawala N. K. (2016). Management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 133, 1901&#x2013;1905. 10.1161/CIRCULATIONAHA.115.015085</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.015085</ArticleId><ArticleId IdType="pubmed">27166348</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai J., Virtue A., Shen J., Wang H., Yang X. F. (2013). An evolving new paradigm: endothelial cells &#x2013; conditional innate immune cells. J. Hematol. and Oncol. 6 (1), 61&#x2013;13. 10.1186/1756-8722-6-61</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-8722-6-61</ArticleId><ArticleId IdType="pmc">PMC3765446</ArticleId><ArticleId IdType="pubmed">23965413</ArticleId></ArticleIdList></Reference><Reference><Citation>Maitra N., Flink I. L., Bahl J. J., Morkin E. (2000). Expression of alpha and beta integrins during terminal differentiation of cardiomyocytes. Cardiovasc Res. 47, 715&#x2013;725. 10.1016/s0008-6363(00)00140-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0008-6363(00)00140-1</ArticleId><ArticleId IdType="pubmed">10974220</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann D. L. (2015). Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ. Res. 116, 1254&#x2013;1268. 10.1161/CIRCRESAHA.116.302317</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.302317</ArticleId><ArticleId IdType="pmc">PMC4380242</ArticleId><ArticleId IdType="pubmed">25814686</ArticleId></ArticleIdList></Reference><Reference><Citation>Marian A. J., Braunwald E. (2017). Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ. Res. 121, 749&#x2013;770. 10.1161/CIRCRESAHA.117.311059</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.117.311059</ArticleId><ArticleId IdType="pmc">PMC5654557</ArticleId><ArticleId IdType="pubmed">28912181</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron B. J. (2002). Hypertrophic cardiomyopathy: a systematic review. JAMA 287, 1308&#x2013;1320. 10.1001/jama.287.10.1308</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.287.10.1308</ArticleId><ArticleId IdType="pubmed">11886323</ArticleId></ArticleIdList></Reference><Reference><Citation>Martino F., Perestrelo A. R., Vinarsk&#xfd; V., Pagliari S., Forte G. (2018). Cellular mechanotransduction: from tension to function. Front. Physiol. 9, 824. 10.3389/fphys.2018.00824</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.00824</ArticleId><ArticleId IdType="pmc">PMC6041413</ArticleId><ArticleId IdType="pubmed">30026699</ArticleId></ArticleIdList></Reference><Reference><Citation>Marwick T. H., Narula J. (2010). Cardiac ultrasound imaging in acute care settings. JACC Cardiovasc Imaging 3, 671&#x2013;672. 10.1016/j.jcmg.2010.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2010.04.005</ArticleId><ArticleId IdType="pubmed">20541726</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathiesen S. B., Lunde M., Aronsen J. M., Romaine A., Kaupang A., Martinsen M., et al. (2019). The cardiac syndecan-4 interactome reveals a role for syndecan-4 in nuclear translocation of muscle LIM protein (MLP). J. Biol. Chem. 294, 8717&#x2013;8731. 10.1074/jbc.RA118.006423</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.006423</ArticleId><ArticleId IdType="pmc">PMC6552415</ArticleId><ArticleId IdType="pubmed">30967474</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui Y., Jia N., Okamoto H., Kon S., Onozuka H., Akino M., et al. (2004). Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-Induced cardiac hypertrophy. Hypertension 43, 1195&#x2013;1201. 10.1161/01.HYP.0000128621.68160.dd</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000128621.68160.dd</ArticleId><ArticleId IdType="pubmed">15123578</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto E., Sasaki S., Kinoshita H., Kito T., Ohta H., Konishi M., et al. (2013). Angiotensin II-induced cardiac hypertrophy and fibrosis are promoted in mice lacking Fgf16. Genes Cells 18, 544&#x2013;553. 10.1111/gtc.12055</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/gtc.12055</ArticleId><ArticleId IdType="pmc">PMC3738920</ArticleId><ArticleId IdType="pubmed">23600527</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthia E. L., Setteducato M. L., Elzeneini M., Vernace N., Salerno M., Kramer C. M., et al. (2022). Circulating biomarkers in hypertrophic cardiomyopathy. J. Am. Heart Assoc. 11, e027618. 10.1161/JAHA.122.027618</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.122.027618</ArticleId><ArticleId IdType="pmc">PMC9851432</ArticleId><ArticleId IdType="pubmed">36382968</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin P. J., Bakall B., Choi J., Liu Z., Sasaki T., Davis E. C., et al. (2007). Lack of fibulin-3 causes early aging and herniation, but not macular degeneration in mice. Hum. Mol. Genet. 16, 3059&#x2013;3070. 10.1093/hmg/ddm264</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm264</ArticleId><ArticleId IdType="pubmed">17872905</ArticleId></ArticleIdList></Reference><Reference><Citation>Mel&#xe9;ndez G. C., McLarty J. L., Levick S. P., Du Y., Janicki J. S., Brower G. L. (2010). Interleukin-6 mediates myocardial fibrosis, concentric hypertrophy and diastolic dysfunction in rats. Hypertension 56, 225&#x2013;231. 10.1161/HYPERTENSIONAHA.109.148635</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.109.148635</ArticleId><ArticleId IdType="pmc">PMC2921860</ArticleId><ArticleId IdType="pubmed">20606113</ArticleId></ArticleIdList></Reference><Reference><Citation>Merline R., Schaefer R. M., Schaefer L. (2009). The matricellular functions of small leucine-rich proteoglycans (SLRPs). J. Cell Commun. Signal 3, 323&#x2013;335. 10.1007/s12079-009-0066-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12079-009-0066-2</ArticleId><ArticleId IdType="pmc">PMC2778586</ArticleId><ArticleId IdType="pubmed">19809894</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezu-Ndubuisi O. J., Maheshwari A. (2020). The role of integrins in inflammation and angiogenesis. Pediatr. Res. 89 (7), 1619&#x2013;1626. 10.1038/s41390-020-01177-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-020-01177-9</ArticleId><ArticleId IdType="pmc">PMC8249239</ArticleId><ArticleId IdType="pubmed">33027803</ArticleId></ArticleIdList></Reference><Reference><Citation>
Miao K., Zhou L., Ba H., Li C., Gu H., Yin B., et al.  (2020). Transmembrane tumor necrosis factor alpha attenuates pressure-overload cardiac hypertrophy <i>via</i> tumor necrosis factor receptor 2. PLoS Biol.
18, e3000967. 10.1371/journal.pbio.3000967

</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000967</ArticleId><ArticleId IdType="pmc">PMC7714153</ArticleId><ArticleId IdType="pubmed">33270628</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed I. A., Gadeau A. P., Hasan A., Abdulrahman N., Mraiche F. O. (2019). Promising therapeutic target in cardiac fibrosis. Cells 8. 10.3390/cells8121558</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8121558</ArticleId><ArticleId IdType="pmc">PMC6952988</ArticleId><ArticleId IdType="pubmed">31816901</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadzadeh N., Lunde I. G., Anden&#xe6;s K., Strand M. E., Aronsen J. M., Skrbic B., et al. (2019). The extracellular matrix proteoglycan lumican improves survival and counteracts cardiac dilatation and failure in mice subjected to pressure overload. Sci. Rep. 9, 9206. 10.1038/s41598-019-45651-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-45651-9</ArticleId><ArticleId IdType="pmc">PMC6591256</ArticleId><ArticleId IdType="pubmed">31235849</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadzadeh N., Melleby A. O., Palmero S., Sjaastad I., Chakravarti S., Engebretsen K. V. T., et al. (2020). Moderate loss of the extracellular matrix proteoglycan lumican attenuates cardiac fibrosis in mice subjected to pressure overload. Cardiology 145, 187&#x2013;198. 10.1159/000505318</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000505318</ArticleId><ArticleId IdType="pmc">PMC7672712</ArticleId><ArticleId IdType="pubmed">31968347</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti F. A., Chauhan A. K., Iaconcig A., Porro F., Baralle F. E., Muro A. F. (2007). A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived. J. Biol. Chem. 282, 28057&#x2013;28062. 10.1074/jbc.M611315200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M611315200</ArticleId><ArticleId IdType="pubmed">17644525</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto H., Takahashi M., Izawa A., Ise H., Hongo M., Kolattukudy P. E., et al. (2006). Cardiac overexpression of monocyte chemoattractant Protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ. Res. 99, 891&#x2013;899. 10.1161/01.RES.0000246113.82111.2d</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000246113.82111.2d</ArticleId><ArticleId IdType="pubmed">16990567</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouw J. K., Ou G., Weaver V. M. (2014). Extracellular matrix assembly: a multiscale deconstruction. Nat. Rev. Mol. Cell Biol. 15, 771&#x2013;785. 10.1038/nrm3902</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3902</ArticleId><ArticleId IdType="pmc">PMC4682873</ArticleId><ArticleId IdType="pubmed">25370693</ArticleId></ArticleIdList></Reference><Reference><Citation>
Naba A., Clauser K. R., Hoersch S., Liu H., Carr S. A., Hynes R. O. (2012). The matrisome: <i>in silico</i> definition and <i>in vivo</i> characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell. Proteomics
11, M111.014647. 10.1074/mcp.M111.014647
</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M111.014647</ArticleId><ArticleId IdType="pmc">PMC3322572</ArticleId><ArticleId IdType="pubmed">22159717</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagase H., Visse R., Murphy G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 69, 562&#x2013;573. 10.1016/j.cardiores.2005.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2005.12.002</ArticleId><ArticleId IdType="pubmed">16405877</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura Y., Kita S., Tanaka Y., Fukuda S., Obata Y., Okita T., et al. (2020). A disintegrin and metalloproteinase 12 prevents heart failure by regulating cardiac hypertrophy and fibrosis. Am. J. Physiol. Heart Circ. Physiol. 318, H238-H251&#x2013;H251. 10.1152/ajpheart.00496.2019</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00496.2019</ArticleId><ArticleId IdType="pubmed">31774689</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakasaki M., Hwang Y., Xie Y., Kataria S., Gund R., Hajam E. Y., et al. (2015). The matrix protein Fibulin-5 is at the interface of tissue stiffness and inflammation in fibrosis. Nat. Commun. 6, 8574. 10.1038/ncomms9574</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9574</ArticleId><ArticleId IdType="pmc">PMC4634219</ArticleId><ArticleId IdType="pubmed">26469761</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikitovic D., Katonis P., Tsatsakis A., Karamanos N. K., Tzanakakis G. N. (2008). Lumican, a small leucine-rich proteoglycan. IUBMB Life 60, 818&#x2013;823. 10.1002/iub.131</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.131</ArticleId><ArticleId IdType="pubmed">18949819</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolov A., Popovski N. (2022). Extracellular matrix in heart disease: focus on circulating collagen type I and III derived peptides as biomarkers of myocardial fibrosis and their potential in the prognosis of heart failure: a concise review. Metabolites 12, 297. 10.3390/metabo12040297</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12040297</ArticleId><ArticleId IdType="pmc">PMC9025448</ArticleId><ArticleId IdType="pubmed">35448484</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris R. A., Moreno-Rodriguez R. A., Sugi Y., Hoffman S., Amos J., Hart M. M., et al. (2008). Periostin regulates atrioventricular valve maturation. Dev. Biol. 316, 200&#x2013;213. 10.1016/j.ydbio.2008.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2008.01.003</ArticleId><ArticleId IdType="pmc">PMC2386672</ArticleId><ArticleId IdType="pubmed">18313657</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris R. A., Potts J. D., Yost M. J., Junor L., Brooks T., Tan H., et al. (2009). Periostin promotes a fibroblastic lineage pathway in atrioventricular valve progenitor cells. Dev. Dyn. 238, 1052&#x2013;1063. 10.1002/dvdy.21933</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.21933</ArticleId><ArticleId IdType="pmc">PMC2886283</ArticleId><ArticleId IdType="pubmed">19334280</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa E., Saito Y., Kuwahara K., Harada M., Miyamoto Y., Hamanaka I., et al. (2002). Fibronectin signaling stimulates BNP gene transcription by inhibiting neuron-restrictive silencer element-dependent repression. Cardiovasc Res. 53, 451&#x2013;459. 10.1016/s0008-6363(01)00492-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0008-6363(01)00492-8</ArticleId><ArticleId IdType="pubmed">11827696</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hanlon R., Grasso A., Roughton M., Moon J. C., Clark S., Wage R., et al. (2010). Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 56, 867&#x2013;874. 10.1016/j.jacc.2010.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2010.05.010</ArticleId><ArticleId IdType="pubmed">20688032</ArticleId></ArticleIdList></Reference><Reference><Citation>Olijnyk D., Ibrahim A. M., Ferrier R. K., Tsuda T., Chu M. L., Gusterson B. A., et al. (2014). Fibulin-2 is involved in early extracellular matrix development of the outgrowing mouse mammary epithelium. Cell Mol. Life Sci. 71, 3811&#x2013;3828. 10.1007/s00018-014-1577-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-014-1577-4</ArticleId><ArticleId IdType="pmc">PMC11113845</ArticleId><ArticleId IdType="pubmed">24522256</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivi&#xe9;ro P., Chassagne C., Salichon N., Corbier A., Hamon G., Marotte F., et al. (2000). Expression of laminin alpha2 chain during normal and pathological growth of myocardium in rat and human. Cardiovasc Res. 46, 346&#x2013;355. 10.1016/s0008-6363(00)00034-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0008-6363(00)00034-1</ArticleId><ArticleId IdType="pubmed">10773239</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivotto I., Maron M. S., Autore C., Lesser J. R., Rega L., Casolo G., et al. (2008). Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 52, 559&#x2013;566. 10.1016/j.jacc.2008.04.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2008.04.047</ArticleId><ArticleId IdType="pubmed">18687251</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke S. A., Dunne A., Monaghan M. G. (2019). The role of macrophages in the infarcted myocardium: orchestrators of ECM remodeling. Front. Cardiovasc Med. 6, 101. 10.3389/fcvm.2019.00101</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2019.00101</ArticleId><ArticleId IdType="pmc">PMC6685361</ArticleId><ArticleId IdType="pubmed">31417911</ArticleId></ArticleIdList></Reference><Reference><Citation>Piek A., de Boer R. A., Sillj&#xe9; H. H. W. (2016). The fibrosis-cell death axis in heart failure. Heart Fail. Rev. 21 (2), 199&#x2013;211. 10.1007/s10741-016-9536-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-016-9536-9</ArticleId><ArticleId IdType="pmc">PMC4762920</ArticleId><ArticleId IdType="pubmed">26883434</ArticleId></ArticleIdList></Reference><Reference><Citation>Piers S. R. D., van Huls van Taxis C. F. B., Tao Q., van der Geest R. J., Askar S. F., Siebelink H. M. J., et al. (2013). Epicardial substrate mapping for ventricular tachycardia ablation in patients with non-ischaemic cardiomyopathy: a new algorithm to differentiate between scar and viable myocardium developed by simultaneous integration of computed tomography and contrast-enhanced magnetic resonance imaging. Eur. Heart J. 34, 586&#x2013;596. 10.1093/eurheartj/ehs382</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehs382</ArticleId><ArticleId IdType="pubmed">23161702</ArticleId></ArticleIdList></Reference><Reference><Citation>Podesser B. K., Kreibich M., Dzilic E., Santer D., F&#xf6;rster L., Trojanek S., et al. (2018). Tenascin-C promotes chronic pressure overload-induced cardiac dysfunction, hypertrophy and myocardial fibrosis. J. Hypertens. 36, 847&#x2013;856. 10.1097/HJH.0000000000001628</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000001628</ArticleId><ArticleId IdType="pubmed">29283973</ArticleId></ArticleIdList></Reference><Reference><Citation>Previs M. J., O'Leary T. S., Morley M. P., Palmer B. M., LeWinter M., Yob J. M., et al. (2022). Defects in the proteome and metabolome in human hypertrophic cardiomyopathy. Circ. Heart Fail 15, E009521. 10.1161/CIRCHEARTFAILURE.121.009521</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.121.009521</ArticleId><ArticleId IdType="pmc">PMC9708114</ArticleId><ArticleId IdType="pubmed">35543134</ArticleId></ArticleIdList></Reference><Reference><Citation>Repetti G. G., Kim Y., Pereira A. C., Ingles J., Russell M. W., Lakdawala N. K., et al. (2021). Discordant clinical features of identical hypertrophic cardiomyopathy twins. Proc. Natl. Acad. Sci. U. S. A. 118, e2021717118. 10.1073/pnas.2021717118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2021717118</ArticleId><ArticleId IdType="pmc">PMC7958207</ArticleId><ArticleId IdType="pubmed">33658374</ArticleId></ArticleIdList></Reference><Reference><Citation>Revelo X. S., Parthiban P., Chen C., Barrow F., Fredrickson G., Wang H., et al. (2021). Cardiac resident macrophages prevent fibrosis and stimulate angiogenesis. Circ. Res. 129, 1086&#x2013;1101. 10.1161/CIRCRESAHA.121.319737</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.319737</ArticleId><ArticleId IdType="pmc">PMC8638822</ArticleId><ArticleId IdType="pubmed">34645281</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricard-Blum S. (2011). The collagen family. Cold Spring Harb. Perspect. Biol. 3, a004978&#x2013;19. 10.1101/cshperspect.a004978</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a004978</ArticleId><ArticleId IdType="pmc">PMC3003457</ArticleId><ArticleId IdType="pubmed">21421911</ArticleId></ArticleIdList></Reference><Reference><Citation>Rienks M., Papageorgiou A. P., Frangogiannis N. G., Heymans S. (2014). Myocardial extracellular matrix: an ever-changing and diverse entity. Circ. Res. 114, 872&#x2013;888. 10.1161/CIRCRESAHA.114.302533</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.114.302533</ArticleId><ArticleId IdType="pubmed">24577967</ArticleId></ArticleIdList></Reference><Reference><Citation>Rixon C., Andreassen K., Shen X., Erusappan P. M., Almaas V. M., Palmero S., et al. (2023). Lumican accumulates with fibrillar collagen in fibrosis in hypertrophic cardiomyopathy. Esc. Heart Fail 10, 858&#x2013;871. 10.1002/ehf2.14234</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.14234</ArticleId><ArticleId IdType="pmc">PMC10053290</ArticleId><ArticleId IdType="pubmed">36444917</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez D., Morrison C. J., Overall C. M. (2010). Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta 1803, 39&#x2013;54. 10.1016/j.bbamcr.2009.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2009.09.015</ArticleId><ArticleId IdType="pubmed">19800373</ArticleId></ArticleIdList></Reference><Reference><Citation>Rold&#xe1;n V., Mar&#xed;n F., Gimeno J. R., Ruiz-Espejo F., Gonz&#xe1;lez J., Feliu E., et al. (2008). Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am. Heart J. 156, 85&#x2013;91. 10.1016/j.ahj.2008.01.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2008.01.035</ArticleId><ArticleId IdType="pubmed">18585501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross R. S. (2002). The extracellular connections: the role of integrins in myocardial remodeling. J. Card. Fail 8, S326&#x2013;S331. 10.1054/jcaf.2002.129263</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/jcaf.2002.129263</ArticleId><ArticleId IdType="pubmed">12555140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross R. S., Borg T. K. (2001). Integrins and the myocardium. Circ. Res. 88, 1112&#x2013;1119. 10.1161/hh1101.091862</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hh1101.091862</ArticleId><ArticleId IdType="pubmed">11397776</ArticleId></ArticleIdList></Reference><Reference><Citation>Saadat S., Noureddini M., Mahjoubin-Tehran M., Nazemi S., Shojaie L., Aschner M., et al. (2020). Pivotal role of TGF-&#x3b2;/Smad signaling in cardiac fibrosis: non-Coding RNAs as effectual players. Front. Cardiovasc Med. 7, 588347. 10.3389/fcvm.2020.588347</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2020.588347</ArticleId><ArticleId IdType="pmc">PMC7868343</ArticleId><ArticleId IdType="pubmed">33569393</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M., Fukuda K., Kodama H., Pan J., Saito M., Matsuzaki J., et al. (2000). Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J. Biol. Chem. 275, 29717&#x2013;29723. 10.1074/jbc.M003128200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M003128200</ArticleId><ArticleId IdType="pubmed">10843995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasi A., Romaine A., Erusappan P. M., Melleby A. O., Hasic A., Dahl C. P., et al. (2023). Temporal expression and spatial distribution of the proteoglycan versican during cardiac fibrosis development. Matrix Biol. Plus 19&#x2013;20, 100135. 10.1016/j.mbplus.2023.100135</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mbplus.2023.100135</ArticleId><ArticleId IdType="pmc">PMC10709089</ArticleId><ArticleId IdType="pubmed">38076279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasse P., Malan D., Fleischmann M., Roell W., Gustafsson E., Bostani T., et al. (2008). Perlecan is critical for heart stability. Cardiovasc Res. 80, 435&#x2013;444. 10.1093/cvr/cvn225</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvn225</ArticleId><ArticleId IdType="pubmed">18694874</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. (2011). The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica Biophysica Acta (BBA) - Mol. Cell Res. 1813, 878&#x2013;888. 10.1016/j.bbamcr.2011.01.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2011.01.034</ArticleId><ArticleId IdType="pubmed">21296109</ArticleId></ArticleIdList></Reference><Reference><Citation>Schram K., Sweeney G. (2008). Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure. Trends Cardiovasc Med. 18, 199&#x2013;205. 10.1016/j.tcm.2008.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2008.10.001</ArticleId><ArticleId IdType="pubmed">19185809</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz J. E. J., Witt S. A., Nieman M. L., Reiser P. J., Engle S. J., Zhou M., et al. (1999). Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J. Clin. Invest 104, 709&#x2013;719. 10.1172/JCI7315</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI7315</ArticleId><ArticleId IdType="pmc">PMC408439</ArticleId><ArticleId IdType="pubmed">10491406</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher S. M., Naga Prasad S. V. (2018). Tumor necrosis Factor-&#x3b1; in heart failure: an updated review. Curr. Cardiol. Rep. 20, 117. 10.1007/s11886-018-1067-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-018-1067-7</ArticleId><ArticleId IdType="pmc">PMC6311126</ArticleId><ArticleId IdType="pubmed">30259192</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwach V., Passier R. (2019). Native cardiac environment and its impact on engineering cardiac tissue. Biomater. Sci. 7, 3566&#x2013;3580. 10.1039/c8bm01348a</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c8bm01348a</ArticleId><ArticleId IdType="pubmed">31338495</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwinger R. H. G., B&#xf6;hm M., Koch A., Schmidt U., Morano I., Eissner H. J., et al. (1994). The failing human heart is unable to use the frank-starling mechanism. Circ. Res. 74, 959&#x2013;969. 10.1161/01.res.74.5.959</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.res.74.5.959</ArticleId><ArticleId IdType="pubmed">8156643</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J. Z., Morgan J., Tesch G. H., Fuller P. J., Young M. J. (2014). CCL2-dependent macrophage recruitment is critical for mineralocorticoid receptor-mediated cardiac fibrosis, inflammation, and blood pressure responses in male mice. Endocrinology 155, 1057&#x2013;1066. 10.1210/en.2013-1772</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2013-1772</ArticleId><ArticleId IdType="pubmed">24428529</ArticleId></ArticleIdList></Reference><Reference><Citation>
Shimojo N., Hashizume R., Kanayama K., Hara M., Suzuki Y., Nishioka T., et al.  (2015). Tenascin-C may accelerate cardiac fibrosis by activating macrophages <i>via</i> the integrin &#x3b1;V&#x3b2;3/Nuclear Factor-&#x3ba;B/Interleukin-6 axis. Hypertension
66, 757&#x2013;766. 10.1161/HYPERTENSIONAHA.115.06004

</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.115.06004</ArticleId><ArticleId IdType="pubmed">26238448</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirakawa K., Sano M. (2021). Osteopontin in cardiovascular diseases. Biomolecules 11, 1047. 10.3390/biom11071047</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11071047</ArticleId><ArticleId IdType="pmc">PMC8301767</ArticleId><ArticleId IdType="pubmed">34356671</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva A. C., Pereira C., Fonseca A. C. R. G., Pinto-do-&#xd3; P., Nascimento D. S. (2020). Bearing my heart: the role of extracellular matrix on cardiac development, homeostasis, and injury response. Front. Cell Dev. Biol. 8, 621644. 10.3389/fcell.2020.621644</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.621644</ArticleId><ArticleId IdType="pmc">PMC7835513</ArticleId><ArticleId IdType="pubmed">33511134</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P., Carraher C., Schwarzbauer J. E. (2010). Assembly of Fibronectin extracellular matrix. Annu. Rev. Cell Dev. Biol. 26, 397&#x2013;419. 10.1146/annurev-cellbio-100109-104020</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100109-104020</ArticleId><ArticleId IdType="pmc">PMC3628685</ArticleId><ArticleId IdType="pubmed">20690820</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinale F. G. (2007). Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 87, 1285&#x2013;1342. 10.1152/physrev.00012.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00012.2007</ArticleId><ArticleId IdType="pubmed">17928585</ArticleId></ArticleIdList></Reference><Reference><Citation>Stansfield W. E., Andersen N. M., Tang R. H., Selzman C. H. (2009). Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart. Ann. Thorac. Surg. 88, 1916&#x2013;1921. 10.1016/j.athoracsur.2009.07.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2009.07.038</ArticleId><ArticleId IdType="pmc">PMC3686640</ArticleId><ArticleId IdType="pubmed">19932262</ArticleId></ArticleIdList></Reference><Reference><Citation>Stetler-Stevenson W. G. (2008). Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal 1, re6. 10.1126/scisignal.127re6</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.127re6</ArticleId><ArticleId IdType="pmc">PMC2493614</ArticleId><ArticleId IdType="pubmed">18612141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K., yuan Y., Jin J. (2021). A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair. Signal Transduct. Target. Ther. 6 (1), 79&#x2013;16. 10.1038/s41392-020-00455-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00455-6</ArticleId><ArticleId IdType="pmc">PMC7897720</ArticleId><ArticleId IdType="pubmed">33612829</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M., Corden B., Cook S. A. (2020). Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? EMBO Mol. Med. 12, e10865. 10.15252/emmm.201910865</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201910865</ArticleId><ArticleId IdType="pmc">PMC7539225</ArticleId><ArticleId IdType="pubmed">32955172</ArticleId></ArticleIdList></Reference><Reference><Citation>Sziksz E., Pap D., Lippai R., B&#xe9;res N. J., Fekete A., Szab&#xf3; A. J., et al. (2015). Fibrosis related inflammatory mediators: role of the IL-10 cytokine family. Mediat. Inflamm. 2015, 764641. 10.1155/2015/764641</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/764641</ArticleId><ArticleId IdType="pmc">PMC4495231</ArticleId><ArticleId IdType="pubmed">26199463</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacer K. F., Bookout A. L., Ding X., Kurosu H., John G. B., Wang L., et al. (2010). Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24, 2050&#x2013;2064. 10.1210/me.2010-0142</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2010-0142</ArticleId><ArticleId IdType="pmc">PMC2954642</ArticleId><ArticleId IdType="pubmed">20667984</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi R., Negishi K., Watanabe A., Arai M., Naganuma F., Ohyama Y., et al. (2011). Serum syndecan-4 is a novel biomarker for patients with chronic heart failure. J. Cardiol. 57, 325&#x2013;332. 10.1016/j.jjcc.2011.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2011.01.012</ArticleId><ArticleId IdType="pubmed">21397460</ArticleId></ArticleIdList></Reference><Reference><Citation>
Takahashi S., Geenen D., Nieves E., Iwazumi T. (1999). Collagenase degrades collagen <i>in vivo</i> in the ischemic heart. Biochimica Biophysica Acta (BBA) - General Subj.
1428, 251&#x2013;259. 10.1016/s0304-4165(99)00090-2
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0304-4165(99)00090-2</ArticleId><ArticleId IdType="pubmed">10434043</ArticleId></ArticleIdList></Reference><Reference><Citation>Takawale A., Zhang P., Patel V. B., Wang X., Oudit G., Kassiri Z. (2017). Tissue inhibitor of matrix Metalloproteinase-1 promotes myocardial fibrosis by mediating CD63-Integrin &#x3b2;1 interaction. Hypertension 69, 1092&#x2013;1103. 10.1161/HYPERTENSIONAHA.117.09045</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.117.09045</ArticleId><ArticleId IdType="pubmed">28373589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallquist M. D., Molkentin J. D. (2017). Redefining the identity of cardiac fibroblasts. Nat. Rev. Cardiol. 14, 484&#x2013;491. 10.1038/nrcardio.2017.57</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2017.57</ArticleId><ArticleId IdType="pmc">PMC6329009</ArticleId><ArticleId IdType="pubmed">28436487</ArticleId></ArticleIdList></Reference><Reference><Citation>Talman A. H., Psaltis P. J., Cameron J. D., Meredith I. T., Seneviratne S. K., Wong D. T. L. (2014). Epicardial adipose tissue: far more than a fat depot. Cardiovasc Diagn Ther. 4, 416&#x2013;429. 10.3978/j.issn.2223-3652.2014.11.05</Citation><ArticleIdList><ArticleId IdType="doi">10.3978/j.issn.2223-3652.2014.11.05</ArticleId><ArticleId IdType="pmc">PMC4278038</ArticleId><ArticleId IdType="pubmed">25610800</ArticleId></ArticleIdList></Reference><Reference><Citation>Talman V., Ruskoaho H. (2016). Cardiac fibrosis in myocardial infarction&#x2014;from repair and remodeling to regeneration. Cell Tissue Res. 365 (3), 563&#x2013;581. 10.1007/s00441-016-2431-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-016-2431-9</ArticleId><ArticleId IdType="pmc">PMC5010608</ArticleId><ArticleId IdType="pubmed">27324127</ArticleId></ArticleIdList></Reference><Reference><Citation>Teekakirikul P., Eminaga S., Toka O., Alcalai R., Wang L., Wakimoto H., et al. (2010). Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by Non-myocyte proliferation and requires Tgf-&#x3b2;. J. Clin. Invest 120, 3520&#x2013;3529. 10.1172/JCI42028</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI42028</ArticleId><ArticleId IdType="pmc">PMC2947222</ArticleId><ArticleId IdType="pubmed">20811150</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian M., Yuan Y.-C., Li J.-Y., Gionfriddo M. R., Huang R.-C. (2015). Tumor necrosis factor-&#x3b1; and its role as a mediator in myocardial infarction: a brief review. Chronic Dis. Transl. Med. 1, 18&#x2013;26. 10.1016/j.cdtm.2015.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cdtm.2015.02.002</ArticleId><ArticleId IdType="pmc">PMC5643772</ArticleId><ArticleId IdType="pubmed">29062983</ArticleId></ArticleIdList></Reference><Reference><Citation>Timpl R., Sasaki T., Kostka G., Chu M. L. (2003). Fibulins: a versatile family of extracellular matrix proteins. Nat. Rev. Mol. Cell Biol. 4 (6), 479&#x2013;489. 10.1038/nrm1130</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm1130</ArticleId><ArticleId IdType="pubmed">12778127</ArticleId></ArticleIdList></Reference><Reference><Citation>Toba H., Cannon P. L., Yabluchanskiy A., Iyer R. P., D'Armiento J., Lindsey M. L. (2017). Transgenic overexpression of macrophage matrix metalloproteinase-9 exacerbates age-related cardiac hypertrophy, vessel rarefaction, inflammation, and fibrosis. Am. J. Physiol. Heart Circ. Physiol. 312, H375-H383&#x2013;H383. 10.1152/ajpheart.00633.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00633.2016</ArticleId><ArticleId IdType="pmc">PMC5402013</ArticleId><ArticleId IdType="pubmed">28011588</ArticleId></ArticleIdList></Reference><Reference><Citation>Travers J. G., Kamal F. A., Robbins J., Yutzey K. E., Burns C. (2017). Cardiac fibrosis: the fibroblast awakens. Circ. Res. 118, 1021&#x2013;1040. 10.1161/CIRCRESAHA.115.306565</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.115.306565</ArticleId><ArticleId IdType="pmc">PMC4800485</ArticleId><ArticleId IdType="pubmed">26987915</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker R. P., Chiquet-Ehrismann R. (2009). The regulation of tenascin expression by tissue microenvironments. Biochim. Biophys. Acta 1793, 888&#x2013;892. 10.1016/j.bbamcr.2008.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2008.12.012</ArticleId><ArticleId IdType="pubmed">19162090</ArticleId></ArticleIdList></Reference><Reference><Citation>Uesugi N., Sakata N. (2005). Role of integrins, including alpha8, for neointima formation after vascular injury. Cardiovasc Res. 65, 766&#x2013;767. 10.1016/j.cardiores.2005.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2005.01.003</ArticleId><ArticleId IdType="pubmed">15721854</ArticleId></ArticleIdList></Reference><Reference><Citation>Valencik M. L., Zhang D., Punske B., Hu P., McDonald J. A., Litwin S. E. (2006). Integrin activation in the heart: a link between electrical and contractile dysfunction? Circ. Res. 99, 1403&#x2013;1410. 10.1161/01.RES.0000252291.88540.ac</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000252291.88540.ac</ArticleId><ArticleId IdType="pubmed">17095723</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdecchia P., Angeli F., Mazzotta G., Garofoli M., Ramundo E., Gentile G., et al. (2012). Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension 60, 34&#x2013;42. 10.1161/HYPERTENSIONAHA.112.191858</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.112.191858</ArticleId><ArticleId IdType="pubmed">22585951</ArticleId></ArticleIdList></Reference><Reference><Citation>Villarreal F. J., Dillmann W. H. (1992). Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen. Am. J. Physiol. 262, H1861&#x2013;H1866. 10.1152/ajpheart.1992.262.6.H1861</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.1992.262.6.H1861</ArticleId><ArticleId IdType="pubmed">1535758</ArticleId></ArticleIdList></Reference><Reference><Citation>
Vistnes M., Aronsen J. M., Lunde I. G., Sjaastad I., Carlson C. R., Christensen G. (2014). Pentosan polysulfate decreases myocardial expression of the extracellular matrix enzyme ADAMTS4 and improves cardiac function <i>in vivo</i> in rats subjected to pressure overload by aortic banding. PLoS One
9, e89621. 10.1371/journal.pone.0089621

</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089621</ArticleId><ArticleId IdType="pmc">PMC3940660</ArticleId><ArticleId IdType="pubmed">24595230</ArticleId></ArticleIdList></Reference><Reference><Citation>
Waleczek F. J. G., Sansonetti M., Xiao K., Jung M., Mitzka S., Dendorfer A., et al.  (2022). Chemical and mechanical activation of resident cardiac macrophages in the living myocardial slice <i>ex vivo</i> model. Basic Res. Cardiol.
117, 63&#x2013;18. 10.1007/s00395-022-00971-2

</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00395-022-00971-2</ArticleId><ArticleId IdType="pmc">PMC9712328</ArticleId><ArticleId IdType="pubmed">36449104</ArticleId></ArticleIdList></Reference><Reference><Citation>WalyEldeen A. A., Sabet S., Anis S. E., Stein T., Ibrahim A. M. (2024). FBLN2 is associated with basal cell markers Krt14 and ITGB1 in mouse mammary epithelial cells and has a preferential expression in molecular subtypes of human breast cancer. Breast Cancer Res. Treat. 208, 673&#x2013;686. 10.1007/S10549-024-07447-Y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10549-024-07447-Y</ArticleId><ArticleId IdType="pmc">PMC11522194</ArticleId><ArticleId IdType="pubmed">39110274</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Hoshijima M., Lam J., Zhou Z., Jokiel A., Dalton N. D., et al. (2006). Cardiomyopathy associated with microcirculation dysfunction in laminin alpha4 chain-deficient mice. J. Biol. Chem. 281, 213&#x2013;220. 10.1074/jbc.M505061200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M505061200</ArticleId><ArticleId IdType="pubmed">16204254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., LeMaire S. A., Chen L., Carter S. A., Shen Y. H., Gan Y., et al. (2005). Decreased expression of fibulin-5 correlates with reduced elastin in thoracic aortic dissection. Surgery 138, 352&#x2013;359. 10.1016/j.surg.2005.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2005.06.006</ArticleId><ArticleId IdType="pubmed">16153447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Lu Y., Xie Y., Shen J., Xiang M. (2019). Emerging roles of proteoglycans in cardiac remodeling. Int. J. Cardiol. 278, 192&#x2013;198. 10.1016/j.ijcard.2018.11.125</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2018.11.125</ArticleId><ArticleId IdType="pubmed">30528626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Chaffee T. S., LaRue R. S., Huggins D. N., Witschen P. M., Ibrahim A. M., et al. (2020). Tissue-resident macrophages promote extracellular matrix homeostasis in the mammary gland stroma of nulliparous mice. Elife 9, 1&#x2013;27. 10.7554/eLife.57438</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.57438</ArticleId><ArticleId IdType="pmc">PMC7297528</ArticleId><ArticleId IdType="pubmed">32479261</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber S., Saftig P. (2012). Ectodomain shedding and ADAMs in development. Development 139, 3693&#x2013;3709. 10.1242/dev.076398</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.076398</ArticleId><ArticleId IdType="pubmed">22991436</ArticleId></ArticleIdList></Reference><Reference><Citation>Widyantoro B., Emoto N., Nakayama K., Anggrahini D. W., Adiarto S., Iwasa N., et al. (2010). Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 121, 2407&#x2013;2418. 10.1161/CIRCULATIONAHA.110.938217</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.938217</ArticleId><ArticleId IdType="pubmed">20497976</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigle E. D., Sole M. J., Williams W. C., Williams W. C., Rojkind M. (1991). Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 17, 1343&#x2013;1351. 10.1016/s0735-1097(10)80145-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0735-1097(10)80145-7</ArticleId><ArticleId IdType="pubmed">2016452</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S., Zhang J., Liu J., Ye J., Xu Y., Wang Z., et al. (2021). The role of interleukin-10 family members in cardiovascular diseases. Int. Immunopharmacol. 94, 107475. 10.1016/j.intimp.2021.107475</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107475</ArticleId><ArticleId IdType="pubmed">33662690</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabluchanskiy A., Ma Y., Iyer R. P., Hall M. E., Lindsey M. L. (2013). Matrix Metalloproteinase-9: many shades of function in cardiovascular disease. Physiology 28, 391&#x2013;403. 10.1152/physiol.00029.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiol.00029.2013</ArticleId><ArticleId IdType="pmc">PMC3858212</ArticleId><ArticleId IdType="pubmed">24186934</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W., Wang P., Zhao C. X., Tang J., Xiao X., Wang D. W. (2009). Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/smad and p38 mitogen-activated protein kinase signaling pathways. Hum. Gene Ther. 20, 1190&#x2013;1200. 10.1089/hum.2008.204</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2008.204</ArticleId><ArticleId IdType="pubmed">19697998</ArticleId></ArticleIdList></Reference><Reference><Citation>
Yang Y., Yu W., Yan W., Xia Q. (2021). Decorin induces cardiac hypertrophy by regulating the CaMKII/MEF-2 signaling pathway <i>in vivo</i>
. Curr. Med. Sci.
41, 857&#x2013;862. 10.1007/s11596-021-2426-y

</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11596-021-2426-y</ArticleId><ArticleId IdType="pubmed">34643879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J., Wang Z., Ye D., Wang Y., Wang M., Ji Q., et al. (2019). Increased Interleukin-11 levels are correlated with cardiac events in patients with chronic heart failure. Mediat. Inflamm. 2019, 1575410. 10.1155/2019/1575410</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/1575410</ArticleId><ArticleId IdType="pmc">PMC6341241</ArticleId><ArticleId IdType="pubmed">30728748</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildirim Z., Swanson K., Wu X., Zou J., Wu J. (2025). Next-gen therapeutics: pioneering drug discovery with iPSCs, genomics, AI, and clinical trials in a dish. Annu. Rev. Pharmacol. Toxicol. 65, 71&#x2013;90. 10.1146/annurev-pharmtox-022724-095035</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-022724-095035</ArticleId><ArticleId IdType="pmc">PMC12011342</ArticleId><ArticleId IdType="pubmed">39284102</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota T., McCourt J., Ma F., Ren S., Li S., Kim T. H., et al. (2020). Type V collagen in scar tissue regulates the size of scar after heart injury. Cell 182, 545&#x2013;562. 10.1016/j.cell.2020.06.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.030</ArticleId><ArticleId IdType="pmc">PMC7415659</ArticleId><ArticleId IdType="pubmed">32621799</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama T., Nakano M., Bednarczyk J. L., McIntyre B. W., Entman M., Mann D. L. (1997). Tumor necrosis Factor-&#x3b1; provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 95, 1247&#x2013;1252. 10.1161/01.cir.95.5.1247</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.95.5.1247</ArticleId><ArticleId IdType="pubmed">9054856</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousif L. F., Di Russo J., Sorokin L. (2013). Laminin isoforms in endothelial and perivascular basement membranes. Cell Adh Migr. 7, 101&#x2013;110. 10.4161/cam.22680</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cam.22680</ArticleId><ArticleId IdType="pmc">PMC3544773</ArticleId><ArticleId IdType="pubmed">23263631</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Wu J., Dong H., Khan S. A., Chu M. L., Tsuda T. (2014). Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor-&#x3b2; signalling. Clin. Sci. (Lond) 126, 275&#x2013;288. 10.1042/CS20120636</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20120636</ArticleId><ArticleId IdType="pmc">PMC4075193</ArticleId><ArticleId IdType="pubmed">23841699</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S., Wu H., Xia W., Chen X., Zhu S., Zhang S., et al. (2014). Periostin expression is upregulated and associated with myocardial fibrosis in human failing hearts. J. Cardiol. 63, 373&#x2013;378. 10.1016/j.jjcc.2013.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2013.09.013</ArticleId><ArticleId IdType="pubmed">24219836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zibadi S., Cordova F., Slack E. H., Watson R. R., Larson D. F. (2011). Leptin&#x2019;s regulation of obesity-induced cardiac extracellular matrix remodeling. Cardiovasc Toxicol. 11, 325&#x2013;333. 10.1007/s12012-011-9124-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12012-011-9124-0</ArticleId><ArticleId IdType="pubmed">21744298</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40841467</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-8312</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>The international journal of cardiovascular imaging</Title><ISOAbbreviation>Int J Cardiovasc Imaging</ISOAbbreviation></Journal><ArticleTitle>Misclassification of recovery in dilated cardiomyopathy by echocardiography as compared to cardiac MRI.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10554-025-03492-w</ELocationID><Abstract><AbstractText>Accurate assessment of cardiac function is the cornerstone of DCM diagnosis and management. Studies have compared CMR and 2D-TTE but the impact of these measurements on HF classification and assessment of EF improvement has not been explored. We aim to compare left ventricular (LV) ejection fraction (EF) and volumes as measured by cardiovascular magnetic resonance (CMR) and two dimensional (2D) transthoracic echocardiography (TTE) in dilated cardiomyopathy (DCM) patients in the initial EF based classification of heart failure (HF) and subsequent follow-up.We compared LVEF, LV end-diastolic volume (LVEDV) and LV end-systolic volumes (ESV) measurements from 130 DCM patients during both their initial visit and their follow-up imaging 12-48 months later. We also assessed the myocardial recovery of patients who were classified as having HFimpEF (EF&#x2009;&lt;&#x2009;40% to EF&#x2009;&#x2265;&#x2009;40% with at least a 10% increase in EF) by 2D-TTE and CMR. We found that 2D-TTE overestimated EF (8.3% (95% CI 7.2 to 9.4), p&#x2009;&lt;&#x2009;0.001) and underestimated LVEDV (-69.0&#xa0;ml (95% CI -77.0 to -61.1), p&#x2009;&lt;&#x2009;0.001) and LVESV (-64.8&#xa0;ml (95% CI -71.6 to -57.9) p&#x2009;&lt;&#x2009;0.001) as compared to CMR. The overestimation of EF was not uniform across the EF spectrum. The lower the LVEF, the greater the overestimation by TTE. This overestimation led to an initial misclassification of 60% of HFrEF patients and a subsequent misclassification of myocardial recovery in 59% of DCM patients. 2D-TTE misclassification of DCM patients may significantly impact the initial treatment choice and follow-up of heart failure patients.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Nature B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mui</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Stanford School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xu</LastName><ForeName>Yuanwei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cardiology Division, Department of Medicine, West China Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pohlman</LastName><ForeName>Neal K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Department of Medicine, Ohio State College of Medicine, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cardiology Division, Department of Medicine, West China Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Siqi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yangjie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cardiology Division, Department of Medicine, West China Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiology Division, Department of Medicine, West China Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weihao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Cardiology Division, Department of Medicine, West China Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yucheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cardiology Division, Department of Medicine, West China Hospital, Chengdu, China. chenyucheng2003@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Division, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China. chenyucheng2003@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Yuchi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Department of Medicine, Ohio State College of Medicine, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81571638</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2023M732461</GrantID><Agency>China Postdoctoral Science Foundation</Agency><Country/></Grant><Grant><GrantID>23NSFSC4589</GrantID><Agency>Natural Science Foundation of Sichuan Province</Agency><Country/></Grant><Grant><GrantID>ZYGD22013</GrantID><Agency>1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Cardiovasc Imaging</MedlineTA><NlmUniqueID>100969716</NlmUniqueID><ISSNLinking>1569-5794</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular magnetic resonance</Keyword><Keyword MajorTopicYN="N">Dilated cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Myocardial recovery</Keyword><Keyword MajorTopicYN="N">Transthoracic echocardiography</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841467</ArticleId><ArticleId IdType="doi">10.1007/s10554-025-03492-w</ArticleId><ArticleId IdType="pii">10.1007/s10554-025-03492-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldberger JJ, Subacius H, Patel T, Cunnane R, Kadish AH (2014) Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 63:1879&#x2013;1889</Citation><ArticleIdList><ArticleId IdType="pubmed">24445228</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferies JL, Towbin JA (2010) Dilated cardiomyopathy. Lancet 375:752&#x2013;762</Citation><ArticleIdList><ArticleId IdType="pubmed">20189027</ArticleId></ArticleIdList></Reference><Reference><Citation>Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK (2016) The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol 67:2996&#x2013;3010</Citation><ArticleIdList><ArticleId IdType="pubmed">27339497</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott P (2000) Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy. Heart 84:106&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">10862601</ArticleId><ArticleId IdType="pmc">1729405</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta M, Hacioglu Y, Kadakia J, Ahmadi N, Gao Y, Mao SS, Budoff MJ (2011) Left ventricular volume: an optimal parameter to detect systolic dysfunction on prospectively triggered 64-multidetector row computed tomography: another step towards reducing radiation exposure. Int J Cardiovasc Imaging 27:1015&#x2013;1023</Citation><ArticleIdList><ArticleId IdType="pubmed">21063782</ArticleId></ArticleIdList></Reference><Reference><Citation>Marwick TH (2018) Ejection fraction pros and cons: JACC state-of-the-art review. J Am Coll Cardiol 72:2360&#x2013;2379</Citation><ArticleIdList><ArticleId IdType="pubmed">30384893</ArticleId></ArticleIdList></Reference><Reference><Citation>Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of America. Circulation 136:e137&#x2013;e161</Citation><ArticleIdList><ArticleId IdType="pubmed">28455343</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonarow GC (2017) Refining classification of heart failure based on ejection fraction. JACC Heart Fail 5:808&#x2013;809</Citation><ArticleIdList><ArticleId IdType="pubmed">29096789</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehman R, Makaryus AN (2020) Cardiac imaging. StatPearls, Treasure Island (FL)</Citation></Reference><Reference><Citation>Webb J, Fovargue L, Tondel K, Porter B, Sieniewicz B, Gould J, Rinaldi CA, Ismail T, Chiribiri A, Carr-White G (2018) The emerging role of cardiac magnetic resonance imaging in the evaluation of patients with HFpEF. Curr Heart Fail Rep 15:1&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">29404975</ArticleId><ArticleId IdType="pmc">5811579</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloomer TN, Plein S, Radjenovic A, Higgins DM, Jones TR, Ridgway JP, Sivananthan MU (2001) Cine MRI using steady state free precession in the radial long axis orientation is a fast accurate method for obtaining volumetric data of the left ventricle. J Magn Reson Imaging 14:685&#x2013;692</Citation><ArticleIdList><ArticleId IdType="pubmed">11747024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S (2005) Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson 7:775&#x2013;782</Citation><ArticleIdList><ArticleId IdType="pubmed">16353438</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowosielski M, Schocke M, Mayr A, Pedarnig K, Klug G, Kohler A, Bartel T, Muller S, Trieb T, Pachinger O, Metzler B (2009) Comparison of wall thickening and ejection fraction by cardiovascular magnetic resonance and echocardiography in acute myocardial infarction. J Cardiovasc Magn Reson 11:22</Citation><ArticleIdList><ArticleId IdType="pubmed">19589148</ArticleId><ArticleId IdType="pmc">2717065</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente AM, Lakdawala NK, Powell AJ, Evans SP, Cirino AL, Orav EJ, MacRae CA, Colan SD, Ho CY (2013) Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet 6:230&#x2013;237</Citation><ArticleIdList><ArticleId IdType="pubmed">23690394</ArticleId><ArticleId IdType="pmc">3974911</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazari H, Belenkie I, Kryski A, White JA, Oudit GY, Thompson R, Fung T, Dehar N, Khan A (2018) Comparison of cardiac magnetic resonance imaging and echocardiography in assessment of left ventricular hypertrophy in Fabry disease. Can J Cardiol 34:1041&#x2013;1047</Citation><ArticleIdList><ArticleId IdType="pubmed">29935990</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O&#x2019;Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I et al (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 93:841&#x2013;842</Citation><ArticleIdList><ArticleId IdType="pubmed">8598070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh FY (1989) Sample size tables for logistic regression. Stat Med 8:795&#x2013;802</Citation><ArticleIdList><ArticleId IdType="pubmed">2772439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 28:1&#x2013;39e14</Citation><ArticleIdList><ArticleId IdType="pubmed">25559473</ArticleId></ArticleIdList></Reference><Reference><Citation>Folland ED, Parisi AF, Moynihan PF, Jones DR, Feldman CL, Tow DE (1979) Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. A comparison of cineangiographic and radionuclide techniques. Circulation 60:760&#x2013;766</Citation><ArticleIdList><ArticleId IdType="pubmed">476879</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Bohm M, Butler J et al (2021) Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 23(3):352&#x2013;380</Citation><ArticleIdList><ArticleId IdType="pubmed">33605000</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 79:e263&#x2013;e421</Citation><ArticleIdList><ArticleId IdType="pubmed">35379503</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruszczynska K, Krzych LJ, Golba KS, Biernat J, Roleder T, Deja MA, Ulbrych P, Malinowski M, Janusiewicz P, Wos S, Baron J (2012) Statistical agreement of left ventricle measurements using cardiac magnetic resonance and 2D echocardiography in ischemic heart failure. Med Sci Monit 18:MT19-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22367134</ArticleId><ArticleId IdType="pmc">3560747</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ (2000) Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 21:1387&#x2013;1396</Citation><ArticleIdList><ArticleId IdType="pubmed">10952828</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90:29&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pubmed">12088775</ArticleId></ArticleIdList></Reference><Reference><Citation>Semelka RC, Tomei E, Wagner S, Mayo J, Caputo G, O&#x2019;Sullivan M, Parmley WW, Chatterjee K, Wolfe C, Higgins CB (1990) Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance studies in the morphologically abnormal left ventricle. Am Heart J 119:1367&#x2013;1373</Citation><ArticleIdList><ArticleId IdType="pubmed">2141222</ArticleId></ArticleIdList></Reference><Reference><Citation>Arraiza M, Azcarate PM, De Cecco CN, Viteri G, Simon-Yarza I, Hernandez-Estefania R, Rabago G, Bastarrika G (2012) Assessment of left ventricular parameters in orthotopic heart transplant recipients using dual-source CT and contrast-enhanced echocardiography: comparison with MRI. Eur J Radiol 81:3282&#x2013;3288</Citation><ArticleIdList><ArticleId IdType="pubmed">22561021</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/american heart association task force on practice guidelines. Circulation 128:e240&#x2013;327</Citation></Reference><Reference><Citation>Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA (2012) Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 59:442&#x2013;451</Citation><ArticleIdList><ArticleId IdType="pubmed">22281246</ArticleId></ArticleIdList></Reference><Reference><Citation>La Canna G, Scarfo I (2020) New and old echographic parameters in heart failure. Eur Heart J Suppl 22(Suppl):L86&#x2013;L92</Citation><ArticleIdList><ArticleId IdType="pubmed">33239981</ArticleId><ArticleId IdType="pmc">7673607</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman ZU, Sethi P, Murtaza G, Virk HUH, Rai A, Mahmod M, Schoondyke J, Albalbissi K (2017) Feature tracking cardiac magnetic resonance imaging: a review of a novel non-invasive cardiac imaging technique. World J Cardiol 9:312&#x2013;319</Citation><ArticleIdList><ArticleId IdType="pubmed">28515849</ArticleId><ArticleId IdType="pmc">5411965</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40839200</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1591-9528</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Clinical and experimental medicine</Title><ISOAbbreviation>Clin Exp Med</ISOAbbreviation></Journal><ArticleTitle>From cardiac injury to omics signatures: a narrative review on biomarkers in septic cardiomyopathy.</ArticleTitle><Pagination><StartPage>298</StartPage><MedlinePgn>298</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10238-025-01842-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Septic cardiomyopathy (SCM) is a frequent and underdiagnosed complication of sepsis that contributes significantly to patient morbidity and mortality. Its pathophysiology involves myocardial inflammation, mitochondrial dysfunction, and microcirculatory abnormalities. Despite growing recognition, the diagnostic approach to SCM remains inconsistent, and validated biomarkers are lacking.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This narrative review explores the current landscape of SCM biomarkers. PubMed, Scopus, and EMBASE were searched from inception to June 2025.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Traditional biomarkers are useful, but nonspecific in the septic context. Emerging biomarkers offer promising diagnostic and prognostic information, particularly in combination. Multi-omics strategies revealed transcriptomic and proteomic profiles to be potentially specific for SCM and may facilitate early detection and risk stratification. However, limitations remain in terms of standardization, assay reproducibility, and clinical translation. Composite biomarker panels and longitudinal monitoring appear to be more informative than single-point measurements.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SCM remains a diagnostic challenge, although biomarker research is rapidly evolving. Integrating traditional and emerging biomarkers, supported by multi-omics and computational tools, may enable a shift toward precision medicine in sepsis-related cardiac dysfunction. Future efforts should focus on consensus definitions, validation in prospective cohorts, and biomarker-guided interventions to improve patient outcomes.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guarino</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine, St. Anna University Hospital of Ferrara, Via A. Moro, 8, 44124, Cona, Ferrara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emergency Department, S. Anna University Hospital of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luppi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine, St. Anna University Hospital of Ferrara, Via A. Moro, 8, 44124, Cona, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maroncelli</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine, St. Anna University Hospital of Ferrara, Via A. Moro, 8, 44124, Cona, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldin</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine, St. Anna University Hospital of Ferrara, Via A. Moro, 8, 44124, Cona, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costanzini</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine, St. Anna University Hospital of Ferrara, Via A. Moro, 8, 44124, Cona, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maritati</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious and Dermatology Diseases, St Anna University Hospital of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contini</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious and Dermatology Diseases, St Anna University Hospital of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sassone</LastName><ForeName>Biagio</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Provincial Cardiology, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Giorgio</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine, St. Anna University Hospital of Ferrara, Via A. Moro, 8, 44124, Cona, Ferrara, Italy. dgrrrt@unife.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spampinato</LastName><ForeName>Michele Domenico</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine, St. Anna University Hospital of Ferrara, Via A. Moro, 8, 44124, Cona, Ferrara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emergency Department, S. Anna University Hospital of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Exp Med</MedlineTA><NlmUniqueID>100973405</NlmUniqueID><ISSNLinking>1591-8890</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Multi-omics</Keyword><Keyword MajorTopicYN="N">Precision medicine</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Septic cardiomyopathy</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: This research does not directly involve patients; hence, ethical approval was deemed unnecessary.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839200</ArticleId><ArticleId IdType="doi">10.1007/s10238-025-01842-5</ArticleId><ArticleId IdType="pii">10.1007/s10238-025-01842-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiu C, Legrand M. Epidemiology of sepsis and septic shock. Curr Opin Anaesthesiol. 2021;34(2):71&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33492864</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">26903338</ArticleId><ArticleId IdType="pmc">4968574</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, M&#xf8;ller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">34599691</ArticleId><ArticleId IdType="pmc">8486643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiscano-Cam&#xf3;n L, Ruiz-Sanmartin A, Baja&#xf1;a I, Bastidas J, Lopez-Martinez R, Franco-Jarava C, Gonzalez JJ, Larrosa N, Riera J, Nuvials-Casals X, Ruiz-Rodr&#xed;guez JC, Ferrer R. Current perspectives in the management of sepsis and septic shock. Front Med. 2024;15(11):1431791.</Citation></Reference><Reference><Citation>Ramasco F, Aguilar G, Aldecoa C, Bakker J, Carmona P, Dominguez D, Galiana M, Hern&#xe1;ndez G, Kattan E, Olea C, Ospina-Tasc&#xf3;n G, P&#xe9;rez A, Ramos K, Ramos S, Tamayo G, Tuero G, ANDROMEDA-SHOCK-2, Spanish Investigators, Sociedad Espa&#xf1;ola de Anestesiolog&#xed;a, Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor (SEDAR). Towards the personalization of septic shock resuscitation: the fundamentals of ANDROMEDA-SHOCK-2 trial. Rev Esp Anestesiol Reanim. 2024;71(2):112&#x2013;24.</Citation></Reference><Reference><Citation>Guarino M, Perna B, Cesaro AE, Maritati M, Spampinato MD, Contini C, De Giorgio R. Update on sepsis and septic shock in adult patients: management in the emergency department. J Clin Med. 2023;12(9):3188.</Citation><ArticleIdList><ArticleId IdType="pubmed">37176628</ArticleId><ArticleId IdType="pmc">10179263</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones TW, Smith SE, Van Tuyl JS, Newsome AS. Sepsis with preexisting heart failure: management of confounding clinical features. J Intensive Care Med. 2021;36(9):989&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">32495686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraiwa H, Kasugai D, Okumura T, Murohara T. Clinical implications of septic cardiomyopathy: a narrative review. Medicine. 2024;103(17):e37940.</Citation><ArticleIdList><ArticleId IdType="pubmed">38669408</ArticleId><ArticleId IdType="pmc">11049701</ArticleId></ArticleIdList></Reference><Reference><Citation>Habimana R, Choi I, Cho HJ, Kim D, Lee K, Jeong I. Sepsis-induced cardiac dysfunction: a review of pathophysiology. Acute Crit Care. 2020;35(2):57&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">32506871</ArticleId><ArticleId IdType="pmc">7280799</ArticleId></ArticleIdList></Reference><Reference><Citation>Beesley SJ, Weber G, Sarge T, Nikravan S, Grissom CK, Lanspa MJ, Shahul S, Brown SM. Septic cardiomyopathy. Crit Care Med. 2018;46(4):625&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">29227368</ArticleId></ArticleIdList></Reference><Reference><Citation>Singam A. Myocardial injury as a harbinger of multi-organ failure in septic shock: a comprehensive review. Cureus. 2024;16(2):e55021.</Citation><ArticleIdList><ArticleId IdType="pubmed">38550421</ArticleId><ArticleId IdType="pmc">10975005</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulido JN, Afessa B, Masaki M, Yuasa T, Gillespie S, Herasevich V, Brown DR, Oh JK. Clinical spectrum, frequency, and significance of myocardial dysfunction in severe sepsis and septic shock. Mayo Clin Proc. 2012;87(7):620&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22683055</ArticleId><ArticleId IdType="pmc">3538477</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M, Mehta A, Machanahalli Balakrishna A, Kalyan Sundaram A, Kanwar A, Singh M, Vallabhajosyula S. Right ventricular dysfunction in sepsis: an updated narrative review. Shock. 2023;59(6):829&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">36943772</ArticleId></ArticleIdList></Reference><Reference><Citation>Bughrara N, Diaz-Gomez JL, Pustavoitau A. Perioperative management of patients with sepsis and septic shock, Part II: ultrasound support for resuscitation. Anesthesiol Clin. 2020;38(1):123&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">32008647</ArticleId></ArticleIdList></Reference><Reference><Citation>De Backer D, Cecconi M, Chew MS, Hajjar L, Monnet X, Ospina-Tasc&#xf3;n GA, Ostermann M, Pinsky MR, Vincent JL. A plea for personalization of the hemodynamic management of septic shock. Crit Care. 2022;26(1):372.</Citation><ArticleIdList><ArticleId IdType="pubmed">36457089</ArticleId><ArticleId IdType="pmc">9714237</ArticleId></ArticleIdList></Reference><Reference><Citation>Boissier F, Aissaoui N. Septic cardiomyopathy: diagnosis and management. J Intensive Med. 2021;2(1):8&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">36789232</ArticleId><ArticleId IdType="pmc">9923980</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones TW, Smith SE, Van Tuyl JS, Newsome AS. Sepsis with preexisting heart failure: management of confounding clinical features. J Intensive Care Med. 2021;36(9):989&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">32495686</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauin A. The main causes and mechanisms of increase in cardiac troponin concentrations other than acute myocardial infarction (Part 1): physical exertion, inflammatory heart disease, pulmonary embolism, renal failure. Sepsis Vasc Health Risk Manag. 2021;21(17):601&#x2013;17.</Citation></Reference><Reference><Citation>Zheng P, Wang X, Guo T, Gao W, Huang Q, Yang J, Gao H, Liu Q. Cardiac troponin as a prognosticator of mortality in patients with sepsis: a systematic review and meta-analysis. Immun Inflamma Dis. 2023;11(9):e1014.</Citation></Reference><Reference><Citation>Li N, Zhang Y, Fan S, Xing J, Liu H. BNP and NT-proBNP levels in patients with sepsis. Front Biosci. 2013;18(4):1237&#x2013;43.</Citation></Reference><Reference><Citation>Yue L, Deng X, Yang M, Li X. Elevated B-type natriuretic peptide (BNP) and soluble thrombomodulin (sTM) indicates severity and poor prognosis of sepsis. Ann Palliat Med. 2021;10(5):5561&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">34044565</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR. Clinical review: sepsis and septic shock&#x2013;the potential of gene arrays. Crit Care. 2012;16(1):204.</Citation><ArticleIdList><ArticleId IdType="pubmed">22316118</ArticleId><ArticleId IdType="pmc">3396217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Liang X, Wu T, Jiang J, Jiang Y, Zhang S, Ruan Y, Zhang H, Zhang C, Chen P, Lv Y, Xin J, Shi D, Chen X, Li J, Xu Y. Integrative analysis of metabolomics and proteomics reveals amino acid metabolism disorder in sepsis. J Transl Med. 2022;20(1):123.</Citation><ArticleIdList><ArticleId IdType="pubmed">35287674</ArticleId><ArticleId IdType="pmc">8919526</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherger SJ, Kalil AC. Sepsis phenotypes, subphenotypes, and endotypes: Are they ready for bedside care? Curr Opin Crit Care. 2024;30(5):406&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">38847501</ArticleId></ArticleIdList></Reference><Reference><Citation>She H, Du Y, Du Y, Tan L, Yang S, Luo X, Li Q, Xiang X, Lu H, Hu Y, Liu L, Li T. Metabolomics and machine learning approaches for diagnostic and prognostic biomarkers screening in sepsis. BMC Anesthesiol. 2023;23(1):367.</Citation><ArticleIdList><ArticleId IdType="pubmed">37946144</ArticleId><ArticleId IdType="pmc">10634148</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Z, Quan Z, Zeng S, Wen L, Wang H. Utilizing omics technologies in the investigation of sepsis-induced cardiomyopathy. Int J Cardiol Heart Vasc. 2024;30(54):101477.</Citation></Reference><Reference><Citation>She H, Tan L, Wang Y, Du Y, Zhou Y, Zhang J, Du Y, Guo N, Wu Z, Li Q, Bao D, Mao Q, Hu Y, Liu L, Li T. Integrative single-cell RNA sequencing and metabolomics decipher the imbalanced lipid-metabolism in maladaptive immune responses during sepsis. Front Immunol. 2023;14:1181697.</Citation><ArticleIdList><ArticleId IdType="pubmed">37180171</ArticleId><ArticleId IdType="pmc">10172510</ArticleId></ArticleIdList></Reference><Reference><Citation>Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. 2018;14(2):121&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">29225343</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao SV, O&#x2019;Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, Davis LL, de Lemos JA, DeWald TA, Elgendy IY, Feldman DN, Goyal A, Isiadinso I, Menon V, Morrow DA, Mukherjee D, Platz E, Promes SB, Sandner S, Sandoval Y, Schunder R, Shah B, Stopyra JP, Talbot AW, Taub PR, Williams MS. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):e771&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">40014670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri&#xe8;re-Steinert S, Valenzuela Jim&#xe9;nez J, Heskia Araya S, Kouyoumdjian T, Ramos-Rojas J, Gajardo AIJ. Early high-sensitivity troponin elevation in predicting short-term mortality in sepsis: a protocol for a systematic review with meta-analysis. PLoS One. 2024;19(10):e0301948.</Citation><ArticleIdList><ArticleId IdType="pubmed">39453928</ArticleId><ArticleId IdType="pmc">11508495</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D, Li H, Lin Y, Liu L, Xu L, Zhang D, Fu Y, Hong J, Miao C. Beyond first-day biomarkers: the critical role of peak cardiac troponin I in sepsis prognosis. Heart Lung. 2025;71:14&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">39914177</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott A, Alhuneafat L, Bartos JA. Troponin&#x2019;s twist: a sepsis story beyond the heart. J Am Heart Assoc. 2025;14(9):e041428.</Citation><ArticleIdList><ArticleId IdType="pubmed">40240917</ArticleId><ArticleId IdType="pmc">12184214</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia MA, Rucci JM, Thai KK, Lu Y, Kipnis P, Go AS, Desai M, Bosch NA, Martinez A, Clancy H, Devis Y, Myers LC, Liu VX, Walkey AJ. Association between troponin I levels during sepsis and postsepsis cardiovascular complications. Am J Respir Crit Care Med. 2021;204(5):557&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">34038701</ArticleId><ArticleId IdType="pmc">8491250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrman RR, Sullivan AN, Favot MJ, Sherwin RL, Reynolds CA, Abidov A, Levy PD. Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic implications of septic cardiomyopathy: a review of the literature. Crit Care. 2018;22(1):112.</Citation><ArticleIdList><ArticleId IdType="pubmed">29724231</ArticleId><ArticleId IdType="pmc">5934857</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi EJ, Nam H, Chung CR, Yang JH, Suh GY, Park S, Lee SY, Hyun DG, Park MH, Lim CM, Ko RE; Korean Sepsis Alliance (KSA) investigators. Impact of Elevated Troponin Level at the Time of Sepsis Recognition on the Clinical Outcomes: A Propensity Score-Matched Cohort Study. J Am Heart Assoc. 2025;14(9):e038651.</Citation></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895&#x2013;e1032.</Citation></Reference><Reference><Citation>Song JL, Fan B, Qiu LQ, Li Q, Chen GY. Brain natriuretic peptide as a predictive marker of mortality in sepsis: an updated systematic review and meta-analysis. BMC Anesthesiol. 2024;24(1):276.</Citation><ArticleIdList><ArticleId IdType="pubmed">39112946</ArticleId><ArticleId IdType="pmc">11304783</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y, Lee JH. Clinical usefulness of NT-proBNP as a prognostic factor for septic shock patients presenting to the emergency department. Sci Rep. 2024;14(1):10999.</Citation><ArticleIdList><ArticleId IdType="pubmed">38744896</ArticleId><ArticleId IdType="pmc">11094059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J, Liang Q, Xi X. NT-proBNP levels might predict outcomes in severe sepsis, but renal function cannot be ignored. Crit Care. 2019;23(1):341.</Citation><ArticleIdList><ArticleId IdType="pubmed">31685007</ArticleId><ArticleId IdType="pmc">6827168</ArticleId></ArticleIdList></Reference><Reference><Citation>De Geer L, Engvall J, Oscarsson A. Strain echocardiography in septic shock&#x2014;a comparison with systolic and diastolic function parameters, cardiac biomarkers and outcome. Crit Care. 2015;19(1):122.</Citation><ArticleIdList><ArticleId IdType="pubmed">25882600</ArticleId><ArticleId IdType="pmc">4374340</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandompatam G, Kashani K, Vallabhajosyula S. The role of natriuretic peptides in the management, outcomes and prognosis of sepsis and septic shock. Rev Bras Ter Intensiva. 2019;31(3):368&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">31618357</ArticleId><ArticleId IdType="pmc">7005946</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen G, Liang W, Jia H, Zheng X. Melatonin relieves sepsis-induced myocardial injury via regulating JAK2/STAT3 signaling pathway. Minerva Med. 2022;113(6):983&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32683850</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisel AS, Bhalla V, Braunwald E. Cardiac biomarkers: a contemporary status report. Nat Clin Pract Cardiovasc Med. 2006;3(1):24&#x2013;34. https://doi.org/10.1038/ncpcardio0405 .</Citation><ArticleIdList><ArticleId IdType="pubmed">16391615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu F, Hu F, Qiu B, Zou H, Xu J. Identification of novel biomarkers in septic cardiomyopathy via integrated bioinformatics analysis and experimental validation. Front Genet. 2022;25(13):929293.</Citation></Reference><Reference><Citation>Skibsted S, Bhasin MK, Aird WC, Shapiro NI. Bench-to-bedside review: future novel diagnostics for sepsis&#x2014;a systems biology approach. Crit Care. 2013;17(5):231.</Citation><ArticleIdList><ArticleId IdType="pubmed">24093155</ArticleId><ArticleId IdType="pmc">4057467</ArticleId></ArticleIdList></Reference><Reference><Citation>Luki&#x107; I, Mihi&#x107; D, Var&#x17e;i&#x107; SC, Relati&#x107; KS, Zibar L, Loinjak D, &#x106;uri&#x107; &#x17d;B, Klobu&#x10d;ar L, Mari&#x10d;i&#x107; L. Septic cardiomyopathy. Rev Cardiovasc Med. 2024;25(1):23.</Citation><ArticleIdList><ArticleId IdType="pubmed">39077653</ArticleId><ArticleId IdType="pmc">11262393</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf8;sj&#xf8; H, Stridsberg M, Ottesen AH, Nyg&#xe5;rd S, Christensen G, Pettil&#xe4; V, Linko R, Karlsson S, Varpula T, Ruokonen E, Omland T, FINNSEPSIS and FINNALI Study Groups. Prognostic value of secretoneurin in critically ill patients with infections. Crit Care Med. 2016;44(10):1882&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">27414477</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf8;sj&#xf8; H, Masson S, Caironi P, Stridsberg M, Magnoli M, Christensen G, Moise G, Urbano MC, Gattinoni L, Pesenti A, Latini R, Omland T, ALBIOS Biomarkers Study Investigators. Prognostic value of secretoneurin in patients with severe sepsis and septic shock: data from the Albumin Italian Outcome Sepsis Study. Crit Care Med. 2018;46(5):e404&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">29481425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima MR, Silva D. Septic cardiomyopathy: a narrative review. Rev Port Cardiol. 2023;42(5):471&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">36893835</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, Hur M, Kim H, Magrini L, Marino R, Di Somma S, GREAT Network. Soluble suppression of tumorigenicity 2 and echocardiography in sepsis. Ann Lab Med. 2016;36(6):590&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">27578513</ArticleId><ArticleId IdType="pmc">5011113</ArticleId></ArticleIdList></Reference><Reference><Citation>Eric S, Zaric RZ, Jevdjic J, Drakulic SM, Stanojevic I, Vojvodic D, Arsenijevic P, Stojanovic B, Jakovljevic S, Markovic N, Zaric M, Canovic P, Nesic J, Zornic N. Interleukin 33, soluble suppression of tumorigenicity 2, interleukin 27, and galectin 3 as predictors for outcome in patients admitted to intensive care units. Open Med. 2023;18(1):20230859.</Citation></Reference><Reference><Citation>Hur M, Kim H, Kim HJ, Yang HS, Magrini L, Marino R, Cardelli P, Di Somma S, GREAT Network. Soluble ST2 has a prognostic role in patients with suspected sepsis. Ann Lab Med. 2015;35(6):570&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26354344</ArticleId><ArticleId IdType="pmc">4579100</ArticleId></ArticleIdList></Reference><Reference><Citation>Battista S, Bima P, Forno D, Luzzi D, Pizzolato E, Ianniello A, Ponzetto F, Rumbolo F, Settanni F, Mengozzi G, Morello F, Lupia E. Plasma soluble suppression of tumorigenesis 2 measured in the emergency department for diagnosis and outcome prediction of sepsis: a single-center prospective study. Clin Chim Acta. 2024;15(553):117710.</Citation></Reference><Reference><Citation>Davini F, Fogolari M, D&#x2019;Avanzo G, Ristori MV, Nucciarelli S, Bani L, Cristiano A, De Cesaris M, Spoto S, Angeletti S. Soluble suppression of tumorigenicity 2 (sST2) as a diagnostic and prognostic marker in acute heart failure and sepsis: a comparative analysis. Diagnostics. 2025;15(8):1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">40310380</ArticleId><ArticleId IdType="pmc">12026315</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Wang J, Hu L, Zhang Y, Li Y, Xuan J, Han S, Qu Y, Yang L, Yang J, Wang J, Wei B. The diagnostic and prognostic value of soluble ST2 in sepsis. Front Med. 2024;21(11):1487443.</Citation></Reference><Reference><Citation>Kim H, Hur M, Moon HW, Yun YM, Di Somma S, GREAT Network. Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. Ann Intensive Care. 2017;7(1):27.</Citation><ArticleIdList><ArticleId IdType="pubmed">28271449</ArticleId><ArticleId IdType="pmc">5340789</ArticleId></ArticleIdList></Reference><Reference><Citation>Juneja D, Jain N, Singh O, Goel A, Arora S. Comparison between presepsin, procalcitonin, and CRP as biomarkers to diagnose sepsis in critically ill patients. J Anaesthesiol Clin Pharmacol. 2023;39(3):458&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">38025554</ArticleId><ArticleId IdType="pmc">10661623</ArticleId></ArticleIdList></Reference><Reference><Citation>Paraskevas T, Chourpiliadi C, Demiri S, Micahilides C, Karanikolas E, Lagadinou M, Velissaris D. Presepsin in the diagnosis of sepsis. Clin Chim Acta. 2023;1(550):117588.</Citation></Reference><Reference><Citation>Liang J, Cai Y, Shao Y. Comparison of presepsin and Mid-regional pro-adrenomedullin in the diagnosis of sepsis or septic shock: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):288.</Citation><ArticleIdList><ArticleId IdType="pubmed">37147598</ArticleId><ArticleId IdType="pmc">10160726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouroupis D, Zografou I, Doukelis P, Patoulias D, Popovic DS, Karakasis P, Pyrpasopoulou A, Stavropoulos K, Papadopoulos C, Giouleme O, Kotsa K, Doumas M, Koufakis T. Presepsin: an emerging biomarker in the management of cardiometabolic disorders. J Pers Med. 2025;15(4):125.</Citation><ArticleIdList><ArticleId IdType="pubmed">40278304</ArticleId><ArticleId IdType="pmc">12028629</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Song J, Park DW, Seok H, Ahn S, Kim J, Park J, Cho HJ, Moon S. Diagnostic and prognostic value of presepsin and procalcitonin in non-infectious organ failure, sepsis, and septic shock: a prospective observational study according to the Sepsis-3 definitions. BMC Infect Dis. 2022;22(1):8.</Citation><ArticleIdList><ArticleId IdType="pubmed">34983420</ArticleId><ArticleId IdType="pmc">8725484</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#x131;y&#x131;k &#x130;, &#xc7;a&#x11f;lar FNT, I&#x15f;&#x131;ksa&#xe7;an N, &#x15e;ahin MH, Karabulut D, Katkat F, Akt&#xfc;rk F. Serum presepsin levels in patients with decompensated heart failure. J Updates Cardiovasc Med. 2018;6(2):60&#x2013;7.</Citation></Reference><Reference><Citation>Samsudin I, Vasikaran SD. Clinical utility and measurement of procalcitonin. Clin Biochem Rev. 2017;38(2):59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">29332972</ArticleId><ArticleId IdType="pmc">5759088</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva MP, Mollar A, Palau P, Carratal&#xe1; A, N&#xfa;&#xf1;ez E, Santas E, Bod&#xed; V, Chorro FJ, Mi&#xf1;ana G, Blasco ML, Sanchis J, N&#xfa;&#xf1;ez J. Procalcitonin and long-term prognosis after an admission for acute heart failure. Eur J Intern Med. 2015;26(1):42&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25592074</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Wang C, Pang S. The diagnostic accuracy of mid-regional pro-adrenomedullin for sepsis: a systematic review and meta-analysis. Minerva Anestesiol. 2021;87(10):1117&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">34134460</ArticleId></ArticleIdList></Reference><Reference><Citation>Spoto S, Basili S, Cangemi R, D&#x2019;Avanzo G, Lupoi DM, Romiti GF, Argemi J, Yuste JR, Lucena F, Locorriere L, Masini F, Testorio G, Calarco R, Fogolari M, Francesconi M, Battifoglia G, Costantino S, Angeletti S. Mid-regional pro-adrenomedullin can predict organ failure and prognosis in sepsis? Int J Mol Sci. 2023;24(24):17429.</Citation><ArticleIdList><ArticleId IdType="pubmed">38139258</ArticleId><ArticleId IdType="pmc">10743785</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone F, Liberale L, Preda A, Schindler TH, Montecucco F. Septic cardiomyopathy: from pathophysiology to the clinical setting. Cells. 2022;11(18):2833.</Citation><ArticleIdList><ArticleId IdType="pubmed">36139408</ArticleId><ArticleId IdType="pmc">9496713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tehrani BN, Sherwood MW, Batchelor WB. The heart of the matter: modulating therapeutic effects of adrenomedullin in cardiogenic shock. Lancet Respir Med. 2022;10(3):224&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">34895482</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye XD, He Y, Wang S, Wong GT, Irwin MG, Xia Z. Heart-type fatty acid binding protein (H-FABP) as a biomarker for acute myocardial injury and long-term post-ischemic prognosis. Acta Pharmacol Sin. 2018;39(7):1155&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">29770799</ArticleId><ArticleId IdType="pmc">6289342</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, Liu L, Zhu X. Correlation of serum H-FABP, sTREM-1, and HMGB1 levels with severity and prognosis of sepsis. Am J Transl Res. 2024;16(10):5846&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">39544769</ArticleId><ArticleId IdType="pmc">11558379</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, Liu G, Guo S, Ren H, Lu H, Zhou L, Bao L. Prognostic value of serum heart-type fatty acid-binding protein in patients with sepsis: a protocol for systematic review and meta-analysis. Medicine. 2021;100(6):e24715.</Citation><ArticleIdList><ArticleId IdType="pubmed">33578613</ArticleId><ArticleId IdType="pmc">10545160</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen FC, Xu YC, Zhang ZC. Multi-biomarker strategy for prediction of myocardial dysfunction and mortality in sepsis. J Zhejiang Univ Sci B. 2020;21(7):537&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">32633108</ArticleId><ArticleId IdType="pmc">7383321</ArticleId></ArticleIdList></Reference><Reference><Citation>Simm M, S&#xf6;derberg E, Larsson A, Castegren M, Nilsen T, Eriksson M, Lipcsey M. Performance of plasma calprotectin as a biomarker of early sepsis: a pilot study. Biomark Med. 2016;10(8):811&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27414210</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobsson G, Papareddy P, Andersson H, Mulholland M, Bhongir R, Ljungcrantz I, Engelbertsen D, Bj&#xf6;rkbacka H, Nilsson J, Manea A, Herwald H, Ruiz-Meana M, Rodr&#xed;guez-Sinovas A, Chew M, Schiopu A. Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction. Crit Care. 2023;27(1):374. https://doi.org/10.1186/s13054-023-04652-x .</Citation><ArticleIdList><ArticleId IdType="pubmed">37773186</ArticleId><ArticleId IdType="pmc">10540409</ArticleId></ArticleIdList></Reference><Reference><Citation>Boussina A, Shashikumar SP, Malhotra A, Owens RL, El-Kareh R, Longhurst CA, Quintero K, Donahue A, Chan TC, Nemati S, Wardi G. Impact of a deep learning sepsis prediction model on quality of care and survival. NPJ Digit Med. 2024;7(1):14.</Citation><ArticleIdList><ArticleId IdType="pubmed">38263386</ArticleId><ArticleId IdType="pmc">10805720</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Li J, Chen M. Bioinformatics analysis of neutrophil-associated hub genes and ceRNA network construction in septic cardiomyopathy. Aging. 2024;16(19):12833&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">39216003</ArticleId><ArticleId IdType="pmc">11501391</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai K, Luo Y, Chen H, Dong Y, Su Y, Lin C, Cai C, Shi Y, Lin S, Lian G, Lin Z, Feng S. Integrative omics analysis identifies biomarkers of septic cardiomyopathy. PLoS One. 2024;19(11):e0310412.</Citation><ArticleIdList><ArticleId IdType="pubmed">39546466</ArticleId><ArticleId IdType="pmc">11567565</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Hua S, Yang J, Cao Y, Gao R, Sun H, Yang K, Wang Y, Peng P. Investigating immune dysregulation and hub genes in septic cardiomyopathy development. Sci Rep. 2024;14(1):21608.</Citation><ArticleIdList><ArticleId IdType="pubmed">39294340</ArticleId><ArticleId IdType="pmc">11411067</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Jiang S, Wang B, He S, Guo X, Lin J, Wei Y. Integrated multi-omics analysis and machine learning developed diagnostic markers and prognostic model based on efferocytosis-associated signatures for septic cardiomyopathy. Clin Immunol. 2024;265:110301.</Citation><ArticleIdList><ArticleId IdType="pubmed">38944364</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu PP, Yu XY, Pan QQ, Ren JJ, Han YX, Zhang K, Wang Y, Huang Y, Ban T. Multi-omics and network-based drug repurposing for septic cardiomyopathy. Pharmaceuticals. 2025;18(1):43.</Citation><ArticleIdList><ArticleId IdType="pubmed">39861106</ArticleId><ArticleId IdType="pmc">11768530</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Wang Q, Ye H, Du Y, Wang M, Guo Y, He S. Identification of STAT3 and MYC as critical ferroptosis-related biomarkers in septic cardiomyopathy: a bioinformatics and experimental study. J Mol Med. 2025;103(1):87&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">39557695</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinzhong Wang MS, Jian Fu MS. STAT3/FoxO3a/Sirt1 pathway inhibition by ginsenoside Rc ameliorates cardiomyocyte damage in septic cardiomyopathy by altering macrophage polarization. J Mol Histol. 2025;56(3):148.</Citation><ArticleIdList><ArticleId IdType="pubmed">40293549</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Kong C, Zheng Z, Li Y. Identification of biomarkers associated with septic cardiomyopathy based on bioinformatics analyses. J Comput Biol. 2020;27(1):69&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">31424269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Chen XK, Zhou L, Wang F, He YJ, Lu BJ, Hu ZG, Li ZX, Xia XW, Wang WE, Zeng CY, Li LP. Chemokine CCL2 promotes cardiac regeneration and repair in myocardial infarction mice via activation of the JNK/STAT3 axis. Acta Pharmacol Sin. 2024;45(4):728&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">38086898</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou HX, Qiu BQ, Zhang ZY, Hu T, Wan L, Liu JC, Huang H, Lai SQ. Dysregulated autophagy-related genes in septic cardiomyopathy: Comprehensive bioinformatics analysis based on the human transcriptomes and experimental validation. Front Cardiovasc Med. 2022;2(9):923066.</Citation></Reference><Reference><Citation>Morrow GB, Mutch NJ. Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Semin Thromb Hemost. 2023;49(3):305&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">36522166</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini F, De Mattei M, Contini C, Tognon MG. Potential use of alpha-1 anti-trypsin in the Covid-19 treatment. Front Cell Dev Biol. 2020;8:577528.</Citation><ArticleIdList><ArticleId IdType="pubmed">33195215</ArticleId><ArticleId IdType="pmc">7644540</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Kong F, Xu X, Song S, Wu Y, Tong J. Identification and exploration of aging-related subtypes and distinctive role of SERPINE1 in heart failure based on single-cell and bulk RNA sequencing data. J Gene Med. 2024;26(1):e3631.</Citation><ArticleIdList><ArticleId IdType="pubmed">38062883</ArticleId></ArticleIdList></Reference><Reference><Citation>Vianello A, Caponi L, Galetta F, Franzoni F, Taddei M, Rossi M, Pietrini P, Santoro G. &#x392;2-microglobulin and TIMP1 are linked together in cardiorenal remodeling and failure. Cardiorenal Med. 2015;5(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">25759695</ArticleId></ArticleIdList></Reference><Reference><Citation>Umbarkar P, Ejantkar S, Ruiz Ramirez SY, Toro Cora A, Zhang Q, Tousif S, Lal H. Cardiac fibroblast GSK-3&#x3b1; aggravates ischemic cardiac injury by promoting fibrosis, inflammation, and impairing angiogenesis. Basic Res Cardiol. 2023;118(1):35.</Citation><ArticleIdList><ArticleId IdType="pubmed">37656238</ArticleId><ArticleId IdType="pmc">11340261</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan R, Liu H, Liang Q. Roles and therapeutic targeting of exosomes in sepsis-induced cardiomyopathy. J Cell Mol Med. 2025;29(8):e70559.</Citation><ArticleIdList><ArticleId IdType="pubmed">40264381</ArticleId><ArticleId IdType="pmc">12015131</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushra ASI, Begum S, Maaria HMS, Jameel T, Khan AA. Molecular basis of sepsis: a new insight into the role of mitochondrial DNA as a damage-associated molecular pattern. Mitochondrion. 2024;79:101967.</Citation><ArticleIdList><ArticleId IdType="pubmed">39343040</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED. Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients. Crit Care. 2006;10(2):R60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16613611</ArticleId><ArticleId IdType="pmc">1550922</ArticleId></ArticleIdList></Reference><Reference><Citation>Refaie MMM, El-Hussieny M, Bayoumi AMA, Abdelraheem WM, Abdel-Hakeem EA, Shehata S. Sacubitril/valsartan alleviates sepsis-induced myocardial injury in rats via dual angiotensin receptor-neprilysin inhibition and modulation of inflammasome/caspase 1/IL1&#x3b2; pathway. Eur J Pharmacol. 2024;15(979):176834.</Citation></Reference><Reference><Citation>Dushpanova A, Agostini S, Ciofini E, Cabiati M, Casieri V, Matteucci M, Del Ry S, Clerico A, Berti S, Lionetti V. Gene silencing of endothelial von Willebrand Factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells. Sci Rep. 2016;22(6):30048.</Citation></Reference><Reference><Citation>Lundberg OH, Bergenzaun L, Ryd&#xe9;n J, Rosenqvist M, Melander O, Chew MS. Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients. Crit Care. 2016;20(1):178.</Citation><ArticleIdList><ArticleId IdType="pubmed">27282767</ArticleId><ArticleId IdType="pmc">4899903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakynthinos GE, Giamouzis G, Xanthopoulos A, Oikonomou E, Kalogeras K, Karavidas N, Dimeas IE, Gialamas I, Gounaridi MI, Siasos G, Vavuranakis M, Zakynthinos E, Tsolaki V. Septic cardiomyopathy: difficult definition, challenging diagnosis, unclear treatment. J Clin Med. 2025;14(3):986.</Citation><ArticleIdList><ArticleId IdType="pubmed">39941657</ArticleId><ArticleId IdType="pmc">11818464</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#x2019;Heureux M, Sternberg M, Brath L, Turlington J, Kashiouris MG. Sepsis-induced cardiomyopathy: a comprehensive review. Curr Cardiol Rep. 2020;22(5):35.</Citation><ArticleIdList><ArticleId IdType="pubmed">32377972</ArticleId><ArticleId IdType="pmc">7222131</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Xu C, Hu Q, Wang Y. Sepsis-induced cardiomyopathy: understanding pathophysiology and clinical implications. Arch Toxicol. 2025;99(2):467&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">39601874</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Sankar J, Narsaria P, Gupta SK, Lodha R, Kabra SK. Clinical and laboratory parameters associated with septic myocardial dysfunction in children with septic shock. Indian J Pediatr. 2021;88(8):809&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">33598863</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg SM. Sepsis-Associated Cardiomyopathy: Long-Term Prognosis, Management, and Guideline-Directed Medical Therapy. Curr Cardiol Rep. 2025;27(1):5.</Citation><ArticleIdList><ArticleId IdType="pubmed">39776326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40838933</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>NPPA-Associated Atrial Dilated Cardiomyopathy: Genotypic and Phenotypic Insights From an Ultrarare Inherited Disorder.</ArticleTitle><Pagination><StartPage>105141</StartPage><MedlinePgn>105141</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.105141</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)01921-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Atrial standstill is a rare arrhythmogenic disorder characterized by complete atrial electrical and mechanical inactivity. We report the 15th documented case of atrial dilated cardiomyopathy associated with the homozygous c.449G&gt;A (p.Arg150Gln) NPPA mutation.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 31-year-old woman presented with persistent atrial fibrillation, biatrial enlargement, and junctional rhythm. Electrophysiological studies confirmed atrial inexcitability. Despite preserved ventricular function, she required permanent His-bundle pacing. Genetic testing later revealed a homozygous NPPA mutation, whereas heterozygous family members remained asymptomatic.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This case highlights the diagnostic value of genetic testing in young patients with atrial fibrillation and no structural heart disease. Early recognition of NPPA-related atrial dilated cardiomyopathy may guide arrhythmia management and anticoagulation strategies, reducing thromboembolic risk.</AbstractText><AbstractText Label="TAKE-HOME MESSAGE" NlmCategory="CONCLUSIONS">Broader implementation of genetic screening in selected individuals with isolated atrial dysfunction may support earlier diagnosis, personalized treatment, and better outcomes in this ultrarare condition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Forleo</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Interdisciplinary Department of Medicine (DIM), University of Bari Aldo Moro, University Hospital Consortium, Polyclinic of Bari, Bari, Italy. Electronic address: cinzia.forleo@uniba.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dicorato</LastName><ForeName>Marco Maria</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Interdisciplinary Department of Medicine (DIM), University of Bari Aldo Moro, University Hospital Consortium, Polyclinic of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carella</LastName><ForeName>Maria Cristina</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Interdisciplinary Department of Medicine (DIM), University of Bari Aldo Moro, University Hospital Consortium, Polyclinic of Bari, Bari, Italy; Internal Medicine Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, University Hospital Consortium, Polyclinic of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basile</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Interdisciplinary Department of Medicine (DIM), University of Bari Aldo Moro, University Hospital Consortium, Polyclinic of Bari, Bari, Italy; Internal Medicine Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, University Hospital Consortium, Polyclinic of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dentamaro</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Interdisciplinary Department of Medicine (DIM), University of Bari Aldo Moro, University Hospital Consortium, Polyclinic of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santobuono</LastName><ForeName>Vincenzo Ezio</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Interdisciplinary Department of Medicine (DIM), University of Bari Aldo Moro, University Hospital Consortium, Polyclinic of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guaricci</LastName><ForeName>Andrea Igoren</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Interdisciplinary Department of Medicine (DIM), University of Bari Aldo Moro, University Hospital Consortium, Polyclinic of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resta</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medical Genetics Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, University Hospital Consortium, Polyclinic of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciccone</LastName><ForeName>Marco Matteo</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Interdisciplinary Department of Medicine (DIM), University of Bari Aldo Moro, University Hospital Consortium, Polyclinic of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arbustini</LastName><ForeName>Eloisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Research, Centre for Inherited Cardiovascular Diseases, IRCCS Foundation, University Hospital Policlinico San Matteo, Pavia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NPPA mutation</Keyword><Keyword MajorTopicYN="N">atrial dilated cardiomyopathy</Keyword><Keyword MajorTopicYN="N">atrial paralysis</Keyword><Keyword MajorTopicYN="N">atrial standstill</Keyword><Keyword MajorTopicYN="N">autosomal recessive cardiomyopathy</Keyword><Keyword MajorTopicYN="N">genetic atrial cardiomyopathy</Keyword><Keyword MajorTopicYN="N">ultrarare cardiac disease</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>10</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40838933</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.105141</ArticleId><ArticleId IdType="pii">S2666-0849(25)01921-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40838920</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2405-5018</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>JACC. Clinical electrophysiology</Title><ISOAbbreviation>JACC Clin Electrophysiol</ISOAbbreviation></Journal><ArticleTitle>Arrhythmogenic Cardiomyopathy Is a New Phenotype Associated With the CACNA1C p.Arg518Cys (R518C) Variant.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S2405-500X(25)00559-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacep.2025.06.039</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boiteux</LastName><ForeName>Cl&#xe9;ment</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence national des troubles du rythme cardiaque h&#xe9;r&#xe9;ditaires ou rares de Lyon (CERA), H&#xf4;pital Louis Pradel, Institut de Cardiologie, Hospices Civils de Lyon, Bron, France; Service de Rythmologie, H&#xf4;pital Louis Pradel, Institut de Cardiologie, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauveau</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Cardiologie, H&#xf4;pital Saint Joseph Saint Luc, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardey</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Service de Rythmologie, H&#xf4;pital Louis Pradel, Institut de Cardiologie, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sebbag</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service d'insuffisance cardiaque assistance et transplantation, H&#xf4;pital Louis Pradel, Institut de Cardiologie, Hospices Civils de Lyon, Bron, France; CarMeN, INSERM UMR 1060, Universit&#xe9; Claude Bernard Lyon 1, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ditac</LastName><ForeName>Geoffroy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de Rythmologie, H&#xf4;pital Louis Pradel, Institut de Cardiologie, Hospices Civils de Lyon, Bron, France; LabTAU, INSERM, Universit&#xe9; Claude Bernard Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cazeneuve</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de cardiog&#xe9;n&#xe9;tique mol&#xe9;culaire, Centre de biologie et pathologie Est, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mewton</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Service d'insuffisance cardiaque assistance et transplantation, H&#xf4;pital Louis Pradel, Institut de Cardiologie, Hospices Civils de Lyon, Bron, France; CarMeN, INSERM UMR 1060, Universit&#xe9; Claude Bernard Lyon 1, Bron, France; Centre d'Investigation Clinique, H&#xf4;pital Louis Pradel, Institut de Cardiologie, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janin</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratoire de cardiog&#xe9;n&#xe9;tique mol&#xe9;culaire, Centre de biologie et pathologie Est, Hospices Civils de Lyon, Bron, France; PGNM, Institut NeuroMyoG&#xe8;ne, INSERM U1315, CNRS UMR 5261, Universit&#xe9; Claude Bernard Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevalier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence national des troubles du rythme cardiaque h&#xe9;r&#xe9;ditaires ou rares de Lyon (CERA), H&#xf4;pital Louis Pradel, Institut de Cardiologie, Hospices Civils de Lyon, Bron, France; Service de Rythmologie, H&#xf4;pital Louis Pradel, Institut de Cardiologie, Hospices Civils de Lyon, Bron, France; MeLiS, Institut NeuroMyoG&#xe8;ne, CNRS UMR 5284, INSERM U1314, Universit&#xe9; Claude Bernard Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delini&#xe8;re</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence national des troubles du rythme cardiaque h&#xe9;r&#xe9;ditaires ou rares de Lyon (CERA), H&#xf4;pital Louis Pradel, Institut de Cardiologie, Hospices Civils de Lyon, Bron, France; Service de Rythmologie, H&#xf4;pital Louis Pradel, Institut de Cardiologie, Hospices Civils de Lyon, Bron, France; MeLiS, Institut NeuroMyoG&#xe8;ne, CNRS UMR 5284, INSERM U1314, Universit&#xe9; Claude Bernard Lyon 1, Lyon, France. Electronic address: antoine.deliniere@chu-lyon.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Clin Electrophysiol</MedlineTA><NlmUniqueID>101656995</NlmUniqueID><ISSNLinking>2405-500X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CACNA1C</Keyword><Keyword MajorTopicYN="N">arrhythmogenic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">congenital long-QT syndrome</Keyword><Keyword MajorTopicYN="N">genetics</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures Dr Delini&#xe8;re has received honoraria for educational lectures from Alnylam, Amgen, Bristol Myers Squibb, and Sanofi, unrelated to the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>10</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40838920</ArticleId><ArticleId IdType="doi">10.1016/j.jacep.2025.06.039</ArticleId><ArticleId IdType="pii">S2405-500X(25)00559-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40833749</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2753-670X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Interdisciplinary cardiovascular and thoracic surgery</Title><ISOAbbreviation>Interdiscip Cardiovasc Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>Transapical beating-heart septal myectomy for obstructive hypertrophic cardiomyopathy with anomalous papillary muscle insertion.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ivaf195</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/icvts/ivaf195</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Anomalous papillary muscles directly inserted into the anterior mitral valve constitute an infrequent anomaly in obstructive hypertrophic cardiomyopathy. This study sought to evaluate the efficacy and safety of a novel approach with transapical beating-heart septal myectomy to relieve obstruction while avoiding abnormal papillary muscle manipulation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Among 439 patients with obstructive hypertrophic cardiomyopathy from March 2023 to February 2024, 27 patients (6.2%) were diagnosed with anomalous papillary muscle directly inserted into the anterior mitral leaflet. Isolated myectomy without papillary muscle intervention was performed in these patients with a transapical beating-heart septal myectomy approach.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age of patients was 54 (47-60) years. The abnormal papillary muscle insertion into the body (Type I/II) and only the free edge (Type III) of anterior mitral valve leaflet were 21 and 6 patients, respectively. There was no operative death, septal perforation, conversion to sternotomy, blood transfusion and no patients with preoperative normal conduction required a pacemaker. The resting left ventricular outflow tract gradient decreased from 110 (70-121) mmHg at baseline to 10 (8-21) mmHg at 12 months. Reduction to a mitral regurgitation grade &#x2264; 1+ was achieved in 25 (92.6%) patients at 12 months. At follow-up 25 (92.6%) patients returned to NYHA class I.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In selected patients with sufficient septal thickness and no intrinsic mitral valve pathology, transapical beating-heart septal myectomy may provide obstruction and mitral regurgitation relief without direct papillary muscle intervention. This new approach without sternotomy or cardiopulmonary bypass increases the options for this infrequent condition.</AbstractText><AbstractText Label="CLINICAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT05332691.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintana</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Hospital Clinic de Barcelona, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yani</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05332691</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Interdiscip Cardiovasc Thorac Surg</MedlineTA><NlmUniqueID>9918540787006676</NlmUniqueID><ISSNLinking>2753-670X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anomalous papillary muscles</Keyword><Keyword MajorTopicYN="N">Obstructive hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Septal myectomy</Keyword><Keyword MajorTopicYN="N">Transapical beating-heart septal myectomy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40833749</ArticleId><ArticleId IdType="doi">10.1093/icvts/ivaf195</ArticleId><ArticleId IdType="pii">8238672</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40824437</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2542-5641</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Chinese medical journal</Title><ISOAbbreviation>Chin Med J (Engl)</ISOAbbreviation></Journal><ArticleTitle>GSTP1-mediated inhibition of ACSL4-dependent ferroptosis via JNK pathway in DOX-induced cardiomyopathy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/CM9.0000000000003758</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Doxorubicin hydrochloride (DOX) is extensively used in the treatment of various tumors. However, its clinical application is limited due to dose-dependent cardiotoxicity. Currently, few effective strategies exist to mitigate or eliminate DOX-induced cardiomyopathy (DIC). Although ferroptosis is implicated in DIC and its inhibition partially alleviates the condition, the direct targets of DOX in the progression of cardiotoxicity remain unclear. This study aimed to discover the direct targets of DOX in ferroptosis-mediated DIC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A DOX pulldown assay was performed to identify proteins specifically binding to DOX in murine hearts, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify candidate proteins. A cardiac injury mouse model was established by DOX treatment. Based on this, multiple ferroptosis biomarkers were detected by flow cytometry, quantitative real-time polymerase chain reaction, western blotting, immunochemistry, etc. Besides, specific activator and inhibitor of signaling pathways were applied to illuminate molecular mechanisms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Glutathione S-transferase P1 (GSTP1) was identified as a DOX target. GSTP1 activity was inhibited in DOX-treated cardiomyocytes, while its overexpression significantly alleviated DIC. Moreover, GSTP1 overexpression inhibited acyl-CoA synthetase long-chain family member 4 (ACSL4)-dependent ferroptosis. Mechanistically, GSTP1 overexpression suppressed c-Jun N-terminal kinase (JNK) phosphorylation, thereby reducing reactive oxygen species (ROS) production and inhibiting ferroptosis in DIC.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study identifies the DOX/GSTP1/JNK axis as a critical pathway mediating ACSL4-dependent ferroptosis in DIC. GSTP1 is highlighted as a potential key mediator of ferroptosis and a promising therapeutic target for DIC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Mingbo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Bioscience and Biotechnology, Chengdu Medical College, Chengdu, Sichuan 610500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Oncology, General Hospital of Western Theater Command of PLA, Chengdu, Sichuan 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xueli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jiaojiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Siyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology, General Hospital of Western Theater Command of PLA, Chengdu, Sichuan 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Oncology, General Hospital of Western Theater Command of PLA, Chengdu, Sichuan 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zegang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Oncology, General Hospital of Western Theater Command of PLA, Chengdu, Sichuan 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Xiaomiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jingwen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Wenwu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin Med J (Engl)</MedlineTA><NlmUniqueID>7513795</NlmUniqueID><ISSNLinking>0366-6999</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Doxorubicin hydrochloride</Keyword><Keyword MajorTopicYN="N">Ferroptosis</Keyword><Keyword MajorTopicYN="N">Glutathione S-transferase P1</Keyword><Keyword MajorTopicYN="N">Reactive oxygen species</Keyword><Keyword MajorTopicYN="N">c-Jun N-terminal kinase pathway</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40824437</ArticleId><ArticleId IdType="doi">10.1097/CM9.0000000000003758</ArticleId><ArticleId IdType="pii">00029330-990000000-01697</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li J, Zhang Y, Zuo Z, Zhang Z, Wang Y, Chang S, et al. Salvianolate injection ameliorates cardiomyopathy by regulating autophagic flux through miR-30a/becn1 axis in zebrafish. Chin Med J 2024. doi: 10.1097/CM9.0000000000003322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000003322</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace KB, Sard&#xe3;o VA, Oliveira PJ. Mitochondrial determinants of doxorubicin-induced cardiomyopathy. Circ Res 2020;126:926&#x2013;941. doi: 10.1161/circresaha.119.314681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.119.314681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyanaraman B. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biol 2020;29:101394. doi: 10.1016/j.redox.2019.101394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2019.101394</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35:495&#x2013;516. doi: 10.1080/01926230701320337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01926230701320337</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res 2019;29:347&#x2013;364. doi: 10.1038/s41422-019-0164-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-019-0164-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett JJ, Trivedi PC, Pulinilkunnil T. Autophagic dysregulation in doxorubicin cardiomyopathy. J Mol Cell Cardiol 2017;104:1&#x2013;8. doi: 10.1016/j.yjmcc.2017.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2017.01.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghigo A, Li M, Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim Biophys Acta 2016;1863:1916&#x2013;1925. doi: 10.1016/j.bbamcr.2016.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2016.01.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Wang H, Han D, Xie E, Yang X, Wei J, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci USA 2019;116:2672&#x2013;2680. doi: 10.1073/pnas.1821022116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1821022116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Chen X, Zhou W, Men H, Bao T, Sun Y, et al. Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways. Acta Pharm Sin B 2022;12:708&#x2013;722. doi: 10.1016/j.apsb.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.10.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol 2017;13:81&#x2013;90. doi: 10.1038/nchembio.2238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.2238</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem Biol 2015;10:1604&#x2013;1609. doi: 10.1021/acschembio.5b00245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.5b00245</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah R, Shchepinov MS, Pratt DA. Resolving the role of lipoxygenases in the initiation and execution of ferroptosis. ACS Cent Sci 2018;4:387&#x2013;396. doi: 10.1021/acscentsci.7b00589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.7b00589</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci USA 2016;113:E4966&#x2013;4975. doi: 10.1073/pnas.1603244113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1603244113</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: Molecular mechanisms and health implications. Cell Res 2021;31:107&#x2013;125. doi: 10.1038/s41422-020-00441-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-00441-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding CC, Rose J, Sun T, Wu J, Chen PH, Lin CC, et al. MESH1 is a cytosolic NADPH phosphatase that regulates ferroptosis. Nat Metab 2020;2:270&#x2013;277. doi: 10.1038/s42255-020-0181-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-020-0181-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 2019;575:693&#x2013;698. doi: 10.1038/s41586-019-1707-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1707-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu B, Kon N, Chen D, Li T, Liu T, Jiang L, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol 2019;21:579&#x2013;591. doi: 10.1038/s41556-019-0305-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-019-0305-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, et al. PEBP1 Wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell 2017;171:628&#x2013;641.e626. doi: 10.1016/j.cell.2017.09.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.09.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 2017;13:91&#x2013;98. doi: 10.1038/nchembio.2239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.2239</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 2014;509:105&#x2013;109. doi: 10.1038/nature13148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13148</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang M, Bi R, Su Y, Quan F, Lin Y, et al. ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury. Redox Biol 2022;51:102262. doi: 10.1016/j.redox.2022.102262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2022.102262</ArticleId></ArticleIdList></Reference><Reference><Citation>Ta N, Qu C, Wu H, Zhang D, Sun T, Li Y, et al. Mitochondrial outer membrane protein FUNDC2 promotes ferroptosis and contributes to doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA 2022;119:e2117396119. doi: 10.1073/pnas.2117396119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2117396119</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y, et al. CD8(+) T&#xa0;cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell 2022;40:365&#x2013;378.e6. doi: 10.1016/j.ccell.2022.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2022.02.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y, Zhang Y, Zhao X, Shao L, Liu G, Sun C, et al. ACSL4 exacerbates ischemic stroke by promoting ferroptosis-induced brain injury and neuroinflammation. Brain Behav Immun 2021;93:312&#x2013;321. doi: 10.1016/j.bbi.2021.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.01.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Feng D, Wang Z, Zhao Y, Sun R, Tian D, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ 2019;26:2284&#x2013;2299. doi: 10.1038/s41418-019-0299-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-019-0299-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Chen Y, Yang Q, Zhao P, Yang M, Wang X, et al. Protosappanin A protects DOX-induced myocardial injury and cardiac dysfunction by targeting ACSL4/FTH1 axis-dependent ferroptosis. Adv Sci (Weinh) 2024;11:e2310227. doi: 10.1002/advs.202310227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202310227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445&#x2013;600. doi: 10.3109/10409239509083491.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10409239509083491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogawa T, Sato Y, Shimoyama R, Kurata W, Tashiro Y, Niitsu Y. Chemoprevention of pancreatic cancer by inhibition of glutathione-S transferase P1. Invest New Drugs 2021;39:1484&#x2013;1492. doi: 10.1007/s10637-021-01129-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10637-021-01129-y</ArticleId></ArticleIdList></Reference><Reference><Citation>FeiFei W, HongHai X, YongRong Y, PingXiang W, JianHua W, XiaoHui Z, et al. FBX8 degrades GSTP1 through ubiquitination to suppress colorectal cancer progression. Cell Death Dis 2019;10:351. doi: 10.1038/s41419-019-1588-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1588-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Uys JD, Mulholland PJ, Townsend DM. Glutathione and redox signaling in substance abuse. Biomed Pharmacother 2014;68:799&#x2013;807. doi: 10.1016/j.biopha.2014.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2014.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee A, Gupta S. The multifaceted role of glutathione S-transferases in cancer. Cancer Lett 2018;433:33&#x2013;42. doi: 10.1016/j.canlet.2018.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2018.06.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y, Ye J, Zhao B, Sun J, Gu N, Chen X, et al. Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis. Redox Biol 2020;36:101677. doi: 10.1016/j.redox.2020.101677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2020.101677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mian OY, Khattab MH, Hedayati M, Coulter J, Abubaker-Sharif B, Schwaninger JM, et al. GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate 2016;76:199&#x2013;206. doi: 10.1002/pros.23111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pros.23111</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei K, Gu X, Alvarado AG, Du Y, Luo S, Ahn EH, et al. Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma. J Hematol Oncol 2020;13:141. doi: 10.1186/s13045-020-00979-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-020-00979-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Holley SL, Fryer AA, Haycock JW, Grubb SE, Strange RC, Hoban PR. Differential effects of glutathione S-transferase pi (GSTP1) haplotypes on cell proliferation and apoptosis. Carcinogenesis 2007;28:2268&#x2013;2273. doi: 10.1093/carcin/bgm135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgm135</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Liang Q, Liu W, Zhang N, Xu L, Zhang X, et al. Ras association domain family member 10 suppresses gastric cancer growth by cooperating with GSTP1 to regulate JNK/c-Jun/AP-1 pathway. Oncogene 2016;35:2453&#x2013;2464. doi: 10.1038/onc.2015.300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2015.300</ArticleId></ArticleIdList></Reference><Reference><Citation>He M, Hu J, Fang T, Tang W, Lv B, Yang B, et al. Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway. Cancer Biol Med 2021;19:90&#x2013;103. doi: 10.20892/j.issn.2095-3941.2020.0313.</Citation><ArticleIdList><ArticleId IdType="doi">10.20892/j.issn.2095-3941.2020.0313</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammad J, Singh RR, Riggle C, Haugrud B, Abdalla MY, Reindl KM. JNK inhibition blocks piperlongumine-induced cell death and transcriptional activation of heme oxygenase-1 in pancreatic cancer cells. Apoptosis 2019;24:730&#x2013;744. doi: 10.1007/s10495-019-01553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-019-01553-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J, Zhang Y, Yu H, Zong Y, Wang D, Zheng J, et al. GPSM1 impairs metabolic homeostasis by controlling a pro-inflammatory pathway in macrophages. Nat Commun 2022;13:7260. doi: 10.1038/s41467-022-34998-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34998-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Farahzadi R, Fathi E, Mesbah-Namin SA, Vietor I. Granulocyte differentiation of rat bone marrow resident C-kit(+) hematopoietic stem cells induced by mesenchymal stem cells could be considered as new option in cell-based therapy. Regen Ther 2023;23:94&#x2013;101. doi: 10.1016/j.reth.2023.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reth.2023.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Farahzadi R, Valipour B, Anakok OF, Fathi E, Montazersaheb S. The effects of encapsulation on NK cell differentiation potency of C-kit+ hematopoietic stem cells via identifying cytokine profiles. Transpl Immunol 2023;77:101797. doi: 10.1016/j.trim.2023.101797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trim.2023.101797</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadokoro T, Ikeda M, Ide T, Deguchi H, Ikeda S, Okabe K, et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight 2023;8:e169756. doi: 10.1172/jci.insight.169756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.169756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Chen L, Zhao J, Zhang W, Jin Z, Sun Y, et al. Lipoxin A4 ameliorates knee osteoarthritis progression in rats by antagonizing ferroptosis through activation of the ESR2/LPAR3/Nrf2 axis in synovial fibroblast-like synoviocytes. Redox Biol 2024;73:103143. doi: 10.1016/j.redox.2024.103143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2024.103143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Liu Z, Li Z, Qi L, Huang T, Li F, et al. Ferroptosis pathways: Unveiling the neuroprotective power of cistache deserticola phenylethanoid glycosides. J Ethnopharmacol 2024;333:118465. doi: 10.1016/j.jep.2024.118465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2024.118465</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Hao D, Jin M, Li Y, Liu Z, Huang Y, et al. Internal ammonium excess induces ROS-mediated reactions and causes carbon scarcity in rice. BMC Plant Biol 2020;20:143. doi: 10.1186/s12870-020-02363-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12870-020-02363-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Wang G, Wu B, Chou WC, Cheng L, Zhou C, et al. DCAF1 regulates Treg senescence via the ROS axis during immunological aging. J Clin Invest 2020;130:5893&#x2013;5908. doi: 10.1172/jci136466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci136466</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y. CB-Dock2: improved protein&#x2013;ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res 2022;50:W159&#x2013;W164. doi: 10.1093/nar/gkac394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac394</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Liu Y, Gan J, Xiao ZX, Cao Y. FitDock: Protein&#x2013;ligand docking by template fitting. Brief Bioinform 2022;23:bbac087 [pii]. doi: 10.1093/bib/bbac087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbac087</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Chen J, Sun M, Zhang L, Yu Y, Mi W, et al. Protection of Ndrg2 deficiency on renal ischemia-reperfusion injury via activating PINK1/Parkin-mediated mitophagy. Chin Med J 2024;137:2603&#x2013;2614. doi: 10.1097/CM9.0000000000002957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000002957</ArticleId></ArticleIdList></Reference><Reference><Citation>Conklin DJ, Haberzettl P, Jagatheesan G, Baba S, Merchant ML, Prough RA, et al. Glutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice. Toxicol Appl Pharmacol 2015;285:136&#x2013;148. doi: 10.1016/j.taap.2015.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2015.03.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson MH, Grant PJ, Hardie LJ, Wild CP. Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J 2000;14:791&#x2013;796. doi: 10.1096/fasebj.14.5.791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.14.5.791</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y. CB-Dock2: Improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res 2022;50:W159&#x2013;W164. doi: 10.1093/nar/gkac394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac394</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CJ, Tu CT, Hsiao CD, Hsieh FJ, Tsai HJ. Germ-line transmission of a myocardium-specific GFP transgene reveals critical regulatory elements in the cardiac myosin light chain 2 promoter of zebrafish. Dev Dyn 2003;228:30&#x2013;40. doi: 10.1002/dvdy.10356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.10356</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Cai Z, Wang H, Han D, Cheng Q, Zhang P, et al. Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-mediated ferroptosis. Circ Res 2020;127:486&#x2013;501. doi: 10.1161/circresaha.120.316509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.120.316509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Arifoglu P, Ronai Z, Tew KD. Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem 2001;276:20999&#x2013;21003. doi: 10.1074/jbc.M101355200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M101355200</ArticleId></ArticleIdList></Reference><Reference><Citation>Tew KD, Townsend DM. Regulatory functions of glutathione S-transferase P1-1 unrelated to detoxification. Drug Metab Rev 2011;43:179&#x2013;193. doi: 10.3109/03602532.2011.552912.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03602532.2011.552912</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, et al. Regulation of JNK signaling by GSTp. EMBO J 1999;18:1321&#x2013;1334. doi: 10.1093/emboj/18.5.1321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/18.5.1321</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RR, Mohammad J, Orr M, Reindl KM. Glutathione S-transferase pi-1 knockdown reduces pancreatic ductal adenocarcinoma growth by activating oxidative stress response pathways. Cancers (Basel) 2020;12:1501. doi: 10.3390/cancers12061501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12061501</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuo QZ, Liu Y, Xiang Z, Yan HF, Zou T, Shu Y, et al. Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion. Signal Transduct Target Ther 2022;7:59. doi: 10.1038/s41392-022-00917-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00917-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Hu C, Kong CY, Song P, Wu HM, Xu SC, et al. FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT. Cell Death Differ 2020;27:540&#x2013;555. doi: 10.1038/s41418-019-0372-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-019-0372-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye ZW, Zhang J, Ancrum T, Manevich Y, Townsend DM, Tew KD. Glutathione S-transferase p-mediated protein S-glutathionylation of resident endoplasmic reticulum proteins influences sensitivity to drug-induced unfolded protein response. Antioxid Redox Signal 2017;26:247&#x2013;261. doi: 10.1089/ars.2015.6486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2015.6486</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Dong X, Zheng S, Sun J, Ye J, Chen J, et al. GSTpi regulates VE-cadherin stabilization through promoting S-glutathionylation of Src. Redox Biol 2020;30:101416. doi: 10.1016/j.redox.2019.101416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2019.101416</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Li XY, Liu YJ, Feng J, Wu Y, Shen HM, et al. Full-coverage regulations of autophagy by ROS: from induction to maturation. Autophagy 2022;18:1240&#x2013;1255. doi: 10.1080/15548627.2021.1984656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2021.1984656</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai J, Hou G, Liu H, Zheng S, Wang X, et al. SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation. Mol Cell 2023;83:4352&#x2013;4369 e8. doi: 10.1016/j.molcel.2023.10.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2023.10.042</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura T, Antoun G, Keir ST, Friedman H, Bigner DD, Ali-Osman F. Phosphorylation of glutathione S-transferase P1 (GSTP1) by epidermal growth factor receptor (EGFR) promotes formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and suppresses JNK downstream signaling and apoptosis in brain tumor cells. J Biol Chem 2015;290:30866&#x2013;30878. doi: 10.1074/jbc.M115.656140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.656140</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Li N, Chen T, Zhang C, Li J, Liu L, et al. Sirt3 promotes sensitivity to sunitinib-induced cardiotoxicity via inhibition of GTSP1/JNK/autophagy pathway in vivo and in vitro. Arch Toxicol 2019;93:3249&#x2013;3260. doi: 10.1007/s00204-019-02573-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00204-019-02573-9</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40832779</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2045-7634</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>16</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cancer medicine</Title><ISOAbbreviation>Cancer Med</ISOAbbreviation></Journal><ArticleTitle>Anthracycline-Induced Cardiomyopathy After Nephro-/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment.</ArticleTitle><Pagination><StartPage>e71158</StartPage><MedlinePgn>e71158</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e71158</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.71158</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long-term childhood cancer survivors (CCS) may develop anthracycline-induced cardiomyopathy. Our cross-sectional study focused on the question of whether a central echocardiographic reference assessment is associated with a higher detection rate of cardiac dysfunction in a population-based cohort of affected children with neuroblastoma or nephroblastoma. We also examined the prevalence of anthracycline-induced cardiomyopathy and its risk factors.</AbstractText><AbstractText Label="METHODS AND PATIENTS" NlmCategory="METHODS">The cohort of this subproject comprises 370 nephroblastoma or neuroblastoma survivors diagnosed with cancer between 1990 and 2012. At study entry, participants were younger than 18&#x2009;years old, had been treated with anthracyclines, and had no documented previous cardiac disease. Data were collected via patient questionnaires, cardiologic examinations in the network of adults with congenital heart defects (Erwachsene mit angeborenem Herzfehler [EMAH]) and a reference assessment of the recorded echocardiography.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of cardiomyopathy in the study cohort (mean age: 12&#x2009;years) was 6.3% at a median of 9.1&#x2009;years after initial cancer diagnosis. Risk factors were an age under 5&#x2009;years at tumor diagnosis and concomitant treatment with cyclophosphamide or radiation. As a central and novel finding, the detection rates by the EMAH cardiologists and the reference center are similarly high but discrepant.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Limitations were mainly due to the low responder rate and incomplete data. This study established a nationwide competence network linking pediatric oncology and cardiology centers across six university hospitals in Germany, enabling data collection on pediatric CCS. Despite lower case numbers compared to adult CCS cohorts, meaningful data were gathered and analyzed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cardiac late effects after anthracycline-based therapy in childhood affect a relevant proportion of long-term CCS at pediatric age. In order to enable timely diagnosis and treatment, preventive examinations are essential and might benefit from additional central reference assessments. Discrepancy in detection of cardiomyopathy by reference and EMAH cardiologists requires further investigation.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kleen</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0004-3672-2619</Identifier><AffiliationInfo><Affiliation>Paediatric Haematology and Oncology, Department of Paediatrics and Adolescent Medicine, University Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebauer</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Clinic 1, University Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spix</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Childhood Cancer Registry, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kronziel</LastName><ForeName>Lea L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Institute of Biometry and Statistics, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;nig</LastName><ForeName>Inke</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Biometry and Statistics, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baust</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Paediatric Haematology and Oncology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calaminus</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Paediatric Haematology and Oncology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Paediatric Oncology and Haematology, University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hero</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Paediatric Oncology and Haematology, University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zolk</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute for Clinical Pharmacology, Immanuel Clinic R&#xfc;dersdorf, Brandenburg Medical School, R&#xfc;dersdorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graf</LastName><ForeName>Norbert</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Paediatric Haematology and Oncology, University Hospital Homburg/Saar, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdul-Khaliq</LastName><ForeName>Hashim</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Paediatric Cardiology, University Hospital Homburg/Saar, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langer</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Paediatric Haematology and Oncology, Department of Paediatrics and Adolescent Medicine, University Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Madeleine Schickedanz Kinderkrebsstiftung</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Med</MedlineTA><NlmUniqueID>101595310</NlmUniqueID><ISSNLinking>2045-7634</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018943">Anthracyclines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018943" MajorTopicYN="Y">Anthracyclines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="Y">Neuroblastoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009396" MajorTopicYN="Y">Wilms Tumor</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007680" MajorTopicYN="Y">Kidney Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073116" MajorTopicYN="N">Cancer Survivors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40832779</ArticleId><ArticleId IdType="pmc">PMC12365662</ArticleId><ArticleId IdType="doi">10.1002/cam4.71158</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Deutsches Kinderkrebsregister DKKR
, Jahresbericht Annual Report 2019 (2019), 7&#x2013;14, https://www.kinderkrebsregister.de/dkkr/ergebnisse/wichtigste&#x2010;ergebnisse.html.</Citation></Reference><Reference><Citation>
Erdmann F., Spix C., and Katalinic A., &#x201c;Krebs in Deutschland f&#xfc;r 2017/2018,&#x201d; Robert Koch&#x2010;Inst. 2021;13, https://www.gekid.de/wp&#x2010;content/uploads/2022/01/krebs_in_deutschland_2021.pdf.</Citation></Reference><Reference><Citation>Oeffinger K. C., Mertens A. C., Sklar C. A., et&#xa0;al., &#x201c;Chronic Health Conditions in Adult Survivors of Childhood Cancer,&#x201d; New England Journal of Medicine 355, no. 15 (2006): 1572&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035650</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebauer J., Baust K., Bardi E., et&#xa0;al., &#x201c;Updated International Guidelines for Survivorship Care After Pediatric Cancer: Practice Implications in a German and Austrian Comprehensive Care Network,&#x201d; Oncology Research and Treatment 46, no. 9 (2023): 382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10614471</ArticleId><ArticleId IdType="pubmed">37517391</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer T., Calaminus G., Graf N., Kaatsch P., Simon T., and Abdul&#x2010;Khaliq H., &#x201c;Antrag an die Madeleine Schickedanz Kinderkrebs&#x2010;Stiftung zum Thema Strukturoptimierung f&#xfc;r krebskranke Kinder nach Anthrazyklintherapie &#x2010; eine Pilotstudie zur Ursache und Fr&#xfc;herkennung der Anthrazyklin&#x2010;induzierten Kardiomyopathie nach Behandlung eines Nephro&#x2010; und Neuroblastoms,&#x201d; (2013).</Citation></Reference><Reference><Citation>Langer T., Meitert J., D&#xf6;rr H. G., Beck J. D., and Paulides M., &#x201c;Erkennen, Vermeiden und Behandeln von Sp&#xe4;tfolgen: Langzeitfolgen von onkologischen Erkrankungen bei Kindern,&#x201d; P&#xe4;diatrie 22, no. 6 (2010): 428&#x2013;433.</Citation></Reference><Reference><Citation>Zamorano J. L., Lancellotti P., Rodriguez Mu&#xf1;oz D., et&#xa0;al., &#x201c;2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC),&#x201d; European Heart Journal 37, no. 36 (2016): 2768&#x2013;2801.</Citation><ArticleIdList><ArticleId IdType="pubmed">27567406</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmaltz A. A., &#x201c;Dilatative Kardiomyopathie Im Kindesalter,&#x201d; Zeitschrift f&#xfc;r Kardiologie 90, no. 4 (2001): 263&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">11381574</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster S., Hahn B., Beck J. D., Calaminus G., Timmermann B., and Langer T., &#x201c;Langzeit &#x2010; Nachsorge von krebskranken Kindern, Jugendlichen und jungen Erwachsenen &#x2013; Vermeiden, Erkennen und Behandeln von Sp&#xe4;tfolgen,&#x201d; AWMF 04/21;6:30.</Citation><ArticleIdList><ArticleId IdType="pubmed">30388336</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz&#x2010;Bose R., Margossian R., Ames B. L., et&#xa0;al., &#x201c;Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy,&#x201d; JACC CardioOncology 4, no. 3 (2022): 354&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537072</ArticleId><ArticleId IdType="pubmed">36213355</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong G. T., Oeffinger K. C., Chen Y., et&#xa0;al., &#x201c;Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer,&#x201d; Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 31, no. 29 (2013): 3673&#x2013;3680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804290</ArticleId><ArticleId IdType="pubmed">24002505</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale D., Colombo A., Bacchiani G., et&#xa0;al., &#x201c;Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy,&#x201d; Circulation 131, no. 22 (2015): 1981&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pubmed">25948538</ArticleId></ArticleIdList></Reference><Reference><Citation>Armenian S. H., Hudson M. M., Mulder R. L., et&#xa0;al., &#x201c;Recommendations for Cardiomyopathy Surveillance for Survivors of Childhood Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group,&#x201d; Lancet Oncology 16, no. 3 (2015): 1&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4485458</ArticleId><ArticleId IdType="pubmed">25752563</ArticleId></ArticleIdList></Reference><Reference><Citation>
Landmesser U., Anker M., Lehmann L. H., Pfister R., Rassaf T., and Tiefenbacher C., Pocket&#x2010;Leitlinie: Kardio&#x2010;Onkologie (Version 2022) (Deutsche Gesellschaft f&#xfc;r Kardiologie &#x2013; Herz&#x2010;und Kreislaufforschung e.V., 2023), https://leitlinien.dgk.org/2023/pocket&#x2010;leitlinie&#x2010;kardio&#x2010;onkologie&#x2010;version&#x2010;2022/.</Citation></Reference><Reference><Citation>Ross R. D., &#x201c;The Ross Classification for Heart Failure in Children After 25&#x2009;Years: A Review and an Age&#x2010;Stratified Revision,&#x201d; Pediatric Cardiology 33, no. 8 (2012): 1295&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pubmed">22476605</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Pal H. J., van Dalen E. C., Hauptmann M., et&#xa0;al., &#x201c;Cardiac Function in 5&#x2010;Year Survivors of Childhood Cancer: A Long&#x2010;Term Follow&#x2010;Up Study,&#x201d; Archives of Internal Medicine 170, no. 14 (2010): 1247&#x2013;1255.</Citation><ArticleIdList><ArticleId IdType="pubmed">20660845</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow E. J., Leger K. J., Bhatt N. S., et&#xa0;al., &#x201c;Paediatric Cardio&#x2010;Oncology: Epidemiology, Screening, Prevention, and Treatment,&#x201d; Cardiovascular Research 115, no. 5 (2019): 922&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6452306</ArticleId><ArticleId IdType="pubmed">30768157</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Pal H. J., van Dalen E. C., van Delden E., et&#xa0;al., &#x201c;High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors,&#x201d; Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30, no. 13 (2012): 1429&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pubmed">22473161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulrooney D. A., Yeazel M. W., Kawashima T., et&#xa0;al., &#x201c;Cardiac Outcomes in a Cohort of Adult Survivors of Childhood and Adolescent Cancer: Retrospective Analysis of the Childhood Cancer Survivor Study Cohort,&#x201d; BMJ (Clinical Research Ed.) 339 (2009): b4606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266843</ArticleId><ArticleId IdType="pubmed">19996459</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhardt M. J., Leerink J. M., Mulder R. L., et&#xa0;al., &#x201c;Systematic Review and Updated Recommendations for Cardiomyopathy Surveillance for Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Late Effects of Childhood Cancer Guideline Harmonization Group,&#x201d; Lancet Oncology 24, no. 3 (2023): e108&#x2013;e120.</Citation><ArticleIdList><ArticleId IdType="pubmed">37052966</ArticleId></ArticleIdList></Reference><Reference><Citation>de Baat E. C., van Dalen E. C., Mulder R. L., et&#xa0;al., &#x201c;Primary Cardioprotection With Dexrazoxane in Patients With Childhood Cancer Who Are Expected to Receive Anthracyclines: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group,&#x201d; Lancet. Child &amp; Adolescent Health 6, no. 12 (2022): 885&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">36174614</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40829702</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-1740</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Progress in cardiovascular diseases</Title><ISOAbbreviation>Prog Cardiovasc Dis</ISOAbbreviation></Journal><ArticleTitle>Left atrial remodeling trajectories in hypertrophic cardiomyopathy: Reframing prognostic assessment through a dynamic lens.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0033-0620(25)00113-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pcad.2025.08.002</ELocationID><Abstract><AbstractText>Hypertrophic cardiomyopathy (HCM) is increasingly recognized as a condition involving not only the left ventricle but also the left atrium (LA). In this issue of Progress in Cardiovascular Diseases, Di Napoli et al. provide compelling evidence that longitudinal trajectories of LA remodeling offer stronger prognostic value for atrial fibrillation (AF), and sudden cardiac death (SCD) in patients with HCM than do static measurements. Using group-based trajectory modeling in a 35-year cohort, the authors identified three distinct phenotypes of LA enlargement. The most adverse phenotype was associated with a 9.3-fold increased risk of AF and a 3.6-fold increased risk of SCD. These findings support dynamic rather than static risk assessment strategies. This editorial explores the methodological and clinical implications of these insights, situating LA remodeling at the forefront of contemporary HCM management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Badano</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Istituto Auxologico Italiano, IRCCS, Milan, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. Electronic address: luigi.badano@unimib.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rella</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Istituto Auxologico Italiano, IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crotti</LastName><ForeName>Lia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Istituto Auxologico Italiano, IRCCS, Milan, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muraru</LastName><ForeName>Denisa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Istituto Auxologico Italiano, IRCCS, Milan, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prog Cardiovasc Dis</MedlineTA><NlmUniqueID>0376442</NlmUniqueID><ISSNLinking>0033-0620</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atrial fibrillation</Keyword><Keyword MajorTopicYN="N">Echocardiography</Keyword><Keyword MajorTopicYN="N">Hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Left atrial remodeling</Keyword><Keyword MajorTopicYN="N">Sudden cardiac death</Keyword><Keyword MajorTopicYN="N">Trajectory modeling</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40829702</ArticleId><ArticleId IdType="doi">10.1016/j.pcad.2025.08.002</ArticleId><ArticleId IdType="pii">S0033-0620(25)00113-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40846350</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>24</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Iron Overload Cardiomyopathy in Myelodysplastic Syndrome: A Fatal Outcome After 20 Years of Chronic Transfusions.</ArticleTitle><Pagination><StartPage>104667</StartPage><MedlinePgn>104667</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.104667</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)01447-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Iron overload cardiomyopathy (IOC) results from excess iron accumulation in the myocardium, usually because of genetic disorders or secondary hemochromatosis by multiple blood transfusions.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 42-year-old man with refractory heart failure was referred to our hospital. He had a history of myelodysplastic syndrome, requiring 112 U of blood transfusions over 16 years. Severe left ventricular dysfunction, elevated ferritin levels, and myocardial iron deposition confirmed by endomyocardial biopsy led to the diagnosis of IOC. Despite intensive management, the patient was discharged after death.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Early IOC typically starts with asymptomatic diastolic dysfunction. Noninvasive modalities (eg, N-terminal pro-B-type natriuretic peptide, T2-star magnetic resonance imaging) are crucial for early detection. Iron chelation therapy may reverse cardiac dysfunction in the early phase but is less effective in advanced phases, highlighting the need for timely intervention.</AbstractText><AbstractText Label="TAKE-HOME MESSAGE" NlmCategory="CONCLUSIONS">Early detection, cardiac monitoring, and close collaboration between hematologists and cardiologists are essential to prevent IOC progression.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayashida</LastName><ForeName>Miyu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nohara</LastName><ForeName>Shoichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamakawa</LastName><ForeName>Rei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishikido</LastName><ForeName>Aya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsushima</LastName><ForeName>Yoshihisa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanai</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishimatsu</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Maki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan. Electronic address: ohtsuka_maki@kurume-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukumoto</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">hemochromatosis</Keyword><Keyword MajorTopicYN="N">iron overload</Keyword><Keyword MajorTopicYN="N">myelodysplastic syndrome</Keyword><Keyword MajorTopicYN="N">transfusion-related complications</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846350</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.104667</ArticleId><ArticleId IdType="pii">S2666-0849(25)01447-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40825382</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6795</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</Title><ISOAbbreviation>J Am Soc Echocardiogr</ISOAbbreviation></Journal><ArticleTitle>Single View Echocardiographic Analysis for LVOT Obstruction Prediction in Hypertrophic Cardiomyopathy: A Deep Learning Approach.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0894-7317(25)00466-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.echo.2025.08.008</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Accurate left ventricular outflow tract obstruction (LVOTO) assessment is crucial for hypertrophic cardiomyopathy (HCM) management and prognosis. Traditional methods, requiring multiple views, Doppler, and provocation, is often infeasible, especially where resources are limited. This study aimed to develop and validate a deep learning (DL) model capable of predicting severe LVOTO in HCM patients using only the parasternal long-axis (PLAX) view from transthoracic echocardiography (TTE).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A DL model was trained on PLAX videos extracted from TTE examinations (developmental dataset, n=1,007) to capture both morphological and dynamic motion features, generating a DL index for LVOTO (DLi-LVOTO, range 0-100). Performance was evaluated in an internal test dataset (ITDS, n=87) and externally validated in the distinct hospital dataset (DHDS, n=1,334) and the LVOTO reduction treatment dataset (n=156).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The model achieved high accuracy in detecting severe LVOTO (pressure gradient&#x2265; 50mmHg), with area under the receiver operating characteristics curve (AUROC) of 0.97 (95% confidence interval: 0.92-1.00) in ITDS and 0.93 (0.92-0.95) in DHDS. At a DLi-LVOTO threshold of 70, the model demonstrated a specificity of 97.3% and negative predictive value (NPV) of 96.1% in ITDS. In DHDS, a cutoff of 60 yielded a specificity of 94.6% and NPV of 95.5%. DLi-LVOTO also decreased significantly after surgical myectomy or Mavacamten treatment, correlating with reductions in peak pressure gradient (p&lt;0.001 for all).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our DL-based approach predicts severe LVOTO using only the PLAX view from TTE, serving as a complementary tool when Doppler assessment is unavailable and for monitoring treatment response.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jiesuck</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jiyeon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ontact Health Inc., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Jaeik</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ontact Health Inc., Seoul, Republic of Korea. Electronic address: jaeik.jeon@ontacthealth.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Yeonyee E</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Ontact Health Inc., Seoul, Republic of Korea. Electronic address: yeonyeeyoon@snubh.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Yeonggul</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ontact Health Inc., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Hyunseok</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CONNECT-AI Research Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung-Ah</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Ontact Health Inc., Seoul, Republic of Korea; CONNECT-AI Research Center, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Hong-Mi</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>In-Chang</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Goo-Yeong</ForeName><Initials>GY</Initials><AffiliationInfo><Affiliation>Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Hyuk-Jae</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Ontact Health Inc., Seoul, Republic of Korea; CONNECT-AI Research Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Soc Echocardiogr</MedlineTA><NlmUniqueID>8801388</NlmUniqueID><ISSNLinking>0894-7317</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">deep learning</Keyword><Keyword MajorTopicYN="N">echocardiography</Keyword><Keyword MajorTopicYN="N">left ventricular outflow tract obstruction</Keyword><Keyword MajorTopicYN="N">prediction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40825382</ArticleId><ArticleId IdType="doi">10.1016/j.echo.2025.08.008</ArticleId><ArticleId IdType="pii">S0894-7317(25)00466-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40832142</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Case Report: Takotsubo cardiomyopathy caused by acute surgical pathology against the background of colorectal cancer.</ArticleTitle><Pagination><StartPage>1586353</StartPage><MedlinePgn>1586353</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1586353</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2025.1586353</ELocationID><Abstract><AbstractText>We present a case of Takotsubo cardiomyopathy (TCM) in a young woman who has developed necrosis and perforation of the sigmoid intestine with a spontaneous opening of the abscess in the abdominal cavity, which caused purulent peritonitis. The patient underwent emergency surgical intervention. The postoperative period was complicated by a clinic of acute respiratory failure and bilateral pneumonia. In five days after surgery, the patient developed laboratory and instrumental signs of acute myocardial infarction. Changes similar to myocardial infarction appeared on electrocardiogram (ECG). Echocardiography revealed akinesis of the apical segments of the left ventricle and the ejection fraction of the left ventricle was reduced (LVEF) from 63 to 31%-35%. The level of NT-proBNP has increased significantly, but the level of troponin I increased to a lesser extent. Coronary angiography demonstrated normal arteries without any obstruction. As a result, a diagnosis Takotsubo cardiomyopathy caused by acute surgical pathology was made. In the future, the patient was discharged in a stable state. Subsequent echocardiography showed normalization of the systolic function of the left ventricle, the disappearance of ECG changes, and a decrease in the level of specific cardiomarkers.</AbstractText><CopyrightInformation>&#xa9; 2025 Potievskaya, Khoronenko, Kononova, Paderina, Fashafsha and Kaprin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Potievskaya</LastName><ForeName>Vera</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>P. Hertsen Moscow Oncology Research Institute-Branch or the Federal State Budgetary Institution "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Russian Medical Academy of Postgraduate Education of Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoronenko</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>P. Hertsen Moscow Oncology Research Institute-Branch or the Federal State Budgetary Institution "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peoples' Friendship University of Russia, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kononova</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>P. Hertsen Moscow Oncology Research Institute-Branch or the Federal State Budgetary Institution "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paderina</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>P. Hertsen Moscow Oncology Research Institute-Branch or the Federal State Budgetary Institution "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fashafsha</LastName><ForeName>Zaki</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>P. Hertsen Moscow Oncology Research Institute-Branch or the Federal State Budgetary Institution "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Personalized Cardiology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaprin</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>P. Hertsen Moscow Oncology Research Institute-Branch or the Federal State Budgetary Institution "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peoples' Friendship University of Russia, Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Takotsubo syndrome</Keyword><Keyword MajorTopicYN="N">acute heart failure</Keyword><Keyword MajorTopicYN="N">perioperative period</Keyword><Keyword MajorTopicYN="N">postoperative complications</Keyword><Keyword MajorTopicYN="N">sigmoid colon cancer</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>5</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40832142</ArticleId><ArticleId IdType="pmc">PMC12358426</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2025.1586353</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ghadri J, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International expert consensus document on takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J. (2018) 39:2032&#x2013;46. 10.1093/eurheartj/ehy076</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy076</ArticleId><ArticleId IdType="pmc">PMC5991216</ArticleId><ArticleId IdType="pubmed">29850871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurisu S, Sato H, Kawagoe T, Ishihara M, Shimatani Y, Nishioka K, et al. Tako-tsubo-like left ventricular dysfunction with ST-segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction. Am Heart J. (2002) 143(3):448&#x2013;55. 10.1067/mhj.2002.120403</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mhj.2002.120403</ArticleId><ArticleId IdType="pubmed">11868050</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavin D, Le Breton H, Daubert C. Human stress cardiomyopathy mimicking acute myocardial syndrome. Heart. (1997) 78:509&#x2013;11. 10.1136/hrt.78.5.509</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.78.5.509</ArticleId><ArticleId IdType="pmc">PMC1892287</ArticleId><ArticleId IdType="pubmed">9415014</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharkey SW, Shear W, Hodges M, Herzog CA. Reversible myocardial contraction abnormalities in patients with an acute noncardiac illness. Chest. (1998) 114:98&#x2013;105. 10.1378/chest.114.1.98</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.114.1.98</ArticleId><ArticleId IdType="pubmed">9674454</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmet WJ, Adriaenssens BF, Dens JA. Apical ballooning of the left ventricle: first series in white patients. Heart. (2003) 89:1027&#x2013;31. 10.1136/heart.89.9.1027</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heart.89.9.1027</ArticleId><ArticleId IdType="pmc">PMC1767823</ArticleId><ArticleId IdType="pubmed">12923018</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar Y, Siew KSW, Connerney M, Ullah W, Alraies MC. Management of Takotsubo syndrome: a comprehensive review. Cureus. (2020) 12(1):e6556. 10.7759/cureus.6556</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.6556</ArticleId><ArticleId IdType="pmc">PMC6996473</ArticleId><ArticleId IdType="pubmed">32042529</ArticleId></ArticleIdList></Reference><Reference><Citation>Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med. (2015) 373(10):929&#x2013;38. 10.1056/NEJMoa1406761</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1406761</ArticleId><ArticleId IdType="pubmed">26332547</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado GA, Truesdell AG, Kirchner RM, Zuzek RW, Pomerantsev EV, Gordon PC, et al. An angiographic and intravascular ultrasound study of the left anterior descending coronary artery in takotsubo cardiomyopathy. Am J Cardiol. (2011) 108(6):888&#x2013;91. 10.1016/j.amjcard.2011.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2011.05.012</ArticleId><ArticleId IdType="pubmed">21741604</ArticleId></ArticleIdList></Reference><Reference><Citation>Naegele M, Flammer AJ, Enseleit F, Roas S, Frank M, Hirt A, et al. Endothelial function and sympathetic nervous system activity in patients with takotsubo syndrome. Int J Cardiol. (2016) 224:226&#x2013;30. 10.1016/j.ijcard.2016.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2016.09.008</ArticleId><ArticleId IdType="pubmed">27661411</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider B, Athanasiadis A, St&#xf6;llberger C, Pistner W, Schwab J, Gottwald U, et al. Gender differences in the manifestation of tako-tsubo cardiomyopathy. Int J Cardiol. (2013) 166(3):584&#x2013;8. 10.1016/j.ijcard.2011.11.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2011.11.027</ArticleId><ArticleId IdType="pubmed">22192296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueyama T, Kasamatsu K, Hano T, Tsuruo Y, Ishikura F. Catecholamines and estrogen are involved in the pathogenesis of emotional stress-induced acute heart attack. Ann N Y Acad Sci. (2008) 1148:479&#x2013;85. 10.1196/annals.1410.079</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1410.079</ArticleId><ArticleId IdType="pubmed">19120144</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorn GW, 2nd. Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol Rev. (2010) 90(3):1013&#x2013;62. 10.1152/physrev.00001.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00001.2010</ArticleId><ArticleId IdType="pubmed">20664078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. (2009) 53(24):2231&#x2013;47. 10.1016/j.jacc.2009.02.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2009.02.050</ArticleId><ArticleId IdType="pubmed">19520246</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A, Noor A, Joshi S, Kim AS. Takotsubo cardiomyopathy in cancer patients. Cardio-Oncol Lond Engl. (2019) 5:7. 10.1186/s40959-019-0042-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40959-019-0042-9</ArticleId><ArticleId IdType="pmc">PMC7048040</ArticleId><ArticleId IdType="pubmed">32154014</ArticleId></ArticleIdList></Reference><Reference><Citation>Basselin C, Fontanges T, Descotes J, Chevalier P, Bui-Xuan B, Feinard G, et al. 5-fluorouracil-induced Tako-Tsubo-like syndrome. Pharmacotherapy. (2011) 31(2):226. 10.1592/phco.31.2.226</Citation><ArticleIdList><ArticleId IdType="doi">10.1592/phco.31.2.226</ArticleId><ArticleId IdType="pubmed">21275498</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk MA, Ozveren O, Cinar V, Erdik B, Oyan B. Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction. Blood Coagul Fibrinolysis. (2013) 24(1):90&#x2013;4. 10.1097/MBC.0b013e3283597605</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MBC.0b013e3283597605</ArticleId><ArticleId IdType="pubmed">23249567</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco TH, Khan A, Joshi V, Thomas B. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag. (2008) 4(6):1367&#x2013;70. 10.2147/tcrm.s3960</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/tcrm.s3960</ArticleId><ArticleId IdType="pmc">PMC2643117</ArticleId><ArticleId IdType="pubmed">19337443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. (2006) 33(5 Suppl 10):S1&#x2013;7. 10.1053/j.seminoncol.2006.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminoncol.2006.08.002</ArticleId><ArticleId IdType="pubmed">17145519</ArticleId></ArticleIdList></Reference><Reference><Citation>Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. (2007) 99(16):1232&#x2013;9. 10.1093/jnci/djm086</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djm086</ArticleId><ArticleId IdType="pubmed">17686822</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaveckait&#x117; S, &#x160;erpytis P, Pe&#x10d;i&#x16b;rait&#x117; D, Puronait&#x117; R, Valevi&#x10d;ien&#x117; N. Clinical features and three-year outcomes of takotsubo (stress) cardiomyopathy: observational data from one center. Hellenic J Cardiol. (2016) 57(6):428&#x2013;34. 10.1016/j.hjc.2016.11.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hjc.2016.11.016</ArticleId><ArticleId IdType="pubmed">28087310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International expert consensus document on takotsubo syndrome (part II): diagnostic workup, outcome, and management. Eur Heart J. (2018) 39(22):2047&#x2013;62. 10.1093/eurheartj/ehy077</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy077</ArticleId><ArticleId IdType="pmc">PMC5991205</ArticleId><ArticleId IdType="pubmed">29850820</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B&#xf6;hm M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. (2023) 44(37):3627&#x2013;39. 10.1093/eurheartj/ehad195</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad195</ArticleId><ArticleId IdType="pubmed">37622666</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina de Chazal H, Del Buono MG, Keyser-Marcus L, Ma L, Moeller FG, Berrocal D, et al. Stress cardiomyopathy diagnosis and treatment: jACC state-of-the-art review. J Am Coll Cardiol. (2018) 72(16):1955&#x2013;71. 10.1016/j.jacc.2018.07.072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.07.072</ArticleId><ArticleId IdType="pmc">PMC7058348</ArticleId><ArticleId IdType="pubmed">30309474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobue Y, Watanabe E, Ichikawa T, Koshikawa M, Yamamoto M, Harada M, et al. Physically triggered takotsubo cardiomyopathy has a higher in-hospital mortality rate. Int J Cardiol. (2017) 235:87&#x2013;93. 10.1016/j.ijcard.2017.02.090</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2017.02.090</ArticleId><ArticleId IdType="pubmed">28262347</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon AR, L&#xf3;pez-Fern&#xe1;ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). Eur Heart J. (2022) 43(41):4229&#x2013;361. 10.1093/eurheartj/ehac244</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac244</ArticleId><ArticleId IdType="pubmed">36017568</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Gil A, G&#xf3;mez-Ruiz &#xc1;J, Gil-Mart&#xed;nez J, Gil-G&#xf3;mez E, Falc&#xf3;n-Ara&#xf1;a L, Cascales-Campos PA. Tako-tsubo syndrome after intraperitoneal hyperthermic chemotherapy (HIPEC) with cisplatin: an unusual complication of cytoreductive surgery plus HIPEC. Clin Exp Metastasis. (2020) 37(3):445&#x2013;6. 10.1007/s10585-020-10034-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10585-020-10034-2</ArticleId><ArticleId IdType="pubmed">32372116</ArticleId></ArticleIdList></Reference><Reference><Citation>Coaguila-Cusicanqui L, Castillo-Atoche V, Montalvo-Suyon R, Cavero-Reyes Y, Failoc-Rojas VE. Case report: takotsubo syndrome in a postoperative patient without cardiological disease. F1000Res. (2022) 11:616. 10.12688/f1000research.122298.2</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.122298.2</ArticleId><ArticleId IdType="pmc">PMC11470228</ArticleId><ArticleId IdType="pubmed">39399786</ArticleId></ArticleIdList></Reference><Reference><Citation>Alta&#x15f; Y, Abdullayeva &#xdc;. case of takotsubo cardiomyopathy after surgical treatment of liver hydatid cyst: a case report. World J Clin Cases. (2023) 11(29):7187&#x2013;92. 10.12998/wjcc.v11.i29.7187</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v11.i29.7187</ArticleId><ArticleId IdType="pmc">PMC10631423</ArticleId><ArticleId IdType="pubmed">37946773</ArticleId></ArticleIdList></Reference><Reference><Citation>Badwan OZ, Abu-Shawer O, Paul A, Faulx M, Barzilai B. Postoperative apical ballooning syndrome following orthotopic liver transplantation. Cureus. (2023) 15:e34450. 10.7759/cureus.34450</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.34450</ArticleId><ArticleId IdType="pmc">PMC9980426</ArticleId><ArticleId IdType="pubmed">36874749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishev D, Noureldine H, Ortiz F. Reverse takotsubo cardiomyopathy in the setting of small bowel obstruction: a case report. Annals of Medicine and Surgery (Lond). (2024) 86(9):5557&#x2013;60. 10.1097/MS9.0000000000002368</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MS9.0000000000002368</ArticleId><ArticleId IdType="pmc">PMC11374296</ArticleId><ArticleId IdType="pubmed">39239061</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazhev Z, Stoev H. Takotsubo cardiomyopathy after elective aortic and mitral valve replacement. Folia Medic. (2020) 62:204&#x2013;7. 10.3897/folmed.62.e47723</Citation><ArticleIdList><ArticleId IdType="doi">10.3897/folmed.62.e47723</ArticleId><ArticleId IdType="pubmed">32337907</ArticleId></ArticleIdList></Reference><Reference><Citation>Soundarrajan D, Singh R, Subramaniam M, Dhanasekararaja P, Rajkumar N, Rajasekaran S. Takotsubo syndrome after bilateral simultaneous total knee arthroplasty - A case report. J Orthop. (2024) 54:1&#x2013;4. 10.1016/j.jor.2024.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jor.2024.03.006</ArticleId><ArticleId IdType="pmc">PMC10943950</ArticleId><ArticleId IdType="pubmed">38496261</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez-Arag&#xf3;n S, Del Pino-Camposeco J, Villanueva-Castro E, Canela-Calderon O, Arriada-Mendicoa JN, Ponce-G&#xf3;mez JA. A postoperative complication of takotsubo syndrome in the spinal surgery: a case report. Cureus. (2023) 15(12):e51034. 10.7759/cureus.51034</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.51034</ArticleId><ArticleId IdType="pmc">PMC10805121</ArticleId><ArticleId IdType="pubmed">38264385</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva M, Carrillo-Alfonso N, Amorim P. Cardiac arrest during spinal surgery: a multidisciplinary approach and management of takotsubo syndrome. Cureus. (2022) 14(12):e32404. 10.7759/cureus.32404</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.32404</ArticleId><ArticleId IdType="pmc">PMC9831275</ArticleId><ArticleId IdType="pubmed">36636538</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40848024</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1942-5546</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Mayo Clinic proceedings</Title><ISOAbbreviation>Mayo Clin Proc</ISOAbbreviation></Journal><ArticleTitle>Association of Pathogenic/Likely Pathogenic Inherited Cardiomyopathy Variants With Heart Failure: A TOPMed Multiancestry Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0025-6196(25)00095-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mayocp.2025.01.021</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the prevalence of pathogenic/likely pathogenic inherited cardiomyopathy variants and their association with heart failure in the (TOPMed) TransOmic for Precision of Medicine cohorts.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cohort study using the TOPMed cohorts, including multi-ancestry US adults (&#x2265;18 years of age) with sequencing data, was conducted. Pathogenic/likely pathogenic inherited cardiomyopathy variant carrier status was determined based on ClinVar variants classified with two or more stars of evidence. Individuals without pathogenic/likely pathogenic variants were used as the reference group. The primary outcome was heart failure , adjudicated by an expert panel. Cox proportional hazards models assessed the association between carrier status and heart failure risk, adjusting for sex, study cohort, coronary artery disease, and genetic ancestry. Age was used as the timescale to account for the effect of variants since birth, and interval censoring was used to handle the uncertainty in the timing of heart failure events.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 30,977 individuals (median age, 61.0 years; 71.3% female; 37.0% non-European ancestry), 229 (0.7%) were identified as pathogenic/likely pathogenic inherited cardiomyopathy variant carriers. There were 3,298 events of heart failure (35 in carriers and 3,263 in non-carriers). The heart failure incidence rate was higher in variant carriers (2.06 per 1000 person-years) compared with noncarriers (1.40 per 1000 person-years), with an adjusted hazard ratio of 1.68 (95% CI, 1.29-2.22).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Approximately 1 in 140 US adults carry a cardiomyopathy variant, which increases heart failure risk. Targeted genetic screening may facilitate early identification and preventive interventions to reduce heart failure risk in carriers.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shetty</LastName><ForeName>Naman S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaonkar</LastName><ForeName>Mokshad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pampana</LastName><ForeName>Akhil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Nirav</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>April P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haring</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Saarland University Hospital, Homburg, Saarland, Germany; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Psaty</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Cardiovascular Health Research Unit, Department of Medicine, Department of Epidemiology, Department of Health Systems and Population Health, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kooperberg</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boerwinkle</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Human Genetics Center, University of Texas Health Science Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotter</LastName><ForeName>Jerome I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Jo&#xe3;o A C</ForeName><Initials>JAC</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kizer</LastName><ForeName>Jorge R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Cardiology Section, San Francisco Veterans Affairs Health Care System, and Departments of Medicine, Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Lisa Warsinger</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Kent D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornage</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Sanjiv J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine and Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rich</LastName><ForeName>Stephen S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Center for Public Health, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasan</LastName><ForeName>Ramachandran S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>University of Texas School of Public Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nassir</LastName><ForeName>Rami</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Umm Al-Qura'a University, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Nursing, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Garima</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA; Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA. Electronic address: parora@uabmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mayo Clin Proc</MedlineTA><NlmUniqueID>0405543</NlmUniqueID><ISSNLinking>0025-6196</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>10</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40848024</ArticleId><ArticleId IdType="doi">10.1016/j.mayocp.2025.01.021</ArticleId><ArticleId IdType="pii">S0025-6196(25)00095-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40821084</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1943-8141</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>American journal of translational research</Title><ISOAbbreviation>Am J Transl Res</ISOAbbreviation></Journal><ArticleTitle>Plasma SFRP2 hypermethylation as a diagnostic biomarker for dilated cardiomyopathy detected by methylation-specific PCR.</ArticleTitle><Pagination><StartPage>5423</StartPage><EndPage>5432</EndPage><MedlinePgn>5423-5432</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.62347/OZQW6493</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the clinical utility of plasma Secreted Frizzled-Related Protein 2 (SFRP2) gene hypermethylation as a non-invasive epigenetic biomarker for diagnosing Dilated cardiomyopathy (DCM) and stratifying cardiac function.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cohort of 482 participants (241 DCM patients and 241 healthy controls) was analyzed. DCM patients were further stratified by New York Heart Association (NYHA) class into better cardiac function (BCF; NYHA I-II) and poor cardiac function (PCF; NYHA III-IV) groups. Methylation-specific polymerase chain reaction (MSP) was used to assess SFRP2 methylation levels. Statistical analyses evaluated its diagnostic value, including receiver operating characteristic (ROC) curve analysis to determine sensitivity and specificity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Plasma SFRP2 methylation levels were significantly higher in DCM patients than in controls (P &lt; 0.001). ROC analysis revealed an area under the curve (AUC) of 0.942, indicating excellent diagnostic performance. Among DCM patients, the PCF group exhibited significantly higher SFRP2 methylation levels compared to the BCF group (P &lt; 0.001). Additionally, SFRP2 methylation showed a strong positive correlation with worsening cardiac function (r = 0.786, P &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Elevated plasma SFRP2 methylation levels in DCM patients, particularly those with poor cardiac function, demonstrate its high diagnostic accuracy and potential to reflect disease severity, supporting its use as a non-invasive clinical biomarker for DCM diagnosis and risk stratification.</AbstractText><CopyrightInformation>AJTR Copyright &#xa9; 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Zengyao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Internal Medicine-Cardiovascular Department, Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People's Hospital Jiujiang 332000, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Internal Medicine-Cardiovascular Department, The First Hospital of Nanchang Nanchang 330000, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Zeqi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Internal Medicine-Cardiovascular Department, The First Affiliated Hospital of Nanchang University Nanchang 330000, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Hanying</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Rheumatology Immunology Department, Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People's Hospital Jiujiang 332000, Jiangxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Transl Res</MedlineTA><NlmUniqueID>101493030</NlmUniqueID><ISSNLinking>1943-8141</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dilated cardiomyopathy</Keyword><Keyword MajorTopicYN="N">SFRP2 methylation</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">cardiac function</Keyword><Keyword MajorTopicYN="N">diagnostic value</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40821084</ArticleId><ArticleId IdType="pmc">PMC12351580</ArticleId><ArticleId IdType="doi">10.62347/OZQW6493</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Orphanou N, Papatheodorou E, Anastasakis A. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments. Heart Fail Rev. 2022;27:1173&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279384</ArticleId><ArticleId IdType="pubmed">34263412</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymans S, Lakdawala NK, Tsch&#xf6;pe C, Klingel K. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches. Lancet. 2023;402:998&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">37716772</ArticleId></ArticleIdList></Reference><Reference><Citation>Faggiano A, Avallone C, Gentile D, Provenzale G, Toriello F, Merlo M, Sinagra G, Carugo S. Echocardiographic advances in dilated cardiomyopathy. J Clin Med. 2021;10:5518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8658091</ArticleId><ArticleId IdType="pubmed">34884220</ArticleId></ArticleIdList></Reference><Reference><Citation>Asselbergs FW, Sammani A, Elliott P, Gimeno JR, Tavazzi L, Tendera M, Kaski JP, Maggioni AP, Rubis PP, Jurcut R, Heli&#xf6; T, Cal&#xf2; L, Sinagra G, Zdravkovic M, Olivotto I, Kavoli&#x16b;nien&#x117; A, Laroche C, Caforio ALP, Charron P Cardiomyopathy &amp; Myocarditis Registry Investigators Group. Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy &amp; Myocarditis registry. ESC Heart Fail. 2021;8:95&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7835585</ArticleId><ArticleId IdType="pubmed">33179448</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T, Okada H, Kanamori H, Miyazaki N, Tsujimoto A, Takada C, Suzuki K, Naruse G, Yoshida A, Nawa T, Tanaka T, Kawasaki M, Ito H, Ogura S, Okura H, Fujiwara T, Fujiwara H, Takemura G. In situ nuclear DNA methylation in dilated cardiomyopathy: an endomyocardial biopsy study. ESC Heart Fail. 2020;7:493&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160509</ArticleId><ArticleId IdType="pubmed">31971668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada K, Misaka T, Yokokawa T, Kimishima Y, Kaneshiro T, Oikawa M, Yoshihisa A, Takeishi Y. Blood-based epigenetic markers of FKBP5 gene methylation in patients with dilated cardiomyopathy. J Am Heart Assoc. 2021;10:e021101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8751844</ArticleId><ArticleId IdType="pubmed">34713710</ArticleId></ArticleIdList></Reference><Reference><Citation>Morival JLP, Widyastuti HP, Nguyen CHH, Zaragoza MV, Downing TL. DNA methylation analysis reveals epimutation hotspots in patients with dilated cardiomyopathy-associated laminopathies. Clin Epigenetics. 2021;13:139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8272901</ArticleId><ArticleId IdType="pubmed">34246298</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Liu X, Zheng H, Zhu H, Mai W, Huang X, Huang Y. Multiple roles of sFRP2 in cardiac development and cardiovascular disease. Int J Biol Sci. 2020;16:730&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7019133</ArticleId><ArticleId IdType="pubmed">32071544</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S, Wei J, Chen P, Chen F, Yang G. Sclerostin aggravates cardiac remodeling after myocardial infarction by inhibition of Wnt/&#x3b2;-catenin signaling pathway. J Thorac Dis. 2022;14:1563&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9186236</ArticleId><ArticleId IdType="pubmed">35693595</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Wu H, Qian H, Li D, Xu H, Chen J, Zhong J, Wu W, Yang H, Chen X, Min X, Chen J. Linggui Zhugan decoction delays ventricular remodeling in rats with chronic heart failure after myocardial infarction through the Wnt/&#x3b2;-catenin signaling pathway. Phytomedicine. 2023;120:155026.</Citation><ArticleIdList><ArticleId IdType="pubmed">37619320</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao M, Wang H, Li W, Jiang X, Wang X, Guo W, Gao P, Zou Y. Inverse associations between circulating Secreted Frizzled Related Protein 2 (sFRP2) and cardiometabolic risk factors. Front Cardiovasc Med. 2021;8:723205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8551478</ArticleId><ArticleId IdType="pubmed">34722660</ArticleId></ArticleIdList></Reference><Reference><Citation>Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016;67:2996&#x2013;3010.</Citation><ArticleIdList><ArticleId IdType="pubmed">27339497</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss HP, Fairweather D, Caforio ALP, Escher F, Hershberger RE, Lipshultz SE, Liu PP, Matsumori A, Mazzanti A, McMurray J, Priori SG. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019;5:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096917</ArticleId><ArticleId IdType="pubmed">31073128</ArticleId></ArticleIdList></Reference><Reference><Citation>Molfino A, Ambrosani F, Udali S, Imbimbo G, Moruzzi S, Castagna A, Pattini P, Tambaro F, Ramaccini C, Muscaritoli M, Friso S. DNA methylation signatures characterize gene expression modulation in lung cancer patients affected by anorexia. Nutrients. 2024;16:3721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11547925</ArticleId><ArticleId IdType="pubmed">39519555</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X, Lai KS, She P, Kang J, Wang T, Li G, Zhou Y, Sun J, Jin D, Xu X, Liao L, Liu J, Lee E, Poss KD, Zhong TP. Induction of Wnt signaling antagonists and p21-activated kinase enhances cardiomyocyte proliferation during zebrafish heart regeneration. J Mol Cell Biol. 2021;13:41&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8035995</ArticleId><ArticleId IdType="pubmed">33582796</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan K, Yu B, Kiwan C, Shalal Y, Filimon S, Cipro M, Shum-Tim D, Cecere R, Schwertani A. The role of Wnt/&#x3b2;-catenin pathway mediators in aortic valve stenosis. Front Cell Dev Biol. 2020;8:862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7513845</ArticleId><ArticleId IdType="pubmed">33015048</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Han X, Yu T, Wang M, Luo W, Zou C, Li X, Li G, Wu G, Wang Y, Liang G. OTUD1 promotes pathological cardiac remodeling and heart failure by targeting STAT3 in cardiomyocytes. Theranostics. 2023;13:2263&#x2013;2280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10157730</ArticleId><ArticleId IdType="pubmed">37153745</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Li H, Hastings MH, Xiao C, Damilano F, Platt C, Lerchenm&#xfc;ller C, Zhu H, Wei XP, Yeri A, Most P, Rosenzweig A. miR-222 inhibits pathological cardiac hypertrophy and heart failure. Cardiovasc Res. 2024;120:262&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10939454</ArticleId><ArticleId IdType="pubmed">38084908</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguado-Alvaro LP, Garitano N, Pelacho B. Fibroblast diversity and epigenetic regulation in cardiac fibrosis. Int J Mol Sci. 2024;25:6004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11172550</ArticleId><ArticleId IdType="pubmed">38892192</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Elkenani M, Tan X, Hain JK, Cui B, Schnelle M, Hasenfuss G, Toischer K, Mohamed BA. DNA methylation analysis identifies novel epigenetic loci in dilated murine heart upon exposure to volume overload. Int J Mol Sci. 2023;24:5885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10059258</ArticleId><ArticleId IdType="pubmed">36982963</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Tan Y, Zhang Y, Zhang S, Duan X, Jiang Y, Li T, Zhou Q, Liu X, Zhan Z. Loss of KDM5B ameliorates pathological cardiac fibrosis and dysfunction by epigenetically enhancing ATF3 expression. Exp Mol Med. 2022;54:2175&#x2013;2187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9794816</ArticleId><ArticleId IdType="pubmed">36481938</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J, Guo N, Tong J, Wang Z. Function of histone methylation and acetylation modifiers in cardiac hypertrophy. J Mol Cell Cardiol. 2021;159:120&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">34175302</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Chen K, Yao Y, Lin Y, Yang J, Zhu Y, Zhou B. TGF&#x3b2;1-induced fibrotic responses of conjunctival fibroblasts through the Wnt/&#x3b2;-Catenin/CRYAB signaling pathway. Am J Pathol. 2024;194:1764&#x2013;1779.</Citation><ArticleIdList><ArticleId IdType="pubmed">38879081</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu HH, Cao G, Wu XQ, Vaziri ND, Zhao YY. Wnt signaling pathway in aging-related tissue fibrosis and therapies. Ageing Res Rev. 2020;60:101063.</Citation><ArticleIdList><ArticleId IdType="pubmed">32272170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gay D, Ghinatti G, Guerrero-Juarez CF, Ferrer RA, Ferri F, Lim CH, Murakami S, Gault N, Barroca V, Rombeau I, Mauffrey P, Irbah L, Treffeisen E, Franz S, Boissonnas A, Combadi&#xe8;re C, Ito M, Plikus MV, Romeo PH. Phagocytosis of Wnt inhibitor SFRP4 by late wound macrophages drives chronic Wnt activity for fibrotic skin healing. Sci Adv. 2020;6:eaay3704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083618</ArticleId><ArticleId IdType="pubmed">32219160</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Duan XL, Qi XL, Meng L, Xu YS, Wu T, Dai PG. Concurrent hypermethylation of SFRP2 and DKK2 Activates the Wnt/&#x3b2;-Catenin pathway and is associated with poor prognosis in patients with gastric cancer. Mol Cells. 2017;40:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5303888</ArticleId><ArticleId IdType="pubmed">28152305</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Zhang Y, Sethi I, Ye L, Trembley MA, Cao Y, Akerberg BN, Xiao F, Zhang X, Li K, Jardin BD, Mazumdar N, Ma Q, He A, Zhou B, Pu WT. GATA4 regulates developing endocardium through interaction with ETS1. Circ Res. 2022;131:e152&#x2013;e168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9669226</ArticleId><ArticleId IdType="pubmed">36263775</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler M, Staniczek T, K&#xfc;rschner SW, Schmid CD, Sch&#xf6;nhaber H, Cordero J, Kessler L, Mathes A, Sticht C, Ne&#xdf;ling M, Uvarovskii A, Anders S, Zhang XJ, von Figura G, Hartmann D, Mogler C, Dobreva G, Schledzewski K, G&#xe9;raud C, Koch PS, Goerdt S. Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling. J Hepatol. 2021;74:380&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">32916216</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Packard EA, Levin MG, Judy RL, Damrauer SM, Day SM, Ritchie MD, Rader DJ Regeneron Genetics Center. A genome-first approach to rare variants in hypertrophic cardiomyopathy genes MYBPC3 and MYH7 in a medical biobank. Hum Mol Genet. 2022;31:827&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8895730</ArticleId><ArticleId IdType="pubmed">34542152</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Peng L, Zhao C. MYH7 in cardiomyopathy and skeletal muscle myopathy. Mol Cell Biochem. 2024;479:393&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">37079208</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YL, Bai J, Yu WJ, Lin QY, Li HH. CD11b mediates hypertensive cardiac remodeling by regulating macrophage infiltration and polarization. J Adv Res. 2024;55:17&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10770112</ArticleId><ArticleId IdType="pubmed">36822392</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavrogeni S, Piaditis G, Bacopoulou F, Chrousos GP. Cardiac remodeling in hypertension: clinical impact on brain, heart, and kidney function. Horm Metab Res. 2022;54:273&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">35352334</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo G, Savoia C. Hypertension and heart failure: from pathophysiology to treatment. Int J Mol Sci. 2024;25:6661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11203528</ArticleId><ArticleId IdType="pubmed">38928371</ArticleId></ArticleIdList></Reference><Reference><Citation>Han C, Zhou MY, Wu JF, Wang B, Ma H, Hu R, Zuo L, Li J, Li XJ, Ta SJ, Fan LN, Liu LW. Myocardial biopsy of Liwen procedure: representability and etiological diagnostic value of cardiac samples obtained by a novel technique in patients with hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi. 2022;50:361&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">35399032</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40845960</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0712</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>European journal of pharmacology</Title><ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Cross-regulation of methylation and oxidative stress: molecular mechanisms and intervention strategies of diabetes cardiomyopathy.</ArticleTitle><Pagination><StartPage>178080</StartPage><MedlinePgn>178080</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejphar.2025.178080</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0014-2999(25)00834-9</ELocationID><Abstract><AbstractText>Diabetic cardiomyopathy (DCM)-a myocardial pathology that is both singular and independent of coronary artery disease and hypertension-constitutes an intrinsically specific cardiac alteration in individuals with diabetes mellitus, whose labyrinthine pathogenesis portends profound compromise of ventricular performance and existential quality of life. In recent years, studies have found that DNA methylation and oxidative stress are closely related to the occurrence and development of diabetic cardiomyopathy. DNA methylation participates in the oxidative damage, metabolic abnormalities, and apoptosis of myocardial cells by regulating the expression of key antioxidant enzymes, inflammatory factors, and mitochondrial function-related genes. Oxidative stress can alter the methylation profile of myocardial cells and exacerbate pathological conditions by activating mechanisms such as DNA methyltransferase. The interaction between the two constitutes an important molecular regulatory axis in diabetes cardiomyopathy. Centering on the intersecting mechanisms of DNA methylation and oxidative stress in diabetic cardiomyopathy, this review dissects their concerted roles in suppressing antioxidant enzyme expression, derailing mitochondrial function, igniting inflammatory cascades, and precipitating cardiomyocyte apoptosis, while systematically enumerating current intervention strategies targeting these pathways-spanning natural products, epigenetic modulators, and antioxidant therapies-with the overarching objective of furnishing both theoretical scaffolding and translational reference for mechanistic inquiry and precision therapeutics in diabetic cardiomyopathy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Ya-Qi</ForeName><Initials>YQ</Initials><AffiliationInfo><Affiliation>College of Pharmacy, North Henan Medical University, Xinxiang, 453003, China. Electronic address: 20242082@sqmc.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jia-Yin</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Pan-Pan</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>College of Pharmacy, North Henan Medical University, Xinxiang, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Chen-Xi</ForeName><Initials>CX</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Tian-Lu</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qi-Rui</ForeName><Initials>QR</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Zheng-Wei</ForeName><Initials>ZW</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dan-Jie</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xi</LastName><ForeName>Yu-Ting</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Qian-Qian</ForeName><Initials>QQ</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China. Electronic address: niuqianqian1995@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China. Electronic address: pengli@xxmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharmacol</MedlineTA><NlmUniqueID>1254354</NlmUniqueID><ISSNLinking>0014-2999</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetic Cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Methylation</Keyword><Keyword MajorTopicYN="N">Oxidative Stress</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40845960</ArticleId><ArticleId IdType="doi">10.1016/j.ejphar.2025.178080</ArticleId><ArticleId IdType="pii">S0014-2999(25)00834-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40830971</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Targeting ATF4-DDIT4/TXNIP induced mitochondrial dysfunction and ferroptosis: ISRIB as novel therapy for septic cardiomyopathy.</ArticleTitle><Pagination><StartPage>938</StartPage><MedlinePgn>938</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">938</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-025-06939-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Sepsis-induced cardiomyopathy (SIC) is a reversible lesion in the early clinical stage, but often induces a high mortality rate in the late stage, and its specific mechanism is unknown. Thus, in-depth exploration of the biological progression mechanism of SIC plays a crucial role.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Through co-immunoprecipitation and molecular biological experiments, the functional interaction relationship between DDIT4 and TXNIP was clarified, and the effect of DDIT4/TXNIP on the progression of SIC was investigated both in vitro/vivo. Additionally, the mechanism of SIC cell death mediated by DDIT4/TXNIP was determined through PCR chip technology, Western blot, immunofluorescence, flow cytometry and in-vivo SIC model experiments. Finally, leveraging the upstream transcription factor ATF4 as a target for the DDIT4/TXNIP pathway, a novel application and translational study of its small-molecule inhibitor ISRIB in SIC was developed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Firstly, in-vitro/vivo experiments demonstrated that DDIT4 exacerbates inflammatory infiltration and cardiac dysfunction in SIC via the TXNIP pathway. Mechanistically, the DDIT4/TXNIP axis promotes SIC progression through ferroptosis mechanisms. Furthermore, our study identified ATF4, an upstream transcription factor of DDIT4/TXNIP, as a key regulatory switch for this biological mechanism. Finally, this study confirmed that ISRIB, a small-molecule inhibitor of ATF4, significantly suppresses inflammation and ferroptosis mediated by DDIT4/TXNIP, thereby markedly improving cardiac function and prognosis in SIC mice.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study revealed that the DDIT4/TXNIP-mediated ferroptosis mechanism exacerbates the inflammatory release and cardiac function decline in SIC. It also clarified that this biological effect is regulated by ATF4. Moreover, it was proposed that the inhibitor ISRIB, which targets ATF4, can significantly attenuate ferroptosis in SIC, while concurrently protecting cardiac function. This finding provides a brand-new therapeutic target and intervention agent for the clinical treatment of SIC.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yiting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Xueping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology and Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zeyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinrun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guotao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wenye</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China. Zln7095@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China. Zln7095@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Provincial Clinical Research Center for Critical Care Medicine, Changsha, 410008, China. Zln7095@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Zhaoxin</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-2368-7840</Identifier><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China. xyqzx@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China. xyqzx@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Provincial Clinical Research Center for Critical Care Medicine, Changsha, 410008, China. xyqzx@csu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>62072471</GrantID><Agency>the National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>1053320231784</GrantID><Agency>Fundamental Research Funds for Central Universities of the Central South University</Agency><Country/></Grant><Grant><GrantID>2023RC1030</GrantID><Agency>Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>145891-90-3</RegistryNumber><NameOfSubstance UI="D051701">Activating Transcription Factor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C081452">Atf4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497109">ATF4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C469991">DDIT4 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051701" MajorTopicYN="Y">Activating Transcription Factor 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="Y">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="Y">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="Y">Carrier Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATF4</Keyword><Keyword MajorTopicYN="N">DDIT4</Keyword><Keyword MajorTopicYN="N">Ferroptosis</Keyword><Keyword MajorTopicYN="N">ISRIB</Keyword><Keyword MajorTopicYN="N">Sepsis-induced cardiomyopathy</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: All animal experiments were approved by the Animal Ethics Committee of Xiangya Hospital, Central South University (No.2024030222). Competing interests: The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>0</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40830971</ArticleId><ArticleId IdType="pmc">PMC12366375</ArticleId><ArticleId IdType="doi">10.1186/s12967-025-06939-9</ArticleId><ArticleId IdType="pii">10.1186/s12967-025-06939-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sasaki K, Gotoh K, Miake S, Setoyama D, Yagi M, Igami K, Uchiumi T, Kang D. P32 is required for appropriate interleukin-6 production upon lps stimulation and protects mice from endotoxin shock. EBioMedicine. 2017;20:161&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5478242</ArticleId><ArticleId IdType="pubmed">28549777</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19952319</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus DC, Pereira CAP, Silva E. Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets. 2006;6:207&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">16787296</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care. 2009;15:392&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19633546</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med. 2001;29:S109&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445744</ArticleId></ArticleIdList></Reference><Reference><Citation>Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, Lemke JH. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;180:1584&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10515819</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, Suzuki Y, Okuda J, Kurazumi T, Suhara T, Ueda T, Nagata H, Morisaki H. Sepsis-induced cardiac dysfunction and beta-adrenergic blockade therapy for sepsis. J Intensive Care. 2017;5:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5335779</ArticleId><ArticleId IdType="pubmed">28270914</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. 2021;18:424&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">33473203</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian G, Huang R, Hu D, Xu M, Chen Y, Ren H, Xu D, Zeng Q. Interleukin-37 attenuates aortic valve lesions by inhibiting m6a-mediated irak-m degradation. Cardiovasc Res. 2025. 10.1093/cvr/cvaf012.</Citation><ArticleIdList><ArticleId IdType="pubmed">39913240</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhidkova EM, Lylova ES, Grigoreva DD, Kirsanov KI, Osipova AV, Kulikov EP, Mertsalov SA, Belitsky GA, Budunova I, Yakubovskaya MG, Lesovaya EA. Nutritional sensor redd1 in cancer and inflammation: friend or foe? Int J Mol Sci. 2022. 10.3390/ijms23179686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9456073</ArticleId><ArticleId IdType="pubmed">36077083</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadon AM, Perez MJ, Hernandez-Saavedra D, Smith LP, Yang Y, Sanders LA, Gandjeva A, Chabon J, Koyanagi DE, Graham BB, Tuder RM, Schmidt EP. Rtp801 suppression of epithelial mtorc1 augments endotoxin-induced lung inflammation. Am J Pathol. 2014;184:2382&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188171</ArticleId><ArticleId IdType="pubmed">25016184</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y, Liu Q, Wu Z, Zhong W, Lin Z, Luo W. Txnip inhibits the progression of osteosarcoma through ddit4-mediated mtorc1 suppression. Am J Cancer Res. 2022;12:3760&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9442022</ArticleId><ArticleId IdType="pubmed">36119812</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Ding W, Yin Z, Liu S, Zhao M, Xu Y, Liu J, Pan W, Peng S, Wei C, Zheng Z, Qin J, Wan J, Wang M. Interleukin-12p40 deficiency attenuates myocardial ferroptosis in doxorubicin-induced chronic cardiomyopathy by inhibiting Th17 differentiation and interleukin-17a production. Cardiovasc Res. 2024;120:2117&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">39298642</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang WS, Sriramaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR. Regulation of ferroptotic cancer cell death by gpx4. Cell. 2014;156:317&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076414</ArticleId><ArticleId IdType="pubmed">24439385</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng H, Yuan J, Wang Z, Mo B, Wang Y, Wang Y, Wang Q. Nr4a3 prevents diabetes induced atrial cardiomyopathy by maintaining mitochondrial energy metabolism and reducing oxidative stress. EBioMedicine. 2024;106: 105268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11334830</ArticleId><ArticleId IdType="pubmed">39098108</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K, Velagapudi S, Akhmedov A, Kraler S, Lapikova-Bryhinska T, Schmiady MO, Wu X, Geng L, Camici GG, Xu A, Luscher TF. Chronic Sirt1 supplementation in diabetic mice improves endothelial function by suppressing oxidative stress. Cardiovasc Res. 2023;119:2190&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10578911</ArticleId><ArticleId IdType="pubmed">37401647</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM, Boniface JJ, Smith R, Lessnick SL, Sahasrabudhe S, Stockwell BR. Ras-raf-mek-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047570</ArticleId><ArticleId IdType="pubmed">17568748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou K, Shen J, Yan J, Zhai C, Zhang J, Pan J, Zhang Y, Jiang Y, Wang Y, Lin RZ, Cong H, Gao S, Zong W. Loss of trim21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin. EBioMedicine. 2021;69: 103456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261003</ArticleId><ArticleId IdType="pubmed">34233258</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med. 1999;106:37S-42S.</Citation><ArticleIdList><ArticleId IdType="pubmed">10390126</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Yao X, Zhang Q, Zhu M, Liu Z, Ci B, Xie Y, Carlson D, Rothermel BA, Sun Y, Levine B, Hill JA, Wolf SE, Minei JP, Zang QS. Beclin-1-dependent autophagy protects the heart during sepsis. Circulation. 2018;138:2247&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6274625</ArticleId><ArticleId IdType="pubmed">29853517</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang Y, Yang D, Yu X, Li H, Lv X, Lu D, Wang H. Beta(1)-adrenoceptor stimulation promotes lps-induced cardiomyocyte apoptosis through activating pka and enhancing camkii and ikappabalpha phosphorylation. Crit Care. 2015;19:76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383083</ArticleId><ArticleId IdType="pubmed">25887954</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Zhou H, Wu H, Wu Q, Duan M, Deng W, Tang Q. Sting-irf3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating nlrp3. Redox Biol. 2019;24: 101215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6529775</ArticleId><ArticleId IdType="pubmed">31121492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Xu J, Li P, Sun S, Kadier Y, Zhou S, Cheng A. Necroptosis and viral myocarditis: tumor necrosis factor alpha as a novel biomarker for the diagnosis of viral myocarditis. Front Cell Dev Biol. 2022;10: 826904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9114881</ArticleId><ArticleId IdType="pubmed">35602592</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Y, Cao G, Lin L, Zhang Y, Luo X, Ma X, Aiyisake A, Cheng Q. Resveratrol attenuates sepsis-induced cardiomyopathy in rats through anti-ferroptosis via the Sirt1/Nrf2 pathway. J Invest Surg. 2023;36: 2157521.</Citation><ArticleIdList><ArticleId IdType="pubmed">36576230</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000;6:1099&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">11106749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Deng J, Yu T, Chen S, Ge Y, Zhou Z, Guo Y, Ying H, Zhai Q, Chen Y, Yuan F, Niu Y, Shu W, Chen H, Ma C, Liu Z, Guo F. Atf4 deficiency promotes intestinal inflammation in mice by reducing uptake of glutamine and expression of antimicrobial peptides. Gastroenterology. 2019;156:1098&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">30452920</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Wen Z, Shao L, Cui Y, Tang X, Miao H, Shi J, Jiang L, Feng S, Zhao Y, Zhang H, Liang Q, Chen D, Zhang Y, Wang C. Atf4 knockdown in macrophage impairs glycolysis and mediates immune tolerance by targeting hk2 and hif-1alpha ubiquitination in sepsis. Clin Immunol. 2023;254:109698.</Citation><ArticleIdList><ArticleId IdType="pubmed">37481013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Ren C, Yao R, Luo Y, Yin Y, Wu Y, Dong N, Zhu X, Yao Y. Sestrin2 protects against lethal sepsis by suppressing the pyroptosis of dendritic cells. Cell Mol Life Sci. 2021;78:8209&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629895</ArticleId><ArticleId IdType="pubmed">34741186</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17:1374&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5048378</ArticleId><ArticleId IdType="pubmed">27629041</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa-Mattioli M, Walter P. The integrated stress response: from mechanism to disease. Science. 2020. 10.1126/science.aat5314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8997189</ArticleId><ArticleId IdType="pubmed">32327570</ArticleId></ArticleIdList></Reference><Reference><Citation>Krukowski K, Nolan A, Frias ES, Boone M, Ureta G, Grue K, Paladini M, Elizarraras E, Delgado L, Bernales S, Walter P, Rosi S. Small molecule cognitive enhancer reverses age-related memory decline in mice. Elife. 2020. 10.7554/eLife.62048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7721440</ArticleId><ArticleId IdType="pubmed">33258451</ArticleId></ArticleIdList></Reference><Reference><Citation>Onat UI, Yildirim AD, Tufanli O, Cimen I, Kocaturk B, Veli Z, Hamid SM, Shimada K, Chen S, Sin J, Shah PK, Gottlieb RA, Arditi M, Erbay E. Intercepting the lipid-induced integrated stress response reduces atherosclerosis. J Am Coll Cardiol. 2019;73:1149&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6424590</ArticleId><ArticleId IdType="pubmed">30871699</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Li Y, Wang C, Gao S, Zhao Y, Yang Z, Wang H, Gao Z, Jiang Y, He Y, Zhao L, Gao H, Yao X, Hu Y. Diterpenoid vinigrol specifically activates atf4/ddit3-mediated perk arm of unfolded protein response to drive non-apoptotic death of breast cancer cells. Pharmacol Res. 2022;182: 106285.</Citation><ArticleIdList><ArticleId IdType="pubmed">35662627</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehart DN, Fang D, Heslop K, Li L, Lemasters JJ, Maldonado EN. Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol. 2018;148:155&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909406</ArticleId><ArticleId IdType="pubmed">29289511</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeschke H, Ramachandran A. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annu Rev Pathol. 2024;19:453&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11131139</ArticleId><ArticleId IdType="pubmed">38265880</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacquemyn J, Ralhan I, Ioannou MS. Driving factors of neuronal ferroptosis. Trends Cell Biol. 2024;34:535&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">38395733</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen E, Fan J, Chen R, Yee S, Peng T. Phospholipase cgamma1 signalling regulates lipopolysaccharide-induced cyclooxygenase-2 expression in cardiomyocytes. J Mol Cell Cardiol. 2007;43:308&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">17655858</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier WJ, Xue J, Luce WA, Liu Y. Mapk signaling drives inflammation in lps-stimulated cardiomyocytes: the route of crosstalk to g-protein-coupled receptors. PLoS ONE. 2012;7: e50071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511453</ArticleId><ArticleId IdType="pubmed">23226236</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Wang W, Zhou H, Wu Q, Duan M, Liu C, Wu H, Deng W, Shen D, Tang Q. Ferritinophagy-mediated ferroptosis is involved in sepsis-induced cardiac injury. Free Radic Biol Med. 2020;160:303&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">32846217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Cao Z, Gui F, Zhang M, Wu X, Peng H, Yu B, Li W, Ai F, Zhang J. Tmem43 protects against sepsis-induced cardiac injury via inhibiting ferroptosis in mice. Cells. 2022. 10.3390/cells11192992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9564110</ArticleId><ArticleId IdType="pubmed">36230956</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Z, Kong B, Fang J, Qin T, Dai C, Shuai W, Huang H. Ferrostatin-1 alleviates lipopolysaccharide-induced cardiac dysfunction. Bioengineered. 2021;12:9367&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8809987</ArticleId><ArticleId IdType="pubmed">34787054</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, Mckeon F, Haber DA. Redd1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell. 2002;10:995&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">12453409</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirado-Hurtado I, Fajardo W, Pinto JA. DNA damage inducible transcript 4 gene: the switch of the metabolism as potential target in cancer. Front Oncol. 2018;8:106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5906527</ArticleId><ArticleId IdType="pubmed">29707520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D, Kim J, Kim J, Choi S, Park M, Park W, Kim S, Lee K, Kim T, Jung J, Choi YK, Ha K, Won M, Billiar TR, Kwon Y, Kim Y. Redd-1 aggravates endotoxin-induced inflammation via atypical NF-kappaB activation. FASEB J. 2018;32:4585&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">29547704</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Q, Liu J, Cao P, Li J, Liu X, Fan X, Liu L, Cheng Y, Xiong W, Li J, Bo H, Zhu Y, Yang F, Hu J, Zhou M, Zhou Y, Zou Q, Zhou J, Cao K. Inhibition of redd1 sensitizes bladder urothelial carcinoma to paclitaxel by inhibiting autophagy. Clin Cancer Res. 2018;24:445&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">29084921</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipina C, Hundal HS. Is redd1 a metabolic eminence grise? Trends Endocrinol Metab. 2016;27:868&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119498</ArticleId><ArticleId IdType="pubmed">27613400</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao S, Dennis M, Song X, Vadysirisack DD, Salunke D, Nash Z, Yang Z, Liesa M, Yoshioka J, Matsuzawa S, Shirihai OS, Lee RT, Reed JC, Ellisen LW. A redd1/txnip pro-oxidant complex regulates atg4b activity to control stress-induced autophagy and sustain exercise capacity. Nat Commun. 2015;6:7014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4421852</ArticleId><ArticleId IdType="pubmed">25916556</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Xue R, Wu D, Wu L, Chen C, Tan W, Chen Y, Dong Y. Redd1 attenuates cardiac hypertrophy via enhancing autophagy. Biochem Biophys Res Commun. 2014;454:215&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25450383</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K, Teoh J, Wang Y, Broskova Z, Bayoumi AS, Tang Y, Su H, Weintraub NL, Kim I. Carvedilol-responsive micrornas, mir-199a-3p and -214 protect cardiomyocytes from simulated ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2016;311:H371&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5005281</ArticleId><ArticleId IdType="pubmed">27288437</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C, Wang R, Li B, Guo Y, Yin T, Xia Y, Zhang F, Lian K, Liu Y, Wang H, Zhang L, Gao E, Yan W, Tao L. Txnip/redd1 signalling and excessive autophagy: a novel mechanism of myocardial ischaemia/reperfusion injury in mice. Cardiovasc Res. 2020;116:645&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">31241142</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez G, Lal H, Fidalgo M, Guerrero A, Zalvide J, Force T, Pombo CM. A novel cardioprotective p38-mapk/mtor pathway. Exp Cell Res. 2011;317:2938&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3215777</ArticleId><ArticleId IdType="pubmed">22001647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Wang B, Chen L, Cai D, Li B, Chen C, Huang E, Liu C, Lin Z, Xie W, Wang H. Dna damage-inducible transcript 4 (ddit4) mediates methamphetamine-induced autophagy and apoptosis through mtor signaling pathway in cardiomyocytes. Toxicol Appl Pharmacol. 2016;295:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">26825372</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Gou Y, Yu H, Ji T, Li Y, Qin L, Sun W. Mechanism of metformin on LPS-induced bacterial myocarditis. Dose Response. 2019;17: 711671055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537499</ArticleId><ArticleId IdType="pubmed">31205455</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P, Zhang L, Gao L, Ding Q, Yang Q, Kuai J. Ulinastatin attenuates lipopolysaccharide-induced cardiac dysfunction by inhibiting inflammation and regulating autophagy. Exp Ther Med. 2020;20:1064&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388552</ArticleId><ArticleId IdType="pubmed">32765659</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand AA, Walter P. Structural insights into ISRIB, a memory-enhancing inhibitor of the integrated stress response. FEBS J. 2020;287:239&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">31550413</ArticleId></ArticleIdList></Reference><Reference><Citation>Goswami P, Akhter J, Mangla A, Suramya S, Jindal G, Ahmad S, Raisuddin S. Downregulation of atf-4 attenuates the endoplasmic reticulum stress-mediated neuroinflammation and cognitive impairment in experimentally induced alzheimer&#x2019;s disease model. Mol Neurobiol. 2024;61:5071&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">38159199</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40833076</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-2818</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis</Title><ISOAbbreviation>Amyloid</ISOAbbreviation></Journal><ArticleTitle>Prognostic role of cardiopulmonary exercise testing in wild-type transthyretin amyloid cardiomyopathy patients treated with tafamidis.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>9</EndPage><MedlinePgn>1-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13506129.2025.2547381</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Tafamidis has demonstrated survival benefits in transthyretin amyloid cardiomyopathy (ATTR-CM), yet variability in therapeutic response underscores the need for reliable tools to predict outcomes. This study evaluates the prognostic utility of cardiopulmonary exercise testing (CPET) in this population.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This retrospective study included tafamidis treated wild-type (ATTRwt) CM patients who completed CPET. Univariable and multivariable Cox regression models were used to evaluate predictors of mortality and composite secondary endpoint (mortality and heart failure admissions).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Total of 105 ATTRwt-CM patients were enrolled with median age of 80&#x2009;years. During median follow-up of 2.1&#x2009;years, 33 (31%) died and 67 (63.8%) had composite outcome of mortality and heart failure hospitalisations. Multivariable analysis showed VE/VCO<sub>2</sub> slope (HR 1.61 per SD, 95% CI: 1.13-2.30, <i>p</i>&#x2009;=&#x2009;0.01), peak circulatory power [CP] (HR 0.43 per SD, 95% CI 0.21-0.89, <i>p</i>&#x2009;=&#x2009;0.02), Mayo stage 3 (HR 5.34, 95% CI: 1.07-26.7, <i>p</i>&#x2009;=&#x2009;0.04) were independent predictors of mortality. The VE/VCO<sub>2</sub> slope (HR 1.57 per SD, 95% CI 1.2, 2.05, p= &lt;0.01), creatinine (HR 1.37 per SD, 95% CI 1.07, 1.76, <i>p</i>&#x2009;=&#x2009;0.01) and Mayo stage 3 (HR 2.49, 95% CI 1.10, 5.66, <i>p</i>&#x2009;=&#x2009;0.03) were independent predictors of composite outcome.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">CPET provides prognostic insights for ATTRwt-CM patients in addition to known prognostic laboratory factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dalia</LastName><ForeName>Tarun</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Disease, University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Zafar</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byer</LastName><ForeName>Stefano H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holder</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daloub</LastName><ForeName>Shaden</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Disease, University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhotra</LastName><ForeName>Anureet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtz</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robl</LastName><ForeName>Tanner</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Zubair</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Disease, University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyloid</MedlineTA><NlmUniqueID>9433802</NlmUniqueID><ISSNLinking>1350-6129</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Wild-type transthyretin amyloid cardiomyopathy</Keyword><Keyword MajorTopicYN="N">cardio-pulmonary exercise testing</Keyword><Keyword MajorTopicYN="N">peak VO2, VE/VCO2 slope, and exercise duration</Keyword><Keyword MajorTopicYN="N">tafamidis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40833076</ArticleId><ArticleId IdType="doi">10.1080/13506129.2025.2547381</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40848038</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-7591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>JACC. Cardiovascular imaging</Title><ISOAbbreviation>JACC Cardiovasc Imaging</ISOAbbreviation></Journal><ArticleTitle>Left Atrial Reservoir Strain Predicts Atrial Fibrillation in Hypertrophic Cardiomyopathy: Insights from the NHLBI HCM Registry.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1936-878X(25)00403-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcmg.2025.07.008</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beyhoff</LastName><ForeName>Niklas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Agnel</LastName><ForeName>Owen P</ForeName><Initials>OP</Initials></Author><Author ValidYN="Y"><LastName>Fenski</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Botrous</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Yi Jie Gifford</ForeName><Initials>YJG</Initials></Author><Author ValidYN="Y"><LastName>Smillie</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Ashkir</LastName><ForeName>Zakariye</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Finnigan</LastName><ForeName>Lucy E M</ForeName><Initials>LEM</Initials></Author><Author ValidYN="Y"><LastName>Dolman</LastName><ForeName>Sarahfaye F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Kolm</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>William S</ForeName><Initials>WS</Initials></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Raymond Y</ForeName><Initials>RY</Initials></Author><Author ValidYN="Y"><LastName>Jerosch-Herold</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Milind Y</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Carolyn Y</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Desvigne-Nickens</LastName><ForeName>Patrice</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>DiMarco</LastName><ForeName>John P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Casadei</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>Hugh C</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Neubauer</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><CollectiveName>HCMR Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Cardiovasc Imaging</MedlineTA><NlmUniqueID>101467978</NlmUniqueID><ISSNLinking>1876-7591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>10</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40848038</ArticleId><ArticleId IdType="doi">10.1016/j.jcmg.2025.07.008</ArticleId><ArticleId IdType="pii">S1936-878X(25)00403-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40843543</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1813-9175</ISSN><JournalIssue CitedMedium="Internet"><Volume>2025</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Multimedia manual of cardiothoracic surgery : MMCTS</Title><ISOAbbreviation>Multimed Man Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Endoscopic treatment of hypertrophic obstructive cardiomyopathy performed via a transmitral approach through a right-sided mini-thoracotomy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1510/mmcts.2025.095</ELocationID><Abstract><AbstractText>The patient was positioned supine with the right chest slightly elevated. Following induction of general anaesthesia and intubation using an endotracheal tube, connection to the cardiopulmonary bypass was established via the groin vessels under the guidance of transoesophageal echocardiography. Additionally, a venous cannula was inserted through the right internal jugular vein to facilitate bicaval cannulation. The surgery was performed via a 5 cm right mini-thoracotomy at the fourth intercostal space. After soft tissue retraction and pericardial traction sutures, a 3D camera port (Aesculap EinsteinVision, Germany) and a Chitwood clamp for aortic cross-clamping were inserted through separate incisions. Antegrade cold blood cardioplegia was administered via a catheter in the ascending aorta. The surgery involved several steps. For the 1st step, transatrial approach to the mitral valve through Waterston's groove was used. After that transmitral approach to the interventricular septum and submitral structures of the left ventricle was performed. Next step was septal myectomy and secondary chordae resection to the mitral valve. Finally, the anterior mitral valve leaflet reattachment to the annulus was done.</AbstractText><CopyrightInformation>&#xa9; The Author 2025. Published by MMCTS on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paivin</LastName><ForeName>Artem</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Saint-Petersburg City Hospital 40 of Kurortny District, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denisyuk</LastName><ForeName>Dmitrii</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Saint-Petersburg City Hospital 40 of Kurortny District, Saint Petersburg, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paivin</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Saint-Petersburg City Hospital 40 of Kurortny District, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khvan</LastName><ForeName>Nikolai</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Saint-Petersburg City Hospital 40 of Kurortny District, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rashidov</LastName><ForeName>Abduvakhov</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Saint-Petersburg City Hospital 40 of Kurortny District, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shomrodov</LastName><ForeName>Nusratullo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Saint-Petersburg City Hospital 40 of Kurortny District, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sichinava</LastName><ForeName>Lana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Saint-Petersburg City Hospital 40 of Kurortny District, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denisyuk</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Saint-Petersburg City Hospital 40 of Kurortny District, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Multimed Man Cardiothorac Surg</MedlineTA><NlmUniqueID>101495626</NlmUniqueID><ISSNLinking>1813-9175</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013908" MajorTopicYN="Y">Thoracotomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002312" MajorTopicYN="Y">Cardiomyopathy, Hypertrophic</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008943" MajorTopicYN="Y">Mitral Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017548" MajorTopicYN="N">Echocardiography, Transesophageal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004724" MajorTopicYN="Y">Endoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Minimally invasive cardiac surgery</Keyword><Keyword MajorTopicYN="N">Mitral repair</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843543</ArticleId><ArticleId IdType="doi">10.1510/mmcts.2025.095</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40847492</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Health Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation.</ArticleTitle><Pagination><StartPage>e038755</StartPage><MedlinePgn>e038755</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.124.038755</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Atrial fibrillation (AF) is common among patients with obstructive hypertrophic cardiomyopathy (oHCM), although the impact of AF on health care resource use and costs is not well defined.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective analysis of claims data from 2016 to 2021 and used <i>International Classification of Diseases, Tenth Revision</i> (<i>ICD-10</i>) codes to identify adult patients with symptomatic oHCM and classify their status with respect to AF as follows: (1) prevalent AF, (2) incident AF, and (3) no AF. Health care resource use and costs for each cohort were analyzed and expressed as per person per year (PPPY).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 22&#x2009;216 patients with symptomatic oHCM, 6677 had prevalent AF (30.1%), 2879 had incident AF (13.0%), and 12&#x2009;660 were without AF (57.0%). Patients with incident AF incurred mean total health care costs that were similar to those with prevalent AF but substantially greater than those without AF (mean, $66&#x2009;619 [95% CI, $59&#x2009;702-$74&#x2009;336] versus $63&#x2009;937 [95% CI, $59&#x2009;803-$68&#x2009;356] versus $46&#x2009;686 [95% CI, $43&#x2009;901-$49&#x2009;648] per person per year, <i>P</i>&lt;0.0001). After adjusting for age, sex, major comorbidities, and septal reduction therapy, mean total health care costs remained greater in the groups with incident and prevalent AF than the group without AF, with trends toward even greater relative costs in the group with incident AF. Similar trends were present in adjusted costs related to hospitalizations, surgeries, and urgent care.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The diagnosis of AF in the setting of symptomatic oHCM not only has important implications for patient management but also substantial economic impacts, as it is associated with significantly greater health care costs and resource use relative to patients with symptomatic oHCM and no AF.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stendahl</LastName><ForeName>John C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-1568-9280</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine Yale School of Medicine New Haven CT USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sen</LastName><ForeName>Sounok</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1806-3566</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine Yale School of Medicine New Haven CT USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butzner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cytokinetics Incorporated South San Francisco CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papademetriou</LastName><ForeName>Eros</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Putnam Associates, LLC Boston MA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potluri</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0509-2659</Identifier><AffiliationInfo><Affiliation>Putnam Associates, LLC Boston MA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Putnam Associates, LLC Boston MA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacoby</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cytokinetics Incorporated South San Francisco CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>James V</ForeName><Initials>JV</Initials><Identifier Source="ORCID">0000-0002-4614-6879</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine Yale School of Medicine New Haven CT USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">health care costs</Keyword><Keyword MajorTopicYN="N">health care resource use</Keyword><Keyword MajorTopicYN="N">hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">obstructive hypertrophic cardiomyopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>1</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40847492</ArticleId><ArticleId IdType="doi">10.1161/JAHA.124.038755</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40827012</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>16</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Effects of Alcohol Septal Ablation on Exercise Hemodynamics, Symptoms, and Quality of Life in Obstructive Hypertrophic Cardiomyopathy.</ArticleTitle><Pagination><StartPage>e041328</StartPage><MedlinePgn>e041328</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.125.041328</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The impact of alcohol septal ablation (ASA) on exercise hemodynamics, symptoms, and quality of life in patients with obstructive hypertrophic cardiomyopathy is poorly described according to contemporary standards. This study aimed to evaluate the effect of ASA on filling pressures at rest and during exercise, left ventricular outflow tract obstruction, symptoms, and quality of life in patients with obstructive hypertrophic cardiomyopathy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective study enrolled 24 patients with obstructive hypertrophic cardiomyopathy referred for ASA. Right-heart catheterization and echocardiography were performed at rest and during exercise, before and &#x2248;7&#x2009;months after ASA. The primary outcome was the difference in pulmonary artery wedge pressure at 75&#x2009;W. Secondary outcomes assessed left ventricular outflow tract gradients, New York Heart Association functional class, and the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ASA significantly reduced pulmonary artery wedge pressure at 75&#x2009;W (33&#xb1;9&#x2009;mm&#x2009;Hg versus 24&#xb1;10&#x2009;mm&#x2009;Hg; <i>P</i>&lt;0.001), decreased left ventricular outflow tract gradients at rest (49 [interquartile range (IQR), 24-90] mm&#x2009;Hg versus 17 [IQR, 14-27] mm&#x2009;Hg; <i>P</i>&lt;0.01), at peak exercise (45 [IQR, 29-90] mm&#x2009;Hg versus 32 [IQR, 21-61] mm&#x2009;Hg; <i>P</i>&#x2009;=&#x2009;0.02), and after exercise (96 [IQR, 34-161] mm&#x2009;Hg versus 28 [IQR, 21-62] mm&#x2009;Hg; <i>P</i>&lt;0.01). The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was significantly increased (65.4&#xb1;16 versus 76.7&#xb1;16; <i>P</i>&lt;0.01). ASA improved New York Heart Association functional class, with 54% in class III before treatment, compared with 13% after treatment (<i>P</i>&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ASA significantly reduced exercise-induced filling pressures and LVOT obstruction, leading to improved symptoms and quality of life in patients with obstructive hypertrophic cardiomyopathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dybro</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-3175-9725</Identifier><AffiliationInfo><Affiliation>Department of Cardiology Aarhus University Hospital Aarhus N Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Torsten B</ForeName><Initials>TB</Initials><Identifier Source="ORCID">0000-0003-1468-7248</Identifier><AffiliationInfo><Affiliation>Department of Cardiology Aarhus University Hospital Aarhus N Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Roni R</ForeName><Initials>RR</Initials><Identifier Source="ORCID">0000-0001-9228-3869</Identifier><AffiliationInfo><Affiliation>Department of Cardiology Aarhus University Hospital Aarhus N Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine Health, Aarhus University Aarhus Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladefoged</LastName><ForeName>Bertil T</ForeName><Initials>BT</Initials><Identifier Source="ORCID">0000-0002-3749-6789</Identifier><AffiliationInfo><Affiliation>Department of Cardiology Aarhus University Hospital Aarhus N Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Anders L D</ForeName><Initials>ALD</Initials><Identifier Source="ORCID">0000-0002-3258-5192</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine Health, Aarhus University Aarhus Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terkelsen</LastName><ForeName>Christian J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0003-0205-9551</Identifier><AffiliationInfo><Affiliation>Department of Cardiology Aarhus University Hospital Aarhus N Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine Health, Aarhus University Aarhus Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Mads J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-9320-8227</Identifier><AffiliationInfo><Affiliation>Department of Cardiology Aarhus University Hospital Aarhus N Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Morten K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Cardiology Aarhus University Hospital Aarhus N Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine Health, Aarhus University Aarhus Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poulsen</LastName><ForeName>Steen H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Cardiology Aarhus University Hospital Aarhus N Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine Health, Aarhus University Aarhus Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3K9958V90M</RegistryNumber><NameOfSubstance UI="D000431">Ethanol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002312" MajorTopicYN="Y">Cardiomyopathy, Hypertrophic</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055011" MajorTopicYN="Y">Ablation Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000431" MajorTopicYN="Y">Ethanol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014694" MajorTopicYN="Y">Ventricular Outflow Obstruction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="Y">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006328" MajorTopicYN="N">Cardiac Catheterization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006346" MajorTopicYN="Y">Heart Septum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011669" MajorTopicYN="N">Pulmonary Wedge Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005080" MajorTopicYN="N">Exercise Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017079" MajorTopicYN="Y">Exercise Tolerance</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">alcohol ablation</Keyword><Keyword MajorTopicYN="N">exercise hemodynamics</Keyword><Keyword MajorTopicYN="N">obstructive hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">septal reduction therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>2</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40827012</ArticleId><ArticleId IdType="doi">10.1161/JAHA.125.041328</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40828458</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1880-344X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Journal of echocardiography</Title><ISOAbbreviation>J Echocardiogr</ISOAbbreviation></Journal><ArticleTitle>Prognostic value of right ventricular ejection fraction using three-dimensional echocardiography in patients with ischemic and dilated cardiomyopathy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12574-025-00704-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There are few studies reporting the prognostic value of three-dimensional echocardiography (3DE)-derived right ventricular ejection fraction (RVEF) in patients with ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">120 ICM and 107 DCM patients who underwent 3DE were retrospectively selected and analyzed using 3DE speckle tracking software. The primary endpoint was a composite of cardiac events, including cardiac death, heart failure hospitalization, myocardial infarction, or ventricular tachyarrhythmia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During a median follow-up of 24.3 and 53.6&#xa0;months, 45 patients in ICM and 39 patients in DCM, respectively, reached the primary endpoint. Univariate analysis showed that RVEF was statistically significantly associated with cardiac events in both groups [ICM, hazard ratio (HR): 0.92, 95% confidence interval (CI) 0.89-0.95; DCM, HR: 0.90, 95% CI 0.86-0.93, respectively]. In multivariable analysis, RVEF (HR: 0.89-0.92, p&#x2009;&lt;&#x2009;0.001) was also statistically significantly associated with cardiac events in both ICM and DCM, even after adjustment for clinical factors, left ventricular (LV) systolic and diastolic parameters, or RV systolic parameters. Kaplan-Meier curves, divided into four groups by RVEF&#x2009;&#x2265;&#x2009;45% and&#x2009;&lt;&#x2009;45% and E/e'&#x2009;&#x2265;&#x2009;14 and&#x2009;&lt;&#x2009;14, showed significant risk stratification for both ICM (p&#x2009;=&#x2009;0.0068) and DCM (p&#x2009;&lt;&#x2009;0.0001). RVEF had incremental prognostic value over age, E/e', and conventional RV systolic parameters, in both ICM and DCM.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study confirms the independent and incremental prognostic value of RVEF over conventional echocardiographic parameters in patients with ICM and DCM and allows detailed risk stratification of cardiac events by RVEF and E/e'.</AbstractText><CopyrightInformation>&#xa9; 2025. Japanese Society of Echocardiography.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kitano</LastName><ForeName>Tetsuji</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8539-5907</Identifier><AffiliationInfo><Affiliation>Department of Clinical Training and Career Support Center, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. syuukyuu1986@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. syuukyuu1986@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagata</LastName><ForeName>Yasufumi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nabeshima</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, Saga, 849-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dohi</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tobata General Hospital, 1-3-33 Fukuryugi, Tobata-ku, Kitakyushu, 804-0025, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Echocardiogr</MedlineTA><NlmUniqueID>101263153</NlmUniqueID><ISSNLinking>1349-0222</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dilated cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Ischemic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Right ventricular ejection fraction</Keyword><Keyword MajorTopicYN="N">Three-dimensional echocardiography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>11</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40828458</ArticleId><ArticleId IdType="doi">10.1007/s12574-025-00704-z</ArticleId><ArticleId IdType="pii">10.1007/s12574-025-00704-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391:572&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">29174292</ArticleId><ArticleId IdType="pmc">5814791</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">34447992</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamaru R, Kohsaka S, Shiraishi Y, et al. Temporal trends in heart failure management and outcomes: insights from a Japanese multicenter registry of tertiary care centers. J Am Heart Axxoc. 2023;12: e031179.</Citation></Reference><Reference><Citation>Tsao CW, Lyass A, Enserro D, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Failure. 2018;6(8):678&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">30007560</ArticleId><ArticleId IdType="pmc">6076350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ide T, Kaku H, Matsushima S, et al. Clinical characteristics and outcomes of hospitalized patients with heart failure from the large-scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF). Circ J. 2021;85:1438&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">33853998</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitai T, Kohsaka S, Kato T et al. JCS/JHFS 2025 guideline on diagnosis and treatment of heart failure. Circ J 2025. In press.</Citation></Reference><Reference><Citation>Kitai T, Miyakoshi C, Morimoto T, et al. Mode of death among Japanese adults with heart failure with preserved, midrange, and reduced ejection fraction. JAMA Netw Open. 2020;3:e204296.</Citation><ArticleIdList><ArticleId IdType="pubmed">32379331</ArticleId><ArticleId IdType="pmc">7206504</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175:996&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">25895156</ArticleId><ArticleId IdType="pmc">4451405</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata Y, Wu VCC, Kado Y, et al. Prognostic value of right ventricular ejection fraction assessed by transthoracic 3D echocardiography. Circ Cardiovasc Imaging. 2017;10:e005384.</Citation><ArticleIdList><ArticleId IdType="pubmed">28174197</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraru D, Badano LP, Nagata Y, et al. Development and prognostic validation of partition values to grade right ventricular dysfunction severity using 3D echocardiography. Eur Heart J Cardiovasc Imaging. 2020;21:10&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">31539046</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitano T, Nabeshima Y, Nagata Y, et al. Prognostic value of the right ventricular ejection fraction using three-dimensional echocardiography: systematic review and meta-analysis. PLoS ONE. 2023;18:e0287924.</Citation><ArticleIdList><ArticleId IdType="pubmed">37418388</ArticleId><ArticleId IdType="pmc">10328342</ArticleId></ArticleIdList></Reference><Reference><Citation>Pecini R, M&#xf8;ller DV, Torp-Pedersen C, et al. Heart failure etiology impacts survival of patients with heart failure. Int J Cardiol. 2011;149:211&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20193969</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies an American Heart Association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. 2006;113:1807&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567565</ArticleId></ArticleIdList></Reference><Reference><Citation>Felker GM, Shaw LK, O&#x2019;Connor CM, et al. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39:210&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788209</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37:1850&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26792875</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xee;j&#xee;iac A, Onciul S, Fuzu C, et al. The prognostic value of right ventricular longitudinal strain and 3D ejection fraction in patients with dilated cardiomyopathy. Int J Cardiovasc Imaging. 2021;37:3233&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">34165699</ArticleId><ArticleId IdType="pmc">8223765</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32:1&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30282592</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">25559473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021;42:681&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">33447845</ArticleId><ArticleId IdType="pmc">7878007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabe MA, Sabe SA, Kusunose K, et al. Predictors and prognostic significance of right ventricular ejection fraction in patients with ischemic cardiomyopathy. Circulation. 2016;134:656&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">27507405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitano T, Nabeshima Y, Takeuchi M. Measurement accuracy of right ventricular parameters using 3D echocardiography Study-level meta-analysis. JACC Cardiovasc Imaging. 2023;16:395&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">36752427</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xee;j&#xee;iac A, Onciul S, Guzu C, et al. The prognostic value of right ventricular longitudinal strain and 3D ejection fraction in patients with dilated cardiomyopathy. Int J Cardiovasc Imaging. 2021;37:3233&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">34165699</ArticleId><ArticleId IdType="pmc">8223765</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayour AA, Tokodi M, Celeng C, et al. Association of right ventricular functional parameters with adverse cardiopulmonary outcomes: a meta-analysis. J Am Soc Echocardiogr. 2023;36:624&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">36773817</ArticleId></ArticleIdList></Reference><Reference><Citation>Otani K, Nabeshima Y, Kitano T, et al. Accuracy of fully automated right ventricular quantification software with 3D echocardiography: direct comparison with cardiac magnetic resonance and semi-automated quantification software. Eur Heart J Cardiovasc Imaging. 2020;21:787&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">31549722</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese D, Rashedi N, Weinert L, et al. Machine learning&#x2013;based three-dimensional echocardiographic quantification of right ventricular size and function: validation against cardiac magnetic resonance. J Am Soc Echocardiogr. 2019;32:969&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">31174940</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40837548</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2950-1334</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2025</Year><Month>Nov</Month></PubDate></JournalIssue><Title>JHLT open</Title><ISOAbbreviation>JHLT Open</ISOAbbreviation></Journal><ArticleTitle>High profile transvalvular microaxial flow pump as a bridge to heart transplantation for amyloid cardiomyopathy: A case series.</ArticleTitle><Pagination><StartPage>100340</StartPage><MedlinePgn>100340</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100340</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhlto.2025.100340</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The definitive treatment for end-stage heart failure (ESHF) due to amyloid cardiomyopathy (ACM) is an orthotopic heart transplant (OHT). However, associated pulmonary hypertension (PH) can present as a contraindication to OHT and be challenging to manage with conventional therapies. We herein reported the successful use of Impella 5.5 in a series of patients with ACM to improve PH and successfully bridge to OHT.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Five patients with ACM associated ESHF were analyzed. All patients had moderate to severe PH on admission. As a bridge to transplant, Impella 5.5 was inserted through the axillary artery, and continued until OHT.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">All patients were male, and mean age was 62.2&#xa0;&#xb1;&#xa0;1.3 years. One patient had light chain associated amyloid cardiomyopathy (AL-CM), 2 had wild-type transthyretin associated amyloid cardiomyopathy (ATTRwt-CM), and 2 had variant transthyretin amyloid cardiomyopathy (ATTRv-CM). Indication for Impella 5.5 was to support acute on chronic heart failure and improve elevated PA pressures. Mean support time was 34.4&#xa0;&#xb1;&#xa0;11.97&#xa0;days. Mean PA pressures decreased from 38.2&#xa0;&#xb1;&#xa0;4.43&#xa0;mm&#xa0;Hg to 27&#xa0;&#xb1;&#xa0;4.24&#xa0;mm&#xa0;Hg, and cardiac index increased from 1.58&#xa0;&#xb1;&#xa0;0.44&#xa0;liter/min/m<sup>2</sup> to 2.46&#xa0;&#xb1;&#xa0;0.43&#xa0;liter/min/m<sup>2</sup>. No major adverse events related to Impella insertion occurred. All patients were successfully transplanted and doing well after OHT with no mortality after a mean follow-up of 13&#xa0;&#xb1;&#xa0;10.88 months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Bridging patients with ACM to OHT remains challenging due to small left ventricular cavity and associated PH. Temporary mechanical circulatory support with Impella 5.5 helps reduce PA pressures and improve cardiac index. Impella 5.5 can be safe and feasible option to bridge patients with ACM to OHT.</AbstractText><CopyrightInformation>&#xa9; Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alomari</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadiwala</LastName><ForeName>Ishaq</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyle</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Transplant, Division of Advanced Heart Failure and Heart Transplantation, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Si</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celik</LastName><ForeName>Nafiye Busra</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Juan C Leoni</ForeName><Initials>JCL</Initials><AffiliationInfo><Affiliation>Department of Transplant, Division of Advanced Heart Failure and Heart Transplantation, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goswami</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Transplant, Division of Advanced Heart Failure and Heart Transplantation, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landolfo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nativi-Nicolau</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Transplant, Division of Advanced Heart Failure and Heart Transplantation, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yip</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Transplant, Division of Advanced Heart Failure and Heart Transplantation, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Parag C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Transplant, Division of Advanced Heart Failure and Heart Transplantation, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sareyyupoglu</LastName><ForeName>Basar</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JHLT Open</MedlineTA><NlmUniqueID>9918716187806676</NlmUniqueID><ISSNLinking>2950-1334</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyloid cardiomyopathy</Keyword><Keyword MajorTopicYN="N">amyloidosis</Keyword><Keyword MajorTopicYN="N">heart transplant</Keyword><Keyword MajorTopicYN="N">impella 5.5</Keyword><Keyword MajorTopicYN="N">mechanical circulatory device</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40837548</ArticleId><ArticleId IdType="pmc">PMC12362077</ArticleId><ArticleId IdType="doi">10.1016/j.jhlto.2025.100340</ArticleId><ArticleId IdType="pii">S2950-1334(25)00135-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Falk R.H., Alexander K.M., Liao R., Dorbala S. AL (light-chain) cardiac amyloidosis. J&#xa0;Am&#xa0;Coll&#xa0;Cardiol. 2016;68:1323&#x2013;1341. doi: 10.1016/j.jacc.2016.06.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.06.053</ArticleId><ArticleId IdType="pubmed">27634125</ArticleId></ArticleIdList></Reference><Reference><Citation>Falk R.H., Comenzo R.L., Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898&#x2013;909. doi: 10.1056/NEJM199709253371306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199709253371306</ArticleId><ArticleId IdType="pubmed">9302305</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall R., Hawkins P.N. Grand rounds - Hammersmith Hospital: cardiac transplantation for AL amyloidosis. BMJ. 1994;309:1135&#x2013;1137. doi: 10.1136/bmj.309.6962.1135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.309.6962.1135</ArticleId><ArticleId IdType="pmc">PMC2541916</ArticleId><ArticleId IdType="pubmed">7987109</ArticleId></ArticleIdList></Reference><Reference><Citation>Conner R., Hosenpud J.D., Norman D.J., Pantely G.A., Cobanoglu A., Starr A. Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease. J Heart Transpl. 1988;7:165&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">3284989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosenpud J.D., DeMarco T., Frazier O.H., et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation. 1991;84:338&#x2013;343. (Suppl)</Citation><ArticleIdList><ArticleId IdType="pubmed">1934428</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattianayagam P.T., Gibbs S.D.J., Pinney J.H., et al. Solid organ transplantation in AL amyloidosis. Am&#xa0;J&#xa0;Transplant. 2010;10:2124&#x2013;2131. doi: 10.1111/j.1600-6143.2010.03227.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2010.03227.x</ArticleId><ArticleId IdType="pubmed">20883547</ArticleId></ArticleIdList></Reference><Reference><Citation>Estep J.D., Bhimaraj A., Cordero-Reyes A.M., Bruckner B., Loebe M., Torre-Amione G. Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management. Methodist DeBakey Cardiovasc&#xa0;J. 2012;8:8. doi: 10.14797/mdcj-8-3-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.14797/mdcj-8-3-8</ArticleId><ArticleId IdType="pmc">PMC3487570</ArticleId><ArticleId IdType="pubmed">23227279</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey B.R., Chung S.S., Spitzer T.R., et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010;90:905&#x2013;911. doi: 10.1097/TP.0b013e3181f10edb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e3181f10edb</ArticleId><ArticleId IdType="pmc">PMC2964067</ArticleId><ArticleId IdType="pubmed">20733534</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray Gilstrap L., Niehaus E., Malhotra R., et al. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J&#xa0;Heart Lung Transplant. 2014;33:149&#x2013;156. doi: 10.1016/j.healun.2013.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2013.09.004</ArticleId><ArticleId IdType="pmc">PMC3946702</ArticleId><ArticleId IdType="pubmed">24200511</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubrey S.W., Burke M.M., Hawkins P.N., Banner N.R. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J&#xa0;Heart Lung Transplant. 2004;23:1142&#x2013;1153. doi: 10.1016/j.healun.2003.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2003.08.027</ArticleId><ArticleId IdType="pubmed">15477107</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q., Moriguchi J., Levine R., et al. Outcomes of heart transplantation in cardiac amyloidosis patients: a single center experience. Transplant&#xa0;Proc. 2021;53:329&#x2013;334. doi: 10.1016/j.transproceed.2020.08.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2020.08.020</ArticleId><ArticleId IdType="pubmed">32917391</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis M.K., Lee P.H.U., Witteles R.M. Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. J&#xa0;Heart Lung Transplant. 2015;34:658&#x2013;666. doi: 10.1016/j.healun.2014.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2014.09.006</ArticleId><ArticleId IdType="pubmed">25444369</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett C.D., Alexander K.M., Zhao H., et al. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation. JACC: Heart Fail. 2020;8:461&#x2013;468. doi: 10.1016/j.jchf.2019.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2019.12.013</ArticleId><ArticleId IdType="pubmed">32387068</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin J.M., Chiu L., Axsom K.M., et al. United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. Clin Transplant. 2020;34 doi: 10.1111/ctr.14028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.14028</ArticleId><ArticleId IdType="pmc">PMC7744118</ArticleId><ArticleId IdType="pubmed">32623785</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus M.J., Smits J.M., Meyer A.L., et al. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation: the eurotransplant experience. J&#xa0;Heart Lung Transplant. 2023;42:778&#x2013;785. doi: 10.1016/j.healun.2023.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2023.01.001</ArticleId><ArticleId IdType="pubmed">36710093</ArticleId></ArticleIdList></Reference><Reference><Citation>Rock J.R., Kos C.A., Lemaire A., et al. Single center first year experience and outcomes with Impella 5.5 left ventricular assist device. J Cardiothorac Surg. 2022;17:124. doi: 10.1186/s13019-022-01871-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-022-01871-1</ArticleId><ArticleId IdType="pmc">PMC9128113</ArticleId><ArticleId IdType="pubmed">35606780</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpuerto A.C., Lele P., Mahr C., Bakthavatsalam R., Khorsandi M., Keenan J.E. Impella 5.5 support prior to heart and kidney transplantation. J&#xa0;Heart Lung Transplant. 2022;41:S494. doi: 10.1016/j.healun.2022.01.1252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2022.01.1252</ArticleId></ArticleIdList></Reference><Reference><Citation>Salas De Armas I.A., Patel M.K., Patel J.A., et al. Insertion of Impella 5.5 via the axillary artery graft under fluoroscopic guidance. Oper&#xa0;Tech&#xa0;Thorac&#xa0;Cardiovasc&#xa0;Surg. 2021;26:462&#x2013;474. doi: 10.1053/j.optechstcvs.2021.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.optechstcvs.2021.05.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Palladini G., Hegenbart U., Milani P., et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325&#x2013;2332. doi: 10.1182/blood-2014-04-570010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-04-570010</ArticleId><ArticleId IdType="pubmed">25115890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechalekar A.D., Schonland S.O., Kastritis E., et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420&#x2013;3427. doi: 10.1182/blood-2012-12-473066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-12-473066</ArticleId><ArticleId IdType="pubmed">23479568</ArticleId></ArticleIdList></Reference><Reference><Citation>Grogan M., Gertz M., McCurdy A., et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience. WJT. 2016;6:380. doi: 10.5500/wjt.v6.i2.380.</Citation><ArticleIdList><ArticleId IdType="doi">10.5500/wjt.v6.i2.380</ArticleId><ArticleId IdType="pmc">PMC4919742</ArticleId><ArticleId IdType="pubmed">27358783</ArticleId></ArticleIdList></Reference><Reference><Citation>Panhwar M.S., Al-Kindi S.G., Tofovic D., Oliveira G.H., Ginwalla M. Waitlist mortality of patients with amyloid cardiomyopathy who are listed for heart transplantation and implications for organ allocation. J&#xa0;Card&#xa0;Fail. 2019;25:767&#x2013;771. doi: 10.1016/j.cardfail.2019.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2019.04.011</ArticleId><ArticleId IdType="pubmed">31018167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristen A.V., Brokbals E., Aus Dem Siepen F., et al. Cardiac amyloid load. J&#xa0;Am&#xa0;Coll&#xa0;Cardiol. 2016;68:13&#x2013;24. doi: 10.1016/j.jacc.2016.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.04.035</ArticleId><ArticleId IdType="pubmed">27364045</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng R.K., Levy W.C., Vasbinder A., et al. Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC: CardioOncology. 2020;2:414&#x2013;424. doi: 10.1016/j.jaccao.2020.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7561022</ArticleId><ArticleId IdType="pubmed">33073249</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra M.R., Canter C.E., Hannan M.M., et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J&#xa0;Heart Lung Transplant. 2016;35:1&#x2013;23. doi: 10.1016/j.healun.2015.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2015.10.023</ArticleId><ArticleId IdType="pubmed">26776864</ArticleId></ArticleIdList></Reference><Reference><Citation>Addonizio L.J., Gersony W.M., Robbins R.C., et al. Elevated pulmonary vascular resistance and cardiac transplantation. Circulation. 1987;76:52&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">3311456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali J.M., Abu-Omar Y. Complications associated with mechanical circulatory support. Ann Transl Med. 2020;8:835. doi: 10.21037/atm.2020.03.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2020.03.152</ArticleId><ArticleId IdType="pmc">PMC7396259</ArticleId><ArticleId IdType="pubmed">32793680</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennel P.J., Lumish H., Kaku Y., et al. A case series analysis on the clinical experience of Impella 5.5&#xa0;at a large tertiary care centre. ESC Heart Fail. 2021;8:3720&#x2013;3725. doi: 10.1002/ehf2.13512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13512</ArticleId><ArticleId IdType="pmc">PMC8497328</ArticleId><ArticleId IdType="pubmed">34402210</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P., Bhatia-Patel S., Yoo B., et al. Impella 5.5 mechanical circulatory support as a bridge to heart transplantation for refractory ventricular tachycardia. J&#xa0;Am&#xa0;Coll&#xa0;Cardiol. 2022;79:2611. doi: 10.1016/S0735-1097(22)03602-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(22)03602-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashistha K., Gajjar K., Tobaa A., Hadi A. Change of heart: interesting case of an Impella 5.5 device precipitating electrical storm and right ventricular failure treated with a heart transplant. J&#xa0;Cardiac Fail. 2022;28:S101. doi: 10.1016/j.cardfail.2022.03.257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2022.03.257</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhout I., Nguyen S.N., Barry O.M., Bacha E.A., Goldstone A.B. Transinnominate Impella 5.5 insertion as a bridge to transplantation in a pediatric patient in refractory cardiogenic shock. JTCVS Techniques. 2022;14:201&#x2013;203. doi: 10.1016/j.xjtc.2022.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xjtc.2022.06.005</ArticleId><ArticleId IdType="pmc">PMC9367200</ArticleId><ArticleId IdType="pubmed">35967222</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernhardt A.M., Potapov E., Schibilsky D., et al. First in man evaluation of a novel circulatory support device: early experience with the Impella 5.5 after CE mark approval in Germany. J&#xa0;Heart&#xa0;Lung Transplant. 2021;40:850&#x2013;855. doi: 10.1016/j.healun.2021.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2021.04.001</ArticleId><ArticleId IdType="pubmed">34030970</ArticleId></ArticleIdList></Reference><Reference><Citation>Nersesian G., Tsch&#xf6;pe C., Spillmann F., et al. Prediction of survival of patients in cardiogenic shock treated by surgically implanted Impella 5+ short-term left ventricular assist device. Interact&#xa0;CardioVasc&#xa0;Thorac&#xa0;Surg. 2020;31:475&#x2013;482. doi: 10.1093/icvts/ivaa150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivaa150</ArticleId><ArticleId IdType="pubmed">32879947</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40843498</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2574-8300</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Circulation. Genomic and precision medicine</Title><ISOAbbreviation>Circ Genom Precis Med</ISOAbbreviation></Journal><ArticleTitle>Novel <i>Cardiac Troponin-I</i> Missense Variant (c.593C&gt;T) Is Associated With Familial Hypertrophic Cardiomyopathy in Golden Retrievers.</ArticleTitle><Pagination><StartPage>e005096</StartPage><MedlinePgn>e005096</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCGEN.125.005096</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Hypertrophic cardiomyopathy (HCM) is a naturally occurring cardiac disorder afflicting humans, cats, rhesus macaques, pigs, and rarely dogs. The disease is characterized by maladaptive left ventricular wall thickening. Over 1500 sarcomere-coding mutations explain HCM in humans, whereas only 3 have been reported in cat breeds. To date, no mutations have been described in dogs. HCM in a nuclear family of Golden Retrievers was identified following the sudden cardiac death of 3 related puppies &lt;2 years of age from 2 dam-offspring repeat matings.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Whole-genome sequencing on the 3 affected puppies, along with nuclear family members (ie, sire, dam, 4 unaffected littermates, 4 unaffected half-siblings), and 1 distantly related, geriatric, cardiovascularly normal Golden Retriever was performed (n=14). Candidate variant genotyping was performed in an unphenotyped cohort of dogs (n=2771) and an expanded population of phenotyped, unrelated Golden Retrievers (n=45). Left ventricular tissue immunofluorescence staining was subsequently performed to investigate incorporation and expression of mutant protein within the cardiac sarcomere of HCM-affected cases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Gross and histopathologic evaluations of the HCM-affected puppies revealed hallmark features of the disease, including cardiomyocyte hypertrophy, interstitial fibrosis, and left-sided congestive heart failure. Segregation analysis of called variants, performed under assumptions of an autosomal-recessive mode of inheritance, identified a single segregating c.593C&gt;T missense variant in <i>TNNI3</i> (<i>Cardiac Troponin-I</i>). This variant was not observed in the unphenotyped (n=2771) nor in the phenotyped, unrelated cohort of dogs (n=45). Immunofluorescence staining of left ventricular tissues did not reveal obvious aberrant protein localization and expression at the sarcomeric level, suggesting the molecular pathogenesis of the <i>TNNI3</i> variant is not related to abnormal protein incorporation within the sarcomere.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This variant represents the first-ever reported HCM-associated variant in any canine species, and its identification holds promise for establishing translational models, genetic screening, and early disease prevention within the breed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rivas</LastName><ForeName>Victor N</ForeName><Initials>VN</Initials><Identifier Source="ORCID">0000-0002-5016-3743</Identifier><AffiliationInfo><Affiliation>Department of Clinical Sciences, North Carolina State University, College of Veterinary Medicine, Raleigh. (V.N.R., M.W.V., D.V.M., S.M.L., J.A.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldsmith</LastName><ForeName>Dayna A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Faculty of Veterinary Medicine, University of Calgary, Alberta, Canada (D.A.G., J.L.D., C.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandewege</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><Identifier Source="ORCID">0000-0003-1115-9087</Identifier><AffiliationInfo><Affiliation>Department of Clinical Sciences, North Carolina State University, College of Veterinary Medicine, Raleigh. (V.N.R., M.W.V., D.V.M., S.M.L., J.A.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ronald H L</ForeName><Initials>RHL</Initials><Identifier Source="ORCID">0000-0002-3325-2744</Identifier></Author><Author ValidYN="Y"><LastName>Losa</LastName><ForeName>Sandra M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, North Carolina State University, College of Veterinary Medicine, Raleigh. (V.N.R., M.W.V., D.V.M., S.M.L., J.A.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leber</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sitthicharoenchai</LastName><ForeName>Panchan</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4412-7121</Identifier><AffiliationInfo><Affiliation>Department of Population Health and Pathobiology, North Carolina State University, College of Veterinary Medicine, Raleigh. (P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawkes</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pulse Veterinary Cardiology, Sherwood Park, Alberta, Canada (K.H.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-7668-6817</Identifier><AffiliationInfo><Affiliation>Faculty of Veterinary Medicine, University of Calgary, Alberta, Canada (D.A.G., J.L.D., C.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legge</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0009-2122-2124</Identifier><AffiliationInfo><Affiliation>Faculty of Veterinary Medicine, University of Calgary, Alberta, Canada (D.A.G., J.L.D., C.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revell</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Highview Animal Clinic Ltd, High River, Alberta, Canada (S.R.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-5611-5745</Identifier><AffiliationInfo><Affiliation>Department of Clinical Sciences, North Carolina State University, College of Veterinary Medicine, Raleigh. (V.N.R., M.W.V., D.V.M., S.M.L., J.A.S.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circ Genom Precis Med</MedlineTA><NlmUniqueID>101714113</NlmUniqueID><ISSNLinking>2574-8300</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aged</Keyword><Keyword MajorTopicYN="N">dogs</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">mutation</Keyword><Keyword MajorTopicYN="N">swine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843498</ArticleId><ArticleId IdType="doi">10.1161/CIRCGEN.125.005096</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40841921</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1752-1947</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of medical case reports</Title><ISOAbbreviation>J Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>A case of adrenal insufficiency presenting with seizures, complicated by developmental cerebral venous anomaly and Takotsubo cardiomyopathy: a case report.</ArticleTitle><Pagination><StartPage>424</StartPage><MedlinePgn>424</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-025-05463-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adrenal insufficiency is a potentially life-threatening condition that often presents with nonspecific symptoms. While fatigue, hypotension, and electrolyte disturbances are common features, seizures and stress-induced cardiomyopathy are rare initial manifestations. This case is reported for its atypical presentation and to highlight the diagnostic challenge it posed in the absence of classic biochemical findings.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">We report a case of a 68-year-old Hispanic woman with diabetes, hypertension, dyslipidemia, and hypopituitarism secondary to Sheehan syndrome, who presented with new-onset seizures after abruptly discontinuing chronic steroid therapy. Her symptoms included progressive weakness and behavioral changes over several weeks. Initial evaluation revealed hyperglycemia, mild hyponatremia, and no hyperkalemia-findings consistent with secondary adrenal insufficiency-associated seizures, although contributing to initial diagnostic uncertainty. Brain imaging incidentally identified a developmental cerebral venous anomaly, which was initially suspected as a potential cause of the seizures. In addition, echocardiographic findings were consistent with Takotsubo cardiomyopathy, likely precipitated by the stress of her medical condition. However, further evaluation confirmed adrenal insufficiency with low cortisol and adrenocorticotropic hormone levels, and subnormal response to cosyntropin stimulation. Management included hydrocortisone for adrenal insufficiency and levetiracetam for seizure prophylaxis, leading to symptom resolution and no recurrence of seizures.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This case emphasizes the importance of maintaining a high index of suspicion for adrenal insufficiency in patients with a suggestive history, even when classic electrolyte abnormalities are absent and neuroimaging reveals confounding findings. Recognizing rare presentations such as seizures and stress cardiomyopathy can prevent delays in diagnosis and improve outcomes.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villegas</LastName><ForeName>Katrina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0004-9191-3880</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, St. Joseph's University Medical Center, 703 Main St, Paterson, NJ, USA. katrinajvillegas@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eason</LastName><ForeName>Brittany</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janiec</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, St. Joseph's University Medical Center, 703 Main St, Paterson, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musallam</LastName><ForeName>Alaa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, St. Joseph's University Medical Center, 703 Main St, Paterson, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammouda</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, St. Joseph's University Medical Center, 703 Main St, Paterson, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldwaik</LastName><ForeName>Samia Ammar</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tailor</LastName><ForeName>Radhika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, St. Joseph's University Medical Center, 703 Main St, Paterson, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Case Rep</MedlineTA><NlmUniqueID>101293382</NlmUniqueID><ISSNLinking>1752-1947</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical><Chemical><RegistryNumber>44YRR34555</RegistryNumber><NameOfSubstance UI="D000077287">Levetiracetam</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000309" MajorTopicYN="Y">Adrenal Insufficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054549" MajorTopicYN="Y">Takotsubo Cardiomyopathy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="Y">Seizures</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077287" MajorTopicYN="N">Levetiracetam</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adrenal insufficiency</Keyword><Keyword MajorTopicYN="N">Corticosteroid withdrawal</Keyword><Keyword MajorTopicYN="N">Developmental venous anomaly</Keyword><Keyword MajorTopicYN="N">Seizures</Keyword><Keyword MajorTopicYN="N">Takotsubo cardiomyopathy</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Our institution does not require ethical approval for reporting individual cases. Consent for publication: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests: The author(s) declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>7</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>7</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841921</ArticleId><ArticleId IdType="doi">10.1186/s13256-025-05463-0</ArticleId><ArticleId IdType="pii">10.1186/s13256-025-05463-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>&#xd8;ksnes M, Husebye ES. Approach to the patient: diagnosis of primary adrenal insufficiency in adults. J Clin Endocrinol Metab. 2023;109(1):269&#x2013;78. https://doi.org/10.1210/clinem/dgad402 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgad402</ArticleId><ArticleId IdType="pubmed">37450570</ArticleId><ArticleId IdType="pmc">10735307</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert&#x2019;s notes: pathophysiology and clinical pearls for internal medicine. McGraw Hill Medical. 2024. https://accessmedicine.mhmedical.com/book.aspx?bookid=3072 . Accessed 8 Dec 2024.</Citation></Reference><Reference><Citation>Husebye ES, Pearce SH, Krone NP, K&#xe4;mpe O. Adrenal insufficiency. Lancet. 2021;397(10274):613&#x2013;29. https://doi.org/10.1016/S0140-6736(21)00136-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00136-7</ArticleId><ArticleId IdType="pubmed">33484633</ArticleId></ArticleIdList></Reference><Reference><Citation>Pazderska A, Pearce SH. Adrenal insufficiency - Recognition and management. Clin Med. 2017;17(3):258&#x2013;62. https://doi.org/10.7861/clinmedicine.17-3-258 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.17-3-258</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams and Victor&#x2019;s principles of neurology. 12th ed. New York: McGraw Hill Medical; 2024. https://accessmedicine.mhmedical.com/book.aspx?bookID=3313 .</Citation></Reference><Reference><Citation>Essentials of modern neuroscience. New York: McGraw Hill Medical; 2024.</Citation></Reference><Reference><Citation>CURRENT Diagnosis &amp; Treatment. Neurology. 3rd ed. New York: McGraw Hill Medical; 2023.</Citation></Reference><Reference><Citation>Ma L, Hoz SS, Grossberg JA, Lang MJ, Gross BA. Developmental venous anomalies. Neurosurg Clin N Am. 2024;35(3):355&#x2013;61. https://doi.org/10.1016/j.nec.2024.02.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nec.2024.02.007</ArticleId><ArticleId IdType="pubmed">38782528</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364&#x2013;89. https://doi.org/10.1210/jc.2015-1710 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2015-1710</ArticleId><ArticleId IdType="pubmed">26760044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano-L&#xf3;pez I, Gonz&#xe1;lez-Bono E. Cortisol levels and seizures in adults with epilepsy: a systematic review. Neurosci Biobehav Rev. 2019;103:216&#x2013;29. https://doi.org/10.1016/j.neubiorev.2019.05.023 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2019.05.023</ArticleId><ArticleId IdType="pubmed">31129236</ArticleId></ArticleIdList></Reference><Reference><Citation>Michels A, Michels N. Addison disease: early detection and treatment principles. Am Fam Physician. 2014;89(7):563&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24695602</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelgawad MS, Aly RA. Value of susceptibility-weighted MR imaging (SWI) in the detection of developmental venous anomaly. Egypt J Radiol Nucl Med. 2020;51:90. https://doi.org/10.1186/s43055-020-00216-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43055-020-00216-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Uchino A, Tokushige K, Baba Y. Aqueductal developmental venous anomaly causing obstructive hydrocephalus: a case report and review of the literature. Radiol Case Rep. 2024;19(5):2024&#x2013;30. https://doi.org/10.1016/j.radcr.2024.02.023 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radcr.2024.02.023</ArticleId><ArticleId IdType="pubmed">38449483</ArticleId><ArticleId IdType="pmc">10917638</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Souza D, Hacking C, Abdeldjalil B, et&#xa0;al. Developmental venous anomaly. Radiopaedia.org. https://doi.org/10.53347/rID-1215 . 2024</Citation></Reference><Reference><Citation>Nowotny H, Ahmed SF, Bensing S, Beun JG, Br&#xf6;samle M, Chifu I, Claahsen van der Grinten H, Clemente M, Falhammar H, Hahner S, Husebye E, Kristensen J, Loli P, Lajic S, Reisch N. Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis. Endocrine. 2021;71(3):586&#x2013;94. https://doi.org/10.1007/s12020-021-02649-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02649-6</ArticleId><ArticleId IdType="pubmed">33661460</ArticleId><ArticleId IdType="pmc">7929907</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40834212</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1678-4170</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Arquivos brasileiros de cardiologia</Title><ISOAbbreviation>Arq Bras Cardiol</ISOAbbreviation></Journal><ArticleTitle>Orientin Alleviates Oxidative Stress And Apoptosis In Diabetic Cardiomyopathy Via The Lncrna H19/Mir-103-3p/ALDH2/PI3K/AKT Axis.</ArticleTitle><Pagination><StartPage>e20240885</StartPage><MedlinePgn>e20240885</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.36660/abc.20240885</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0066-782X2025000700305</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Diabetic cardiomyopathy (DCM) is an irreversible cardiovascular complication of diabetes mellitus characterized by detrimental cardiac remodeling. Orientin, a water-soluble flavonoid present in many medicinal plants, exerts various pharmacological effects.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the cardioprotective effects of orientin in diabetic conditions and elucidate the mechanisms associated with non-coding RNAs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The streptozotocin-induced DCM model was established by a combined use of streptozotocin and a high-fat diet. Cardiac structure and function in diabetes mellitus mice were evaluated using histological and echocardiographic analyses. Masson, TUNEL, western blot, and ELISA in mouse hearts were performed to analyze cardiac fibrosis, apoptosis, and oxidative stress. Expression levels of lncRNA H19, miR-103-3p, ALDH2, and PI3K/AKT-related proteins in mouse heart and HL-1 cells were evaluated using real-time qPCR or western blot. The significance level was set at p&lt;0.05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Orientin improved cardiac function and ameliorated cardiac injury in diabetic mice. Orientin inhibited cardiac fibrosis, reduced cardiomyocyte apoptosis, and increased the activities of antioxidant enzymes. In pathological conditions, H19 and ALDH2 levels were reduced while miR-103-3p levels increased, which were reversed by orientin. H19 upregulated ALDH2 expression by binding to miR-103-3p and activated the PI3K/AKT pathway in high glucose-treated HL-1 cells. H19 depletion or PI3K inhibitor reversed the effects of orientin on apoptosis and oxidative stress in HL-1 cells under high glucose conditions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings reveal a protective mechanism of orientin in DCM, which involves the regulation of the H19/miR-103-3p/ALDH2/PI3K/AKT signaling axis, providing a potential strategy for treating DCM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Wuhan Third Hospital, Wuhan - China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Xiaofang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Wuhan Third Hospital, Wuhan - China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Wuhan Third Hospital, Wuhan - China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Wuhan Third Hospital, Wuhan - China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0000-0796-357X</Identifier><AffiliationInfo><Affiliation>Wuhan Third Hospital, Wuhan - China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>por</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>A Orientina Alivia o Estresse Oxidativo e a Apoptose na Cardiomiopatia Diab&#xe9;tica por Meio do Eixo Lncrna H19/Mir-103-3p/ALDH2/PI3K/AKT.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Arq Bras Cardiol</MedlineTA><NlmUniqueID>0421031</NlmUniqueID><ISSNLinking>0066-782X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.2.1.3</RegistryNumber><NameOfSubstance UI="D000071396">Aldehyde Dehydrogenase, Mitochondrial</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>IAX93XCW6C</RegistryNumber><NameOfSubstance UI="C065886">orientin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C094335">H19 long non-coding RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.2.1.3</RegistryNumber><NameOfSubstance UI="C515029">ALDH2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058065" MajorTopicYN="Y">Diabetic Cardiomyopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062085" MajorTopicYN="Y">RNA, Long Noncoding</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005419" MajorTopicYN="Y">Flavonoids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071396" MajorTopicYN="N">Aldehyde Dehydrogenase, Mitochondrial</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="Y">Glucosides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="FUNDAMENTO" NlmCategory="OBJECTIVE">A cardiomiopatia diab&#xe9;tica (CMD) &#xe9; uma complica&#xe7;&#xe3;o cardiovascular irrevers&#xed;vel do diabetes mellitus, caracterizada por remodela&#xe7;&#xe3;o card&#xed;aca prejudicial. A orientina, um flavonoide hidrossol&#xfa;vel presente em muitas plantas medicinais, exerce diversos efeitos farmacol&#xf3;gicos.</AbstractText><AbstractText Label="OBJETIVOS" NlmCategory="OBJECTIVE">Investigar os efeitos cardioprotetores da orientina em condi&#xe7;&#xf5;es diab&#xe9;ticas e elucidar os mecanismos associados aos RNAs n&#xe3;o codificantes.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">O modelo CMD induzido por estreptozotocina foi estabelecido pelo uso combinado de estreptozotocina e uma dieta rica em gordura. A estrutura e a fun&#xe7;&#xe3;o card&#xed;aca em camundongos com diabetes mellitus foram avaliadas por meio de an&#xe1;lises histol&#xf3;gicas e ecocardiogr&#xe1;ficas. Masson, TUNEL, western blot e ELISA em cora&#xe7;&#xf5;es de camundongos foram realizados para analisar fibrose card&#xed;aca, apoptose e estresse oxidativo. Os n&#xed;veis de express&#xe3;o de lncRNA H19, miR-103-3p, ALDH2 e prote&#xed;nas relacionadas a PI3K/AKT em c&#xe9;lulas card&#xed;acas de camundongos e HL-1 foram avaliados por qPCR em tempo real ou western blot. O n&#xed;vel de signific&#xe2;ncia foi estabelecido em p&lt;0,05.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">A orientina melhorou a fun&#xe7;&#xe3;o card&#xed;aca e amenizou a les&#xe3;o card&#xed;aca em camundongos diab&#xe9;ticos. A orientina inibiu a fibrose card&#xed;aca, reduziu a apoptose dos cardiomi&#xf3;citos e aumentou a atividade de enzimas antioxidantes. Em condi&#xe7;&#xf5;es patol&#xf3;gicas, os n&#xed;veis de H19 e ALDH2 foram reduzidos, enquanto os n&#xed;veis de miR-103-3p aumentaram, o que foi revertido pela orientina. A H19 aumentou a express&#xe3;o de ALDH2 ligando-se a miR-103-3p e ativou a via PI3K/AKT em c&#xe9;lulas HL-1 tratadas com altos n&#xed;veis de glicose. A deple&#xe7;&#xe3;o de H19 ou o inibidor de PI3K reverteram os efeitos da orientina na apoptose e no estresse oxidativo em c&#xe9;lulas HL-1 sob condi&#xe7;&#xf5;es de altos n&#xed;veis de glicose.</AbstractText><AbstractText Label="CONCLUS&#xd5;ES" NlmCategory="UNASSIGNED">Esses achados revelam um mecanismo protetor da orientina na CMD, que envolve a regula&#xe7;&#xe3;o do eixo de sinaliza&#xe7;&#xe3;o H19/miR-103-3p/ALDH2/PI3K/AKT, fornecendo uma estrat&#xe9;gia potencial para o tratamento da CMD.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>14</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40834212</ArticleId><ArticleId IdType="doi">10.36660/abc.20240885</ArticleId><ArticleId IdType="pii">S0066-782X2025000700305</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40825464</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1913</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>The American journal of cardiology</Title><ISOAbbreviation>Am J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Implication of Angio-based Microvascular Resistance, a Measure of Coronary Microvascular Dysfunction Severity, for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0002-9149(25)00478-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjcard.2025.08.021</ELocationID><Abstract><AbstractText>Coronary microvascular dysfunction (CMD) is a common feature in patients with hypertrophic cardiomyopathy (HCM). CMD is a risk factor for atrial fibrillation (AF) in the general population. However, the relationship between CMD and AF prevalence in HCM patients has not been fully explored. This study aimed to investigate whether Angio-based Microvascular Resistance (AMR), as an index of coronary microcirculatory function, is associated with the prevalence of AF in a large cohort of HCM patients.A total of 607 patients with HCM who underwent coronary angiography were included. AMR was retrospectively calculated using a wire-free angiography method in coronary arteries, and an average value of AMR &#x2265; 250 mmHg*s/m was defined as indicative of CMD. Our results showed that patients with CMD were more often male, with higher smoking rates and a higher prevalence of hypertension The prevalence of AF increased in patients with CMD (26.3% vs 11.0%; P &lt; 0.001), or across AHI quartiles (7.1%, 11.3%, 16.2%, and 26.8%, respectively; P for trend &lt;0.001). After adjusting for age, sex, BMI, Hyperlipidemia, hypertension, left atrial diameter, creatinine and obstructive HCM, the presence of CMD (odds ratio, 3.12; 95% CI: 1.89-5.18, P &lt; 0.001) or highest AMR quartile (odds ratio, 6.08 95% CI: 2.76 - 13.38, P &lt; 0.001) were significantly associated with AF. In conclusion, AMR, as a marker of microvascular dysfunction, is independently associated with the prevalence of AF in patients with HCM. For HCM patients, these findings suggest that evaluating AMR could provide valuable insights into the risk of AF.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pei</LastName><ForeName>Yingqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Haobo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Chong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, the Affiliated Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Fasheng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Weixian</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tianjie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China. Electronic address: tianjie.wang@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Jiansong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China. Electronic address: fwyuanjs@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Cardiol</MedlineTA><NlmUniqueID>0207277</NlmUniqueID><ISSNLinking>0002-9149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">angio-based microvascular resistance</Keyword><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">coronary microvascular dysfunction</Keyword><Keyword MajorTopicYN="N">hypertrophic cardiomyopathy</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40825464</ArticleId><ArticleId IdType="doi">10.1016/j.amjcard.2025.08.021</ArticleId><ArticleId IdType="pii">S0002-9149(25)00478-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40843892</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2571-841X</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Reports (MDPI)</Title><ISOAbbreviation>Reports (MDPI)</ISOAbbreviation></Journal><ArticleTitle>A Case of Success: Guidelines-Based Treatment to Control Atrial Fibrillation-Induced Cardiomyopathy-Atrioventricular Node Ablation and Cardiac Resynchronization Therapy to the Rescue.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">150</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/reports8030150</ELocationID><Abstract><AbstractText><b>Background and Clinical Significance</b>: Heart failure with reduced ejection fraction (HFrEF) and atrial fibrillation (AF) frequently coexist, creating a complex clinical interplay that exacerbates morbidity and mortality. AF can directly precipitate or worsen HFrEF through mechanisms such as tachycardia-induced cardiomyopathy, loss of atrial contribution to ventricular filling, and irregular ventricular response. The use of evidence-based therapies improves clinical outcomes in patients with HFrEF. <b>Case Presentation</b>: We present a clinical case of a 58-year-old man with left bundle branch block (LBBB), tachysystolic AF, and the aforementioned induced HFrEF. The patient's medical treatment was optimized according to recent guidelines. Subsequent to the improvements in HF treatment, the patient's echocardiographic data showed a higher left ventricle ejection fraction (LVEF); however, it remained below 35%. Moreover, tachysystolia persisted and was not sufficiently controlled with medications. Therefore, an upgrade of the pacemaker to cardiac resynchronization therapy (CRT) following the destruction of the AV node was performed to control tachysystolic AF and worsening of HF. After the treatment adjustments, the patient's symptoms regressed, and echocardiography showed improved LVEF up to 41%. <b>Conclusions</b>: This case highlights the successful identification and timely application of intensive heart rate control management and heart failure induced by AF treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jonaitien&#x117;</LastName><ForeName>Neda</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Eiveni&#x173; St. 2, LT-50161 Kaunas, Lithuania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lithuanian Society of Cardiology, Eiveni&#x173; St. 2, LT-50161 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramantauskait&#x117;</LastName><ForeName>Gryt&#x117;</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Eiveni&#x173; St. 2, LT-50161 Kaunas, Lithuania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lithuanian Society of Cardiology, Eiveni&#x173; St. 2, LT-50161 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laukaitien&#x117;</LastName><ForeName>Jolanta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Eiveni&#x173; St. 2, LT-50161 Kaunas, Lithuania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lithuanian Society of Cardiology, Eiveni&#x173; St. 2, LT-50161 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Reports (MDPI)</MedlineTA><NlmUniqueID>101757880</NlmUniqueID><ISSNLinking>2571-841X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">optimal treatment</Keyword><Keyword MajorTopicYN="N">reduced ejection fraction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843892</ArticleId><ArticleId IdType="doi">10.3390/reports8030150</ArticleId><ArticleId IdType="pii">reports8030150</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40832996</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-2092</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology</Title><ISOAbbreviation>Europace</ISOAbbreviation></Journal><ArticleTitle>Different underlying aetiologies in patients presenting with ventricular tachycardia fulfilling task force criteria for arrhythmogenic right ventricular cardiomyopathy: initial suspicion based on the 12-lead electrocardiogram.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">euaf136</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/europace/euaf136</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The task force criteria (TFC) for arrhythmogenic right ventricular cardiomyopathy (ARVC) are highly sensitive but lack specificity. Atypical RV involvement (aRVi) may indicate different underlying aetiologies and prognosis, requiring specific therapeutic interventions. We aimed to evaluate the role of the baseline 12-lead ECG for initial suspicion of aRVi.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From the Netherlands Heart Institute Arrhythmogenic Cardiomyopathy (NHI-ACM) registry, patients were selected who (i) fulfilled TFC for definite ARVC, (ii) presented with sustained ventricular tachycardia (VT), and (iii) underwent genetic testing. The first available ECG after VT was evaluated. PR prolongation &#x2265;220&#x2005;ms and/or a surface area of the maximum R'-wave in V1-V3 of &#x2265;1.65&#x2005;mm2 was defined as an aRVi-ECG. Patients with an ARVC-related pathogenic/likely pathogenic variant (P/LP+) were classified as 'ARVC'. Data of P/LP- were reviewed by an expert panel and classified as either 'ARVC' or 'different aetiology' based on consensus.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 159 patients were included (122 P/LP+ and 37 P/LP- patients). Nineteen patients had an aRVi-ECG [11 (9%) P/LP+ vs. 8 (22%) P/LP-, P = 0.038]. Of the P/LP- patients, 17 (46%) were classified as 'different aetiology' (e.g. myocarditis, ischaemia, sarcoidosis), including all 8 patients with an aRVi-ECG. Among the P/LP+ patients with an aRVi-ECG, 46% carried the p.Arg14del phospholamban pathogenic variant, and 64% died compared to 15 and 19% of P/LP+ patients without an aRVi-ECG, respectively (both P &lt; 0.01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In P/LP- patients presenting with VT and fulfilling TFC, an aRVi-ECG should raise suspicion for a different underlying aetiology. In P/LP+ patients, an aRVi-ECG may identify those with poor outcome.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoogendoorn</LastName><ForeName>Jarieke C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-8090-2447</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Willem Einthoven Center for Cardiac Arrhythmia Research and Management (WECAM), Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosman</LastName><ForeName>Laurens P</ForeName><Initials>LP</Initials><Identifier Source="ORCID">0000-0001-5037-1158</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Heijden</LastName><ForeName>Jeroen F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Haga Ziekenhuis, Den Haag, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilde</LastName><ForeName>Arthur A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-0528-0852</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Heart Centre, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart ).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Maarten P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-1493-2998</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yap</LastName><ForeName>Sing-Chien</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0003-4520-2725</Identifier><AffiliationInfo><Affiliation>European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart ).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Tintelen</LastName><ForeName>J Peter</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0003-3854-6749</Identifier><AffiliationInfo><Affiliation>Department of Genetics, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dooijes</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0312-5354</Identifier><AffiliationInfo><Affiliation>Department of Genetics, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Te Riele</LastName><ForeName>Anneline S J M</ForeName><Initials>ASJM</Initials><Identifier Source="ORCID">0000-0002-4694-4790</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart ).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeppenfeld</LastName><ForeName>Katja</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7034-1017</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Willem Einthoven Center for Cardiac Arrhythmia Research and Management (WECAM), Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Edwards Lifesciences</Agency><Country/></Grant><Grant><Agency>Biotronik</Agency><Country/></Grant><Grant><Agency>Medtronic</Agency><Country/></Grant><Grant><Agency>Boston Scientific</Agency><Country/></Grant><Grant><Agency>Biosense Webster</Agency><Country/></Grant><Grant><Acronym>ZONMW_</Acronym><Agency>ZonMw</Agency><Country>Netherlands</Country></Grant><Grant><GrantID>#101115536</GrantID><Agency>Horizon IMPACT</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Europace</MedlineTA><NlmUniqueID>100883649</NlmUniqueID><ISSNLinking>1099-5129</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019571" MajorTopicYN="Y">Arrhythmogenic Right Ventricular Dysplasia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="Y">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017180" MajorTopicYN="Y">Tachycardia, Ventricular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Arrhythmogenic right ventricular cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Cardiac sarcoidosis</Keyword><Keyword MajorTopicYN="N">Electrocardiogram</Keyword><Keyword MajorTopicYN="N">Ventricular tachycardia</Keyword></KeywordList><CoiStatement>Conflict of interest: A.A.W.: member of the scientific advisory board of Thryv Therapeutics and ARMGO. S.-C.Y. has received honoraria from Boston Scientific, Medtronic, Biotronik, Acutus Medical, and Sanofi. In addition, he has received research grants from Medtronic, Biotronik, and Boston Scientific. A.S.J.M.T.R. is a consultant for Tenaya Therapeutics, BioMarin, and Rocket Pharmaceuticals outside of the scope of the submitted work. All remaining authors have declared no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>7</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40832996</ArticleId><ArticleId IdType="pmc">PMC12365759</ArticleId><ArticleId IdType="doi">10.1093/europace/euaf136</ArticleId><ArticleId IdType="pii">8238475</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Basso &#xa0;C, Corrado &#xa0;D, Marcus &#xa0;FI, Nava &#xa0;A, Thiene &#xa0;G. Arrhythmogenic right ventricular cardiomyopathy. Lancet &#xa0;2009;373:1289&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">19362677</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus &#xa0;FI, McKenna &#xa0;WJ, Sherrill &#xa0;D, Basso &#xa0;C, Bauce &#xa0;B, Bluemke &#xa0;DA &#xa0;et al. &#xa0;Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation &#xa0;2010;121:1533&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860804</ArticleId><ArticleId IdType="pubmed">20172911</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneweg &#xa0;JA, Bhonsale &#xa0;A, James &#xa0;CA, te Riele &#xa0;AS, Dooijes &#xa0;D, Tichnell &#xa0;C &#xa0;et al. &#xa0;Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet &#xa0;2015;8:437&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">25820315</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado &#xa0;D, van Tintelen &#xa0;PJ, McKenna &#xa0;WJ, Hauer &#xa0;RNW, Anastastakis &#xa0;A, Asimaki &#xa0;A &#xa0;et al. &#xa0;Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J &#xa0;2020;41:1414&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138528</ArticleId><ArticleId IdType="pubmed">31637441</ArticleId></ArticleIdList></Reference><Reference><Citation>Venlet &#xa0;J, Piers &#xa0;SR, Jongbloed &#xa0;JD, Androulakis &#xa0;AF, Naruse &#xa0;Y, den Uijl &#xa0;DW &#xa0;et al. &#xa0;Isolated subepicardial right ventricular outflow tract scar in athletes with ventricular tachycardia. J Am Coll Cardiol &#xa0;2017;69:497&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">28153106</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips &#xa0;B, Madhavan &#xa0;S, James &#xa0;CA, te Riele &#xa0;AS, Murray &#xa0;B, Tichnell &#xa0;C &#xa0;et al. &#xa0;Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol &#xa0;2014;7:230&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24585727</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogendoorn &#xa0;JC, Ninaber &#xa0;MK, Piers &#xa0;SRD, de Riva &#xa0;M, Grauss &#xa0;RW, Bogun &#xa0;FM &#xa0;et al. &#xa0;The harm of delayed diagnosis of arrhythmogenic cardiac sarcoidosis: a case series. Europace &#xa0;2020;22:1376&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478317</ArticleId><ArticleId IdType="pubmed">32898252</ArticleId></ArticleIdList></Reference><Reference><Citation>te Riele &#xa0;AS, James &#xa0;CA, Groeneweg &#xa0;JA, Sawant &#xa0;AC, Kammers &#xa0;K, Murray &#xa0;B &#xa0;et al. &#xa0;Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Eur Heart J &#xa0;2016;37:755&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">26314686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogendoorn &#xa0;JC, Venlet &#xa0;J, Out &#xa0;YNJ, Man &#xa0;S, Kumar &#xa0;S, Sramko &#xa0;M &#xa0;et al. &#xa0;The precordial R&#x2019; wave: a novel discriminator between cardiac sarcoidosis and arrhythmogenic right ventricular cardiomyopathy in patients presenting with ventricular tachycardia. Heart Rhythm &#xa0;2021;18:1539&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">33957319</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosman &#xa0;LP, Verstraelen &#xa0;TE, van Lint &#xa0;FHM, Cox &#xa0;M, Groeneweg &#xa0;JA, Mast &#xa0;TP &#xa0;et al. &#xa0;The Netherlands Arrhythmogenic Cardiomyopathy Registry: design and status update. Neth Heart J &#xa0;2019;27:480&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773794</ArticleId><ArticleId IdType="pubmed">30997596</ArticleId></ArticleIdList></Reference><Reference><Citation>James &#xa0;CA, Jongbloed &#xa0;JDH, Hershberger &#xa0;RE, Morales &#xa0;A, Judge &#xa0;DP, Syrris &#xa0;P &#xa0;et al. &#xa0;International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the clinical genome resource framework. Circ Genom Precis Med &#xa0;2021;14:e003273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8205996</ArticleId><ArticleId IdType="pubmed">33831308</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards &#xa0;S, Aziz &#xa0;N, Bale &#xa0;S, Bick &#xa0;D, Das &#xa0;S, Gastier-Foster &#xa0;J &#xa0;et al. &#xa0;Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med &#xa0;2015;17:405&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Surawicz &#xa0;B, Childers &#xa0;R, Deal &#xa0;BJ, Gettes &#xa0;LS, Bailey &#xa0;JJ, Gorgels &#xa0;A &#xa0;et al. &#xa0;AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol &#xa0;2009;53:976&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">19281930</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain &#xa0;R, Dalal &#xa0;D, Daly &#xa0;A, Tichnell &#xa0;C, James &#xa0;C, Evenson &#xa0;A &#xa0;et al. &#xa0;Electrocardiographic features of arrhythmogenic right ventricular dysplasia. Circulation &#xa0;2009;120:477&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814546</ArticleId><ArticleId IdType="pubmed">19635971</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasperetti &#xa0;A, Rossi &#xa0;VA, Chiodini &#xa0;A, Casella &#xa0;M, Costa &#xa0;S, Akdis &#xa0;D &#xa0;et al. &#xa0;Differentiating hereditary arrhythmogenic right ventricular cardiomyopathy from cardiac sarcoidosis fulfilling 2010 ARVC Task Force Criteria. Heart Rhythm &#xa0;2021;18:231&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32976989</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasaiwala &#xa0;SC, Finn &#xa0;C, Delpriore &#xa0;J, Leya &#xa0;F, Gagermeier &#xa0;J, Akar &#xa0;JG &#xa0;et al. &#xa0;Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol &#xa0;2009;20:473&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19017339</ArticleId></ArticleIdList></Reference><Reference><Citation>Dechering &#xa0;DG, Kochh&#xe4;user &#xa0;S, Wasmer &#xa0;K, Zellerhoff &#xa0;S, Pott &#xa0;C, K&#xf6;be &#xa0;J &#xa0;et al. &#xa0;Electrophysiological characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm &#xa0;2013;10:158&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">23070261</ArticleId></ArticleIdList></Reference><Reference><Citation>Youden &#xa0;WJ. Index for rating diagnostic tests. Cancer &#xa0;1950;3:32&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15405679</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus &#xa0;FI, Fontaine &#xa0;GH, Guiraudon &#xa0;G, Frank &#xa0;R, Laurenceau &#xa0;JL, Malergue &#xa0;C &#xa0;et al. &#xa0;Right ventricular dysplasia: a report of 24 adult cases. Circulation &#xa0;1982;65:384&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">7053899</ArticleId></ArticleIdList></Reference><Reference><Citation>Te Riele &#xa0;AS, James &#xa0;CA, Philips &#xa0;B, Rastegar &#xa0;N, Bhonsale &#xa0;A, Groeneweg &#xa0;JA &#xa0;et al. &#xa0;Mutation-positive arrhythmogenic right ventricular dysplasia/cardiomyopathy: the triangle of dysplasia displaced. J Cardiovasc Electrophysiol &#xa0;2013;24:1311&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3971054</ArticleId><ArticleId IdType="pubmed">23889974</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar &#xa0;S, Baldinger &#xa0;SH, Kapur &#xa0;S, Romero &#xa0;J, Mehta &#xa0;NK, Mahida &#xa0;S &#xa0;et al. &#xa0;Right ventricular scar-related ventricular tachycardia in nonischemic cardiomyopathy: electrophysiological characteristics, mapping, and ablation of underlying heart disease. J Cardiovasc Electrophysiol &#xa0;2018;29:79&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">28940781</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepehrkhouy &#xa0;S, Gho &#xa0;J, van Es &#xa0;R, Harakalova &#xa0;M, de Jonge &#xa0;N, Dooijes &#xa0;D &#xa0;et al. &#xa0;Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies. Heart Rhythm &#xa0;2017;14:1024&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">28365402</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasir &#xa0;K, Bomma &#xa0;C, Tandri &#xa0;H, Roguin &#xa0;A, Dalal &#xa0;D, Prakasa &#xa0;K &#xa0;et al. &#xa0;Electrocardiographic features of arrhythmogenic right ventricular dysplasia/cardiomyopathy according to disease severity: a need to broaden diagnostic criteria. Circulation &#xa0;2004;110:1527&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15381658</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanawuttiwat &#xa0;T, Te Riele &#xa0;AS, Philips &#xa0;B, James &#xa0;CA, Murray &#xa0;B, Tichnell &#xa0;C &#xa0;et al. &#xa0;Electroanatomic correlates of depolarization abnormalities in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol &#xa0;2016;27:443&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">26757204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kloosterman &#xa0;M, Boonstra &#xa0;MJ, Roudijk &#xa0;RW, Bourfiss &#xa0;M, van der Schaaf &#xa0;I, Velthuis &#xa0;BK &#xa0;et al. &#xa0;Body surface potential mapping detects early disease onset in plakophilin-2-pathogenic variant carriers. Europace &#xa0;2023;25:euad197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10368448</ArticleId><ArticleId IdType="pubmed">37433034</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorzi &#xa0;A, Migliore &#xa0;F, Elmaghawry &#xa0;M, Silvano &#xa0;M, Marra &#xa0;MP, Niero &#xa0;A &#xa0;et al. &#xa0;Electrocardiographic predictors of electroanatomic scar size in arrhythmogenic right ventricular cardiomyopathy: implications for arrhythmic risk stratification. J Cardiovasc Electrophysiol &#xa0;2013;24:1321&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosman &#xa0;LP, Cadrin-Tourigny &#xa0;J, Bourfiss &#xa0;M, Aliyari Ghasabeh &#xa0;M, Sharma &#xa0;A, Tichnell &#xa0;C &#xa0;et al. &#xa0;Diagnosing arrhythmogenic right ventricular cardiomyopathy by 2010 Task Force Criteria: clinical performance and simplified practical implementation. Europace &#xa0;2020;22:787&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7203633</ArticleId><ArticleId IdType="pubmed">32294163</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogendoorn &#xa0;JC, Sramko &#xa0;M, Venlet &#xa0;J, Siontis &#xa0;KC, Kumar &#xa0;S, Singh &#xa0;R &#xa0;et al. &#xa0;Electroanatomical voltage mapping to distinguish right-sided cardiac sarcoidosis from arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol &#xa0;2020;6:696&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">32553221</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Leur &#xa0;RR, Taha &#xa0;K, Bos &#xa0;MN, van der Heijden &#xa0;JF, Gupta &#xa0;D, Cramer &#xa0;MJ &#xa0;et al. &#xa0;Discovering and visualizing disease-specific electrocardiogram features using deep learning: proof-of-concept in phospholamban gene mutation carriers. Circ Arrhythm Electrophysiol &#xa0;2021;14:e009056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7892204</ArticleId><ArticleId IdType="pubmed">33401921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhonsale &#xa0;A, Groeneweg &#xa0;JA, James &#xa0;CA, Dooijes &#xa0;D, Tichnell &#xa0;C, Jongbloed &#xa0;JD &#xa0;et al. &#xa0;Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J &#xa0;2015;36:847&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">25616645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeppenfeld &#xa0;K, Tfelt-Hansen &#xa0;J, de Riva &#xa0;M, Winkel &#xa0;BG, Behr &#xa0;ER, Blom &#xa0;NA &#xa0;et al. &#xa0;2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J &#xa0;2022;43:3997&#x2013;4126.</Citation><ArticleIdList><ArticleId IdType="pubmed">36017572</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasperetti &#xa0;A, James &#xa0;CA, Carrick &#xa0;RT, Protonotarios &#xa0;A, Te Riele &#xa0;A, Cadrin-Tourigny &#xa0;J &#xa0;et al. &#xa0;Arrhythmic risk stratification in arrhythmogenic right ventricular cardiomyopathy. Europace &#xa0;2023;25:euad312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10674106</ArticleId><ArticleId IdType="pubmed">37935403</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40836019</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1084</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>European radiology</Title><ISOAbbreviation>Eur Radiol</ISOAbbreviation></Journal><ArticleTitle>Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging for non-sustained ventricular tachycardia and sudden cardiac death in hypertrophic cardiomyopathy: a meta-analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00330-025-11961-y</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Non-sustained ventricular tachycardia (NSVT) is an independent predictor of sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM). This meta-analysis evaluates the prognostic value of late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) for predicting NSVT and its association with SCD in HCM.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We screened electronic databases for studies evaluating the prognostic value of LGE in predicting NSVT and SCD in HCM patients. A random-effects model estimated pooled sensitivity, specificity, accuracy, predictive values, and likelihood ratios for NSVT prediction. Association between LGE extent and NSVT incidence was analyzed using weighted mean differences (WMDs), while pooled odds ratios (ORs) with 95% CIs were calculated to assess LGE's association with SCD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 20 studies, LGE showed a pooled sensitivity, specificity, and accuracy of 91.33% (95% CI: 88.81-93.86), 37.45% (95% CI: 31.60-43.31), and 52.86% (95% CI: 45.73-59.98), respectively, for NSVT prediction. Positive and negative likelihood ratios and predictive values were, 1.40 and 0.23, and 36.35% and 92.03%, respectively. Patients with NSVT had a significantly greater LGE extent than those without (WMD: 5.95%, 95% CI: 3.08-8.81, p&#x2009;&lt;&#x2009;0.0001). NSVT prevalence was 28.73% (95% CI: 20.91-36.54). Additionally, LGE presence and SCD were significantly associated (OR 3.64, 95% CI: 2.36-5.61, p&#x2009;&lt;&#x2009;0.00001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LGE on CMR shows high sensitivity but limited specificity and accuracy for NSVT prediction. Moreover, LGE presence was significantly associated with SCD, and NSVT patients had greater LGE extent. Nonetheless, variability in predictive values and likelihood ratios underscores the need to combine LGE with other imaging biomarkers.</AbstractText><AbstractText Label="KEY POINTS" NlmCategory="CONCLUSIONS">Question Can LGE on CMR predict NSVT and SCD in HCM patients? Findings LGE demonstrated high sensitivity but limited specificity for NSVT prediction. Moreover, LGE presence was significantly associated with SCD, and NSVT patients had greater LGE extent. Clinical relevance LGE on CMR is a valuable marker for NSVT prediction and SCD in HCM patients, but it is not widely integrated into clinical practice. Our study highlights the need to integrate LGE with other imaging biomarkers for improved risk stratification.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to European Society of Radiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siddiqi</LastName><ForeName>Ahmed Kamal</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0001-5612-8626</Identifier><AffiliationInfo><Affiliation>Division of Cardiothoracic Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA. ahmed.kamal.siddiqi@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maniya</LastName><ForeName>Muhammad Talha</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Ziauddin Medical University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilen</LastName><ForeName>Ozlem</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdou</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Cecco</LastName><ForeName>Carlo N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Division of Cardiothoracic Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Laboratory for Cardiothoracic Imaging and Artificial Intelligence, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naeem</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiothoracic Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Radiol</MedlineTA><NlmUniqueID>9114774</NlmUniqueID><ISSNLinking>0938-7994</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hypertrophic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Late gadolinium enhancement</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Non-sustained ventricular tachycardia</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword></KeywordList><CoiStatement>Compliance with ethical standards. Guarantor: The scientific guarantor of this publication is Ahmed Kamal Siddiqi. Conflict of interest: Dr. De Cecco receives research support from/is a consultant for: Siemens, Cleerly, Elucid, Xeos, Bayer. No other conflicts of interest to disclose. Statistics and biometry: One of the authors has significant statistical expertise. Informed consent: This study is a systematic review and meta-analysis, so written informed consent was not required for this study. Ethical approval: This study was a systematic review and meta-analysis, so Institutional Review Board approval was not required because of the nature of the study. Study subjects or cohorts overlap: Not applicable. Methodology: Systematic review and meta-analysis</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40836019</ArticleId><ArticleId IdType="doi">10.1007/s00330-025-11961-y</ArticleId><ArticleId IdType="pii">10.1007/s00330-025-11961-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Authors/Task Force Members, Elliott PM, Anastasakis A et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733&#x2013;2779. https://doi.org/10.1093/eurheartj/ehu284</Citation></Reference><Reference><Citation>Varnava AM, Elliott PM, Mahon N et al (2001) Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 88:275&#x2013;279. https://doi.org/10.1016/S0002-9149(01)01640-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9149(01)01640-X</ArticleId><ArticleId IdType="pubmed">11472707</ArticleId></ArticleIdList></Reference><Reference><Citation>Christiaans I, Van Engelen K, Van Langen IM et al (2010) Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace 12:313&#x2013;321. https://doi.org/10.1093/europace/eup431</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/eup431</ArticleId><ArticleId IdType="pubmed">20118111</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Kardiol Pol 72:1054&#x2013;1126. https://doi.org/10.5603/KP.2014.0212</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/KP.2014.0212</ArticleId><ArticleId IdType="pubmed">25524376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ommen SR, Mital S, Burke MA et al (2020) 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 76:e159&#x2013;e240. https://doi.org/10.1016/j.jacc.2020.08.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.08.045</ArticleId><ArticleId IdType="pubmed">33229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron BJ, Casey SA, Chan RH et al (2015) Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol 116:757&#x2013;764. https://doi.org/10.1016/j.amjcard.2015.05.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2015.05.047</ArticleId><ArticleId IdType="pubmed">26183790</ArticleId></ArticleIdList></Reference><Reference><Citation>Katritsis DG, Zareba W, Camm AJ (2012) Nonsustained ventricular tachycardia. J Am Coll Cardiol 60:1993&#x2013;2004. https://doi.org/10.1016/j.jacc.2011.12.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2011.12.063</ArticleId><ArticleId IdType="pubmed">23083773</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Liu S, Shen L et al (2020) Correlations between cardiac troponin I and nonsustained ventricular tachycardia in hypertrophic obstructive cardiomyopathy. Clin Cardiol 43:1150&#x2013;1159. https://doi.org/10.1002/clc.23425</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.23425</ArticleId><ArticleId IdType="pubmed">32810305</ArticleId><ArticleId IdType="pmc">7534013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Lian Z, Rowin EJ et al (2017) Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 10:e004604. https://doi.org/10.1161/CIRCEP.116.004604</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCEP.116.004604</ArticleId><ArticleId IdType="pubmed">28314849</ArticleId></ArticleIdList></Reference><Reference><Citation>Monserrat L, Elliott PM, Gimeno JR et al (2003) Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. J Am Coll Cardiol 42:873&#x2013;879. https://doi.org/10.1016/S0735-1097(03)00827-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(03)00827-1</ArticleId><ArticleId IdType="pubmed">12957435</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron BJ, Savage DD, Wolfson JK, Epstein SE (1981) Prognostic significance of 24&#x2009;h ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 48:252&#x2013;257. https://doi.org/10.1016/0002-9149(81)90604-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(81)90604-4</ArticleId><ArticleId IdType="pubmed">7196685</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Yu M, Yuan J et al (2020) Cardiac troponin I is associated with non-sustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy. Heart Vessels 35:876&#x2013;885. https://doi.org/10.1007/s00380-019-01549-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00380-019-01549-0</ArticleId><ArticleId IdType="pubmed">31907598</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308&#x2013;1320. https://doi.org/10.1001/jama.287.10.1308</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.287.10.1308</ArticleId><ArticleId IdType="pubmed">11886323</ArticleId></ArticleIdList></Reference><Reference><Citation>Magr&#xec; D, De Cecco CN, Piccirillo G et al (2014) Myocardial repolarization dispersion and late gadolinium enhancement in patients with hypertrophic cardiomyopathy. Circ J 78:1216&#x2013;1223. https://doi.org/10.1253/circj.CJ-13-1423</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-13-1423</ArticleId><ArticleId IdType="pubmed">24632791</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozo E, Viliani D, Aguirre N et al (2016) Early gadolinium enhancement in hypertrophic cardiomyopathy: a potential premature marker of myocardial damage. Int J Cardiovasc Imaging 32:1635&#x2013;1643. https://doi.org/10.1007/s10554-016-0954-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-016-0954-5</ArticleId><ArticleId IdType="pubmed">27503551</ArticleId></ArticleIdList></Reference><Reference><Citation>Green JJ, Berger JS, Kramer CM, Salerno M (2012) Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 5:370&#x2013;377. https://doi.org/10.1016/j.jcmg.2011.11.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2011.11.021</ArticleId><ArticleId IdType="pubmed">22498326</ArticleId></ArticleIdList></Reference><Reference><Citation>Adabag AS, Maron BJ, Appelbaum E et al (2008) Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51:1369&#x2013;1374. https://doi.org/10.1016/j.jacc.2007.11.071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2007.11.071</ArticleId><ArticleId IdType="pubmed">18387438</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H, Park C, Kim Y et al (2020) Burden of premature ventricular contractions beyond nonsustained ventricular tachycardia is related to the myocardial extracellular space expansion in patients with hypertrophic-cardiomyopathy. Clin Cardiol 43:1317&#x2013;1325. https://doi.org/10.1002/clc.23445</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.23445</ArticleId><ArticleId IdType="pubmed">32815161</ArticleId><ArticleId IdType="pmc">7661646</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinshtein R, Glockner JF, Ommen SR et al (2010) Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 3:51&#x2013;58. https://doi.org/10.1161/CIRCHEARTFAILURE.109.854026</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.109.854026</ArticleId><ArticleId IdType="pubmed">19850699</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury L, Mahrholdt H, Wagner A et al (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40:2156&#x2013;2164. https://doi.org/10.1016/S0735-1097(02)02602-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(02)02602-5</ArticleId><ArticleId IdType="pubmed">12505229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail TF, Jabbour A, Gulati A et al (2014) Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart 100:1851&#x2013;1858. https://doi.org/10.1136/heartjnl-2013-305471</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2013-305471</ArticleId><ArticleId IdType="pubmed">24966307</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron BJ, Maron MS, Lesser JR et al (2008) Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol 101:544&#x2013;547. https://doi.org/10.1016/j.amjcard.2007.09.101</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2007.09.101</ArticleId><ArticleId IdType="pubmed">18312775</ArticleId></ArticleIdList></Reference><Reference><Citation>Klopotowski M, Kukula K, Malek LA et al (2016) The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. J Cardiol 68:49&#x2013;56. https://doi.org/10.1016/j.jjcc.2015.07.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2015.07.020</ArticleId><ArticleId IdType="pubmed">26363820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaos A, Daskalopoulos GN, Kamperidis V et al (2024) Quantitative late gadolinium enhancement cardiac magnetic resonance and sudden death in hypertrophic cardiomyopathy: a meta-analysis. JACC Cardiovasc Imaging 17:489&#x2013;497. https://doi.org/10.1016/j.jcmg.2023.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2023.07.005</ArticleId><ArticleId IdType="pubmed">37632503</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BM, Dorfman AL, Yu S et al (2014) Clinical significance of late gadolinium enhancement in patients &lt;20 years of age with hypertrophic cardiomyopathy. Am J Cardiol 113:1234&#x2013;1239. https://doi.org/10.1016/j.amjcard.2013.12.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2013.12.034</ArticleId><ArticleId IdType="pubmed">24513464</ArticleId></ArticleIdList></Reference><Reference><Citation>Teraoka K, Hirano M, Ookubo H et al (2004) Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 22:155&#x2013;161. https://doi.org/10.1016/j.mri.2003.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mri.2003.08.009</ArticleId><ArticleId IdType="pubmed">15010107</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10: 89. https://doi.org/10.1186/s13643-021-01626-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-021-01626-4</ArticleId><ArticleId IdType="pubmed">33781348</ArticleId><ArticleId IdType="pmc">8008539</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Mulder F, Leeflang M et al (2022) QUAPAS: an adaptation of the QUADAS-2 tool to assess prognostic accuracy studies. Ann Intern Med 175:1010&#x2013;1018. https://doi.org/10.7326/M22-0276</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-0276</ArticleId><ArticleId IdType="pubmed">35696685</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumont C, Monserrat L, Soler R et al (2007) Clinical significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol 60:15&#x2013;23. https://doi.org/10.1016/S1885-5857(07)60101-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1885-5857(07)60101-7</ArticleId><ArticleId IdType="pubmed">17288951</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrow PP, Klimeczek P, Vliegenthart R et al (2007) Late hyperenhancement in gadolinium-enhanced magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia. Int J Cardiovasc Imaging 24:77&#x2013;83. https://doi.org/10.1007/s10554-007-9209-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-007-9209-9</ArticleId><ArticleId IdType="pubmed">17624806</ArticleId></ArticleIdList></Reference><Reference><Citation>Pay&#xe1; E, Mar&#xed;n F, Gonz&#xe1;lez J et al (2008) Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications. J Card Fail 14:414&#x2013;419. https://doi.org/10.1016/j.cardfail.2008.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2008.02.006</ArticleId><ArticleId IdType="pubmed">18514934</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hanlon R, Grasso A, Roughton M et al (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56:867&#x2013;874. https://doi.org/10.1016/j.jacc.2010.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2010.05.010</ArticleId><ArticleId IdType="pubmed">20688032</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelbaum E, Maron BJ, Adabag S et al (2012) Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 5:78&#x2013;85. https://doi.org/10.1161/CIRCIMAGING.111.963819</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCIMAGING.111.963819</ArticleId><ArticleId IdType="pubmed">22135401</ArticleId></ArticleIdList></Reference><Reference><Citation>Suwa K, Satoh H, Sano M et al (2014) Functional, morphological and electrocardiographical abnormalities in patients with apical hypertrophic cardiomyopathy and apical aneurysm: correlation with cardiac MR. Open Heart 1:e000124. https://doi.org/10.1136/openhrt-2014-000124</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2014-000124</ArticleId><ArticleId IdType="pubmed">25332823</ArticleId><ArticleId IdType="pmc">4189224</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130:484&#x2013;495. https://doi.org/10.1161/CIRCULATIONAHA.113.007094</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.007094</ArticleId><ArticleId IdType="pubmed">25092278</ArticleId></ArticleIdList></Reference><Reference><Citation>Magr&#xec; D, Piccirillo G, Ricotta A et al (2015) Spatial QT dispersion predicts nonsustained ventricular tachycardia and correlates with confined systodiastolic dysfunction in hypertrophic cardiomyopathy. Cardiology 131:122&#x2013;129. https://doi.org/10.1159/000377622</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000377622</ArticleId><ArticleId IdType="pubmed">25925893</ArticleId></ArticleIdList></Reference><Reference><Citation>McLELLAN AJA, Ellims AH, Prabhu S et al (2016) Diffuse ventricular fibrosis on cardiac magnetic resonance imaging associates with ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 27:571&#x2013;580. https://doi.org/10.1111/jce.12948</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jce.12948</ArticleId><ArticleId IdType="pubmed">26840595</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissler-Snir A, Hindieh W, Spears DA et al (2019) The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: a delayed contrast-enhanced magnetic resonance study. J Cardiovasc Electrophysiol 30:651&#x2013;657. https://doi.org/10.1111/jce.13855</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jce.13855</ArticleId><ArticleId IdType="pubmed">30680853</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine J, Collins JD, Ogele E et al (2020) Relation of late gadolinium enhancement and extracellular volume fraction to ventricular arrhythmias in hypertrophic cardiomyopathy. Am J Cardiol 131:104&#x2013;108. https://doi.org/10.1016/j.amjcard.2020.06.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2020.06.040</ArticleId><ArticleId IdType="pubmed">32718552</ArticleId></ArticleIdList></Reference><Reference><Citation>Park YJ, Park S-J, Kim E-K et al (2020) Semi-quantitative versus quantitative assessments of late gadolinium enhancement extent for predicting spontaneous ventricular tachyarrhythmia events in patients with hypertrophic cardiomyopathy. Sci Rep 10:2920. https://doi.org/10.1038/s41598-020-59804-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-59804-8</ArticleId><ArticleId IdType="pubmed">32076039</ArticleId><ArticleId IdType="pmc">7031259</ArticleId></ArticleIdList></Reference><Reference><Citation>Karabinowska-Ma&#x142;ocha A, Dziewi&#x119;cka E, Bany&#x15b; P et al (2022) The relationship between cardiac magnetic resonance-assessed replacement and interstitial fibrosis and ventricular arrhythmias in hypertrophic cardiomyopathy. J Pers Med 12:294. https://doi.org/10.3390/jpm12020294</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12020294</ArticleId><ArticleId IdType="pubmed">35207782</ArticleId><ArticleId IdType="pmc">8876292</ArticleId></ArticleIdList></Reference><Reference><Citation>Hen Y, Iguchi N, Machida H et al (2013) High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Heart Vessels 28:742&#x2013;749. https://doi.org/10.1007/s00380-012-0300-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00380-012-0300-3</ArticleId><ArticleId IdType="pubmed">23097076</ArticleId></ArticleIdList></Reference><Reference><Citation>Aquaro GD, Masci P, Formisano F et al (2010) Usefulness of delayed enhancement by magnetic resonance imaging in hypertrophic cardiomyopathy as a marker of disease and its severity. Am J Cardiol 105:392&#x2013;397. https://doi.org/10.1016/j.amjcard.2009.09.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2009.09.045</ArticleId><ArticleId IdType="pubmed">20102955</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron MS, Appelbaum E, Harrigan CJ et al (2008) Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 1:184&#x2013;191. https://doi.org/10.1161/CIRCHEARTFAILURE.108.768119</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.108.768119</ArticleId><ArticleId IdType="pubmed">19808288</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai V, Sharma P, Agrawal S, Agrawal DK (2017) Relevance of mouse models of cardiac fibrosis and hypertrophy in cardiac research. Mol Cell Biochem 424:123&#x2013;145. https://doi.org/10.1007/s11010-016-2849-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-016-2849-0</ArticleId><ArticleId IdType="pubmed">27766529</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper LT, Baughman KL, Feldman AM et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116:2216&#x2013;2233. https://doi.org/10.1161/CIRCULATIONAHA.107.186093</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.186093</ArticleId><ArticleId IdType="pubmed">17959655</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruder O, Wagner A, Jensen CJ et al (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56:875&#x2013;887. https://doi.org/10.1016/j.jacc.2010.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2010.05.007</ArticleId><ArticleId IdType="pubmed">20667520</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon DH, Setser RM, Popovi&#x107; ZB et al (2008) Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging 24:617&#x2013;625. https://doi.org/10.1007/s10554-008-9292-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-008-9292-6</ArticleId><ArticleId IdType="pubmed">18204915</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolph A, Abdel-Aty H, Bohl S et al (2009) Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy. J Am Coll Cardiol 53:284&#x2013;291. https://doi.org/10.1016/j.jacc.2008.08.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2008.08.064</ArticleId><ArticleId IdType="pubmed">19147047</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon JCC, Reed E, Sheppard MN et al (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43:2260&#x2013;2264. https://doi.org/10.1016/j.jacc.2004.03.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2004.03.035</ArticleId><ArticleId IdType="pubmed">15193690</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz C, Schwarz M, Ilic I et al (2013) Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. Can J Cardiol 29:358&#x2013;363. https://doi.org/10.1016/j.cjca.2012.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2012.05.004</ArticleId><ArticleId IdType="pubmed">22749647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ommen SR, Mital S, Burke MA et al (2020) 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 142:e533&#x2013;e557. https://doi.org/10.1161/CIR.0000000000000938</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000938</ArticleId><ArticleId IdType="pubmed">33215938</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon JCC, McKenna WJ, McCrohon JA et al (2003) Toward clinical risk assessment inhypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41:1561&#x2013;1567. https://doi.org/10.1016/S0735-1097(03)00189-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(03)00189-X</ArticleId><ArticleId IdType="pubmed">12742298</ArticleId></ArticleIdList></Reference><Reference><Citation>Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336:775&#x2013;785. https://doi.org/10.1056/NEJM199703133361107</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199703133361107</ArticleId><ArticleId IdType="pubmed">9052657</ArticleId></ArticleIdList></Reference><Reference><Citation>Briasoulis A, Mallikethi-Reddy S, Palla M et al (2015) Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart 101:1406&#x2013;1411. https://doi.org/10.1136/heartjnl-2015-307682</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2015-307682</ArticleId><ArticleId IdType="pubmed">26060120</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Zhou J (2024) Reversed septal curvature is associated with nonsustained ventricular tachycardia in hypertrophic cardiomyopathy. Am J Cardiol 210:195&#x2013;200. https://doi.org/10.1016/j.amjcard.2023.10.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2023.10.056</ArticleId><ArticleId IdType="pubmed">37884111</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron BJ (2010) Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 121:445&#x2013;456. https://doi.org/10.1161/CIRCULATIONAHA.109.878579</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.878579</ArticleId><ArticleId IdType="pubmed">20100987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitkungvan D, Nabi F, Kim RJ et al (2018) Myocardial fibrosis in patients with primary mitral regurgitation with and without prolapse. J Am Coll Cardiol 72:823&#x2013;834. https://doi.org/10.1016/j.jacc.2018.06.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.06.048</ArticleId><ArticleId IdType="pubmed">30115220</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng Z, Yao J, Chan RH et al (2016) Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 9:1392&#x2013;1402. https://doi.org/10.1016/j.jcmg.2016.02.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2016.02.031</ArticleId><ArticleId IdType="pubmed">27450876</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40843112</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2950-1334</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JHLT open</Title><ISOAbbreviation>JHLT Open</ISOAbbreviation></Journal><ArticleTitle>Development of severe pre-capillary pulmonary hypertension 7 years after heart transplant.</ArticleTitle><Pagination><StartPage>100274</StartPage><MedlinePgn>100274</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100274</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhlto.2025.100274</ELocationID><Abstract><AbstractText>We present the case of a patient who developed severe pre-capillary pulmonary hypertension 7&#xa0;years after heart transplantation. The transplantation was performed due to the dilated phase of hypertrophic cardiomyopathy with combined post- and pre-capillary pulmonary hypertension (CpcPH), which had initially improved. This case highlights the potential underlying factors contributing to pulmonary arterial hypertension in patients with CpcPH and the importance of careful long-term follow-up after heart transplantation.</AbstractText><CopyrightInformation>&#xa9; 2025 International Society for Heart and Lung Transplantation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takano</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukamoto</LastName><ForeName>Yasumasa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JHLT Open</MedlineTA><NlmUniqueID>9918716187806676</NlmUniqueID><ISSNLinking>2950-1334</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Combined post- and pre-capillary pulmonary hypertension</Keyword><Keyword MajorTopicYN="N">Heart transplantation</Keyword><Keyword MajorTopicYN="N">Left ventricular assist device</Keyword><Keyword MajorTopicYN="N">Pulmonary arterial hypertension</Keyword><Keyword MajorTopicYN="N">Upfront combination therapy</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Takeshi Ogo reports a relationship with Nippon Shinyaku Co Ltd that includes: speaking and lecture fees. Takeshi Ogo reports a relationship with Janssen Pharmaceutical KK that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843112</ArticleId><ArticleId IdType="pmc">PMC12366527</ArticleId><ArticleId IdType="doi">10.1016/j.jhlto.2025.100274</ArticleId><ArticleId IdType="pii">S2950-1334(25)00069-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sato T., Seguchi O., Morikawa N., et al. A heart transplant candidate with severe pulmonary hypertension and extremely high pulmonary vascular resistance. J Artif Organs. 2013;16:253&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">23443326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Peng L., Zhao C. MYH7 in cardiomyopathy and skeletal muscle myopathy. Mol Cell Biochem. 2024;479:393&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">37079208</ArticleId></ArticleIdList></Reference><Reference><Citation>Anegawa E., Seguchi O., Mochizuki H., et al. Pulmonary vascular reverse remodeling after left ventricular assist device implantation in patients with pulmonary hypertension. ASAIO J. 2023;69:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">36716069</ArticleId></ArticleIdList></Reference><Reference><Citation>Gude E., Simonsen S., Geiran O.R., et al. Pulmonary hypertension in heart transplantation: discrepant prognostic impact of pre-operative compared with 1-year post-operative right heart hemodynamics. J Hear Lung Transplant. 2010;29:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">19837606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahsan S.A., Berger J.I., Lanier G. De Novo pulmonary arterial hypertension after heart transplantation. J Card Fail. 2020;26:S107.</Citation></Reference><Reference><Citation>Karamian G., Mahgoub A., Cossio M. Tacrolimus-induced pulmonary arterial hypertension. Chest. 2020;158:A2145.</Citation></Reference><Reference><Citation>Spiekerkoetter E., Sung Y.K., Sudheendra D., et al. Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. Eur Respir J. 2017;50:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">28893866</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40842968</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2090-6404</ISSN><JournalIssue CitedMedium="Print"><Volume>2025</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Case reports in cardiology</Title><ISOAbbreviation>Case Rep Cardiol</ISOAbbreviation></Journal><ArticleTitle>Pneumococcal Pyopericardium With Xiphoid Osteomyelitis in HIV/AIDS: A Rare but Potentially Fatal Complication.</ArticleTitle><Pagination><StartPage>5008190</StartPage><MedlinePgn>5008190</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5008190</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/cric/5008190</ELocationID><Abstract><AbstractText><b>Background:</b> Purulent pericarditis is a rare, life-threatening condition that has become exceedingly uncommon due to widespread use of antibiotics. However, immunocompromised patients remain susceptible to such opportunistic infections. It is typically caused by direct extension or hematogenous spread from a secondary bacterial source. <b>Case Description:</b> We report a 55-year-old man with HIV cardiomyopathy who was transferred from an outside facility for chest pain and dyspnea, with an electrocardiogram suggestive of an ST-segment elevation myocardial infarction, prompting emergent cardiac catheterization, which revealed normal coronary arteries. A bedside echocardiogram revealed a large pericardial effusion with tamponade physiology, leading to pericardiocentesis. The pericardial fluid analysis revealed a high white blood cell count and a significantly elevated lactate dehydrogenase level, and cultures were positive for <i>Streptococcus pneumoniae</i>. Despite receiving antibiotics, the effusion reaccumulated, necessitating a subxiphoid pericardial wash and drainage. The xiphoid biopsy was consistent with acute osteomyelitis. The patient was discharged with long-term antibiotics and scheduled outpatient follow-ups. <b>Conclusion:</b> This case illustrates an unusual presentation of HIV-AIDS, highlighting advancements in managing pneumococcal pyopericardium with tamponade and the ongoing risk of opportunistic infections despite antiretroviral treatment. Though rare, pyopericardium can be fatal; so prompt diagnosis and multidisciplinary management are essential to improve outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Nihar Jena et al. Case Reports in Cardiology published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jena</LastName><ForeName>Nihar</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-7702-9034</Identifier><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saeed</LastName><ForeName>Izza</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Mackenzie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tocquica</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7753-5570</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Trinity Health Oakland/Wayne State University, Pontiac, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avula</LastName><ForeName>Sreekant</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3909-2531</Identifier><AffiliationInfo><Affiliation>Department of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayyed</LastName><ForeName>Ramiz</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bastidas</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Studeny</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Case Rep Cardiol</MedlineTA><NlmUniqueID>101576452</NlmUniqueID><ISSNLinking>2090-6404</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">Streptococcus pneumoniae</Keyword><Keyword MajorTopicYN="N">pericardial tamponade</Keyword><Keyword MajorTopicYN="N">pyopericardium</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>4</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40842968</ArticleId><ArticleId IdType="pmc">PMC12367396</ArticleId><ArticleId IdType="doi">10.1155/cric/5008190</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maisch B., Seferovi&#x107; P. M., Risti&#x107; A. D., et al. Guidelines on the Diagnosis and Management of Pericardial Diseases Executive Summary: The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. European Heart Journal . 2004;25(7):587&#x2013;610. doi: 10.1016/j.ehj.2004.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ehj.2004.02.002</ArticleId><ArticleId IdType="pubmed">15120056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagrist&#xe0;-Sauleda J., Barrab&#xe9;s J. A., Permanyer-Miralda G., Soler-Soler J. Purulent Pericarditis: Review of a 20-Year Experience in a General Hospital. Journal of the American College of Cardiology . 1993;22(6):1661&#x2013;1665. doi: 10.1016/0735-1097(93)90592-O.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0735-1097(93)90592-O</ArticleId><ArticleId IdType="pubmed">8227835</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandell L. A., Wunderink R. G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases . 2007;44(Supplement_2):S27&#x2013;S72. doi: 10.1086/511159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/511159</ArticleId><ArticleId IdType="pmc">PMC7107997</ArticleId><ArticleId IdType="pubmed">17278083</ArticleId></ArticleIdList></Reference><Reference><Citation>Heffernan R. T., Barrett N. L., Gallagher K. M., et al. Declining Incidence of Invasive Streptococcus pneumoniae Infections Among Persons With AIDS in an Era of Highly Active Antiretroviral Therapy, 1995&#x2013;2000. Journal of Infectious Diseases . 2005;191(12):2038&#x2013;2045. doi: 10.1086/430356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/430356</ArticleId><ArticleId IdType="pubmed">15897989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind A., Reinsch N., Neuhaus K., et al. Pericardial Effusion of HIV-Infected Patients - Results of a Prospective Multicenter Cohort Study in the Era of Antiretroviral Therapy. European Journal of Medical Research . 2011;16(11):480&#x2013;483. doi: 10.1186/2047-783X-16-11-480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2047-783X-16-11-480</ArticleId><ArticleId IdType="pmc">PMC3351804</ArticleId><ArticleId IdType="pubmed">22027640</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaduri-McIntosh S., Prasad M., Moltedo J., V&#xe1;zquez M. Purulent Pericarditis Caused by Group A Streptococcus. Texas Heart Institute Journal . 2006;33(4):519&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1764956</ArticleId><ArticleId IdType="pubmed">17215986</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith Z. A., Wimbush S. Pneumococcal Pyopericardium Masquerading as Acute Coronary Syndrome. Journal of the Intensive Care Society . 2012;13(1):43&#x2013;46. doi: 10.1177/175114371201300112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/175114371201300112</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir S., Fauci A. S. B-Cell Exhaustion in HIV infection. Current Opinion in HIV and AIDS . 2014;9(5):472&#x2013;477. doi: 10.1097/COH.0000000000000092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COH.0000000000000092</ArticleId><ArticleId IdType="pubmed">25023621</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullers J. A. Insights Into the Interaction Between Influenza Virus and Pneumococcus. Clinical Microbiology Reviews . 2006;19(3):571&#x2013;582. doi: 10.1128/CMR.00058-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00058-05</ArticleId><ArticleId IdType="pmc">PMC1539103</ArticleId><ArticleId IdType="pubmed">16847087</ArticleId></ArticleIdList></Reference><Reference><Citation>Cracknell B. R. S., Ail D. The Unmasking of a Pyopericardium. BMJ Case Reports . 2015;2015 doi: 10.1136/bcr-2014-207441.bcr2014207441</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2014-207441</ArticleId><ArticleId IdType="pmc">PMC4368986</ArticleId><ArticleId IdType="pubmed">25737219</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40843009</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1226-8453</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of ginseng research</Title><ISOAbbreviation>J Ginseng Res</ISOAbbreviation></Journal><ArticleTitle>Ginsenoside Rb1 ameliorates post-doxorubicin treatment myocardial hypertrophy via CaN/NFATc4/GATA4.</ArticleTitle><Pagination><StartPage>585</StartPage><EndPage>593</EndPage><MedlinePgn>585-593</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jgr.2025.06.003</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Myocardial hypertrophy is a crucial pathological change that occurs during post-anthracycline treatment cardiomyopathy. The effects of ginsenoside Rb1 (Rb1) on anthracycline-induced hypertrophy remain unclear. This study aimed to explore the antihypertrophic effect of Rb1 on post-doxorubicin (DOX) treatment myocardial hypertrophy and underlying mechanism.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Post-DOX treatment myocardial hypertrophy was induced 12 days or 22&#xa0;h after 15&#xa0;mg/kg DOX injection in C57BL/6 mice or 2&#xa0;h DOX (2&#xa0;&#x3bc;M) incubation in H9c2 cardiomyoblasts. Rb1 was administered 2 days before DOX exposure for 14 consecutive days or 6&#xa0;h before DOX incubation for 30&#xa0;h. Heart weight/Body weight (HW/BW), heart weight/tibia length (HW/TL) ratios, echocardiography, WGA staining and the contents of &#x3b1;-SMA, BNP and &#x3b2;-MCH were used to validate myocardial hypertrophy. HE staining, Masson staining, and transmission electron microscopy were performed to assess changes in cardiac morphology. Fluo-3/AM fluorescence was applied to measure the cytosolic free calcium concentration. Western blot, immunohistochemical and immunofluorescence staining were used to assess the expression of CaNB&#x3b2;/NFATc4/GATA4 signaling.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Rb1 significantly decreased the HW/BW, HW/TL and LVd mass/BW ratios, reduced the cardiomyocyte area and the expression of BNP, &#x3b2;-MHC and &#x3b1;-SMA. Rb1 also relieved myocardial fibrosis and subcellar structure changes and improved the cardiac hemodynamics of post-DOX treatment mice. Rb1 decreased post-DOX treatment calcium overload. Consistent with these findings, <i>in vivo</i> and <i>in vitro</i> CaN, NFATc4 and GATA4 overexpression was rectified.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Rb1 ameliorated post-doxorubicin treatment myocardial hypertrophy, which may be correlated with CaN/NFAT/GATA4 downregulation.</AbstractText><CopyrightInformation>&#xa9; 2025 The Korean Society of Ginseng. Publishing services by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jin-Jin</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Air Force Medical Center, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Li-Xia</ForeName><Initials>LX</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, Huzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Wen-Jing</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Huan-Huan</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jun-Wei</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Ping-Ying</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Rui-Lan</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Rui-Xing</ForeName><Initials>RX</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jian-Feng</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gui</LastName><ForeName>Long-Xin</ForeName><Initials>LX</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Min-Xia</ForeName><Initials>MX</Initials><AffiliationInfo><Affiliation>Public Technology Service Center, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jun-Jin</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Public Technology Service Center, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhi-Hong</ForeName><Initials>ZH</Initials><AffiliationInfo><Affiliation>Public Technology Service Center, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jia-Lin</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics &amp; Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Mo-Jun</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Hai-Xia</ForeName><Initials>HX</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhi-Juan</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Ginseng Res</MedlineTA><NlmUniqueID>100890690</NlmUniqueID><ISSNLinking>1226-8453</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CaN/NFATc4/GATA4</Keyword><Keyword MajorTopicYN="N">Fibrosis</Keyword><Keyword MajorTopicYN="N">Ginsenoside Rb1</Keyword><Keyword MajorTopicYN="N">Myocardial hypertrophy</Keyword><Keyword MajorTopicYN="N">Post-doxorubicin treatment</Keyword></KeywordList><CoiStatement>The authors declare no potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>4</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843009</ArticleId><ArticleId IdType="pmc">PMC12365550</ArticleId><ArticleId IdType="doi">10.1016/j.jgr.2025.06.003</ArticleId><ArticleId IdType="pii">S1226-8453(25)00095-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sheibani M., Azizi Y., Shayan M., Nezamoleslami S., Eslami F., Farjoo M.H., et al. Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol. 2022;22(4):292&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">35061218</ArticleId></ArticleIdList></Reference><Reference><Citation>Bristow M.R., Mason J.W., Billingham M.E., Daniels J.R. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978;88(2):168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">626445</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokorna Z., Kollarova-Brazdova P., Lencova-Popelova O., Jirkovsky E., Kubes J., Mazurova Y., et al. Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up. Clin Sci (Lond) 2022;136(1):139&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">34878093</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinzel F.R., Hohendanner F., Jin G., Sedej S., Edelmann F. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. Journal of applied physiology (Bethesda, Md : 1985) 2015;119(10):1233&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4652334</ArticleId><ArticleId IdType="pubmed">26183480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins B.J., Dai Y.S., Bueno O.F., Parsons S.A., Xu J., Plank D.M., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94(1):110&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656927</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J.J., Son C.O., Kim H.Y., Han B.H., Lee Y.J., Lee H.S., et al. Betulinic acid protects DOX-triggered cardiomyocyte hypertrophy response through the GATA-4/Calcineurin/NFAT pathway. Molecules. 2020;26(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7795060</ArticleId><ArticleId IdType="pubmed">33374365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S., Volden P., Timm D., Mao K., Xu X., Liang Q. Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem. 2010;285(1):793&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804228</ArticleId><ArticleId IdType="pubmed">19901028</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H., Liu H., Zhu J.H., Wang S.Y., Zhou S.S., Kong M., et al. Efficacy of ginseng and its ingredients as adjuvants to chemotherapy in non-small cell lung cancer. Food Funct. 2021;12(5):2225&#x2013;2241.</Citation><ArticleIdList><ArticleId IdType="pubmed">33595586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Wang Z., Huang Y., O'Barr S.A., Wong R.A., Yeung S., et al. Ginseng and anticancer drug combination to improve cancer chemotherapy: a critical review. Evid Based Complement Alternat Med. 2014;2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4021740</ArticleId><ArticleId IdType="pubmed">24876866</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Cui Y., Xiong M., Li M., Wang P., Cui J., et al. Dual activity of ginsenoside Rb1 in hypertrophic cardiomyocytes and activated macrophages: implications for the therapeutic intervention of cardiac hypertrophy. J Inflamm Res. 2021;14:1789&#x2013;1806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8108398</ArticleId><ArticleId IdType="pubmed">33981156</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X., Wang S., Zou X., Jing Y., Yang R., Li S., et al. Ginsenoside Rb1 improves cardiac function and remodeling in heart failure. Exp Anim. 2017;66(3):217&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5543242</ArticleId><ArticleId IdType="pubmed">28367863</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Wang Y., Ma Z., Liang Q., Tang X., Tan H., et al. Ginsenoside Rb1 inhibits doxorubicin-triggered H9C2 cell apoptosis via aryl hydrocarbon receptor. Biomol Ther (Seoul) 2017;25(2):202&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340546</ArticleId><ArticleId IdType="pubmed">27829271</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullah C.S., Alam S., Aishwarya R., Miriyala S., Bhuiyan M.A.N., Panchatcharam M., et al. Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. Sci Rep. 2019;9(1):2002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376057</ArticleId><ArticleId IdType="pubmed">30765730</ArticleId></ArticleIdList></Reference><Reference><Citation>Pointon A.V., Walker T.M., Phillips K.M., Luo J., Riley J., Zhang S.D., et al. Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS One. 2010;5(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2939875</ArticleId><ArticleId IdType="pubmed">20856801</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y., Wang Z., Yang Y., Shen M., Hu H., Chen C., et al. Ginsenoside Rb1 regulates CPT1A deacetylation to inhibit intramuscular fat infiltration after rotator cuff tear. iScience. 2024;27(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11277379</ArticleId><ArticleId IdType="pubmed">39071885</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzahrani A.M., Rajendran P., Veeraraghavan V.P., Hanieh H. Cardiac protective effect of kirenol against doxorubicin-induced cardiac hypertrophy in H9c2 cells through Nrf2 signaling via PI3K/AKT pathways. Int J Mol Sci. 2021;22(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8004766</ArticleId><ArticleId IdType="pubmed">33806909</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Wang X., Ma Y., Shi Y. The effect of ginsenoside RB1, diazoxide, and 5-Hydroxydecanoate on hypoxia-reoxygenation injury of H9C2 cardiomyocytes. Evid Based Complement Alternat Med. 2019;2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6930760</ArticleId><ArticleId IdType="pubmed">31915449</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L.X., Wang R.X., Jiang J.F., Yi G.C., Chang J.J., He R.L., et al. TRPC6 promotes daunorubicin-induced mitochondrial fission and cell death in rat cardiomyocytes with the involvement of ERK1/2-DRP1 activation. Toxicol Appl Pharmacol. 2023;470</Citation><ArticleIdList><ArticleId IdType="pubmed">37178933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.Y., Kim S.J., Kim B.J., Rah S.Y., Chung S.M., Im M.J., et al. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med. 2006;38(5):535&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079870</ArticleId></ArticleIdList></Reference><Reference><Citation>Villani F., Favalli L., Piccinini F. Relationship between the effect on calcium turnover and early cardiotoxicity of doxorubicin and 4'-epi-doxorubicin in Guinea pig heart muscle. Tumori. 1980;66(6):689&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">6940313</ArticleId></ArticleIdList></Reference><Reference><Citation>Keung E.C., Toll L., Ellis M., Jensen R.A. L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations. J Clin Investig. 1991;87(6):2108&#x2013;2113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296967</ArticleId><ArticleId IdType="pubmed">1645752</ArticleId></ArticleIdList></Reference><Reference><Citation>Shati A.A. Doxorubicin-induces NFAT/Fas/FasL cardiac apoptosis in rats through activation of calcineurin and P38 MAPK and inhibition of mTOR signalling pathways. Clin Exp Pharmacol Physiol. 2020;47(4):660&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">31811646</ArticleId></ArticleIdList></Reference><Reference><Citation>Park A.M., Nagase H., Liu L., Vinod Kumar S., Szwergold N., Wong C.M., et al. Mechanism of anthracycline-mediated down-regulation of GATA4 in the heart. Cardiovasc Res. 2011;90(1):97&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058732</ArticleId><ArticleId IdType="pubmed">21084315</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y.J. Cell signaling pathways for the regulation of GATA4 transcription factor: implications for cell growth and apoptosis. Cell Signal. 2011;23(7):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078531</ArticleId><ArticleId IdType="pubmed">21376121</ArticleId></ArticleIdList></Reference><Reference><Citation>Pintusophon S., Niu W., Duan X.N., Olaleye O.E., Huang Y.H., Wang F.Q., et al. Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions. Acta Pharmacol Sin. 2019;40(10):1351&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786404</ArticleId><ArticleId IdType="pubmed">31358899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Oh T.K., Kim Y.H., Lee J., Moon J.M., Park Y.S., et al. Pharmacokinetics of ginsenoside Rb1, Rg3, Rk1, Rg5, F2, and compound K from red ginseng extract in healthy Korean volunteers. Evid Based Complement Alternat Med. 2022;2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8803428</ArticleId><ArticleId IdType="pubmed">35111231</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P., Xu Y., Yin H., Wang J., Chen K., Li Y. Developmental toxicity research of ginsenoside Rb1 using a whole mouse embryo culture model. Birth Defects Res B Dev Reprod Toxicol. 2005;74(2):207&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834894</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y., Shen L., Liu K.J., Tso P., Xiong Y., Wang G., et al. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats. Diabetes. 2010;59(10):2505&#x2013;2512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3279544</ArticleId><ArticleId IdType="pubmed">20682695</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon J.H., Lee J., Choi M.K., Song I.S. Pharmacokinetics of ginsenosides following repeated oral administration of red ginseng extract significantly differ between species of experimental animals. Arch Pharm Res. 2020;43(12):1335&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">33225388</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q.F., Fang X.L., Chen D.F. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol. 2003;84(2&#x2013;3):187&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">12648814</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.K., Choi M.S., Park H.S., Kee K.H., Kim D.H., Yoo H.H. Pharmacokinetic profiling of ginsenosides, Rb1, Rd, and Rg3, in mice with antibiotic-induced gut microbiota alterations: implications for variability in the therapeutic efficacy of red ginseng extracts. Foods. 2023;12(23)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10706259</ArticleId><ArticleId IdType="pubmed">38231867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40843042</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2053-8855</ISSN><JournalIssue CitedMedium="Print"><Volume>2025</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Oxford medical case reports</Title><ISOAbbreviation>Oxf Med Case Reports</ISOAbbreviation></Journal><ArticleTitle>Avascular necrosis as an uncommon manifestation in glycogen storage disease type III: diagnostic and therapeutic challenges.</ArticleTitle><Pagination><StartPage>omaf145</StartPage><MedlinePgn>omaf145</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">omaf145</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/omcr/omaf145</ELocationID><Abstract><AbstractText>Glycogen storage disease type III (GSD III), or Cori disease, is a rare autosomal recessive disorder caused by a debranching enzyme deficiency, leading to abnormal glycogen accumulation. Clinical features include hepatomegaly, hypoglycemia, myopathy, and cardiomyopathy. Avascular necrosis (AVN), the death of bone tissue due to poor blood supply, is an uncommon but severe complication of GSD III. This report discusses a 19-year-old female with a known diagnosis of GSD III who developed AVN, presenting with chronic right hip pain, muscle weakness, and hypoglycemic seizures. Diagnostic challenges were resolved using imaging studies. Management included dietary adjustments to stabilize blood glucose, symptomatic treatment, lipid-lowering agents, and osteoporosis therapy to address skeletal complications. This case highlights the importance of multidisciplinary care, regular monitoring, and individualized management to address rare complications and improve outcomes in GSD III.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gorial</LastName><ForeName>Faiq I</ForeName><Initials>FI</Initials><Identifier Source="ORCID">0000-0002-2760-5566</Identifier><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Internal Medicine, College of Medicine, University of Baghdad, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awadh</LastName><ForeName>Nabaa Ihsan</ForeName><Initials>NI</Initials><Identifier Source="ORCID">0000-0002-7634-0146</Identifier><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Internal Medicine, College of Medicine, University of Baghdad, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khunda</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Internal Medicine, College of Medicine, University of Baghdad, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Badri</LastName><ForeName>Sajjad Ghanim</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0009-0003-6259-1045</Identifier><AffiliationInfo><Affiliation>College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alibrahimi</LastName><ForeName>Ali Falah</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>University of Baghdad, Alkindy College of Medicine, Baghdad, Iraq.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oxf Med Case Reports</MedlineTA><NlmUniqueID>101642070</NlmUniqueID><ISSNLinking>2053-8855</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">avascular necrosis</Keyword><Keyword MajorTopicYN="N">glycogen storage disease type III</Keyword><Keyword MajorTopicYN="N">multidisciplinary management</Keyword></KeywordList><CoiStatement>There is no conflict of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843042</ArticleId><ArticleId IdType="pmc">PMC12365979</ArticleId><ArticleId IdType="doi">10.1093/omcr/omaf145</ArticleId><ArticleId IdType="pii">omaf145</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lucchiari &#xa0;S, Santoro &#xa0;D, Pagliarani &#xa0;S. et al. &#xa0;Clinical, biochemical, and genetic features of glycogen debranching enzyme deficiency. Acta Myol &#xa0;2007;26:72&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949315</ArticleId><ArticleId IdType="pubmed">17915576</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;m&#xfc;&#x15f; &#xa0;E, &#xd6;zen &#xa0;H. Glycogen storage diseases: an update. World J Gastroenterol &#xa0;2023;29:3932&#x2013;63. 10.3748/wjg.v29.i25.3932</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v29.i25.3932</ArticleId><ArticleId IdType="pmc">PMC10354582</ArticleId><ArticleId IdType="pubmed">37476587</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones &#xa0;LC, Hungerford &#xa0;DS. Osteonecrosis: etiology, diagnosis, and treatment. Curr Opin Rheumatol &#xa0;2004;16:443&#x2013;9. 10.1097/01.moo.0000127829.34643.fd</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.moo.0000127829.34643.fd</ArticleId><ArticleId IdType="pubmed">15201609</ArticleId></ArticleIdList></Reference><Reference><Citation>Assouline-Dayan &#xa0;Y, Chang &#xa0;C, Greenspan &#xa0;A. et al. &#xa0;Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum &#xa0;2002;32:94&#x2013;124. 10.1053/sarh.2002.33724b</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/sarh.2002.33724b</ArticleId><ArticleId IdType="pubmed">12430099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha &#xa0;JS, Cho &#xa0;HM, Lee &#xa0;HJ. et al. &#xa0;Bilateral avascular necrosis of the femoral head in a patient with asymptomatic adrenal Incidentaloma. Hip Pelvis &#xa0;2019;31:120&#x2013;3. 10.5371/hp.2019.31.2.120</Citation><ArticleIdList><ArticleId IdType="doi">10.5371/hp.2019.31.2.120</ArticleId><ArticleId IdType="pmc">PMC6546673</ArticleId><ArticleId IdType="pubmed">31198779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen &#xa0;RK. Management of avascular necrosis of femoral head at pre-collapse stage. Indian J Orthop &#xa0;2009;43:6&#x2013;16. 10.4103/0019-5413.45318</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0019-5413.45318</ArticleId><ArticleId IdType="pmc">PMC2739499</ArticleId><ArticleId IdType="pubmed">19753173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sentner &#xa0;CP, Hoogeveen &#xa0;IJ, Weinstein &#xa0;DA. et al. &#xa0;Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. J Inherit Metab Dis &#xa0;2016;39:697&#x2013;704. 10.1007/s10545-016-9932-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10545-016-9932-2</ArticleId><ArticleId IdType="pmc">PMC4987401</ArticleId><ArticleId IdType="pubmed">27106217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou &#xa0;JY, Jun &#xa0;HS, Mansfield &#xa0;BC. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes. J Inherit Metab Dis &#xa0;2015;38:511&#x2013;9. 10.1007/s10545-014-9772-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10545-014-9772-x</ArticleId><ArticleId IdType="pubmed">25288127</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleuran &#xa0;T, Overgaard &#xa0;S, Vilstrup &#xa0;H. et al. &#xa0;Cirrhosis is a risk factor for total hip arthroplasty for avascular necrosis. Acta Orthop &#xa0;2016;87:231&#x2013;4. 10.3109/17453674.2016.1151122</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17453674.2016.1151122</ArticleId><ArticleId IdType="pmc">PMC4900083</ArticleId><ArticleId IdType="pubmed">26900635</ArticleId></ArticleIdList></Reference><Reference><Citation>Hines JT, Jo WL, Cui Q. et al. Osteonecrosis of the Femoral Head: an Updated Review of ARCO on Pathogenesis, Staging and Treatment. J Korean Med Sci. 2021;36:e177. 10.3346/jkms.2021.36.e177</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2021.36.e177</ArticleId><ArticleId IdType="pmc">PMC8216992</ArticleId><ArticleId IdType="pubmed">34155839</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein &#xa0;DA, Wolfsdorf &#xa0;JI. Continuous glucose therapy with uncooked cornstarch affects glycemic control and variability in glycogen storage disease type III. J Clin Endocrinol Metab &#xa0;2002;87:4418&#x2013;24.</Citation></Reference><Reference><Citation>Garbade &#xa0;SF, Ederer &#xa0;V, Burgard &#xa0;P. et al. &#xa0;Impact of glycogen storage disease type I on adult daily life: a survey. Orphanet J Rare Dis &#xa0;2021;16:371. 10.1186/s13023-021-02006-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-021-02006-w</ArticleId><ArticleId IdType="pmc">PMC8414849</ArticleId><ArticleId IdType="pubmed">34479584</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohn &#xa0;A, Ohri &#xa0;A. Diabetes mellitus in a patient with glycogen storage disease type Ia: a case report. J Med Case Rep &#xa0;2017;11:319. 10.1186/s13256-017-1462-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-017-1462-5</ArticleId><ArticleId IdType="pmc">PMC5682031</ArticleId><ArticleId IdType="pubmed">29127952</ArticleId></ArticleIdList></Reference><Reference><Citation>Derks &#xa0;TG, Smit &#xa0;GP. Dietary management in glycogen storage disease type III: what is the evidence? &#xa0;J Inherit Metab Dis &#xa0;2015;38:545&#x2013;50. 10.1007/s10545-014-9756-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10545-014-9756-x</ArticleId><ArticleId IdType="pubmed">25164784</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846301</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8414</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Journal of cardiac failure</Title><ISOAbbreviation>J Card Fail</ISOAbbreviation></Journal><ArticleTitle>Advancements and Challenges in Acute Heart Failure Management in Korea: Initial Report and Insights from the Korean Heart Failure III Registry.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1071-9164(25)00371-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cardfail.2025.07.023</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Heart failure (HF) is a major global health burden. Building on two prior national registries, the Korean Heart Failure III (KorHF III) registry provides a contemporary evaluation of clinical characteristics, treatment patterns, and outcomes in patients hospitalized with acute HF (AHF) in Korea.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">KorHF III prospectively enrolled 7,351 AHF patients from 47 tertiary hospitals between March 2018 and December 2022, with a 2-year follow-up. HF with reduced ejection fraction (HFrEF) accounted for 57.3% of cases. Common comorbidities included hypertension (59.5%) and diabetes (40.0%). The most frequent etiologies were ischemic heart disease (27.7%) and dilated cardiomyopathy (24.9%). At discharge, 74.3% of patients received angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor-neprilysin inhibitors (ARNIs); 68.5% received beta-blockers; and 57.4% received mineralocorticoid receptor antagonists (MRAs). Sodium-glucose cotransporter 2 inhibitor prescription was 15.8%. In-hospital mortality was 2.2%, and 2-year mortality was 20.9%, highest among patients with HF with preserved ejection fraction (HFpEF, 24.6%). Hyponatremia was independently associated with in-hospital (hazard ratio [HR] 2.50, p&lt;0.001) and post-discharge mortality (HR 1.72, p&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">KorHF III provides the most comprehensive and current assessment of AHF in Korea. Despite high prescription rates of guideline-directed medical therapy (GDMT) and low in-hospital mortality, long-term mortality is substantial. These findings emphasize the need for improved post-discharge care and highlight hyponatremia as a key prognostic factor in AHF management.</AbstractText><AbstractText Label="LAY SUMMARY" NlmCategory="BACKGROUND">This study looked at how patients with acute heart failure (AHF) are being treated in Korea today. Over 7,000 people who were admitted to 47 hospitals between 2018 and 2022 were included. The goal was to better understand their health conditions, treatments, and survival after leaving the hospital. The study found that care inside hospitals has improved. Death rates during hospital stays were low (2.2%), and many patients received recommended medications for heart failure. However, the study also showed that many patients still faced serious risks after they left the hospital. Within two years, about 1 in 5 patients had died, especially those with more complex conditions like kidney problems or low sodium levels. These results show that Korea has made progress in treating heart failure in hospitals, but more attention is needed to support patients after they go home. Better follow-up care and long-term treatment plans may help improve survival and quality of life.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Huijin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Electronic address: gmlwls0227@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eung Ju</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea. Electronic address: withnoel@empas.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Seong Woo</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym University, Hwaseong, Korea. Electronic address: hansw29@hallym.or.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Seong-Mi</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea. Electronic address: smparkmd@korea.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyung-Seop</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, School of Medicine, Keimyung University, Dongsan Hospital, Daegu, South Korea. Electronic address: khyungseop@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Myung-Chan</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Chungbuk National University School of Medicine, Cheongju, Korea. Electronic address: mccho@chungbuk.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Hyo-Suk</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea School of Medicine, Uijeongbu, Korea. Electronic address: alaco0502@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Mi-Seung</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Heart Center, Gachon University, Gil Medical Center, Inchon, South Korea. Electronic address: miseung@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Seok-Jae</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Gyeongsang National University College of Medicine, Jinju, Korea. Electronic address: edison71@hanmail.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Jin-Ok</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea. Electronic address: jojeong@cnu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dong Heon</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Kyungpook National University, Taegu, Korea. Electronic address: ddhyang@knu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyun</LastName><ForeName>Junho</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Electronic address: guswnsghek@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jin Oh</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Cardiovascular Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: choijean5@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hae-Young</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Electronic address: hylee612@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Byung-Su</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Wonju College of Medicine, Yonsei University, Wonju, Korea. Electronic address: yubs@yonsei.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Seok-Min</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 134 Sinchon-dong, Seodaemun-gu, Seoul, Korea. Electronic address: smkang@yuhs.ac.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Dong-Ju</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea. Electronic address: djchoi@snubh.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hyun-Jai</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Electronic address: hyunjaicho@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>KorHF III investigators</CollectiveName><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Card Fail</MedlineTA><NlmUniqueID>9442138</NlmUniqueID><ISSNLinking>1071-9164</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute heart failure</Keyword><Keyword MajorTopicYN="N">Guideline-directed medical therapy</Keyword><Keyword MajorTopicYN="N">Hyponatremia</Keyword><Keyword MajorTopicYN="N">Korean Heart Failure III registry</Keyword></KeywordList><CoiStatement>Declaration of competing interest Nothing to declare</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846301</ArticleId><ArticleId IdType="doi">10.1016/j.cardfail.2025.07.023</ArticleId><ArticleId IdType="pii">S1071-9164(25)00371-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846282</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-429X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance</Title><ISOAbbreviation>J Cardiovasc Magn Reson</ISOAbbreviation></Journal><ArticleTitle>ScarNet: A Novel Foundation Model for Automated Myocardial Scar Quantification from Late Gadolinium-Enhancement Images.</ArticleTitle><Pagination><StartPage>101945</StartPage><MedlinePgn>101945</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jocmr.2025.101945</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1097-6647(25)00107-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Late Gadolinium Enhancement (LGE) imaging remains the gold standard for assessing myocardial fibrosis and scarring, with left ventricular (LV) LGE presence and extent serving as a predictor of major adverse cardiac events (MACE). Despite its clinical significance, LGE-based LV scar quantification is not used routinely due to the labor-intensive manual segmentation and substantial inter-observer variability.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed ScarNet that synergistically combines a transformer-based encoder in Medical Segment Anything Model (MedSAM), which we fine-tuned with our dataset, and a convolution-based decoder in U-Net with tailored attention blocks to automatically segment myocardial scar boundaries while maintaining anatomical context. This network was trained and fine-tuned on an existing database of 401 ischemic cardiomyopathy patients (4,137 2D LGE images) with expert segmentation of myocardial and scar boundaries in LGE images, validated on 100 patients (1,034 2D LGE images) during training, and tested on unseen set of 184 patients (1,895 2D LGE images). Ablation studies were conducted to validate each architectural component's contribution.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 184 independent testing patients, ScarNet achieved accurate scar boundary segmentation (median DICE=0.912 [interquartile range (IQR): 0.863-0.944], concordance correlation coefficient [CCC]=0.963), significantly outperforming both MedSAM (median DICE=0.046 [IQR: 0.043-0.047], CCC=0.018) and nnU-Net (median DICE=0.638 [IQR: 0.604-0.661], CCC=0.734). For scar volume quantification, ScarNet demonstrated excellent agreement with manual analysis (CCC=0.995, percent bias=-0.63%, CoV=4.3%) compared to MedSAM (CCC=0.002, percent bias=-13.31%, CoV=130.3%) and nnU-Net (CCC=0.910, percent bias=-2.46%, CoV=20.3%). Similar trends were observed in the Monte Carlo simulations with noise perturbations. The overall accuracy was highest for SCARNet (sensitivity=95.3%; specificity=92.3%), followed by nnU-Net (sensitivity=74.9%; specificity=69.2%) and MedSAM (sensitivity=15.2%; specificity=92.3%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ScarNet outperformed MedSAM and nnU-Net for predicting myocardial and scar boundaries in LGE images of patients with ischemic cardiomyopathy. The Monte Carlo simulations demonstrated that ScarNet is less sensitive to noise perturbations than other tested networks.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tavakoli</LastName><ForeName>Neda</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Electronic address: https://twitter.com/neda_tv.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahsepar</LastName><ForeName>Amir Ali</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benefield</LastName><ForeName>Brandon C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Medicine (Division of Cardiology), Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Daming</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Tapia</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, Northwestern University, Evanston, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiffers</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, Northwestern University, Evanston, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberger</LastName><ForeName>Jeffrey J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Edwin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine (Division of Cardiology), Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsaggelos</LastName><ForeName>Aggelos K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, Northwestern University, Evanston, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Medicine (Division of Cardiology), Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiovasc Magn Reson</MedlineTA><NlmUniqueID>9815616</NlmUniqueID><ISSNLinking>1097-6647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac MRI</Keyword><Keyword MajorTopicYN="N">Deep Learning</Keyword><Keyword MajorTopicYN="N">Foundation Models</Keyword><Keyword MajorTopicYN="N">Late Gadolinium Enhancement</Keyword><Keyword MajorTopicYN="N">Medical Image Segmentation</Keyword><Keyword MajorTopicYN="N">Myocardial Scar Quantification</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Neda Tavakoli reports financial support was provided by National Institutes of Health, Radiological Society of North America, American Heart Association. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846282</ArticleId><ArticleId IdType="doi">10.1016/j.jocmr.2025.101945</ArticleId><ArticleId IdType="pii">S1097-6647(25)00107-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40841918</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Detecting heart failure in severe asthma patients using speckle tracking echocardiography.</ArticleTitle><Pagination><StartPage>374</StartPage><MedlinePgn>374</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">374</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-025-05587-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To determine the presence of acute myocardial dysfunction in status asthmaticus.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">From 2006 to 2025, we studied severe asthma patients, healthy controls, and weightlifters performing bench press. Group differences were evaluated using echocardiography with Speckle Tracking by velocity vector imaging (VVI). Asthma patients were followed for 6 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 357 participants, 169 were controls. The median age of asthmatic patients (n&#x2009;=&#x2009;188) was 58.11&#x2009;&#xb1;&#x2009;12.97 years, comparable to controls. Thirty-one patients died. All patients with severe asthma demonstrated reduced biventricular strain. After bench press, all echocardiographic values were higher compared to non-sportsmen and asthmatic patients. Acute asthma patients demonstrated lower strain in the four cavities, and more asynchrony versus controls. Right ventricular global longitudinal strain was ([-&#x2009;27.56&#x2009;&#xb1;&#x2009;4.56] in the control group, [-&#x2009;24.08&#x2009;&#xb1;&#x2009;1.23] in the basal weightlifters' group, [-&#x2009;30.88&#x2009;&#xb1;&#x2009;1.02] after bench press and [-&#x2009;17.98&#x2009;&#xb1;&#x2009;2.57] in severe asthma, p value&#x2009;=&#x2009;0.0001). Left ventricular global longitudinal strain (%) were (-&#x2009;21.02&#x2009;&#xb1;&#x2009;3.28, -&#x2009;19.34&#x2009;&#xb1;&#x2009;3.78, -&#x2009;25.21&#x2009;&#xb1;&#x2009;9.32, -&#x2009;14.88&#x2009;&#xb1;&#x2009;1.27, p value&#x2009;=&#x2009;0.012) respectively. Multivariate analysis identified right atrial pump strain (OR 0.457 [0.189-0.746]) and as factors associated with mortality. Mechanical Ventilation was associated with RVGLS (OR 0.637, CI 95% [0.248-0.925]) and right atrial pump strain (OR 0.783, CI 95% [0.349-0.967]). At 6 months follow-up, asthmatic patients exhibited lower deformity parameters and decreased Speckle Tracking vectorial velocity analysis in all cardiac chambers compared to control groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with acute asthma exhibit decreased strain in all cardiac chambers, which remains reduced at the six-month follow-up. Asthma may contribute to latent heart failure.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hidalgo-Mart&#xed;n</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Departamento de Ciencias de la Salud, Hospital Universitario de Ja&#xe9;n. Universidad de Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Carmen Ruiz-Iniesta</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IES. Santa Catalina, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pola-Gallego-de-Guzm&#xe1;n</LastName><ForeName>Mar&#xed;a Dolores</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Departamento de Ciencias de la Salud, Hospital Universitario de Ja&#xe9;n. Universidad de Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manetsberger</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Departamento de Ciencias de la Salud, Hospital Universitario de Ja&#xe9;n. Universidad de Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, University of Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Lechuga</LastName><ForeName>Mar&#xed;a Bel&#xe9;n</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Departamento de Ciencias de la Salud, Hospital Universitario de Ja&#xe9;n. Universidad de Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Cuadra</LastName><ForeName>Jos&#xe9; &#xc1;ngel</ForeName><Initials>J&#xc1;</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Hospital Universitario Torrec&#xe1;rdenas, Almer&#xed;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo-Portellano</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Departamento de Ciencias de la Salud, Hospital Universitario de Ja&#xe9;n. Universidad de Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manzano-Moreno</LastName><ForeName>Juan Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Departamento de Ciencias de la Salud, Hospital Universitario de Ja&#xe9;n. Universidad de Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colmenero-Aguilar</LastName><ForeName>Crisp&#xed;n</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Departamento de Ciencias de la Salud, Hospital Universitario de Ja&#xe9;n. Universidad de Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellanos-Hern&#xe1;ndez</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Departamento de Ciencias de la Salud, Hospital Universitario de Ja&#xe9;n. Universidad de Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Guerrero</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Cardiovascular Hemodynamics Unit, University Hospital of Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xe1;fales-Perucha</LastName><ForeName>Blanca Irene</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Critical Care Department, Hospital Universitario San Jorge de Huesca, Huesca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavilla-Lerma</LastName><ForeName>Mar&#xed;a Leyre</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, University of Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caballero-G&#xf3;mez</LastName><ForeName>Natacha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, University of Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera-Fern&#xe1;ndez</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Departamento de Ciencias de la Salud, Hospital Universitario de Ja&#xe9;n. Universidad de Ja&#xe9;n, Ja&#xe9;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Bail&#xe9;n</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7885-0847</Identifier><AffiliationInfo><Affiliation>Intensive Care Unit, Departamento de Ciencias de la Salud, Hospital Universitario de Ja&#xe9;n. Universidad de Ja&#xe9;n, Ja&#xe9;n, Spain. ruizbailen@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, University of Ja&#xe9;n, Ja&#xe9;n, Spain. ruizbailen@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Andalusian Health Service. SAS Project n&#xba; PI-0585-2012.</GrantID><Agency>Servicio Andaluz de Salud</Agency><Country/></Grant><Grant><GrantID>Andalusian Health Service. SAS Project n&#xba; PI-0585-2012.</GrantID><Agency>Servicio Andaluz de Salud</Agency><Country/></Grant><Grant><GrantID>Andalusian Health Service. SAS Project n&#xba; PI-0585-2012.</GrantID><Agency>Servicio Andaluz de Salud</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="Y">Echocardiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Echocardiography</Keyword><Keyword MajorTopicYN="N">Intensive care medicine</Keyword><Keyword MajorTopicYN="N">Myocardial dysfunction</Keyword><Keyword MajorTopicYN="N">Severe asthma</Keyword><Keyword MajorTopicYN="N">Status asthmaticus</Keyword><Keyword MajorTopicYN="N">Strain</Keyword><Keyword MajorTopicYN="N">Strain rate</Keyword><Keyword MajorTopicYN="N">Stress cardiomyopathy</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The study has ethical approval, and the patients signed the informed consent for their participation. Project n&#xba; PI-0585-2012.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>16</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>16</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841918</ArticleId><ArticleId IdType="doi">10.1186/s13054-025-05587-1</ArticleId><ArticleId IdType="pii">10.1186/s13054-025-05587-1</ArticleId><ArticleId IdType="pmc">PMC12369098</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al Khodari K, Alhaj Tahtouh R, Abdullatef WK, Al Khodari M. Takotsubo (stress) cardiomyopathy induced by acute asthma exacerbation in elderly woman. Clin Case Rep. 2023;11(3):e7074. doi: 10.1002/ccr3.7074. PMID: 36911627; PMCID: PMC9995802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9995802</ArticleId><ArticleId IdType="pubmed">36911627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Huang X, Yu D, Xu C, Wang Y, Wang X, Shen Y. Asthma and the risk of cardiovascular diseases and mortality: a meta-analysis of cohort studies. Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251333965. doi: 10.1177/17534666251333965. Epub 2025 Apr 24. PMID: 40272211; PMCID: PMC12035221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12035221</ArticleId><ArticleId IdType="pubmed">40272211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladner J, Sawsan A, Nofal A, Rana M, Ammar M, Saba J, Audureau E. Factors impacting chronic disease medication adherence in the UAE: a prospective cohort study, 2021&#x2013;2022. J Comp Eff Res. 2025 May 5:e250020. doi: 10.57264/cer-2025-0020. Epub ahead of print. PMID: 40321131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12142380</ArticleId><ArticleId IdType="pubmed">40321131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Li P, Li Y, Xing Y, Ma Z, Dong C, Feng L, et al. Predicting Prolonged Hospitalization in Asthma Patients: Model Development and External Validation. J Asthma. 2025 May 3:1&#x2013;15. doi: 10.1080/02770903.2025.2500081. Epub ahead of print. PMID: 40317238.</Citation><ArticleIdList><ArticleId IdType="pubmed">40317238</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahi W, Hussain I, Quinones MA, Zoghbi WA, Shah DJ, Nagueh SF. Noninvasive Prediction of Pulmonary Capillary Wedge Pressure in Patients With Normal Left Ventricular Ejection Fraction: Comparison of Cardiac Magnetic Resonance With Comprehensive Echocardiography. J Am Soc Echocardiogr. 2024;37(5):486&#x2013;494. doi: 10.1016/j.echo.2024.02.001. Epub 2024 Feb 12. PMID: 38354759.</Citation><ArticleIdList><ArticleId IdType="pubmed">38354759</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Qui&#xf1;ones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol. 1997;30(6):1527-33. doi: 10.1016/s0735-1097(97)00344-6. PMID: 9362412.</Citation><ArticleIdList><ArticleId IdType="pubmed">9362412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuecherer HF, Kusumoto F, Muhiudeen IA, Cahalan MK, Schiller NB. Pulmonary venous flow patterns by transesophageal pulsed Doppler echocardiography: relation to parameters of left ventricular systolic and diastolic function. Am Heart J. 1991;122(6):1683-93. doi: 10.1016/0002-8703(91)90287-r. PMID: 1957763.</Citation><ArticleIdList><ArticleId IdType="pubmed">1957763</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr. 2015;28(2):183&#x2013;&#x2009;93. doi: 10.1016/j.echo.2014.11.003. PMID: 25623220.</Citation><ArticleIdList><ArticleId IdType="pubmed">25623220</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Hodovan J, Sharma A, Morello M, Varli O, Gholson B, Lindner JR. Impact of Length Indexing of Deformation in Echocardiographic Evaluation of Right Ventricular Function. J Am Soc Echocardiogr. 2025;38(3):187&#x2013;194. doi: 10.1016/j.echo.2024.11.011. Epub 2024 Dec 17. PMID: 39701430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12208099</ArticleId><ArticleId IdType="pubmed">39701430</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia BC, Lai A, Singh S, Samtani R, Bienstock S, Liao S, et al. Validation of American Society of Echocardiography Guideline-Recommended Parameters of Right Ventricular Dysfunction Using Artificial Intelligence Compared With Cardiac Magnetic Resonance Imaging. J Am Soc Echocardiogr. 2023;36(9):967&#x2013;977. doi: 10.1016/j.echo.2023.05.015. Epub 2023 Jun 17. PMID: 37331608.</Citation><ArticleIdList><ArticleId IdType="pubmed">37331608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson JC, Colquitt JL, Doan TT, Liu AM, Lilje CG, Denfield SW, et al. Global Longitudinal Strain Analysis of the Single Right Ventricle: Leveling the Playing Field. J Am Soc Echocardiogr. 2022;35(6):657&#x2013;663. doi: 10.1016/j.echo.2022.03.003. Epub 2022 Mar 8. PMID: 35271990.</Citation><ArticleIdList><ArticleId IdType="pubmed">35271990</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckberg GD, Clemente C, Cox JL, Coghlan HC, Castella M, Torrent-Guasp F, Gharib M. The structure and function of the helical heart and its buttress wrapping. IV. Concepts of dynamic function from the normal macroscopic helical structure. Semin Thorac Cardiovasc Surg. 2001;13(4):342&#x2013;&#x2009;57. doi: 10.1053/stcs.2001.29956. PMID: 11807733. 41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11807733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocica MJ, Corno AF, Carreras-Costa F, Ballester-Rodes M, Moghbel MC, Cueva CN, Lackovic V, Kanjuh VI, Torrent-Guasp F. The helical ventricular myocardial band: global, three-dimensional, functional architecture of the ventricular myocardium. Eur J Cardiothorac Surg. 2006;29 Suppl 1:S21-40. doi: 10.1016/j.ejcts.2006.03.011. Epub 2006 Mar 24. PMID: 16563790.</Citation><ArticleIdList><ArticleId IdType="pubmed">16563790</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fager&#xe5;s M, Cosio BG, et al. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults. Am J Respir Crit Care Med. 2024;210(7):869&#x2013;880. doi: 10.1164/rccm.202311-2192OC. PMID: 38701495; PMCID: PMC11506911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11506911</ArticleId><ArticleId IdType="pubmed">38701495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghandi Y, Habibi D, Abasi M. The Effect of Bronchial Asthma on Interatrial Electromechanical Delay Coupling Obtained Using Tissue Doppler Imaging. Iran J Med Sci. 2019;44(3):196&#x2013;203. PMID: 31182885; PMCID: PMC6525734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525734</ArticleId><ArticleId IdType="pubmed">31182885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt Yilmaz HE, Yilmaz M, &#x15e;en N, Altin C, &#xdc;nsal ZE, Tekin A, Ak&#xe7;ay &#x15e;. Assessment of atrial fibrillation and ventricular arrhythmia risk in patients with asthma by P wave/corrected QT interval dispersion. Eur Rev Med Pharmacol Sci. 2018;22(3):756&#x2013;762. doi: 10.26355/eurrev_201802_14308. PMID: 29461607.</Citation><ArticleIdList><ArticleId IdType="pubmed">29461607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Bail&#xe9;n M, Cobo-Molinos J, Espada-Fuentes JC, Castillo-Rivera AM, Mart&#xed;nez-Ram&#xed;rez MJ, C&#xe1;rdenas-Cruz A. The Acute Asthma: It&#x2019;s just a Respiratory Disease? A Speckle Tracking. J Clin Respir Dis Care 2016, 2:4. DOI: 10.4172/2472-1247.1000122.</Citation></Reference><Reference><Citation>Abbas AM, Mousa HH, Biomy R, Hussein MA, Reyad HM, Elagamy O. Tissue Doppler Echocardiography As A Predictor Of Early Subclinical Right Ventricular Diastolic Dysfunction In Asthmatic Children. J Pak Med Assoc. 2023;73(Suppl 4)(4):S151-S155. doi: 10.47391/JPMA.EGY-S4-31. PMID: 37482849&#x2013;.</Citation><ArticleIdList><ArticleId IdType="pubmed">37482849</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas AM, Mousa HH, Biomy R, Elagamy O. Can Speckle Tracking Of Right Ventricle Add Value For Evaluation Of Asthma Severity In Children? J Pak Med Assoc. 2023;73(Suppl 4)(4):S156-S160. doi: 10.47391/JPMA.EGY-S4-32. PMID: 37482850.</Citation><ArticleIdList><ArticleId IdType="pubmed">37482850</ArticleId></ArticleIdList></Reference><Reference><Citation>Baysal SS, Has M. Assessment of biventricular function with speckle tracking echocardiography in newly-diagnosed adult-onset asthma. J Asthma. 2022;59(2):306&#x2013;314. doi: 10.1080/02770903.2020.1847928. Epub 2020 Nov 16. PMID: 33158387.</Citation><ArticleIdList><ArticleId IdType="pubmed">33158387</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelmohsen G, Mohamed H, Mohsen M, Abdelaziz O, Ahmed D, Abdelsalam M, Dohain A. Evaluation of cardiac function in pediatric patients with mild to moderate bronchial asthma in the era of cardiac strain imaging. Pediatr Pulmonol. 2019;54(12):1905&#x2013;1913. doi: 10.1002/ppul.24485. Epub 2019 Aug 19. PMID: 31424175.</Citation><ArticleIdList><ArticleId IdType="pubmed">31424175</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Raimondo D, Musiari G, Rizzo G, Pirera E, Benfante A, Battaglia S, et al. Echocardiographic Evaluation of the Cardiac Chambers in Asthmatic Patients: The BADA (Blood Pressure Levels, Clinical Features and Markers of Subclinical Cardiovascular Damage of Asthma Patients) Study-ECO. J Pers Med. 2022;12(11):1847. doi: 10.3390/jpm12111847. PMID: 36579553; PMCID: PMC9694451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9694451</ArticleId><ArticleId IdType="pubmed">36579553</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuleta I, Eckstein N, Aurich F, Nickenig G, Schaefer C, Skowasch D, Schueler R. Reduced longitudinal cardiac strain in asthma patients. J Asthma. 2019;56(4):350&#x2013;359. doi: 10.1080/02770903.2018.1466311. Epub 2018 May 18. PMID: 29668337.</Citation><ArticleIdList><ArticleId IdType="pubmed">29668337</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozde C, Dogru M, Ozde &#x15e;, Kayapinar O, Kaya A, Korkmaz A: Subclinical right ventricular dysfunction in intermittent and persistent mildly asthmatic children on tissue Doppler echocardiography and serum NTproBNP: observational study. Pediatr Int. 2018, 60:1024-32. 10.1111/ped.13689 22.</Citation><ArticleIdList><ArticleId IdType="pubmed">30179288</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo RAM, Ruiz-Bail&#xe9;n M, Rucabado Aguilar L Takotsubo cardiomyopathy&#x2013;a clinical review. Med Sci Monit 2011;17: RA135-RA147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539553</ArticleId><ArticleId IdType="pubmed">21629203</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Wang Y, Liang J, Zuo X, Li Q, Sherif AA, Zhang J, Xu Y, et al. Takotsubo syndrome and respiratory diseases: a systematic review. Eur Heart J Open. 2022;2(2):oeac009. doi: 10.1093/ehjopen/oeac009. PMID: 35919117; PMCID: PMC9242042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9242042</ArticleId><ArticleId IdType="pubmed">35919117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Bail&#xe9;n M, Aguayo de Hoyos E, Ruiz-Navarro S, D&#xed;az-Castellanos MA, Rucabado-AL, et al. Reversible myocardial dysfunction after cardiopulmonary resuscitation. Resuscitation 2005;66: 175&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">16053943</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz Bail&#xe9;n M. Reversible myocardial dysfunction in critically ill, noncardiac patients: a review. Crit Care Med. 2002;30(6):1280-90. doi: 10.1097/00003246-200206000-00020. PMID: 12072682.</Citation><ArticleIdList><ArticleId IdType="pubmed">12072682</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz Bail&#xe9;n M, Cobo Molinos J, Espada-Fuentes JC, Castillo-Rivera AM, Mart&#xed;nez-Amat A, Mart&#xed;nez Ram&#xed;rez MJ. Left Ventricular Function Improve after Bench Press: A Speckle Tracking and 3D Echocardiography Study. J Sports Med Doping Stud. 2017; 7:1 DOI: 10.4172/2161-0673.1000186.</Citation></Reference><Reference><Citation>James MD, Phillips DB, Domnik NJ, Neder JA. Pathophysiological mechanisms of exertional dyspnea in people with cardiopulmonary disease: Recent advances. Respir Physiol Neurobiol. 2025;336:104423. doi: 10.1016/j.resp.2025.104423. Epub ahead of print. PMID: 40164293.</Citation><ArticleIdList><ArticleId IdType="pubmed">40164293</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Guerra S, Ledford JG, Kraft M, Li H, Hastie AT, Castro M, et al. Low CC16 mRNA Expression Levels in Bronchial Epithelial Cells Are Associated with Asthma Severity. Am J Respir Crit Care Med. 2023;207(4):438&#x2013;451. doi: 10.1164/rccm.202206-1230OC. PMID: 36066606; PMCID: PMC9940145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9940145</ArticleId><ArticleId IdType="pubmed">36066606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge Y, Zuo R, Xi H, Zhang C, Li W, Chen Y, Set al. Multimorbidity Patterns of Asthma Exacerbation in an Older Cohort: Prognostic Implications. J Allergy Clin Immunol Pract. 2025 Apr 8:S2213-2198(25)00312-5. doi: 10.1016/j.jaip.2025.03.047. Epub ahead of print. PMID: 40209928.</Citation><ArticleIdList><ArticleId IdType="pubmed">40209928</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters MC, Mauger D, Ross KR, Phillips B, Gaston B, Cardet JC, et al, Phipatanakul W, Jarjour NN, Castro M, Wenzel SE, Hastie A, Moore W, Bleecker E, Fahy JV, Denlinger LC. Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency. Am J Respir Crit Care Med. 2020;202(7):973&#x2013;982. doi: 10.1164/rccm.201909-1813OC. PMID: 32479111; PMCID: PMC7528796.&#x2013;.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7528796</ArticleId><ArticleId IdType="pubmed">32479111</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed SU, Clements D, Jackson DJ, Philp C, Billington CK, Soomro I, et al. Matrix Metalloproteinase-1 Activation Contributes to Airway Smooth Muscle Growth and Asthma Severity. Am J Respir Crit Care Med. 2017;195(8):1000&#x2013;1009. doi: 10.1164/rccm.201604-0822OC. PMID: 27967204; PMCID: PMC5422648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5422648</ArticleId><ArticleId IdType="pubmed">27967204</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel JM. Multisystem Inflammatory Syndrome in Children (MIS-C). Curr Allergy Asthma Rep. 2022;22(5):53&#x2013;60. doi: 10.1007/s11882-022-01031-4. Epub 2022 Mar 22. PMID: 35314921; PMCID: PMC8938222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938222</ArticleId><ArticleId IdType="pubmed">35314921</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyack L, Garcha G, Shah R, Ortiz Gonzalez Y, Vollenweider M, Salimian M, Cheung W. Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma. J Cardiol Cases. 2023;28(3):100&#x2013;104. doi: 10.1016/j.jccase.2023.04.012. PMID: 37671259; PMCID: PMC10477040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10477040</ArticleId><ArticleId IdType="pubmed">37671259</ArticleId></ArticleIdList></Reference><Reference><Citation>Vodaphone N, Stern DA, Ledford JG, Spangenberg AL, Zhai J, Wright AL, et al. Circulating CC16 and Asthma: A Population-based, Multicohort Study from Early Childhood through Adult Life. Am J Respir Crit Care Med. 2023;208(7):758&#x2013;769. doi: 10.1164/rccm.202301-0041OC. PMID: 37523710; PMCID: PMC10563188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10563188</ArticleId><ArticleId IdType="pubmed">37523710</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang WY, Jiao RH, Ma SL, Dai JS, Zhu HF, Wu MY, et al. Serum inflammatory factors, vitamin D levels, and asthma severity in children with comorbid asthma and obesity/overweight: a comparative study. Front Pediatr. 2025;13:1439841. doi: 10.3389/fped.2025.1439841. PMID: 40083433; PMCID: PMC11903463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11903463</ArticleId><ArticleId IdType="pubmed">40083433</ArticleId></ArticleIdList></Reference><Reference><Citation>Santib&#xe1;&#xf1;ez M, Ruiz-Cubill&#xe1;n JJ, Ag&#xfc;ero J, Exp&#xf3;sito A, Abascal B, Garc&#xed;a-Rivero JL, Amado CA, Hernando MM, Ruiz-Azcona L, Barreiro E, N&#xfa;&#xf1;ez-Robainas A, Cifri&#xe1;n JM, Fernandez-Olmo I. Personal exposure to particulate matter oxidative potential and airway inflammation: differences between asthmatic and non-asthmatic adults. Int J Hyg Environ Health. 2025;267:114589. doi: 10.1016/j.ijheh.2025.114589. Epub ahead of print. PMID: 40328045.</Citation><ArticleIdList><ArticleId IdType="pubmed">40328045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Bail&#xe9;n M, Romero-Bermejo FJ, Rucabado-Aguilar L, P&#xe9;rez-Valenzuela J, Ferrezuelo-Mata &#xc1;, Ram&#xed;rez-S&#xe1;nchez M, et al. Myocardial dysfunction in the critically ill patient: is it really reversible? Int J Cardiol. 2010;145(3):615-6. doi: 10.1016/j.ijcard.2010.09.032. Epub 2010 Oct 20. PMID: 20937534.</Citation><ArticleIdList><ArticleId IdType="pubmed">20937534</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LC, Khunger A, Aji W. Takotsubo cardiomyopathy in a female presenting with status asthmaticus: a case report and review of literature. Egypt Heart J. 2022;74(1):72. doi: 10.1186/s43044-022-00310-9. PMID: 36183036; PMCID: PMC9526768.).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9526768</ArticleId><ArticleId IdType="pubmed">36183036</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatri SB, Iaccarino JM, Barochia A, Soghier I, Akuthota P, Brady A, et al; American Thoracic Society Assembly on Allergy, Immunology, and Inflammation. Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2021;204(10):e97-e109. doi: 10.1164/rccm.202109-2093ST. PMID: 34779751; PMCID: PMC8759314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8759314</ArticleId><ArticleId IdType="pubmed">34779751</ArticleId></ArticleIdList></Reference><Reference><Citation>Adair D, Bagheri A, Yosef M, Khalatbari S, Lewis T, Mohan A, Lugogo N. High Interleukin (IL)-6 is Associated with Lower Lung Function and Increased Likelihood of Metabolic Dysfunction in Asthma. Pulm Ther. 2025;11(1):41&#x2013;54. doi: 10.1007/s41030-024-00281-z. Epub 2024 Dec 23. PMID: 39714726; PMCID: PMC11861817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11861817</ArticleId><ArticleId IdType="pubmed">39714726</ArticleId></ArticleIdList></Reference><Reference><Citation>Munshi H, Bathobakae L, Sorathia A, John R, Romero J, Elkattawy S, Virk H. Stress in Focus: A Rare Case of Mid-Ventricular Takotsubo Cardiomyopathy Presenting as Cardiac Asthma. J Investig Med High Impact Case Rep. 2025 Jan-Dec;13:23247096251336631. doi: 10.1177/23247096251336631. Epub 2025 May 10. PMID: 40346990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12065979</ArticleId><ArticleId IdType="pubmed">40346990</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabbay JM, Fishman MD, Bajaj BVM, Guenther CS, Graham RJ, Perez JM. Efficacy of parenteral bronchodilators on ventilatory outcomes in pediatric critical asthma: a national cohort study. Allergy Asthma Proc. 2025;46(1):e6-e12. doi: 10.2500/aap.2025.46.240099. PMID: 39741368.</Citation><ArticleIdList><ArticleId IdType="pubmed">39741368</ArticleId></ArticleIdList></Reference><Reference><Citation>Persch H, Bizjak DA, Takabayashi K, Schober F, Winkert K, Dreyhaupt J, et al. Left ventricular systolic function after inhalation of beta-2 agonists in healthy athletes. Sci Rep. 2024;14(1):23437. doi: 10.1038/s41598-024-74095-z. PMID: 39379505; PMCID: PMC11461498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11461498</ArticleId><ArticleId IdType="pubmed">39379505</ArticleId></ArticleIdList></Reference><Reference><Citation>Krings JG, Gerald JK, Blake KV, Krishnan JA, Reddel HK, Bacharier LB, et al. A Call for the United States to Accelerate the Implementation of Reliever Combination Inhaled Corticosteroid-Formoterol Inhalers in Asthma. Am J Respir Crit Care Med. 2023;207(4):390&#x2013;405. doi: 10.1164/rccm.202209-1729PP. PMID: 36538711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9940146</ArticleId><ArticleId IdType="pubmed">36538711</ArticleId></ArticleIdList></Reference><Reference><Citation>Turcatel G, Xiao Y, Caveney S, Gnacadja G, Kim J, Molfino NA. Predicting Asthma Exacerbations Using Machine Learning Models. Adv Ther. 2024 Nov 18. doi: 10.1007/s12325-024-03053. PMID: 39556295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11782383</ArticleId><ArticleId IdType="pubmed">39556295</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Zeng X, Tan R, Li T, Lin R, Wang C, Zhang Y, Luo X. Raman spectroscopic fingerprinting for the identification and quantitative analysis of sports doping &#x3b2; - agonists based on gold nanopolyhedra. Spectrochim Acta A Mol Biomol Spectrosc. 2025;330:125698. doi: 10.1016/j.saa.2025.125698. Epub 2025 Jan 4. PMID: 39798512.).</Citation><ArticleIdList><ArticleId IdType="pubmed">39798512</ArticleId></ArticleIdList></Reference><Reference><Citation>Burchert H, Lapidaire W, Williamson W, McCourt A, Dockerill C, Woodward W, et al. Aerobic Exercise Training Response in Preterm-Born Young Adults with Elevated Blood Pressure and Stage 1 Hypertension: A Randomized Clinical Trial. Am J Respir Crit Care Med. 2023;207(9):1227&#x2013;1236. doi: 10.1164/rccm.202205-0858OC. PMID: 36459100; PMCID: PMC1016176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10161761</ArticleId><ArticleId IdType="pubmed">36459100</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagnesi M, Cotter G, Davison BA, Freund Y, Voors AA, Edwards C, et al. Burst steroid therapy and quality of life in patients with acute heart failure: Insights from the CORTAHF trial. ESC Heart Fail. 2025;12(3):1620&#x2013;1629. doi: 10.1002/ehf2.15235. Epub 2025 Feb 11. PMID: 39934967; PMCID: PMC12055404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12055404</ArticleId><ArticleId IdType="pubmed">39934967</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Wang L, Zhang L, Wang Q, Li L, Liu Y, et al. Asthma exacerbation comorbidity index (AECI): Predicting in-hospital adverse outcomes. Respir Med. 2025 Apr-May;240:108024. doi: 10.1016/j.rmed.2025.108024. Epub 2025 Mar 3. PMID: 40043919.</Citation><ArticleIdList><ArticleId IdType="pubmed">40043919</ArticleId></ArticleIdList></Reference><Reference><Citation>Mein SA, Ferrera MC. Management of Asthma and COPD Exacerbations in Adults in the ICU. CHEST Crit Care. 2025;3(1):100107. doi: 10.1016/j.chstcc.2024.100107. Epub 2024 Nov 8. PMID: 40330435; PMCID: PMC12054689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12054689</ArticleId><ArticleId IdType="pubmed">40330435</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertini P, Sangalli F, Meani P, Marabotti A, Rubino A, Scolletta S, et al; ITACTAIC. Establishing an Extracorporeal Cardiopulmonary Resuscitation Program. Medicina (Kaunas). 2024;60(12):1979. doi: 10.3390/medicina60121979. PMID: 39768859; PMCID: PMC11676360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11676360</ArticleId><ArticleId IdType="pubmed">39768859</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Bail&#xe9;n M, Hidalgo-Mart&#xed;n J, Ramos Cuadra J&#xc1;, Manetsberger J, Pola Gallego de Guzm&#xe1;n MD, D&#xed;az-Castellanos M&#xc1;, et al. Right Ventricular Strain and Outflow Tract Velocity Time Integral Are Associated with Mortality in Critically Ill Patients with Pulmonary Embolism. Am J Respir Crit Care Med. 2025 Mar 28. doi: 10.1164/rccm.202407-1433OC. Epub ahead of print. PMID: 40153695.</Citation><ArticleIdList><ArticleId IdType="pubmed">40153695</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavasini R, Tavazzi G, Biscaglia S, Guerra F, Pecoraro A, Zaraket F, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis. Chron Respir Dis. 2017;14(2):117&#x2013;126. doi: 10.1177/1479972316674393. Epub 2016 Dec 15. PMID: 27956645; PMCID: PMC5720220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5720220</ArticleId><ArticleId IdType="pubmed">27956645</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepelis A, Brumpton BM, Laugsand LE, Dalen H, Langhammer A, Janszky I, Strand LB. Asthma, asthma control and risk of acute myocardial infarction: HUNT study. Eur J Epidemiol. 2019;34(10):967&#x2013;977. doi: 10.1007/s10654-019-00562-x. Epub 2019 Sep 11. PMID: 31512117.</Citation><ArticleIdList><ArticleId IdType="pubmed">31512117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Li P, Li Y, Xing Y, Ma Z, Dong C, Feng L, et al. Predicting prolonged hospitalization in asthma patients: model development and external validation. J Asthma. 2025 May 10:1&#x2013;11. doi: 10.1080/02770903.2025.2500081. Epub ahead of print. PMID: 40317238.</Citation><ArticleIdList><ArticleId IdType="pubmed">40317238</ArticleId></ArticleIdList></Reference><Reference><Citation>Goette A, Corradi D, Dobrev D, Aguinaga L, Cabrera JA, Chugh SS, et al. Atrial cardiomyopathy revisited-evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Europace. 2024;26(9):euae204. doi: 10.1093/europace/euae204. PMID: 39077825; PMCID: PMC11431804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11431804</ArticleId><ArticleId IdType="pubmed">39077825</ArticleId></ArticleIdList></Reference><Reference><Citation>Konior-Rozlachowska A, Siedlinski M, Szczepaniak P, Nosalski R, Murray E, Mikolajczyk TP. Systemic and vascular inflammation in experimental allergic asthma. J Physiol Pharmacol. 2021;72(2). doi: 10.26402/jpp.2021.2.03. Epub 2021 Aug 6. PMID: 34374654.</Citation><ArticleIdList><ArticleId IdType="pubmed">34374654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell V, McCabe EL, Larson MG, Rong J, Merz AA, Osypiuk E. Relations Between Aortic Stiffness and Left Ventricular Mechanical Function in the Community. J Am Heart Assoc. 2017; 9;6(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5523643</ArticleId><ArticleId IdType="pubmed">28069573</ArticleId></ArticleIdList></Reference><Reference><Citation>Zapolski T, Fumaga J, Jaroszynski A, Wysocka A, Rudzki S, Wysokinski A. The reverse remodeling of the aorta in patients after renal transplantation&#x2013; the value of aortic stiffness index: prospective echocardiographic study. BMC Nephrology. 2017;18:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5260005</ArticleId><ArticleId IdType="pubmed">28114900</ArticleId></ArticleIdList></Reference><Reference><Citation>La Via L, Cuttone G, Misseri G, Sorbello M, Pappalardo F, Maniaci A, et al. The use of noninvasive positive pressure ventilation for severe asthma: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Expert Rev Respir Med. 2025;19(2):165&#x2013;173. doi: 10.1080/17476348.2025.2454947. Epub 2025 Jan 19. PMID: 39825601.</Citation><ArticleIdList><ArticleId IdType="pubmed">39825601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Bail&#xe9;n M, Hidalgo-Mart&#xed;n J, Ramos Cuadra J&#xc1;, Manetsberger J, Pola Gallegode Guzm&#xe1;n MD, D&#xed;az-Castellanos M&#xc1;, Casado-Santa-B&#xe1;rbara P, Dagomar Lohman J,C&#xe1;rdenas-Cruz A, Clau-Terr&#xe9; F, Lavilla-Lerma ML. Right ventricular strain and outflowtract velocity time integral are associated with mortality in critically ill patients withpulmonary embolism. Am J Respir Crit Care Med. 2025 Mar;28. https://doi.org/10.1164/rccm.202407-1433OC. Epub ahead of print. PMID: 40153695.</Citation><ArticleIdList><ArticleId IdType="pubmed">40153695</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40841640</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1477-7517</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Harm reduction journal</Title><ISOAbbreviation>Harm Reduct J</ISOAbbreviation></Journal><ArticleTitle>Harm reduction measures in a recreational gym user with anabolic androgenic steroid dependence: a case report in the context of current best clinical practice.</ArticleTitle><Pagination><StartPage>144</StartPage><MedlinePgn>144</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">144</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12954-025-01294-w</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The non-medical use of androgens among recreational gym users has become a global substance use concern. Complications from use particularly appear to affect the cardiovascular system, including the development of cardiovascular events, as well as anabolic steroid-induced cardiomyopathy (ASIC). Furthermore, the development of substance dependence with a specific withdrawal syndrome appears to be common and is contributed by the development of endocrine dysfunction related to anabolic steroid-induced hypogonadism. A 38-year-old male law enforcement officer and recreational bodybuilder presented with multiple health complaints following years of supraphysiologic androgen use and polypharmacy. Key symptoms included new-onset subacute dyspnea, dizziness, palpitations, headaches, and recurrent failed attempts at androgen cessation. Clinical findings showed abnormal blood pressure, testicular atrophy, plethoric appearance, and laboratory evidence of progressive polycythemia (hematocrit: 56.9%; normal&#x2009;&lt;&#x2009;49%), elevated testosterone, and suppressed luteinizing and follicle-stimulating hormones. He was at risk for muscle dysmorphia and met criteria for androgen dependence. Diagnosis confirmed ASIC. Treatment consisted of recurrent bloodletting for polycythemia, guideline-based cardiac management, and a structured endocrine regimen (tapered transdermal testosterone, oral Tamoxifen, subcutaneous human chorionic gonadotropin) to support androgen discontinuation and hormonal recovery. At 4&#xa0;months, ASIC had normalized, and he was asymptomatic. However, after 6&#xa0;months, he developed laboratory-confirmed idiopathic primary hypogonadism and began guideline-directed testosterone replacement. Despite more than a year of abstinence from non-medical androgen use and normalization of cardiac function, the patient died from a cardiovascular event, highlighting the possibly persistent risks of prior androgen use.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Non-medical androgen use is a growing global issue among recreational gym-goers. The intersection of severe health risks and substance dependence highlights the urgent need for an integrated, medical and harm-reduction approach-ideally delivered in specialized primary care settings. Early detection of cardiovascular risk factors is crucial for mitigating the often-overlooked yet potentially reversible complications. A reassessment of legal and clinical measures is warranted to optimize harm reduction and provision of care. Despite best practices and a year of abstinence from non-medical androgen use, the patient's fatal outcome underscores the critical need for further research, heightened awareness, and more robust prevention and harm reduction strategies for those affected by non-medical androgen use.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Magnolini</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Arud Centre for Addiction Medicine, Schuetzengasse 31, 8001, Zurich, Switzerland. r.magnolini@arud.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Primary Care, University Hospital Zurich, University of Zurich, Zurich, Switzerland. r.magnolini@arud.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottoni</LastName><ForeName>Sofia Laura</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Institute of Primary Care, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammer</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>HerzGefaessZentrum im Park, Hirslanden Group, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Herzpraxis Stadelhofen, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capraro</LastName><ForeName>Jo&#xeb;l</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology and Metabolism, Cantonal Hospital Aarau, Aarau, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruggmann</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Arud Centre for Addiction Medicine, Schuetzengasse 31, 8001, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Primary Care, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senn</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Primary Care, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Harm Reduct J</MedlineTA><NlmUniqueID>101153624</NlmUniqueID><ISSNLinking>1477-7517</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D045930">Anabolic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000728">Androgens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000094343">Anabolic Androgenic Steroids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045930" MajorTopicYN="Y">Anabolic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="Y">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040261" MajorTopicYN="Y">Harm Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000728" MajorTopicYN="Y">Androgens</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094343" MajorTopicYN="N">Anabolic Androgenic Steroids</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Addiction</Keyword><Keyword MajorTopicYN="N">Anabolic androgenic steroids</Keyword><Keyword MajorTopicYN="N">Cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Hypogonadism</Keyword><Keyword MajorTopicYN="N">Polycythemia</Keyword><Keyword MajorTopicYN="N">Substance use disorder</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This case report does not require ethical approval. Consent for publication: The patient has read the final manuscript for initial submission and provided informed consent for publication. Competing interests: The authors have no relevant financial or non-financial interests to disclose. We can report that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>16</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>16</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>23</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841640</ArticleId><ArticleId IdType="doi">10.1186/s12954-025-01294-w</ArticleId><ArticleId IdType="pii">10.1186/s12954-025-01294-w</ArticleId><ArticleId IdType="pmc">PMC12369084</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy. 2012;32(10):910&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23033230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnecaze AK, O&#x2019;Connor T, Burns CA. Harm reduction in male patients actively using anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs): a review. J Gen Intern Med. 2021;36(7):2055&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8298654</ArticleId><ArticleId IdType="pubmed">33948794</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnecaze AK, O&#x2019;Connor T, Aloi JA. Characteristics and attitudes of men using anabolic androgenic steroids (AAS): a survey of 2385 men. Am J Mens Health. 2020;14(6): 1557988320966536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7739101</ArticleId><ArticleId IdType="pubmed">33307930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanayama G, Pope HG. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018;464:4&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">28245998</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullen C, Whalley BJ, Schifano F, Baker JS. Anabolic androgenic steroid abuse in the United Kingdom: an update. Br J Pharmacol. 2020. 10.1111/bph.14995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7174889</ArticleId><ArticleId IdType="pubmed">31989581</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieschlag E, Vorona E. Doping with anabolic androgenic steroids (AAS): adverse effects on non-reproductive organs and functions. Rev Endocr Metab Disord. 2015;16(3):199&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">26373946</ArticleId></ArticleIdList></Reference><Reference><Citation>Christou MA, Christou PA, Markozannes G, Tsatsoulis A, Mastorakos G, Tigas S. Effects of anabolic androgenic steroids on the reproductive system of athletes and recreational users: a systematic review and meta-analysis. Sports Med. 2017;47(9):1869&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">28258581</ArticleId></ArticleIdList></Reference><Reference><Citation>Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Tr&#xe6;rup Andersen J, Andersen MA, Johansson KS, et al. Cardiovascular disease in anabolic androgenic steroid users. Circulation. 2025;151:828&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">39945117</ArticleId></ArticleIdList></Reference><Reference><Citation>Albano GD, Amico F, Cocimano G, Liberto A, Maglietta F, Esposito M, et al. Adverse effects of anabolic-androgenic steroids: a literature review. Healthcare. 2021;9(1): 97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832337</ArticleId><ArticleId IdType="pubmed">33477800</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito M, Salerno M, Calvano G, Agliozzo R, Ficarra V, Sessa F, et al. Impact of anabolic androgenic steroids on male sexual and reproductive function: a systematic review. Panminerva Med. 2023;65(1):43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">35146992</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadah K, Gopi G, Lingireddy A, Blumer V, Dewald T, Mentz RJ. Anabolic androgenic steroids and cardiomyopathy: an update. Front Cardiovasc Med. 2023;10: 1214374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10412093</ArticleId><ArticleId IdType="pubmed">37564909</ArticleId></ArticleIdList></Reference><Reference><Citation>Pope HG, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am J Addict. 2014;23(4):371&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3961570</ArticleId><ArticleId IdType="pubmed">24112239</ArticleId></ArticleIdList></Reference><Reference><Citation>Skauen JE, Pallesen S, Bj&#xf8;rnebekk A, Chegeni R, Syvertsen A, Petr&#xf3;czi A, et al. Prevalence and correlates of androgen dependence: a meta-analysis, meta-regression analysis and qualitative synthesis. Curr Opin Endocrinol Diabetes Obes. 2023. 10.1097/MED.0000000000000822.</Citation><ArticleIdList><ArticleId IdType="pubmed">37410490</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24636400</ArticleId></ArticleIdList></Reference><Reference><Citation>Solanki P, Eu B, Smith J, Allan C, Lee K. Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review. Endocr Connect. 2023. 10.1530/EC-23-0358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620455</ArticleId><ArticleId IdType="pubmed">37855241</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnolini R, Kossinna K, Bjasch D, Kruijver M, Bruggmann P, Senn O. Feasibility of implementing current best clinical practice for people who are using anabolic androgenic steroids within a Swiss primary care practice: a quality assurance study. Swiss Med Wkly. 2025;155(2): 4225. 10.57187/s.4225.</Citation><ArticleIdList><ArticleId IdType="pubmed">39977451</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache. 2013;53(10):1541&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24266334</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant B, Kean J, Vali N, Campbell J, Maden L, Bijral P, et al. The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men. Subst Abuse Treat Prev Policy. 2023;18(1): 66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10640727</ArticleId><ArticleId IdType="pubmed">37951896</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant B, Campbell J, Pradeep A, Burns AD, Bassett P, Abbara A, et al. Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men: a single center retrospective study. Eur J Endocrinol. 2023;189(6):601&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">38102386</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeeck A, Welter V, Alatas H, Hildebrandt T, Lahmann C, Hartmann A. Muscle dysmorphic disorder inventory (MDDI): validation of a German version with a focus on gender. PLoS ONE. 2018;13(11): e0207535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6239320</ArticleId><ArticleId IdType="pubmed">30444914</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Issues for DSM-V: clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am J Psychiatry. 2009;166(6):642&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696068</ArticleId><ArticleId IdType="pubmed">19487399</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912&#x2013;4018.</Citation><ArticleIdList><ArticleId IdType="pubmed">39210715</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinemann LA, Saad F, Zimmermann T, Novak A, Myon E, Badia X, et al. The Aging Males&#x2019; Symptoms (AMS) scale: update and compilation of international versions. Health Qual Life Outcomes. 2003;1:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC155679</ArticleId><ArticleId IdType="pubmed">12747807</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, et al. European academy of andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: European Society of Endocrinology. Andrology. 2020;8(5):970&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">32026626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">37326322</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vincentis S, Rochira V. Update on acquired hypogonadism in men living with HIV: pathogenesis, clinic, and treatment. Front Endocrinol (Lausanne). 2023;14: 1201696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10338827</ArticleId><ArticleId IdType="pubmed">37455928</ArticleId></ArticleIdList></Reference><Reference><Citation>Afolabi JM, Kirabo A. HIV and cardiovascular disease. Circ Res. 2024;134(11):1512&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11132120</ArticleId><ArticleId IdType="pubmed">38781297</ArticleId></ArticleIdList></Reference><Reference><Citation>Parente Filho SLA, Gomes PEAC, Forte GA, Lima LLL, Silva J&#xfa;nior GBD, Meneses GC, et al. Kidney disease associated with androgenic-anabolic steroids and vitamin supplements abuse: be aware! Nefrologia (Engl Ed). 2020;40(1):26&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">31585781</ArticleId></ArticleIdList></Reference><Reference><Citation>Smoliga JM, Wilber ZT, Robinson BT. Premature death in bodybuilders: what do we know? Sports Med. 2023;53(5):933&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9885939</ArticleId><ArticleId IdType="pubmed">36715876</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnolini R, Falcato L, Cremonesi A, Schori D, Bruggmann P. Fake anabolic androgenic steroids on the black market - a systematic review and meta-analysis on qualitative and quantitative analytical results found within the literature. BMC Public Health. 2022;22(1): 1371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9288681</ArticleId><ArticleId IdType="pubmed">35842594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruijver M, Bruggmann P, Magnolini R. Evidence of use and users of image- and performance-enhancing drugs in sports in Switzerland: a scoping literature review and implications for Swiss drug policy. Swiss Med Wkly. 2023;153: 40080.</Citation><ArticleIdList><ArticleId IdType="pubmed">37245119</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014;24(5):383&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">24582699</ArticleId></ArticleIdList></Reference><Reference><Citation>Iff S, Butzke I, Quednow B, Gupta R, Imboden C, Claussen M. &#xab;Image and performance enhancing drugs&#xbb; im Freizeitsport. Swiss Med Forum. 2021;21:843&#x2013;7.</Citation></Reference><Reference><Citation>Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780436</ArticleId><ArticleId IdType="pubmed">19922565</ArticleId></ArticleIdList></Reference><Reference><Citation>Szalavitz M, Rigg KK, Wakeman SE. Drug dependence is not addiction-and it matters. Ann Med. 2021;53(1):1989&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8583742</ArticleId><ArticleId IdType="pubmed">34751058</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz MA, Taylor D. Addiction and physical dependence are not the same thing. Lancet Psychiatry. 2023;10(8):e23.</Citation><ArticleIdList><ArticleId IdType="pubmed">37479345</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey O, Keen S, Parrish M, van Teijlingen E. Support for people who use anabolic androgenic steroids: a systematic scoping review into what they want and what they access. BMC Public Health. 2019;19(1): 1024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670144</ArticleId><ArticleId IdType="pubmed">31366349</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroid use. J Intern Med. 2019;285(3):333&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30460728</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough D, Webb R, Enright KJ, Lane KE, McVeigh J, Stewart CE, et al. How the love of muscle can break a heart: impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health. Rev Endocr Metab Disord. 2021;22(2):389&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087567</ArticleId><ArticleId IdType="pubmed">33269425</ArticleId></ArticleIdList></Reference><Reference><Citation>Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Horwitz H. Mortality among users of anabolic steroids. JAMA. 2024. 10.1001/jama.2024.3180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10941020</ArticleId><ArticleId IdType="pubmed">38483396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Guerra AI, Tapia J, Men&#xe9;ndez-Quintanal LM, Lucena JS. Sudden cardiac death in anabolic androgenic steroids abuse: case report and literature review. Forensic Sci Res. 2019;4(3):267&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6713204</ArticleId><ArticleId IdType="pubmed">31489392</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit DL, Voogel AJ, den Heijer M, de Ronde W. Anabolic androgenic steroids induce reversible left ventricular hypertrophy and cardiac. Dysfunction echocardiography results of the HAARLEM study. Front Reprod Health. 2021;3:732318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9580689</ArticleId><ArticleId IdType="pubmed">36304014</ArticleId></ArticleIdList></Reference><Reference><Citation>Doleeb S, Kratz A, Salter M, Thohan V. Strong muscles, weak heart: testosterone-induced cardiomyopathy. ESC Heart Fail. 2019;6(5):1000&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816072</ArticleId><ArticleId IdType="pubmed">31287235</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohsenin V. Obstructive sleep apnea and hypertension: a critical review. Curr Hypertens Rep. 2014;16(10): 482.</Citation><ArticleIdList><ArticleId IdType="pubmed">25139780</ArticleId></ArticleIdList></Reference><Reference><Citation>Basheer B, Ila V, Barros R, Mesquita F, Lopes LS, Lima VFN, et al. Management of adverse effects in testosterone replacement therapy. Int Braz J Urol. 2025. 10.1590/s1677-5538.ibju.2025.9904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12052019</ArticleId><ArticleId IdType="pubmed">39908204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;2012: 540398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296170</ArticleId><ArticleId IdType="pubmed">22518126</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5614517</ArticleId><ArticleId IdType="pubmed">28533317</ArticleId></ArticleIdList></Reference><Reference><Citation>Drezner JA, Sharma S, Baggish A, Papadakis M, Wilson MG, Prutkin JM, et al. International criteria for electrocardiographic interpretation in athletes: consensus statement. Br J Sports Med. 2017;51(9):704&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">28258178</ArticleId></ArticleIdList></Reference><Reference><Citation>Drezner JA, Ackerman MJ, Anderson J, Ashley E, Asplund CA, Baggish AL, et al. Electrocardiographic interpretation in athletes: the &#x201c;Seattle criteria.&#x201d; Br J Sports Med. 2013;47(3):122&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">23303758</ArticleId></ArticleIdList></Reference><Reference><Citation>Estes EH, Zhang ZM, Li Y, Tereschenko LG, Soliman EZ. The romhilt-estes left ventricular hypertrophy score and its components predict all-cause mortality in the general population. Am Heart J. 2015;170(1):104&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646417</ArticleId><ArticleId IdType="pubmed">26093870</ArticleId></ArticleIdList></Reference><Reference><Citation>Courand PY, Lantelme P, Gosse P. Electrocardiographic detection of left ventricular hypertrophy: time to forget the Sokolow-Lyon index? Arch Cardiovasc Dis. 2015;108(5):277&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">25937357</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillai AA, Fazal S, Mukkamalla SKR, Babiker HM. Polycythemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.</Citation><ArticleIdList><ArticleId IdType="pubmed">30252337</ArticleId></ArticleIdList></Reference><Reference><Citation>Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost. 1997;23(5):441&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">9387203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S, M&#xfc;nster AB, Gram J, Sidelmann JJ. Anabolic androgenic steroid abuse: the effects on thrombosis risk, coagulation, and fibrinolysis. Semin Thromb Hemost. 2018;44(8):734&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">30267392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018;6(1):77&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5690890</ArticleId><ArticleId IdType="pubmed">28526632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond P, Verdegaal T, Smit DL. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocr Connect. 2024;13(10):e240283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11466264</ArticleId><ArticleId IdType="pubmed">39212549</ArticleId></ArticleIdList></Reference><Reference><Citation>Furrer H. Prevalence and clinical significance of splenomegaly in asymptomatic human immunodeficiency virus type 1-infected adults. Swiss HIV cohort study. Clin Infect Dis. 2000;30(6):943&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10880308</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar Neto JO, da Silva CA, Bruno da Silva CA, Pinto DV, Caminha JSR, de Matos RS, et al. Anabolic androgenic steroid-induced hypogonadism, a reversible condition in male individuals? A systematic review. Andrologia. 2021;53(7):e14062.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887077</ArticleId></ArticleIdList></Reference><Reference><Citation>van Breda E, Keizer HA, Kuipers H, Wolffenbuttel BH. Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. Int J Sports Med. 2003;24(3):195&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740738</ArticleId></ArticleIdList></Reference><Reference><Citation>Havnes IA, Henriksen HCB, Johansen PW, Bj&#xf8;rnebekk A, Neupane SP, Hisdal J, et al. Off-label use of clomiphene citrate to treat anabolic androgenic steroid induced hypogonadism upon cessation among men (CloTASH) - a pilot study protocol. MethodsX. 2024;13: 102810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11253696</ArticleId><ArticleId IdType="pubmed">39022178</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit DL, Buijs MM, de Hon O, den Heijer M, de Ronde W. Disruption and recovery of testicular function during and after androgen abuse: the HAARLEM study. Hum Reprod. 2021;36(4):880&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">33550376</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, et al. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024;390(3):203&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">38231621</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhasin S, Thompson IM. Prostate risk and monitoring during testosterone replacement therapy. J Clin Endocrinol Metab. 2024;109(8):1975&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">38753865</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksen HCB, J&#xf8;rgensen AP, Bj&#xf8;rnebekk A, Neupane SP, Havnes IA. Clomiphene citrate and optional human chorionic gonadotropin for treating male hypogonadism arising from long-term anabolic-androgenic steroid use&#x2014;a pilot study. Performance Enhancement Health. 2024. 10.1016/j.peh.2024.100283.</Citation></Reference><Reference><Citation>Piatkowski T, Gibbs N, Dunn M. Beyond the law: on Etiocaasu, help-seeking and health outcomes in Australia. J Criminol. 2024;57:62&#x2013;82. 10.1177/26338076231209044.</Citation></Reference><Reference><Citation>Dunn M, Piatkowski T, Whiteside B, Eu B. Exploring the experiences of general practitioners working with patients who use performance and image enhancing drugs. Perform Enhanc Health. 2023;11(2):100247. 10.1016/j.peh.2023.100247.</Citation></Reference><Reference><Citation>Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med. 2013;2(5):38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833570</ArticleId><ArticleId IdType="pubmed">24416692</ArticleId></ArticleIdList></Reference><Reference><Citation>Seara FAC, Olivares EL, Nascimento JHM. Anabolic steroid excess and myocardial infarction: from ischemia to reperfusion injury. Steroids. 2020;161: 108660.</Citation><ArticleIdList><ArticleId IdType="pubmed">32492466</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JD, Wu YQ. Anabolic-androgenic steroids and cardiovascular risk. Chin Med J (Engl). 2019;132(18):2229&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6797160</ArticleId><ArticleId IdType="pubmed">31478927</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit DL, Bond P, de Ronde W. Health effects of androgen abuse: a review of the HAARLEM study. Curr Opin Endocrinol Diabetes Obes. 2022;29(6):560&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">35938779</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond P, Smit DL, de Ronde W. Anabolic-androgenic steroids: How do they work and what are the risks? Front Endocrinol (Lausanne). 2022;13:1059473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9837614</ArticleId><ArticleId IdType="pubmed">36644692</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnon LR, Sadasivan C, Perera K, Oudit GY. Cardiac complications of common drugs of abuse: pharmacology, toxicology, and management. Can J Cardiol. 2022;38(9):1331&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">34737034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilonze OJ, Enyi CO, Ilonze CC. Cardiomyopathy and heart failure secondary to anabolic-androgen steroid abuse. Proc (Bayl Univ Med Cent). 2022;35(3):363&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9037463</ArticleId><ArticleId IdType="pubmed">35518797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40846960</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1824-7288</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Italian journal of pediatrics</Title><ISOAbbreviation>Ital J Pediatr</ISOAbbreviation></Journal><ArticleTitle>An uncommon case of neonatal asphyxia associated with infantile-onset Pompe disease.</ArticleTitle><Pagination><StartPage>260</StartPage><MedlinePgn>260</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13052-025-02088-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pompe disease, also known as glycogenosis type II or acid maltase deficiency, is an autosomal recessive disease caused by a deficiency of alpha-glucosidase. The severity depends mainly on the type of mutation, which in turn determines early or late onset; therapy modifies the outcome but does not alter the severity of the disease at presentation.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">We present a case report of a male infant, inborn and delivered at a gestational age of 39 weeks. Medical history reveals consanguineous parents with no invasive screening tests performed during pregnancy. They chose not to undergo prenatal screening even though they were aware of the risks associated with their consanguinity. At birth, the newborn was atonic and pale, with a heart rate of 70&#xa0;bpm. During resuscitation, an umbilical venous catheter was placed, and three doses of adrenaline and one dose of bicarbonate were administered. At the Neonatal Intensive Care Unit, he underwent therapeutic hypothermia. Echocardiography, performed a few hours later, revealed severe biventricular and septal hypertrophy consistent with non-obstructive hypertrophic cardiomyopathy. During recovery, even after the discontinuation of hypothermia, the newborn exhibited abnormal neurological signs, including axial hypotonia and a tendency to keep his mouth open with tongue protrusion. Given the clinical picture and the early detection of septal and biventricular hypertrophy, genetic testing was performed, revealing a homozygous c.2560&#xa0;C&#x2009;&gt;&#x2009;T variant in the acid alpha-glucosidase gene (both parents were carriers), described in scientific literature as a class 5 pathogenic variant associated with glycogenosis type II (Pompe disease).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Pompe disease is a rare genetic disorder and may be difficult to diagnose at birth. Suspicion should arise in the presence of hypertrophic cardiomyopathy, especially when associated with a history of neonatal asphyxia and abnormal neurological signs. An accurate diagnosis and early treatment are essential to improving the patient's survival and quality of life.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leo</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0000-8795-5886</Identifier><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, Azienda USL-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy. francesco.leo@ausl.re.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barchi</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Postgraduate School of Pediatrics, Department of Medical and Surgical Sciences of the Mother, Children, and Adults, University of Modena and Reggio Emilia, 41125, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Postgraduate School of Pediatrics, Department of Medical and Surgical Sciences of the Mother, Children, and Adults, University of Modena and Reggio Emilia, 41125, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balestri</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, Azienda USL-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chesi</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, Azienda USL-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Dio</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, Azienda USL-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garavelli</LastName><ForeName>Livia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Genetics Unit, Department of Mother and Children, Azienda USL-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iughetti</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Postgraduate School of Pediatrics, Department of Medical and Surgical Sciences of the Mother, Children, and Adults, University of Modena and Reggio Emilia, 41125, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gargano</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, Azienda USL-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ital J Pediatr</MedlineTA><NlmUniqueID>101510759</NlmUniqueID><ISSNLinking>1720-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006009" MajorTopicYN="Y">Glycogen Storage Disease Type II</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001238" MajorTopicYN="Y">Asphyxia Neonatorum</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asphyxia</Keyword><Keyword MajorTopicYN="N">Heart disease</Keyword><Keyword MajorTopicYN="N">Leonatal</Keyword><Keyword MajorTopicYN="N">Newborn screening</Keyword><Keyword MajorTopicYN="N">Pompe disease</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Written informed consent was obtained from the patient&#x2019;s legal guardian for publication of this case report and any accompanying images. Conflict of interest: The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846960</ArticleId><ArticleId IdType="doi">10.1186/s13052-025-02088-3</ArticleId><ArticleId IdType="pii">10.1186/s13052-025-02088-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile pompe&#x2019;s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">12897283</ArticleId></ArticleIdList></Reference><Reference><Citation>Meena NK, Raben N. Pompe disease: new developments in an old lysosomal storage disorder. Biomolecules. 2020;10(9):1339. https://doi.org/10.3390/biom10091339 . Published 2020 Sep 18.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10091339</ArticleId><ArticleId IdType="pubmed">32962155</ArticleId><ArticleId IdType="pmc">7564159</ArticleId></ArticleIdList></Reference><Reference><Citation>Gragnaniello V, Pijnappel PWWM, Burlina AP, In't Groen SLM, Gueraldi D, Cazzorla C, Maines E, Polo G, Salviati L, Di Salvo G, Burlina AB. Newborn screening for Pompe disease in Italy: Long-term results and future challenges. Mol Genet Metab Rep. 2022 Oct https://doi.org/10.1016/j.ymgmr.2022.100929</Citation></Reference><Reference><Citation>Howell RR, Byrne B, Darras BT et al. Diagnostic challenges for Pompe disease: an under-recognized cause of floppy baby syndrome. Genet Med. 2006;8(5):289&#x2013;&#x2009;96. https://doi.org/10.1097/01.gim.0000204462.42910.b8 . PMID: 16702878.</Citation></Reference><Reference><Citation>Hagemans ML, Winkel LP, Hop WC et al. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology. 2005;64(12):2139-41. https://doi.org/10.1212/01.WNL.0000165979.46537.56 . PMID: 15985590.</Citation></Reference><Reference><Citation>Kross M, Pomponio RJ, van Vliet L, Palmer RE, Phipps M, Van der Helm R, Halley D, Reuser A. GAA database consortium. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat. 2008;29:E13&#x2013;26.</Citation></Reference><Reference><Citation>Kishnani PS, Hwu WL, Mandel H, Infantile-Onset Pompe Disease Natural History Study Group. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671&#x2013;676. doi: 10.1016/j.jpeds.2005.11.033. PMID: 16737883.</Citation></Reference><Reference><Citation>Reuser AJJ, van der Ploeg AT, Chien YH, et al. GAA variants and pheno- types among 1,079 patients with Pompe disease. Data from the Pompe registry. Hum Mutat. 2019;40(11):2146&#x2013;64. https://doi.org/10.1002/humu.23878 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23878</ArticleId><ArticleId IdType="pubmed">31342611</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishnani PS, Hwu WL, Mandel H, et al. Infantile-Onset Pompe Disease Natural History Study Group. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671&#x2013;676. https://doi.org/10.1016/j.jpeds.2005.11.033 PMID: 16737883.</Citation></Reference><Reference><Citation>Oba SM, Shinjo, et al. Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations. J Neurol. 2009;256:1881&#x2013;90.</Citation></Reference><Reference><Citation>Cohen JL, et al. In utero Enzyme-Replacement therapy for Infantile-Onset pompe&#x2019;s disease. N Engl J Med. 2022;387:2150&#x2013;8. https://doi.org/10.1056/NEJMoa2200587 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200587</ArticleId><ArticleId IdType="pubmed">36351280</ArticleId><ArticleId IdType="pmc">10794051</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yang Y, Wang B, et al. Infantile Pompe disease: a case report and review of the Chinese literature. Exp Ther Med. 2016;11:235&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26889246</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton BK, Kronn DF, Hwu WL, Pompe Disease Newborn Screening Working Group. The initial evaluation of patients after positive newborn screening: Recommended algorithms leading to a confirmed diagnosis of pompe disease. Pediatrics. 2017;140(Suppl 1):S14-S23. https://doi.org/10.1542/peds.2016-0280D . PMID: 29162674.</Citation></Reference><Reference><Citation>Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14(1):135&#x2013;42. https://doi.org/10.1038/gim.2011.4 . PMID: 22237443; PMCID: PMC3711224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2011.4</ArticleId><ArticleId IdType="pubmed">22237443</ArticleId><ArticleId IdType="pmc">3711224</ArticleId></ArticleIdList></Reference><Reference><Citation>Salabarria SM, Nair J, Clement N, et al. Advancements in AAV-mediated gene therapy for Pompe disease. J Neuromuscul Dis. 2020;7(1):15&#x2013;31. https://doi.org/10.3233/JND-190426 . PMID: 31796685; PMCID: PMC7029369.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-190426</ArticleId><ArticleId IdType="pubmed">31796685</ArticleId><ArticleId IdType="pmc">7029369</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi, et al. Infantile Pompe disease with intrauterine onset: a case report and literature review. Ital J Pediatr. 2022;48:187. https://doi.org/10.1186/s13052-022-01379-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-022-01379-3</ArticleId><ArticleId IdType="pubmed">36411466</ArticleId><ArticleId IdType="pmc">9677902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronn DF, Day-Salvatore D, Hwu WL, Pompe Disease Newborn Screening Working Group. Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum. Pediatrics. 2017;140(Suppl 1):S24-S45. https://doi.org/10.1542/peds.2016-0280E . PMID: 29162675.</Citation></Reference><Reference><Citation>Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66(3):329&#x2013;35. https://doi.org/10.1203/PDR.0b013e3181b24e94 . PMID: 19542901; PMCID: PMC3129995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e3181b24e94</ArticleId><ArticleId IdType="pubmed">19542901</ArticleId><ArticleId IdType="pmc">3129995</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40833405</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>34</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A FRET assay to monitor different structural states of human &#x3b2;-cardiac myosin including the interacting-heads motif.</ArticleTitle><Pagination><StartPage>e2504562122</StartPage><MedlinePgn>e2504562122</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2504562122</ELocationID><Abstract><AbstractText>In cardiac muscle, myosin molecules exist in multiple structural states as they transit through their ATPase cycle, including an off-cycle resting or OFF-state with their catalytic heads in a folded structure known as the interacting-heads motif (IHM). The blocked head configuration (BHC) of the IHM is unusual because its light chain binding region is held in an exaggerated prestroke angle stabilized by interactions with its own S2 tail. An additional partial OFF-state, where the second head of the IHM is not folded back onto the blocked head, has been proposed, which still has the blocked head interacting with S2. Many mutations in the human &#x3b2;-cardiac myosin gene that cause hypertrophic cardiomyopathy are thought to destabilize (decrease the population of) the OFF-states. The effects of pathogenic mutations on the folded back structural states are often studied using indirect assays, including a single-ATP turnover assay that detects the biochemical state of myosin functionally. Here, we use a fluorescence resonance energy transfer (FRET) based sensor for direct quantification in solution of the myosin BHC state. Using the FRET sensor, we provide evidence that the myosin tail acts as an activator of the recovery stroke transition after ATP binding to poststroke state apomyosin and that BHC formation is rapid after ATP binding and depends on formation of the prestroke state. We propose that the positively charged loop 2 of the prestroke state head interacts with the Ring 2 cluster of negatively charged residues on the S2 tail to form a preBHC state that facilitates BHC state formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goluguri</LastName><ForeName>Rama Reddy</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Cardiovascular Institute, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guhathakurta</LastName><ForeName>Piyali</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nandwani</LastName><ForeName>Neha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Cardiovascular Institute, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawood</LastName><ForeName>Aminah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Cardiovascular Institute, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokota</LastName><ForeName>Seiji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Cardiovascular Institute, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roopnarine</LastName><ForeName>Osha</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>David D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruppel</LastName><ForeName>Kathleen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Cardiovascular Institute, Stanford, CA 94305.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spudich</LastName><ForeName>James A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-4324-4254</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Cardiovascular Institute, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2GM33289</GrantID><Agency>HHS | NIH | National Institute of General Medical Sciences (NIGMS)</Agency><Country/></Grant><Grant><GrantID>HL117138</GrantID><Agency>HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)</Agency><Country/></Grant><Grant><GrantID>23POST1027175</GrantID><Agency>American Heart Association (AHA)</Agency><Country/></Grant><Grant><GrantID>22POST908934</GrantID><Agency>American Heart Association (AHA)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D024723">Ventricular Myosins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.1</RegistryNumber><NameOfSubstance UI="D018995">Myosin Heavy Chains</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D031541" MajorTopicYN="Y">Fluorescence Resonance Energy Transfer</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024723" MajorTopicYN="Y">Ventricular Myosins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018995" MajorTopicYN="Y">Myosin Heavy Chains</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BHC</Keyword><Keyword MajorTopicYN="N">BOT</Keyword><Keyword MajorTopicYN="N">FRET sensor</Keyword><Keyword MajorTopicYN="N">human &#x3b2;-cardiac myosin</Keyword><Keyword MajorTopicYN="N">interacting heads motif</Keyword></KeywordList><CoiStatement>Competing interests statement:J.A.S. is cofounder and on the Scientific Advisory Board of Cytokinetics, Inc., a company developing small-molecule therapeutics for the treatment of hypertrophic cardiomyopathy and other cardiac and skeletal muscle diseases. J.A.S. is cofounder and CEO, and K.M.R. is cofounder and Research and Clinical Advisor, of Kainomyx, Inc., a company developing small molecule therapeutics targeting cytoskeletal proteins for a variety of clinical conditions. D.D.T. is a founder and serves as executive officer for Photonic Pharma LLC (PP), a company involved in the early phase of drug discovery, for treatment of diseases involving myosin and other proteins. O.R. is the sole proprietor of Editing Science LLC, which had no role in this study. J.A.S. owns stock in Cytokinetics, Inc, worth &gt; $5,000.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>10</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40833405</ArticleId><ArticleId IdType="doi">10.1073/pnas.2504562122</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40833743</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-4898</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Accounts of chemical research</Title><ISOAbbreviation>Acc Chem Res</ISOAbbreviation></Journal><ArticleTitle>Nanocatalytic Antioxidation: A General Chemical Approach for Alleviating Oxidative Stress in Diseases.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.accounts.5c00408</ELocationID><Abstract><AbstractText>ConspectusThe overexpression of reactive oxygen species (ROS) is one of the major causes of various human diseases, including cardiovascular diseases, neurodegenerative diseases, and multiple inflammations, by initiating local oxidative stress at specific sites. The excessive ROS not only leads to oxidative injury of normal functional cells but also activates immune cells to aggravate inflammation. Therefore, scavenging excessive ROS is a feasible strategy for treating these diseases. Although many molecular drugs (such as <i>N</i>-acetylcysteine and coenzyme Q10) have been approved for antioxidative therapies, from the perspective of chemical reaction, these antioxidant molecules can only act as reactants to react with ROS, leading to a nonsustainable antioxidative effect, largely compromising therapeutic outcome.Our research team has proposed the concept of "nanocatalytic medicine", which aims to use nanoparticles to trigger catalytic reactions in pathological sites, regulating the concentrations of ROS efficiently and sustainably for disease treatments. Till now, most efforts have been focusing on the development of pro-oxidative nanocatalysts to catalyze ROS generation for tumor therapy, which induces oxidative damage of cancer cells, while the antioxidative nanocatalysts for treating other oxidative stress-related diseases have been less reported, and the chemical strategy of nanocatalytic antioxidation has rarely been discussed specifically, which is in contrast to the conventional nanocatalytic pro-oxidation approach for tumor therapy.During the last several years, our laboratory has developed various catalytic antioxidative nanosystems to trigger nanocatalytic antioxidation reactions for treating multiple diseases, including ischemic cardiomyopathy, diabetic cardiomyopathy, aortic dissection, alcoholic liver injury, inflammatory bowel disease, psoriasis, atopic dermatitis, rheumatoid arthritis, etc. From the perspective of chemical reaction, these nanosystems act as catalysts in antioxidation reactions and therefore will not be consumed but can lead to a sustainable and highly efficient antioxidative effect. Such a strategy not only largely elevates therapeutic efficacy but also reduces the doses of therapeutic agents required for administration. Moreover, the established catalytic antioxidation reactions may modulate the immune microenvironments at pathological sites, resulting in favorable therapeutic outcomes. In this Account, we will discuss the recent advances in our laboratory in the design and fabrication of antioxidative nanocatalysts for various disease treatments, highlighting nanocatalytic antioxidation as a general chemical strategy for alleviating oxidative stress in diseases. The material chemistry of these catalytic antioxidative nanosystems will be elucidated, which underlies elevated therapeutic outcome. It is expected that such a chemical strategy of nanocatalytic antioxidation will make a significant contribution to disease treatments in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Bowen</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-8934-0276</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Jianlin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8790-195X</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, P. R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acc Chem Res</MedlineTA><NlmUniqueID>0157313</NlmUniqueID><ISSNLinking>0001-4842</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40833743</ArticleId><ArticleId IdType="doi">10.1021/acs.accounts.5c00408</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40834826</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-0834</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology</Title><ISOAbbreviation>J Vet Cardiol</ISOAbbreviation></Journal><ArticleTitle>Interobserver repeatability of interventricular septal wall measurements in cats.</ArticleTitle><Pagination><StartPage>17</StartPage><EndPage>24</EndPage><MedlinePgn>17-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvc.2025.07.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1760-2734(25)00081-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Clinically, echocardiography is the gold standard test for diagnosing hypertrophic cardiomyopathy in cats. Low interobserver variability for echocardiographic measurements has generally been reported in the literature. We hypothesized that interobserver variability is high when measuring the interventricular septum (IVS) thickness in cats.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Echocardiographic right-sided parasternal left ventricular (LV) outflow tract views from four cats with different LV morphologies were selected. Five measurements of the IVS in each picture were performed by 29 veterinary cardiologists and cardiology residents from different institutions. Intraclass correlation coefficient (ICC) was applied for data analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Interobserver repeatability was poor for the base of the IVS (partial ICC: 0.4) and moderate for the rest of the IVS (partial ICC: 0.6). A range of 0.7 mm between the lower and upper limits of measurements was found for each picture and region of the IVS. Around 27% of variance in measurements was associated with training location (country), whereas around 73% of the variance was attributable to the observer.</AbstractText><AbstractText Label="STUDY LIMITATIONS" NlmCategory="CONCLUSIONS">Study limitations included the use of still pictures and assessment of one echocardiographic parameter only.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">As hypothesized, the interobserver repeatability of IVS measurements using the right-sided parasternal LV outflow tract view in cats was poor to moderate. This finding is relevant when comparing and interpreting measurements obtained by different observers. Additionally, the influence of training location may need to be considered when interpreting results of variability studies involving observers from the same facility.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pires</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathobiology, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada; Department of Clinical Studies, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sears</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raheb</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Studies, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonfara</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Studies, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada. Electronic address: sfonfara@uoguelph.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Vet Cardiol</MedlineTA><NlmUniqueID>101163270</NlmUniqueID><ISSNLinking>1760-2734</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Echocardiography</Keyword><Keyword MajorTopicYN="N">Feline</Keyword><Keyword MajorTopicYN="N">HCM</Keyword><Keyword MajorTopicYN="N">Hypertrophy</Keyword><Keyword MajorTopicYN="N">Variability</Keyword></KeywordList><CoiStatement>Conflicts of Interest Statement The authors do not have any conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40834826</ArticleId><ArticleId IdType="doi">10.1016/j.jvc.2025.07.007</ArticleId><ArticleId IdType="pii">S1760-2734(25)00081-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">20301438</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK1261</ArticleId></ArticleIdList><Book><Publisher><PublisherName>University of Washington, Seattle</PublisherName><PublisherLocation>Seattle (WA)</PublisherLocation></Publisher><BookTitle book="gene">GeneReviews<sup>&#xae;</sup></BookTitle><PubDate><Year>1993</Year></PubDate><BeginningDate><Year>1993</Year></BeginningDate><EndingDate><Year>2025</Year></EndingDate><AuthorList Type="editors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Margaret P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Jerry</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mirzaa</LastName><ForeName>Ghayda M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Pagon</LastName><ForeName>Roberta A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Stephanie E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Amemiya</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author></AuthorList><Medium>Internet</Medium></Book><ArticleTitle book="gene" part="gsd2">Pompe Disease</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Sperry</LastName><ForeName>Ethan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leslie</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cincinnati STAR Center for Lysosomal Diseases, Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pena</LastName><ForeName>Loren</ForeName><Initials>L</Initials></Author></AuthorList><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText Label="CLINICAL CHARACTERISTICS">Pompe disease can be classified by age of onset, organ involvement, severity, and rate of progression into infantile-onset Pompe disease (IOPD) (i.e., individuals with onset before age 12 months with cardiomyopathy) and late-onset Pompe disease (LOPD) (i.e., individuals with onset before age 12 months without cardiomyopathy, and all individuals with onset after age 12 months). Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress. Cardiomegaly and hypertrophic cardiomyopathy is usually identified in the first weeks of life and progress to left ventricular outflow obstruction and diminished lung volume. Progressive deposition of glycogen results in conduction defects with shortening of the PR interval on EKG. In untreated infants, death commonly occurs in the first two years of life from cardiopulmonary insufficiency. In those in whom enzyme replacement therapy (ERT) is initiated before age six months and before the need for ventilatory assistance, a majority have improved survival, improved ventilator-independent survival, reduced cardiac mass, and significantly improved acquisition of motor skills compared to untreated individuals. LOPD can manifest from the first decade to as late as the seventh decade of life with progressive proximal muscle weakness primarily affecting the lower limbs, which may require use of a wheelchair. Respiratory insufficiency progressing to respiratory failure is a significant cause of morbidity and mortality. Some adults have developed arteriopathy, including dilatation of the ascending thoracic aorta. Scoliosis is also frequent.</AbstractText><AbstractText Label="DIAGNOSIS/TESTING">The diagnosis of Pompe disease is established in a proband who has deficiency of acid alpha-glucosidase (GAA) enzyme activity in isolated lymphocytes or mixed leukocytes and/or by identification of biallelic pathogenic (or likely pathogenic) variants in <i>GAA</i> by molecular genetic testing in a proband with an out-of-range newborn screening result and/or suggestive clinical features.</AbstractText><AbstractText Label="MANAGEMENT"><i>Targeted therapies</i>: Although ERT should be initiated as soon as the diagnosis of IOPD or symptomatic Pompe disease is established, it is appropriate to determine cross-reactive immunologic material (CRIM) status prior to initiating ERT, as individuals who do not produce CRIM (i.e., who are CRIM negative) generally develop high titer anti-rhGAA antibodies during ERT and require modified therapy protocols using immunomodulation early in the treatment course, optimally before the first infusion. ERT options include alglucosidase alfa for both IOPD and LOPD; avalglucosidase for individuals with LOPD who are older than age one year; and cipaglucosidase alfa with miglustat for adults with LOPD who weigh at least 40 kg and are not improving on their current ERT regimen. <i>Supportive care</i>: Medical intervention for cardiomyopathy needs to be individualized as use of standard drugs may be contraindicated in certain stages of the disease process. Management of conduction disturbances includes avoidance of stress, infection, fever, dehydration, and anesthesia; medical therapy, if indicated, often necessitates a careful balance of ventricular function and should be undertaken by a cardiologist familiar with Pompe disease. Speech therapy and augmented communication devices may be helpful for those with communication difficulties. Feeding therapy and consideration of a gastrostomy tube is recommended for those who have feeding/nutritional difficulties. Respiratory support for those with respiratory insufficiency may include CPAP and BiPAP; tracheostomy may be considered in those with macroglossia and severe respiratory insufficiency. Standard treatment for arteriopathy, muscle weakness, scoliosis, osteoporosis, and hearing loss. <i>Surveillance:</i> At each visit, measure growth parameters and evaluate nutritional status and safety of oral intake; monitor those with seizures as clinically indicated; assess for new manifestations (seizures, changes in tone, movement disorders); monitor developmental progress and educational needs; assess mobility and self-help skills; assess for scoliosis; monitor for evidence of aspiration and respiratory insufficiency; assess respiratory status with regard to cough, difficulty breathing, wheezing, fatigability, and exercise intolerance; obtain electrolytes, BUN, creatinine, liver function tests, CK level, and urine total glucotetrasaccharide (Hex4) level. At least annually, bone mineral density screening (DXA) in those with LOPD (in those with IOPD, DXA scan every two to three years until puberty, then every one to two years); pulmonary function tests; echocardiography (to include assessment for aortic dilatation in those with LOPD); EKG; audiology evaluation; BNP level (if there are concerns for evolving cardiomyopathy). At least every five years, MR cerebral angiography to evaluate for progressive dilation of cerebral vasculature. As clinically indicated, brain imaging to evaluate for intracranial vasculopathy (in those with LOPD); chest radiograph; whole-body MRI to evaluate muscle disease burden; polysomnography; videofluoroscopic swallow study; 24-hour ambulatory EKG (Holter monitoring). <i>Agents/circumstances to avoid:</i> The use of digoxin, ionotropes, diuretics, and afterload-reducing agents may worsen left ventricular outflow obstruction, although they may be indicated in later stages of the disease; hypotension and volume depletion should be avoided. Anesthesia should be used only when absolutely necessary because reduced cardiovascular return and underlying respiratory insufficiency pose significant risks. <i>Evaluation of relatives at risk:</i> Testing of all at-risk sibs of any age is warranted to allow for early diagnosis and treatment with ERT. If a molecular diagnosis has been established in the proband, molecular genetic prenatal testing of a fetus at risk may be performed; for at-risk newborn sibs (when prenatal testing was not performed), in parallel with newborn screening, either test for the familial <i>GAA</i> pathogenic variants or measure GAA enzyme activity. <i>Pregnancy management:</i> Several women with LOPD have been treated with ERT during pregnancy and lactation with no reported adverse effects on the fetus and no adverse events during infusions.</AbstractText><AbstractText Label="GENETIC COUNSELING">Pompe disease is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a <i>GAA</i> pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the <i>GAA</i> pathogenic variants have been identified in an affected family member, molecular genetic carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.</AbstractText><CopyrightInformation>Copyright &#xa9; 1993-2025, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="gene" part="gsd2" sec="gsd2.Summary">Summary</SectionTitle></Section><Section><SectionTitle book="gene" part="gsd2" sec="gsd2.Diagnosis">Diagnosis</SectionTitle></Section><Section><SectionTitle book="gene" part="gsd2" sec="gsd2.Clinical_Characteristics">Clinical Characteristics</SectionTitle></Section><Section><SectionTitle book="gene" part="gsd2" sec="gsd2.Genetically_Related_Allelic_Disorde">Genetically Related (Allelic) Disorders</SectionTitle></Section><Section><SectionTitle book="gene" part="gsd2" sec="gsd2.Differential_Diagnosis">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="gene" part="gsd2" sec="gsd2.Management">Management</SectionTitle></Section><Section><SectionTitle book="gene" part="gsd2" sec="gsd2.Genetic_Counseling">Genetic Counseling</SectionTitle></Section><Section><SectionTitle book="gene" part="gsd2" sec="gsd2.Resources">Resources</SectionTitle></Section><Section><SectionTitle book="gene" part="gsd2" sec="gsd2.Molecular_Genetics">Molecular Genetics</SectionTitle></Section><Section><SectionTitle book="gene" part="gsd2" sec="gsd2.Chapter_Notes">Chapter Notes</SectionTitle></Section><Section><SectionTitle book="gene" part="gsd2" sec="gsd2.References">References</SectionTitle></Section></Sections><KeywordList Owner="NLM"><Keyword MajorTopicYN="N">Acid Alpha-Glucosidase Deficiency</Keyword><Keyword MajorTopicYN="N">Acid Maltase Deficiency</Keyword><Keyword MajorTopicYN="N">GAA Deficiency</Keyword><Keyword MajorTopicYN="N">Glycogenosis Type II</Keyword><Keyword MajorTopicYN="N">Glycogen Storage Disease Type II (GSD II)</Keyword><Keyword MajorTopicYN="N">Acid Alpha-Glucosidase Deficiency</Keyword><Keyword MajorTopicYN="N">Acid Maltase Deficiency</Keyword><Keyword MajorTopicYN="N">GAA Deficiency</Keyword><Keyword MajorTopicYN="N">Glycogen Storage Disease Type II (GSD II)</Keyword><Keyword MajorTopicYN="N">Glycogenosis Type II</Keyword><Keyword MajorTopicYN="N">Lysosomal alpha-glucosidase</Keyword><Keyword MajorTopicYN="N">GAA</Keyword><Keyword MajorTopicYN="N">Pompe Disease</Keyword></KeywordList><ContributionDate><Year>2007</Year><Month>8</Month><Day>31</Day></ContributionDate><DateRevised><Year>2025</Year><Month>8</Month><Day>21</Day></DateRevised><ItemList ListType="Synonyms"><Item>Acid Alpha-Glucosidase Deficiency</Item><Item>Acid Maltase Deficiency</Item><Item>GAA Deficiency</Item><Item>Glycogenosis Type II</Item><Item>Glycogen Storage Disease Type II (GSD II)</Item></ItemList><ReferenceList><Reference><Citation>Ami&#xf1;oso C, Vallespin E, Fern&#xe1;ndez L, Arrabal LF, Desviat LR, P&#xe9;rez B, Santos F, Solera J. Identification of the first deletion-insertion involving the complete structure of GAA gene and part of CCDC40 gene mediated by an Alu element. Gene. 2013;519:169-72.</Citation><ArticleIdList><ArticleId IdType="pubmed">23402890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansong AK, Li JS, Nozik-Grayck E, Ing R, Kravitz RM, Idriss SF, Kanter RJ, Rice H, Chen YT, Kishnani PS. Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet Med. 2006;8:297-301</Citation><ArticleIdList><ArticleId IdType="pubmed">16702879</ArticleId></ArticleIdList></Reference><Reference><Citation>Avanti M, Martin A, Columbres RC, Mozaffar T, Kimonis V. Effects of enzyme replacement therapy on bone density in late onset Pompe disease. Mol Genet Metab. 2023;140:107644.</Citation><ArticleIdList><ArticleId IdType="pubmed">37515933</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, Kishnani PS. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J. Med Genet C Semin Med Genet. 2012;160C:40-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278076</ArticleId><ArticleId IdType="pubmed">22252923</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Vlach J, Raben N, Nagaraju K, Adams EM, Hermans MM, Reuser AJ, Brooks SS, Tifft CJ, Hirschhorn R, Huie ML, Nicolino M, Plotz PH. The African origin of the common mutation in African American patients with glycogen-storage disease type II. Am J Hum Genet. 1998;62:991-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377028</ArticleId><ArticleId IdType="pubmed">9529346</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrow TA, Bailey LA, Kinnett DG, Hopkin RJ. Acute progression of neuromuscular findings in infantile Pompe disease. Pediatr Neurol. 2010;42:455-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien YH, Tsai WH, Chang CL, Chiu PC, Chou YY, Tsai FJ, Wong SL, Lee NC, Hwu WL. Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences. Mol Genet Metab Rep. 2020;23:100591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7193123</ArticleId><ArticleId IdType="pubmed">32373469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JL, Chakraborty P, Fung-Kee-Fung K, Schwab ME, Bali D, Young SP, Gelb MH, Khaledi H, DiBattista A, Smallshaw S, Moretti F, Wong D, Lacroix C, El Demellawy D, Strickland KC, Lougheed J, Moon-Grady A, Lianoglou BR, Harmatz P, Kishnani PS, MacKenzie TC. IIn Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease. N Engl J Med. 2022;387:2150-8. </Citation><ArticleIdList><ArticleId IdType="pmc">PMC10794051</ArticleId><ArticleId IdType="pubmed">36351280</ArticleId></ArticleIdList></Reference><Reference><Citation>Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45:319-33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534745</ArticleId><ArticleId IdType="pubmed">22173792</ArticleId></ArticleIdList></Reference><Reference><Citation>de Faria DOS, 't Groen S, Hoogeveen-Westerveld M, Nino MY, van der Ploeg AT, Bergsma AJ, Pijnappel W. Update of the Pompe variant database for the prediction of clinical phenotypes: novel disease-associated variants, common sequence variants, and results from newborn screening. Hum Mutat. 2021;42:119-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7898817</ArticleId><ArticleId IdType="pubmed">33560568</ArticleId></ArticleIdList></Reference><Reference><Citation>DeRuisseau LR, Fuller DD, Qiu K, DeRuisseau KC, Donnelly WH Jr, Mah C, Reier PJ, Byrne BJ. Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci U S A. 2009;106:9419-24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695054</ArticleId><ArticleId IdType="pubmed">19474295</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries JM, Brugma JD, Ozkan L, Steegers EA, Reuser AJ, Van Doorn PA, van der Ploeg AT. First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease. Mol Genet Metab. 2011;104: 552-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21967859</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B, Group CI. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 2021;20:1012-26.</Citation><ArticleIdList><ArticleId IdType="pubmed">34800399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebbink BJ, Aarsen FK, van Gelder CM, van den Hout JM, Weisglas-Kuperus N, Jaeken J, Lequin MH, Arts WF, van der Ploeg AT. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology. 2012;78:1512-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22539577</ArticleId></ArticleIdList></Reference><Reference><Citation>Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, Herzog RW, Modica RF, Lew J, Lawrence RM, Byrne BJ. B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2013;163:847-54.e1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3981605</ArticleId><ArticleId IdType="pubmed">23601496</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Gharbawy AH, Bhat G, Murillo JE, Thurberg BL, Kampmann C, Mengel KE, Kishnani PS. Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered. Mol Genet Metab. 2011;103: 362-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21605996</ArticleId></ArticleIdList></Reference><Reference><Citation>Goker-Alpan O, Kasturi VG, Sohi MK, Limgala RP, Austin SL, Jennelle T, Banikazemi M, Kishnani PS. Pregnancy outcomes in late onset Pompe disease. Life (Basel). 2020;10:194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556025</ArticleId><ArticleId IdType="pubmed">32932790</ArticleId></ArticleIdList></Reference><Reference><Citation>Gragnaniello V, Pijnappel P, Burlina AP, In 't Groen SLM, Gueraldi D, Cazzorla C, Maines E, Polo G, Salviati L, Di Salvo G, Burlina AB. Newborn screening for Pompe disease in Italy: Long-term results and future challenges. Mol Genet Metab Rep. 2022;33:100929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9597184</ArticleId><ArticleId IdType="pubmed">36310651</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, Goldwaser T, Chen E, Sparks TN, Reddi HV, Rajkovic A, Dungan JS; ACMG Professional Practice and Guidelines Committee. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23:1793-806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8488021</ArticleId><ArticleId IdType="pubmed">34285390</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ng&#xf6;r D, de Vries JM, Hop WC, Reuser AJ, van Doorn PA, van der Ploeg AT, Hagemans ML. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis. 2011;6:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135500</ArticleId><ArticleId IdType="pubmed">21631931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensel O, Hanisch F, Stock K, Stoevesandt D, Deschauer M, M&#xfc;ller T. Morphology and function of cerebral arteries in adults with pompe disease. JIMD Rep. 2015;20:27-33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4375123</ArticleId><ArticleId IdType="pubmed">25614309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermans MM, van Leenen D, Kroos MA, Beesley CE, Van Der Ploeg AT, Sakuraba H, Wevers R, Kleijer W, Michelakakis H, Kirk EP, Fletcher J, Bosshard N, Basel-Vanagaite L, Besley G, Reuser AJ. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat. 2004;23:47-56.</Citation><ArticleIdList><ArticleId IdType="pubmed">14695532</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschhorn R, Huie ML. Frequency of mutations for glycogen storage disease type II in different populations: the del525T and delexon 18 mutations are not generally "common" in white populations. J Med Genet. 1999;36:85-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1762954</ArticleId><ArticleId IdType="pubmed">9950376</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet A, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:3389-420.</Citation></Reference><Reference><Citation>Hobson-Webb LD, Dearmey S, Kishnani PS. The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings. Clin Neurophysiol. 2011;122:2312-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21570905</ArticleId></ArticleIdList></Reference><Reference><Citation>Holbeck-Brendel M, Poulsen BK. Treatment with enzyme replacement therapy during pregnancy in a patient with Pompe disease. Neuromuscul Disord. 2017;27:956-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28735900</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr. 2015;166:172-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25444528</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsueh CY, Huang CY, Yang CF, Chang CC, Lin WS, Cheng HL, Wu SL, Cheng YF, Niu DM. Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy. Orphanet J Rare Dis. 2021;16:348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340467</ArticleId><ArticleId IdType="pubmed">34353347</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SJ, Amendola LM, Sternen DL. Variation among DNA banking consent forms: points for clinicians to bank on. J Community Genet. 2022;13:389-97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9314484</ArticleId><ArticleId IdType="pubmed">35834113</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones HN, Moss T, Edwards L, Kishnani PS. Increased inspiratory and expiratory muscle strength following respiratory muscle strength training (RMST) in two patients with late-onset Pompe disease. Mol Genet Metab. 2011;104:417-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">21641843</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf3;nsson H, Sulem P, Kehr B, Kristmundsdottir S, Zink F, Hjartarson E, Hardarson MT, Hjorleifsson KE, Eggertsson HP, Gudjonsson SA, Ward LD, Arnadottir GA, Helgason EA, Helgason H, Gylfason A, Jonasdottir A, Jonasdottir A, Rafnar T, Frigge M, Stacey SN, Th Magnusson O, Thorsteinsdottir U, Masson G, Kong A, Halldorsson BV, Helgason A, Gudbjartsson DF, Stefansson K. Parental influence on human germline de novo mutations in 1,548 trios from Iceland. Nature. 2017;549:519-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">28959963</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J, et al. Timing of diagnosis of patients with Pompe disease: data from the Pompe registry. Am J Med Genet A. 2013;161A:2431-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">23997011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, Bauer MS, Jokic M, Tsai CE, Tsai BW, Morgan C, O'Meara T, Richards S, Tsao EC, Mandel H. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66:329-35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3129995</ArticleId><ArticleId IdType="pubmed">19542901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishnani PS, Diaz-Manera J, Toscano A, Clemens PR, Ladha S, Berger KI, Kushlaf H, Straub V, Carvalho G, Mozaffar T, Roberts M, Attarian S, Chien YH, Choi YC, Day JW, Erdem-Ozdamar S, Illarioshkin S, Goker-Alpan O, Kostera-Pruszczyk A, van der Ploeg AT, An Haack K, Huynh-Ba O, Tammireddy S, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023;80:558-67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10087094</ArticleId><ArticleId IdType="pubmed">37036722</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, Bali D, Smith SA, Li JS, Mandel H, Koeberl D, Rosenberg A, Chen YT. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99:26-33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3721340</ArticleId><ArticleId IdType="pubmed">19775921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O'Grady G, Patterson MC, Rapoport DM, Slonim A, Spencer CT, Tifft CJ, Watson MS. Pompe disease diagnosis and management guideline. Genet Med. 2006;8:267-88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110959</ArticleId><ArticleId IdType="pubmed">16702877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronn DF, Day-Salvatore D, Hwu WL, Jones SA, Nakamura K, Okuyama T, Swoboda KJ, Kishnani PS, Pompe Disease Newborn Screening Working G. Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum. Pediatrics. 2017;140:S24-S45.</Citation><ArticleIdList><ArticleId IdType="pubmed">29162675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroos M, Manta P, Mavridou I, Muntoni F, Halley D, Van der Helm R, Zaifeiriou D, Van der Ploeg A, Reuser A, Michelakakis H. Seven cases of Pompe disease from Greece. J Inherit Metab Dis. 2006;29:556-63.</Citation><ArticleIdList><ArticleId IdType="pubmed">16838077</ArticleId></ArticleIdList></Reference><Reference><Citation>Labrousse P, Chien YH, Pomponio RJ, Keutzer J, Lee NC, Akmaev VR, Scholl T, Hwu WL. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Mol Genet Metab. 2010;99:379-83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20080426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CJ, Hsu TR, Yang CF, Chen SJ, Chuang YC, Niu DM. Cognitive development in infantile-onset Pompe disease under very early enzyme replacement therapy. J Child Neurol. 2016;31:1617-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">27655474</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee NC, Chang KL, In 't Groen SLM, de Faria DOS, Huang HJ, Pijnappel W, Hwu WL, Chien YH. Outcome of later-onset Pompe disease identified through newborn screening. J Pediatr. 2022;244:139-47 e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">34995642</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine JC, Kishnani PS, Chen YT, Herlong JR, Li JS. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol. 2008;29:1033-42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683920</ArticleId><ArticleId IdType="pubmed">18661169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin N, Huang J, Violante S, Orsini J, Caggana M, Hughes E, Stevens C, DiAntonio L, Liao HC, Hong X, Ghomashchi F, Kumar AB, Zhou H, Kornreich R, Wasserstein M, Gelb MH, Yu C. Liquid chromatography-tandem mass spectrometry assay of leukocyte acid alpha-glucosidase for post newborn screening evaluation of Pompe disease. Clin Chem. 2017;63:842-51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5413112</ArticleId><ArticleId IdType="pubmed">28196920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mah CS, Falk DJ, Germain SA, Kelley JS, Lewis MA, Cloutier DA, DeRuisseau LR, Conlon TJ, Cresawn KO, Fraites TJ Jr, Campbell-Thompson M, Fuller DD, Byrne BJ. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther. 2010;18:502-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839425</ArticleId><ArticleId IdType="pubmed">20104213</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra K, Carrington DC, Liebeskind DS. Restrictive Arteriopathy in Late-Onset Pompe Disease: Case Report and Review of the Literature. J Stroke Cerebrovasc Dis. 2017;26:e172-e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28647415</ArticleId></ArticleIdList></Reference><Reference><Citation>McCready ME, Carson NL, Chakraborty P, Clarke JT, Callahan JW, Skomorowski MA, Chan AK, Bamforth F, Casey R, Rupar CA, Geraghty MT. Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a Canadian cohort of individuals with glycogen storage disease, type II. Mol Genet Metab. 2007;92:325-35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17723315</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick EM, Zolkipli-Cunningham Z, Falk MJ. Mitochondrial disease genetics update: recent insights into the molecular diagnosis and expanding phenotype of primary mitochondrial disease. Curr Opin Pediatr. 2018;30:714-24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6467265</ArticleId><ArticleId IdType="pubmed">30199403</ArticleId></ArticleIdList></Reference><Reference><Citation>Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, Jones SA, Olson R, White A, Wells C, Bali D, Case LE, Young SP, Rosenberg AS, Kishnani PS. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14:135-42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711224</ArticleId><ArticleId IdType="pubmed">22237443</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalvo AL, Bembi B, Donnarumma M, Filocamo M, Parenti G, Rossi M, Merlini L, Buratti E, De Filippi P, Dardis A, Stroppiano M, Ciana G, Pittis MG. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat. 2006;27:999-1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917947</ArticleId></ArticleIdList></Reference><Reference><Citation>Moschetti M, Lo Curto A, Giacomarra M, Francofonte D, Zizzo C, Messina E, Duro G, Colomba P. Mutation spectra of GAA gene in Pompe disease: current knowledge and results of an Italian study. Int J Mol Sci. 2024; 25:9139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11394944</ArticleId><ArticleId IdType="pubmed">39273088</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, Arnold GL, Pivnick EK, Ottinger CJ, Robinson PH, Loo JC, Smitka M, Jardine P, Tat&#xf2; L, Chabrol B, McCandless S, Kimura S, Mehta L, Bali D, Skrinar A, Morgan C, Rangachari L, Corzo D, Kishnani PS. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009;11:210-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19287243</ArticleId></ArticleIdList></Reference><Reference><Citation>Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease: a comprehensive overview. Ann Transl Med. 2019;7:278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642931</ArticleId><ArticleId IdType="pubmed">31392190</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfrimmer C, Smitka M, Muschol N, Husain RA, Huemer M, Hennermann JB, Schuler R, Hahn A. Long-Term Outcome of Infantile Onset Pompe Disease Patients Treated with Enzyme Replacement Therapy - Data from a German-Austrian Cohort. J Neuromuscul Dis. 2024;11:167-77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10789365</ArticleId><ArticleId IdType="pubmed">38043017</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittis MG, Donnarumma M, Montalvo AL, Dominissini S, Kroos M, Rosano C, Stroppiano M, Bianco MG, Donati MA, Parenti G, D&#x2019;Amico A, Ciana G, Di Rocco M, Reuser A, Bembi B, Filocamo M. Molecular and functional characterization of eight novel GAA mutations in Italian infants with Pompe disease. Hum Mutat. 2008;29:E27-36.</Citation><ArticleIdList><ArticleId IdType="pubmed">18429042</ArticleId></ArticleIdList></Reference><Reference><Citation>Prater SN, Banugaria SG, Dearmey SM, Botha EG, Stege EM, Case LE, Jones HN, Phornphutkul, C, Wang RY, Young SP, Kishnani PS. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 2012;14:800-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947503</ArticleId><ArticleId IdType="pubmed">22538254</ArticleId></ArticleIdList></Reference><Reference><Citation>Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med. 2002;2:145-66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11949932</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts M, Kishnani PS, van der Ploeg AT, Muller-Felber W, Merlini L, Prasad S, Case LE. The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe Registry. Mol Genet Metab. 2011;104: 574-82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21930409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacconi S, Bocquet JD, Chanalet S, Tanant V, Salviati L, Desnuelle C. Abnormalities of cerebral arteris are frequent in patients with late-onset Pompe disease. J Neurol. 2010;257:1730-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">20559845</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacconi S, Wahbi K, Theodore G, Garcia J, Salviati L, Bouhour F, Vial C, Duboc D, Laforet P, Desnuelle C. Atrio-ventricular block requiring pacemaker in patients with late onset Pompe disease. Neuromuscul Disord. 2014;24:648-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">24844452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarah B, Giovanna B, Emanuela K, Nadi N, Jose V, Alberto P. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis. J Neurol. 2022;269:733-41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782782</ArticleId><ArticleId IdType="pubmed">33851281</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanzer A, Gorlach J, Claudi K, Hahn A. Severe distal muscle involvement and mild sensory neuropathy in a boy with infantile onset Pompe disease treated with enzyme replacement therapy for 6 years. Neuromuscul Disord. 2019;29:477-82.</Citation><ArticleIdList><ArticleId IdType="pubmed">31101460</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoser B, Kishnani PS, Bratkovic D, Byrne BJ, Claeys KG, D&#xed;az-Manera J, Lafor&#xea;t P, Roberts M, Toscano A, van der Ploeg AT, Castelli J, Goldman M, Holdbrook F, Sitaraman Das S, Wasfi Y, Mozaffar T; ATB200-07 Study Group. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07). J Neurol. 2024;271:2810-23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11055775</ArticleId><ArticleId IdType="pubmed">38418563</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforet P, Toscano A, Castelli J, Diaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS, Group PS. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 2021;20:1027-37.</Citation><ArticleIdList><ArticleId IdType="pubmed">34800400</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, Karamouzian M, Toscano A. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264:621-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">27372449</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng B, Chu YP, Wong WT, Yau EKC, Chen SPL, Luk WH. Improvement of bone mineral density after enzyme replacement therapy in Chinese late-onset Pompe disease patients. BMC Res Notes. 2017;10:351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5534128</ArticleId><ArticleId IdType="pubmed">28754168</ArticleId></ArticleIdList></Reference><Reference><Citation>Shieh JJ, Lin CY. Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect. Hum Mutat. 1998;11:306-12.</Citation><ArticleIdList><ArticleId IdType="pubmed">9554747</ArticleId></ArticleIdList></Reference><Reference><Citation>Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr. 2000;137:283-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10931430</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BK, Martin AD, Lawson LA, Vernot V, Marcus J, Islam S, Shafi N, Corti M, Collins SW, Byrne BJ. Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: clinical evidence of respiratory plasticity. Exp Neurol. 2017;287:216-24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5178134</ArticleId><ArticleId IdType="pubmed">27453480</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD&#xae;): optimizing its use in a clinical diagnostic or research setting. Hum Genet. 2020;139:1197-207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497289</ArticleId><ArticleId IdType="pubmed">32596782</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockton DW, Kishnani P, van der Ploeg A, Llerena J, Jr., Boentert M, Roberts M, Byrne BJ, Araujo R, Maruti SS, Thibault N, Verhulst K, Berger KI. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start. J Neurol. 2020;267:3038-53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7501128</ArticleId><ArticleId IdType="pubmed">32524257</ArticleId></ArticleIdList></Reference><Reference><Citation>Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, Deschauer M, Breunig F, Glocker FX, Vielhaber S, Brejova A, Hilz M, Reiners K, M&#xfc;ller-Felber W, Mengel E, Spranger M, Schoser B. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol. 2010;257:91-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19649685</ArticleId></ArticleIdList></Reference><Reference><Citation>Su X, Sheng H, Huang Y, Li X, Zhang W, Zhao X, Li C, Liu L. Clinical and GAA gene mutation analysis in 21 Chinese patients with classic infantile pompe disease. Eur J Med Genet. 2020;63:103997.</Citation><ArticleIdList><ArticleId IdType="pubmed">32711049</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang H, Feuchtbaum L, Sciortino S, Matteson J, Mathur D, Bishop T, Olney RS. The First Year Experience of Newborn Screening for Pompe Disease in California. Int J Neonatal Screen. 2020;6:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7422988</ArticleId><ArticleId IdType="pubmed">33073007</ArticleId></ArticleIdList></Reference><Reference><Citation>van Capelle CI, Goedegebure A, Homans NC, Hoeve HL, Reuser AJ, van der Ploeg AT. Hearing loss in Pompe disease revisited: results from a study of 24 children. J Inherit Metab Dis. 2010;33:597-602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946566</ArticleId><ArticleId IdType="pubmed">20596893</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Beek NA, van Capelle CI, van der Velden-van Etten KI, Hop WC, van den Berg B, Reuser AJ, van Doorn PA, van der Ploeg AT, Stam H. Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Mol Genet Metab. 2011;104:129-36.</Citation><ArticleIdList><ArticleId IdType="pubmed">21763167</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Dorpel JJA, Mackenbach MJ, Dremmen MHG, van der Vlugt WMC, Rizopoulos D, van Doorn PA, van der Ploeg AT, Muetzel R, van der Beek N, van den Hout JMP. Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning. J Inherit Metab Dis. 2024;47:716-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">38584574</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, Bakker HD, Loonen MC, de Klerk JB, Reuser AJ, van der Ploeg AT. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112:332-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">12897283</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Kraan M, Kroos MA, Joosse M, Bijvoet AG, Verbeet MP, Kleijer WJ, Reuser AJ. Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun. 1994;203:1535-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">7945303</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Lafor&#xea;t P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med. 2010;362:1396-406.</Citation><ArticleIdList><ArticleId IdType="pubmed">20393176</ArticleId></ArticleIdList></Reference><Reference><Citation>Viamonte M, Tuna I, Rees J. Dilated Cerebral Arteriopathy in Classical Pompe Disease: A Novel Finding. Pediatr Neurol. 2020;108:117-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">32248988</ArticleId></ArticleIdList></Reference><Reference><Citation>Winchester B, Bali D, Bodamer OA, Caillaud C, Christensen E, Cooper A, Cupler E, Deschauer M, Fumi&#x107; K, Jackson M, Kishnani P, Lacerda L, Ledvinov&#xe1; J, Lugowska A, Lukacs Z, Maire I, Mandel H, Mengel E, M&#xfc;ller-Felber W, Piraud M, Reuser A, Rupar T, Sinigerska I, Szlago M, Verheijen F, van Diggelen OP, Wuyts B, Zakharova E, Keutzer J, et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab. 2008;93:275-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">18078773</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler M, von Landenberg C, Kuchenbecker K, Reimann J, Kornblum C. Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease. Neuromuscul Disord. 2022;32:195-205.</Citation><ArticleIdList><ArticleId IdType="pubmed">35120758</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CF, Liao TE, Chu YL, Chen LZ, Huang LY, Yang TF, Ho HC, Kao SM, Niu DM. Long-term outcomes of very early treated infantile-onset Pompe disease with short-term steroid premedication: experiences from a nationwide newborn screening programme. J Med Genet. 2023;60:430-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">36137614</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CF, Yang CC, Liao HC, Huang LY, Chiang CC, Ho HC, Lai CJ, Chu TH, Yang TF, Hsu TR, Soong WJ, Niu DM. Very early treatment for infantile-onset Pompe disease contributes to better outcomes. J Pediatr. 2016;169:174-80e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">26685070</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampieri S, Buratti E, Dominissini S, Montalvo AL, Pittis MG, Bembi B, Dardis A. Slicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes. Eur J Hum Genet. 2011;19:422-31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060314</ArticleId><ArticleId IdType="pubmed">21179066</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Yu X, Li D, He J, Li Y, Zhang B, Zhang N, Wang Q, Yan C. Intracranial vasculopathy: an important organ damage in young adult patients with late-onset Pompe disease. Orphanet J Rare Dis. 2024;19:267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11250947</ArticleId><ArticleId IdType="pubmed">39010129</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20301438</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40834968</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8278</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Mitochondrion</Title><ISOAbbreviation>Mitochondrion</ISOAbbreviation></Journal><ArticleTitle>Computational discovery of novel SIRT4 inhibitors for cardiac hypertrophy treatment.</ArticleTitle><Pagination><StartPage>102076</StartPage><MedlinePgn>102076</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mito.2025.102076</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-7249(25)00073-X</ELocationID><Abstract><AbstractText>Cardiac hypertrophy is characterized by the enlargement of the heart muscle, often resulting from conditions such as hypertrophic cardiomyopathy (HCM) and physiological hypertrophy. SIRT4 plays a crucial role in cardiac hypertrophy, primarily through its regulation of oxidative stress and mitochondrial function. Therefore, downregulating SIRT4 could help slow the progression of cardiac hypertrophy. This study investigates novel therapeutic approaches for cardiac hypertrophy through various computational strategies, such as Virtual screening, ADMET predictions, molecular docking, and molecular dynamics simulations, to identify potential drug candidates, DB12561 (Hit2), that could inhibit the SIRT4 protein.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. and Mitochondria Research Society. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jena</LastName><ForeName>Vaishnavi</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu 632014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naidu</LastName><ForeName>B Aparna</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu 632014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Deepak</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu 632014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Praisy Joy</ForeName><Initials>PJ</Initials><Suffix>1st</Suffix><AffiliationInfo><Affiliation>School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu 632014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muniyan</LastName><ForeName>Rajiniraja</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu 632014, India. Electronic address: rajiniraja.m@vit.ac.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mitochondrion</MedlineTA><NlmUniqueID>100968751</NlmUniqueID><ISSNLinking>1567-7249</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DrugBank database</Keyword><Keyword MajorTopicYN="N">Molecular docking</Keyword><Keyword MajorTopicYN="N">Molecular dynamics simulation</Keyword><Keyword MajorTopicYN="N">Sirtuin</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>19</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40834968</ArticleId><ArticleId IdType="doi">10.1016/j.mito.2025.102076</ArticleId><ArticleId IdType="pii">S1567-7249(25)00073-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40835111</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-1740</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Progress in cardiovascular diseases</Title><ISOAbbreviation>Prog Cardiovasc Dis</ISOAbbreviation></Journal><ArticleTitle>Updates in fluorodeoxyglucose positron emission tomography (<sup>18</sup>FDG-PET) in the diagnosis and management of cardiac sarcoidosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0033-0620(25)00115-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pcad.2025.08.004</ELocationID><Abstract><AbstractText>Cardiac sarcoidosis (CS) is an infiltrative cardiomyopathy characterized by non-caseating granulomatous inflammation that results in significant morbidity and mortality. It has become increasingly recognized over the past several decades; however, diagnosis remains challenging due to its heterogeneous nature and limited diagnostic yield of endomyocardial biopsy. As such, there has been increasing reliance on advanced cardiac imaging to aid in the diagnosis and management of CS. Fluorodeoxyglucose positron emission tomography ((Al-Kindi and Oliveira, 2015<sup>18)</sup>FDG-PET) has emerged as the most robust imaging modality and remains the preferred method for assessing active inflammation, treatment response, and surveillance. Nevertheless, it requires meticulous patient preparation and image acquisition to ensure optimal imaging and interpretation. This article aims to provide a comprehensive review of the various imaging modalities used for the diagnosis of CS, with a particular focus on the intricacies of (Al-Kindi and Oliveira, 2015<sup>18)</sup>FDG-PET, including the latest advancements in patient preparation and study interpretation. Other future directions for the diagnosis and management of CS will also be discussed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kronzer</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagan</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ledet</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knott</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bois</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: Bois.John@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Askew</LastName><ForeName>J Wells</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chareonthaitawee</LastName><ForeName>Panithaya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prog Cardiovasc Dis</MedlineTA><NlmUniqueID>0376442</NlmUniqueID><ISSNLinking>0033-0620</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">18-fluorodeoxyglucose</Keyword><Keyword MajorTopicYN="N">Cardiac magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">Cardiac sarcoidosis</Keyword><Keyword MajorTopicYN="N">Endomyocardial biopsy</Keyword><Keyword MajorTopicYN="N">Positron emission tomography</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>19</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40835111</ArticleId><ArticleId IdType="doi">10.1016/j.pcad.2025.08.004</ArticleId><ArticleId IdType="pii">S0033-0620(25)00115-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40835365</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-3597</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of the American College of Cardiology</Title><ISOAbbreviation>J Am Coll Cardiol</ISOAbbreviation></Journal><ArticleTitle>Clinical Outcomes of Conduction System Pacing vs Right Ventricular Septal Pacing in Atrioventricular Block: The CSPACE Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>563</StartPage><EndPage>573</EndPage><MedlinePgn>563-573</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacc.2025.06.043</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0735-1097(25)06986-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with atrioventricular (AV) block receiving right ventricular (RV) pacing are at risk of pacing-induced cardiomyopathy (PICM), need for upgrade to biventricular cardiac resynchronization therapy (CRT), heart failure hospitalization (HFH), and mortality. Conduction system pacing (CSP) is a promising pacing strategy to mitigate these adverse outcomes.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to compare the clinical outcomes between RV septal pacing (RVsP) and CSP.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A randomized controlled trial (RCT) was performed in 202 consecutive patients with pacing indication for AV block without CRT indication, with a 1:1 randomization allocation ratio between RVsP and CSP. The primary outcome was a composite endpoint of PICM, upgrade to biventricular CRT, HFH, and all-cause mortality. This trial was registered with the Australian New Zealand Clinical Trials Registry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CSP was successful in 89 of 101 patients (88.1%). After a mean follow-up period of 25.2 &#xb1; 11.8 months, CSP was associated with lower composite endpoint (7.17 vs 20.69 events per 100 person-years; HR: 0.35; 95% CI: 0.19-0.64; P &lt; 0.001) primarily driven by lower PICM (CSP 4.58 vs RVsP 14.69 events per 100-person-years; HR: 0.31; 95% CI: 0.15-0.67; P = 0.002) and need for CRT upgrade (0 vs 1.92 events per 100-person-years; HR: 1.65e<sup>-9</sup>; 95% CI: 0-&#x221e;; P = 0.043). There was no difference in HFH (CSP 0.48 vs RVsP 2.92 events per 100-person years; HR: 0.16; 95% CI: 0.02-1.37, P = 0.057) or all-cause mortality (CSP 2.86 vs RVsP 4.72 events per 100-person-years; HR: 0.61; 95% CI: 0.22-1.69; P = 0.337). Lead revision occurred more with CSP (8 patients [7.9%] vs 1 patient [1.0%]; P = 0.017).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This RCT demonstrates the superiority of CSP over RVsP in achieving improved clinical outcomes and supports the indication of CSP as an upfront pacing technique for patients with AV block. (CSPACE: A Randomised Controlled Trial Comparing Right Ventricular Pacing with Conduction System Pacing; ACTRN12619001613190).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Chee Loong Dominic</ForeName><Initials>CLD</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia; Department of Cardiology, Northern Health, Melbourne, Victoria, Australia. Electronic address: cl.chow@unimelb.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Chiew</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia; Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutherland</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northern Health, Melbourne, Victoria, Australia; Department of Cardiology, Alfred Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obeyesekere</LastName><ForeName>Manoj Niranjan</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Geoffrey R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia; Department of Cardiology, Northern Health, Melbourne, Victoria, Australia; Department of Cardiology, Austin Health, Heidelberg, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eastwood</LastName><ForeName>Charles M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abduloska</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davey</LastName><ForeName>Christian M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>School of Mathematics and Statistics, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhutani</LastName><ForeName>Amandeep Singh</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asari</LastName><ForeName>Fari</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Aakaash D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahin</LastName><ForeName>Muhtasim Rahman</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Amarpal Karamjit</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tacey</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Northern Centre for Health Education Research, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gaal</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia; Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vijayaraman</LastName><ForeName>Pugazhendhi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Geisinger Heart Institute, Wilkes-Barre, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Han S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia; Department of Cardiology, Northern Health, Melbourne, Victoria, Australia; Department of Cardiology, Austin Health, Heidelberg, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Uwais</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia; Department of Cardiology, Northern Health, Melbourne, Victoria, Australia; Department of Cardiology, St Vincent's Hospital, East Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Cardiol</MedlineTA><NlmUniqueID>8301365</NlmUniqueID><ISSNLinking>0735-1097</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054537" MajorTopicYN="Y">Atrioventricular Block</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002304" MajorTopicYN="Y">Cardiac Pacing, Artificial</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058406" MajorTopicYN="N">Cardiac Resynchronization Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054088" MajorTopicYN="Y">Ventricular Septum</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006329" MajorTopicYN="Y">Heart Conduction System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">His-bundle pacing</Keyword><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">atrioventricular block</Keyword><Keyword MajorTopicYN="N">cardiac resynchronization therapy</Keyword><Keyword MajorTopicYN="N">conduction system pacing</Keyword><Keyword MajorTopicYN="N">left bundle branch pacing</Keyword><Keyword MajorTopicYN="N">pacing-induced cardiomyopathy</Keyword><Keyword MajorTopicYN="N">right ventricular pacing</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures Dr Chow is supported by a National Health and Medical Research Council scholarship and a National Heart Foundation grant. The funders had no influence on the design or execution of the trial, data collection or analysis, or writing of the paper. Dr Vijayaraman has received speaker honoraria, consultation, fellowship, and research support from Medtronic; has consulted and received honoraria from Abbott, Biotronic, and Boston Scientific; and holds a patent for HBP delivery tool. Dr Lim has received research support from Abbott and Medtronic. Dr Mohamed has received speaker honoraria, research, and training funds from Abbott, Biotronik, and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>20</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40835365</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2025.06.043</ArticleId><ArticleId IdType="pii">S0735-1097(25)06986-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40835112</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-1740</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Progress in cardiovascular diseases</Title><ISOAbbreviation>Prog Cardiovasc Dis</ISOAbbreviation></Journal><ArticleTitle>Radionuclide imaging techniques for assessing myocardial viability: Clinical applications, evidence, and future directions.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0033-0620(25)00116-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pcad.2025.08.005</ELocationID><Abstract><AbstractText>Ischemic cardiomyopathy (ICM) is a leading cause of heart failure globally. Myocardial viability testing aims to identify dysfunctional but potentially reversible myocardium in patients with ICM. This review examines the clinical application and diagnostic performance of radionuclide imaging techniques including thallium-201 (<sup>201</sup>Tl) and technetium-99&#x202f;m (<sup>99m</sup>Tc) single positron emission tomography (SPECT), and flourine-18-flourodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography (PET) for assessing myocardial viability. <sup>201</sup>TI SPECT assesses viability via active myocardial uptake and delayed redistribution but is limited by prolonged protocols and suboptimal image quality. <sup>99m</sup>Tc-labeled agents (sestamibi and tetrofosmin) offer improved spatial resolution, shorter half-life, and higher photon energy, enabling faster imaging and better image quality. When combined with nitrate augmentation or gated imaging, <sup>99m</sup>Tc SPECT enhances detection of viable but under perfused myocardium. <sup>18</sup>F-FDG PET is considered the gold standard modality for viability assessment due to its superior sensitivity, image quality and quantitative capabilities for myocardial blood flow. While observational studies associate viability with improved outcomes after revascularization, randomized trials have yielded mixed results. However, contemporary guidelines continue to support viability testing in selected high-risk patients. Emerging technologies including novel PET tracers, artificial intelligence, and hybrid imaging may further improve diagnostic accuracy and clinical utility of radionuclide viability testing. Radionuclide imaging remains a valuable tool in assessing myocardial viability in ICM. While PET offers superior diagnostic accuracy, SPECT remains widely used given its accessibility. Future studies incorporating modern imaging technologies and contemporary heart failure therapies are needed to clarify the role of viability testing in guiding revascularization strategies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Knott</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kronzer</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anavekar</LastName><ForeName>Nandan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chareonthaitawee</LastName><ForeName>Panithaya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Askew</LastName><ForeName>J Wells</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: Askew.John@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prog Cardiovasc Dis</MedlineTA><NlmUniqueID>0376442</NlmUniqueID><ISSNLinking>0033-0620</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ischemic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Myocardial viability</Keyword><Keyword MajorTopicYN="N">Positron emission tomography</Keyword><Keyword MajorTopicYN="N">Radionuclide viability testing</Keyword><Keyword MajorTopicYN="N">Single positron emission tomography</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>19</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40835112</ArticleId><ArticleId IdType="doi">10.1016/j.pcad.2025.08.005</ArticleId><ArticleId IdType="pii">S0033-0620(25)00116-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40837922</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Cardiac Complications in Cancer Patients Following Chemotherapy and Radiotherapy.</ArticleTitle><Pagination><StartPage>e88372</StartPage><MedlinePgn>e88372</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e88372</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.88372</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiac complications are critical concerns in the management of cancer patients, particularly following chemotherapy and radiotherapy. These treatments, while effective against cancer, pose&#xa0;significant risks to cardiovascular health, potentially leading to conditions such as cardiomyopathy, arrhythmias, and coronary artery disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study investigates the prevalence and nature of cardiac complications among cancer patients in Bangladesh who have undergone chemotherapy, radiotherapy, or both.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">This prospective cross-sectional observational study was conducted from April 2023 to May 2024 at the Bangladesh Medical University (BMU) in Dhaka, Bangladesh. A total of 339 cancer patients, aged over 18, who received chemotherapy, radiotherapy, or both, were included. Patients were evaluated for cardiac complications during and after treatment using clinical assessments and diagnostic tests, while&#xa0;the&#xa0;clinical indicators were measured (e.g., ECG, ECHO, biomarkers). Data were analyzed using IBM&#xa0;SPSS&#xa0;Statistics for Windows, Version 23 (Released 2015; IBM Corp., Armonk, New York, United States), with statistical significance set at a <i>P-</i>value &lt;0.05. Clinical features and cardiac complications were observed among the patients undergoing chemotherapy and radiotherapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age of participants was 52.4 years. Cardiac complications were observed in a significant proportion of patients. Statistically significant increases in hypertension, diabetes, and levels of cardiac biomarkers (Troponin-I, NT-proBNP, CK-MB) were noted post-treatment compared to pre-treatment values (<i>P</i> &lt; 0.001). Specifically, 83 (24.5%) patients developed hypertension, 70 (20.6%) diabetes, and notable elevations in cardiac biomarkers were recorded, indicating heightened cardiac risk.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The study highlights a substantial burden of cardiac complications in cancer patients receiving chemotherapy and/or radiotherapy in Bangladesh. These findings underscore the need for integrated oncologic and cardiac care to monitor and manage cardiovascular health in cancer patients. Further research is necessary to develop targeted interventions to mitigate these risks in the Bangladeshi population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, Bhuiyan et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhuiyan</LastName><ForeName>Md Zillur Rahman</ForeName><Initials>MZR</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Bangladesh Medical University, Dhaka, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoque</LastName><ForeName>Harisul</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bangabandhu Sheikh Mujib Medical University Hospital, Dhaka, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alam</LastName><ForeName>Sarwar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Bangladesh Medical University, Dhaka, BGD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer radiotherapy</Keyword><Keyword MajorTopicYN="N">cardiac complications</Keyword><Keyword MajorTopicYN="N">chemotherapy-related toxicity</Keyword><Keyword MajorTopicYN="N">critical care cardiology</Keyword><Keyword MajorTopicYN="N">radiation and clinical oncology</Keyword></KeywordList><CoiStatement>Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Institutional Review Board of Bangladesh Medical University Formerly Bangabandhu Sheikh Mujib Medical University issued approval Memo No. BSMMU/2024/3325. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40837922</ArticleId><ArticleId IdType="pmc">PMC12364381</ArticleId><ArticleId IdType="doi">10.7759/cureus.88372</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Surgical complications and their impact on patients' psychosocial well-being: a systematic review and meta-analysis. Pinto A, Faiz O, Davis R, Almoudaris A, Vincent C. BMJ Open. 2016;6:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4762142</ArticleId><ArticleId IdType="pubmed">26883234</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnosis and management of noncardiac complications in adults with congenital heart disease: a scientific statement from the American Heart Association. Lui GK, Saidi A, Bhatt AB, et al. Circulation. 2017;136:0&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">28993401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lung Cancer in Bangladesh. Islam MR, Siddiqua SM, Islam R, et al. J Thorac Oncol. 2023;18:972&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">37479327</ArticleId></ArticleIdList></Reference><Reference><Citation>Access to public health facilities in Bangladesh: a study on facility utilisation and burden of treatment. Mannan MA. https://www.jstor.org/stable/44730025 Bangladesh Dev Stud. 2013;36:25&#x2013;80.</Citation></Reference><Reference><Citation>Unequal access to health care facilities and its impact on achieving Sustainable Development Goals: Bangladesh perspective. Ahmed M. https://www.researchgate.net/publication/362057733_UNEQUAL_ACCESS_TO_HEALTH_CARE_FACILITIES_AND_ITS_IMPACT_ON_ACHIEVING_SUSTAINABLE_DEVELOPMENT_GOALS_BANGLADESH_PERSPECTIVE J Community Posit Pract. 2022;22:120&#x2013;144.</Citation></Reference><Reference><Citation>Ansar A. Victoria: La Trobe University; 2021. Exploring the Timeliness of Care for Patients with Lung Cancer in Bangladesh.</Citation></Reference><Reference><Citation>Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019. EClinicalMedicine. 2023;59:101936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7614570</ArticleId><ArticleId IdType="pubmed">37229504</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigating Bangladeshi rural women&#x2019;s awareness and knowledge of cervical cancer and attitude towards HPV vaccination: a community-based cross-sectional analysis. Banik R, Naher S, Rahman M, Gozal D. J Cancer Educ. 2022;37:449&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">32734448</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiotoxicity of cancer treatments: focus on anthracycline cardiomyopathy. Nishi M, Wang PY, Hwang PM. Arterioscler Thromb Vasc Biol. 2021;41:2648&#x2013;2660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8551037</ArticleId><ArticleId IdType="pubmed">34587760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, Chatterjee S, Solanki B. Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology. 2022. Cardiovascular complication from cancer therapy; pp. 165&#x2013;193.</Citation></Reference><Reference><Citation>de Andrade Martins W, Renni MJ, Issa AF. Nuclear Cardiology: Basic and Advanced Concepts in Clinical Practice. Cham: Springer ; 2021. The clinical aspects of heart damage by chemotherapy and radiotherapy; pp. 675&#x2013;689.</Citation></Reference><Reference><Citation>Cardiotoxicity of radiation therapy: mechanisms, management, and mitigation. Ell P, Martin JM, Cehic DA, Ngo DT, Sverdlov AL. Curr Treat Options Oncol. 2021;22:70.</Citation><ArticleIdList><ArticleId IdType="pubmed">34110500</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiation oncologists' perspectives on reducing radiation-induced heart disease in early breast cancer. Mahdavi H. Curr Probl Cancer. 2020;44:100509.</Citation><ArticleIdList><ArticleId IdType="pubmed">31748146</ArticleId></ArticleIdList></Reference><Reference><Citation>What should laypersons know about cancer? Towards an operational definition of cancer literacy. Diviani N, Schulz PJ. Patient Educ Couns. 2011;85:487&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">20926225</ArticleId></ArticleIdList></Reference><Reference><Citation>Variation in geographic access to chemotherapy by definitions of providers and service locations: a population-based observational study. Schroeder MC, Chapman CG, Nattinger MC, Halfdanarson TR, Abu-Hejleh T, Tien YY, Brooks JM. BMC Health Serv Res. 2016;16:274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4950719</ArticleId><ArticleId IdType="pubmed">27430623</ArticleId></ArticleIdList></Reference><Reference><Citation>2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Cosentino F, Grant PJ, Aboyans V, et al. Eur Heart J. 2020;41:255&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">31497854</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomarkers-a general review. Aronson JK, Ferner RE. Curr Protoc Pharmacol. 2017;76:9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28306150</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Mehta LS, Watson KE, Barac A, et al. Circulation. 2018;137:0&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6722327</ArticleId><ArticleId IdType="pubmed">29437116</ArticleId></ArticleIdList></Reference><Reference><Citation>Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan. Shaikh AS, Saleem AF, Mohsin SS, Alam MM, Ahmed MA. BMJ Open. 2013;3:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840341</ArticleId><ArticleId IdType="pubmed">24259388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. Hsieh JC, Hsu CL, Ng SH, et al. Jpn J Clin Oncol. 2015;45:819&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">26056323</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart failure in relation to anthracyclines and other chemotherapies. Agunbiade TA, Zaghlol RY, Barac A. Methodist Debakey Cardiovasc J. 2019;15:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6977567</ArticleId><ArticleId IdType="pubmed">31988684</ArticleId></ArticleIdList></Reference><Reference><Citation>Analysis of risk factors associated with breast cancer in women: a systematic review and meta-analysis. Liu H, Shi S, Gao J, Guo J, Li M, Wang L. Transl Cancer Res. 2022;11:1344&#x2013;1353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9189186</ArticleId><ArticleId IdType="pubmed">35706783</ArticleId></ArticleIdList></Reference><Reference><Citation>TLR4-a pertinent player in radiation-induced heart disease? Gawali B, Sridharan V, Krager KJ, Boerma M, Pawar SA. Genes (Basel) 2023;14:1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10218711</ArticleId><ArticleId IdType="pubmed">37239362</ArticleId></ArticleIdList></Reference><Reference><Citation>Subclinical cardiac damage in cancer patients before chemotherapy. Fabiani I, Panichella G, Aimo A, et al. Heart Fail Rev. 2022;27:1091&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197815</ArticleId><ArticleId IdType="pubmed">34318387</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk of ischemic heart disease in women after radiotherapy for breast cancer. Darby SC, Ewertz M, McGale P, et al. N Engl J Med. 2013;368:987&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">23484825</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissue Reactions and Mechanism in Cardiovascular Diseases Induced by Radiation. Liu XC, Zhou PK. Int J Mol Sci. 2022;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9738833</ArticleId><ArticleId IdType="pubmed">36499111</ArticleId></ArticleIdList></Reference><Reference><Citation>Postoperative complications and long-term survival after complex cancer resection. Nathan H, Yin H, Wong SL. Ann Surg Oncol. 2017;24:638&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">27619939</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Darby SC, McGale P, Taylor CW, Peto R. Lancet Oncol. 2005;6:557&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054566</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40837903</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>The Quiet Burden of Iron: A Rare Case of Hereditary Hemochromatosis in Pakistan.</ArticleTitle><Pagination><StartPage>e88355</StartPage><MedlinePgn>e88355</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e88355</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.88355</ELocationID><Abstract><AbstractText>Hereditary hemochromatosis is characterized by excessive iron absorption through the gut and its deposition in the body. In many instances, symptoms do not arise until significant organ damage has occurred. Diagnosing a case of hereditary hemochromatosis is difficult even after the appearance of symptoms due to the diverse clinical presentations. Genetic testing should be done, whenever possible, to determine the underlying genetic abnormality. We present the case of a 42-year-old man who came to us with complaints of generalized body swelling and shortness of breath on exertion. He was found to have liver cirrhosis, dilated cardiomyopathy, and heart failure with reduced ejection fraction, bronze diabetes, and hypogonadotropic hypogonadism. He was diagnosed with hereditary hemochromatosis based on the clinical findings, markedly elevated serum ferritin levels (&gt;2000 ng/dl), transferrin saturation (98%), and imaging, which revealed pathology involving the liver, pancreas, spleen, and the pituitary gland. Genetic testing could not be done due to the scarcity of resources. The patient underwent phlebotomy initially but was later put on an oral iron chelator, deferasirox, due to a drop in hemoglobin levels. This publication highlights the diagnostic challenge posed by hereditary hemochromatosis, particularly in regions with low disease prevalence, and the need for early detection to prevent advanced organ dysfunction.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, Batool et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Batool</LastName><ForeName>Maha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine, Gulab Devi Teaching Hospital, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehsan</LastName><ForeName>Noor</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Internal Medicine, Gulab Devi Teaching Hospital, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imran</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine, Gulab Devi Teaching Hospital/Al-Aleem Medical College, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qaisar</LastName><ForeName>Wafa</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Internal Medicine, Gulab Devi Teaching Hospital/Al-Aleem Medical College, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malik</LastName><ForeName>Mahmood N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Internal Medicine, Gulab Devi Teaching Hospital/Al-Aleem Medical College, Lahore, PAK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bronze diabetes</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">hereditary hemochromatosis</Keyword><Keyword MajorTopicYN="N">hypogonadotropic hypogonadism</Keyword><Keyword MajorTopicYN="N">iron overload</Keyword><Keyword MajorTopicYN="N">liver cirrhosis</Keyword></KeywordList><CoiStatement>Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40837903</ArticleId><ArticleId IdType="pmc">PMC12362553</ArticleId><ArticleId IdType="doi">10.7759/cureus.88355</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Porter JL, Rawla P. Treasure Island (FL): StatPearls [Internet]; 2024. Hemochromatosis.</Citation></Reference><Reference><Citation>Iron storage disease in Asia-Pacific populations: the importance of non-HFE mutations. McDonald CJ, Wallace DF, Crawford DH, Subramaniam VN. J Gastroenterol Hepatol. 2013;28:1087&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">23577916</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathogenesis, diagnosis, and clinical implications of hereditary hemochromatosis-the cardiological point of view. Dani&#x142;owicz-Szymanowicz L, &#x15a;wi&#x105;tczak M, Sikorska K, et al. Diagnostics (Basel) 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8304945</ArticleId><ArticleId IdType="pubmed">34359361</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes. Grosse SD, Gurrin LC, Bertalli NA, Allen KJ. Genet Med. 2018;20:383&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5797490</ArticleId><ArticleId IdType="pubmed">28771247</ArticleId></ArticleIdList></Reference><Reference><Citation>Association of frequency of hereditary hemochromatosis (HFE) gene mutations (H63D and C282Y) with iron overload in beta-thalassemia major patients in Pakistan. Sharif Y, Irshad S, Tariq A, Rasheed S, Tariq MH. Saudi Med J. 2019;40:887&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6790492</ArticleId><ArticleId IdType="pubmed">31522215</ArticleId></ArticleIdList></Reference><Reference><Citation>Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: A prospective longitudinal observational study. Nowak A, Giger RS, Krayenbuehl PA. Medicine (Baltimore) 2018;97:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6211894</ArticleId><ArticleId IdType="pubmed">30335010</ArticleId></ArticleIdList></Reference><Reference><Citation>A "mix and match" in hemochromatosis-a case report and literature focus on the liver. Cobilinschi CO, S&#x103;ulescu I, Caraiola S, et al. Medicina (Kaunas) 2023;59</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10534457</ArticleId><ArticleId IdType="pubmed">37763705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemochromatosis in heart failure: clinical presentation, diagnosis, and treatment. Sguario RMR, Biselli B, Seguro LFBDC. ABC Heart Fail Cardiomyop. 2024;4:20240041.</Citation></Reference><Reference><Citation>Hereditary hemochromatosis: a literature review and case report. Allen MK. Physiother Can. 2010;62:276&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911836</ArticleId><ArticleId IdType="pubmed">21629607</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation. Girelli D, Marchi G, Busti F. Hematology Am Soc Hematol Educ Program. 2024;2024:434&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11665571</ArticleId><ArticleId IdType="pubmed">39644049</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnosis and treatment of hemochromatosis. Adams PC, Ryan JD. https://www.cghjournal.org/article/S1542-3565(24)01136-4/fulltext Clin Gastroenterol Hepatol. 2025:29&#x2013;2025.</Citation><ArticleIdList><ArticleId IdType="pubmed">39889898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hereditary hemochromatosis: rapid evidence review. Kane SF, Roberts C, Paulus R. https://pubmed.ncbi.nlm.nih.gov/34523883/ Am Fam Physician. 2021;104:263&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">34523883</ArticleId></ArticleIdList></Reference><Reference><Citation>Interventions for hereditary haemochromatosis. Buzzetti E, Kalafateli M, Thorburn D, et al. Cochrane Database Syst Rev. 2017;3:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464659</ArticleId><ArticleId IdType="pubmed">28273330</ArticleId></ArticleIdList></Reference><Reference><Citation>Liver iron content determination by magnetic resonance imaging. Tziomalos K, Perifanis V. World J Gastroenterol. 2010;16:1587&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848367</ArticleId><ArticleId IdType="pubmed">20355237</ArticleId></ArticleIdList></Reference><Reference><Citation>Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report. Cooray SD, Heerasing NM, Selkrig LA, et al. J Med Case Rep. 2018;12:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5787235</ArticleId><ArticleId IdType="pubmed">29373985</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40836258</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1348-8945</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Tropical medicine and health</Title><ISOAbbreviation>Trop Med Health</ISOAbbreviation></Journal><ArticleTitle>Parasitic infections and the development of endomyocardial fibrosis: systematic review of case reports and case series.</ArticleTitle><Pagination><StartPage>112</StartPage><MedlinePgn>112</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">112</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41182-025-00793-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Endomyocardial fibrosis (EMF) is a chronic restrictive cardiomyopathy prevalent in tropical regions, often underdiagnosed and associated with poor outcomes. Although its etiology remains unclear, parasitic infections such as schistosomiasis, filariasis, and trypanosomiasis have been implicated in its development. This study conducted a systematic review of case reports and case series to assess the correlation between parasitic infections and the development of EMF, identifying clinical patterns, implicated parasites, diagnostic approaches, and clinical outcomes, aiming to improve strategies for prevention, diagnosis, and treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following PRISMA 2020 guidelines, we searched multiple databases for case reports and case series describing patients with confirmed EMF associated with parasitic infections. 12 studies met the inclusion criteria, comprising 8 case reports and 4 case series, encompassing a total of 16 patients diagnosed with EMF related to parasitic infections.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The pooled analysis demonstrated that parasitic infections were predominantly caused by Schistosoma mansoni (10/16; 62.5%), followed by Schistosoma haematobium (3/16; 18.75%), with rare cases of Trypanosoma cruzi and Wuchereria bancrofti (1/16 each; 6.25%). Common clinical manifestations included signs of fibrosis of the right ventricular endocardium (81%), dilated right atrium (75%), pericardial effusion (75%), edema of both lower limbs (63%), and ascites (63%) and symptoms included abdominal distention (63%) and dyspnea (63%. Diagnosis was primarily established by echocardiography (92%), with additional confirmation by other imaging techniques and histopathology. Treatment mainly consisted of antiparasitic therapy and diuretics, with a survival rate of 50%, while 19% (3/16) of patients died from multi-organ failure and thromboembolic complications.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This systematic review suggests a potential association between parasitic infections, particularly Schistosoma mansoni, and the development of endomyocardial fibrosis. Despite the limited sample size, the findings highlight the importance of early diagnosis and antiparasitic treatment. The variability in diagnostic and therapeutic approaches underscores the need for standardized guidelines and prospective studies in endemic areas to enhance clinical recognition and improve patient outcomes.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aizeque</LastName><ForeName>Abel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7593-9539</Identifier><AffiliationInfo><Affiliation>Faculty of Health Sciences, Catholic University of Mozambique, Beira, Mozambique. abelaizeque@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kihunyu</LastName><ForeName>Alex Mwangi</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0009-0008-3924-2898</Identifier><AffiliationInfo><Affiliation>College of Health Sciences, University of Nairobi, Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odusola</LastName><ForeName>Olamide Daniel</ForeName><Initials>OD</Initials><Identifier Source="ORCID">0009-0001-0108-028X</Identifier><AffiliationInfo><Affiliation>College of Medicine, University of Ibadan, Ibadan, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saka</LastName><ForeName>Sulymon A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0009-0003-8502-2064</Identifier><AffiliationInfo><Affiliation>Irrua Specialist Teaching Hospital, Irrua, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ambrose Alli University, Ekpoma, Edo State, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aray</LastName><ForeName>Abdinasir Mohamed</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0009-0008-1614-7564</Identifier><AffiliationInfo><Affiliation>Simad University, Mogadishu, Somalia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Trop Med Health</MedlineTA><NlmUniqueID>101215093</NlmUniqueID><ISSNLinking>1348-8945</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Endomyocardial fibrosis</Keyword><Keyword MajorTopicYN="N">Filariasis</Keyword><Keyword MajorTopicYN="N">Parasitic diseases</Keyword><Keyword MajorTopicYN="N">Schistosomiasis</Keyword><Keyword MajorTopicYN="N">Trypanosomiasis</Keyword></KeywordList><CoiStatement>Declarations. Ethical approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40836258</ArticleId><ArticleId IdType="pmc">PMC12366135</ArticleId><ArticleId IdType="doi">10.1186/s41182-025-00793-7</ArticleId><ArticleId IdType="pii">10.1186/s41182-025-00793-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Smith J, Brown L. Pathogenesis of endomyocardial fibrosis. J Cardiol. 2018;45(2):112&#x2013;8.</Citation></Reference><Reference><Citation>Silva A, Souza R. Schistosomiasis and its cardiovascular implications. Trop Med Infect Dis. 2020;4(1):67&#x2013;72.</Citation></Reference><Reference><Citation>Diaz M, Perez J. Filariasis and endomyocardial fibrosis: a case study. Int J Cardiol. 2017;220:88&#x2013;92.</Citation></Reference><Reference><Citation>Pinto A, Fernandes M. Trypanosomiasis and cardiac fibrosis. Heart J. 2019;10(3):52&#x2013;8.</Citation></Reference><Reference><Citation>Oliveira M, Costa P. Parasitic infections in tropical regions: association with endomyocardial fibrosis. Trop Health Sci. 2021;15(1):45&#x2013;51.</Citation></Reference><Reference><Citation>Thompson R, Harris M. Chronic inflammation and endomyocardial fibrosis: a review. J Immunol. 2022;56(5):223&#x2013;8.</Citation></Reference><Reference><Citation>Gupta S, Kumar V. Immunological mechanisms in endomyocardial fibrosis due to parasitic infections. Clin Immunol. 2021;15(4):139&#x2013;45.</Citation></Reference><Reference><Citation>Martin G, Clarke M. A systematic review of parasitic infections and heart disease. Eur J Med. 2023;38(6):201&#x2013;12.</Citation></Reference><Reference><Citation>Silva L, Costa A. Mechanisms of immune-mediated fibrosis in tropical diseases. Cardiovasc Res. 2018;85(7):756&#x2013;66.</Citation></Reference><Reference><Citation>Johnson A, Smith T. The role of case reports in understanding rare diseases: a review. Clin Pract Cardiol. 2017;12(3):99&#x2013;104.</Citation></Reference><Reference><Citation>Martins F, Souza M. Parasitic infections and endocardial fibrosis: an underexplored connection. Trop Med J. 2022;18(4):245&#x2013;52.</Citation></Reference><Reference><Citation>Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizeque A, Aray A, Kihunyu AM. Correlation between parasitic infections and the development of endocardial fibrosis: a systematic review. PROSPERO; 2025. https://www.crd.york.ac.uk/PROSPERO2/view/CRD420250654156.</Citation></Reference><Reference><Citation>Joanna Briggs Institute. The Joanna Briggs Institute critical appraisal tools for use in JBI systematic reviews: checklist for analytical cross sectional studies. Joanna Briggs Institute, Adelaide; 2017. https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Analytical_Cross_Sectional_Studies2017_0.pdf</Citation></Reference><Reference><Citation>Assimeng MM, Amidu N, Donkor S, et al. Schistosomiasis-associated endomyocardial fibrosis in Ghanaian children: case series and review. Trop Med Int Health. 2014;19(6):745&#x2013;52.</Citation></Reference><Reference><Citation>Bustinduy AL, Kabagambe EK, Menon MP, et al. Schistosomiasis-induced endomyocardial fibrosis in a Ugandan child: a case report. BMC Infect Dis. 2014;14:345.</Citation></Reference><Reference><Citation>Carneiro J, Rocha P, Santos D, et al. Endomyocardial fibrosis associated with Schistosoma mansoni and Trypanosoma cruzi co-infection: a case report from Brazil. Rev Soc Bras Med Trop. 2011;44(3):381&#x2013;4.</Citation></Reference><Reference><Citation>Gran K, Camara M, Diallo D, et al. Pediatric endomyocardial fibrosis secondary to Schistosoma intercalatum and S. haematobium co-infection: a case report from Guinea. Cardiol Young. 2011;21(5):515&#x2013;20.</Citation></Reference><Reference><Citation>Hotta T, Lima R, Oliveira F, et al. Trypanosoma cruzi-associated endomyocardial fibrosis in Brazil: case report. Rev Bras Cardiol. 2016;29(2):120&#x2013;4.</Citation></Reference><Reference><Citation>Martin W. Wuchereria bancrofti infection presenting as restrictive cardiomyopathy in Nigeria: a case report. Trop Cardiol. 2008;14(2):101&#x2013;4.</Citation></Reference><Reference><Citation>Mocumbi AO. Schistosomiasis-induced endomyocardial fibrosis in Mozambique: a pediatric case report. Heart Views. 2016;17(1):12&#x2013;6.</Citation></Reference><Reference><Citation>Onakpoya OH, El-Gohary Y, Abdallah M, et al. Endomyocardial fibrosis associated with Schistosoma mansoni infection: report of two Egyptian cases. J Trop Pediatr. 2010;56(5):341&#x2013;5.</Citation></Reference><Reference><Citation>Romero M, Silva R, Santos F, et al. Schistosoma mansoni-related endomyocardial fibrosis: case report from Brazil. Arq Bras Cardiol. 2022;119(4):765&#x2013;70.</Citation></Reference><Reference><Citation>Sarazin M, Tribouilloy C, Mah&#xe9; I, et al. Endomyocardial fibrosis in a French patient with Schistosoma mansoni infection: case report and literature review. Eur Heart J. 2003;24(6):556&#x2013;60.</Citation></Reference><Reference><Citation>Mohamed Ayman H, El-Massry KM, Abdel-Aal F, et al. Schistosoma mansoni infection presenting with endomyocardial fibrosis: case series from Egypt. Am J Trop Med Hyg. 1995;52(6):519&#x2013;24.</Citation></Reference><Reference><Citation>Soarres FF, Almeida LM, Pinto LM, et al. Late-onset endomyocardial fibrosis in Brazil: a case report with left ventricular thrombosis. Arq Bras Cardiol. 2023;120(5):1020&#x2013;5.</Citation></Reference><Reference><Citation>Andrade JL, Souza AS, Reis VM, et al. Pathogenesis of schistosomal endomyocardial fibrosis: a histopathologic study. Am J Trop Med Hyg. 1996;55(2):125&#x2013;32.</Citation></Reference><Reference><Citation>Siqueira RF, Rocha MO, Lopes AA, et al. Hepatosplenic schistosomiasis and cardiac involvement: a clinicopathological correlation. Rev Soc Bras Med Trop. 2001;34(1):25&#x2013;30.</Citation></Reference><Reference><Citation>Mocumbi AO, Ferreira MB, Yacoub MH. Endomyocardial fibrosis: a form of restrictive cardiomyopathy. Heart. 2008;94(7):836&#x2013;43.</Citation></Reference><Reference><Citation>Mocumbi AO. Endomyocardial fibrosis: a neglected tropical disease. Heart. 2012;98(21):1565&#x2013;72.</Citation></Reference><Reference><Citation>Mankad R, Bonnichsen C, Mankad S. Eosinophilic heart disease: a practical review. Clin Cardiol. 2016;39(9):547&#x2013;54.</Citation></Reference><Reference><Citation>Nutman TB. Lymphatic filariasis. Infect Dis Clin North Am. 2010;24(3):613&#x2013;28.</Citation></Reference><Reference><Citation>Marin-Neto JA, Cunha-Neto E, Maciel BC, et al. Pathogenesis of chronic Chagas heart disease. Circulation. 2007;115(9):1109&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17339569</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham BB, Langleben D, Simonneau G. Schistosomiasis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182(2):123&#x2013;32.</Citation></Reference><Reference><Citation>Andrade ZA. Schistosomal pulmonary arterial hypertension: immunopathogenesis and treatment. Mem Inst Oswaldo Cruz. 2009;104(Suppl 1):139&#x2013;46.</Citation></Reference><Reference><Citation>Mehta SK, Shivaprasad C, Kumar V, et al. Pulmonary vascular lesions in schistosomiasis: histopathologic features. Am J Trop Med Hyg. 1998;59(3):388&#x2013;92.</Citation></Reference><Reference><Citation>Fallon PG. Schistosome-induced immunopathology: lessons from animal models. Trends Parasitol. 2000;16(4):145&#x2013;51.</Citation></Reference><Reference><Citation>Brambilla DJ, den Hollander NS, Neumann DA, et al. Eosinophil-mediated cardiac injury in helminth infection. J Infect Dis. 1993;167(5):1254&#x2013;8.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40837345</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1948-9358</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>World journal of diabetes</Title><ISOAbbreviation>World J Diabetes</ISOAbbreviation></Journal><ArticleTitle>Metabolic score for insulin resistance is associated with adverse cardiovascular events in patients with type 2 diabetes.</ArticleTitle><Pagination><StartPage>108671</StartPage><MedlinePgn>108671</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">108671</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4239/wjd.v16.i8.108671</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiovascular disease represents a major complication in patients with type 2 diabetes mellitus (T2DM), with insulin resistance (IR) recognized as a key underlying pathophysiological mechanism. The metabolic score for IR (METS-IR), a simple, non-invasive, and insulin-independent surrogate marker of IR, has been validated for risk stratification and prognostic assessment in conditions such as hypertension, ischemic cardiomyopathy, and T2DM. Monitoring fluctuations in METS-IR levels among individuals with T2DM may facilitate early identification of elevated cardiovascular risk and inform timely therapeutic adjustments.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate the association between METS-IR and cardiovascular risk in patients with T2DM and to evaluate its potential utility as a predictive biomarker.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study represents a secondary analysis of a multicenter randomized controlled trial, ultimately including 10191 patients with T2DM aged 40 years to 79 years, with a follow-up duration of approximately 10 years. Baseline METS-IR was calculated using triglycerides, body mass index, high-density lipoprotein cholesterol and fasting plasma glucose. The predictive value of METS-IR for major adverse cardiovascular events (MACEs), all-cause mortality, congestive heart failure, and major coronary heart disease events, was assessed using Cox proportional hazards models, restricted cubic spline analysis, and stratified subgroup analyses. Multivariable adjustments were performed to account for potential confounding factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of MACEs increased steadily across higher METS-IR quartiles. After adjusting for multiple confounding factors, hazard ratios comparing the highest to the lowest METS-IR quartile were 1.25 [95% confidence interval (CI): 1.08-1.45] for MACEs, 1.55 (95%CI: 1.23-1.96) for cardiovascular death, 1.39 (95%CI: 1.21-1.59) for all-cause mortality, 2.22 (95%CI: 1.74-2.82) for congestive heart failure, and 1.35 (95%CI: 1.17-1.56) for major coronary heart disease. Restricted cubic spline analysis supported a positive, dose-dependent relationship between rising METS-IR levels and cardiovascular risk. Moreover, adding METS-IR to conventional risk prediction models enhanced their performance, as evidenced by improvements in the C-statistic, net reclassification improvement, and integrated discrimination improvement. Subgroup analyses indicated possible interactions between METS-IR, hemoglobin A1c levels, and aspirin therapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">METS-IR shows a strong correlation with cardiovascular risk in individuals with T2DM. Tracking METS-IR levels could enhance risk assessment and the prediction of cardiovascular events.</AbstractText><CopyrightInformation>&#xa9;The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xin</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Na-Ling</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xin</LastName><ForeName>Cai-Yan</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Fuzhou Medical College, Nanchang University, Fuzhou 344000, Jiangxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Jiang-Rong</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xin-Qun</ForeName><Initials>XQ</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yi-Heng</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiang-Yu</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China. xiangyuzhang@csu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Diabetes</MedlineTA><NlmUniqueID>101547524</NlmUniqueID><ISSNLinking>1948-9358</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atherosclerosis</Keyword><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Insulin resistance</Keyword><Keyword MajorTopicYN="N">Metabolic score for insulin resistance</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword></KeywordList><CoiStatement>Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40837345</ArticleId><ArticleId IdType="pmc">PMC12362426</ArticleId><ArticleId IdType="doi">10.4239/wjd.v16.i8.108671</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513&#x2013;1530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5081106</ArticleId><ArticleId IdType="pubmed">27061677</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11057359</ArticleId><ArticleId IdType="pubmed">34879977</ArticleId></ArticleIdList></Reference><Reference><Citation>Safiri S, Karamzad N, Kaufman JS, Bell AW, Nejadghaderi SA, Sullman MJM, Moradi-Lakeh M, Collins G, Kolahi AA. Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019. Front Endocrinol (Lausanne) 2022;13:838027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8915203</ArticleId><ArticleId IdType="pubmed">35282442</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino F, Verma S, Ambery P, Treppendahl MB, van Eickels M, Anker SD, Cecchini M, Fioretto P, Groop PH, Hess D, Khunti K, Lam CSP, Richard-Lordereau I, Lund LH, McGreavy P, Newsome PN, Sattar N, Solomon S, Weidinger F, Zannad F, Zeiher A. Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table. Eur Heart J. 2023;44:4141&#x2013;4156.</Citation><ArticleIdList><ArticleId IdType="pubmed">37448181</ArticleId></ArticleIdList></Reference><Reference><Citation>Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17:83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5994068</ArticleId><ArticleId IdType="pubmed">29884191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, Song X, Ren Y, Shan PF. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10:14790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478957</ArticleId><ArticleId IdType="pubmed">32901098</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D, Viveros-Ruiz T, Cruz-Bautista I, Romo-Romo A, S&#xe1;nchez-L&#xe1;zaro D, Meza-Oviedo D, Vargas-V&#xe1;zquez A, Campos OA, Sevilla-Gonz&#xe1;lez MDR, Martag&#xf3;n AJ, Hern&#xe1;ndez LM, Mehta R, Caballeros-Barrag&#xe1;n CR, Aguilar-Salinas CA. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol. 2018;178:533&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">29535168</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan M, Zhao X, Li S, Miao G, Bai L, Zhang Q, Yang W, Zhao X. Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001-2018. Cardiovasc Diabetol. 2024;23:243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11238348</ArticleId><ArticleId IdType="pubmed">38987779</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14:575&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3217209</ArticleId><ArticleId IdType="pubmed">22055501</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo E, Wang D, Yan G, Qiao Y, Liu B, Hou J, Tang C. High triglyceride-glucose index is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention. Cardiovasc Diabetol. 2019;18:150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6852896</ArticleId><ArticleId IdType="pubmed">31722708</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Zhao L, Lu Y, Meng X, Zhou X. Association between non-insulin-based insulin resistance indices and cardiovascular events in patients undergoing percutaneous coronary intervention: a retrospective study. Cardiovasc Diabetol. 2023;22:161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10311786</ArticleId><ArticleId IdType="pubmed">37386494</ArticleId></ArticleIdList></Reference><Reference><Citation>James DE, St&#xf6;ckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol. 2021;22:751&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">34285405</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pino A, DeFronzo RA. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev. 2019;40:1447&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445419</ArticleId><ArticleId IdType="pubmed">31050706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Ballantyne CM. Metabolic Inflammation and Insulin Resistance in Obesity. Circ Res. 2020;126:1549&#x2013;1564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250139</ArticleId><ArticleId IdType="pubmed">32437299</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576:51&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">31802013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrannini G, De Bacquer D, Erlund I, Gyberg V, Kotseva K, Mellbin L, Norhammar A, Schnell O, Tuomilehto J, Vihervaara T, Wood D, Ryd&#xe9;n L. Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V Population. Diabetes Care. 2022;45:2111&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pubmed">35771773</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao K, Yang J, Wu M, Zhang H, Zhao X, Dong Y. Association Between the Metabolic Score for Insulin Resistance and Hypertension in Adults: A Meta-Analysis. Horm Metab Res. 2023;55:256&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">36796411</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai KZ, Chu CC, Huang WC, Sui X, Lavie CJ, Lin GM. Prediction of various insulin resistance indices for the risk of hypertension among military young adults: the CHIEF cohort study, 2014-2020. Cardiovasc Diabetol. 2024;23:141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11046748</ArticleId><ArticleId IdType="pubmed">38664804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Gao L, Li S, Luo M, Chen L, Xi Q, Zhao Z, Zhao Q, Yang T, Zeng Q, Li X, Huang Z, Duan A, Wang Y, Luo Q, Guo Y, Liu Z. Association of non-insulin-based insulin resistance indices with disease severity and adverse outcome in idiopathic pulmonary arterial hypertension: a multi-center cohort study. Cardiovasc Diabetol. 2024;23:154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11069206</ArticleId><ArticleId IdType="pubmed">38702735</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Liu F, Li W, Zhang J, Zhang T, Yu X, Luo J, Zhao Q, Zhang J, Fang B, Yang Y, Li X. Metabolic Score for Insulin Resistance (METS-IR) Predicts Adverse Cardiovascular Events in Patients with Type 2 Diabetes and Ischemic Cardiomyopathy. Diabetes Metab Syndr Obes. 2023;16:1283&#x2013;1295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10167964</ArticleId><ArticleId IdType="pubmed">37179787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Tang H, Tian J, Xie Y, Wu Y. Non-insulin-based insulin resistance indices predict early neurological deterioration in elderly and middle-aged acute ischemic stroke patients in Northeast China. Sci Rep. 2024;14:16138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11245490</ArticleId><ArticleId IdType="pubmed">38997399</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirjalili SR, Soltani S, Meybodi ZH, Marques-Vidal P, Firouzabadi DD, Eshraghi R, Restrepo D, Ghoshouni H, Sarebanhassanabadi M. Which surrogate insulin resistance indices best predict coronary artery disease? A machine learning approach. Cardiovasc Diabetol. 2024;23:214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11193173</ArticleId><ArticleId IdType="pubmed">38907271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H, Jia Z, Li YT, Yu X, Wang JJ, Xie YJ, Hernandez J, Wang HHX. Metabolic Score for Insulin Resistance and New-Onset Type 2 Diabetes in a Middle-Aged and Older Adult Population: Nationwide Prospective Cohort Study and Implications for Primary Care. JMIR Public Health Surveill. 2024;10:e49617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11184265</ArticleId><ArticleId IdType="pubmed">38569189</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, Zou H, Meng X, Li D, Li W, Chen X, Yang Y, Yu X. Predictive values of metabolic score for insulin resistance on risk of major adverse cardiovascular events and comparison with other insulin resistance indices among Chinese with and without diabetes mellitus: Results from the 4C cohort study. J Diabetes Investig. 2023;14:961&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10360377</ArticleId><ArticleId IdType="pubmed">37132055</ArticleId></ArticleIdList></Reference><Reference><Citation>Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545&#x2013;2559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4551392</ArticleId><ArticleId IdType="pubmed">18539917</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L, Tai S, Sun J, Zhang N, Zhou Y, Xing Z, Wang Y, Zhou S. Remnant Cholesterol and Its Visit-to-Visit Variability Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes: Findings From the ACCORD Cohort. Diabetes Care. 2022;45:2136&#x2013;2143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9472497</ArticleId><ArticleId IdType="pubmed">35834242</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Shah H, Bueno Junior CR, Sun X, Mitri J, Sambataro M, Sambado L, Gerstein HC, Fonseca V, Doria A, Pop-Busui R. Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. Diabetes Care. 2021;44:164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7783932</ArticleId><ArticleId IdType="pubmed">33144354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KJ, Tilling KM, Cornish RP, Little RJA, Bell ML, Goetghebeur E, Hogan JW, Carpenter JR STRATOS initiative. Framework for the treatment and reporting of missing data in observational studies: The Treatment And Reporting of Missing data in Observational Studies framework. J Clin Epidemiol. 2021;134:79&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8168830</ArticleId><ArticleId IdType="pubmed">33539930</ArticleId></ArticleIdList></Reference><Reference><Citation>Madley-Dowd P, Hughes R, Tilling K, Heron J. The proportion of missing data should not be used to guide decisions on multiple imputation. J Clin Epidemiol. 2019;110:63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547017</ArticleId><ArticleId IdType="pubmed">30878639</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999;8:3&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10347857</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48:S207&#x2013;S238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11635050</ArticleId><ArticleId IdType="pubmed">39651970</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X, Chen S, Xu Q, Xia X, Zhang Y, Wang P, Wu S, Wang A. Magnitude and time course of insulin resistance accumulation with the risk of cardiovascular disease: an 11-years cohort study. Cardiovasc Diabetol. 2023;22:339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10720129</ArticleId><ArticleId IdType="pubmed">38093281</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Wang J, Zhang M, Li X, Fan Y, Zhou X, Sun Y, Qiu Z. Biological aging mediates the associations of metabolic score for insulin resistance with all-cause and cardiovascular disease mortality among US adults: A nationwide cohort study. Diabetes Obes Metab. 2024;26:3552&#x2013;3564.</Citation><ArticleIdList><ArticleId IdType="pubmed">38853301</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Song G, Hu D, Li G, Liu Q, Tang X. Association of METS-IR with incident hypertension in non-overweight adults based on a cohort study in Northeastern China. Eur J Public Health. 2022;32:884&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9713393</ArticleId><ArticleId IdType="pubmed">36162420</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YX, Pu SD, Zhang YT, Tong XW, Sun XT, Shan YY, Gao XY. Insulin resistance is associated with the presence and severity of retinopathy in patients with type 2 diabetes. Clin Exp Ophthalmol. 2024;52:63&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">38130181</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570&#x2013;2581.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020339</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenen M, Hill MA, Cohen P, Sowers JR. Obesity, Adipose Tissue and Vascular Dysfunction. Circ Res. 2021;128:951&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8026272</ArticleId><ArticleId IdType="pubmed">33793327</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55:31&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8773457</ArticleId><ArticleId IdType="pubmed">35021057</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasanthakumar A, Chisanga D, Blume J, Gloury R, Britt K, Henstridge DC, Zhan Y, Torres SV, Liene S, Collins N, Cao E, Sidwell T, Li C, Spallanzani RG, Liao Y, Beavis PA, Gebhardt T, Trevaskis N, Nutt SL, Zajac JD, Davey RA, Febbraio MA, Mathis D, Shi W, Kallies A. Sex-specific adipose tissue imprinting of regulatory T cells. Nature. 2020;579:581&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241647</ArticleId><ArticleId IdType="pubmed">32103173</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo D, Zhang C, Zhang M, Wu Z, Liu X, Zhang Y, Liu L, Sun M, Yang J. Metabolic score for insulin resistance predicts major adverse cardiovascular event in premature coronary artery disease. Aging (Albany NY) 2024;16:6364&#x2013;6383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11042949</ArticleId><ArticleId IdType="pubmed">38568104</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokicka D, Hudzik B, Wr&#xf3;bel M, Sto&#x142;tny T, Sto&#x142;tny D, Nowowiejska-Wiewi&#xf3;ra A, Rokicka S, G&#x105;sior M, Strojek K. The prognostic impact of insulin resistance surrogates in patients with acute myocardial infarction with and without type 2 diabetes. Cardiovasc Diabetol. 2024;23:147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11059609</ArticleId><ArticleId IdType="pubmed">38685054</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7:e1332&#x2013;e1345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7025029</ArticleId><ArticleId IdType="pubmed">31488387</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">18212285</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Q, Kuang M, Lu S, Huang X, Wang C, Zhang S, Sheng G, Zou Y. Association between MetS-IR and prediabetes risk and sex differences: a cohort study based on the Chinese population. Front Endocrinol (Lausanne) 2023;14:1175988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10226663</ArticleId><ArticleId IdType="pubmed">37255977</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakis MK, Harshfield EL, Malik R, Franceschini N, Langenberg C, Wareham NJ, Markus HS, Dichgans M. Diabetes Mellitus, Glycemic Traits, and Cerebrovascular Disease: A Mendelian Randomization Study. Neurology. 2021;96:e1732&#x2013;e1742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055310</ArticleId><ArticleId IdType="pubmed">33495378</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HS, Blann AD, Chong AY, Freestone B, Lip GY. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care. 2004;27:2918&#x2013;2924.</Citation><ArticleIdList><ArticleId IdType="pubmed">15562207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840575</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-3871</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Heart rhythm</Title><ISOAbbreviation>Heart Rhythm</ISOAbbreviation></Journal><ArticleTitle>Is Left Bundle Branch Area Pacing the Optimal Pacing Strategy for Bradyarrhythmia with Preserved Ejection Fraction? A Network Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1547-5271(25)02759-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hrthm.2025.08.017</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiac physiologic pacing (CPP), including biventricular pacing (BiVP), left bundle branch area pacing (LBBAP), and His bundle pacing (HBP), has become a preferred strategy over right ventricular pacing (RVP) due to the lower risk of pacing-induced cardiomyopathy. However, the evidence supporting CPP use in bradyarrhythmia with preserved left ventricular ejection fraction (LVEF) remains limited.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our network meta-analysis aims to explore outcomes of CPP in bradyarrhythmia with preserved LVEF.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A literature review was conducted from the inception of PubMed to April 2025. Eligibility criteria were adults who underwent pacing for bradyarrhythmia. Studies must have had mean LVEF of at least 50% or less than 10% of heart failure patients, and must be head-to-head comparisons among BiVP, LBBAP, HBP, and RVP. Primary endpoint was a composite of all-cause mortality and hospitalization for heart failure (HHF). Secondary endpoints were dyssynchrony index, LVEF, paced QRS duration, procedural success, fluoroscopy duration, and procedure-related complications.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 29 studies involving 8,795 patients (mean age 70.7&#xb1;11.33 years, mean LVEF 58.9&#xb1;8.7%) were included. LBBAP demonstrated a lower risk of composite primary endpoint compared to RVP (OR 0.42, 95%CI:0.25-0.70, p=0.001), with the highest P-scores (0.931). LBBAP achieved the lowest dyssynchrony index and narrowest paced QRS duration. BiVP showed the highest LVEF at follow-up. HBP had the lowest procedural success, the longest fluoroscopy duration, and the highest procedure-related complications.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LBBAP has the potential to be a first-line CPP strategy in bradyarrhythmia with preserved LVEF, due to its efficacy in reducing HHF and all-cause mortality.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pajareya</LastName><ForeName>Patavee</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, TH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuanchai</LastName><ForeName>Watsapon</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, TH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siranart</LastName><ForeName>Noppachai</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, TH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phutinart</LastName><ForeName>Somkiat</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, TH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chumpangern</LastName><ForeName>Yanisa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, TH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Eugene H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: echung13@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Rhythm</MedlineTA><NlmUniqueID>101200317</NlmUniqueID><ISSNLinking>1547-5271</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biventricular Pacing</Keyword><Keyword MajorTopicYN="N">Bradyarrhythmia</Keyword><Keyword MajorTopicYN="N">Cardiac Physiologic Pacing</Keyword><Keyword MajorTopicYN="N">Conduction System Pacing</Keyword><Keyword MajorTopicYN="N">His Bundle Pacing</Keyword><Keyword MajorTopicYN="N">Left Bundle Branch Area Pacing</Keyword><Keyword MajorTopicYN="N">Preserved Ejection Fraction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>19</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840575</ArticleId><ArticleId IdType="doi">10.1016/j.hrthm.2025.08.017</ArticleId><ArticleId IdType="pii">S1547-5271(25)02759-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40839755</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1945-7197</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>The Journal of clinical endocrinology and metabolism</Title><ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation></Journal><ArticleTitle>Magnesium Depletion, Metabolic Impairment, and Cardiac Alterations: The NAKO-MRI Study with Mendelian Randomization.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">dgaf476</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1210/clinem/dgaf476</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Magnesium deficiency may contribute to subclinical cardiac changes, particularly metabolic diastolic cardiomyopathy.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the association between magnesium depletion, metabolic syndrome (MetS), and MRI-derived cardiac alterations in a population-based sample.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We cross-sectionally analyzed N = 9568 participants from the baseline examination of the German National Cohort (NAKO) who underwent whole-body MRI. Associations of serum magnesium and magnesium depletion score (MDS) with MetS and cardiac alterations were assessed using multivariable logistic and linear regression, respectively. Two-sample Mendelian Randomization was performed to evaluate the potential causal relationship between serum magnesium and MRI-derived cardiac parameters.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our analysis revealed no correlation between serum magnesium and MDS (Spearman's rho = 0.065; p &lt; 0.001). A 1-SD increase in serum magnesium was associated with lower MetS prevalence (OR 0.93 [95% CI: 0.88, 0.99]) and reduced left and right ventricular systolic and diastolic volumes. Higher MDS, indicating magnesium deficiency, was linked to increased MetS prevalence (OR per 1-unit 1.32 [95% CI: 1.23, 1.41]) and its individual components. Furthermore, higher MDS was associated with increased LVRI (Estimate 0.012 g/mL [95% CI: 0.008, 0.017]) and decreased left ventricular end-diastolic volume (Estimate -1.132 mL/m2 [95% CI: -1.538, -0.727]), indicating concentric hypertrophy. Two-sample Mendelian Randomization suggested no causal relationship between serum magnesium and MRI-derived cardiac markers.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Magnesium depletion may serve as an early indicator of cardiac impairment. However, Mendelian Randomization results do not support a causal role of serum magnesium on cardiac structure and morphology.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shugaa Addin</LastName><ForeName>Nuha</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1499-9885</Identifier><AffiliationInfo><Affiliation>Institute of Epidemiology, Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Medical Faculty, Ludwig-Maximilians-Universit&#xe4;t (LMU), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pettenkofer School of Public Health, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuppert</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9675-803X</Identifier><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Full</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Hermann</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>German Cancer Research Center, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xf6;rr</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute f&#xfc;r Community Medicine, SHIP/KEF, University Medicine Greifswald, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research (DZHK), partner site Greifswald, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keil</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Social Medicine, Epidemiology and Health Economics, Charit&#xe9; - Universit&#xe4;tsmeditzin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology and Biometry, University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Institute of Health I, Bavarian Health and Food Safety Authority, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Kr&#xfc;chten</LastName><ForeName>Ricarda</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meinel</LastName><ForeName>Felix G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, University Medical Centre Rostock, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niendorf</LastName><ForeName>Thoralf</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7584-6527</Identifier><AffiliationInfo><Affiliation>Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pischon</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Molecular Epidemiology Research Group, Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>B&#xf6;rge</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University of Duisburg-Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulz-Menger</LastName><ForeName>Jeanette</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3100-1092</Identifier><AffiliationInfo><Affiliation>Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t Zu Berlin, Experimental Clinical Research Center, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research (DZHK), partner site Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwichtenberg</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University of Duisburg-Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xf6;lzke</LastName><ForeName>Henry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7003-399X</Identifier><AffiliationInfo><Affiliation>Institute f&#xfc;r Community Medicine, SHIP/KEF, University Medicine Greifswald, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willich</LastName><ForeName>Stefan N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Institute of Social Medicine, Epidemiology and Health Economics, Charit&#xe9; - Universit&#xe4;tsmeditzin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bamberg</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7460-3942</Identifier><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Annette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology, Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Medical Faculty, Ludwig-Maximilians-Universit&#xe4;t (LMU), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pettenkofer School of Public Health, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Disease Research (DZHK), Munich Heart Alliance, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlett</LastName><ForeName>Christopher L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0002-1576-1481</Identifier><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rospleszcz</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4788-2341</Identifier><AffiliationInfo><Affiliation>Institute of Epidemiology, Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Endocrinol Metab</MedlineTA><NlmUniqueID>0375362</NlmUniqueID><ISSNLinking>0021-972X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Magnesium</Keyword><Keyword MajorTopicYN="N">cardiac function</Keyword><Keyword MajorTopicYN="N">cardiac morphology</Keyword><Keyword MajorTopicYN="N">magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">metabolic syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>14</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839755</ArticleId><ArticleId IdType="doi">10.1210/clinem/dgaf476</ArticleId><ArticleId IdType="pii">8239413</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40839769</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2350</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Human reproduction (Oxford, England)</Title><ISOAbbreviation>Hum Reprod</ISOAbbreviation></Journal><ArticleTitle>Fertility status and risk of pediatric cardiovascular diseases: a population-based nested case-control study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">deaf161</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/humrep/deaf161</ELocationID><Abstract><AbstractText Label="STUDY QUESTION" NlmCategory="OBJECTIVE">Is parental fertility status and use of IVF associated with the risk of pediatric cardiovascular diseases among offspring aged 0-13&#x2009;years, and is this association mediated by perinatal factors?</AbstractText><AbstractText Label="SUMMARY ANSWER" NlmCategory="CONCLUSIONS">Children conceived through IVF and those born to parents with subfertility (defined as one partner with an infertility diagnosis and not using ART for the study pregnancy) have an increased risk for congenital heart defects, partly explained by multiple gestations.</AbstractText><AbstractText Label="WHAT IS KNOWN ALREADY" NlmCategory="BACKGROUND">Evidence indicates that children born following IVF have an increased risk of premature vascular aging. However, the risk of developing cardiovascular diseases during childhood and the extent to which such risks are associated with adverse perinatal outcomes remains uncertain.</AbstractText><AbstractText Label="STUDY DESIGN, SIZE, DURATION" NlmCategory="METHODS">This nationwide, population-based, nested case-control study included registry data from 2&#xa0;228&#xa0;073 parents-child triads in Taiwan from 1 January 2004 to 31 December 2017. Offspring were categorized into three groups based on their parents' fertility status (fertile [achieved spontaneous conception, no infertility diagnosis], subfertility, and IVF [conception via IVF, including ICSI]). The three groups were followed from birth (between 1 January 2004 and 31 December 2017) until they developed the outcomes of interest, met any exclusion criteria, died, or until the end of the study period (31 December 2017), whichever came first.</AbstractText><AbstractText Label="PARTICIPANTS/MATERIALS, SETTING, METHODS" NlmCategory="METHODS">In the study cohort, we identified 41&#xa0;113 children with newly diagnosed pediatric cardiovascular diseases and used incidence density sampling to match each case to four controls (n&#x2009;=&#x2009;169&#xa0;850), based on age, sex, mother's residential township at delivery, and the calendar date of the pediatric cardiovascular disease diagnosis. Pediatric cardiovascular diseases included diagnoses of congenital heart defects, hypertensive diseases, cardiomyopathy, and arrhythmia. Conditional logistic regression was performed to examine the association between fertility status and pediatric cardiovascular diseases. Causal mediation analysis was used to test for mediation by multiple gestations, preterm birth, and low birth weight.</AbstractText><AbstractText Label="MAIN RESULTS AND THE ROLE OF CHANCE" NlmCategory="RESULTS">During 11.5 million person-years of follow-up (median [interquartile range, IQR], 6&#x2009;years [2-10]), IVF conception was associated with an increased risk of congenital heart defects compared with subfertility (odds ratio [OR], 1.47; 95% CI, 1.36-1.60; incidence rate difference [IRD], 375.1 per 100&#xa0;000 person-years [95% CI, 331.8-418.3]) and fertile group (OR, 1.72; 95% CI, 1.60-1.85; IRD, 445.7 per 100&#xa0;000 person-years [95% CI, 403.0-488.3]). Subfertility was associated with a 1.19-fold higher risk of congenital heart defects (95% CI, 1.16-1.23; IRD, 70.6 per 100&#xa0;000 person-years [95% CI, 61.9-79.4]) than fertile group. Multiple gestations accounted for 31.16% of the association between IVF and congenital heart defects compared with subfertility and for 54.26% of the association compared with fertile group. No significant associations were found between fertility status and hypertensive diseases, cardiomyopathy, or arrhythmias.</AbstractText><AbstractText Label="LIMITATIONS, REASONS FOR CAUTION" NlmCategory="CONCLUSIONS">Although the national data with a long follow-up period were used, the duration may still be insufficient to detect potential risks for hypertensive diseases, cardiomyopathy, and arrhythmia. Lack of data on pregnancy terminations could lead to underestimation of congenital heart defects risk.</AbstractText><AbstractText Label="WIDER IMPLICATIONS OF THE FINDINGS" NlmCategory="CONCLUSIONS">These findings suggest that a reduction in the occurrence of multiple gestations may help reduce the risk of congenital heart defects related to IVF conception. IVF conception should prompt consideration of fetal echocardiography, particularly in mothers with multiple gestations.</AbstractText><AbstractText Label="STUDY FUNDING/COMPETING INTEREST(S)" NlmCategory="BACKGROUND">This study was supported by grants from Shin Kong Wu Ho-Su Memorial Hospital (No. 109GB006-1). The funders had no role in the study design, data collection, analysis, interpretation, report writing, or the decision to submit the article for publication. The authors have no competing interests to disclose.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">N/A.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Shiue-Shan</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0001-7949-1663</Identifier><AffiliationInfo><Affiliation>Institute of Public Health, National Yang Ming Chiao Tung University, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yen-Tsung</ForeName><Initials>YT</Initials><Identifier Source="ORCID">0000-0001-7657-0040</Identifier><AffiliationInfo><Affiliation>Institute of Statistical Science, Academia Sinica, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yi-Ting</ForeName><Initials>YT</Initials><Identifier Source="ORCID">0000-0002-2605-2664</Identifier><AffiliationInfo><Affiliation>Institute of Statistical Science, Academia Sinica, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chien</LastName><ForeName>Li-Yin</ForeName><Initials>LY</Initials><Identifier Source="ORCID">0000-0002-4210-2975</Identifier><AffiliationInfo><Affiliation>Institute of Community Health Care, College of Nursing, National Yang Ming Chiao Tung University, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>109GB006-1</GrantID><Agency>Shin Kong Wu Ho-Su Memorial Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Reprod</MedlineTA><NlmUniqueID>8701199</NlmUniqueID><ISSNLinking>0268-1161</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IVF</Keyword><Keyword MajorTopicYN="N">congenital heart defects</Keyword><Keyword MajorTopicYN="N">infertility</Keyword><Keyword MajorTopicYN="N">multiple gestations</Keyword><Keyword MajorTopicYN="N">nested case&#x2013;control study</Keyword><Keyword MajorTopicYN="N">offspring</Keyword><Keyword MajorTopicYN="N">pediatric cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">subfertility</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>14</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839769</ArticleId><ArticleId IdType="doi">10.1093/humrep/deaf161</ArticleId><ArticleId IdType="pii">8239425</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40838915</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-3117</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</Title><ISOAbbreviation>J Heart Lung Transplant</ISOAbbreviation></Journal><ArticleTitle>The International Society for Heart and Lung Transplantation Guidelines for the Management of Pediatric Heart Failure (Update From 2014).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1053-2498(25)02030-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.healun.2025.06.003</ELocationID><Abstract><AbstractText>Pediatric heart failure (HF) secondary to cardiomyopathies, acquired heart disease, and congenital heart disease is associated with significant morbidity and mortality. These guidelines represent an update from the International Society for Heart and Lung Transplantation guidelines for the management of pediatric HF that were published in 2014 and incorporate interval advancements in medical therapies and new approaches in the evaluation and management of children with HF.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital Westmead, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azeka</LastName><ForeName>Estela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pediatric Cardiology and Adults with Congenital Heart Disease, Instituto do Cora&#xe7;&#xe3;o (InCor), Hospital das Cl&#xed;nicas HCFMUSP, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adorisio</LastName><ForeName>Rachele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Feto-Neonatal-Cardiovascular Integrated Area, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blume</LastName><ForeName>Elizabeth D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Boston Children's Hospital and the Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogle</LastName><ForeName>Carmel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Maryland,&#xa0;College Park, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chubb</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conway</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Alberta, Stollery Children's Hospital, Edmonton, Alberta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cousino</LastName><ForeName>Melissa K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edelson</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Katrina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Great Ormond Street Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holinski</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Alberta, Stollery Children's Hospital, Edmonton, Alberta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janousek</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Leipzig Heart Center, Strumpellstrasse, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lal</LastName><ForeName>Ashwin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Utah, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Columbia University, New York City, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorts</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cincinnati Children's Hospital, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado Anschutz Medical Campus and Heart Institute, Children's Hospital Colorado, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>David N</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California. Electronic address: davidnr@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossano</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Electronic address: rossanoj@chop.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Shelley D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado Anschutz Medical Campus and Heart Institute, Children's Hospital Colorado, Aurora, Colorado. Electronic address: shelley.miyamoto@childrenscolorado.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Heart Lung Transplant</MedlineTA><NlmUniqueID>9102703</NlmUniqueID><ISSNLinking>1053-2498</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">congenital heart disease</Keyword><Keyword MajorTopicYN="N">pediatric heart failure</Keyword><Keyword MajorTopicYN="N">preserved ejection fraction</Keyword><Keyword MajorTopicYN="N">reduced ejection fraction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>10</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40838915</ArticleId><ArticleId IdType="doi">10.1016/j.healun.2025.06.003</ArticleId><ArticleId IdType="pii">S1053-2498(25)02030-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840694</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-1186</ISSN><JournalIssue CitedMedium="Internet"><Volume>220</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Pharmacological research</Title><ISOAbbreviation>Pharmacol Res</ISOAbbreviation></Journal><ArticleTitle>Palmitoylation in cardiometabolic diseases: From molecular mechanisms to clinical implications.</ArticleTitle><Pagination><StartPage>107921</StartPage><MedlinePgn>107921</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phrs.2025.107921</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1043-6618(25)00346-9</ELocationID><Abstract><AbstractText>Cardiometabolic diseases (CMDs), encompassing both cardiovascular diseases and metabolic syndromes, are among the leading causes of global morbidity and mortality. Protein S-palmitoylation, a reversible lipid-based post-translational modification, has emerged as a crucial regulator of cellular function and homeostasis. Palmitoylation is catalysed by palmitoyl transferases (PATs), also known as ZDHHC (zinc finger Asp-His-His-Cys) proteins, while a series of deacylases mediate the process of depalmitoylation. By modulating protein hydrophobicity, stability, subcellular localization, enzymatic activity, and membrane trafficking, palmitoylation exerts profound effects on cellular function. Physiologically, maintaining normal palmitoylation-depalmitoylation cycle are crucial in regulating the activity and membrane localization of ion channels involved in cardiomyocyte electrophysiology, modulating endothelial metabolism, cell-cell interactions, and repair following vascular injury, as well as influencing insulin signalling in cardiomyocyte metabolism. In the aspect of pathogenesis, palmitoylation influences the development of CMDs such as coronary artery disease (CAD), heart failure (HF), hypertension, type 2 diabetes (T2D), diabetic cardiomyopathy (DbCM), obesity, and non-alcoholic fatty liver disease (NAFLD). Dysregulation of the palmitoylation-depalmitoylation cycle contributes to these pathological processes, exacerbating disease progression. This review systematically explores the biological functions of palmitoylation in cardiometabolic physiology and diseases, discussing potential therapeutic targets within the palmitoylation pathway. By maintaining normal palmitoylation-depalmitoylation cycle and preventing its dysregulation, novel strategies for the prevention and treatment of CMDs may be developed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Shenghui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China; Department of Intensive Care Unit, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: shenghuifeng0429@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Electronic address: jay0416@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Linjuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, PR China. Electronic address: 727456372@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: fwyy2803@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Wengen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China. Electronic address: 18170044224@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Pharmacol Res</MedlineTA><NlmUniqueID>8907422</NlmUniqueID><ISSNLinking>1043-6618</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiometabolic diseases</Keyword><Keyword MajorTopicYN="N">Molecular mechanism</Keyword><Keyword MajorTopicYN="N">Palmitoylation</Keyword><Keyword MajorTopicYN="N">Therapeutic targets</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>19</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840694</ArticleId><ArticleId IdType="doi">10.1016/j.phrs.2025.107921</ArticleId><ArticleId IdType="pii">S1043-6618(25)00346-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40841103</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0873</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JACC. CardioOncology</Title><ISOAbbreviation>JACC CardioOncol</ISOAbbreviation></Journal><ArticleTitle>Clonal Hematopoiesis in Cancer and Cardiovascular Disease: JACC: CardioOncology State-of-the-Art Review.</ArticleTitle><Pagination><StartPage>470</StartPage><EndPage>495</EndPage><MedlinePgn>470-495</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccao.2025.06.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0873(25)00249-2</ELocationID><Abstract><AbstractText>Emerging evidence suggests a dynamic relationship exists between cancer and cardiovascular disease (CVD). CVD is common among cancer survivors; however, it also may increase the risk of developing cancer. The underlying factors driving this connection remain poorly understood. Aging, chronic inflammation, and perturbed immune signaling are shared hallmarks of cancer and CVD. Clonal hematopoiesis (CH), the age-related accumulation of somatic mutations in hematopoietic cells leading to cells with a growth advantage, is associated with immune dysregulation in elderly people. Growing evidence suggests that CH is a risk factor for CVD. Although the link between CH and hematological cancer is well established, its relationship to solid organ cancers is far less understood. This review provides an in-depth analysis of the evidence linking CH with solid organ malignancies and explores its role as a shared risk factor for the development of both CVD and cancer. Furthermore, it discusses the potential mechanisms by which CH may contribute to CVD among cancer survivors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Megan A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia, USA. Electronic address: kw9ar@virginia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC CardioOncol</MedlineTA><NlmUniqueID>101761697</NlmUniqueID><ISSNLinking>2666-0873</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CHIP</Keyword><Keyword MajorTopicYN="N">LOY</Keyword><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">cardiotoxicity</Keyword><Keyword MajorTopicYN="N">coronary artery disease</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">mCAs</Keyword><Keyword MajorTopicYN="N">solid organ tumors</Keyword><Keyword MajorTopicYN="N">therapy-related clonal hematopoiesis</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures These studies were supported by National Institutes of Health grants AG073249 and AG086508, Department of Defense grant CA210887, and National Aeronautics and Space Administration grant 80NSSC21K0549 to Dr Walsh. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841103</ArticleId><ArticleId IdType="doi">10.1016/j.jaccao.2025.06.006</ArticleId><ArticleId IdType="pii">S2666-0873(25)00249-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846497</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-7793</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>The Journal of physiology</Title><ISOAbbreviation>J Physiol</ISOAbbreviation></Journal><ArticleTitle>Species-specific impact of hyperglycaemia-induced cardiac ROS: Not all mammals are created equal.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1113/JP288976</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wende</LastName><ForeName>Adam R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-5536-4675</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HL133011</GrantID><Agency>NIH&#xa0;</Agency><Country/></Grant><Grant><GrantID>HL152354</GrantID><Agency>NIH&#xa0;</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Physiol</MedlineTA><NlmUniqueID>0266262</NlmUniqueID><ISSNLinking>0022-3751</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CaMKII</Keyword><Keyword MajorTopicYN="N">GlcNAc</Keyword><Keyword MajorTopicYN="N">NOX2</Keyword><Keyword MajorTopicYN="N">ROS</Keyword><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846497</ArticleId><ArticleId IdType="doi">10.1113/JP288976</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Chatham, J. C., Zhang, J., &amp; Wende, A. R. (2021). Role of O&#x2010;linked N&#x2010;acetylglucosamine protein modification in cellular (Patho)physiology. Physiological Reviews, 101(2), 427&#x2013;493.</Citation></Reference><Reference><Citation>Heather, L. C., Hafstad, A. D., Halade, G. V., Harmancey, R., Mellor, K. M., Mishra, P. K., Mulvihill, E. E., Nabben, M., Nakamura, M., Rider, O. J., Ruiz, M., Wende, A. R., &amp; Ussher, J. R. (2022). Guidelines on models of diabetic heart disease. American Journal of Physiology&#x2010;Heart and Circulatory Physiology, 323(1), H176&#x2013;H200.</Citation></Reference><Reference><Citation>Hegyi, B., Bers, D. M., &amp; Bossuyt, J. (2019). CaMKII signaling in heart diseases: Emerging role in diabetic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 127, 246&#x2013;259.</Citation></Reference><Reference><Citation>Lu, S., Baier, M. J., Polonen, R. P., Liao, Z., Martin, J. L., Ginsburg, K. S., Mustroph, J., &amp; Bers, D. M. (2025). Hyperglycaemia&#x2010;induced reactive oxygen species production in cardiac ventricular myocytes differs among mammals. The Journal of Physiology. Advance online publication. https://doi.org/10.1113/JP287886.</Citation></Reference><Reference><Citation>Pogwizd, S. M., &amp; Bers, D. M. (2008). Rabbit models of heart disease. Drug Discovery Today:Disease Models, 5(3), 185&#x2013;193.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40846378</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>24</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Eosinophilic Myocarditis Associated With Chronic Eosinophilic Leukemia.</ArticleTitle><Pagination><StartPage>104805</StartPage><MedlinePgn>104805</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.104805</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)01585-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Eosinophilic myocarditis (EM) is a rare, dangerous complication of eosinophil-predominant disease. Its presentation varies greatly, with detrimental consequences including arrhythmia, heart failure, and sudden cardiac death.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 58-year-old woman with chronic eosinophilic leukemia presented with worsening dyspnea and was found to have EM and left ventricular apical thrombus based on characteristic imaging findings. She was started on a heparin drip, corticosteroids, imatinib, and furosemide. She did not experience complications of myocarditis while admitted, and biventricular function was preserved.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">There is a paucity of established guidelines regarding the diagnosis of EM. However, there may be a crucial role for imaging modalities in workup and diagnosis, one that may save patients from invasive procedures.</AbstractText><AbstractText Label="TAKE-HOME MESSAGES" NlmCategory="CONCLUSIONS">This case highlights the utility of noninvasive imaging as well as the importance of early recognition and multidisciplinary management. Clinicians should consider EM as part of the differential diagnosis when managing patients with eosinophilia and signs of cardiomyopathy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Venkataramany</LastName><ForeName>Barat S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Electronic address: venkatbs@ucmail.uc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brar</LastName><ForeName>Amerpreet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Health and Disease, University of Cincinnati Medical Center, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahart</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Health and Disease, University of Cincinnati Medical Center, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Health and Disease, University of Cincinnati Medical Center, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laipply</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Health and Disease, University of Cincinnati Medical Center, Ohio, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac MRI</Keyword><Keyword MajorTopicYN="N">cardiac imaging</Keyword><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">eosinophilic myocarditis</Keyword><Keyword MajorTopicYN="N">myocarditis</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846378</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.104805</ArticleId><ArticleId IdType="pii">S2666-0849(25)01585-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846526</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-861X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of cardiovascular computed tomography</Title><ISOAbbreviation>J Cardiovasc Comput Tomogr</ISOAbbreviation></Journal><ArticleTitle>Cardiac CT fractal analysis of LV noncompaction and common cardiomyopathies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1934-5925(25)00420-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcct.2025.08.004</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Left ventricular noncompaction (LVNC), or hypertrabeculation, is a myocardial condition that remains challenging to diagnose and differentiate from other cardiomyopathies. This study evaluated the ability of cardiac CT to differentiate between LVNC, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and controls using fractal analysis of LV trabeculae.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Subjects with LVNC, HCM, DCM, as well as controls, who underwent coronary CT angiography were included. LV trabecular structure was quantified using fractal analysis on a stack of 15 short-axis CT images. For each subject, maximum (FD<sub>max</sub>) and average (FD<sub>global</sub>) fractal dimensions were reported. A subset of subjects also had clinically acquired cardiac MRI (CMR) exams for comparison. One-way ANOVA, Pearson correlation, and Bland-Altman analysis were used for statistical analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 313 subjects (median age: 58.8 [48.1-68.0] years, 153 male) categorized into Control (89), LVNC (46), HCM (106), and DCM (72) cohorts. FD<sub>max</sub> was significantly higher in LVNC (1.379 &#x200b;&#xb1; &#x200b;0.047) than in Control (1.305 &#x200b;&#xb1; &#x200b;0.033), HCM (1.321 &#x200b;&#xb1; &#x200b;0.040), and DCM (1.344 &#x200b;&#xb1; &#x200b;0.054) cohorts; all p &#x200b;&lt; &#x200b;0.001. Similarly, FD<sub>global</sub> was significantly higher in LVNC (1.279 &#x200b;&#xb1; &#x200b;0.041) than in the other cohorts; all p &#x200b;&lt; &#x200b;0.05. In a subset of 132 subjects with both CT and CMR exams, fractal dimensions from the two modalities were strongly correlated (r &#x200b;= &#x200b;0.63, p &#x200b;&lt; &#x200b;0.0001), with CT-derived values being higher (1.337 &#x200b;&#xb1; &#x200b;0.049 vs. 1.262 &#x200b;&#xb1; &#x200b;0.045, p &#x200b;&lt; &#x200b;0.0001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CT-derived fractal dimensions of LV trabecular structure were significantly higher in LVNC compared to control subjects, HCM, and DCM. CT-derived fractal dimensions strongly correlated with, but were higher than, those from cardiac MRI in the same subjects.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manohar</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, USA; Department of Radiology, Stanford University, Stanford, CA, USA; Cardiovascular Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo</LastName><ForeName>Edgard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cardiovascular Institute, Stanford University, Stanford, CA, USA; Tilman J. Fertitta Family College of Medicine, University of Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunderson</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiovascular Institute, Stanford University, Stanford, CA, USA; School of Medicine, University of Nevada Reno, Reno, NV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mistelbauer</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagherzadeh</LastName><ForeName>Shadi Peighambari</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haddad</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, USA; Cardiovascular Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caliskan</LastName><ForeName>Kadir</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budde</LastName><ForeName>Ricardo P J</ForeName><Initials>RPJ</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung-Pyo</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Whal</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Radiology, Seoul National University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owens</LastName><ForeName>Anjali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litt</LastName><ForeName>Harold</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheeler</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Deborah H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>W H Wilson</ForeName><Initials>WHW</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieman</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, USA; Department of Radiology, Stanford University, Stanford, CA, USA; Cardiovascular Institute, Stanford University, Stanford, CA, USA. Electronic address: knieman@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiovasc Comput Tomogr</MedlineTA><NlmUniqueID>101308347</NlmUniqueID><ISSNLinking>1876-861X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Coronary CT angiography</Keyword><Keyword MajorTopicYN="N">Fractal analysis</Keyword><Keyword MajorTopicYN="N">Hypertrabeculation</Keyword><Keyword MajorTopicYN="N">Left ventricular noncompaction</Keyword></KeywordList><CoiStatement>Declaration of competing interest Dr. Nieman reports unrestricted institutional research support from Siemens Healthineers, Bayer, HeartFlow Inc., and Novartis; consulting for Cleerly, Artrya, RapidAI, Novartis, and Siemens Medical Solutions USA; and equity in Lumen Therapeutics. Prof. Budde and Dr. Hirsch report institutional research support from Siemens Healthineers, Bayer, HeartFlow Inc., and Bracco. Dr. Hirsch received consultancy fees from GE Healthcare and speaker fees from GE Healthcare, Bayer, and Bristol Myers Squibb. He is also a member of the medical advisory board of Medis Medical Imaging Systems and was the MRI corelab supervisor of Cardialysis BV until 2022. Dr. Wheeler reports consulting for Cytokinetics, research support from BMS, Cytokinetics, Salubris Bio, and Alexion. Dr. Owens reports consulting for Alexion, Avidity, Bayer, BMS, Cytokinetics, Corvista, Imbria, Lexeo, Stealth, Edgewise, Tenaya, Biomarin, and research grant from BMS. Dr. Litt reports institutional research support from Siemens Healthineers, Philips Healthcare, Canon Healthcare, and Heartflow Inc. Dr. Tang served as consultant for Sequana Medical, Cardiol Therapeutics, Genomics plc, Zehna Therapeutics, Renovacor, WhiteSwell, Kiniksa, Boston Scientific, and CardiaTec Biosciences and has received honorarium from Springer Nature and American Board of Internal Medicine.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>21</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846526</ArticleId><ArticleId IdType="doi">10.1016/j.jcct.2025.08.004</ArticleId><ArticleId IdType="pii">S1934-5925(25)00420-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40845481</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2452-302X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>JACC. Basic to translational science</Title><ISOAbbreviation>JACC Basic Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Precision Medicine: Therapeutically Targeting Mitochondrial Alterations in Heart Failure.</ArticleTitle><Pagination><StartPage>101345</StartPage><MedlinePgn>101345</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacbts.2025.101345</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2452-302X(25)00297-9</ELocationID><Abstract><AbstractText>A substantial component of the increasing global burden of cardiovascular disease is attributed to heart failure (HF), affecting over 64 million adults worldwide. Maladaptive mitochondrial respiratory alterations and oxidative stress are major contributors to HF development and progression, with subsequent downstream myocardial energetic impairment as a strong predictor of mortality. Current conventional therapeutic approaches, including renin-angiotensin-aldosterone system inhibition and &#x3b2;-adrenergic blockade, target neurohormonal aspects of HF and are effective in slowing disease progression. However, although these therapies may be associated with some improvement in myocardial energetics, they do not specifically address alterations in myocardial mitochondrial respiration or redox homeostasis. Targeting mitochondria has hence become a promising approach for more effective and tailored therapies. This review summarizes metabolic derangements that drive HF progression, with a specific focus on mitochondria. Importantly, here we address the essential knowledge gaps in the field, highlighting key translational strategies used to date, and the challenges associated with therapeutically targeting mitochondrial pathways, alongside recent developments seeking to deploy novel mitochondrial-targeted therapeutic approaches to treat HF.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Alex M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia; St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lees</LastName><ForeName>Jarmon G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia; St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia; Department of Medicine and Surgery, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Physiology, Development and Neuroscience, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velagic</LastName><ForeName>Anida</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Shiang Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia; St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia; Department of Medicine and Surgery, University of Melbourne, Melbourne, Victoria, Australia; National Heart Research Institute Singapore, National Heart Centre, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Blasio</LastName><ForeName>Miles J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Rebecca H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia. Electronic address: Rebecca.Ritchie@monash.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Basic Transl Sci</MedlineTA><NlmUniqueID>101677259</NlmUniqueID><ISSNLinking>2452-302X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">drug discovery</Keyword><Keyword MajorTopicYN="N">myocardial metabolism</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">pharmacotherapy</Keyword><Keyword MajorTopicYN="N">respiration</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures This work was supported by the Heart Foundation Australia Vanguard (108447-2024-VG to RHR and SYL) and Diabetes Australia Research Program (DARP, Y24G-DEBM to MDB). Dr Murray has received consulting fees from Rivus Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40845481</ArticleId><ArticleId IdType="doi">10.1016/j.jacbts.2025.101345</ArticleId><ArticleId IdType="pii">S2452-302X(25)00297-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40844021</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8298</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Future cardiology</Title><ISOAbbreviation>Future Cardiol</ISOAbbreviation></Journal><ArticleTitle>Early diagnosis of cardiac involvement in Anderson-Fabry disease using cardiac MRI parameters.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>10</EndPage><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14796678.2025.2550107</ELocationID><Abstract><AbstractText>Anderson-Fabry disease (AFD) is a rare, X-linked, lysosomal storage disorder caused by the absence or deficiency of alpha-galactosidase A activity, leading to the progressive accumulation of sphingolipids in multiple organ systems, including the heart. Cardiac involvement accounts for&#x2009;&gt;&#x2009;50% of AFD-related mortality and is a primary determinant of disease prognosis. AFD cardiomyopathy is heterogenous with key features that include left ventricular hypertrophy, conduction disturbances, myocardial fibrosis and valvular disease. Early diagnosis and treatment are crucial to prevent progressive and irreversible myocardial damage. Electrocardiography and echocardiography are effective and inexpensive first-line modalities to detect abnormalities that suggest cardiac involvement in patients with AFD. However, cardiovascular magnetic resonance imaging (CMR) can provide a more comprehensive assessment of myocardial tissue characteristics and cardiac structure and function. Recent studies have strengthened the role of T1 mapping, myocardial strain and late gadolinium enhancement using CMR in the assessment of patients with AFD. Whilst CMR is less widely available than electrocardiography and echocardiography, it has the potential to improve the diagnosis, monitoring and prognostication of patients with AFD. In the future, advanced CMR techniques may further refine risk stratification, guide therapeutic decisions and facilitate earlier interventions that can ultimately improve patient outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical School, The University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dwivedi</LastName><ForeName>Girish</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0717-740X</Identifier><AffiliationInfo><Affiliation>Medical School, The University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harry Perkins Institute of Medical Research, Perth, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Fiona Stanley Hospital, Perth, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CardioInnovate Translational Lab, Victor Chang Cardiac Research Institute, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boon</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Fiona Stanley Hospital, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8922-7583</Identifier><AffiliationInfo><Affiliation>Medical School, The University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology, Royal Perth Hospital, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Nick S R</ForeName><Initials>NSR</Initials><Identifier Source="ORCID">0000-0002-7222-7314</Identifier><AffiliationInfo><Affiliation>Medical School, The University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harry Perkins Institute of Medical Research, Perth, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Fiona Stanley Hospital, Perth, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Future Cardiol</MedlineTA><NlmUniqueID>101239345</NlmUniqueID><ISSNLinking>1479-6678</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Anderson-Fabry Disease (AFD) is a rare genetic disorder that causes accumulation of harmful substances to build up in the body. The heart is the most commonly affected organ and has a significant impact on lifespan and wellbeing. Over time, this can lead to thickened heart walls, rhythm disturbances and even heart failure. Treatment can work only if heart disease is not too severe, therefore early detection is important to patient outcomes. This article reviews how cardiac MRIs (CMR) can spot signs of AFD affecting the heart earlier than traditional investigations. Strain analysis and T1 mapping have been found to potentially detect heart involvement prior to the onset of symptoms or obvious structural defects. We discuss how these MRI tools can help to recognize disease earlier so that doctors can prescribe treatment and therefore improve long-term outcomes for patients.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anderson-Fabry disease</Keyword><Keyword MajorTopicYN="N">Cardiovascular magnetic resonance</Keyword><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">myocardial</Keyword><Keyword MajorTopicYN="N">sphingolipid</Keyword><Keyword MajorTopicYN="N">ventricular hypertrophy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>7</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40844021</ArticleId><ArticleId IdType="doi">10.1080/14796678.2025.2550107</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40844727</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-8312</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>The international journal of cardiovascular imaging</Title><ISOAbbreviation>Int J Cardiovasc Imaging</ISOAbbreviation></Journal><ArticleTitle>Optimizing synthetic hematocrit for cardiac MRI: a multivariable model calibrated with standardized venous sampling.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10554-025-03504-9</ELocationID><Abstract><AbstractText>Cardiac magnetic resonance (CMR) is a key modality for non-invasive extracellular volume (ECV) quantification, typically requiring venous hematocrit (Hct). However, fluctuations in Hct can affect accuracy. This study aimed to develop a synthetic Hct model integrating age, sex, and pre- and post-contrast blood pool T1 values, calibrated against an optimized venous Hct reference. Cardiac MRI data from 253 patients, including those with various pathologies and normal findings, were retrospectively analyzed for ECV calculations. To minimize postural fluctuations, venous Hct samples were taken after the patients remained in a stable supine position for at least 15&#xa0;min, just before contrast injection. Hct<sub>syn</sub> values were derived from pre-contrast and post-contrast T1 mapping sequences. A comprehensive Hct<sub>syn</sub> model was developed by integrating age, sex, and both pre- and post-contrast blood pool T1 values. Unlike previous studies, these variables were evaluated collectively, and the model was calibrated using an optimized venous Hct reference. The performance of the derived model at high ECV values was further evaluated in the hypertrophic cardiomyopathy (HCM) subcohort. The Hct<sub>syn</sub> model showed strong agreement with measured ECV (bias: 0.31%, RMSE: 1.25, CCC: 0.949). In the HCM subcohort, it maintained high correlation (r&#x2009;=&#x2009;0.98) with a clinically acceptable bias of -&#x2009;1.16%. Compared to sex-specific formulas by Chen et al., the model demonstrated improved performance (R&#xb2; = 0.56) with lower variability. This standardized synthetic Hct model enables accurate, non-invasive ECV estimation without blood sampling and demonstrates superior performance, especially in patients with elevated ECV values.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Nature B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#xd6;zcan</LastName><ForeName>&#xc7;a&#x11f;r&#x131;</ForeName><Initials>&#xc7;</Initials><Identifier Source="ORCID">0009-0008-4275-3963</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Ankara Etimesgut &#x15e;ehit Sait Ert&#xfc;rk State Hospital, Ulubatl&#x131; Hasan St., No: 5, Etimesgut, TR-06790, &#x130;stasyon NBHD, Ankara, T&#xfc;rkiye, Turkey. md.cagriozcan@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi&#x11f;it</LastName><ForeName>Hasan</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0949-357X</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Ankara Training and Research Hospital, Ankara, TR- 06230, T&#xfc;rkiye, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc7;etin</LastName><ForeName>Mehmet Serkan</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-3983-0496</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Ankara Bilkent City Hospital, Ankara, TR-06800, T&#xfc;rkiye, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;zcan</LastName><ForeName>&#x130;rem</ForeName><Initials>&#x130;</Initials><Identifier Source="ORCID">0009-0006-1342-5675</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Ankara G&#xfc;lhane Training and Research Hospital, Ankara, TR-06010, T&#xfc;rkiye, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokur</LastName><ForeName>O&#x11f;uzhan</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-3319-6663</Identifier><AffiliationInfo><Affiliation>Department of Radiology, K&#xfc;tahya Health Sciences University, K&#xfc;tahya, TR-43020, T&#xfc;rkiye, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Cardiovasc Imaging</MedlineTA><NlmUniqueID>100969716</NlmUniqueID><ISSNLinking>1569-5794</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac magnetic resonance imaging (CMR imaging)</Keyword><Keyword MajorTopicYN="N">Diffuse interstitial myocardial fibrosis</Keyword><Keyword MajorTopicYN="N">Extracellular vol&#xfc;me fraction (ECV fraction)</Keyword><Keyword MajorTopicYN="N">Hematocrit</Keyword><Keyword MajorTopicYN="N">Myocardial mapping</Keyword></KeywordList><CoiStatement>Declarations. Compenting interests: The authors declare that they have no competing interests. Ethics approval and consent to participate: Under the Declaration of Helsinki, the ethics committee approval was obtained by the Ankara Training and Research Hospital Clinical Research Ethics Committee on 08 January 2025. The ethics committee application number was E-24-360. Consent for publication: Due to the retrospective nature of the study, obtaining additional consent from the patients was not required. Declaration of generative AI and AI-assisted technologies in the writing process: During the preparation of this work, the author(s) used OpenAI&#x2019;s ChatGPT in order to assist with English language editing, clarity improvements, and academic phrasing during the drafting of the manuscript&#x2019;s Introduction, Methods, Discussion and Conclusion sections. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>11</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40844727</ArticleId><ArticleId IdType="doi">10.1007/s10554-025-03504-9</ArticleId><ArticleId IdType="pii">10.1007/s10554-025-03504-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European association for cardiovascular imaging (EACVI). J Cardiovasc Magn Reson 19(1):1&#x2013;24</Citation></Reference><Reference><Citation>Arheden Hk, Saeed M, Higgins CB, Gao D-W, Ursell PC, Bremerich J et al (2000) Reperfused rat myocardium subjected to various durations of ischemia: estimation of the distribution volume of contrast material with echo-planar MR imaging. Radiology 215(2):520&#x2013;528</Citation><ArticleIdList><ArticleId IdType="pubmed">10796935</ArticleId></ArticleIdList></Reference><Reference><Citation>Arheden Hk, Saeed M, Higgins CB, Gao D-W, Bremerich J, Wyttenbach R et al (1999) Measurement of the distribution volume of gadopentetate dimeglumine at echo-planar MR imaging to quantify myocardial infarction: comparison with 99mTc-DTPA autoradiography in rats. Radiology 211(3):698&#x2013;708</Citation><ArticleIdList><ArticleId IdType="pubmed">10352594</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirup P (2003) Haematocrit: within-subject and seasonal variation. Sports Med 33:231&#x2013;243</Citation><ArticleIdList><ArticleId IdType="pubmed">12656642</ArticleId></ArticleIdList></Reference><Reference><Citation>Su M-Y, Huang Y-S, Niisato E, Chow K, Juang J-MJ, Wu C-K et al (2020) Is a timely assessment of the hematocrit necessary for cardiovascular magnetic resonance&#x2013;derived extracellular volume measurements? J Cardiovasc Magn Reson 22(1):77. https://doi.org/10.1186/s12968-020-00689-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-020-00689-x</ArticleId><ArticleId IdType="pubmed">33250055</ArticleId><ArticleId IdType="pmc">7702722</ArticleId></ArticleIdList></Reference><Reference><Citation>Robison S, Karur GR, Wald RM, Thavendiranathan P, Crean AM, Hanneman K (2018) Noninvasive hematocrit assessment for cardiovascular magnetic resonance extracellular volume quantification using a point-of-care device and synthetic derivation. J Cardiovasc Magn Reson 20(1):19</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-018-0443-1</ArticleId><ArticleId IdType="pubmed">29544519</ArticleId><ArticleId IdType="pmc">5856214</ArticleId></ArticleIdList></Reference><Reference><Citation>Engblom H, Kanski M, Kopic S, Nordlund D, Xanthis CG, Jablonowski R et al (2018) Importance of standardizing timing of hematocrit measurement when using cardiovascular magnetic resonance to calculate myocardial extracellular volume (ECV) based on pre-and post-contrast T1 mapping. J Cardiovasc Magn Reson 20(1):46</Citation><ArticleIdList><ArticleId IdType="pubmed">29950178</ArticleId><ArticleId IdType="pmc">6022290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundvall J, Bjerkhoel P, Quittenbaum S, Lindgren P (1996) Rapid plasma volume decline upon quiet standing reflects large filtration capacity in dependent limbs. Acta Physiol Scand 158(2):161&#x2013;167</Citation><ArticleIdList><ArticleId IdType="pubmed">8899063</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob G, Ertl AC, Shannon JR, Furlan R, Robertson RM, Robertson D (1998) Effect of standing on neurohumoral responses and plasma volume in healthy subjects. J Appl Physiol 84(3):914&#x2013;921</Citation><ArticleIdList><ArticleId IdType="pubmed">9480952</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana M, Banypersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T et al (2015) Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology 277(2):388&#x2013;397</Citation><ArticleIdList><ArticleId IdType="pubmed">25997029</ArticleId></ArticleIdList></Reference><Reference><Citation>Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V et al (2013) Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 6(1):34&#x2013;39</Citation><ArticleIdList><ArticleId IdType="pubmed">23192846</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD et al (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3(2):155&#x2013;164</Citation><ArticleIdList><ArticleId IdType="pubmed">20159642</ArticleId></ArticleIdList></Reference><Reference><Citation>Treibel TA, Nasis A, Fontana M, Maestrini V, Castelletti S, Bhuva AN et al (2015) An instantaneous ECV with no blood sampling: using native blood T1 for hematocrit is as good as standard ECV. J Cardiovasc Magn Reson 17:1&#x2013;2</Citation></Reference><Reference><Citation>Yin J, Qin J, Liu W, Zhu Y, Zhou X, Wang Y et al (2024) A comparative study of synthetic and venous hematocrit for calculating cardiovascular magnetic resonance-derived extracellular volume. Int J Cardiovasc Imaging. https://doi.org/10.1007/s10554-023-03044-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-023-03044-0</ArticleId><ArticleId IdType="pubmed">39390286</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Doeblin P, Al-Tabatabaee S, Klingel K, Tanacli R, Jakob Wei&#xdf; K et al (2022) Synthetic extracellular volume in cardiac magnetic resonance without blood sampling: a reliable tool to replace conventional extracellular volume. Circ Cardiovasc Imaging 15(4):e013745</Citation><ArticleIdList><ArticleId IdType="pubmed">35360924</ArticleId><ArticleId IdType="pmc">9015035</ArticleId></ArticleIdList></Reference><Reference><Citation>Opatril L, Panovsky R, Machal J, Holecek T, Masarova L, Feitova V et al (2021) Extracellular volume quantification using synthetic haematocrit assessed from native and post-contrast longitudinal relaxation T1 times of a blood pool. BMC Cardiovasc Disord 21(1):363. https://doi.org/10.1186/s12872-021-02179-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-021-02179-z</ArticleId><ArticleId IdType="pubmed">34330214</ArticleId><ArticleId IdType="pmc">8325220</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y, Zhang X, Zhou X, Wang J (2018) Extracellular volume fraction measurements derived from the longitudinal relaxation of blood-based synthetic hematocrit may lead to clinical errors in 3 T cardiovascular magnetic resonance. J Cardiovasc Magn Reson 20(1):56</Citation><ArticleIdList><ArticleId IdType="pubmed">30089499</ArticleId><ArticleId IdType="pmc">6083590</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim E-H, Le T-T, Bryant J, Chung Y-C, Su B, Gan J et al (2018) Importance of sex-specific regression models to estimate synthetic hematocrit and extracellular volume fraction. JACC Cardiovasc Imaging 11(9):1366&#x2013;1367</Citation><ArticleIdList><ArticleId IdType="pubmed">29454764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kammerlander AA, Duca F, Binder C, Aschauer S, Zotter-Tufaro C, Koschutnik M et al (2018) Extracellular volume quantification by cardiac magnetic resonance imaging without hematocrit sampling: ready for prime time? Wien Klin Wochenschr 130:190&#x2013;196</Citation><ArticleIdList><ArticleId IdType="pubmed">28980127</ArticleId></ArticleIdList></Reference><Reference><Citation>Fent GJ, Garg P, Foley JR, Swoboda PP, Dobson LE, Erhayiem B et al (2017) Synthetic myocardial extracellular volume fraction. JACC Cardiovasc Imaging 10(11):1402&#x2013;1404</Citation><ArticleIdList><ArticleId IdType="pubmed">28216005</ArticleId></ArticleIdList></Reference><Reference><Citation>Treibel TA, Fontana M, Maestrini V, Castelletti S, Rosmini S, Simpson J et al (2016) Automatic measurement of the myocardial interstitium: synthetic extracellular volume quantification without hematocrit sampling. JACC: Cardiovasc Imaging 9(1):54&#x2013;63</Citation><ArticleIdList><ArticleId IdType="pubmed">26762875</ArticleId></ArticleIdList></Reference><Reference><Citation>Raucci FJ Jr, Parra DA, Christensen JT, Hernandez LE, Markham LW, Xu M et al (2016) Synthetic hematocrit derived from the longitudinal relaxation of blood can lead to clinically significant errors in measurement of extracellular volume fraction in pediatric and young adult patients. J Cardiovasc Magn Reson 19(1):58</Citation></Reference><Reference><Citation>Bluemke DA, Kawel-Boehm N (2016) Can a MR imaging scanner accurately measure hematocrit to determine ECV fraction? JACC Cardiovasc Imaging. https://doi.org/10.1016/j.jcmg.2015.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2015.11.009</ArticleId><ArticleId IdType="pubmed">27639760</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zcan &#xc7;, Yi&#x11f;it H, &#xc7;etin MS, &#xd6;zcan &#x130; (2024) Analysis of myocardial T1, T2, and T2* values by age, sex, and cardiac segments in normal population: a prospective study. Int J Cardiovasc Imaging. https://doi.org/10.1007/s10554-024-03241-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-024-03241-5</ArticleId><ArticleId IdType="pubmed">39283474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottbrecht M, Kramer CM, Salerno M (2019) Native T1 and extracellular volume measurements by cardiac MRI in healthy adults: a meta-analysis. Radiology 290(2):317</Citation><ArticleIdList><ArticleId IdType="pubmed">30422092</ArticleId></ArticleIdList></Reference><Reference><Citation>Piechnik SK, Ferreira VM, Lewandowski AJ, Ntusi NAB, Banerjee R, Holloway C et al (2013) Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using shmolli. J Cardiovasc Magn Reson 15(1):13. https://doi.org/10.1186/1532-429X-15-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1532-429X-15-13</ArticleId><ArticleId IdType="pubmed">23331520</ArticleId><ArticleId IdType="pmc">3610210</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C et al (2023) 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 44(37):3503&#x2013;3626. https://doi.org/10.1093/eurheartj/ehad194</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad194</ArticleId><ArticleId IdType="pubmed">37622657</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG et al (2020) Standardized image interpretation and post-processing in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 22(1):19. https://doi.org/10.1186/s12968-020-00610-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-020-00610-6</ArticleId><ArticleId IdType="pubmed">32160925</ArticleId><ArticleId IdType="pmc">7066763</ArticleId></ArticleIdList></Reference><Reference><Citation>Green SB (1991) How many subjects does it take to do a regression analysis. Multivar Behav Res 26(3):499&#x2013;510</Citation></Reference><Reference><Citation>Biso S, Weber J, Philip S, Omar K (2024) Excellent reproducibility of synthetic ECV without blood extraction across different cardiomyopathies using published regression. J Cardiovasc Magn Reson. https://doi.org/10.1016/j.jocmr.2024.100910</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocmr.2024.100910</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellman P, Wilson JR, Xue H, Bandettini WP, Shanbhag SM, Druey KM et al (2012) Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience. J Cardiovasc Magn Reson 14(1):64. https://doi.org/10.1186/1532-429x-14-64</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1532-429x-14-64</ArticleId><ArticleId IdType="pubmed">22967246</ArticleId><ArticleId IdType="pmc">3442966</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40843717</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2076-3271</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Medical sciences (Basel, Switzerland)</Title><ISOAbbreviation>Med Sci (Basel)</ISOAbbreviation></Journal><ArticleTitle>Impact of Catheter Ablation on Functional Capacity and Cardiac Stress Markers in Patients with Premature Ventricular Contractions.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">95</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medsci13030095</ELocationID><Abstract><AbstractText><b>Background:</b> Premature ventricular contractions (PVCs) are common arrhythmias associated with symptoms such as fatigue and, in severe cases, PVC-induced cardiomyopathy. Catheter ablation (CA) is a primary treatment for symptomatic PVCs, particularly when pharmacological therapies fail or are undesired. While improvements in: quality-of-life following ablation are documented, its impact on functional capacity remains underexplored. <b>Objectives:</b> This study evaluated the impact of CA on functional capacity and cardiac stress markers in patients with symptomatic PVCs using cardiopulmonary exercise testing (CPET) and NT-proBNP levels. <b>Methods:</b> A total of 30 patients underwent successful PVC ablation and completed baseline and follow-up CPET evaluations under the Bruce protocol. PVC burden, left ventricular ejection fraction (LVEF), NT-proBNP levels, and CPET parameters, including VO<sub>2</sub> max, METS, ventilatory efficiency, and anaerobic threshold (AT), were analyzed pre- and post-ablation. <b>Results:</b> PVC burden significantly decreased post-ablation (23,509.3 &#xb1; 10,700.47 to 1759 &#xb1; 1659.15, <i>p</i> &lt; 0.001). CPET revealed improved functional capacity, with VO<sub>2</sub> max increasing from 24.97 &#xb1; 4.16 mL/kg/min to 26.02 &#xb1; 4.34 mL/kg/min (<i>p</i> = 0.0096) and METS from 7.16 &#xb1; 1.17 to 7.48 &#xb1; 1.24 (<i>p</i> = 0.0103). NT-proBNP significantly decreased (240.93 &#xb1; 156.54 pg/mL to 138.47 &#xb1; 152.91 pg/mL, <i>p</i> = 0.0065). LVEF and ventilatory efficiency metrics (VE/VO<sub>2</sub> and VE/VCO<sub>2</sub>) remained stable. <b>Conclusions:</b> Catheter ablation improves functional capacity, reduces cardiac stress, and minimizes medication dependency in patients with symptomatic PVCs. These findings support the utility of ablation in enhancing aerobic capacity and overall exercise performance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheilas</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><Identifier Source="ORCID">0009-0005-5789-0256</Identifier><AffiliationInfo><Affiliation>Onassis Cardiac Surgery Center, 17674 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dritsas</LastName><ForeName>Athanasios</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Onassis Cardiac Surgery Center, 17674 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinos</LastName><ForeName>Antonios</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0005-4669-0179</Identifier><AffiliationInfo><Affiliation>Onassis Cardiac Surgery Center, 17674 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkirgkinoudi</LastName><ForeName>Evangelia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Onassis Cardiac Surgery Center, 17674 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filandrianos</LastName><ForeName>Giorgos</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-7015-7746</Identifier><AffiliationInfo><Affiliation>Artificial Intelligence Lab, National Technical University of Athens, 15780 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatziantoniou</LastName><ForeName>Anastasios</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0000-4937-1396</Identifier><AffiliationInfo><Affiliation>Onassis Cardiac Surgery Center, 17674 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kariki</LastName><ForeName>Ourania</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Onassis Cardiac Surgery Center, 17674 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mililis</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Onassis Cardiac Surgery Center, 17674 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saplaouras</LastName><ForeName>Athanasios</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8200-4050</Identifier><AffiliationInfo><Affiliation>Onassis Cardiac Surgery Center, 17674 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostopoulou</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Onassis Cardiac Surgery Center, 17674 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Letsas</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Onassis Cardiac Surgery Center, 17674 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Efremidis</LastName><ForeName>Michalis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Onassis Cardiac Surgery Center, 17674 Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Med Sci (Basel)</MedlineTA><NlmUniqueID>101629322</NlmUniqueID><ISSNLinking>2076-3271</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>114471-18-0</RegistryNumber><NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C109794">pro-brain natriuretic peptide (1-76)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018879" MajorTopicYN="Y">Ventricular Premature Complexes</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017115" MajorTopicYN="Y">Catheter Ablation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005080" MajorTopicYN="N">Exercise Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NT-proBNP</Keyword><Keyword MajorTopicYN="N">cardiopulmonary exercise testing (CPET)</Keyword><Keyword MajorTopicYN="N">catheter ablation</Keyword><Keyword MajorTopicYN="N">functional capacity</Keyword><Keyword MajorTopicYN="N">premature ventricular contractions (PVCs)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843717</ArticleId><ArticleId IdType="doi">10.3390/medsci13030095</ArticleId><ArticleId IdType="pii">medsci13030095</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40843768</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2076-3271</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Medical sciences (Basel, Switzerland)</Title><ISOAbbreviation>Med Sci (Basel)</ISOAbbreviation></Journal><ArticleTitle>Health-Related Quality-of-Life Measures in Patients with Heart Failure Cardiogenic Shock Following Axillary Mechanical Circulatory Support.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">146</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medsci13030146</ELocationID><Abstract><AbstractText><b>Background:</b> Patients with end-stage heart failure-related cardiogenic shock (HF-CS) are conclusively associated with a poor health-related quality of life (HRQL). Axillary mechanical circulatory support (aMCS), such as the Impella 5.5, is increasingly used in this population and may improve HRQL during hospitalization by providing enhanced left ventricular unloading. We aimed to assess changes in HRQL between admission and two weeks after Impella 5.5 placement in patients with HF-CS, using the Kansas City Cardiomyopathy Questionnaire (KCCQ). <b>Methods:</b> We conducted a prospective longitudinal analysis on patients with the Impella 5.5 between May 2023 and July 2023. Participants completed the condensed KCCQ-12 at admission and again two weeks post-implantation. Changes in the scores were evaluated using the Wilcoxon signed-rank test. <b>Results:</b> Fifteen patients were enrolled. The median age was 59 years (50-63), and the median ejection fraction at implantation was 20% (15-30). On admission, most patients reported an overall HRQL of poor-to-fair (46.7%) according to the summary KCCQ-12 score. The median overall summary score increased significantly after Impella 5.5 support (50.52 vs. 28.13, <i>p</i> = 0.005). Symptom frequency (70.83 vs. 43.75, <i>p</i> = 0.009) and quality-of-life (50.00 vs. 12.50, <i>p</i> = 0.023) domains improved significantly, while physical limitation showed a positive trend and social limitation remained unchanged. These HRQL improvements occurred alongside a significant shift toward lower SCAI shock stages, marked increases in cardiac output and cardiac index, and no escalation in vasoactive-inotropic requirements. <b>Conclusions:</b> Impella 5.5 support in HF-CS patients was associated with early and clinically meaningful improvements in HRQL, particularly in symptom frequency and quality of life, during the critical pre-transplant or recovery period. These findings suggest that the Impella 5.5 may provide both physiological and patient-perceived benefits in this high-risk population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mautong</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Health, Universidad Esp&#xed;ritu Santo-Ecuador, Samborond&#xf3;n 092301, Guayas, Ecuador.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>John H. Stroger Jr. Hospital of Cook County, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Aarti</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0006-2502-6153</Identifier><AffiliationInfo><Affiliation>Division of Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Shriya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>St. Elizabeth Medical Center, Boston, MA 02135, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Jose</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8616-6321</Identifier><AffiliationInfo><Affiliation>Division of Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leoni</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7820-3842</Identifier><AffiliationInfo><Affiliation>Division of Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goswami</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0921-1416</Identifier><AffiliationInfo><Affiliation>Division of Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Med Sci (Basel)</MedlineTA><NlmUniqueID>101629322</NlmUniqueID><ISSNLinking>2076-3271</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">KCCQ</Keyword><Keyword MajorTopicYN="N">KCCQ-12</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">the Impella</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843768</ArticleId><ArticleId IdType="doi">10.3390/medsci13030146</ArticleId><ArticleId IdType="pii">medsci13030146</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>